FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Pellicano, R El-Serag, HB Rizzetto, M AF Pellicano, R. El-Serag, H. B. Rizzetto, M. TI Hepatocellular carcinoma at the cutting edge of science and practice SO MINERVA MEDICA LA English DT Editorial Material ID LIVER-TRANSPLANTATION; UNITED-STATES; HEPATITIS-B; SORAFENIB; SURVEILLANCE; THERAPY; CANCER C1 [Pellicano, R.; Rizzetto, M.] Molinette Hosp SGAS, Dept Gastroenterol & Hepatol, Turin, Italy. [El-Serag, H. B.] Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA. [El-Serag, H. B.] Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA. [El-Serag, H. B.] Baylor Coll Med, Houston, TX 77030 USA. RP Pellicano, R (reprint author), Molinette Mauriziano Hosp, Dept Gastroenterol & Hepatol, Via Cavour 31, I-10123 Turin, Italy. EM rinaldo_pellican@hot-mail.com NR 20 TC 0 Z9 0 U1 0 U2 0 PU EDIZIONI MINERVA MEDICA PI TURIN PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY SN 0026-4806 J9 MINERVA MED JI Minerva Med. PD DEC PY 2010 VL 101 IS 6 BP 391 EP 393 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 711HR UT WOS:000286578300003 PM 21196898 ER PT J AU Rodriguez, AL Grier, MD Jones, CK Herman, EJ Kane, AS Smith, RL Williams, R Zhou, Y Marlo, JE Days, EL Blatt, TN Jadhav, S Menon, UN Vinson, PN Rook, JM Stauffer, SR Niswender, CM Lindsley, CW Weaver, CD Conn, PJ AF Rodriguez, Alice L. Grier, Mark D. Jones, Carrie K. Herman, Elizabeth J. Kane, Alexander S. Smith, Randy L. Williams, Richard Zhou, Ya Marlo, Joy E. Days, Emily L. Blatt, Tasha N. Jadhav, Satyawan Menon, Usha N. Vinson, Paige N. Rook, Jerri M. Stauffer, Shaun R. Niswender, Colleen M. Lindsley, Craig W. Weaver, C. David Conn, P. Jeffrey TI Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity SO MOLECULAR PHARMACOLOGY LA English DT Article ID MGLU5 RECEPTOR; LOCOMOTOR-ACTIVITY; BINDING-SITE; ANTAGONIST; POTENT; 2-METHYL-6-(PHENYLETHYNYL)PYRIDINE; PHARMACOLOGY; ANXIETY; FENOBAM; MPEP AB Modulators of metabotropic glutamate receptor subtype 5 (mGluR5) may provide novel treatments for multiple central nervous system (CNS) disorders, including anxiety and schizophrenia. Although compounds have been developed to better understand the physiological roles of mGluR5 and potential usefulness for the treatment of these disorders, there are limitations in the tools available, including poor selectivity, low potency, and limited solubility. To address these issues, we developed an innovative assay that allows simultaneous screening for mGluR5 agonists, antagonists, and potentiators. We identified multiple scaffolds that possess diverse modes of activity at mGluR5, including both positive and negative allosteric modulators (PAMs and NAMs, respectively). 3-Fluoro-5-(3-(pyridine-2-yl)-1,2,4-oxadiazol-5-yl) benzonitrile (VU0285683) was developed as a novel selective mGluR5 NAM with high affinity for the 2-methyl-6-(phenyl-ethynyl)-pyridine (MPEP) binding site. VU0285683 had anxiolytic-like activity in two rodent models for anxiety but did not potentiate phen-cyclidine-induced hyperlocomotor activity. (4-Hydroxypiperidin-1-yl)(4-phenylethynyl) phenyl) methanone (VU0092273) was identified as a novel mGluR5 PAM that also binds to the MPEP site. VU0092273 was chemically optimized to an orally active analog, N-cyclobutyl-6-((3-fluorophenyl) ethynyl) nicotinamide hydrochloride (VU0360172), which is selective for mGluR5. This novel mGluR5 PAM produced a dose-dependent reversal of amphetamine-induced hyperlocomotion, a rodent model predictive of antipsychotic activity. Discovery of structurally and functionally diverse allosteric modulators of mGluR5 that demonstrate in vivo efficacy in rodent models of anxiety and antipsychotic activity provide further support for the tremendous diversity of chemical scaffolds and modes of efficacy of mGluR5 ligands. In addition, these studies provide strong support for the hypothesis that multiple structurally distinct mGluR5 modulators have robust activity in animal models that predict efficacy in the treatment of CNS disorders. C1 [Conn, P. Jeffrey] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. [Jones, Carrie K.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN USA. [Lindsley, Craig W.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA. [Rodriguez, Alice L.; Jones, Carrie K.; Herman, Elizabeth J.; Kane, Alexander S.; Williams, Richard; Zhou, Ya; Marlo, Joy E.; Jadhav, Satyawan; Menon, Usha N.; Vinson, Paige N.; Rook, Jerri M.; Stauffer, Shaun R.; Niswender, Colleen M.; Lindsley, Craig W.; Weaver, C. David; Conn, P. Jeffrey] Vanderbilt Univ, Vanderbilt Program Drug Discovery, Nashville, TN 37232 USA. [Days, Emily L.; Blatt, Tasha N.; Weaver, C. David] Vanderbilt Univ, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA. RP Conn, PJ (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 1215D Light Hall,2215 Garland Ave, Nashville, TN 37232 USA. EM jeff.conn@vanderbilt.edu RI Conn, Peter/D-7848-2012; Zhou, Ya/F-1220-2013 FU National Institutes of Health National Institute of Neurological Disorders and Stroke [1F32-NS049865, R01-NS031373]; National Institutes of Health National Institute of Mental Health [R01-MH062646, R01-MH074953]; National Institutes of Health National Institute on Drug Abuse [1R01-DA023947-01]; Vanderbilt is a center in the National Institutes of Health FX This work was supported by the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grants 1F32-NS049865, R01-NS031373]; the National Institutes of Health National Institute of Mental Health [Grants R01-MH062646, R01-MH074953]; and the National Institutes of Health National Institute on Drug Abuse [Grant 1R01-DA023947-01]. Vanderbilt is a center in the National Institutes of Health-supported Molecular Libraries Screening Centers Network. NR 52 TC 104 Z9 106 U1 0 U2 3 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0026-895X J9 MOL PHARMACOL JI Mol. Pharmacol. PD DEC PY 2010 VL 78 IS 6 BP 1105 EP 1123 DI 10.1124/mol.110.067207 PG 19 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 680WC UT WOS:000284267200014 PM 20923853 ER PT J AU Tanaka, H Kono, E Tran, CP Miyazaki, H Yamashiro, J Shimomura, T Fazli, L Wada, R Huang, JT Vessella, RL An, JB Horvath, S Gleave, M Rettig, MB Wainberg, ZA Reiter, RE AF Tanaka, Hiroshi Kono, Evelyn Tran, Chau P. Miyazaki, Hideyo Yamashiro, Joyce Shimomura, Tatsuya Fazli, Ladan Wada, Robert Huang, Jiaoti Vessella, Robert L. An, Jaibin Horvath, Steven Gleave, Martin Rettig, Matthew B. Wainberg, Zev A. Reiter, Robert E. TI Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance SO NATURE MEDICINE LA English DT Article ID MESENCHYMAL TRANSITION; ANDROGEN RECEPTOR; ANTITUMOR-ACTIVITY; STEM-CELLS; PROGRESSION; THERAPY; INDEPENDENCE; INCREASES; PATHWAY; BIOLOGY AB The transition from androgen-dependent to castration-resistant prostate cancer (CRPC) is a lethal event of uncertain molecular etiology. Comparing gene expression in isogenic androgen-dependent and CRPC xenografts, we found a reproducible increase in N-cadherin expression, which was also elevated in primary and metastatic tumors of individuals with CRPC. Ectopic expression of N-cadherin in nonmetastatic, androgen-dependent prostate cancer models caused castration resistance, invasion and metastasis. Monoclonal antibodies against the ectodomain of N-cadherin reduced proliferation, adhesion and invasion of prostate cancer cells in vitro. In vivo, these antibodies slowed the growth of multiple established CRPC xenografts, blocked local invasion and metastasis and, at higher doses, led to complete regression. N-cadherin-specific antibodies markedly delayed the time to emergence of castration resistance, markedly affected tumor histology and angiogenesis, and reduced both AKT serine-threonine kinase activity and serum interleukin-8 (IL-8) secretion. These data indicate that N-cadherin is a major cause of both prostate cancer metastasis and castration resistance. Therapeutic targeting of this factor with monoclonal antibodies may have considerable clinical benefit. (C) 2010 Nature America, Inc. All rights reserved. C1 [Tanaka, Hiroshi; Kono, Evelyn; Tran, Chau P.; Yamashiro, Joyce; Shimomura, Tatsuya; Wada, Robert; An, Jaibin; Rettig, Matthew B.; Reiter, Robert E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Tanaka, Hiroshi; Kono, Evelyn; Tran, Chau P.; Yamashiro, Joyce; Shimomura, Tatsuya; Huang, Jiaoti; Rettig, Matthew B.; Wainberg, Zev A.; Reiter, Robert E.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Miyazaki, Hideyo] Univ Tokyo, Dept Urol, Tokyo, Japan. [Fazli, Ladan; Gleave, Martin] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V5Z 1M9, Canada. [Huang, Jiaoti] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. [Vessella, Robert L.] Univ Washington, Med Ctr, Dept Urol, Puget Sound Vet Hlth Care Adm, Seattle, WA 98195 USA. [An, Jaibin; Rettig, Matthew B.] Vet Affairs Greater Los Angeles Healthcare Syst W, Dept Med, Los Angeles, CA USA. [Horvath, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Horvath, Steven] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA. [Wainberg, Zev A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA. [Reiter, Robert E.] Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA. RP Reiter, RE (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. EM rreiter@mednet.ucla.edu FU US National Cancer Institute Prostate Cancer SPORE at the University of California-Los Angeles [P50CA092131-09]; US Department of Defense [W81XWH-06-1-0324, W81XWH-09-1-0630, PC061456]; Takeda Pharmaceuticals; Jean Perkins Foundation; American Cancer Society [RSG-07-092-01-TBE] FX This work was supported in parts by the US National Cancer Institute Prostate Cancer SPORE at the University of California-Los Angeles (P50CA092131-09 to R. E. R.), US Department of Defense Prostate Cancer Research grants (W81XWH-06-1-0324 to Z.A.W., W81XWH-09-1-0630 to R. E. R. and M. B. R., PC061456 to J.H.), Takeda Pharmaceuticals, the Jean Perkins Foundation and the American Cancer Society (RSG-07-092-01-TBE to J.H.). We also thank S. and L. Resnick, the Prostate Cancer Foundation and the Luskin Foundation for generous support and J. Said and N. Doan for immunohistochemical assessments. LNCaP-CL1 cells were provided by C. L. Tso (University of California-Los Angeles). Plasmid p Delta VPR was provided by I. Chen (University of California-Los Angeles). NR 28 TC 131 Z9 137 U1 0 U2 21 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD DEC PY 2010 VL 16 IS 12 BP 1414 EP U96 DI 10.1038/nm.2236 PG 8 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 690ZH UT WOS:000285048900035 PM 21057494 ER PT J AU McGregor, R Siegel, JM AF McGregor, Ronald Siegel, Jerome M. TI Illuminating the locus coeruleus: control of posture and arousal SO NATURE NEUROSCIENCE LA English DT Editorial Material ID IN-VIVO MICRODIALYSIS; RELEASE; NEURONS; PONTINE; CATAPLEXY; NUCLEUS; ATONIA; CELLS C1 [McGregor, Ronald; Siegel, Jerome M.] Vet Adm Greater Los Angeles Healthcare Syst, North Hills, CA USA. [McGregor, Ronald; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [McGregor, Ronald; Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. RP McGregor, R (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, North Hills, CA USA. EM icelos@gmail.com; jsiegel@ucla.edu NR 15 TC 11 Z9 11 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1097-6256 J9 NAT NEUROSCI JI Nat. Neurosci. PD DEC PY 2010 VL 13 IS 12 BP 1448 EP 1449 DI 10.1038/nn1210-1448 PG 3 WC Neurosciences SC Neurosciences & Neurology GA 684CW UT WOS:000284525800005 PM 21102568 ER PT J AU Peralta, CA Lin, F Shlipak, MG Siscovick, D Lewis, C Jacobs, DR Bibbins-Domingo, K AF Peralta, Carmen A. Lin, Feng Shlipak, Michael G. Siscovick, David Lewis, Cora Jacobs, David R., Jr. Bibbins-Domingo, Kirsten TI Race differences in prevalence of chronic kidney disease among young adults using creatinine-based glomerular filtration rate-estimating equations SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE chronic kidney disease; glomerular filtration rate; race ID STAGE RENAL-DISEASE; SERUM CREATININE; GFR; PERFORMANCE; HEALTH AB Background. Despite a higher incidence of end-stage renal disease (stage 5), blacks have been shown to have the same or lower prevalence of chronic kidney disease (CKD stages 3 and 4). Current creatinine-based glomerular filtration rate (GFR)-estimating equations may misclassify young, healthy blacks. Methods. Among 3501 young adults (mean age 45), we compared the prevalence of CKD in blacks and whites using the Modification of Diet in Renal Disease (MDRD) and the CKD Epidemiology Collaboration (CKD-EPI) equations. In addition, we used measured creatinine excretion rates to determine the actual excretion ratio for CARDIA (race coefficient 12%) and applied this to the CKD-EPI equation. We also studied the prevalence of CKD risk factors among black and white participants near the CKD threshold cut-off (eGFR CKD-EPI 60-80 mL/min/1.73 m(2)) to estimate the relative likelihood of misclassification in blacks and whites. Results. Using the MDRD equation, prevalence of CKD stages 4 and 5 was higher for blacks compared with whites (0.6% vs. 0.1%, P-value 0.05). In contrast, prevalence of eGFR <60 mL/min/1.73 m(2) was significantly higher for whites (3.6%) compared with blacks (1.9%), due to higher prevalence of stage 3 among whites. Prevalence of CKD was similar for blacks and whites using CKD-EPI equation (1.2%), but was higher among blacks when using the CARDIA-derived race coefficient (1.6% vs. 1.2%, P-value = 0.03). Among persons with eGFR by CKD-EPI of 60-80 mL/min/1.73 m(2), blacks had higher levels of albuminuria, uric acid, systolic blood pressure and higher diabetes prevalence. Conclusions. CKD classification among young blacks is very sensitive to the race coefficients. Despite whites having higher rates of CKD stage 3, blacks with eGFRs just above the CKD threshold had higher rates of CKD risk factors. Current equations used to define CKD may systematically miss a high-risk group of blacks at a time in the disease course when interventions are crucial. C1 [Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Peralta, Carmen A.; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Lin, Feng; Shlipak, Michael G.; Bibbins-Domingo, Kirsten] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Siscovick, David] Univ Washington, Dept Med & Epidemiol, Seattle, WA 98195 USA. [Lewis, Cora] Univ Alabama, Div Prevent Med, Birmingham, AL USA. [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA. [Bibbins-Domingo, Kirsten] San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA 94110 USA. [Bibbins-Domingo, Kirsten] San Francisco Gen Hosp, UCSF Ctr Vulnerable Populat San Francisco, San Francisco, CA 94110 USA. RP Peralta, CA (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM Carmenalicia.peralta@ucsf.edu FU NIDDK [1K23DK082793-01] FX C.A.P. is funded by grant 1K23DK082793-01 from NIDDK. NR 15 TC 16 Z9 16 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD DEC PY 2010 VL 25 IS 12 BP 3934 EP 3939 DI 10.1093/ndt/gfq299 PG 7 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 685PK UT WOS:000284640400022 PM 20519233 ER PT J AU Wasterlain, CG Thompson, KW Suchomelova, L Niquet, J AF Wasterlain, Claude G. Thompson, Kerry W. Suchomelova, Lucie Niquet, Jerome TI Brain Energy Metabolism During Experimental Neonatal Seizures SO NEUROCHEMICAL RESEARCH LA English DT Article DE Epilepsy; Neonatal seizures; Energy metabolism; ATP; Brain development; Hypoglycemia ID NUCLEAR-MAGNETIC-RESONANCE; PROLONGED EPILEPTIC SEIZURES; INDUCED NEURONAL INJURY; IMMATURE RAT-BRAIN; FEBRILE SEIZURES; CEREBRAL METABOLISM; RECURRENT SEIZURES; COMBINED H-1; INVIVO P-31; DAMAGE AB During flurothyl seizures in 4-day-old rats, cortical concentration of ATP, phosphocreatine and glucose fell while lactate rose. Cortical energy use rate more than doubled, while glycolytic rate increased fivefold. Calculation of the cerebral metabolic balance during sustained seizures suggests that energy balance could be maintained in hyperglycemic animals, and would decline slowly in normoglycemia, but would be compromised by concurrent hypoglycemia, hyperthermia or hypoxia. These results suggest that the metabolic challenge imposed on the brain by this model of experimental neonatal seizures is milder than that seen at older ages, but can become critical when associated with other types of metabolic stress. C1 [Wasterlain, Claude G.; Thompson, Kerry W.; Suchomelova, Lucie; Niquet, Jerome] VA Greater Angeles Hlth Care Syst, Epilepsy Res Lab, W Los Angels, CA 90073 USA. [Thompson, Kerry W.] Occidental Coll, Dept Biol, Los Angeles, CA 90041 USA. [Wasterlain, Claude G.; Thompson, Kerry W.; Suchomelova, Lucie; Niquet, Jerome] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Wasterlain, CG (reprint author), VA Greater Angeles Hlth Care Syst, Epilepsy Res Lab, 11301 Wilshire Blvd, W Los Angels, CA 90073 USA. EM wasterla@ucla.edu FU VHA Research Service; NINDS [RO1-NS13515] FX Supported by VHA Research Service and by research grant RO1-NS13515 from NINDS. A large part of the credit for this work belongs to Dr. Thomas E. Duffy, who unfortunately died before its completion. We are indebted to Barbara Blackburn for preparation of the manuscript, and to Roger Baldwin for superb technical help. I (CGW) am particularly indebted to Dr Abel Lajtha for his support during my early days as a neurochemist. He was both a mentor and an inspiration, and was always available and generous with fresh ideas, new techniques and very wise advice. Abel and Claude Baxter welcomed me into the Society for Neurochemistry, which was a young and vibrant meeting place for all kinds of scientists. Abel was a strong leader, but his style was so kind and unassuming that I always felt like he was helping me to find my own way. There are only a few people whose influence on the world has been exclusively positive, and he is one of those elite few. I hope that he will continue to provide wisdom and inspiration to present and future neurochemists. NR 56 TC 13 Z9 15 U1 0 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-3190 J9 NEUROCHEM RES JI Neurochem. Res. PD DEC PY 2010 VL 35 IS 12 SI SI BP 2193 EP 2198 DI 10.1007/s11064-010-0339-4 PG 6 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 695IX UT WOS:000285364900037 PM 21136154 ER PT J AU Fabrizio, KS Keltner, NL AF Fabrizio, Katherine S. Keltner, Norman L. TI Traumatic Brain Injury in Operation Enduring Freedom/Operation Iraqi Freedom: A Primer SO NURSING CLINICS OF NORTH AMERICA LA English DT Article DE Brain injury; Blast; Military; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DISORDERS; PART II; AFGHANISTAN; SOLDIERS; WAR; CONSEQUENCES; DEPRESSION; RECOVERY; LONG AB In greater numbers than in prior conflicts, service members deployed as part of Operation Enduring Freedom and Operation Iraqi Freedom have an increased risk of experiencing a traumatic brain injury (TBI). The basics of TBI are discussed, with particular attention paid to blast-related events, as this is a common mechanism of injury in this population. Particular attention is focused on the pharmacologic treatment of the sequlae of TBI and common comorbid conditions. C1 [Fabrizio, Katherine S.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. [Keltner, Norman L.] Univ Alabama, Sch Nursing, Birmingham, AL 35294 USA. RP Fabrizio, KS (reprint author), Birmingham Vet Affairs Med Ctr, Phys Med & Rehabil 117,700 S 19th St, Birmingham, AL 35233 USA. EM Katherine.Fabrizio@va.gov NR 39 TC 10 Z9 10 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0029-6465 J9 NURS CLIN N AM JI Nurs. Clin. North Am. PD DEC PY 2010 VL 45 IS 4 BP 569 EP + DI 10.1016/j.cnur.2010.06.003 PG 13 WC Nursing SC Nursing GA 683AI UT WOS:000284443700006 PM 20971337 ER PT J AU Cole, GM Ma, QL Frautschy, SA AF Cole, Greg M. Ma, Qiu-Lan Frautschy, Sally A. TI Dietary fatty acids and the aging brain SO NUTRITION REVIEWS LA English DT Review DE Alzheimer's disease; amyloid; dementia; docosahexaenoic acid (DHA); omega-3 fatty acid (n-3) ID MILD COGNITIVE IMPAIRMENT; RETINOID-X-RECEPTOR; DISEASE MOUSE MODEL; ALZHEIMERS-DISEASE; DOCOSAHEXAENOIC ACID; AMYLOID-BETA; DENDRITIC PATHOLOGY; MEDITERRANEAN DIET; SYNAPTIC PROTEINS; CONTROLLED-TRIAL AB Aging contributes to physiological decline and vulnerability to disease. In the brain, even with minimal neuronal loss, aging increases oxidative damage, inflammation, demyelination, impaired processing, and metabolic deficits, particularly during pathological brain aging. In this review, the possible role of docosahexaenoic acid (DHA) in the prevention of age-related disruption of brain function is discussed. High-fat diabetogenic diets, cholesterol, and the omega-6 fatty acid arachidonate and its prostaglandin metabolites have all been implicated in promoting the pathogenesis of Alzheimer's disease. Evidence presented here shows DHA acts to oppose this, exerting a plethora of pleiotropic activities to protect against the pathogenesis of Alzheimer's disease. C1 [Cole, Greg M.; Ma, Qiu-Lan; Frautschy, Sally A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Cole, Greg M.; Frautschy, Sally A.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Cole, Greg M.; Ma, Qiu-Lan; Frautschy, Sally A.] Greater Los Angeles Vet Affairs Healthcare Syst, Geriatr Res Educ & Clin Ctr, VA Med Ctr, North Hills, CA USA. RP Cole, GM (reprint author), Greater Los Angeles Healthcare Syst, GRECC Vet Affairs, Res 151,Bldg 7,Rm A101,16111 Plummer St, North Hills, CA 91343 USA. EM gmcole@ucla.edu FU National Center for Complementary and Alternative Medicine (NCCAM) [NIH R01 AT3008, NIA R01AG13471, VA MERIT, AG021975] FX Funding. This work was supported by National Center for Complementary and Alternative Medicine (NCCAM) NIH R01 AT3008, NIA R01AG13471, VA MERIT (SAF, GMC), AG021975 (SAF). NR 80 TC 33 Z9 33 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0029-6643 EI 1753-4887 J9 NUTR REV JI Nutr. Rev. PD DEC PY 2010 VL 68 IS 12 SU 2 BP S102 EP S111 DI 10.1111/j.1753-4887.2010.00345.x PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 684WZ UT WOS:000284587300007 PM 21091943 ER PT J AU Ng, E Ilsen, PF AF Ng, Eileen Ilsen, Pauline F. TI Orbital Metastases SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION LA English DT Article DE Orbital metastasis; Radiation; Palliative therapy; Proptosis; Ptosis; Diplopia ID RENAL-CELL CARCINOMA; RADIATION-INDUCED MENINGIOMAS; BREAST-CARCINOMA; TUMORS; CANCER; EYE; MELANOMA; ADENOCARCINOMA; RETINOPATHY; MANAGEMENT AB BACKGROUND: Orbital metastasis, although uncommon, is a condition optometrists should consider in a patient presenting with proptosis, ptosis, diplopia, or a lid mass with a history of cancer. However, in as many as 19% of cases, patients have no prior or concurrent history of systemic cancer when presenting with ophthalmic symptoms. If suspecting an orbital metastasis, neuroimaging is important, as well as a referral to the patient's primary care provider, oncologist, and ophthalmologist. CASE REPORTS: Three patients with orbital metastasis are discussed. The first was a 55-year-old white man who initially presented with a left ptosis of unclear etiology. Magnetic resonance imaging of his orbits and an orbital biopsy found metastatic esophageal adenocarcinoma. Radiotherapy and chemotherapy were initiated, but the patient died shortly afterward. The second patient was a 49-year-old black man who also presented with a ptosis of the right upper eyelid. An area of the retina appeared elevated; ophthalmic B-scan and computed tomography of the orbits confirmed the presence of a mass, determined to be metastatic lung carcinoma to the right orbit. A course of radiotherapy was initiated, but the patient died 3 clays after completing therapy. The last case was a 77-year-old white man with a history of metastasis to the left orbit from non-Hodgkin's lymphoma. On examination, he had proptosis of the left eye, initially thought to be caused by a recurrence of the metastasis. However, a computed tomography scan showed a new meningioma in the same orbit, and treatment was started. The proptosis improved, and the patient continues to be followed up regularly. CONCLUSIONS: Any patient with proptosis and/or ptosis with a history of cancer should be evaluated for orbital metastasis. Optometrists should keep in mind that an orbital metastasis may represent the initial manifestation of undiagnosed systemic cancer. Prognosis can be poor, and thus treatment is sometimes palliative in nature, intending to slow the progression of the disease instead of providing a cure. Optometry 2010;81:647-657 C1 W Los Angeles Vet Affairs Healthcare Ctr, Los Angeles, CA USA. So Calif Coll Optometry, Los Angeles, CA USA. RP Ng, E (reprint author), W Los Angeles Vet Affairs Healthcare, Optometry, Bldg 304,Room 2-111,11031 Wilshire Blvd, Los Angeles, CA 90073 USA. EM eng510@gmail.com NR 53 TC 5 Z9 5 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-1839 J9 OPTOMETRY JI Optometry PD DEC PY 2010 VL 81 IS 12 BP 647 EP 657 DI 10.1016/j.optm.2010.07.026 PG 11 WC Ophthalmology SC Ophthalmology GA 778ML UT WOS:000291708300005 PM 21111373 ER PT J AU Singh, JA Ayub, S AF Singh, J. A. Ayub, S. TI Accuracy of VA databases for diagnoses of knee replacement and hip replacement SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE Hip replacement; Knee replacement; Validity; Databases; Veterans Affairs ID HEALTH-CARE-SYSTEM; VETERANS; QUALITY AB Purpose: To examine the validity of International Classification of Diseases-Ninth Revision (ICD-9) and Current Procedural Terminology (CPT) codes for knee replacement and hip replacement in Veterans Affairs (VA) databases. Methods: From a cohort of veterans who received health care at Minneapolis VA Medical Center and/or affiliated medical facilities, we obtained four random samples of 50 patients each with: neither hip nor knee replacement code, knee replacement code only, hip replacement code only and both knee and hip replacement codes. The gold standard was documentation of knee or hip replacement surgery in patient medical records. Accuracy of ICD-9 or CPT code for knee and hip replacement was assessed by calculating sensitivity, specificity, positive and negative predictive values (PPV and NPV). Results: Of the 200 patients, medical records were available for 166:140 (70%) had complete medical records and 26 (13%) had incomplete medical records. Knee replacement codes were accurate with excellent PPV of 95%, sensitivity of 95%, specificity of 96% and NPV of 96%. Hip replacement codes were accurate with excellent PPV of 98%, sensitivity of 96%, specificity of 99% and NPV of 96%. Sensitivity analyses that included incomplete charts had little impact on these estimates. The procedure dates found in VA databases matched exactly with medical records in 96%. Conclusions: The ICD-9 and CPT codes for knee replacement and hip replacement in VA databases are valid. These codes may be used to identify cohorts of veterans with knee replacement and hip replacement for research studies. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International. C1 [Singh, J. A.] Univ Alabama, Birmingham, AL 35294 USA. [Singh, J. A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Singh, J. A.] Mayo Clin, Sch Med, Dept Hlth Sci Res, Rochester, MN USA. [Singh, J. A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA. [Singh, J. A.] VA Med Ctr, Minneapolis, MN USA. [Ayub, S.] Univ Minnesota, Div Rheumatol, Minneapolis, MN USA. RP Singh, JA (reprint author), Univ Alabama, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU Allergan; Takeda; Savient; Wyeth; Amgen; URL pharmaceuticals; NIH (Mayo Clinic Center for Clinical and Translational Research) [KL2 RR024151-01]; Birmingham VA Medical Center, Alabama, USA FX There are no financial conflicts related to this work. JAS has received speaker honoraria from Abbott; research and travel grants from Allergan, Takeda, Savient, Wyeth and Amgen; and consultant fees from Savient and URL pharmaceuticals. SA has no financial conflicts.; JAS's time was protected for research through a NIH CTSA Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) grant. The funding source had no contributions to design or conduct of study, preparation of manuscript or decision to submit it for publication. This material is the result of work supported by the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA. NR 14 TC 20 Z9 20 U1 0 U2 1 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD DEC PY 2010 VL 18 IS 12 BP 1639 EP 1642 DI 10.1016/j.joca.2010.10.003 PG 4 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 701IT UT WOS:000285812300012 PM 20950694 ER PT J AU Nazar, G Garmendia, ML Royer, M McDowell, JA Weymuller, EA Yueh, B AF Nazar, Gonzalo Garmendia, Maria Luisa Royer, Michel McDowell, Jennifer A. Weymuller, Ernest A., Jr. Yueh, Bevan TI Spanish validation of the University of Washington Quality of Life questionnaire for head and neck cancer patients SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article ID PERFORMANCE STATUS SCALE; OROPHARYNGEAL CANCER; UW-QOL; DOMAIN; LARYNGECTOMY; DISABILITY AB OBJECTIVE: The University of Washington Quality of Life (UW-QOL) questionnaire is one of the most widely used instruments to evaluate the quality of life of head and neck cancer patients. The aim of this study was to perform a Spanish translation and validation of the UW-QOL questionnaire. STUDY DESIGN: A cross-sectional study. SETTING: Three tertiary-care hospitals and a laryngectomee rehabilitation center. SUBJECTS AND METHODS: The translation and cultural adaptation of the questionnaire were performed following accepted international guidelines. The psychometric validation was performed on a consecutive series of patients treated for squamous cell carcinoma of the upper aerodigestive tract with no signs of relapse, recruited from May 2007 to December 2008. Eligible subjects were invited to complete the Spanish version of the UW-QOL questionnaire during routine clinical consultation, and complete it again within 15 days. Subjects also completed a validated Spanish version of the Goldberg Mental Health Survey and were evaluated by the use of the Karnofsky Index. RESULTS: A Spanish version of the questionnaire was developed in iterative fashion. In the psychometric validation process, a total of 76 patients were analyzed. Reliability was excellent, including both internal consistency (Cronbach's alpha of 0.84) and test-retest reliability (intraclass correlation coefficient between 0.91 and 0.97 with a confidence interval of 95%). Construct validity was supported by statistically significant relationships between the Karnofsky Index, the Goldberg Mental Health Survey, and the translated UW-QOL questionnaire. CONCLUSION: The Spanish version of the UW-QOL questionnaire appears to be culturally appropriate and psychometrically valid. Copyright (C) 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved. C1 [Nazar, Gonzalo] Clin Las Condes, Dept Otolaryngol, Santiago, Chile. [Garmendia, Maria Luisa] Univ Chile, Sch Publ Hlth, Santiago, Chile. [Royer, Michel] Univ Chile, Hosp Clin, Dept Otolaryngol, Santiago, Chile. [McDowell, Jennifer A.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [Weymuller, Ernest A., Jr.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA. RP Nazar, G (reprint author), Clin Las Condes, Dept Otolaryngol, Lo Fontecilla 441, Santiago, Chile. RI Garmendia, Maria Luisa/H-7417-2013 OI Garmendia, Maria Luisa/0000-0002-0589-6091; Yueh, Bevan/0000-0003-1380-1053 FU Chilean Society of Otolaryngology, Head and Neck Surgery FX This study was financially supported by the Chilean Society of Otolaryngology, Head and Neck Surgery The funding organization had no influence in study design, data analysis or manuscript writing The Chilean Society of Otolaryngology only demands that the paper resulting from the funded research must be published in a medical journal NR 29 TC 8 Z9 8 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD DEC PY 2010 VL 143 IS 6 BP 801 EP 807 DI 10.1016/j.otohns.2010.08.008 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 690BF UT WOS:000284974400012 PM 21109081 ER PT J AU Morasco, BJ Duckart, JP Carr, TP Deyo, RA Dobscha, SK AF Morasco, Benjamin J. Duckart, Jonathan P. Carr, Thomas P. Deyo, Richard A. Dobscha, Steven K. TI Clinical characteristics of veterans prescribed high doses of opioid medications for chronic non-cancer pain SO PAIN LA English DT Article DE Chronic pain; Opioids; Epidemiology; Quality of life; Pain/drug therapy ID PRIMARY-CARE PHYSICIANS; CHRONIC BACK-PAIN; ADMINISTRATIVE DATA; NONMALIGNANT PAIN; ATTITUDES; PRESCRIPTIONS; THERAPY; ASSOCIATION; MANAGEMENT; DISORDERS AB Little is known about patients prescribed high doses of opioids to treat chronic non-cancer pain, though these patients may be at higher risk for medication-related complications. We describe the prevalence of high-dose opioid use and associated demographic and clinical characteristics among veterans treated in a VA regional healthcare network. Veterans with chronic non-cancer pain prescribed high doses of opioids (>= 180 mg/day morphine equivalent; n = 478) for 90+ consecutive days were compared to two groups with chronic pain: Traditional-dose (5-179 mg/day; n = 500) or no opioid (n = 500). High-dose opioid use occurred in 2.4% of all chronic pain patients and in 8.2% of all chronic pain patients prescribed opioids long-term. The average dose in the high-dose group was 324.9 (SD = 285.1) mg/day. The only significant demographic difference among groups was race (p = 0.03) with black veterans less likely to receive high doses. High-dose patients were more likely to have four or more pain diagnoses and the highest rates of medical, psychiatric, and substance use disorders. After controlling for demographic factors and VA facility, neuropathy, low back pain, and nicotine dependence diagnoses were associated with increased likelihood of high-dose prescriptions. High-dose patients frequently did not receive care consistent with treatment guidelines: there was frequent use of short-acting opioids, urine drug screens were administered to only 25.7% of patients in the prior year, and 32.0% received concurrent benzodiazepine prescriptions, which may increase risk for overdose and death. Further study is needed to identify better predictors of high-dose usage, as well as the efficacy and safety of such dosing. Published by Elsevier B.V. on behalf of International Association for the Study of Pain. C1 [Morasco, Benjamin J.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97201 USA. [Carr, Thomas P.] Oregon Hlth & Sci Univ, Div Gen Med & Geriatr, Dept Med, Primary Care Div,Portland VA Med Ctr, Portland, OR 97201 USA. [Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA. [Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA. [Duckart, Jonathan P.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA. RP Morasco, BJ (reprint author), Portland VA Med Ctr R&D99, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM benjamin.morasco@va.gov FU National Institute on Drug Abuse [K23DA023467]; VA Health Services Research and Development service; National Center for Research Resources, a component of the National Institutes of Health [Ul1RR024140]; NIH Roadmap for Medical Research FX This study was supported in part by award K23DA023467 from the National Institute on Drug Abuse to Dr. Morasco. Jonathan Duckart, MPS, was supported by a Research Enhancement Award Program grant from the VA Health Services Research and Development service. The authors appreciate assistance from Sharon Medley and for the support provided by the Oregon Clinical and Translational Research Institute, Grant number Ul1RR024140 from the National Center for Research Resources, a component of the National Institutes of Health and NIH Roadmap for Medical Research. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, National Institute on Drug Abuse, or the Department of Veterans Affairs. NR 55 TC 79 Z9 80 U1 2 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD DEC PY 2010 VL 151 IS 3 BP 625 EP 632 DI 10.1016/j.pain.2010.08.002 PG 8 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 673KC UT WOS:000283657300014 PM 20801580 ER PT J AU Meiksin, R Chang, JC Bhargava, T Arnold, R Dado, D Frankel, R Rodriguez, KL Ling, B Zickmund, S AF Meiksin, Rebecca Chang, Judy C. Bhargava, Tina Arnold, Robert Dado, Diane Frankel, Richard Rodriguez, Keri L. Ling, Bruce Zickmund, Susan TI Now is the chance: Patient-provider communication about unplanned pregnancy during the first prenatal visit SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Patient-provider relationship; Communication; Prenatal care; Pregnancy; Unplanned ID UNINTENDED PREGNANCY; WOMEN; DEPRESSION; HEALTH AB Objective: Unplanned pregnancy is associated with psychosocial stress, post-partum depression, and future unplanned pregnancies. Our study describes how topics related to unplanned pregnancy were addressed with patients during the first prenatal visit. Methods: We audio-recorded and transcribed initial prenatal visits between 48 patients and 16 providers from a clinic serving racially diverse, lower-socio-economic patients. We conducted a fine-grained thematic analysis of cases in which the patient's pregnancy was unplanned. Results: Of the 48 patients, 35 (73%) had unplanned pregnancies. Twenty-nine visits for unplanned pregnancies (83%) included discussion of the patient's feelings about the pregnancy. Approximately half (51%) of the visits touched on partner or other types of social support. Six patients (17%) were offered referrals to counseling or social services. Only four visits (11%) touched on future birth control options. Conclusion: Most initial prenatal visits for unplanned pregnancies included discussion of patient feelings about the pregnancy. However, opportunities to discuss future birth control and for more in-depth follow-up regarding social support and psychological risks associated with unplanned pregnancy were typically missed. Practice implications: Obstetrics care providers should be cautious about making assumptions and should consider discussing pregnancy circumstances and psychosocial issues in more depth when treating patients facing unplanned pregnancy. Published by Elsevier Ireland Ltd. C1 [Meiksin, Rebecca] VA Puget Sound, Seattle, WA 98101 USA. [Meiksin, Rebecca] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Chang, Judy C.; Dado, Diane] Magee Womens Hosp, Pittsburgh, PA USA. [Bhargava, Tina] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Arnold, Robert; Rodriguez, Keri L.; Ling, Bruce; Zickmund, Susan] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Frankel, Richard] Indiana Univ Sch Med, Med & Regenstrief Inst, Bloomington, IN USA. [Rodriguez, Keri L.; Ling, Bruce; Zickmund, Susan] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Rodriguez, Keri L.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Meiksin, R (reprint author), VA Puget Sound, Metropolitan Pk W,Suite 1400,1100 Olive Way, Seattle, WA 98101 USA. EM Rebecca.Meiksin@va.gov FU Association of Professors of Gynecology and Obstetrics/Abbott Medical Education; Scaife Family Foundation; NIH/NICHD [5 K12HD43441-04 PI]; Agency for Healthcare Research and Quality [1 K08 HS13913-01A1]; Veterans Affairs Health Services Research Development FX Financial support came from an Association of Professors of Gynecology and Obstetrics/Abbott Medical Education Program Award, the Scaife Family Foundation, and a Building Interdisciplinary Research Careers in Women's Health Award (NIH/NICHD 5 K12HD43441-04 PI Roberts; Scholar Chang). The efforts of Dr. Chang were also supported by the Agency for Healthcare Research and Quality (1 K08 HS13913-01A1). The efforts of Drs. Rodriguez and Zickmund were respectively sponsored by the Veterans Affairs Health Services Research & Development Merit Review Entry Program (MREP) and Investigator-Initiative Merit Review Award Program. None of the sponsors of this study had any role in the study design; collection, analysis and interpretation of the data; writing of the report; or decision to submit the paper for publication. NR 25 TC 8 Z9 9 U1 2 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD DEC PY 2010 VL 81 IS 3 SI SI BP 462 EP 467 DI 10.1016/j.pec.2010.09.002 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 707OH UT WOS:000286295400023 PM 20884161 ER PT J AU Bhargava, P Parisi, M AF Bhargava, Puneet Parisi, Marguerite TI Infected thyroglossal duct cyst SO PEDIATRIC RADIOLOGY LA English DT Editorial Material C1 [Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98108 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Parisi, Marguerite] Univ Washington, Dept Radiol, Seattle, WA 98105 USA. [Parisi, Marguerite] Seattle Childrens Hosp, Seattle, WA 98105 USA. RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, Mailbox 358280,S-114 Radiol,1660 S Columbian Way, Seattle, WA 98108 USA. EM bhargp@u.washington.edu RI Bhargava, Puneet /F-1330-2011 OI Bhargava, Puneet/0000-0002-3849-9666 NR 2 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0301-0449 J9 PEDIATR RADIOL JI Pediatr. Radiol. PD DEC PY 2010 VL 40 SU 1 BP 84 EP 84 DI 10.1007/s00247-010-1563-4 PG 1 WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging GA 692KZ UT WOS:000285153000040 ER PT J AU Bhargava, P Phillips, G AF Bhargava, Puneet Phillips, Grace TI Giant gastric bezoar presenting as an acute abdominal emergency SO PEDIATRIC RADIOLOGY LA English DT Editorial Material C1 [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Bhargava, Puneet; Phillips, Grace] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Phillips, Grace] Seattle Childrens Hosp, Div Computed Tomog, Seattle, WA USA. RP Bhargava, P (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-114 Radiol,Mail Stop 35828, Seattle, WA 98108 USA. EM bhargp@u.washington.edu RI Bhargava, Puneet /F-1330-2011 OI Bhargava, Puneet/0000-0002-3849-9666 NR 2 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0301-0449 J9 PEDIATR RADIOL JI Pediatr. Radiol. PD DEC PY 2010 VL 40 SU 1 BP 99 EP 99 DI 10.1007/s00247-009-1511-3 PG 1 WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging GA 692KZ UT WOS:000285153000049 ER PT J AU Boulware, DR Meya, DB Bergemann, TL Wiesner, DL Rhein, J Musubire, A Lee, SJ Kambugu, A Janoff, EN Bohjanen, PR AF Boulware, David R. Meya, David B. Bergemann, Tracy L. Wiesner, Darin L. Rhein, Joshua Musubire, Abdu Lee, Sarah J. Kambugu, Andrew Janoff, Edward N. Bohjanen, Paul R. TI Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study SO PLOS MEDICINE LA English DT Article ID COLONY-STIMULATING FACTOR; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; ALLERGIC BRONCHOPULMONARY MYCOSIS; ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; CD4(+) T-CELLS; RESTORATION DISEASE; INFECTED PATIENTS; RISK-FACTORS AB Background: Although antiretroviral therapy (ART) improves survival in persons with cryptococcal meningitis (CM) and AIDS, ART frequently elicits HIV immune reconstitution inflammatory syndrome (IRIS), an exaggerated and frequently deadly inflammatory reaction that complicates recovery from immunodeficiency. The pathogenesis of IRIS is poorly understood and prediction of IRIS is not possible. Methods and Findings: We prospectively followed 101 ART-naive Ugandans with AIDS and recent CM for one year after initiating ART, and used Luminex multiplex assays to compare serum cytokine levels in participants who did or did not develop IRIS. IRIS occurred in 45% of participants with recent CM on ART, including 30% with central nervous system (CNS) manifestations. The median time to CM-IRIS was 8.8 wk on ART. Overall mortality on ART was 36% with IRIS and 21% without IRIS. CM-IRIS was independently associated with death (HR = 2.3, 95% CI 1.1-5.1, p = 0.04). Patients experiencing subsequent CM-IRIS had 4-fold higher median serum cryptococcal antigen (CRAG) levels pre-ART (p = 0.006). Higher pre-ART levels of interleukin (IL)-4 and IL-17 as well as lower tumor necrosis factor (TNF)-alpha, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and vascular endothelial growth factor (VEGF) predicted future IRIS in multivariate analyses (area under the curve [AUC] = 0.82). An algorithm based on seven pre-ART serum biomarkers was a robust tool for stratifying high (83%), moderate (48%), and low risk (23%) for IRIS in the cohort. After ART was initiated, increasing levels of C-reactive protein (CRP), D-dimer, IL-6, IL-7, IL-13, G-CSF, or IL-1RA were associated with increasing hazard of IRIS by time-to-event analysis (each p <= 0.001). At the time of IRIS onset, multiple proinflammatory cytokine responses were present, including CRP and IL-6. Mortality was predicted by pre-ART increasing IL-17, decreasing GM-CSF, and CRP level >32 mg/l (highest quartile). Pre-ART CRP level >32 mg/l alone was associated with future death (OR = 8.3, 95% CI 2.7-25.6, p<0.001). Conclusions: Pre-ART increases in Th-17 and Th-2 responses (e.g., IL-17, IL-4) and lack of proinflammatory cytokine responses (e.g., TNF-alpha, G-CSF, GM-CSF, VEGF) predispose individuals to subsequent IRIS, perhaps as biomarkers of immune dysfunction and poor initial clearance of CRAG. Although requiring validation, these biomarkers might be an objective tool to stratify the risk of CM-IRIS and death, and could be used clinically to guide when to start ART or use prophylactic interventions. C1 [Boulware, David R.; Meya, David B.; Rhein, Joshua; Lee, Sarah J.; Kambugu, Andrew; Bohjanen, Paul R.] Univ Minnesota, Dept Med, Div Infect Dis & Int Med, Minneapolis, MN 55455 USA. [Boulware, David R.; Wiesner, Darin L.; Rhein, Joshua; Bohjanen, Paul R.] Univ Minnesota, Ctr Infect Dis & Microbiol Translat Res, Minneapolis, MN 55455 USA. [Meya, David B.; Musubire, Abdu; Kambugu, Andrew] Makerere Univ, Infect Dis Inst, Kampala, Uganda. [Bergemann, Tracy L.] Univ Minnesota, Div Biostat, Sch Publ Hlth, Minneapolis, MN 55455 USA. [Janoff, Edward N.] Univ Colorado, Mucosal & Vaccine Res Program Colorado MAVRC, Div Infect Dis, Denver Sch Med,Denver Vet Affairs Med Ctr, Denver, CO 80202 USA. [Bohjanen, Paul R.] Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA. RP Boulware, DR (reprint author), Univ Minnesota, Dept Med, Div Infect Dis & Int Med, Box 736 UMHC, Minneapolis, MN 55455 USA. EM boulw001@umn.edu RI Boulware, David/B-5516-2011; Boulware, David/I-4533-2013; Bohjanen, Paul/B-2329-2015 OI Bohjanen, Paul/0000-0002-2772-3597; Meya, David/0000-0002-4138-240X; Bergemann, Tracy/0000-0003-3902-2605; Boulware, David/0000-0002-4715-0060 FU University of Minnesota Academic Health Center; NIH National Institute of Allergy and Infectious Diseases [T32AI055433-03, L30AI066779, K12RR023247-04, K23AI073192, R03AI078750]; Minnesota Medical Foundation; Tibotec REACH Initiative; University of Minnesota; Academic Alliance Foundation; Mucosal and Vaccine Research Program Colorado; Veterans Affairs Research Service FX This work was supported by the University of Minnesota Academic Health Center (PRB, DBM), NIH National Institute of Allergy and Infectious Diseases (DRB: T32AI055433-03; L30AI066779; K12RR023247-04; K23AI073192. PRB: R03AI078750), Minnesota Medical Foundation (PRB, DRB, DBM), Tibotec REACH Initiative (PRB, DRB, DBM), University of Minnesota Dean's Grant-in-Aid (DRB), Academic Alliance Foundation (AK, DBM), Mucosal and Vaccine Research Program Colorado (ENJ), and the Veterans Affairs Research Service (ENJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 67 TC 105 Z9 105 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD DEC PY 2010 VL 7 IS 12 AR e1000384 DI 10.1371/journal.pmed.1000384 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 697GA UT WOS:000285499600010 PM 21253011 ER PT J AU Elder, GA Mitsis, EM Ahlers, ST Cristian, A AF Elder, Gregory A. Mitsis, Effie M. Ahlers, Stephen T. Cristian, Adrian TI Blast-induced Mild Traumatic Brain Injury SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Blast-related brain injury; Improvised explosive device; Posttraumatic stress disorder; Traumatic brain injury ID POSTTRAUMATIC-STRESS-DISORDER; CENTRAL-NERVOUS-SYSTEM; DIFFUSE AXONAL INJURY; ADULT-RAT BRAIN; PERSISTENT POSTCONCUSSIVE SYMPTOMS; TYMPANIC-MEMBRANE PERFORATION; LASTING IMPULSE NOISE; NON-PENETRATIVE BLAST; WHITE-MATTER INJURY; HEAD-INJURY AB Traumatic brain injury (TBI) has been a major cause of mortality and morbidity in the wars in Iraq and Afghanistan Blast exposure has been the most common cause of TBI, occurring through multiple mechanisms What is less clear is whether the primary blast wave causes brain damage through mechanisms that are distinct from those common in civilian TBI and whether multiple exposures to low-level blast can lead to long-term sequelae Complicating TBI in soldiers is the high prevalence of posttraumatic stress disorder At present the relationship is unclear Resolution of these issues will affect both treatment strategies and strategies for the protection of troops in the field C1 [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA. [Elder, Gregory A.; Mitsis, Effie M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Mitsis, Effie M.; Cristian, Adrian] James J Peters Vet Affairs Med Ctr, Rehabil Med Serv, Bronx, NY 10468 USA. [Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Silver Spring, MD 20910 USA. [Cristian, Adrian] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. RP Elder, GA (reprint author), James J Peters Vet Affairs Med Ctr, Neurol Serv, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. NR 105 TC 73 Z9 74 U1 2 U2 15 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD DEC PY 2010 VL 33 IS 4 BP 757 EP + DI 10.1016/j.psc.2010.08.001 PG 26 WC Psychiatry SC Psychiatry GA 694TA UT WOS:000285320700003 PM 21093677 ER PT J AU Riggio, S AF Riggio, Silvana TI Traumatic Brain Injury and Its Neurobehavioral Sequelae SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Traumatic brain injury; Postconcussive syndrome; Neuropsychiatric disorders; Frontal lobe seizures ID POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; CHRONIC PAIN; PSYCHIATRIC-DISORDERS; SYMPTOMS; FATIGUE; ASSOCIATION; PREVALENCE; CONCUSSION; DISABILITY AB The neurobehavioral sequelae (NBS) of traumatic brain injury (TBI) consist of a spectrum of somatic neurological and psychiatric symptoms The challenge for clinicians lies in understanding the interface of the various symptoms and how they interrelate with other entities Specifically, the challenge is differentiating post-TBI-related symptoms from pre-existing or de novo psychiatric neurological and/or systemic disorders A comprehensive evaluation and a multidisciplinary approach to evaluating patients are essential to be able to develop the differential diagnosis needed to design a management plan that maximizes recovery C1 [Riggio, Silvana] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Riggio, Silvana] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Riggio, Silvana] James J Peters VAMC, Dept Psychiat, Bronx, NY USA. RP Riggio, S (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. NR 46 TC 15 Z9 15 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD DEC PY 2010 VL 33 IS 4 BP 807 EP + DI 10.1016/j.psc.2010.08.004 PG 14 WC Psychiatry SC Psychiatry GA 694TA UT WOS:000285320700006 PM 21093680 ER PT J AU Pasinetti, GM Fivecoat, H Ho, L AF Pasinetti, Giulio Maria Fivecoat, Hayley Ho, Lap TI Personalized Medicine in Traumatic Brain Injury SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Postconscussive traumatic brain injury; MicroRNA; Biomarker; Personalized medicine ID AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; COGNITIVE REHABILITATION; BREAST-CANCER; TASK-FORCE; EXPRESSION; RISK; TAU; CHEMOTHERAPY; MECHANISMS AB Patients who have sustained a mild traumatic brain injury (TBI) from both civilian and military populations exhibit clinical symptoms of varying severity with minimal to profound impact on their daily functioning Although most patients make a full recovery, a subgroup of mild TBI patients develop cognitive somatic, and neurobehavioral sequelae that generally resolve over 3 to 6 months a smaller subgroup develop persisting symptoms The reason why a mild TBI results in varying clinical symptoms is currently unknown Based on evidence that microRNA species in peripheral blood mononuclear cells (PBMCs) may reflect molecular alterations in neurodegenerative disorders it can be hypothesized that at early preclinical phases of the disease PBMC may provide an ideal and clinically assessable window' into the brain Thus it is conceivable that changes in the expression profile of clinically accessible biological indices (biomarkers) such as microRNA in PBMC may reflect molecular alterations C1 [Pasinetti, Giulio Maria; Fivecoat, Hayley; Ho, Lap] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY 10468 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. NR 40 TC 5 Z9 5 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD DEC PY 2010 VL 33 IS 4 BP 905 EP + DI 10.1016/j.psc.2010.09.003 PG 11 WC Psychiatry SC Psychiatry GA 694TA UT WOS:000285320700011 PM 21093685 ER PT J AU Goldstein, G Luther, JF Haas, GL Appelt, CJ Gordon, AJ AF Goldstein, Gerald Luther, James F. Haas, Gretchen L. Appelt, Cathleen J. Gordon, Adam J. TI Factor Structure and Risk Factors for the Health Status of Homeless Veterans SO PSYCHIATRIC QUARTERLY LA English DT Article DE Homeless; Health status; Comorbidity ID SERIOUS MENTAL-ILLNESS AB Homeless veterans have numerous health problems that have been previously characterized as falling into four major subgroups; addiction, psychosis, vascular disorders, and generalized medical and psychiatric illness. Comorbid conditions are common, often involving a combination of psychiatric and medical disorders. Using data from the same survey of homeless veterans that was used to establish these subgroups with cluster analysis, the present study examined the structure of these subgroup patterns through the use of factor analysis. This analysis yielded a five factor solution. They were named "Cardiac", Mood, Stress, Addiction, and Psychosis factors. Factor scores were computed and an odds ratio analysis was accomplished to determine the association between obtaining a high score on a given factor with a number of sociodemographic and homelessness related variables. It was concluded that health status of homeless veterans is a complex condition, but has a clear latent structure demonstrated by factor analysis. Scoring high or low on a particular factor is associated with numerous historical and sociodemographic considerations, notably age, ethnicity, and employment status. C1 [Goldstein, Gerald; Luther, James F.; Haas, Gretchen L.; Appelt, Cathleen J.; Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Goldstein, Gerald; Luther, James F.; Haas, Gretchen L.; Appelt, Cathleen J.; Gordon, Adam J.] Univ Pittsburgh, Pittsburgh, PA USA. [Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. RP Goldstein, G (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. EM ggold@nb.net FU NIMH NIH HHS [T32 MH15169] NR 16 TC 2 Z9 2 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-2720 J9 PSYCHIAT QUART JI Psychiatr. Q. PD DEC PY 2010 VL 81 IS 4 BP 311 EP 323 DI 10.1007/s11126-010-9140-4 PG 13 WC Psychiatry SC Psychiatry GA 666ED UT WOS:000283094300005 PM 20532627 ER PT J AU Denneson, LM Basham, C Dickinson, KC Crutchfield, MC Millet, L Shen, X Dobscha, SK AF Denneson, Lauren M. Basham, Chandra Dickinson, Kathryn C. Crutchfield, Megan C. Millet, Lisa Shen, Xun Dobscha, Steven K. TI Suicide Risk Assessment and Content of VA Health Care Contacts Before Suicide Completion by Veterans in Oregon SO PSYCHIATRIC SERVICES LA English DT Article ID MENTAL-HEALTH; DEPRESSION; POPULATION; STRATEGIES; MORTALITY; VALIDITY; SYSTEM; DEATH; IRAQ AB Objective: This study described health care contacts at a Department of Veterans Affairs (VA) medical center in Oregon in the year before death of veterans who completed suicide. Methods: Oregon Violent Death Reporting System (OVDRS) data and VA administrative data were linked to identify the 112 veterans who completed suicide in Oregon between 2000 and 2005 and who had contact with a single VA medical center in the year before death. Medical records were reviewed to collect data on clinician assessment of suicide risk and reasons for the last contact. Results: In the year before death, 54 veterans (48%) had one or more mental health contacts and 71 (63%) had one or more primary care contacts. The mean age was 57; common diagnoses included mood disorders (38%) and cardiovascular disease (38%). The median number of days between the last contact and date of death was 42 (range=0-358). Thirty-six last contacts (32%) were patient initiated for new or exacerbated medical concerns, and 76 (68%) were follow-ups for ongoing problems. Clinicians noted that 41 patients (37%) were experiencing emotional distress at the last contact. Thirteen of the 18 patients (72%) who were assessed for suicidal ideation at their last contact denied such thoughts. Conclusions: During their last contact, most veterans were seen for routine medical care and few endorsed thoughts of suicide. Results underscore challenges that clinicians face in identifying and caring for veterans at risk of suicide in health care settings. Additional research is indicated to identify better ways to facilitate communication of suicidal thoughts when they are present. (Psychiatric Services 61:1192-1197, 2010) C1 [Denneson, Lauren M.; Dickinson, Kathryn C.; Crutchfield, Megan C.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Portland, OR 97207 USA. [Basham, Chandra] ZoomCare PC, Hillsboro, OR USA. [Millet, Lisa; Shen, Xun] Injury & Violence Prevent Program, Oregon Publ Hlth Div, Portland, OR USA. RP Denneson, LM (reprint author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM lauren.denneson@va.gov FU VA; Veterans Health Administration; VA Health Services [DHI-08-096] FX This article is based on work supported in part by the VA, the Veterans Health Administration, and VA Health Services Research and Development Service Project DHI-08-096. The views expressed are those of the authors and do not necessarily reflect the position or policy of the VA or the U.S. government. NR 23 TC 22 Z9 22 U1 3 U2 5 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD DEC PY 2010 VL 61 IS 12 BP 1192 EP 1197 DI 10.1176/appi.ps.61.12.1192 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 688DE UT WOS:000284829200006 PM 21123402 ER PT J AU Hansen, RA Chen, SY Gaynes, BN Maciejewski, ML AF Hansen, Richard A. Chen, Shih-Yin Gaynes, Bradley N. Maciejewski, Matthew L. TI Relationship of Pharmaceutical Promotion to Antidepressant Switching and Adherence: A Retrospective Cohort Study SO PSYCHIATRIC SERVICES LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; PRESCRIPTION DRUGS; PHARMACY RECORDS; CONSUMER; DEPRESSION; PHYSICIANS; VALIDATION; REQUESTS; THERAPY; IMPACT AB Objective: Patient nonadherence and early discontinuation of antidepressant treatment are common. Pharmaceutical promotion to consumers and physicians may influence this behavior. The objectives of this study were to explore whether promotional spending is related to early antidepressant switching, acute-phase adherence, and continuation-phase adherence. Methods: A retrospective cohort study was conducted with national promotional expenditure data merged with medical and prescription claims data from a large national health plan affiliated with i3 Innovus. Included were records for continuously insured adults with major depression who received a new prescription for an antidepressant: 5,010 were in the cohort assessed for switching, 4,457 were in the cohort assessed for acute-phase adherence, and 1,772 were in the cohort assessed for continuation-phase adherence. National promotional efforts were estimated by examining inflation-adjusted spending on direct-to-consumer advertising (DTCA) and physician detailing. Clinical guidelines were used to create proxies for aspects of treatment outcomes, including antidepressant switching and adherence in the acute phase and adherence in the continuation phase. Logistic regression models estimated the association between promotional variables and these outcomes. Results: Patients taking medications that were more highly promoted to physicians were less likely to switch medications (odds ratio [ OR]=.61) and were more likely to be adherent during the acute phase of treatment (OR=1.13). DTCA had little effect on switching or antidepressant adherence. Conclusions: Detailing to physicians was associated with lower rates of medication switching and had a positive relationship with patient adherence during early antidepressant treatment. This finding indicates that certain aspects of promotion may have beneficial effects on antidepressant use. (Psychiatric Services 61:1232-1238, 2010) C1 [Hansen, Richard A.] Univ N Carolina, Div Pharmaceut Outcomes & Policy, Chapel Hill, NC USA. [Gaynes, Bradley N.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. [Chen, Shih-Yin] United BioSource Corp, Ctr Hlth Econ & Sci Policy, Lexington, MA USA. [Maciejewski, Matthew L.] Duke Univ, US Dept Vet Affairs, Ctr Hlth Serv Res Primary Care, Med Ctr, Durham, NC USA. [Maciejewski, Matthew L.] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27710 USA. RP Hansen, RA (reprint author), Auburn Univ, Harrison Sch Pharm, Dept Pharm Care Syst, 207 Dunstan Hall, Auburn, AL 26849 USA. EM rah0019@auburn.edu OI Gaynes, Bradley/0000-0002-8283-5030; Hansen, Richard/0000-0002-4578-6698 FU American Association of Colleges of Pharmacy; National Institutes of Health [K12RR023248]; Takeda Pharmaceuticals; GlaxoSmithKline; Bristol-Myers Squibb; M-3 Information; Novartis FX A portion of this work was funded by the new investigator program of the American Association of Colleges of Pharmacy. Dr. Hansen was supported by grant K12RR023248 from the National Institutes of Health at the time of this work. The authors thank Emily Brouwer, Pharm.D., for her contributions to data management; David Ridley, Ph.D., for his contribution to study design; and Julie Donohue, Ph.D., for her insightful comments on the manuscript.; Dr. Hansen has received consulting fees and research support from Takeda Pharmaceuticals and GlaxoSmithKline. Dr. Gaynes has received consulting fees and research support from Bristol-Myers Squibb, M-3 Information, and Novartis, and he has served as an advisor to Bristol-Myers Squibb. Dr. Maciejewski has received consulting fees from Takeda Pharmaceuticals. Dr. Chen reports no competing interests. NR 35 TC 6 Z9 7 U1 3 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD DEC PY 2010 VL 61 IS 12 BP 1232 EP 1238 DI 10.1176/appi.ps.61.12.1232 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 688DE UT WOS:000284829200012 PM 21123408 ER PT J AU Phelan, CH Love, GD Ryff, CD Brown, RL Heidrich, SM AF Phelan, Cynthia H. Love, Gayle D. Ryff, Carol D. Brown, Roger L. Heidrich, Susan M. TI Psychosocial Predictors of Changing Sleep Patterns in Aging Women A Multiple Pathway Approach SO PSYCHOLOGY AND AGING LA English DT Article DE sleep older women; psychological well being; depression; health ID QUALITY-OF-LIFE; OLDER-ADULTS; COMPLAINTS; HEALTH; COMMUNITY; PREVALENCE; INSOMNIA; MODEL; INDEX; INTERLEUKIN-6 AB The authors of this investigation sought to examine changes in the sleep quality of older women over time and to determine whether dimensions of psychological well being health (subjective health and number of illnesses) and psychological distress (depression and anxiety) predict these changes A secondary analysis was conducted with a longitudinal sample of aging women (Kwan Love Ryff & Essex 2003) Of 518 community dwelling older women in the parent study, 115 women (baseline M age = 67 years SD = 7 18) with data at baseline, 8 years, and 10 years were used for this investigation Participants completed self administered questionnaires and participated in in home interviews and observations Growth curve modeling was used to examine the overall linear trajectories of sleep quality Growth mixture modeling was used to examine whether there were different patterns of change in sleep quality over time and to examine baseline predictors of each pattern Sleep quality declined over time but not for all women Two distinctly different sleep patterns emerged good but declining sleep quality and disrupted sleep quality Higher psychological well being (positive relations with others environmental mastery personal growth purpose in life and self acceptance) fewer Illnesses and lower depression scores at baseline predicted reduced odds for membership in the disrupted sleep group Future research is needed to examine whether interventions focused on maintaining or enhancing psychological well being could minimize later life declines in sleep quality C1 [Phelan, Cynthia H.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. [Love, Gayle D.; Ryff, Carol D.] Univ Wisconsin, Inst Aging, Madrid, Spain. [Brown, Roger L.; Heidrich, Susan M.] Univ Wisconsin, Sch Nursing, Madison, WI USA. RP Phelan, CH (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, 2500 Overlook Terrace, Madison, WI 53705 USA. FU NCRR NIH HHS [M01 RR003186, M01 RR003186-20, M01 RR03186]; NIA NIH HHS [R01-AG0879]; NIMH NIH HHS [P50 MH061083, P50 MH061083-01, P50 MH61083] NR 52 TC 19 Z9 20 U1 2 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0882-7974 J9 PSYCHOL AGING JI Psychol. Aging PD DEC PY 2010 VL 25 IS 4 BP 858 EP 866 DI 10.1037/a0019622 PG 9 WC Gerontology; Psychology, Developmental SC Geriatrics & Gerontology; Psychology GA 701IM UT WOS:000285811600012 PM 20731498 ER PT J AU Lozano, BE Stephens, RS AF Lozano, Brian E. Stephens, Robert S. TI Comparison of Participatively Set and Assigned Goals in the Reduction of Alcohol Use SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE goal setting; alcohol; college students; social cognitive theory ID COLLEGE-STUDENT DRINKERS; SELF-EFFICACY; CONSTRUCT-VALIDITY; TASK-PERFORMANCE; FOLLOW-UP; CONTROLLED DRINKING; SETTING PROCESS; COMMITMENT; ABSTINENCE; ACCEPTANCE AB The effects of setting goals on goal commitment, self-efficacy for goal achievement, and goal achievement in the context of an alcohol use intervention were examined using an experimental design in which participants were randomized to participatively set goals. assigned goals. and no goal conditions. One hundred and twenty-six heavy-drinking college students received a single cognitive-behavioral assessment/intervention session and completed measures of goal commitment. self-efficacy for goal achievement, and alcohol use. Results were consistent with, and expanded upon, previous research by demonstrating that having a goal for limiting alcohol consumption was predictive of lower quantity and frequency of alcohol use relative to not having a goal. Participation in goal setting yielded greater goal commitment and self-efficacy for goal achievement than assigned goals. but did not result in significantly greater reductions in alcohol use relative to assigned goals. Goal commitment and self-efficacy explained unique variance in the prediction of alcohol use at follow-up. Findings support the importance of goal setting in alcohol interventions and suggest areas for further research. C1 [Lozano, Brian E.] Ralph H Johnson VAMC, Mental Hlth Serv 116, Charleston, SC 29401 USA. [Stephens, Robert S.] Virginia Polytech Inst & State Univ, Dept Psychol, Blacksburg, VA 24061 USA. RP Lozano, BE (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM Brian.Lozano@va.gov NR 61 TC 11 Z9 11 U1 3 U2 8 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD DEC PY 2010 VL 24 IS 4 BP 581 EP 591 DI 10.1037/a0021444 PG 11 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA 705WJ UT WOS:000286171100004 PM 21198221 ER PT J AU Kim, HJ Park, SH Pickhardt, PJ Yoon, SN Lee, SS Yee, J Kim, DH Kim, AY Kim, JC Yu, CS Ha, HK AF Kim, Hye Jin Park, Seong Ho Pickhardt, Perry J. Yoon, Sang Nam Lee, Seung Soo Yee, Judy Kim, David H. Kim, Ah Young Kim, Jin Cheon Yu, Chang Sik Ha, Hyun Kwon TI CT Colonography for Combined Colonic and Extracolonic Surveillance after Curative Resection of Colorectal Cancer SO RADIOLOGY LA English DT Article ID COMPUTED TOMOGRAPHIC COLONOGRAPHY; FOLLOW-UP; ADVANCED NEOPLASIA; COLONOSCOPY; POPULATION; EXPERIENCE; RISK; FEASIBILITY; RECURRENCE; ADENOMAS AB Purpose: To determine the accuracy of contrast material-enhanced computed tomographic (CT) colonography for postoperative surveillance in colorectal cancer patients without clinical or laboratory evidence of disease recurrence. Materials and Methods: The Institutional Review Board approved this HIPAA-compliant study and waived informed consent. Between January 2006 and December 2007, 742 consecutive patients without clinical or laboratory evidence of recurrence following curative-intent colorectal cancer surgery underwent contrast-enhanced CT colonography. Of these, 548 patients who had subsequent colonoscopy and pathologic confirmation of colonic lesions (reference standard) were included in the colonic analysis. All 742 patients were included in the extracolonic analysis. Sensitivity and specificity of CT colonography for nonanastomotic colonic lesions at least 6 mm in size and anastomotic lesions of any size, including performance according to lesion histologic type, were determined. Diagnostic yields of contrast-enhanced CT colonography for colonic cancers and for extracolonic recurrences were obtained. Results: CT colonography depicted all six metachronous cancers and one anastomotic recurrence within the colon in six patients (0.8%; 95% confidence interval [CI]: 0.3%, 1.8%]), for per-patient and per-lesion sensitivities of 100% (95% CIs: 64.3%, 100% and 67.8%, 100%, respectively). All cancer lesions within the colon were amenable to additional curative treatment. CT colonography per-patient and per-lesion sensitivity was 81.8% (95% CI: 60.9%, 93.3%) and 80.8% (95% CI: 64.3%, 97.2%), respectively, for advanced neoplasia and 80.0% (95% CI: 68.6%, 88.1%) and 78.5% (95% CI: 68.3%, 88.7%), respectively, for all adenomatous lesions. Negative predictive values for adenocarcinoma, advanced neoplasia, and all adenomatous lesions were 100%, 99.1%, and 97.0%, respectively. CT colonography specificity was 93.1% (95% CI: 90.4%, 95.2%). Contrast-enhanced CT colonography enabled detection of extracolonic recurrences in an additional 11 patients (1.5%; 95% CI: 0.8%, 2.7%). Conclusion: Contrast-enhanced CT colonography is an accurate and practical surveillance tool following colorectal cancer surgery in patients without clinical or laboratory evidence of recurrence, allowing for simultaneous less-invasive evaluation of both colon and extracolonic organs. (C)RSNA, 2010 C1 [Kim, Hye Jin; Park, Seong Ho; Lee, Seung Soo; Kim, Ah Young; Ha, Hyun Kwon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul 138736, South Korea. [Kim, Hye Jin; Park, Seong Ho; Lee, Seung Soo; Kim, Ah Young; Ha, Hyun Kwon] Univ Ulsan, Coll Med, Asan Med Ctr, Res Inst Radiol, Seoul 138736, South Korea. [Yoon, Sang Nam; Kim, Jin Cheon; Yu, Chang Sik] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul 138736, South Korea. [Pickhardt, Perry J.; Kim, David H.] Univ Wisconsin, Sch Med, Dept Radiol, Madison, WI USA. [Yee, Judy] Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, Dept Radiol, San Francisco, CA 94143 USA. RP Park, SH (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Asanbyeongwon Gil 86, Seoul 138736, South Korea. EM seonghopark@paran.com OI Park, Seong Ho/0000-0002-1257-8315 FU NCI NIH HHS [R01 CA144835] NR 29 TC 28 Z9 30 U1 2 U2 5 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD DEC PY 2010 VL 257 IS 3 BP 697 EP 704 DI 10.1148/radiol.10100385 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 683IL UT WOS:000284469300014 PM 20876390 ER PT J AU Bespalova, IN Durner, M Ritter, BP Angelo, GW Rossy-Fullana, E Carrion-Baralt, J Schmeidler, J Silverman, JM AF Bespalova, Irina N. Durner, Martina Ritter, Benjamin P. Angelo, Gary W. Rossy-Fullana, Enrique Carrion-Baralt, Jose Schmeidler, James Silverman, Jeremy M. TI Non-synonymous variants in the AMACR gene are associated with schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; 5p13; AMACR; Genetic association; Case control study ID METHYLACYL-COA-RACEMASE; 409 EUROPEAN-ANCESTRY; GENOME-WIDE SCAN; PROSTATE-CANCER; FATTY-ACIDS; REVEALS ALTERATIONS; GENDER-DIFFERENCES; EXPRESSION; LOCUS; RISK AB Background The AMACR gene is located in the schizophrenia susceptibility locus on chromosome 5p13 previously identified in a large Puerto Rican pedigree of Spanish origin The AMACR-encoded protein is an enzyme involved in the metabolism of branched chain fatty and bile acids The enzyme deficiency causes structural and functional brain changes and disturbances in fatty acid and oxidative phosphorylation pathways observed in individuals with schizophrenia Therefore AMACR is both a positional and functional candidate gene for susceptibility to schizophrenia Methods The study had a two step design we performed mutation analysis of the coding and flanking regions of AMACR in affected members of the pedigree and tested the detected sequence variants for association with schizophrenia in a Puerto Rican case-control sample (n = 383) of Spanish descent Results and conclusion We identified three missense variants segregating with the disorder in the family rs2278008 rs2287939 and rs10941112 Two of them rs2278008 and rs2287939 demonstrated significant differences in genotype (P = 4 x 10(-4) P = 4 x 10(-4)) and allele (P = 1 x10(-4) P = 9 5 x 10(-5)) frequencies in unrelated male patients compare to controls with the odds ratios (OR) 2 24 (95% Cl 1 48-3 40) and 225 (95% Cl 1 49-3 38) respectively The G-C-G haplotype of rs2278008-rs2287939 rs10941112 revealed the most significant association with schizophrenia (P = 425 x 10(-6) OR = 2 96 95% Cl 1 85-4 76) in male subjects There were no statistically significant differences in genotype allele and haplotype frequencies between female schizophrenia subjects and controls Our results suggest that AMACR may play a significant role in susceptibility to schizophrenia in male patients (C) 2010 Elsevier B V All rights reserved C1 [Bespalova, Irina N.; Durner, Martina; Ritter, Benjamin P.; Angelo, Gary W.; Schmeidler, James; Silverman, Jeremy M.] Mt Sinai Med Ctr, Dept Psychiat, New York, NY 10029 USA. [Bespalova, Irina N.; Durner, Martina; Ritter, Benjamin P.; Angelo, Gary W.; Silverman, Jeremy M.] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Rossy-Fullana, Enrique] San Juan Vet Affairs Med Ctr, San Juan, PR USA. [Carrion-Baralt, Jose] Univ Puerto Rico, San Juan, PR 00936 USA. RP Bespalova, IN (reprint author), Mt Sinai Med Ctr, Dept Psychiat, 1 Gustave Levy Pl,Box 1230, New York, NY 10029 USA. FU National Alliance for Research on Schizophrenia and Depression (NARSAD); National Institute of Mental Health (NIMH) [RO3MH082134 01, RO3MH082134]; Department of Veterans Affairs (VA); NINDC [R01NS37466] FX Funding for this study was provided by the National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award to INB the National Institute of Mental Health (NIMH) Award RO3MH082134 01 to INB and The Department of Veterans Affairs (VA) Merit Award to JMS The funding sources had no further role in study design in the collection analysis and interpretation of data; The authors thank all the subjects for their participation in the study and Mount Sinai Core Facility for sequencing our samples This study was supported by the NIMH Award RO3MH082134 (INB) the NARSAD Young Investigator Award (INB) the NINDC Award R01NS37466 (MD) and the Department of Veterans Affairs Merit Award (JMS) NR 73 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2010 VL 124 IS 1-3 BP 208 EP 215 DI 10.1016/j.schres.2010.08.040 PG 8 WC Psychiatry SC Psychiatry GA 694UE UT WOS:000285323700028 PM 20875727 ER PT J AU Conhaim, RL Mangino, MJ Dovi, WF Watson, KE Warner, TF Harms, BA AF Conhaim, Robert L. Mangino, Martin J. Dovi, William F. Watson, Kal E. Warner, Thomas F. Harms, Bruce A. TI MICROTHROMBUS FORMATION MAY TRIGGER LUNG INJURY AFTER ACUTE BLOOD LOSS SO SHOCK LA English DT Article DE Acute lung injury; shock lung; acute respiratory distress syndrome; pulmonary microcirculation; microcirculatory thrombosis ID INTERALVEOLAR PERFUSION; RAT LUNGS; SEPSIS AB We showed previously that acute blood loss, without resuscitation, caused marked maldistribution of interalveolar perfusion. Because hemorrhage is a known risk factor for the development of lung injury, the goal of our present studies was to determine if there was a correlation between perfusion maldistribution and the subsequent development of lung injury after blood loss. Specifically, we wanted to know if the perfusion maldistribution might be due to microthrombus formation and/or leukocyte sequestration within the pulmonary microcirculation. We bled rats (30% blood loss) and harvested their lungs 45 min or 24 h later. Lungs were prepared for perfusion distribution analysis, Western blot analysis to measure whole-lung fibrinogen concentrations, and for immunohistochemistry to measure fibrin deposition and leukocyte deposition (CD16 fluorescence). Perfusion was significantly maldistributed at 45 min and 24 h (P < 0.05). At 45 min, whole-lung fibrinogen concentrations were less than half that in controls (P < 0.05), whereas numbers of fibrin microthrombi were 2.5-fold greater than control by 45 min (not statistically significant) and were 4.5-fold greater by 24 h (P = 0.01). Leukocyte deposition was two-fold greater than control by 45 min (not statistically significant) and was 4-fold greater by 24 h (P = 0.02). Fibrin-to-leukocyte nearest-neighbor distances remained unchanged (18.1 [SD, 1.1] mu m) even as the numbers of both increased with time after blood loss. Our results suggest that soluble fibrinogen polymerized to insoluble fibrin within minutes after acute blood loss, which caused perfusion maldistribution and attracted leukocytes. The development of lung injury after blood loss may be a consequence of leukocyte chemoattraction to fibrin microthrombi that seem to form within minutes after blood loss. C1 [Conhaim, Robert L.; Watson, Kal E.; Harms, Bruce A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Conhaim, Robert L.; Dovi, William F.; Warner, Thomas F.; Harms, Bruce A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Mangino, Martin J.] Virginia Commonwealth Univ, Dept Surg, Richmond, VA USA. RP Conhaim, RL (reprint author), H5-301 BX3236,600 Highland Ave, Madison, WI 53792 USA. EM conhaim@surgery.wisc.edu FU Department of Veterans Affairs FX This study was supported by a grant from the Department of Veterans Affairs. NR 17 TC 8 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1073-2322 J9 SHOCK JI Shock PD DEC PY 2010 VL 34 IS 6 BP 601 EP 607 DI 10.1097/SHK.0b013e3181e46e2a PG 7 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA 680LW UT WOS:000284234400009 PM 20442694 ER PT J AU Seelig, AD Jacobson, IG Smith, B Hooper, TI Boyko, EJ Gackstetter, GD Gehrman, P Macera, CA Smith, TC AF Seelig, Amber D. Jacobson, Isabel G. Smith, Besa Hooper, Tomoko I. Boyko, Edward J. Gackstetter, Gary D. Gehrman, Philip Macera, Carol A. Smith, Tyler C. CA Millennium Cohort Study Team TI Sleep Patterns Before, During, and After Deployment to Iraq and Afghanistan SO SLEEP LA English DT Article DE Sleep; deployment; Millennium Cohort; mental health; veterans ID POSTTRAUMATIC-STRESS-DISORDER; MILITARY DEPLOYMENT; MILLENNIUM COHORT; GENERAL-POPULATION; COMBAT DEPLOYMENT; DECISION-MAKING; YOUNG-ADULTS; DURATION; DEPRIVATION; HEALTH AB Study Objectives: To determine the associations between deployment in support of the wars in Iraq and Afghanistan and sleep quantity and quality. Design: Longitudinal cohort study Setting: The Millennium Cohort Study survey is administered via a secure website or US mail. Participants: Data were from 41,225 Millennium Cohort members who completed baseline (2001-2003) and follow-up (2004-2006) surveys. Participants were placed into 1 of 3 exposure groups based on their deployment status at follow-up: nondeployed, survey completed during deployment, or survey completed postdeployment. Interventions: N/A Measurements and Results: Study outcomes were self-reported sleep duration and trouble sleeping, defined as having trouble falling asleep or staying asleep. Adjusted mean sleep duration was significantly shorter among those in the deployed and postdeployment groups compared with those who did not deploy. Additionally, male gender and greater stress were significantly associated with shorter sleep duration. Personnel who completed their survey during deployment or postdeployment were significantly more likely to have trouble sleeping than those who had not deployed. Lower self-reported general health, female gender, and reporting of mental health symptoms at baseline were also significantly associated with increased odds of trouble sleeping. Conclusions: Deployment significantly influenced sleep quality and quantity in this population though effect size was mediated with statistical modeling that included mental health symptoms. Personnel reporting combat exposures or mental health symptoms had increased odds of trouble sleeping. These findings merit further research to increase understanding of temporal relationships between sleep and mental health outcomes occurring during and after deployment. C1 [Seelig, Amber D.; Jacobson, Isabel G.; Smith, Besa; Smith, Tyler C.] USN, Hlth Res Ctr, Dept Deployment Hlth Res, San Diego, CA 92106 USA. [Hooper, Tomoko I.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Gackstetter, Gary D.] Analyt Serv Inc ANSER, Arlington, VA USA. [Gehrman, Philip] Univ Penn, Dept Psychiat, Penn Sleep Ctr, Philadelphia, PA 19104 USA. [Seelig, Amber D.; Macera, Carol A.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA. RP Seelig, AD (reprint author), USN, Hlth Res Ctr, Dept Deployment Hlth Res, 140 Sylvester Rd, San Diego, CA 92106 USA. EM amber.seelig@med.navy.mil OI Boyko, Edward/0000-0002-3695-192X FU Henry M. Jackson Foundation FX In addition to the authors, the Millennium Cohort Study Team includes Melissa Bagnell, Lacy Farnell, Gia Gumbs, Nisara Granado, Jaime Horton, Kelly Jones, Molly Kelton, Cynthia LeardMann, Travis Leleu, Gordon Lynch, Jamie McGrew, Amanda Pietrucha, Teresa Powell, Donald Sandweiss, Beverly Sheppard, Katherine Snell, Steven Spiegel, Kari Welch, Martin White, James Whitmer, and Charlene Wong, from the Department of Deployment Health Research, Naval Health Research Center, San Diego, CA; Paul Amoroso, from the Madigan Army Medical Center, Tacoma, WA; Gregory Gray, from the College of Public Health and Health Professions, University of Florida, Gainesville, FL; James Riddle; Margaret Ryan from the Naval Hospital Camp Pendleton, Camp Pendleton, CA; and Timothy Wells from the US Air Force Research Laboratory, Wright-Patterson Air Force Base, OH.; The authors thank the Millennium Cohort Study participants, without whom these analyses would not be possible. We thank Scott Seggerman from the Management Information Division, US Defense Manpower Data Center, Monterey, CA; Michelle Stoia from the Naval Health Research Center; and all the professionals from the US Army Medical Research and Materiel Command, especially those from the Military Operational Medicine Research Program, Fort Detrick, MD. We appreciate the support of the Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD. NR 41 TC 65 Z9 65 U1 1 U2 11 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD DEC 1 PY 2010 VL 33 IS 12 BP 1615 EP 1622 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 686TZ UT WOS:000284719900006 PM 21120123 ER PT J AU Leger, D Partinen, M Hirshkowitz, M Chokroverty, S Hedner, J AF Leger, Damien Partinen, Markku Hirshkowitz, Max Chokroverty, Sudhansu Hedner, Jan CA EQUINOX Evaluation Daytime QUality TI Characteristics of insomnia in a primary care setting: EQUINOX survey of 5293 insomniacs from 10 countries SO SLEEP MEDICINE LA English DT Article DE Insomnia; Epidemiology; Difficulties initiating sleep; Difficulties maintaining sleep; Nocturnal awakenings; Non restorative sleep; Primary care ID GENERAL-POPULATION; SLEEP; PREVALENCE; ADULTS; COMPLAINTS AB Objective: To describe the characteristics of insomnia in primary care physicians' (PCPs') practices in 10 countries and to understand how the difficulty of maintaining sleep (DMS) was or was not associated with other insomnia symptoms such as difficulty initiating sleep (DIS), early morning awakenings (EMA) or nonrestorative sleep (NRS) in PCPs patients with insomnia. Methods: International, noninterventional, cross-sectional, observational survey conducted in a primary care setting in subjects complaining of sleep disturbances in 10 countries. A questionnaire based on DSM-IV and ICSD criteria was administered. Results: Thirteen thousand one hundred twenty-four subjects were enrolled by 647 physicians; 5293 of them (32.6%) had insomnia and were surveyed. The population was predominantly female (63.9%) with a mean age of 47.8 +/- 15.3 years; 39.9% of these patients have already been treated for sleep difficulties. Combination of all types of insomnia symptoms (DIS + DMS + EMA + NRS) was the most frequently reported combination (38.6% of the subjects), while the percentage of subjects presenting with only one type of insomnia symptom (DIS, DMS, EMA or NRS) was very low: 3%, 1.8%, 0.9% and 1.4% respectively. DMS was on average the most commonly reported insomnia symptom (80.2%). Multiple logistic regression showed that DMS, EMA and NRS symptoms were significantly linked with each other and also to other insomnia criteria (sleep satisfaction, sleep quality, sleep duration, number of hours of sleep, frequency of insomnia symptoms, wake up rested / unrested and non restorative sleep). Conclusions: Patients visiting PCPs with insomnia are likely to present with severe and poly-symptomatic insomnia. (C) 2010 Elsevier B.V. All rights reserved. C1 [Leger, Damien] Univ Paris 05, APHP, Ctr Sommeil & Vigilance, Hotel Dieu Paris, F-75004 Paris, France. [Partinen, Markku] Rinnekoti Res Ctr, Skogby Sleep Clin, Espoo, Finland. [Hirshkowitz, Max] VA Med Ctr, Sleep Disorders & Res Ctr, Houston, TX USA. [Chokroverty, Sudhansu] JFK Med Ctr, New Jersey Neurosci Inst, Edison, NJ USA. [Hedner, Jan] Sahlgrens Univ Hosp, Dept Resp Med & Allergol, Sleep Lab Unit, Gothenburg, Sweden. RP Leger, D (reprint author), Univ Paris 05, Pl Parvis Notre Dame, F-75181 Paris 04, France. EM damien.leger@htd.aphp.fr FU Sanofi Aventis FX This survey has been supported by Sanofi Aventis. All authors have been sponsored to design the protocol and review the data as a scientific advisory board. NR 29 TC 21 Z9 21 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1389-9457 J9 SLEEP MED JI Sleep Med. PD DEC PY 2010 VL 11 IS 10 SI SI BP 987 EP 998 DI 10.1016/j.sleep.2010.04.019 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA 704AD UT WOS:000286022600006 PM 21093363 ER PT J AU Leger, D Partinen, M Hirshkowitz, M Chokroverty, S Touchette, E Hedner, J AF Leger, Damien Partinen, Markku Hirshkowitz, Max Chokroverty, Sudhansu Touchette, Evelyne Hedner, Jan CA EQUINOX Evaluation Daytime QUality TI Daytime consequences of insomnia symptoms among outpatients in primary care practice: EQUINOX international survey SO SLEEP MEDICINE LA English DT Article DE Insomnia; Difficulty initiating sleep; Difficulty maintaining sleep; Early morning awakening; Non-restorative sleep; Daytime consequences; International survey ID QUALITY-OF-LIFE; GENERAL-POPULATION; PSYCHIATRIC-DISORDERS; SLEEP DISTURBANCES; PREVALENCE; ADULTS; MANAGEMENT; COMPLAINTS; IMPACT AB Objective: To assess the daytime consequences in outpatients suffering from different insomnia symptoms in primary care practice. Methods: An international cross-sectional survey was conducted in 5293 outpatients complaining of sleep disturbances in primary care practice. A sleep questionnaire addressing daytime consequences, insomnia symptoms, socio-demographic characteristics, and other sleep variables was administered by 647 physicians in 10 countries. Results: Overall, 20-33% of subjects reported "severe" daytime impairments associated with sleep disturbances. Approximately 45% of patients complaining of sleep disturbances in primary, care practice suffered from a combination of insomnia symptoms. Patients suffering from all insomnia symptoms reported the most severe daytime functioning impairments compared with patients suffering from initiation or maintenance insomnia only. Conversely, the majority of patients suffering from non-restorative sleep reported little daytime functioning impairments compared to the patients suffering from other combinations of insomnia symptoms. The strongest risk factor associated with "severe" daytime functioning impairments was sleep quality perception. Conclusions: Primary insomnia disturbs subjective daytime functioning. A report of combined insomnia symptoms reflected the most damaging insomnia subtype and had a negative impact on a wide range of daytime functioning consequences. (C) 2010 Elsevier B.V. All rights reserved. C1 [Leger, Damien; Touchette, Evelyne] Univ Paris 05, APHP, Ctr Sommeil & Vigilance, Hotel Dieu Paris, F-75181 Paris 04, France. [Partinen, Markku] Rinnekoti Res Ctr, Skogby Sleep Clin, Espoo, Finland. [Hirshkowitz, Max] VA Med Ctr, Sleep Disorders & Res Ctr, Houston, TX USA. [Chokroverty, Sudhansu] JFK Med Ctr, New Jersey Neurosci Inst, Edison, NJ USA. [Hedner, Jan] Sahlgrens Univ Hosp, Dept Resp Med & Allergol, Sleep Lab Unit, Gothenburg, Sweden. RP Leger, D (reprint author), Univ Paris 05, APHP, Ctr Sommeil & Vigilance, Hotel Dieu Paris, 1 Pl Parvis Notre Dame, F-75181 Paris 04, France. EM damien.leger@htd.aphp.fr RI Touchette, Evelyne/A-3592-2013 OI Touchette, Evelyne/0000-0002-0557-9352 FU Sanofi-Aventis FX This survey has been supported by Sanofi-Aventis. All authors have been sponsored to design the protocol and review the data as a scientific advisory board. NR 31 TC 11 Z9 14 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1389-9457 J9 SLEEP MED JI Sleep Med. PD DEC PY 2010 VL 11 IS 10 SI SI BP 999 EP 1009 DI 10.1016/j.sleep.2010.04.018 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA 704AD UT WOS:000286022600007 PM 20965779 ER PT J AU Livingston, JD Boyd, JE AF Livingston, James D. Boyd, Jennifer E. TI Correlates and consequences of internalized stigma for people living with mental illness: A systematic review and meta-analysis SO SOCIAL SCIENCE & MEDICINE LA English DT Review DE Stigma; Mental illness; Meta-analysis; Systematic review ID QUALITY-OF-LIFE; SCHIZOPHRENIA SPECTRUM DISORDERS; MODIFIED LABELING THEORY; DEPRESSION SELF-STIGMA; PRIMARY-CARE PATIENTS; STRESS-COPING MODEL; PERCEIVED STIGMA; HEALTH-SERVICES; SOCIAL ANXIETY; PSYCHIATRIC OUTPATIENTS AB An expansive body of research has investigated the experiences and adverse consequences of internalized stigma for people with mental illness. This article provides a systematic review and meta-analysis of the extant research regarding the empirical relationship between internalized stigma and a range of sociodemographic, psychosocial, and psychiatric variables for people who live with mental illness. An exhaustive review of the research literature was performed on all articles published in English that assessed a statistical relationship between internalized stigma and at least one other variable for adults who live with mental illness. In total, 127 articles met the inclusion criteria for systematic review, of which, data from 45 articles were extracted for meta-analyses. None of the sociodemographic variables that were included in the study were consistently or strongly correlated with levels of internalized stigma. The review uncovered a striking and robust negative relationship between internalized stigma and a range of psychosocial variables (e.g., hope, self-esteem, and empowerment). Regarding psychiatric variables, internalized stigma was positively associated with psychiatric symptom severity and negatively associated with treatment adherence. The review draws attention to the lack of longitudinal research in this area of study which has inhibited the clinical relevance of findings related to internalized stigma. The study also highlights the need for greater attention on disentangling the true nature of the relationship between internalized stigma and other psychosocial variables. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Livingston, James D.] Prov Hlth Serv Author, BC Mental Hlth Serv, Forens Psychiat Serv Commiss, Port Coquitlam, BC V3C 5X9, Canada. [Livingston, James D.] Prov Hlth Serv Author, Addict Serv, Forens Psychiat Serv Commiss, Port Coquitlam, BC V3C 5X9, Canada. [Livingston, James D.] Simon Fraser Univ, Sch Criminol, Burnaby, BC V5A 1S6, Canada. [Boyd, Jennifer E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Boyd, Jennifer E.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Livingston, JD (reprint author), Prov Hlth Serv Author, BC Mental Hlth Serv, Forens Psychiat Serv Commiss, 70 Colony Farm Rd, Port Coquitlam, BC V3C 5X9, Canada. EM jlivingston@forensic.bc.ca NR 171 TC 286 Z9 299 U1 16 U2 130 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD DEC PY 2010 VL 71 IS 12 BP 2150 EP 2161 DI 10.1016/j.socscimed.2010.09.030 PG 12 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 702RN UT WOS:000285912300013 PM 21051128 ER PT J AU Smith, MW Chen, S Siroka, AM Hamlett-Berry, K AF Smith, Mark W. Chen, Shuo Siroka, Andrew M. Hamlett-Berry, Kim TI Using policy to increase prescribing of smoking cessation medications in the VA healthcare system SO TOBACCO CONTROL LA English DT Article ID TOBACCO-DEPENDENCE TREATMENT; SUSTAINED-RELEASE BUPROPION; NICOTINE PATCH; SERVICES; LESSONS AB Background Since 2002 the US Veterans Affairs (VA) healthcare system has initiated national policies and programmes to reduce smoking among its patients and to increase evidence-based treatment for smoking. Objective To document changes in dispensing rates of cessation-related medications in VA from 2004 to 2008. Design Retrospective analysis of VA administrative data. Results Prescription fills for nicotine replacement therapy (NAT), and for bupropion among NAT users, each grew more than 60% in four years. The increase stemmed primarily from treating more people rather than from filling more prescriptions per person. Conclusion The results provide strong support for the efficacy of these policies and illustrate how healthcare systems can successfully employ multiple strategies to increase evidence-based smoking-cessation treatment. C1 [Smith, Mark W.; Chen, Shuo; Siroka, Andrew M.] Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA USA. [Smith, Mark W.] Stanford Med Sch, Ctr Primary Care & Outcomes Res, Stanford, CA USA. [Hamlett-Berry, Kim] US Dept Vet Affairs, Publ Hlth Strateg Hlth Care Grp, Off Publ Hlth Policy & Prevent, Washington, DC USA. RP Smith, MW (reprint author), VA Palo Alto Hlth Care Syst 650 617 2630, Hlth Econ Resource Ctr, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA. EM mark.smith9@va.gov RI Smith, Mark/G-1522-2012 OI Smith, Mark/0000-0002-4582-9088 FU Clinical Science Research and Development Service, US Department of Veterans Affairs [519] FX Funding was provided by the Cooperative Studies Program of the Clinical Science Research and Development Service, US Department of Veterans Affairs (CSP #519). The views expressed here are those of the authors and riot necessarily those of the US Department of Veterans Affairs. NR 27 TC 8 Z9 8 U1 1 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0964-4563 J9 TOB CONTROL JI Tob. Control PD DEC PY 2010 VL 19 IS 6 BP 507 EP 511 DI 10.1136/tc.2009.035147 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 681WI UT WOS:000284353800020 PM 20870742 ER PT J AU Morgan, KL Estevez, AO Mueller, CL Cacho-Valadez, B Miranda-Vizuete, A Szewczyk, NJ Estevez, M AF Morgan, Kathleen L. Estevez, Annette O. Mueller, Catherine L. Cacho-Valadez, Briseida Miranda-Vizuete, Antonio Szewczyk, Nathaniel J. Estevez, Miguel TI The Glutaredoxin GLRX-21 Functions to Prevent Selenium-Induced Oxidative Stress in Caenorhabditis elegans SO TOXICOLOGICAL SCIENCES LA English DT Article DE selenium; antioxidant; toxicity; glutaredoxin; glutathione; glrx-21 ID AMYOTROPHIC-LATERAL-SCLEROSIS; THIOREDOXIN REDUCTASE; REDUCED GLUTATHIONE; CANCER PREVENTION; SODIUM SELENITE; AQUATIC BIRDS; DNA-DAMAGE; CELL-DEATH; C-ELEGANS; TOXICITY AB Selenium is an essential micronutrient that functions as an antioxidant. Yet, at higher concentrations, selenium is pro-oxidant and toxic. In extreme cases, exposures to excess selenium can lead to death or selenosis, a syndrome characterized by teeth, hair and nail loss, and nervous system alterations. Recent interest in selenium as an anti- tumorigenic agent has reemphasized the need to understand the mechanisms underlying the cellular consequences of increased selenium exposure. We show here, that in the nematode, Caenorhabditis elegans, selenium has a concentration range in which it functions as an antioxidant, but beyond this range it exhibits a dose- and time-dependent lethality. Oxidation-induced fluorescence emitted by the dye, carboxy-H(2)DCFDA, indicative of reactive oxygen species formation was significantly higher in animals after a brief exposure to 5mM sodium selenite. Longer-term exposures lead to a progressive selenium-induced motility impairment that could be partially prevented by coincident exposure to the cellular antioxidant-reduced glutathione. The C elegans glrx-21 gene belongs to the family of glutaredoxins (glutathione-dependent oxidoreductases) and the glrx-21(tm2921) allele is a null mutation that renders animals hypersensitive for the selenium-induced motility impairment, but not lethality. In addition, the lethality of animals with the tm2921 mutation exposed to selenium was unaffected by the addition of reduced glutathione, suggesting that GLRX-21 is required for glutathione to moderate this selenium-induced lethality. Our findings provide the first description of selenium-induced toxicity in C elegans and support its use as a model for elucidating the mechanisms of selenium toxicity. C1 [Morgan, Kathleen L.; Estevez, Miguel] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev 151U, Dept Neurol, Pittsburgh, PA 15240 USA. [Morgan, Kathleen L.; Estevez, Annette O.; Mueller, Catherine L.; Estevez, Miguel] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Cacho-Valadez, Briseida; Miranda-Vizuete, Antonio] Univ Pablo de Olavide, CSIC, CABD, Seville 41013, Spain. [Cacho-Valadez, Briseida; Miranda-Vizuete, Antonio] Univ Pablo de Olavide, Dept Fisiol Anat & Biol Celular, Seville 41013, Spain. [Miranda-Vizuete, Antonio] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla, Seville 41013, Spain. [Szewczyk, Nathaniel J.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA. RP Estevez, M (reprint author), Univ Arizona, Dept Neurol, 1501 N Campbell Ave, Tucson, AZ 85724 USA. EM estevezm@email.arizona.edu RI Miranda-Vizuete, Antonio/D-6927-2012; IBIS, FISIOLOGIA/O-9485-2015 OI Miranda-Vizuete, Antonio/0000-0002-6856-5396; Szewczyk, Nathaniel/0000-0003-4425-9746 FU Office of Research and Development, Department of Veterans Affairs; National Institutes of Environmental Health Sciences [R21-ES012305]; Arthritis and Musculoskeletal and Skin Diseases [R01-AR054342]; Instituto de Salud Carlos III [PI050065, PI080557]; Fondo Social Europeo, FEDER; Junta de Andalucia, Spain [P07-CVI-02697, P08-CVI-03629]; CONACYT, Mexico FX This work was supported by a Career Development Award (M. E.) provided through the Office of Research and Development, Department of Veterans Affairs, the National Institutes of Environmental Health Sciences (R21-ES012305 to A. E. and M. E.) and Arthritis and Musculoskeletal and Skin Diseases (R01-AR054342 to N.J.S.), the Instituto de Salud Carlos III (Projects PI050065 and PI080557, co-financed with the Fondo Social Europeo, FEDER) and Junta de Andalucia (Projects P07-CVI-02697 and P08-CVI-03629), Spain (A. M.-V.) and a predoctoral fellowship from CONACYT, Mexico (B.C.-V.). NR 90 TC 20 Z9 24 U1 2 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1096-6080 J9 TOXICOL SCI JI Toxicol. Sci. PD DEC PY 2010 VL 118 IS 2 BP 530 EP 543 DI 10.1093/toxsci/kfq273 PG 14 WC Toxicology SC Toxicology GA 682WB UT WOS:000284432600019 PM 20833709 ER PT J AU De Gasperi, R Sosa, MAG Naumowicz, Z Hof, PR Notterpek, L Davis, KL Buxbaum, JD Elder, GA AF De Gasperi, Rita Sosa, Miguel A. Gama Naumowicz, Zuzanna Hof, Patrick R. Notterpek, Lucia Davis, Kenneth L. Buxbaum, Joseph D. Elder, Gregory A. TI PERIPHERAL MYELIN PROTEIN-22 IS EXPRESSED IN CNS MYELIN SO TRANSLATIONAL NEUROSCIENCE LA English DT Article DE Myelin; Peripheral myelin protein-22; Schizophrenia AB Myelin abnormalities exist in schizophrenia leading to the hypothesis that oligodendrocyte dysfunction plays a role in the pathophysiology of the disease. The expression of the mRNA for the peripheral myelin protein-22 (PMP-22) is decreased in schizophrenia and recent genetic evidence suggests a link between PMP-22 and schizophrenia. While PMP-22 mRNA is found in both rodent and human brain it has been generally thought that no protein expression occurs. Here we show that PMP-22 protein is present in myelin isolated from adult mouse and human brain. These results suggest that PMP-22 protein likely plays a role in the maintenance and function of central nervous system (CNS) myelin and provide an explanation for why altered PMP-22 expression may be pathophysiologically relevant in a CNS disorder such as schizophrenia. C1 [De Gasperi, Rita; Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA. [De Gasperi, Rita; Sosa, Miguel A. Gama; Naumowicz, Zuzanna; Davis, Kenneth L.; Buxbaum, Joseph D.; Elder, Gregory A.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Hof, Patrick R.; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Hof, Patrick R.] Mt Sinai Sch Med, Dept Geriatr & Palliat Care, New York, NY 10029 USA. [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA. [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Notterpek, Lucia] Univ Florida, Coll Med, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA. RP De Gasperi, R (reprint author), James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA. EM gregory.elder@mssm.edu OI Buxbaum, Joseph/0000-0001-8898-8313 FU Mount Sinai Silvio Conte Neuroscience Center (NIH) [P50 MH36692] FX This research was supported by the Mount Sinai Silvio Conte Neuroscience Center (NIH grant P50 MH36692). We thank Dr. Vahram Haroutunian for providing frozen samples of postmortem human brain. NR 21 TC 5 Z9 5 U1 0 U2 3 PU VERSITA PI WARSAW PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND SN 2081-3856 J9 TRANSL NEUROSCI JI Transl. Neurosci. PD DEC PY 2010 VL 1 IS 4 BP 282 EP 285 DI 10.2478/v10134-010-0038-3 PG 4 WC Neurosciences SC Neurosciences & Neurology GA V20QA UT WOS:000208153300004 PM 21572910 ER PT J AU Sun, HY Shields, RK Cacciarelli, TV Muder, RR Singh, N AF Sun, H. -Y. Shields, R. K. Cacciarelli, T. V. Muder, R. R. Singh, N. TI A novel combination regimen for the treatment of refractory bacteremia due to multidrug-resistant Pseudomonas aeruginosa in a liver transplant recipient SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE multidrug resistant; Pseudomonas aeruginosa; liver transplant; biliary cast syndrome; combination regimen ID BILIARY CAST SYNDROME; GRAM-NEGATIVE BACILLI; BLOOD-STREAM INFECTIONS; BETA-LACTAM MONOTHERAPY; ACINETOBACTER-BAUMANNII; INTRAVENOUS COLISTIN; MOUSE MODEL; THERAPY; METAANALYSIS; RIFAMPIN AB P>Both bacteremia and biliary cast syndrome are serious post-transplant complications in liver transplant recipients. In the setting of increasing drug resistance in the current era, management of infections caused by multidrug-resistant (MDR) bacteria has proven challenging. We present a case of a liver transplant recipient who developed biliary cast syndrome and intractable MDR Pseudomonas bacteremia that failed to resolve with conventional antimicrobial therapy and which was finally controlled by a novel combination regimen of colistimethate, doripenem, and tobramycin. Future studies validating the clinical efficacy of this combination strategy are warranted. C1 [Sun, H. -Y.; Cacciarelli, T. V.; Muder, R. R.; Singh, N.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sun, H. -Y.] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan. [Sun, H. -Y.] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan. [Shields, R. K.; Muder, R. R.; Singh, N.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Shields, R. K.] Univ Pittsburgh, Med Ctr, Antibiot Management Program, Pittsburgh, PA USA. [Cacciarelli, T. V.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA. RP Singh, N (reprint author), VA Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu OI SUN, HSIN-YUN/0000-0003-0074-7721 NR 44 TC 11 Z9 11 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1398-2273 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD DEC PY 2010 VL 12 IS 6 BP 555 EP 560 DI 10.1111/j.1399-3062.2010.00543.x PG 6 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA 689BS UT WOS:000284902900014 PM 20626709 ER PT J AU Schneeberger, S Amberger, A Mandl, J Hautz, T Renz, O Obrist, P Meusburger, H Brandacher, G Mark, W Strobl, D Troppmair, J Pratschke, J Margreiter, R Kuznetsov, AV AF Schneeberger, Stefan Amberger, Albert Mandl, Julia Hautz, Theresa Renz, Oliver Obrist, Peter Meusburger, Hugo Brandacher, Gerald Mark, Walter Strobl, Daniela Troppmair, Jakob Pratschke, Johann Margreiter, Raimund Kuznetsov, Andrey V. TI Cold ischemia contributes to the development of chronic rejection and mitochondrial injury after cardiac transplantation SO TRANSPLANT INTERNATIONAL LA English DT Article DE cardiac transplantation; chronic rejection; cold ischemia; mitochondrial function; respirometry ID CORONARY-ARTERY-DISEASE; REAL-TIME PCR; HEART-TRANSPLANTATION; ALLOGRAFT-REJECTION; REPERFUSION INJURY; MUSCLE-FIBERS; MINIMUM INFORMATION; MICROARRAY DATA; RAT-HEART; MODEL AB P>Chronic rejection (CR) remains an unsolved hurdle for long-term heart transplant survival. The effect of cold ischemia (CI) on progression of CR and the mechanisms resulting in functional deficit were investigated by studying gene expression, mitochondrial function, and enzymatic activity. Allogeneic (Lew -> F344) and syngeneic (Lew -> Lew) heart transplantations were performed with or without 10 h of CI. After evaluation of myocardial contraction, hearts were excised at 2, 10, 40, and 60 days for investigation of vasculopathy, gene expression, enzymatic activities, and mitochondrial respiration. Gene expression studies identified a gene cluster coding for subunits of the mitochondrial electron transport chain regulated in response to CI and CR. Myocardial performance, mitochondrial function, and mitochondrial marker enzyme activities declined in all allografts with time after transplantation. These declines were more rapid and severe in CI allografts (CR-CI) and correlated well with progression of vasculopathy and fibrosis. Mitochondria related gene expression and mitochondrial function are substantially compromised with the progression of CR and show that CI impacts on progression, gene profile, and mitochondrial function of CR. Monitoring mitochondrial function and enzyme activity might allow for earlier detection of CR and cardiac allograft dysfunction. C1 [Schneeberger, Stefan; Hautz, Theresa; Renz, Oliver; Meusburger, Hugo; Brandacher, Gerald; Mark, Walter; Strobl, Daniela; Troppmair, Jakob; Pratschke, Johann; Margreiter, Raimund; Kuznetsov, Andrey V.] Innsbruck Med Univ, Daniel Swarovski Res Lab, Ctr Operat Med, Dept Visceral Transplant & Thorac Surg, A-6020 Innsbruck, Austria. [Schneeberger, Stefan; Brandacher, Gerald] UPMC, Div Plast Surg, Dept Surg, Pittsburgh, PA USA. [Schneeberger, Stefan] VA Univ Dr, Dept Surg, Pittsburgh, PA USA. [Schneeberger, Stefan] VA Pittsburgh Healthcare Syst, Univ Dr Div, Dept Surg, Pittsburgh, PA USA. [Amberger, Albert; Mandl, Julia] Innsbruck Med Univ, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria. [Obrist, Peter] St Vinzenz Hosp Zams, Dept Pathol, Zams, Austria. [Kuznetsov, Andrey V.] Innsbruck Med Univ, Cardiac Surg Res Lab, Dept Cardiac Surg, Ctr Operat Med, A-6020 Innsbruck, Austria. RP Schneeberger, S (reprint author), Innsbruck Med Univ, Daniel Swarovski Res Lab, Ctr Operat Med, Dept Visceral Transplant & Thorac Surg, Anichstr 35, A-6020 Innsbruck, Austria. EM stefan.schneeberger@i-med.ac.at RI Brandacher, Gerald/L-7540-2016 FU Austrian Cancer Society/Tyrol; Medizinischer Forschungsfonds Tirol (MFF) [23]; Tiroler Versicherungen; Hypo Bank Tirol FX This work was supported by the Austrian Cancer Society/Tyrol, the Medizinischer Forschungsfonds Tirol (MFF, grant #. 23) and unrestricted educational grants from the 'Tiroler Versicherungen' and the 'Hypo Bank Tirol' awarded to Stefan Schneeberger. NR 43 TC 6 Z9 7 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0934-0874 J9 TRANSPL INT JI Transpl. Int. PD DEC PY 2010 VL 23 IS 12 BP 1282 EP 1292 DI 10.1111/j.1432-2277.2010.01126.x PG 11 WC Surgery; Transplantation SC Surgery; Transplantation GA 678JN UT WOS:000284070000011 PM 20561305 ER PT J AU Orloff, MJ Isenberg, JI Wheeler, HO Haynes, KS Jinich-Brook, H Rapier, R Vaida, F Hye, RJ Orloff, SL AF Orloff, M. J. Isenberg, J. I. Wheeler, H. O. Haynes, K. S. Jinich-Brook, H. Rapier, R. Vaida, F. Hye, R. J. Orloff, S. L. TI Liver Transplantation in a Randomized Controlled Trial of Emergency Treatment of Acutely Bleeding Esophageal Varices in Cirrhosis SO TRANSPLANTATION PROCEEDINGS LA English DT Article; Proceedings Paper CT 23rd International Congress of the-Transplantation-Society CY AUG 15-19, 2010 CL Vancouver, CANADA SP Transplantat Soc ID PORTOSYSTEMIC STENT-SHUNT; PRIOR PORTASYSTEMIC SHUNT; PORTACAVAL-SHUNT; PORTAL-HYPERTENSION; CONSORT STATEMENT; HEMORRHAGE; SURVIVAL; ENCEPHALOPATHY; MANAGEMENT; SCLEROTHERAPY AB Background. Bleeding esophageal varices (BEV) in cirrhosis has been considered an indication for liver transplantation (LT). This issue was examined in a randomized controlled trial (ROT) of unselected, consecutive patients with advanced cirrhosis and BEV that compared endoscopic sclerotherapy (EST; n = 106) to emergency direct portacaval shunt (EPCS; n = 105). Methods. Diagnostic work-up and treatment were initiated within 8 hours. Patients were evaluated for LT on admission and repeatedly thereafter; 96% underwent over 10 years of regular follow-up. The analysis was supplemented by 1300 unrandomized cirrhotic patients who previously underwent portacaval shunt (PCS) with 100% follow-up. Results. In the RCT long-term bleeding control was 100% following EPCS, only 20% following EST. Also, 3-, 5-, 10-, and 15-year survival rates were 75%, 73%, 46%, and 46%, respectively, following EPCS compared with 44%, 21%, 9%, and 9% following EST, respectively (P <.001). Only 13 RCT patients (6%) were ultimately referred for LT mainly because of progressive liver failure; only 7 (3%) were approved for LT and only 4 (2%) underwent LT. The 1- and 5-year LT survival rates were 0.68% and 0, respectively, compared with 81% and 73%, respectively, after EPCS. In the 1300 unrandomized PCS patients, 50 (3.8%) were referred and 19 (1.5%) underwent LT. The 5-year survival rate was 53% compared with 72% for all 1300 patients. Conclusions. If bleeding is permanently controlled, as occurred invariably following EPCS, cirrhotic patients with BEV seldom require LT. PCS is effective first-line and long-term treatment. Should LT be required in patients with PCS, although technically more demanding, numerous studies have shown that PCS does not increase mortality or complications. EST is not effective emergency or long-term therapy. C1 [Orloff, M. J.; Hye, R. J.] UCSD Med Ctr, Dept Surg, San Diego, CA 92103 USA. [Isenberg, J. I.; Wheeler, H. O.; Haynes, K. S.; Jinich-Brook, H.; Rapier, R.] UCSD Med Ctr, Dept Med Gastroenterol, San Diego, CA 92103 USA. [Vaida, F.] UCSD Med Ctr, Dept Family & Prevent Med Biostat & Bioinformat, San Diego, CA 92103 USA. [Orloff, S. L.] Oregon Hlth & Sci Univ, Dept Surg, Div Abdominal Organ Transplantat, Portland, OR 97201 USA. [Orloff, S. L.] Portland VA Med Ctr, Portland, OR USA. RP Orloff, MJ (reprint author), UCSD Med Ctr, Dept Surg, 200 W Arbor Dr, San Diego, CA 92103 USA. EM morloff@ucsd.edu OI Hye, Robert/0000-0002-7733-6173 FU NIDDK NIH HHS [R01 DK041920, R01 DK041920-07]; PHS HHS [234-2005-370011C] NR 47 TC 8 Z9 8 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0041-1345 J9 TRANSPL P JI Transplant. Proc. PD DEC PY 2010 VL 42 IS 10 BP 4101 EP 4108 DI 10.1016/j.transproceed.2010.09.035 PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 700IQ UT WOS:000285732200054 PM 21168637 ER PT J AU Chen, DH Sul, Y Weiss, M Hillel, A Lipe, H Wolff, J Matsushita, M Raskind, W Bird, T AF Chen, D. -H. Sul, Y. Weiss, M. Hillel, A. Lipe, H. Wolff, J. Matsushita, M. Raskind, W. Bird, T. TI CMT2C with vocal cord paresis associated with short stature and mutations in the TRPV4 gene SO NEUROLOGY LA English DT Article ID SPINAL MUSCULAR-ATROPHY; MARIE-TOOTH DISEASE; SENSORY NEUROPATHY; HEREDITARY MOTOR; LOCALIZATION; DISORDERS; SPECTRUM; HMSN2C; TYPE-2 AB Background: Recently, mutations in the transient receptor potential cation channel, subfamily V, member 4 gene (TRPV4) have been reported in Charcot-Marie-Tooth Type 2C (CMT2C) with vocal cord paresis. Other mutations in this same gene have been described in separate families with various skeletal dysplasias. Further clarification is needed of the different phenotypes associated with this gene. Methods: We performed clinical evaluation, electrophysiology, and genetic analysis of the TRPV4 gene in 2 families with CMT2C. Results: Two multigenerational families had a motor greater than sensory axonal neuropathy associated with variable vocal cord paresis. The vocal cord paresis varied from absent to severe, requiring permanent tracheotomy in 2 subjects. One family with mild neuropathy also manifested pronounced short stature, more than 2 SD below the average height for white Americans. There was one instance of dolichocephaly. A novel S542Y mutation in the TRPV4 gene was identified in this family. The other family had a more severe, progressive, motor neuropathy with sensory loss, but less remarkable short stature and an R315W mutation in TRPV4. Third cranial nerve involvement and sleep apnea occurred in one subject in each family. Conclusion: CMT2C with axonal neuropathy, vocal cord paresis, and short stature is a unique syndrome associated with mutations in the TRPV4 gene. Mutations in TRPV4 can cause abnormalities in bone, peripheral nerve, or both and may result in highly variable orthopedic and neurologic phenotypes. Neurology (R) 2010;75:1968-1975 C1 [Chen, D. -H.; Weiss, M.; Bird, T.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Sul, Y.; Matsushita, M.; Raskind, W.; Bird, T.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Hillel, A.] Univ Washington, Sch Med, Dept Otolaryngol, Seattle, WA 98195 USA. [Raskind, W.; Bird, T.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Lipe, H.; Wolff, J.; Bird, T.] VA Puget Sound Hlth Care Syst, Res Educ Ctr, Geriatr, Seattle, WA USA. [Lipe, H.; Wolff, J.; Bird, T.] VA Puget Sound Hlth Care Syst, Ctr Clin, Geriatr, Seattle, WA USA. [Raskind, W.] VA Puget Sound Hlth Care Syst, Ctr Clin, Mental Illness, Seattle, WA USA. [Raskind, W.] VA Puget Sound Hlth Care Syst, Res Educ Ctr, Mental Illness, Seattle, WA USA. RP Bird, T (reprint author), 1660 S Columbian Way,S-182 GRECC, Seattle, WA 98108 USA. EM tomnroz@uw.edu FU Athena Diagnostics, Inc.; Department of Veterans Affairs Merit Review; NIH [R01 NS069719, R01 HD054562, HD054562, RC1 AG035681, RC2 HG005608, R01 AG033693, P50 HD055782, AG005136, R01 MH069867]; Seattle Puget Sound Veterans Affairs Mental Illness Research, Education and Clinical Center; Puget Sound Veterans Affairs Medical Center; Department of Veterans Affairs; Springer-Verlag GmbH Biomedical Sciences FX Dr. Chen receives licensing fees for PKCgamma in diagnosis of SCA14 from Athena Diagnostics, Inc. Ms. Sul reports no disclosures. Dr. Weiss has received speaker honoraria from Athena Diagnostics, Inc., and Talecris Biotherapeutics; serves on the editorial boards of Muscle and Nerve and the Journal of Clinical Neuromuscular Disease; has served as a consultant for Genzyme Corporation and for Washington State Department of Labor and Industries; and serves on the speakers' bureau for Athena Diagnostics, Inc. Dr. Hillel reports no disclosures. Ms. Lipe receives research support from a Department of Veterans Affairs Merit Review Grant. Mr. Wolff reports no disclosures. Mr. Matsushita receives research support from the NIH (R01 NS069719 [technician] and R01 HD054562 [technician]), and from the Seattle Puget Sound Veterans Affairs Mental Illness Research, Education and Clinical Center. Dr. Raskind serves on the editorial boards of the American Journal of Medical Genetics (Neuropsychiatric Genetics Section); the Journal of Learning Disabilities, The Open Genomics Journal, and Neuropsychopharmacology; receives licensing fees for PKCgamma in diagnosis of SCA14 from Athena Diagnostics, Inc.; receives research support from the NIH (R01 NS069719 [PI], HD054562 [PI], RC1 AG035681 [PI], RC2 HG005608 [PI], R01 AG033693 [coinvestigator], and P50 HD055782 [coinvestigator]) and from the Puget Sound Veterans Affairs Medical Center; and her spouse serves on the editorial boards of the Journal of Geriatric Psychiatry and Neurology, Alzheimer Disease and Associated Disorders: An International Journal, and the European Neurological Journal; receives research support from the NIH (AG005136 and R01 MH069867) and from the Department of Veterans Affairs; and served as an expert witness on behalf of Johnson & Johnson on galantamine patent case. Dr. Bird serves on scientific advisory boards for the Association for Frontotemporal Dementia and the CMT Association; has received funding for travel and speaker honoraria from Athena Diagnostics, Inc.; serves on the editorial boards of Brain and Neurology Today; is listed as a co-inventor on and receives license fees from Athena Diagnostics, Inc. for patents re: PKCgamma in diagnosis of SCA14 and Mutations Associated With A Human Demyelinating Neuropathy (Charcot-Marie-Tooth Disease Type 1C); receives royalties from the publication of Human Genetics: Principles and Approaches, 4th ed. (Springer-Verlag GmbH Biomedical Sciences, 2010); serves on the speakers' bureau for Athena Diagnostics, Inc.; and receives research support from the Department of Veterans Affairs. NR 26 TC 33 Z9 34 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 30 PY 2010 VL 75 IS 22 BP 1968 EP 1975 DI 10.1212/WNL.0b013e3181ffe4bb PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 686GW UT WOS:000284685800009 PM 21115951 ER PT J AU Cheng, EM Tonn, S Swain-Eng, R Factor, SA Weiner, WJ Bever, CT AF Cheng, E. M. Tonn, S. Swain-Eng, R. Factor, S. A. Weiner, W. J. Bever, C. T., Jr. CA Amer Acad Neurology Parkinson Dis TI Quality improvement in neurology: AAN Parkinson disease quality measures Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology SO NEUROLOGY LA English DT Article ID MOVEMENT-DISORDER SOCIETY; JOINT TASK-FORCE; STANDARDS SUBCOMMITTEE; PRACTICE PARAMETER; OF-NEUROLOGY; THERAPEUTIC MANAGEMENT; PHYSICIAN PERFORMANCE; EUROPEAN FEDERATION; INVITED ARTICLE; HEALTH AB Background: Measuring the quality of health care is a fundamental step toward improving health care and is increasingly used in pay-for-performance initiatives and maintenance of certification requirements. Measure development to date has focused on primary care and common conditions such as diabetes; thus, the number of measures that apply to neurologic care is limited. The American Academy of Neurology (AAN) identified the need for neurologists to develop measures of neurologic care and to establish a process to accomplish this. Objective: To adapt and test the feasibility of a process for independent development by the AAN of measures for neurologic conditions for national measurement programs. Methods: A process that has been used nationally for measure development was adapted for use by the AAN. Topics for measure development are chosen based upon national priorities, available evidence base from a systematic literature search, gaps in care, and the potential impact for quality improvement. A panel composed of subject matter and measure development methodology experts oversees the development of the measures. Recommendation statements and their corresponding level of evidence are reviewed and considered for development into draft candidate measures. The candidate measures are refined by the expert panel during a 30-day public comment period and by review by the American Medical Association for Current Procedural Terminology (CPT) II codes. All final AAN measures are approved by the AAN Board of Directors. Results: Parkinson disease (PD) was chosen for measure development. A review of the medical literature identified 258 relevant recommendation statements. A 28-member panel approved 10 quality measures for PD that included full specifications and CPT II codes. Conclusion: The AAN has adapted a measure development process that is suitable for national measurement programs and has demonstrated its capability to independently develop quality measures. Neurology (R) 2010;75:2021-2027 C1 [Tonn, S.; Swain-Eng, R.] Amer Acad Neurol, St Paul, MN 55116 USA. [Cheng, E. M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Cheng, E. M.] VA Greater Angeles, Dept Neurol, Los Angeles, CA USA. [Factor, S. A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Weiner, W. J.; Bever, C. T., Jr.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA. [Bever, C. T., Jr.] VA Maryland Hlth Care Syst, Res Serv, Baltimore, MD USA. [Bever, C. T., Jr.] VA Maryland Hlth Care Syst, Dept Neurol, Baltimore, MD USA. RP Cheng, EM (reprint author), Amer Acad Neurol, 1080 Montreal Ave, St Paul, MN 55116 USA. EM quality@aan.com FU NIH/NINDS [K23NS058571]; VA Parkinson's Disease Research, Education, and Clinical Center; Department of Veterans Affairs; California Office of Statewide Planning and Development; National Multiple Sclerosis Society; American Heart Association; Pfizer Inc.; CDC; Parkinson's Disease Diagnosis and Clinical Management (Demos); Drug Induced Movement Disorders (Blackwell Futura); Teva Pharmaceutical Industries Ltd.; Ipsen; UCB; Schering-Plough Corp.; publication of Neurology for the Non-Neurologist; Hopkins University; Handbook of Clinical Neurology Hyperkinetic Disorders; Novartis; Santhera Pharmaceuticals; Boehringer Ingelheim; Abraxis BioScience, Inc.; publication of Ambulatory Medicine; National MS Society FX Dr. Cheng serves as a consultant for the National Parkinson Foundation and receives research support from the NIH/NINDS (K23NS058571 [PI]), the VA Parkinson's Disease Research, Education, and Clinical Center, the Department of Veterans Affairs, the California Office of Statewide Planning and Development, the National Multiple Sclerosis Society, and the American Heart Association. Ms. Tonn is a full-time employee of the American Academy of Neurology (AAN) and served as project director for AAN grants from Pfizer Inc. and the CDC. Ms. Swain-Eng is a full-time employee of the American Academy of Neurology. Dr. Factor has served on scientific advisory boards for Lundbeck Inc., Allergan, Inc., and UCB; serves as a section editor for Current Treatment Options in Neurology; receives royalties from the publication of Parkinson's Disease Diagnosis and Clinical Management (Demos, 2008) and Drug Induced Movement Disorders (Blackwell Futura, 2005); has given expert testimony, prepared affidavits, and served as a consultant for Boehringer Ingelheim; and receives research support from Teva Pharmaceutical Industries Ltd., Ipsen, UCB, and Schering-Plough Corp. Dr. Weiner has served on scientific advisory boards for Santhera Pharmaceuticals and Rexahn Pharmaceuticals, Inc.; serves on the editorial boards of Parkinsonism and Related Disorders and Neurological Reviews, and as Editor of Treatment Options in Neurology; receives royalties from the publication of Neurology for the Non-Neurologist (6th edition, Kluwer/Lippincott 2010), Parkinson's Disease: A Complete Guide for Patients and Family (Hopkins University Press 2nd edition, 2007), and Handbook of Clinical Neurology Hyperkinetic Disorders (Elsevier, 2011); has received honoraria from Santhera Pharmaceuticals and Novartis; has received research support from Novartis, Santhera Pharmaceuticals, Boehringer Ingelheim, and has provided expert testimony and served as a subject matter expert in legal proceedings. Dr. Bever serves on the editorial board of the MS Quarterly Report; is listed as a co-inventor on and receives royalties from Abraxis BioScience, Inc. for a pending patent re: Use of hematogenous stem cells in neuronal replacement therapy and gene delivery; receives royalties from the publication of Ambulatory Medicine (Lippincott Williams & Wilkins, 7th edition, 2006); and has received research support from the Department of Veterans Affairs and the National MS Society. NR 39 TC 42 Z9 43 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 30 PY 2010 VL 75 IS 22 BP 2021 EP 2027 DI 10.1212/WNL.0b013e3181ff96dd PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 686GW UT WOS:000284685800017 PM 21115958 ER PT J AU Yehuda, R Golier, JA Bierer, LM Mikhno, A Pratchett, LC Burton, CL Makotkine, I Devanand, DP Pradhaban, G Harvey, PD Mann, JJ AF Yehuda, Rachel Golier, Julia A. Bierer, Linda M. Mikhno, Arthur Pratchett, Laura C. Burton, Charles L. Makotkine, Iouri Devanand, D. P. Pradhaban, Gnanavalli Harvey, Philip D. Mann, J. John TI Hydrocortisone responsiveness in Gulf War veterans with PTSD: Effects on ACTH, declarative memory hippocampal [(18)F]FDG uptake on PET SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE PTSD; Gulf War veterans; Hippocampus; Cortisol; Glucocorticoid receptors; Episodic memory; [(18)F]FDG-PET ID POSTTRAUMATIC-STRESS-DISORDER; MILD COGNITIVE IMPAIRMENT; CHILDHOOD SEXUAL-ABUSE; GLUCOCORTICOID-RECEPTORS; COMBAT VETERANS; ALZHEIMERS-DISEASE; MAJOR DEPRESSION; HOLOCAUST SURVIVORS; TRAUMA SURVIVORS; PLASMA-CORTISOL AB Neuroendocrine, cognitive and hippocampal alterations have been described in Gulf War (GW) veterans, but their inter-relationships and significance for posttraumatic stress disorder (PTSD) have not been described. Hydrocortisone (Hcort) was administered to GW veterans with (PTSD+ n = 12) and without (PTSD- n = 8) chronic PTSD in a randomized, placebo-controlled, double-blind challenge. Changes in plasma ACTH, memory, and hippocampal [(18)F]FDG uptake on positron emission tomography were assessed. The low-dose dexamethasone suppression test was also administered. The PTSD+ group showed greater cortisol and ACTH suppression, reflecting greater peripheral glucocorticoid receptor (GR) responsiveness, and did not show an Hcort-induced decrement in delayed recall or retention. The groups had comparable relative regional hippocampal [(18)F]FDG uptake at baseline, but only the PTSD group had an Hcort-associated decrease in hippocampal [(18)F]FDG uptake. Asymmetry in hippocampal hemispheric volumes differed between PTSD+ and PTSD- groups. This asymmetry was associated with cortisol, ACTH, retention and functional hippocampal asymmetry before, but not after, Hcort administration. Differences in brain metabolic responses between GW veterans with and without PTSD may reflect differences in peripheral and central GR responsiveness. Published by Elsevier Ireland Ltd. C1 [Yehuda, Rachel; Golier, Julia A.; Bierer, Linda M.; Pratchett, Laura C.; Burton, Charles L.; Makotkine, Iouri] Mt Sinai Sch Med, Dept Psychiat, Traumat Stress Studies Div, New York, NY 10029 USA. [Yehuda, Rachel; Golier, Julia A.; Bierer, Linda M.; Pratchett, Laura C.; Burton, Charles L.; Makotkine, Iouri] James J Peters Vet Affairs Med Ctr, PTSD Program, Bronx, NY USA. [Devanand, D. P.; Pradhaban, Gnanavalli; Harvey, Philip D.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA. [Devanand, D. P.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA. [Mikhno, Arthur; Mann, J. John] New York State Psychiat Inst & Hosp, Dept Mol Imaging & Neuropathol, New York, NY 10032 USA. [Devanand, D. P.; Pradhaban, Gnanavalli; Harvey, Philip D.] Columbia Univ, Coll Phys & Surg, Div Geriatr Psychiat, New York, NY USA. [Harvey, Philip D.] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA. RP Yehuda, R (reprint author), Mt Sinai Sch Med, Dept Psychiat, Traumat Stress Studies Div, New York, NY 10029 USA. EM rachel.yehuda@va.gov FU VA MERIT; National Center for Research Resources, National Institutes of Health [5 MO1 RR00071] FX This grant was primarily supported by a VA MERIT entitled "Glucocorticoid Responsivity in Gulf War Veterans." In addition, partial support was obtained by a grant (5 MO1 RR00071) for the Mount Sinai General Clinical Research Center from the National Center for Research Resources, National Institutes of Health. The authors would like to acknowledge several colleagues for work on this project. First, thanks to Josef Machac, M.D. and Ash Rafique, B.S. at the Mount Sinai Hospital Clinical Neuroimaging Laboratory, to Janelle Wohltmann, B.A., Research Coordinator, to Lisa Tischler, Ph.D., Sharon Y. Jedel, Psy.D., and Ellen Labinsky, Ph.D. for psychological assessments of the subjects, to Ken Belzer, Ph.D., for statistical consultation, and most of all, the Gulf War Veterans who participated in this research. NR 99 TC 20 Z9 20 U1 3 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD NOV 30 PY 2010 VL 184 IS 2 BP 117 EP 127 DI 10.1016/j.pscychresns.2010.06.010 PG 11 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 681TF UT WOS:000284341500007 PM 20934312 ER PT J AU Tien, PC Schneider, MF Cox, C Cohen, M Karim, R Lazar, J Young, M Glesby, MJ AF Tien, Phyllis C. Schneider, Michael F. Cox, Christopher Cohen, Mardge Karim, Roksana Lazar, Jason Young, Mary Glesby, Marshall J. TI HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study SO AIDS LA English DT Article DE HAART; HIV; lipids; lipoprotein particle concentrations; women ID MAGNETIC-RESONANCE SPECTROSCOPY; REGIONAL ADIPOSE-TISSUE; ANTIRETROVIRAL THERAPY; CARDIOVASCULAR-DISEASE; INFECTED WOMEN; HEART-DISEASE; MEN; RISK; SIZE; HETEROGENEITY AB Background: Changes in lipoprotein particle concentrations, especially greater small low-density lipoprotein particle (LDL-p) and lower small high-density lipoprotein particle (HDL-p) may provide information regarding cardiovascular disease (CVD) risk above and beyond that which is provided by standard lipids. We quantified the association HIV and HAART use had with LDL-p and HDL-p. Methods: Cross-sectional study of 1077 individuals classified by HIV/HAART status (361 HIV-uninfected, 128 HIV-infected/HAART naive, 588 HIV-infected/on HAART) enrolled in the Women's Interagency HIV Study. Nuclear magnetic resonance spectroscopy estimated total and subclass lipoprotein particle concentrations. Quantile regression models were used to estimate differences in the 10th, 25th, 50th, 75th, and 90th percentiles of the distributions of lipoprotein particle concentrations between the two HIV-infected exposure groups and HIV-uninfected controls after adjustment for demographic, nonlipid metabolic factors, and standard lipids. Results: Compared with HIV-uninfected women, those on HAART had greater 75th and 90th percentiles of small LDL-p; there was little difference between HIV-infected/HAART naive and HIV-uninfected women. After adjustment for triglycerides, the association of HAART with greater 75th and 90th percentiles of small LDL-p was attenuated and no longer significant. In contrast, after adjustment for triglycerides, HIV infection irrespective of HAART status remained associated with significantly lower 10th, 25th, 50th, 75th, and 90th percentiles of small HDL-p. Conclusion: Our findings suggest that testing for LDL-p confers little additional information beyond triglycerides levels when assessing CVD risk. Further investigation is needed to examine the role of HDL-p in the link between HIV and CVD in women. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Tien, Phyllis C.] Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, San Francisco, CA 94121 USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Schneider, Michael F.; Cox, Christopher] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Cohen, Mardge] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge] Rush Univ, Dept Med, Chicago, IL 60612 USA. [Karim, Roksana] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA. [Lazar, Jason] SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA. [Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA. [Glesby, Marshall J.] Weill Cornell Med Coll, Dept Med, New York, NY USA. RP Tien, PC (reprint author), Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, 111W,4150 Clement St, San Francisco, CA 94121 USA. EM ptien@ucsf.edu FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590, K23-AI-66943-04, K24-AI-078884]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI ) [UL1 RR024131] FX Data in this manuscript were collected by the WIHS Collaborative Study Group with centers (principal investigators) at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, New York (Howard Minkoff); Washington DC Metropolitan Consortium (M.Y.); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (M. C.); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). P. C. T. and M.J.G. are supported by the National Institute of Allergy and Infectious Diseases through K23-AI-66943-04 and K24-AI-078884, respectively. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. All authors played a role in editing the manuscript and approved the text as submitted to AIDS. P. C. T. designed the study and wrote the manuscript. M. F. S. and C. C. performed the data analysis and assisted in the interpretation of statistical data. M. C., R. K., M.Y., J.L., and M.J.G. reviewed and edited the manuscript. NR 28 TC 9 Z9 9 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD NOV 27 PY 2010 VL 24 IS 18 BP 2809 EP 2817 DI 10.1097/QAD.0b013e32833fcb3b PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 678EU UT WOS:000284057300007 PM 20871387 ER PT J AU Mandal, CC Ghosh-Choudhury, T Yoneda, T Choudhury, GG Ghosh-Choudhury, N AF Mandal, Chandi Charan Ghosh-Choudhury, Triparna Yoneda, Toshi Choudhury, Goutam Ghosh Ghosh-Choudhury, Nandini TI Fish oil prevents breast cancer cell metastasis to bone SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Osteolytic metastasis; DHA; EPA; Fish oil diet ID NUDE-MICE; LUNG METASTASIS; CD44; GROWTH; PROGRESSION; EXPRESSION; OMEGA-3-FATTY-ACIDS; HYALURONAN; TUMORS; ACID AB The data derived from epidemiological and animal models confirm a beneficial effect of fish oil (rich in omega-3 polyunsaturated fatty acids) in the amelioration of tumor growth and progression including breast cancer The breast cancer patients often develop bone metastasis evidenced by osteolytic lesions leading to severe pain and bone fracture Using a mouse model of MDA-MB-231 human breast cancer cell metastasis to bone here we show that fish oil diet enriched in DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) prevents the formation of osteolytic lesions in bone indicating suppression of cancer cell metastasis to bone These results are supported by our data showing both DHA and EPA significantly attenuate the migration/invasion of MDA-MB-231 breast cancer cells in culture The mechanism that limits breast cancer cells to selective metastasis to bone remains hitherto unexplored Aberrant Increased expression of CD44 is associated with generation of cancer stem cells which contribute to metastasis of breast cancer cells We demonstrate that DHA and EPA significantly inhibit the expression of CD44 protein and mRNA by a transcriptional mechanism Furthermore we show markedly reduced levels of CD44 mRNA and protein in the tumors of mice which were fed fish oil diet than those in control diet Our data provide the first evidence for a salutary effect of fish oil on breast cancer metastasis to bone Our results identify a novel function of the fish oil active components DHA and EPA which target the cell-intrinsic pro-metastatic molecule CD44 to inhibit migration/invasion Published by Elsevier Inc C1 [Choudhury, Goutam Ghosh; Ghosh-Choudhury, Nandini] VA Res S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Mandal, Chandi Charan; Ghosh-Choudhury, Triparna; Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Yoneda, Toshi; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Choudhury, GG (reprint author), VA Res S Texas Vet Hlth Care Syst, San Antonio, TX USA. FU NIH [RO1 DK50190, RO1 AR52425]; Juvenile Diabetes Research Foundation [1-2008-185]; Cancer Therapy and Research Center University of Texas Health Science Center at San Antonio; VA FX NIH RO1 AR52425 VA Merit review grants and Ronald Williams Orthopedic Award (Cancer Therapy and Research Center University of Texas Health Science Center at San Antonio) to NGC supported this work GGC is a recipient of VA Senior Research Career Scientist Award and is supported by VA Research Service Merit Review grant NIH RO1 DK50190 grant and Juvenile Diabetes Research Foundation 1-2008-185 grant NR 34 TC 29 Z9 35 U1 5 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD NOV 26 PY 2010 VL 402 IS 4 BP 602 EP 607 DI 10.1016/j.bbrc.2010.10.063 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 692QW UT WOS:000285171200005 PM 20971068 ER PT J AU Eid, AA Ford, BM Block, K Kasinath, BS Gorin, Y Ghosh-Choudhury, G Barnes, JL Abboud, HE AF Eid, Assaad A. Ford, Bridget M. Block, Karen Kasinath, Balakuntalam S. Gorin, Yves Ghosh-Choudhury, Goutam Barnes, Jeffrey L. Abboud, Hanna E. TI AMP-activated Protein Kinase (AMPK) Negatively Regulates Nox4-dependent Activation of p53 and Epithelial Cell Apoptosis in Diabetes SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NADPH OXIDASES; MEMBRANE THICKNESS; PODOCYTE DEPLETION; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; SKELETAL-MUSCLE; TRANSGENIC MICE; GLUCOSE-UPTAKE; RAT-KIDNEY; YEAST SNF1 AB Diabetes and high glucose (HG) increase the generation of NADPH oxidase-derived reactive oxygen species and induce apoptosis of glomerular epithelial cells (podocytes). Loss of podocytes contributes to albuminuria, a major risk factor for progression of kidney disease. Here, we show that HG inactivates AMP-activated protein kinase (AMPK), up-regulates Nox4, enhances NADPH oxidase activity, and induces podocyte apoptosis. Activation of AMPK blocked HG-induced expression of Nox4, NADPH oxidase activity, and apoptosis. We also identified the tumor suppressor protein p53 as a mediator of podocyte apoptosis in cells exposed to HG. Inactivation of AMPK by HG up-regulated the expression and phosphorylation of p53, and p53 acted downstream of Nox4. To investigate the mechanism of podocyte apoptosis in vivo, we used OVE26 mice, a model of type 1 diabetes. Glomeruli isolated from these mice showed decreased phosphorylation of AMPK and enhanced expression of Nox4 and p53. Pharmacologic activation of AMPK by 5-aminoimidazole-4-carboxamide-1-riboside in OVE26 mice attenuated Nox4 and p53 expression. Administration of 5-aminoimidazole-4-carboxamide-1-riboside also prevented renal hypertrophy, glomerular basement thickening, foot process effacement, and podocyte loss, resulting in marked reduction in albuminuria. Our results uncover a novel function of AMPK that integrates metabolic input to Nox4 and provide new insight for activation of p53 to induce podocyte apoptosis. The data indicate the potential therapeutic utility of AMPK activators to block Nox4 and reactive oxygen species generation and to reduce urinary albumin excretion in type 1 diabetes. C1 [Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Block, Karen; Kasinath, Balakuntalam S.; Ghosh-Choudhury, Goutam; Barnes, Jeffrey L.; Abboud, Hanna E.] Vet Affairs Res, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Goutam] S Texas Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Abboud, HE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM abboud@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925 FU National Institutes of Health [CA131272, R01 DK079996, R01 DK50190, R01 DK080106, DK-R01-078971]; George O'Brien Kidney Center [DK061597]; National Kidney Foundation; Juvenile Diabetes Research Foundation; Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health Grants CA131272 (to K. B.), R01 DK079996 (to Y. G.), R01 DK50190 (to G. G.-C.), R01 DK080106 (to J. L. B.), and DK-R01-078971 (to H. E. A.) and George O'Brien Kidney Center-Morphology Core Grant DK061597 (to J. L. B.). This work was also supported by a National Kidney Foundation postdoctoral fellowship grant and a Juvenile Diabetes Research Foundation grant (to A. A. E.), a Juvenile Diabetes Research Foundation regular research grant (to Y. G.), and a Juvenile Diabetes Research Foundation grant and a Veterans Affairs merit review grant (to H. E. A.). NR 71 TC 93 Z9 96 U1 2 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 26 PY 2010 VL 285 IS 48 BP 37503 EP 37512 DI 10.1074/jbc.M110.136796 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 682ST UT WOS:000284424000042 PM 20861022 ER PT J AU Hoang, B Frost, P Shi, YJ Belanger, E Benavides, A Pezeshkpour, G Cappia, S Guglielmelli, T Gera, J Lichtenstein, A AF Hoang, Bao Frost, Patrick Shi, Yijiang Belanger, Eileen Benavides, Angelica Pezeshkpour, Gholam Cappia, Susanna Guglielmelli, Tommasina Gera, Joseph Lichtenstein, Alan TI Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor SO BLOOD LA English DT Article ID MAMMALIAN TARGET; AKT KINASE; PHASE-I; RAPAMYCIN; CELLS; PHOSPHORYLATION; TRANSLATION; MUTATIONS; RICTOR; DEXAMETHASONE AB Although preclinical work with rapalogs suggests potential in treatment of multiple myeloma (MM), they have been less successful clinically. These drugs allostearically inhibit the mammalian target of rapamycin kinase primarily curtailing activity of the target of rapamycin complex (TORC)1. To assess if the mammalian target of rapamycin within the TORC2 complex could be a better target in MM, we tested a new agent, pp242, which prevents activation of TORC2 as well as TORC1. Although comparable to rapamy-cin against phosphorylation of the TORC1 substrates p70S6kinase and 4E-BP-1, pp242 could also inhibit phosphorylation of AKT on serine 473, a TORC2 substrate, while rapamycin was ineffective. pp242 was also more effective than rapamycin in achieving cytoreduction and apoptosis in MM cells. In addition, pp242 was an effective agent against primary MM cells in vitro and growth of 8226 cells in mice. Knockdown of the TORC2 complex protein, rictor, was deleterious to MM cells further supporting TORC2 as the critical target for pp242. TORC2 activation was frequently identified in primary specimens by immunostaining for AKT phosphorylation on serine 473. Potential mechanisms of up-regulated TORC2 activity in MM were stimulation with interleukin-6 or insulin-like growth factor 1, and phosphatase and tensin homolog or RAS alterations. Combining pp242 with bortezomib led to synergistic anti-MM effects. These results support TORC2 as a therapeutic target in MM. (Blood. 2010; 116(22): 4560-4568) C1 [Hoang, Bao; Frost, Patrick; Shi, Yijiang; Belanger, Eileen; Benavides, Angelica; Gera, Joseph; Lichtenstein, Alan] Univ Calif Los Angeles, Div Hematol Oncol, Greater Los Angeles Vet Adm VA Healthcare Ctr, Los Angeles, CA USA. [Hoang, Bao; Frost, Patrick; Shi, Yijiang; Belanger, Eileen; Benavides, Angelica; Gera, Joseph; Lichtenstein, Alan] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA. [Pezeshkpour, Gholam] Greater Los Angeles VA Healthcare Ctr, Dept Pathol, Los Angeles, CA USA. [Pezeshkpour, Gholam] Univ So Calif, Sch Med, Los Angeles, CA USA. [Cappia, Susanna; Guglielmelli, Tommasina] Univ Turin, Turin, Italy. [Cappia, Susanna; Guglielmelli, Tommasina] San Luigi Hosp, Turin, Italy. RP Lichtenstein, A (reprint author), W Los Angeles Vet Adm Hosp, W111H,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM alan.lichtenstein@med.va.gov OI Frost, Patrick/0000-0003-3348-5983 FU National Institutes of Health [RO1 CA109312, RO1 CA111448]; Department of Defense; Veterans Administration FX This work was supported by National Institutes of Health grants RO1 CA109312 and RO1 CA111448 and research funds of the Department of Defense and Veterans Administration. NR 37 TC 61 Z9 66 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 25 PY 2010 VL 116 IS 22 BP 4560 EP 4568 DI 10.1182/blood-2010-05-285726 PG 9 WC Hematology SC Hematology GA 685BT UT WOS:000284599900029 PM 20686120 ER PT J AU Shah, ND Montori, VM Krumholz, HM Tu, K Alexander, GC Jackevicius, CA AF Shah, Nilay D. Montori, Victor M. Krumholz, Harlan M. Tu, Karen Alexander, G. Caleb Jackevicius, Cynthia A. TI Responding to an FDA Warning - Geographic Variation in the Use of Rosiglitazone. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Shah, Nilay D.; Montori, Victor M.] Mayo Clin, Knowledge & Encounter Res Unit, Rochester, MN 55905 USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, New Haven, CT USA. [Krumholz, Harlan M.] Yale New Haven Med Ctr, New Haven, CT 06504 USA. [Tu, Karen; Jackevicius, Cynthia A.] Univ Toronto, Toronto, ON, Canada. [Tu, Karen] Toronto Western Hosp, Family Hlth Team, Toronto, ON M5T 2S8, Canada. [Tu, Karen; Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Alexander, G. Caleb] Univ Chicago, Chicago, IL 60637 USA. [Alexander, G. Caleb] Univ Illinois, Chicago Sch Pharm, Chicago, IL USA. [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Shah, ND (reprint author), Mayo Clin, Knowledge & Encounter Res Unit, Rochester, MN 55905 USA. OI Montori, Victor/0000-0003-0595-2898 NR 6 TC 37 Z9 37 U1 0 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 25 PY 2010 VL 363 IS 22 BP 2081 EP 2084 DI 10.1056/NEJMp1011042 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 684XE UT WOS:000284587800001 PM 21083379 ER PT J AU Baicu, CF Li, JY Zhang, YH Kasiganesan, H Yamane, K Zile, MR Bradshaw, AD AF Baicu, Catalin F. Li, Jiayu Zhang, Yuhua Kasiganesan, Harinath Yamane, Kentaro Zile, Michael R. Bradshaw, Amy D. TI Increased Interstitial Collagen in Chronic Pressure Overload Hypertrophy is Associated with a Change in Cardiac Fibroblast Phenotype and An Increase in SPARC Expression SO CIRCULATION LA English DT Meeting Abstract DE Hypertrophy; Cells; Remodeling C1 [Baicu, Catalin F.; Li, Jiayu; Zhang, Yuhua; Kasiganesan, Harinath; Yamane, Kentaro; Zile, Michael R.; Bradshaw, Amy D.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A13030 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601132 ER PT J AU Bradley, SM Bryson, CL Maynard, C Maddox, TM Fihn, SD AF Bradley, Steven M. Bryson, Chris L. Maynard, Charles Maddox, Thomas M. Fihn, Stephan D. TI Influence of Recent Hospitalization for Non-coronary Events on the Use of Preventive Medications for Coronary Artery Disease SO CIRCULATION LA English DT Meeting Abstract DE Coronary artery disease; Prevention; Drugs; Health services research; Patient care C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Colorado, Denver Vet Affairs Med Cntr, Denver, CO 80202 USA. RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12098 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600739 ER PT J AU DeSantis, SM Toole, JM Kratz, JM Uber, WE Wheat, MJ Stroud, MR Ikonomidis, JS Spinale, FG AF DeSantis, Stacia M. Toole, J. M. Kratz, John M. Uber, Walter E. Wheat, Margaret J. Stroud, Martha R. Ikonomidis, John S. Spinale, Francis G. TI Early Postoperative Outcomes and Blood Product Utilization in Adult Cardiac Surgery: The Post-Aprotinin Era SO CIRCULATION LA English DT Meeting Abstract DE Cardiac surgery; Fibrinolytic agents C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A9456 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600410 ER PT J AU Dixon, JA Gaillard, WF Rivers, WT Koval, CN Stroud, RE Mukherjee, R Spinale, FG AF Dixon, Jennifer A. Gaillard, William F. Rivers, William T. Koval, Christine N. Stroud, Robert E. Mukherjee, Rupak Spinale, Francis G. TI Identification of a Unique Proteolytic-Profibrotic Interaction Following Myocardial Infarction Which is Amplified Following a Second Episode of Ischemia-Reperfusion SO CIRCULATION LA English DT Meeting Abstract DE Myocardial infarction; Ischemia reperfusion; Proteolytic enzymes C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A13284 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601217 ER PT J AU Dixon, JA Gorman, RC Stroud, RE Meyer, EC O'Quinn, EC Baker, NL Morita, M Hamamoto, H Ryan, LP Gorman, JH Spinale, FG AF Dixon, Jennifer A. Gorman, Robert C. Stroud, Robert E. Meyer, Evan C. O'Quinn, Elizabeth C. Baker, Nathaniel L. Morita, Masato Hamamoto, Hirotsugu Ryan, Liam P. Gorman, Joseph H. Spinale, Francis G. TI Targeted Regional Injection of Biocomposite Microspheres Alters Post Myocardial Infarction Remodeling and Matrix Proteolytic Pathways SO CIRCULATION LA English DT Meeting Abstract DE Myocardial infarction; Remodeling; Proteolytic enzymes C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A9196 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600370 ER PT J AU Dixon, JA Goodman, AM Gaillard, WF Rivers, WT McKinney, RA Mukherjee, R Baker, NL Ikonomidis, JS Spinale, FG AF Dixon, Jennifer A. Goodman, Amy M. Gaillard, William F. Rivers, William T. McKinney, Richard A. Mukherjee, Rupak Baker, Nathaniel L. Ikonomidis, John S. Spinale, Francis G. TI Hemodynamics and Myocardial Blood Flow Patterns Following Placement of a Cardiac Passive Restraint Device in a Model of Dilated Cardiomyopathy SO CIRCULATION LA English DT Meeting Abstract DE Cardiomyopathy; Surgery; Device; Blood flow C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. Paracor, Sunnyvale, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A9037 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600347 ER PT J AU Graham, EM Atz, AM Butts, RJ Baker, NL Stroud, RE Deardorff, RL Reeves, ST Bradley, SM Spinale, FG AF Graham, Eric M. Atz, Andrew M. Butts, Ryan J. Baker, Nathaniel L. Stroud, Robert E. Deardorff, Rachael L. Reeves, Scott T. Bradley, Scott M. Spinale, Francis G. TI Preoperative Steroid Treatment Does Not Improve Markers of Inflammation or Outcomes Following Cardiac Surgery in Neonates SO CIRCULATION LA English DT Meeting Abstract DE Pediatrics; Cardiac surgery; Inflammation C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A10816 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600550 ER PT J AU Graham, EM Atz, AM Butts, RJ Baker, NL Zyblewski, SC Deardorff, RL Reeves, ST Bradley, SM Spinale, FG AF Graham, Eric M. Atz, Andrew M. Butts, Ryan J. Baker, Nathaniel L. Zyblewski, Sinai C. Deardorff, Rachael L. Reeves, Scott T. Bradley, Scott M. Spinale, Francis G. TI Standardized Preoperative Corticosteroid Treatment in Neonates Undergoing Cardiac Surgery-Results From a Randomized Trial SO CIRCULATION LA English DT Meeting Abstract DE Cardiac surgery; Pediatrics C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A10814 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600549 ER PT J AU Greyson, CR Ye, SY Lu, L Xu, Y Schwartz, GG Ahmad, H AF Greyson, Clifford R. Ye, Shuyu Lu, Li Xu, Ya Schwartz, Gregory G. Ahmad, Hasan TI Acute Right Ventricular Pressure Overload Disrupts Organization of the Focal Adhesion Protein Talin SO CIRCULATION LA English DT Meeting Abstract DE Pulmonary heart disease; Proteolytic enzymes; Acute heart failure; Contractility; Pathology C1 [Greyson, Clifford R.; Ye, Shuyu; Lu, Li; Xu, Ya; Schwartz, Gregory G.; Ahmad, Hasan] Denver VAMC, Denver, CO USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A16249 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602115 ER PT J AU Ikonomidis, JS Jones, JA O'Quinn, EC Elefteriades, JA Stroud, RE Bavaria, JE Gorman, JH Gorman, RC Spinale, FG AF Ikonomidis, John S. Jones, Jeffrey A. O'Quinn, Elizabeth C. Elefteriades, John A. Stroud, Robert E. Bavaria, Joseph E. Gorman, Joseph H. Gorman, Robert C. Spinale, Francis G. TI Direct Profiling of MicroRNA in Thoracic Aortic Aneurysms: Relationship to Aortic Expansion and Growth SO CIRCULATION LA English DT Meeting Abstract DE Aortic aneurysm; Remodeling C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. Yale Univ, New Haven, CT USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A15773 PG 3 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601934 ER PT J AU Jones, JA Bouges, S Zavadzkas, JA Rivers, WT Brinsa, TA Stroud, RE Spinale, FG Mukherjee, R Ikonomidis, JS AF Jones, Jeffrey A. Bouges, Shenikqua Zavadzkas, Jouzas A. Rivers, William T. Brinsa, Thersa A. Stroud, Robert E. Spinale, Francis G. Mukherjee, Rupak Ikonomidis, John S. TI Membrane Type-1 Matrix Metalloproteinase Activity and in vivo Abundance Using Targeted Microbubble Imaging, Intensify During Thoracic Aortic Aneurysm Formation: Relationship to Change in Aortic Diameter SO CIRCULATION LA English DT Meeting Abstract DE Aortic aneurysm; Remodeling; Proteolytic enzymes C1 [Jones, Jeffrey A.; Bouges, Shenikqua; Zavadzkas, Jouzas A.; Rivers, William T.; Brinsa, Thersa A.; Stroud, Robert E.; Spinale, Francis G.; Mukherjee, Rupak; Ikonomidis, John S.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12403 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600827 ER PT J AU Jones, JA Prescott, CB Stroud, RE Spinale, FG Ikonomidis, JS AF Jones, Jeffrey A. Prescott, Corey B. Stroud, Robert E. Spinale, Francis G. Ikonomidis, John S. TI Latent Transforming Growth Factor-beta Binding Protein-1 is Cleaved by Matrix Metalloproteinase-2 During Thoracic Aortic Aneurysm Development SO CIRCULATION LA English DT Meeting Abstract DE Aortic aneurysm; Remodeling; Proteolytic enzymes C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12406 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600829 ER PT J AU Mukherjee, R Adams, DK Clarke, EK McClure, CD Stroud, RE McKinney, RA Spinale, FG Gold, MR AF Mukherjee, Rupak Adams, Deborah K. Clarke, Elizabeth K. McClure, Catherine D. Stroud, Robert E. McKinney, Richard A. Spinale, Francis G. Gold, Michael R. TI Differential Plasma Profiles of Matrix Metalloproteinases and Tissue Inhibitors of the Metalloproteinases with Atrial Fibrillation: Relation to Recurrence Following Cardioversion SO CIRCULATION LA English DT Meeting Abstract DE Atrial fibrillation; Biomarkers; Proteolytic enzymes C1 [Mukherjee, Rupak; Adams, Deborah K.; Clarke, Elizabeth K.; McClure, Catherine D.; Stroud, Robert E.; McKinney, Richard A.; Spinale, Francis G.; Gold, Michael R.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A13798 PG 3 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601367 ER PT J AU Mukherjee, R Rivers, WT Patel, RK Stroud, RE Spinale, FG AF Mukherjee, Rupak Rivers, William T. Patel, Risha K. Stroud, Robert E. Spinale, F. G. TI Membrane Type-1 Matrix Metalloproteinase Activity and Specific In Vivo Quantitation Using Specific Targeted Microbubble Imaging: Relation to Left Ventricular Remodeling Following Myocardial Infarction SO CIRCULATION LA English DT Meeting Abstract DE Myocardial infarction; Proteolytic enzymes; Imaging agents C1 [Mukherjee, Rupak; Rivers, William T.; Patel, Risha K.; Stroud, Robert E.; Spinale, F. G.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A10086 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600426 ER PT J AU Mukherjee, R Rivers, WT Stroud, RE Patel, RK Ruddy, JM Spinale, FG AF Mukherjee, Rupak Rivers, William T. Stroud, Robert E. Patel, Risha K. Ruddy, Jean M. Spinale, Francis G. TI Chronic Localized High-Frequency Electrical Stimulation Within the Myocardial Infarct Attenuates Infarct Expansion Through Transforming Growth Factor-beta Signaling SO CIRCULATION LA English DT Meeting Abstract DE Myocardial infarction; Remodeling; Growth factors C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A10085 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600425 ER PT J AU Reust, DL Dixon, JA McKinney, RA Patel, RK Rivers, WT Mukherjee, R Stroud, RE Reeves, ST Abernathy, JH Spinale, FG AF Reust, Daryl L. Dixon, Jennifer A. McKinney, Richard A. Patel, Risha K. Rivers, William T. Mukherjee, Rupak Stroud, Robert E. Reeves, Scott T. Abernathy, James H. Spinale, Francis G. TI Continuous Localized Monitoring of Plasmin Activity Identifies Differential and Regional Effects of the Serine Protease Inhibitor Aprotinin: Relevance to Antifibrinolytic Therapy SO CIRCULATION LA English DT Meeting Abstract DE Cardiac surgery; Fibrinolytic agents C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12431 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600839 ER PT J AU Spinale, FG Toole, JM Yarbrough, WM Patel, RK O'Quinn, EC Gengler, I Gillis, JF Stroud, RE Ikonomidis, JS AF Spinale, Francis G. Toole, John M. Yarbrough, William M. Patel, Risha K. O'Quinn, Elizabeth C. Gengler, Isabelle Gillis, Jenna F. Stroud, Robert E. Ikonomidis, John S. TI The Unique Membrane Type-1 Matrix Metalloproteinase is Constitutively Active Within the Human Myocardial Interstitium and Dynamically Changes with Ischemia-Reperfusion SO CIRCULATION LA English DT Meeting Abstract DE Ischemia reperfusion; Proteolytic enzymes; Myocardium C1 [Spinale, Francis G.; Toole, John M.; Yarbrough, William M.; Patel, Risha K.; O'Quinn, Elizabeth C.; Gengler, Isabelle; Gillis, Jenna F.; Stroud, Robert E.; Ikonomidis, John S.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A15925 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602017 ER PT J AU Spinale, FG Zavadzkas, JA Stroud, RE Rivers, WT McKinney, RA Chang, EI Plyler, RA Bouges, S Mukherjee, R AF Spinale, Francis G. Zavadzkas, Juozas A. Stroud, Robert E. Rivers, William T. McKinney, Richard A. Chang, Eileen I. Plyler, Rebecca A. Bouges, Shenikqua Mukherjee, Rupak TI Myocardial Induction of Tissue Inhibitor of Matrix Metalloproteinase-4 Modifies Post Myocardial Infarction Left Ventricular Remodeling SO CIRCULATION LA English DT Meeting Abstract DE Myocardial infarction; Remodeling; Proteolytic enzymes C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A15791 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601942 ER PT J AU Spinale, FG Mukherjee, R Zavadzkas, JA Koval, CN Stroud, RE Rivers, WT McKinney, RA AF Spinale, Francis G. Mukherjee, Rupak Zavadzkas, Juozas A. Koval, Christine N. Stroud, Robert E. Rivers, William T. McKinney, Richard A. TI Altering Myocardial Membrane Type-1 Following Myocardial Infarction Directly Affects LV Remodeling and Function Through a Novel Fibrotic Signaling Cascade SO CIRCULATION LA English DT Meeting Abstract DE Myocardial infarction; Proteolytic enzymes; Remodeling C1 [Spinale, Francis G.; Mukherjee, Rupak; Zavadzkas, Juozas A.; Koval, Christine N.; Stroud, Robert E.; Rivers, William T.; McKinney, Richard A.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12801 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601075 ER PT J AU Spinale, FG Zavadzkas, JA Koval, CN Stroud, RE Plyler, RA Rivers, WT McKinney, RA Mukherjee, R AF Spinale, Francis G. Zavadzkas, Juozas A. Koval, Christine N. Stroud, Robert E. Plyler, Rebecca A. Rivers, William T. McKinney, Richard A. Mukherjee, Rupak TI Direct Regulation of Myocardial Membrane Type-1 Following Myocardial Infarction Causes Changes in Survival, Function and Remodeling SO CIRCULATION LA English DT Meeting Abstract DE Myocardial infarction; Proteolytic enzymes; Remodeling C1 [Spinale, Francis G.; Zavadzkas, Juozas A.; Koval, Christine N.; Stroud, Robert E.; Plyler, Rebecca A.; Rivers, William T.; McKinney, Richard A.; Mukherjee, Rupak] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12796 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601071 ER PT J AU Stroud, RE Ikonomidis, JS Yarbrough, WM Toole, JM O'Quinn, EC Gengler, I Spinale, FG AF Stroud, Robert E. Ikonomidis, John S. Yarbrough, William M. Toole, John M. O'Quinn, Elizabeth C. Gengler, Isabelle Spinale, Francis G. TI The Human Myocardial Interstitium Contains a Specific Portfolio of microRNAs which are Dynamically Regulated Following Ischemia-Reperfusion SO CIRCULATION LA English DT Meeting Abstract DE Ischemia reperfusion; Myocardium C1 [Stroud, Robert E.; Ikonomidis, John S.; Yarbrough, William M.; Toole, John M.; O'Quinn, Elizabeth C.; Gengler, Isabelle; Spinale, Francis G.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A13152 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601168 ER PT J AU Tsai, TT Messenger, JC Brennan, JM Patel, UD Dai, D Piana, R Anstrom, KJ Eisenstein, EL Dokholyan, RS Peterson, ED Douglas, PS AF Tsai, Thomas T. Messenger, John C. Brennan, J. Matthew Patel, Uptal D. Dai, David Piana, Robert Anstrom, Kevin J. Eisenstein, Eric L. Dokholyan, Rachel S. Peterson, Eric D. Douglas, Pamela S. TI Contemporary Risk of Follow-up Adverse Events in Older Patients with Chronic Kidney Disease and Dialysis Undergoing Percutaneous Coronary Interventions: A Report from the Merged NCDR CMS Registry SO CIRCULATION LA English DT Meeting Abstract DE Percutaneous coronary intervention; Renal function; Aging; Health services research C1 Denver VAMC, Denver, CO USA. Univ Colorado Denver, Denver, CO USA. Duke Univ, Med Cntr, Durham, NC USA. Vanderbilt Univ, Med Cntr, Nashville, TN USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A19884 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231603306 ER PT J AU Yarbrough, WM Van Laer, A Rivers, WT McKinney, RA O'Quinn, EC Black, LE Stroud, RE Zile, MR Mukherjee, R Spinale, FG AF Yarbrough, William M. Van Laer, An Rivers, William T. McKinney, Richard A. O'Quinn, Elizabeth C. Black, Laurel E. Stroud, Robert E. Zile, Michael R. Mukherjee, Rupak Spinale, Francis G. TI Direct Modulation of Myocardial Tissue Inhibitor of Matrix Metalloproteinase-4 Alters the Course of Myocardial Growth and Matrix Remodeling with Pressure Overload SO CIRCULATION LA English DT Meeting Abstract DE Hypertrophy; Remodeling C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A13228 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601200 ER PT J AU Yarbrough, WM Van Laer, A Rivers, WT McKinney, RA Black, LE Stroud, RE Zile, MR Mukherjee, R Spinale, FG AF Yarbrough, William M. Van Laer, An Rivers, William T. McKinney, Richard A. Black, Laurel E. Stroud, Robert E. Zile, Michael R. Mukherjee, Rupak Spinale, Francis G. TI Tissue Inhibitor of Matrix Metalloproteinase-4 Overexpression and Deletion- Effects on Survival and Collagen Accumulation with Pressure Overload Hypertrophy SO CIRCULATION LA English DT Meeting Abstract DE Hypertrophy; Remodeling; Proteolytic enzymes C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12601 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600905 ER PT J AU Zile, MR Baicu, CF Van Laer, A Patel, RK Black, LE Stroud, RE Mukherjee, R Spinale, FG AF Zile, Michael R. Baicu, Catalin F. Van Laer, An Patel, Risha K. Black, Laurel E. Stroud, Robert E. Mukherjee, Rupak Spinale, Francis G. TI Role of Membrane Type-1 Matrix Metalloproteinase Expression in Pressure-Overload Induced Left Ventricular Remodeling SO CIRCULATION LA English DT Meeting Abstract DE Hypertrophy; Proteolytic enzymes; Remodeling C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A13207 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601188 ER PT J AU Zile, MR DeSantis, SM Baicu, CF Prescott, CB Stroud, RE Thompson, SB McClure, CD Spinale, FG AF Zile, Michael R. DeSantis, Stacia M. Baicu, Catalin F. Prescott, Corey B. Stroud, Robert E. Thompson, Sheila B. McClure, Catherine D. Spinale, Francis G. TI Plasma Galectin-3 Levels in Patients with Structural and Clinical Manifestations of Hypertensive Heart Disease: Relationship to Determinants of Matrix Composition SO CIRCULATION LA English DT Meeting Abstract DE Hypertension; Heart disease C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12433 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600840 ER PT J AU Zile, MR Baicu, CF Stroud, RE Van Laer, A Mukherjee, R Spinale, FG AF Zile, Michael R. Baicu, Catalin F. Stroud, Robert E. Van Laer, An Mukherjee, Rupak Spinale, Francis G. TI Effects of Pressure-Overload Induced Left Ventricular Remodeling on Membrane Type-1 Matrix Metalloproteinase Promoter Activation and Expression SO CIRCULATION LA English DT Meeting Abstract DE Hypertrophy; Proteolytic enzymes C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12438 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600842 ER PT J AU Zile, MR Mehurg, SM O'Quinn, EC Stroud, RE DeSantis, SM Spinale, FG AF Zile, Michael R. Mehurg, Shannon M. O'Quinn, Elizabeth C. Stroud, Robert E. DeSantis, Stacia M. Spinale, Francis G. TI Plasma microRNA in Patients with Hypertensive Heart Disease: Differential Expression in Left Ventricular Hypertrophy versus Diastolic Heart Failure SO CIRCULATION LA English DT Meeting Abstract DE Hypertension; Heart failure C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12427 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600837 ER PT J AU Kullgren, JT Galbraith, AA Hinrichsen, VL Miroshnik, I Penfold, RB Rosenthal, MB Landon, BE Lieu, TA AF Kullgren, Jeffrey T. Galbraith, Alison A. Hinrichsen, Virginia L. Miroshnik, Irina Penfold, Robert B. Rosenthal, Meredith B. Landon, Bruce E. Lieu, Tracy A. TI Health Care Use and Decision Making Among Lower-Income Families in High-Deductible Health Plans SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID BLUNT INSTRUMENT; INSURANCE; COMMUNICATION; AWARENESS; COSTS AB Background: Lower-income families may face unique challenges in high-deductible health plans (HDHPs). Methods: We administered a cross-sectional survey to a stratified random sample of families in a New England health plan's HDHP with at least $500 in annualized out-of-pocket expenditures. Lower-income families were defined as having incomes that were less than 300% of the federal poverty level. Primary outcomes were costrelated delayed or foregone care, difficulty understanding plans, unexpected costs, information-seeking, and likelihood of families asking their physician about hypothetical recommended services subject to the plan deductible. Multivariate logistic regression was used to control for potential confounders of associations between income group and primary outcomes. Results: Lower-income families (n= 141) were more likely than higher-income families (n= 273) to report costrelated delayed or foregone care (57% vs 42%; adjusted odds ratio [AOR], 1.81; 95% confidence interval [CI], 1.15-2.83]). There were no differences in plan understanding, unexpected costs, or information-seeking by income. Lower-income families were more likely than others to say they would ask their physician about a $100 blood test (79% vs 63%; AOR, 1.97; 95% CI, 1.18-3.28) or a $1000 screening colonoscopy (89% vs 80%; AOR, 2.04; 95% CI, 1.06-3.93) subject to the plan deductible. Conclusions: Lower-income families with out-of-pocket expenditures in an HDHP were more likely than higher-income families to report cost-related delayed or foregone care but did not report more difficulty understanding or using their plans, and might be more likely to question services requiring out-of-pocket expenditures. Policymakers and physicians should consider focused monitoring and benefit design modifications to support lower-income families in HDHPs. C1 [Kullgren, Jeffrey T.] Univ Penn, Robert Wood Johnson Fdn Clin Scholars, Philadelphia, PA 19104 USA. [Kullgren, Jeffrey T.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Kullgren, Jeffrey T.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Lieu, Tracy A.] Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA. [Kullgren, Jeffrey T.] Brigham & Womens Hosp, Residency Program Primary Care & Populat Hlth, Boston, MA 02115 USA. [Kullgren, Jeffrey T.; Galbraith, Alison A.; Hinrichsen, Virginia L.; Miroshnik, Irina; Penfold, Robert B.; Lieu, Tracy A.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA. [Galbraith, Alison A.; Hinrichsen, Virginia L.; Miroshnik, Irina; Penfold, Robert B.; Lieu, Tracy A.] Ctr Child Hlth Care Studies, Boston, MA USA. [Rosenthal, Meredith B.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Landon, Bruce E.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. RP Kullgren, JT (reprint author), Univ Penn, Robert Wood Johnson Fdn Clin Scholars, 1303B Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM kullgren@mail.med.upenn.edu OI Rosenthal, Meredith/0000-0003-3410-0184 FU National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland [HD053440]; NICHD [HD047667, HD052742] FX This study was supported by an R21 grant (HD053440) from the National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland. Dr Lieu's effort was supported in part by a K24 Mid-Career Development Award from NICHD (HD047667). Dr Galbraith's effort was supported in part by a K23 Mentored Career Development Award from NICHD (HD052742). NR 28 TC 21 Z9 21 U1 0 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 22 PY 2010 VL 170 IS 21 BP 1918 EP 1925 DI 10.1001/archinternmed.2010.428 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 683MN UT WOS:000284480000012 PM 21098352 ER PT J AU Ancha, HR Fajardo, NR Bauman, WA Rosman, AS Galea, M Creasey, G Korsten, MA AF Ancha, Hanumantha R. Fajardo, Noel R. Bauman, William A. Rosman, Alan S. Galea, Marinella Creasey, Graham Korsten, Mark A. TI Absence of high amplitude propagating contractions in subjects with chronic spinal cord injury SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Spinal cord injury; Neurogenic bowel; Bowel motility; High amplitude propagating contractions; Motility index ID COLONIC MOTOR-ACTIVITY; SLOW-TRANSIT CONSTIPATION; 24 HOUR; MOTILITY; MANOMETRY AB AIM: To investigate the presence or absence of high amplitude propagating contractions (HAPC), as well as the other measures of colonic motility, in persons with spinal cord injury (SCI). METHODS: Prolonged colonic ambulatory manometric studies were performed on 14 male volunteers: 8 with SCI (mean age, 59 +/- 13 years; mean duration of injury, 13 +/- 4 years) and 6 healthy able-bodied controls (mean age, 57 +/- 10 years). A solid-state manometry catheter was endoscopically clipped to the splenic flexure. Recording was performed for > 24 h after manometric catheter placement. RESULTS: HAPC were absent in individuals with SCI during pre-sleep, sleep, and post-sleep phases. HAPC were significantly increased after awakening in non-SCI controls (0.8 +/- 0.2 HAPC/h vs 10.5 +/- 2.0 HAPC/h, P < 0.005). The motility index was lower in those with SCI than in controls pre- and post-sleep (SCI vs non-SCI: Pre-sleep, 2.4 +/- 0.4 vs 8.8 +/- 1.9, P < 0.01; Post-sleep, 4.3 +/- 0.8 vs 16.5 +/- 4.5, P < 0.05). However; a sleep-induced depression of colonic motility was observed in both the SCI and non-SCI groups (Pre-sleep vs Sleep, non-SCI: 8.8 1.9 vs 2.1 +/- 0.9, P < 0.002; SCI: 2.4 +/- 0.4 vs 0.2 +/- 0.03, P < 0.001), with the motility index of those with SCI during sleep not significantly different than that of the controls. CONCLUSION: HAPC were not observed in individuals with SCI pre- or post-sleep. A sleep-induced depression in general colonic motility was evident in SCI and control subjects. (C) 2010 Baishideng. All rights reserved. C1 [Korsten, Mark A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Ancha, Hanumantha R.; Fajardo, Noel R.; Bauman, William A.; Rosman, Alan S.; Korsten, Mark A.] James J Peters VA Med Ctr, Rehabil Res & Dev Ctr Excellence Med Consequences, Bronx, NY 10468 USA. [Bauman, William A.; Rosman, Alan S.; Korsten, Mark A.] Mt Sinai Sch Med, Dept Med, Bronx, NY 10468 USA. [Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, Bronx, NY 10468 USA. [Galea, Marinella] James J Peters VA Med Ctr, Spinal Cord Injury Serv, Bronx, NY 10468 USA. [Creasey, Graham] VA Med Ctr, Spinal Cord Injury Serv, Palo Alto, CA 94304 USA. RP Korsten, MA (reprint author), James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. EM mark.korsten@va.gov FU Department of Veterans Affairs Rehabilitation Research and Development Service Center of Excellence for the Medical Consequences of Spinal Cord Injury [B4162C] FX Supported by The Department of Veterans Affairs Rehabilitation Research and Development Service Center of Excellence for the Medical Consequences of Spinal Cord Injury (B4162C) NR 22 TC 1 Z9 2 U1 0 U2 0 PU BAISHIDENG PUBLISHING GROUP INC PI PLEASANTON PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA SN 1007-9327 EI 2219-2840 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD NOV 21 PY 2010 VL 16 IS 43 BP 5435 EP 5439 DI 10.3748/wjg.v16.i43.5435 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 683SC UT WOS:000284494500006 PM 21086560 ER PT J AU Bagby, GC Yates, J Anur, P Rathbuin, K Harrington, C Pasquini, R Pelz, C AF Bagby, Grover C., Jr. Yates, Jane Anur, Praveen Rathbuin, Keaney Harrington, Christina Pasquini, Ricardo Pelz, Carl TI Clonal Evolution In Fanconi Anemia; The Role of HOXA9 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Pelz, Carl] Oregon Hlth & Sci Univ, Mol & Med Genet & Stem Cell Ctr, Portland, OR 97201 USA. [Bagby, Grover C., Jr.] Portland VA Med Ctr, Portland, OR USA. [Yates, Jane; Rathbuin, Keaney] NW VA Canc Res Ctr, Portland, OR USA. [Harrington, Christina] Gene Microarray Shared Resource, Portland, OR USA. [Pasquini, Ricardo] Univ Fed Parana, Hosp Clin, BR-80060000 Curitiba, Parana, Brazil. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 61 EP 61 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200127 ER PT J AU D'Souza, S Kurihara, N Shiozawa, Y Taichman, R Galson, D Roodman, D AF D'Souza, Sonia Kurihara, Noriyoshi Shiozawa, Yusuke Taichman, Russell Galson, Deborah Roodman, David TI Annexin II Interactions with the Annexin II Receptor Enhance Multiple Myeloma Cell Adhesion and Growth In the Bone Marrow Microenvironment SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [D'Souza, Sonia; Kurihara, Noriyoshi; Galson, Deborah; Roodman, David] Univ Pittsburgh, Bone Biol Ctr, UPMC, Pittsburgh, PA USA. [D'Souza, Sonia; Kurihara, Noriyoshi; Galson, Deborah; Roodman, David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Shiozawa, Yusuke; Taichman, Russell] Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 62 EP 62 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200131 ER PT J AU Teramachi, J Windle, JJ Roodman, D Kurihara, N AF Teramachi, Jumpei Windle, Jolene J. Roodman, David Kurihara, Noriyoshi TI The ZZ Domain of Sequestosome-1/p62 Plays An Important Role In Stromal Cell Support of Myeloma Cell Growth and Osteoclast Formation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Teramachi, Jumpei; Roodman, David; Kurihara, Noriyoshi] Univ Pittsburgh, Pittsburgh, PA USA. [Teramachi, Jumpei; Roodman, David; Kurihara, Noriyoshi] UPMC, Ctr Bone Biol, Pittsburgh, PA USA. [Windle, Jolene J.] Virginia Commonwealth Univ, Richmond, VA USA. [Roodman, David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 62 EP 62 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200129 ER PT J AU Li, SR Pal, R Monaghan, S Schafer, P Ouyang, H Mapara, MY Lentzsch, S AF Li, Shirong Pal, Rekha Monaghan, Sara Schafer, Peter Ouyang, Hongjiao Mapara, Markus Y. Lentzsch, Suzanne TI C/EBPb Is a Critical Mediator of Resistance to IMiD (R) Immunomodulatory Compounds and Affected by IMiD Compounds Via Control of Protein Translation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Li, Shirong; Pal, Rekha; Mapara, Markus Y.; Lentzsch, Suzanne] Univ Pittsburgh, Inst Canc, Div Hematol Oncol, Pittsburgh, PA USA. [Monaghan, Sara] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA USA. [Schafer, Peter] Celgene Corp, Translat Dev, Summit, NJ USA. [Ouyang, Hongjiao] VA Pittsburgh Healthcare Syst, Ctr Bone Biol, Pittsburgh, PA USA. RI mapara, markus/A-2134-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 64 EP 65 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200136 ER PT J AU Sorror, ML Storer, B Sandmaier, BM Franke, GN Laport, GG Chauncey, T Agura, E Maris, MT Wade, J Pulsipher, MA Maziarz, RT Sahebi, F McSweeney, P Bruno, B Vindelov, L Yeager, AM Rezvani, A Niederwieser, DW Blume, KG Storb, RF Maloney, DG AF Sorror, Mohamed L. Storer, Barry Sandmaier, Brenda M. Franke, Georg N. Laport, Ginna G. Chauncey, Thomas Agura, Edward Maris, Michael T. Wade, James Pulsipher, Michael A. Maziarz, Richard T. Sahebi, Firoozeh McSweeney, Peter Bruno, Benedetto Vindelov, Lars Yeager, Andrew M. Rezvani, Andrew Niederwieser, Dietger W. Blume, Karl G. Storb, Rainer F. Maloney, David G. TI Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Sorror, Mohamed L.; Storer, Barry; Sandmaier, Brenda M.; Chauncey, Thomas; Rezvani, Andrew; Storb, Rainer F.; Maloney, David G.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Franke, Georg N.; Niederwieser, Dietger W.] Univ Leipzig, Leipzig, Germany. [Laport, Ginna G.; Blume, Karl G.] Stanford Univ, Stanford, CA 94305 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Agura, Edward] Baylor Univ, Dallas, TX USA. [Maris, Michael T.] Rocky Mt Canc Ctr, Denver, CO USA. [Wade, James] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Sahebi, Firoozeh] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [McSweeney, Peter] Univ Colorado, Boulder, CO 80309 USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [Vindelov, Lars] Rigshosp, DK-2100 Copenhagen, Denmark. [Yeager, Andrew M.] Univ Arizona, Tucson, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 553 EP 553 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201395 ER PT J AU Varadarajan, P Toro, J Craig, RM Schneider, D Chao, JH Haile, D Freytes, CO AF Varadarajan, Prakash Toro, Juan Craig, Robert M. Schneider, Deanna Chao, Ju-Hsien Haile, David Freytes, Cesar O. TI Does Bisphosphonate-Induced Osteonecrosis of the Jaw (BONJ) Preclude Intensive Chemotherapy? Oral and Infectious Toxicities Associated with Autotransplantation In Patients with BONJ SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Varadarajan, Prakash; Haile, David; Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Toro, Juan; Craig, Robert M.; Schneider, Deanna; Chao, Ju-Hsien] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 562 EP 563 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201417 ER PT J AU Sorror, ML Storer, B Sandmaier, BM Braunert, L Laport, GG Chauncey, T Bredeson, C Maziarz, RT Pulsipher, MA Agura, E Mans, MT Vindelov, L Sahebi, F McSweeney, P Bruno, B Langston, A Storb, RF Maloney, DG AF Sorror, Mohamed L. Storer, Barry Sandmaier, Brenda M. Braunert, Leanthe Laport, Ginna G. Chauncey, Thomas Bredeson, Christopher Maziarz, Richard T. Pulsipher, Michael A. Agura, Edward Mans, Michael T. Vindelov, Lars Sahebi, Firoozeh McSweeney, Peter Bruno, Benedetto Langston, Amelia Storb, Rainer F. Maloney, David G. TI Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Sorror, Mohamed L.; Storer, Barry; Sandmaier, Brenda M.; Chauncey, Thomas; Storb, Rainer F.; Maloney, David G.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Braunert, Leanthe] Univ Leipzig, Leipzig, Germany. [Laport, Ginna G.] Stanford Univ, Stanford, CA 94305 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Bredeson, Christopher] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA. [Agura, Edward] Baylor Univ, Dallas, TX USA. [Mans, Michael T.] Rocky Mt Canc Ctr, Denver, CO USA. [Vindelov, Lars] Rigshosp, DK-2100 Copenhagen, Denmark. [Sahebi, Firoozeh] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [McSweeney, Peter] Univ Colorado, Boulder, CO 80309 USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [Langston, Amelia] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 978 EP 978 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202587 ER PT J AU Sorror, ML Storer, B Sandmaier, BM Chauncey, T Maris, MT Storb, RF Maloney, DG AF Sorror, Mohamed L. Storer, Bany Sandmaier, Brenda M. Chauncey, Thomas Maris, Michael T. Storb, Rainer F. Maloney, David G. TI Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Sorror, Mohamed L.; Storer, Bany; Sandmaier, Brenda M.; Chauncey, Thomas] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Maris, Michael T.] Rocky Mt Canc Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 979 EP 979 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202588 ER PT J AU Doolittle, ND Kraemer, DF Lacy, C Tyson, RM Neuwelt, EA AF Doolittle, Nancy D. Kraemer, Dale F. Lacy, Cynthia Tyson, Rose Marie Neuwelt, Edward A. TI Enhanced Delivery of Rituximab In Combination with Methotrexate-Based Blood-Brain Barrier Disruption for patients with Newly Diagnosed Primary CNS Lymphoma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Dept Neurosurg, Portland, OR 97201 USA. [Kraemer, Dale F.] Oregon State Univ, Dept Pharm Practice, Portland, OR USA. [Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 1 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1151 EP 1151 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203124 ER PT J AU Scott, BL Gooley, TA Linenberger, ML Sandmaier, BM Myerson, D Chauncey, T Appelbaum, FR Deeg, HJ AF Scott, Bart Lee Gooley, Ted A. Linenberger, Michael L. Sandmaier, Brenda M. Myerson, David Chauncey, Thomas Appelbaum, Frederick R. Deeg, H. Joachim TI International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Scott, Bart Lee; Gooley, Ted A.; Linenberger, Michael L.; Sandmaier, Brenda M.; Myerson, David; Chauncey, Thomas; Appelbaum, Frederick R.; Deeg, H. Joachim] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1272 EP 1272 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203417 ER PT J AU Gyurkocza, B Storb, R Storer, BE Chauncey, T Lange, T Laport, GG Langston, A Pulsipher, MA Bredeson, C Maziarz, R Bruno, B Petersen, F Maris, M Agura, E Yeager, AM Bethge, WA Sahebi, F Appelbaum, FR Maloney, DG Estey, EH Sandmaier, BM AF Gyurkocza, Boglarka Storb, Rainer Storer, Barry E. Chauncey, Thomas Lange, Thoralf Laport, Ginna G. Langston, Amelia Pulsipher, Michael A. Bredeson, Christopher Maziarz, Richard Bruno, Benedetto Petersen, Finn Maris, Michael Agura, Edward Yeager, Andrew M. Bethge, Wolfgang A. Sahebi, Firoozeh Appelbaum, Frederick R. Maloney, David G. Estey, Elihu H. Sandmaier, Brenda M. TI A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Gyurkocza, Boglarka; Storb, Rainer; Storer, Barry E.; Appelbaum, Frederick R.; Maloney, David G.; Estey, Elihu H.; Sandmaier, Brenda M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Gyurkocza, Boglarka; Storb, Rainer; Storer, Barry E.; Appelbaum, Frederick R.; Maloney, David G.; Estey, Elihu H.; Sandmaier, Brenda M.] Univ Washington, Seattle, WA 98195 USA. [Chauncey, Thomas] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Lange, Thoralf] Univ Leipzig, Leipzig, Germany. [Laport, Ginna G.] Stanford Univ, Stanford, CA 94305 USA. [Langston, Amelia] Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA. [Pulsipher, Michael A.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Bredeson, Christopher] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Maziarz, Richard] Oregon Hlth & Sci Univ, Ctr Clin Canc, Portland, WI USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [Petersen, Finn] LDS Hosp, Intermountain Blood & Marrow Trans Prog, Salt Lake City, UT USA. [Maris, Michael] Rocky Mt Blood & Marrow Trans, Denver, CO USA. [Agura, Edward] Baylor Univ, Med Ctr, BMT, Dallas, TX USA. [Yeager, Andrew M.] Univ Arizona, Tucson, AZ USA. [Bethge, Wolfgang A.] Univ Tubingen, Dept Med Hematol Oncol, Tubingen, Germany. [Sahebi, Firoozeh] City Hope Natl Med Ctr, Duarte, CA 91010 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1415 EP 1416 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203781 ER PT J AU Hutchinson, CB Crow, JH Qin, H Lu, CM Sebastain, S Rehder, C Lagoo, AS Goodman, B Horwitz, ME Rizzieri, DA Datto, M Buckley, P Wang, E AF Hutchinson, Charles Blake Crow, Jennifer H. Qin Huang Lu, Chuanyi M. Sebastain, Siby Rehder, Catherine Lagoo, Anand S. Goodman, Barbara Horwitz, Mitchell E. Rizzieri, David A. Datto, Michael Buckley, Patrick Wang, Endi TI Donor Cell Leukemia: A Clinicopathological Study of 9 Cases and a Comprehensive Review of Literature SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Hutchinson, Charles Blake; Crow, Jennifer H.; Sebastain, Siby; Rehder, Catherine; Lagoo, Anand S.; Goodman, Barbara; Datto, Michael; Buckley, Patrick; Wang, Endi] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA. [Qin Huang] City Hope Natl Canc Ctr, Dept Pathol, Duarte, CA USA. [Lu, Chuanyi M.] San Francisco VA Med Ctr, Lab Med Serv, San Francisco, CA USA. [Horwitz, Mitchell E.; Rizzieri, David A.] Duke Univ, Med Ctr, Div Cellular Therapy, Durham, NC USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1423 EP 1424 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203797 ER PT J AU Utz, K Neumon, B Frye, BL Chao, JH Toro, J Haile, D Freytes, C AF Utz, Kenneth Neumon, Bonita Frye, Brenda L. Chao, Ju-Hsien Toro, Juan Haile, David Freytes, Cesar TI Have Clinicians Adopted the International Uniform Response Criteria (IURC) for Multiple Myeloma (MM)? Adherence to the IURC for Posttransplant Evaluations In Patients with Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Utz, Kenneth] S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp, Dept Pharm, San Antonio, TX USA. [Frye, Brenda L.] Audie Murphy Vet Affairs BMT, San Antonio, TX USA. [Freytes, Cesar] Audie L Murphy Mem Vet Adm Med Ctr, Med Serv 111 BMT, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 43 EP 43 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200085 ER PT J AU Devine, EB Williams, EC Martin, DP Sittig, DF Tarczy-Hornoch, P Payne, TH Sullivan, SD AF Devine, Emily Beth Williams, Emily C. Martin, Diane P. Sittig, Dean F. Tarczy-Hornoch, Peter Payne, Thomas H. Sullivan, Sean D. TI Prescriber and staff perceptions of an electronic prescribing system in primary care: a qualitative assessment SO BMC MEDICAL INFORMATICS AND DECISION MAKING LA English DT Article ID PHYSICIAN ORDER ENTRY; CLINICAL DECISION-SUPPORT; ADVERSE DRUG EVENTS; MEDICATION ERRORS; INFORMATION-TECHNOLOGY; CROSS-SITE; HEALTH-CARE; IMPLEMENTATION; EXPERIENCES; HOSPITALS AB Background: The United States (US) Health Information Technology for Economic and Clinical Health Act of 2009 has spurred adoption of electronic health records. The corresponding meaningful use criteria proposed by the Centers for Medicare and Medicaid Services mandates use of computerized provider order entry (CPOE) systems. Yet, adoption in the US and other Western countries is low and descriptions of successful implementations are primarily from the inpatient setting; less frequently the ambulatory setting. We describe prescriber and staff perceptions of implementation of a CPOE system for medications (electronic-or e-prescribing system) in the ambulatory setting. Methods: Using a cross-sectional study design, we conducted eight focus groups at three primary care sites in an independent medical group. Each site represented a unique stage of e-prescribing implementation - pre/transition/post. We used a theoretically based, semi-structured questionnaire to elicit physician (n = 17) and staff (n = 53) perceptions of implementation of the e-prescribing system. We conducted a thematic analysis of focus group discussions using formal qualitative analytic techniques (i.e. deductive framework and grounded theory). Two coders independently coded to theoretical saturation and resolved discrepancies through discussions. Results: Ten themes emerged that describe perceptions of e-prescribing implementation: 1) improved availability of clinical information resulted in prescribing efficiencies and more coordinated care; 2) improved documentation resulted in safer care; 3) efficiencies were gained by using fewer paper charts; 4) organizational support facilitated adoption; 5) transition required time; resulted in workload shift to staff; 6) hardware configurations and network stability were important in facilitating workflow; 7) e-prescribing was time-neutral or time-saving; 8) changes in patient interactions enhanced patient care but required education; 9) pharmacy communications were enhanced but required education; 10) positive attitudes facilitated adoption. Conclusions: Prescribers and staff worked through the transition to successfully adopt e-prescribing, and noted the benefits. Overall impressions were favorable. No one wished to return to paper-based prescribing. C1 [Devine, Emily Beth; Sullivan, Sean D.] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA. [Devine, Emily Beth; Tarczy-Hornoch, Peter] Univ Washington, Dept Med Educ & Biomed Informat, Seattle, WA 98195 USA. [Williams, Emily C.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Williams, Emily C.; Martin, Diane P.; Sullivan, Sean D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Sittig, Dean F.] Univ Texas Houston, Sch Hlth Informat Sci, UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX 77030 USA. [Payne, Thomas H.; Sullivan, Sean D.] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Devine, EB (reprint author), Univ Washington, Pharmaceut Outcomes Res & Policy Program, Box 357630, Seattle, WA 98195 USA. EM bdevine@uw.edu OI Tarczy-Hornoch, Peter/0000-0003-1047-179X FU AHRQ Health Information Technology [5-UC1 HS015319]; AHRQ Mentored Clinical Scientist Training [5-K-08-HS014739] FX AHRQ Health Information Technology Grant #: 5-UC1 HS015319 (PI: Sullivan) AHRQ Mentored Clinical Scientist Training Grant #: 5-K-08-HS014739 (PI: Devine) NR 57 TC 9 Z9 9 U1 6 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6947 J9 BMC MED INFORM DECIS JI BMC Med. Inform. Decis. Mak. PD NOV 19 PY 2010 VL 10 AR 72 DI 10.1186/1472-6947-10-72 PG 12 WC Medical Informatics SC Medical Informatics GA 688VR UT WOS:000284883200001 PM 21087524 ER PT J AU Coker, TR Chan, LS Newberry, SJ Limbos, MA Suttorp, MJ Shekelle, PG Takata, GS AF Coker, Tumaini R. Chan, Linda S. Newberry, Sydne J. Limbos, Mary Ann Suttorp, Marika J. Shekelle, Paul G. Takata, Glenn S. TI Diagnosis, Microbial Epidemiology, and Antibiotic Treatment of Acute Otitis Media in Children A Systematic Review SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID PNEUMOCOCCAL CONJUGATE VACCINE; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND TRIAL; PRESCRIBING STRATEGIES; CLINICAL-EFFICACY; GENERAL-PRACTICE; AMOXICILLIN; MANAGEMENT; CEFACLOR; PLACEBO AB Context Acute otitis media (AOM) is the most common condition for which antibiotics are prescribed for US children; however, wide variation exists in diagnosis and treatment. Objectives To perform a systematic review on AOM diagnosis, treatment, and the association of heptavalent pneumococcal conjugate vaccine (PCV7) use with AOM microbiology. Data Sources PubMed, Cochrane Databases, and Web of Science, searched to identify articles published from January 1999 through July 2010. Study Selection Diagnostic studies with a criterion standard, observational studies and randomized controlled trials comparing AOM microbiology with and without PCV7, and randomized controlled trials assessing antibiotic treatment. Data Extraction Independent article review and study quality assessment by 2 investigators with consensus resolution of discrepancies. Results Of 8945 citations screened, 135 were included. Meta-analysis was performed for comparisons with 3 or more trials. Few studies examined diagnosis; otoscopic findings of tympanic membrane bulging (positive likelihood ratio, 51[95% confidence interval {CI}, 36-73]) and redness (positive likelihood ratio, 8.4 [95% CI, 7-11]) were associated with accurate diagnosis. In the few available studies, prevalence of Streptococcus pneumoniae decreased (eg, 33%-48% vs 23%-31% of AOM isolates), while that of Haemophilus influenzae increased (41%-43% vs 56%-57%) pre-vs post-PCV7. Short-term clinical success was higher for immediate use of ampicillin or amoxicillin vs placebo(73% vs 60%; pooled rate difference, 12% [95% CI, 5%-18%]; number needed to treat, 9 [95% CI, 6-20]), while increasing the rate of rash or diarrhea by 3% to 5%. Two of 4 studies showed greater clinical success for immediate vs delayed antibiotics(95% vs 80%; rate difference, 15% [95% CI, 6%-24%] and 86% vs 70%; rate difference, 16% [95% CI, 6%-26%]). Data are absent on long-term effects on antimicrobial resistance. Meta-analyses in general showed no significant differences in antibiotic comparative effectiveness. Conclusions Otoscopic findings are critical to accurate AOM diagnosis. AOM microbiology has changed with use of PCV7. Antibiotics are modestly more effective than no treatment but cause adverse effects in 4% to 10% of children. Most antibiotics have comparable clinical success. JAMA. 2010; 304(19): 2161-2169 C1 [Coker, Tumaini R.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Pediat, Los Angeles, CA 90024 USA. [Coker, Tumaini R.] RAND, Santa Monica, CA USA. [Chan, Linda S.] Los Angeles Cty USC Med Ctr, Div Biostat & Outcomes Assessment, Los Angeles, CA USA. [Chan, Linda S.; Limbos, Mary Ann; Takata, Glenn S.] USC Keck Sch Med, Los Angeles, CA USA. [Newberry, Sydne J.; Suttorp, Marika J.; Shekelle, Paul G.] RAND Hlth, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA. [Shekelle, Paul G.] W Los Angeles VA Med Ctr, Los Angeles, CA USA. [Takata, Glenn S.] Childrens Hosp Los Angeles, Div Gen Pediat, Los Angeles, CA 90027 USA. RP Coker, TR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA RAND Ctr Adolescent Hlth Promot, 10960 Wilshire Blvd,Ste 1550, Los Angeles, CA 90024 USA. EM tcoker@mednet.ucla.edu FU Agency for Healthcare Research and Quality (AHRQ) [290-2007-10056]; EPC FX This article is based on research conducted by the Southern California Evidence-based Practice Center (EPC) under contract with the Agency for Healthcare Research and Quality (AHRQ) (contract 290-2007-10056). This work was commissioned by AHRQ as an update to an earlier report and in support of the update of practice guidelines.; AHRQ had a role, through its sponsorship of the EPC program, in the general methods of EPC systematic reviews and in development of the key questions for each review. However, AHRQ had no role in the specific conduct of the review; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. NR 70 TC 101 Z9 104 U1 1 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 17 PY 2010 VL 304 IS 19 BP 2161 EP 2169 DI 10.1001/jama.2010.1651 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 680XC UT WOS:000284269800027 PM 21081729 ER PT J AU Nardone, DA AF Nardone, David A. TI Open Notes: Sharing Physician Notes With Patients SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 Portland VA Med Ctr, Portland, OR 97239 USA. RP Nardone, DA (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 16 PY 2010 VL 153 IS 10 BP 690 EP 690 DI 10.1059/0003-4819-153-10-201011160-00023 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 680ES UT WOS:000284215800031 PM 21079235 ER PT J AU Turner, EH AF Turner, Erick H. TI Reboxetine in depression All the relevant data? SO BRITISH MEDICAL JOURNAL LA English DT Letter ID TRIALS C1 [Turner, Erick H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Turner, Erick H.] Portland VA Med Ctr, P3MHDC, Portland, OR 97239 USA. RP Turner, EH (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA. EM turnere@ohsu.edu NR 6 TC 4 Z9 4 U1 0 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BRIT MED J JI Br. Med. J. PD NOV 16 PY 2010 VL 341 AR c6487 DI 10.1136/bmj.c6487 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 684WJ UT WOS:000284585600004 PM 21081614 ER PT J AU Seetharaman, SV Taylor, AB Holloway, S Hart, PJ AF Seetharaman, Sai V. Taylor, Alexander B. Holloway, Stephen Hart, P. John TI Structures of mouse SOD1 and human/mouse SOD1 chimeras SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article DE Copper-zinc superoxide dismutase; Amyotrophic lateral sclerosis; X-ray crystallography; Protein aggregation ID AMYOTROPHIC-LATERAL-SCLEROSIS; ZINC SUPEROXIDE-DISMUTASE; MOTOR-NEURON DISEASE; WILD-TYPE; TRANSGENIC MICE; POSTTRANSLATIONAL MODIFICATIONS; ATOMIC STRUCTURES; CRYSTAL-STRUCTURE; COPPER CHAPERONE; FAMILIAL ALS AB Mutations in human copper-zinc superoxide dismutase (SOD1) cause an inherited form of amyotrophic lateral sclerosis (ALS). Inclusions enriched in pathogenic SOD1 accumulate in the spinal cords of transgenic mice expressing these proteins, but endogenous mouse SOD1 is not found as a component of these aggregates. In the accompanying paper, Karch and colleagues analyze aggregation propensities of human/mouse SOD1 chimeras in cell culture and identify two sequence elements in the human enzyme that seem to enhance its aggregation relative to the mouse enzyme. Here, we report the first structure of mouse SOD1 along with those of SOD1 chimeras in which residues 1-80 come from human SOD1 and residues 81-153 come from mouse SOD1 and vice versa. Taken together, the structural and cell-based data suggest a model in which residues Q42 and Q123 in mouse SOD1 modulate non-native SOD1-SOD1 intermolecular interactions at edge strands in the SOD1 Greek key beta-barrel. (C) 2010 Elsevier Inc. All rights reserved. C1 [Seetharaman, Sai V.; Taylor, Alexander B.; Holloway, Stephen; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, XRay Crystallog Core Lab, San Antonio, TX 78229 USA. [Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Hart, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. EM pjhart@biochem.uthscsa.edu FU NIH-NINDS [R01-NS39112, P01-NS04913]; William and Ella Owens Medical Research Foundation; Judith and Jean Pape Adams Charitable Foundation; X-ray Crystallography Core Laboratory; UTHSCSA FX This work was supported by Grants from the NIH-NINDS R01-NS39112 (to PJH), P01-NS04913 (to JSV, DRB, and PJH). SVS was supported in part by the William and Ella Owens Medical Research Foundation and the Judith and Jean Pape Adams Charitable Foundation. Support for the X-ray Crystallography Core Laboratory by the UTHSCSA Executive Research Committee and the San Antonio Cancer Institute is also gratefully acknowledged. We thank Celeste Karch, Mercedes Prudencio, and David Borchelt for continued collaboration and invaluable insight into the biological aspects of aggregation of SOD1 and the SOD1 chimera structures described in this paper. NR 62 TC 8 Z9 11 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD NOV 15 PY 2010 VL 503 IS 2 BP 183 EP 190 DI 10.1016/j.abb.2010.08.014 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 662JU UT WOS:000282804400003 PM 20727846 ER PT J AU Porter, MP AF Porter, Michael P. TI Examining the Association Between Delay in Diagnosis and Decreased Survival in Bladder Cancer SO CANCER LA English DT Editorial Material ID RADICAL CYSTECTOMY; GENDER C1 [Porter, Michael P.] Univ Washington, Dept Urol, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Porter, MP (reprint author), 1660 S Columbian Way S-112-GU, Seattle, WA 98108 USA. EM mporter@u.washington.edu NR 9 TC 4 Z9 4 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD NOV 15 PY 2010 VL 116 IS 22 BP 5122 EP 5125 DI 10.1002/cncr.25290 PG 4 WC Oncology SC Oncology GA 678CP UT WOS:000284047400003 PM 20665888 ER PT J AU Yukl, SA Gianella, S Sinclair, E Epling, L Li, QS Duan, LJ Choi, ALM Girling, V Ho, T Li, PL Fujimoto, K Lampiris, H Hare, CB Pandori, M Haase, AT Gunthard, HF Fischer, M Shergill, AK McQuaid, K Havlir, DV Wong, JK AF Yukl, Steven A. Gianella, Sara Sinclair, Elizabeth Epling, Lorrie Li, Qingsheng Duan, Lijie Choi, Alex L. M. Girling, Valerie Ho, Terence Li, Peilin Fujimoto, Katsuya Lampiris, Harry Hare, C. Bradley Pandori, Mark Haase, Ashley T. Guenthard, Huldrych F. Fischer, Marek Shergill, Amandeep K. McQuaid, Kenneth Havlir, Diane V. Wong, Joseph K. TI Differences in HIV Burden and Immune Activation within the Gut of HIV-Positive Patients Receiving Suppressive Antiretroviral Therapy SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; CD38 ANTIGEN-EXPRESSION; DNA CPG METHYLATION; T-CELL-ACTIVATION; LYMPHOID-TISSUE; HISTONE ACETYLATION; VIRAL SUPPRESSION; TYPE-1 INFECTION; PROGNOSTIC VALUE; RECTAL MUCOSA AB Background. The gut is a major reservoir for human immunodeficiency virus (HIV) in patients receiving antiretroviral therapy (ART). We hypothesized that distinct immune environments within the gut may support varying levels of HIV. Methods. In 8 HIV-1-positive adults who were receiving ART and had CD4(+) T cell counts of >200 cells/mu L and plasma viral loads of <40 copies/mu L, levels of HIV and T cell activation were measured in blood samples and endoscopic biopsy specimens from the duodenum, ileum, ascending colon, and rectum. Results. HIV DNA and RNA levels per CD4(+) T cell were higher in all 4 gut sites compared with those in the blood. HIV DNA levels increased from the duodenum to the rectum, whereas the median HIV RNA level peaked in the ileum. HIV DNA levels correlated positively with T cell activation markers in peripheral blood mononuclear cells (PBMCs) but negatively with T cell activation markers in the gut. Multiply spliced RNA was infrequently detected in gut, and ratios of unspliced RNA to DNA were lower in the colon and rectum than in PBMCs, which reflects paradoxically low HIV transcription, given the higher level of T cell activation in the gut. Conclusions. HIV DNA and RNA are both concentrated in the gut, but the inverse relationship between HIV DNA levels and T cell activation in the gut and the paradoxically low levels of HIV expression in the large bowel suggest that different processes drive HIV persistence in the blood and gut. C1 [Yukl, Steven A.; Choi, Alex L. M.; Li, Peilin; Fujimoto, Katsuya; Lampiris, Harry; Shergill, Amandeep K.; McQuaid, Kenneth; Wong, Joseph K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Yukl, Steven A.; Sinclair, Elizabeth; Epling, Lorrie; Choi, Alex L. M.; Girling, Valerie; Ho, Terence; Li, Peilin; Fujimoto, Katsuya; Lampiris, Harry; Hare, C. Bradley; Shergill, Amandeep K.; McQuaid, Kenneth; Havlir, Diane V.; Wong, Joseph K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sinclair, Elizabeth; Epling, Lorrie; Girling, Valerie; Ho, Terence; Hare, C. Bradley; Havlir, Diane V.] San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Pandori, Mark] Dept Publ Hlth, San Francisco, CA USA. [Li, Qingsheng; Duan, Lijie; Haase, Ashley T.] Univ Minnesota, Minneapolis, MN USA. [Gianella, Sara; Guenthard, Huldrych F.; Fischer, Marek] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland. RP Yukl, SA (reprint author), 4150 Clement St,111W3, San Francisco, CA 94121 USA. EM steven.yukl@ucsf.edu RI gunthard, huldrych/F-1724-2011; Fujimoto, Katsuya/G-2835-2012; Infektiologie, USZ/A-6921-2011 OI gunthard, huldrych/0000-0002-1142-6723; FU US Department of Veterans Affairs; National Institutes of Health [P30-AI027763, NS051145, T32 AI60530]; Swiss National Science Foundation [324730-130865, 3100A0-112670] FX US Department of Veterans Affairs (Merit Award to J.K.W. and S.Y.); National Institutes of Health (grant P30-AI027763 to S.Y., grant NS051145 to J.K.W. and S.Y., and grant T32 AI60530 to D. V. H. and S.Y.); Swiss National Science Foundation (grant to S. G., grant 324730-130865 to H. F. G., and grant 3100A0-112670 to M.F.). NR 47 TC 135 Z9 135 U1 2 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 15 PY 2010 VL 202 IS 10 BP 1553 EP 1561 DI 10.1086/656722 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 665SY UT WOS:000283057000014 PM 20939732 ER PT J AU Montine, TJ Shi, M Quinn, JF Peskind, ER Craft, S Ginghina, C Chung, KA Kim, H Galasko, DR Jankovic, J Zabetian, CP Leverenz, JB Zhang, J AF Montine, Thomas J. Shi, Min Quinn, Joseph F. Peskind, Elaine R. Craft, Suzanne Ginghina, Carmen Chung, Kathryn A. Kim, Hojoong Galasko, Douglas R. Jankovic, Joseph Zabetian, Cyrus P. Leverenz, James B. Zhang, Jing TI CSF A beta(42) and tau in Parkinson's Disease with Cognitive Impairment SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; cognitive impairment; CSF biomarkers; A beta(42); tau ID CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; BIOMARKERS; DEMENTIA; RATIO; BETA AB We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF A beta(42), total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls <= 50 years (35), Controls > 50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Ab42 was reduced in PD-CIND (P < 0.05) and PD-D (P < 0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Ab42 may be a common feature of PD-CIND and PD-D. (c) 2010 Movement Disorder Society C1 [Montine, Thomas J.; Shi, Min; Ginghina, Carmen; Zhang, Jing] Univ Washington, Dept Pathol, Sch Med, Seattle, WA 98104 USA. [Quinn, Joseph F.; Chung, Kathryn A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Peskind, Elaine R.; Craft, Suzanne] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98104 USA. [Peskind, Elaine R.; Leverenz, James B.] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, VA NW Network Mental Illness Res, Seattle, WA USA. [Craft, Suzanne; Kim, Hojoong; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Kim, Hojoong; Zabetian, Cyrus P.; Leverenz, James B.] Univ Washington, Dept Neurol, Sch Med, Seattle, WA 98104 USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Jankovic, Joseph] Baylor Coll Med, Parkinsons Dis Ctr, Houston, TX 77030 USA. [Jankovic, Joseph] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA. RP Montine, TJ (reprint author), Univ Washington, Dept Pathol, Sch Med, 300 9th Ave,Room 713B, Seattle, WA 98104 USA. EM tmontine@uw.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558 FU NIH [ES004696, NS057567, AG025327, AG033398, NS060252, NS062684, AG05136, AG08017] FX This work was supported by grants from the NIH (ES004696, NS057567, AG025327, AG033398, NS060252, NS062684, AG05136, and AG08017), the Michael J. Fox Foundation, the VA, and the Nancy and Buster Alvord Endowment. This support had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. We thank Dr. Kathleen Montine for editorial assistance. NR 19 TC 86 Z9 89 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV 15 PY 2010 VL 25 IS 15 BP 2682 EP 2685 DI 10.1002/mds.23287 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 678FX UT WOS:000284060600032 PM 20818673 ER PT J AU Yin, MT Shi, QH Hoover, DR Anastos, K Sharma, A Young, M Levine, A Cohen, MH Shane, E Golub, ET Tien, PC AF Yin, Michael T. Shi, Qiuhu Hoover, Donald R. Anastos, Kathryn Sharma, Anjali Young, Mary Levine, Alexandra Cohen, Mardge H. Shane, Elizabeth Golub, Elizabeth T. Tien, Phyllis C. TI Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study SO AIDS LA English DT Article DE fracture; fragility fracture; HIV-infected women; premenopausal ID BONE-MINERAL DENSITY; ANTIRETROVIRAL THERAPY; AIDS PATIENTS; MEN; OSTEOPOROSIS; PREVALENCE; OSTEOPENIA; INITIATION; DECREASES; EFAVIRENZ AB Background: The clinical importance of the association of HIV infection and antiretroviral therapy (ART) with low bone mineral density (BMD) in premenopausal women is uncertain because BMD stabilizes on established ART and fracture data are limited. Methods: We measured time to first new fracture at any site with median follow-up of 5.4 years in 2391 (1728 HIV-infected, 663 HIV-uninfected) participants in the Women's Interagency HIV Study (WIHS). Self-report of fracture was recorded at semiannual visits. Proportional hazard models assessed predictors of incident fracture. Results: At baseline, HIV-infected women were older (40 +/- 9 vs. 36 +/- 10 years, P<0.0001), more likely to report postmenopausal status and be hepatitis C virus-infected, and weighed less than HIV-uninfected women. Among HIV-infected women, mean CD4(+) cell count was 482 cells/mu l; 66% were taking ART. Unadjusted incidence of fracture did not differ between HIV-infected and uninfected women (1.8 vs. 1.4/100 person-years, respectively, P - 0.18). In multivariate models, white (vs. African-American) race, hepatitis C virus infection, and higher serum creatinine, but not HIV serostatus, were statistically significant predictors of incident fracture. Among HIV-infected women, older age, white race, current cigarette use, and history of AIDS-defining illness were associated with incidence of new fracture. Conclusion: Among predominantly premenopausal women, there was little difference in fracture incidence rates by HIV status, rather traditional risk factors were important predictors. Further research is necessary to characterize fracture risk in HIV-infected women during and after the menopausal transition. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Yin, Michael T.] Columbia Univ, Div Infect Dis, Med Ctr, New York, NY 10032 USA. [Shi, Qiuhu] New York Med Coll, Valhalla, NY 10595 USA. [Hoover, Donald R.] Rutgers State Univ, Piscataway, NJ USA. [Anastos, Kathryn] Montefiore Med Ctr, Bronx, NY 10467 USA. [Sharma, Anjali] SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA. [Young, Mary] Georgetown Sch Med, Washington, DC USA. [Levine, Alexandra] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Golub, Elizabeth T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Tien, Phyllis C.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge H.] Rush Univ, Dept Med, Chicago, IL 60612 USA. RP Yin, MT (reprint author), Columbia Univ, Div Infect Dis, Med Ctr, 630 W168th St,PH8-876, New York, NY 10032 USA. EM Mty4@columbia.edu FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590, K23 AI 059884, K23 AI 066943]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI) [UL1 RR024131] FX The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). Drs. Yin and Tien are supported by the National Institute of Allergy and Infectious Diseases through K23 AI 059884 and K23 AI 066943, respectively. NR 36 TC 48 Z9 48 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD NOV 13 PY 2010 VL 24 IS 17 BP 2679 EP 2686 DI 10.1097/QAD.0b013e32833f6294 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 672KV UT WOS:000283582800010 PM 20859192 ER PT J AU Ducharme, N Banks, WA Morley, JE Robinson, SM Niehoff, ML Mattern, C Farr, SA AF Ducharme, Nicole Banks, William A. Morley, John E. Robinson, Sandra M. Niehoff, Michael L. Mattern, Claudia Farr, Susan A. TI Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration (vol 641, pg 128, 2010) SO EUROPEAN JOURNAL OF PHARMACOLOGY LA English DT Correction C1 [Ducharme, Nicole; Banks, William A.; Morley, John E.; Robinson, Sandra M.; Niehoff, Michael L.; Farr, Susan A.] St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr, St Louis, MO 63103 USA. [Ducharme, Nicole; Morley, John E.; Robinson, Sandra M.; Niehoff, Michael L.; Farr, Susan A.] Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, St Louis, MO USA. [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Mattern, Claudia] M&P Pharma AG, CH-6370 Stans, Switzerland. RP Banks, WA (reprint author), St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr, St Louis, MO 63103 USA. EM wabanks1@uw.edu RI morley, john/F-9177-2011 OI morley, john/0000-0001-6444-2965 NR 1 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-2999 J9 EUR J PHARMACOL JI Eur. J. Pharmacol. PD NOV 10 PY 2010 VL 646 IS 1-3 BP 46 EP 46 DI 10.1016/j.ejphar.2010.07.021 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 662YY UT WOS:000282851400006 ER PT J AU Crum-Cianflone, NF Roediger, M Hullsiek, KH Ganesan, A Landrum, M Weintrob, A Agan, B Medina, S Rahkola, J Hale, B Janoff, EN AF Crum-Cianflone, Nancy F. Roediger, Mollie Hullsiek, Kathy Huppler Ganesan, Anuradha Landrum, Michael Weintrob, Amy Agan, Brian Medina, Sheila Rahkola, Jeremy Hale, Braden Janoff, Edward N. CA Infect Dis Clinical Res Program HI TI The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection SO VACCINE LA English DT Article DE Ethnicity; Antibodies; Pneumococcal vaccination; HIV ID IMMUNODEFICIENCY-VIRUS-INFECTION; HIV-1-INFECTED UGANDAN ADULTS; POLYSACCHARIDE VACCINE; RISK-FACTORS; RESISTANCE PATTERNS; CLINICAL-FEATURES; CHARLESTON COUNTY; CONJUGATE VACCINE; SOUTH-CAROLINA; DISEASE AB Ethnicity may be associated with the incidence of pneumococcal infections and the frequency of protective vaccine responses. Earlier studies have suggested that HIV-infected persons of black ethnicity develop less robust immune responses to pneumococcal vaccination that may relate to their higher incidence of invasive disease. We evaluated the association of ethnicity with capsule-specific antibody responses to pneumococcal revaccination, with either the pneumococcal conjugate (PCV) or polysaccharide (PPV) vaccines among 188 HIV-infected adults. The proportion of the 77 African Americans (AA) and 111 Caucasians with comparable virologic and immunologic parameters who achieved a positive immune response (>= 2-fold rise in capsule-specific IgG from baseline with post-vaccination value >= 1 mu g/mL for >= 2 of 4 serotypes) at day 60 after revaccination was similar (43% vs. 49%, respectively, p = 0.65). Results were also similar when vaccine types (PPV and PCV) were examined separately. Mean changes in log(10) transformed IgG levels from baseline to days 60 and 180 post-vaccination were also not significantly different between AA and Caucasians. In summary, in this ethnically diverse cohort with equal access to care, we did not observe differential antibody responses between AA and Caucasian HIV-infected adults after pneumococcal revaccination. Published by Elsevier Ltd. C1 [Crum-Cianflone, Nancy F.] USN, San Diego Med Ctr, Clin Invest Dept KCA, San Diego, CA 92134 USA. [Crum-Cianflone, Nancy F.; Roediger, Mollie; Hullsiek, Kathy Huppler; Ganesan, Anuradha; Landrum, Michael; Weintrob, Amy; Agan, Brian; Medina, Sheila; Hale, Braden] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA. [Roediger, Mollie; Hullsiek, Kathy Huppler] Univ Minnesota, Div Biostat, Minneapolis, MN USA. [Ganesan, Anuradha] Natl Naval Med Ctr, Bethesda, MD USA. [Landrum, Michael] San Antonio Mil Med Ctr, San Antonio, TX USA. [Weintrob, Amy] Walter Reed Army Med Ctr, Washington, DC 20307 USA. [Rahkola, Jeremy; Janoff, Edward N.] Univ Colorado, Mucosal & Vaccine Res Program Colorado MAVRC, Denver, CO 80202 USA. [Hale, Braden] USN, Hlth Res Ctr, San Diego, CA 92134 USA. [Rahkola, Jeremy; Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Crum-Cianflone, NF (reprint author), USN, San Diego Med Ctr, Clin Invest Dept KCA, 34800 Bob Wilson Dr,Ste 5, San Diego, CA 92134 USA. EM nancy.crum@med.navy.mil OI Agan, Brian/0000-0002-5114-1669 FU Department of Defense (DoD) through the Uniformed Services University of the Health Sciences [IDCRP RV-150]; National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) [Y1-AI-5072]; Veterans Affairs Research Service FX Support for this work (IDCRP RV-150) was provided by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed through the Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072. Additional support was obtained from the Veterans Affairs Research Service. NR 27 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD NOV 10 PY 2010 VL 28 IS 48 BP 7583 EP 7588 DI 10.1016/j.vaccine.2010.09.056 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 696HN UT WOS:000285432600002 PM 20887830 ER PT J AU De Sousa, M Smith, D Corcoran, A Bailey, FA Furman, C Ritchie, C Rosenfeld, K Shreve, S Casarett, D AF De Sousa, Maysa Smith, Dawn Corcoran, Amy Bailey, F. Amos Furman, Christian Ritchie, Christine Rosenfeld, Kenneth Shreve, Scott Casarett, David TI Families' Perceptions of Inpatient and Home Hospice Care at End-of-Life SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter ID TERMINALLY-ILL C1 [De Sousa, Maysa; Smith, Dawn; Casarett, David] Ctr Hlth Equ Res & Promot, Dept Vet Affairs Med Ctr, Philadelphia, PA USA. [Corcoran, Amy; Casarett, David] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Bailey, F. Amos] Safe Harbor Palliat Care, Dept Vet Affairs Med Ctr, Birmingham, AL USA. [Furman, Christian] Univ Louisville, Div Geriatr Med, Louisville, KY 40292 USA. [Ritchie, Christine] Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Dept Vet Affairs Med Ctr, Birmingham, AL USA. [Rosenfeld, Kenneth] Dept Vet Affairs Med Ctr, Greater Los Angeles, CA USA. [Shreve, Scott] Hosp & Palliat Care, Dept Vet Affairs, Washington, DC USA. RP Casarett, D (reprint author), Philadelphia VA Ctr Hlth Equ Res & Promot, Inst Aging, Ctr Bioeth, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM Casarett@mail.med.upenn.edu FU PHS HHS [K01 HP00084-02] NR 6 TC 4 Z9 4 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 8 PY 2010 VL 170 IS 20 BP 1856 EP 1857 DI 10.1001/archinternmed.2010.392 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 676SC UT WOS:000283937600023 PM 21059980 ER PT J AU Pierce, A Wei, R Halade, D Yoo, SE Ran, QT Richardson, A AF Pierce, Anson Wei, Rochelle Halade, Dipti Yoo, Si-Eun Ran, Qitao Richardson, Arlan TI A Novel mouse model of enhanced proteostasis: Full-length human heat shock factor 1 transgenic mice SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Aggresome; Chaperones; Heat shock proteins; Heat shock response; Polyglutamine; Heat shock transcription factor 1 ID TRANSCRIPTION FACTOR; OXIDATIVE STRESS; PROTEINS; DISEASE; HSF1; ACTIVATION; AGGRESOMES; ASSOCIATION; DEGRADATION; REPRESSION AB The heat shock response (HSR) is controlled by the master transcriptional regulator heat shock factor 1 (HSF1). HSF1 maintains proteostasis and resistance to stress through production of heat shock proteins (HSPs). No transgenic model exists that overexpresses HSF1 in tissues of the central nervous system (CNS). We generated a transgenic mouse overexpressing full-length non-mutant HSF1 and observed a 2-4-fold increase in HSF1 mRNA and protein expression in all tissues studied of HSF1 transgenic (HSF1(+/0)) mice compared to wild type (WT) littermates, including several regions of the CNS. Basal expression of HSP70 and 90 showed only mild tissue-specific changes: however, in response to forced exercise, the skeletal muscle HSR was more elevated in HSF1(+/0) mice compared to WT littermates and in fibroblasts following heat shock, as indicated by levels of inducible HSP70 mRNA and protein. HSF1(+/0) cells elicited a significantly more robust HSR in response to expression of the 82 repeat polyglutamine-YFP fusion construct (Q82YFP) and maintained proteasome-dependent processing of Q82YFP compared to WT fibroblasts. Overexpression of HSF1 was associated with fewer, but larger Q82YFP aggregates resembling aggresomes in HSF1(+/0) cells, and increased viability. Therefore, our data demonstrate that tissues and cells from mice overexpressing full-length non-mutant HSF1 exhibit enhanced proteostasis. Published by Elsevier Inc. C1 [Pierce, Anson; Yoo, Si-Eun; Ran, Qitao; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Pierce, Anson; Wei, Rochelle; Halade, Dipti; Yoo, Si-Eun; Ran, Qitao; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Pierce, Anson; Ran, Qitao; Richardson, Arlan] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78284 USA. RP Pierce, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM piercea2@uthscsa.edu RI Pierce, Anson/D-1079-2012 OI Pierce, Anson/0000-0002-1383-0180 FU VA career development award [VISN17]; Semp Russ Foundation of the San Antonio Area Foundation FX This work was supported by a VA career development award, VISN17 grant, and by the Semp Russ Foundation of the San Antonio Area Foundation to A.P. NR 28 TC 11 Z9 11 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD NOV 5 PY 2010 VL 402 IS 1 BP 59 EP 65 DI 10.1016/j.bbrc.2010.09.111 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 679TB UT WOS:000284182600011 PM 20920476 ER PT J AU Yang, L Hu, HM Zielinska-Kwiatkowska, A Chansky, HA AF Yang, Liu Hu, Hsien-Ming Zielinska-Kwiatkowska, Anna Chansky, Howard A. TI FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Ewing's sarcoma; EWS-Fli1; Oncogenic fusion protein; FOXO1; RNA interference; Inducible siRNA; Tumor suppressor gene ID FORKHEAD TRANSCRIPTION FACTORS; RNA INTERFERENCE; DNA-BINDING; EXPRESSION; CANCER; RECEPTOR; GROWTH; TUMORS; TRANSLOCATION; REPRESSION AB Ewing's family tumors are characterized by a specific t(11;22) chromosomal translocation that results in the formation of EWS-Fli1 oncogenic fusion protein. To investigate the effects of EWS-Fli1 on gene expression, we carried out DNA microarray analysis after specific knockdown of EWS-Fli1 through transfection of synthetic siRNAs. EWS-Fli1 knockdown increased expression of genes such as DKK1 and p57 that are known to be repressed by EWS-Fli1 fusion protein. Among other potential EWS-Fli1 targets identified by our microarray analysis, we have focused on the FOXO1 gene since it encodes a potential tumor suppressor and has not been previously reported in Ewing's cells. To better understand how EWS-Fli1 affects FOXO1 expression, we have established a doxycycline-inducible siRNA system to achieve stable and reversible knockdown of EWS-Fli1 in Ewing's sarcoma cells. Here we show that FOXO1 expression in Ewing's cells has an inverse relationship with EWS-Fli1 protein level, and FOXO1 promoter activity is increased after doxycycline-induced EWS-Fli1 knockdown. In addition, we have found that direct binding of EWS-Fli1 to FOXO1 promoter is attenuated after doxycycline-induced siRNA knockdown of the fusion protein. Together, these results suggest that suppression of FOXO1 function by EWS-Fli1 fusion protein may contribute to cellular transformation in Ewing's family tumors. (C) 2010 Elsevier Inc. All rights reserved. C1 [Yang, Liu] Univ Washington, Sch Med, Dept Orthoped, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA. RP Yang, L (reprint author), Univ Washington, Sch Med, Dept Orthoped, 1660 S Columbian Way,GMR 151, Seattle, WA 98108 USA. EM lyang@u.washington.edu FU Veterans Affairs Merit Review Award; Public Health Service Grant [RO1 AR051455] FX This work was supported by Public Health Service Grant RO1 AR051455 (to L.Y.) and by a Veterans Affairs Merit Review Award (to H.A.C.). NR 27 TC 9 Z9 10 U1 3 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD NOV 5 PY 2010 VL 402 IS 1 BP 129 EP 134 DI 10.1016/j.bbrc.2010.09.129 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 679TB UT WOS:000284182600023 PM 20933505 ER PT J AU Weisbart, RH Chan, G Heinze, E Mory, R Nishimura, RN Colburn, K AF Weisbart, Richard H. Chan, Grace Heinze, Emil Mory, Rachel Nishimura, Robert N. Colburn, Keith TI BRAF Drives Synovial Fibroblast Transformation in Rheumatoid Arthritis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID B-RAF; SIGNALING PATHWAY; JOINT DESTRUCTION; MUTATIONS; CANCER; GENE; ACTIVATION; MECHANISM; MELANOMA AB Synovial fibroblasts destroy articular cartilage and bone in rheumatoid arthritis, but the mechanism of fibroblast transformation remains elusive. Because gain-of-function mutations of BRAF can transform fibroblasts, we examined BRAF in rheumatoid synovial fibroblasts. The strong gain-of-function mutation, V600R, of BRAF found in melanomas and other cancers was identified in first passage synovial fibroblasts from two of nine rheumatoid arthritis patients and confirmed by restriction site mapping. BRAF-specific siRNA inhibited proliferation of synovial fibroblasts with V600R mutations. A BRAF aberrant splice variant with an intact kinase domain and partial loss of the N-terminal autoinhibitory domain was identified in fibroblasts from an additional patient, and fibroblast proliferation was inhibited by BRAF-specific siRNA. Our finding is the first to establish mechanisms for fibroblast transformation responsible for destruction of articular cartilage and bone in rheumatoid arthritis and establishes a new target for therapeutic intervention. C1 [Weisbart, Richard H.; Chan, Grace] Vet Affairs Greater Los Angeles Hlth Care Syst, Dept Res, Sepulveda, CA 91343 USA. [Heinze, Emil; Mory, Rachel] Olive View UCLA Med Ctr, Dept Med, Sylmar, CA 91342 USA. [Nishimura, Robert N.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Colburn, Keith] Vet Affairs Med Ctr, Dept Med, Loma Linda, CA 92357 USA. [Colburn, Keith] Loma Linda Univ, Dept Med, Loma Linda, CA 92354 USA. RP Weisbart, RH (reprint author), 16111 Plummer St, North Hills, CA 91343 USA. EM rweisbar@ucla.edu NR 22 TC 4 Z9 8 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 5 PY 2010 VL 285 IS 45 BP 34299 EP 34303 DI 10.1074/jbc.C110.168195 PG 5 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 673KL UT WOS:000283659100002 PM 20843808 ER PT J AU Abdallah, RT Keum, JS Lee, MH Wang, B Gooz, M Luttrell, DK Luttrell, LM Jaffa, AA AF Abdallah, Rany T. Keum, Joo-Seob Lee, Mi-Hye Wang, Bing Gooz, Monika Luttrell, Deirdre K. Luttrell, Louis M. Jaffa, Ayad A. TI Plasma Kallikrein Promotes Epidermal Growth Factor Receptor Transactivation and Signaling in Vascular Smooth Muscle through Direct Activation of Protease-activated Receptors SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID OXIDE-GENERATING VASODILATORS; MOLECULAR-WEIGHT KININOGEN; RAT CAROTID-ARTERY; NITRIC-OXIDE; ENDOTHELIAL-CELLS; ATHEROSCLEROTIC LESIONS; SUBSTRATE-SPECIFICITY; THROMBIN RECEPTORS; CORONARY-ARTERIES; GENE-EXPRESSION AB The kallikrein-kinin system, along with the interlocking reninangiotensin system, is a key regulator of vascular contractility and injury response. The principal effectors of the kallikrein-kinin system are plasma and tissue kallikreins, proteases that cleave high molecular weight kininogen to produce bradykinin. Most of the cellular actions of kallikrein (KK) are thought to be mediated by bradykinin, which acts via G protein-coupled B1 and B2 bradykinin receptors on VSMCs and endothelial cells. Here, we find that primary aortic vascular smooth muscle but not endothelial cells possess the ability to activate plasma prekallikrein. Surprisingly, exposing VSMCs to prekallikrein leads to activation of the ERK1/2 mitogen-activated protein kinase cascade via a mechanism that requires kallikrein activity but does not involve bradykinin receptors. In transfected HEK293 cells, we find that plasma kallikrein directly activates G protein-coupled protease-activated receptors (PARs) 1 and 2, which possess consensus kallikrein cleavage sites, but not PAR4. In vascular smooth muscles, KK stimulates ADAM (a disintegrin and metalloprotease) 17 activity via a PAR1/2 receptor-dependent mechanism, leading sequentially to release of the endogenous ADAM17 substrates, amphiregulin and tumor necrosis factor-alpha, metalloprotease-dependent transactivation of epidermal growth factor receptors, and metalloprotease and epidermal growth factor receptor-dependent ERK1/2 activation. These results suggest a novel mechanism of bradykinin-independent kallikrein action that may contribute to the regulation of vascular responses in pathophysiologic states, such as diabetes mellitus. C1 [Abdallah, Rany T.; Keum, Joo-Seob; Lee, Mi-Hye; Wang, Bing; Gooz, Monika; Luttrell, Deirdre K.; Luttrell, Louis M.; Jaffa, Ayad A.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Jaffa, AA (reprint author), Amer Univ Beirut, Fac Med, Dept Biochem, Beirut, Lebanon. EM aj24@aub.edu.lb FU National Institutes of Health [HL087986, HL077192, DK55524]; South Carolina Center for Biomedical Research Excellence in Cardiovascular Diseases; Department of Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health Grants HL087986 and HL077192 (to A. A. J.), and DK55524 (to L. M. L.). This work was also supported by the South Carolina Center for Biomedical Research Excellence in Cardiovascular Diseases (to D. K. L.) and Department of Veterans Affairs Research Enhancement Award Program awards. NR 66 TC 24 Z9 25 U1 0 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 5 PY 2010 VL 285 IS 45 BP 35206 EP 35215 DI 10.1074/jbc.M110.171769 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 673KL UT WOS:000283659100094 PM 20826789 ER PT J AU Wong, KK Muller, MLTM Kuwabara, H Studenski, SA Bohnen, NI AF Wong, Ka Kit Muller, Martijn L. T. M. Kuwabara, Hiroto Studenski, Stephanie A. Bohnen, Nicolaas I. TI Olfactory loss and nigrostriatal dopaminergic denervation in the elderly SO NEUROSCIENCE LETTERS LA English DT Article DE Aging; Basal ganglia; Dopamine; Nigrostriatal; Olfaction; positron emission tomography ID C-11 METHYL TRIFLATE; LEWY BODY DISEASE; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; PET RADIOLIGANDS; IN-VIVO; DEMENTIA; AGE; DYSFUNCTION AB Olfactory dysfunction may precede common neurodegenerative disorders in the elderly, such as Alzheimer (AD) or Parkinson disease (PD). However, pathobiological mechanisms of olfactory loss in the elderly are poorly understood. Although nigrostriatal dopaminergic denervation is a key patholobiological feature of PD, age-associated nigrostriatal denervation (AASDD) occurs also with normal aging and can be more prominent in some elderly. We investigated the relationship between AASDD and olfactory performance in community-dwelling subjects. Community-dwelling subjects (n = 73, 44 F/29 M, mean age 64.0 +/- 16.4, range 20-85) underwent brain dopamine transporter (DAT)[C-11]2-beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (beta-CFT) positron emission tomography (PET) imaging and olfactory assessment using the 40-odor University of Pennsylvania Smell Identification Test (UPSIT). Subjects with clinical or DAT PET evidence of Parkinson disease (PD) were not eligible for the study. AASDD was defined based on normative data in young and middle-aged subjects. Compared to a mild and general linear decline in odor identification observed in most subjects (R-2 = 0.18, P = 0.0002), there were 13 subjects who deviated below the 5% confidence interval level in age-predicted UPSIT scores. Analysis limited to elderly subjects 60 years and over demonstrated a significant association between poor smell (n = 10 out of 49, 20.4%) and AASDD (chi(2) = 4.4, P<0.05). There is a significant association between olfactory dysfunction and more prominent nigrostriatal denervation in the elderly. Olfactory assessment may have potential as a screening tool to detect age-accelerated neurodegeneration in the elderly. Published by Elsevier Ireland Ltd. C1 [Muller, Martijn L. T. M.; Bohnen, Nicolaas I.] Univ Michigan, Dept Radiol, Funct Neuroimaging Cognit & Mobil Lab, Ann Arbor, MI 48105 USA. [Wong, Ka Kit; Bohnen, Nicolaas I.] GRECC, VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Muller, Martijn L. T. M.; Bohnen, Nicolaas I.] Univ Michigan, Dept Radiol, Dept Neurol, Ann Arbor, MI 48105 USA. [Kuwabara, Hiroto] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA. [Studenski, Stephanie A.] GRECC, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Studenski, Stephanie A.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. RP Bohnen, NI (reprint author), Univ Michigan, Dept Radiol, Funct Neuroimaging Cognit & Mobil Lab, 24 Frank Lloyd Wright Dr,Box 362, Ann Arbor, MI 48105 USA. EM nbohnen@umich.edu RI Muller, Martijn/A-7205-2010 OI Muller, Martijn/0000-0002-1133-7202 FU Department of Veterans Affairs FX This study was funded by the Department of Veterans Affairs. NR 32 TC 20 Z9 21 U1 1 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD NOV 5 PY 2010 VL 484 IS 3 BP 163 EP 167 DI 10.1016/j.neulet.2010.08.037 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 664XX UT WOS:000282998400001 PM 20727944 ER PT J AU Maes, K Nemeth, E Roodman, GD Huston, A Esteve, F Freytes, C Callander, N Katodritou, E Tussing-Humphreys, L Rivera, S Vanderkerken, K Lichtenstein, A Ganz, T AF Maes, Ken Nemeth, Elizabeta Roodman, G. David Huston, Alissa Esteve, Flavia Freytes, Cesar Callander, Natalie Katodritou, Eirini Tussing-Humphreys, Lisa Rivera, Seth Vanderkerken, Karin Lichtenstein, Alan Ganz, Tomas TI In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2 SO BLOOD LA English DT Article ID EXPRESSION; IL-6; PROMOTER; CELLS; RECEPTORS; CYTOKINES; BMP; INFLAMMATION; INDUCTION; SURVIVAL AB Hepcidin is the principal iron-regulatory hormone and a pathogenic factor in anemia of inflammation. Patients with multiple myeloma (MM) frequently present with anemia. We showed that MM patients had increased serum hepcidin, which inversely correlated with hemoglobin, suggesting that hepcidin contributes to MM-related anemia. Searching for hepcidin-inducing cytokines in MM, we quantified the stimulation of hepcidin promoter-luciferase activity in HuH7 cells by MM sera. MM sera activated the hepcidin promoter significantly more than did normal sera. We then examined the role of bone morphogenetic proteins (BMPs) and interleukin-6 (IL-6), the major transcriptional regulators of hepcidin. Mutations in both BMP-responsive elements abrogated the activation dramatically, while mutations in the IL-6-responsive signal transducer and activator of transcription 3-binding site (STAT3-BS) had only a minor effect. Cotreatment with anti-BMP-2/4 or noggin-Fc blocked the promoter induction with all MM sera, anti-IL-6 blocked it with a minority of sera, whereas anti-BMP-4, -6, or -9 antibodies had no effect. BMP-2-immunodepleted MM sera had decreased promoter stimulatory capacity, and BMP-2 concentrations in MM sera were significantly higher than in normal sera. Our results demonstrate that BMP-2 is a major mediator of the hepcidin stimulatory activity of MM sera. (Blood. 2010;116(18):3635-3644) C1 [Nemeth, Elizabeta; Rivera, Seth; Ganz, Tomas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Nemeth, Elizabeta; Rivera, Seth; Ganz, Tomas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. [Maes, Ken; Vanderkerken, Karin] Vrije Univ Brussel VUB, Dept Hematol & Immunol, Brussels, Belgium. [Roodman, G. David; Huston, Alissa; Esteve, Flavia] Univ Pittsburgh, Sch Med & Pittsburgh, VA Med Ctr, Pittsburgh, PA USA. [Freytes, Cesar] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Hosp, San Antonio, TX 78229 USA. [Callander, Natalie] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Hematol, Madison, WI USA. [Katodritou, Eirini] Theagen Canc Ctr, Dept Hematol, Thessaloniki, Greece. [Tussing-Humphreys, Lisa] USDA ARS, Baton Rouge, LA USA. [Lichtenstein, Alan] W Los Angeles VA Univ Calif Los Angeles Med Ctr, Los Angeles, CA USA. RP Ganz, T (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 10833 Le Conte Ave,CHS 37-055, Los Angeles, CA 90095 USA. EM tganz@mednet.ucla.edu RI Vanderkerken, Karin/I-3513-2013 FU National Institutes of Health [RO1 DK 065029]; UCLA-Jonsson Comprehensive Cancer Center; VA, Los Angeles, CA FX This work was funded by National Institutes of Health grant RO1 DK 065029 (T.G. and E.N.), an Interdisciplinary Seed Grant from the UCLA-Jonsson Comprehensive Cancer Center (E.N., A.L., and T.G.), and by research support from the VA, Los Angeles, CA (A.L.). NR 33 TC 68 Z9 73 U1 1 U2 8 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 4 PY 2010 VL 116 IS 18 BP 3635 EP 3644 DI 10.1182/blood-2010-03274571 PG 10 WC Hematology SC Hematology GA 675SM UT WOS:000283853200034 PM 20679527 ER PT J AU Allen, KD Oddone, EZ Coffman, CJ Datta, SK Juntilla, KA Lindquist, JH Walker, TA Weinberger, M Bosworth, HB AF Allen, Kelli D. Oddone, Eugene Z. Coffman, Cynthia J. Datta, Santanu K. Juntilla, Karen A. Lindquist, Jennifer H. Walker, Tessa A. Weinberger, Morris Bosworth, Hayden B. TI Telephone-Based Self-management of Osteoarthritis A Randomized Trial SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID PHYSICAL-ACTIVITY; HEALTH-STATUS; KNEE OSTEOARTHRITIS; EDUCATION-PROGRAMS; CLINICAL-TRIALS; CHRONIC DISEASE; ARTHRITIS; VETERANS; INTERVENTIONS; OUTCOMES AB Background: Osteoarthritis is a leading cause of pain and disability, and self-management behaviors for osteoarthritis are underutilized. Objective: To examine the effectiveness of a telephone-based self-management intervention for hip or knee osteoarthritis in a primary care setting. Design: Randomized clinical trial with equal assignment to osteoarthritis self-management, health education (attention control), and usual care control groups. (ClinicalTrials.gov registration number: NCT00288912) Setting: Primary care clinics in a Veterans Affairs Medical Center. Patients: 515 patients with symptomatic hip or knee osteoarthritis. Intervention: The osteoarthritis self-management intervention involved educational materials and 12 monthly telephone calls to support individualized goals and action plans. The health education intervention involved nonosteoarthritis educational materials and 12 monthly telephone calls related to general health screening topics. Measurements: The primary outcome was score on the Arthritis Impact Measurement Scales-2 pain subscale (range, 0 to 10). Pain was also assessed with a 10-cm visual analog scale. Measurements were collected at baseline and 12 months. Results: 461 participants (90%) completed the 12-month assessment. The mean Arthritis Impact Measurement Scales-2 pain score in the osteoarthritis self-management group was 0.4 point lower (95% CI, -0.8 to 0.1 point; P = 0.105) than in the usual care group and 0.6 point lower (CI, -1.0 to -0.2 point; P = 0.007) than in the health education group at 12 months. The mean visual analog scale pain score in the osteoarthritis self-management group was 1.1 points lower (CI, -1.6 to -0.6 point; P < 0.001) than in the usual care group and 1.0 point lower (CI, -1.5 to -0.5 point; P < 0.001) than in the health education group. Health care use did not differ across the groups. Limitation: The study was conducted at 1 Veterans Affairs Medical Center, and the sample consisted primarily of men. Conclusion: A telephone-based osteoarthritis self-management program produced moderate improvements in pain, particularly compared with a health education control group. C1 Duke Univ, Med Ctr, Durham Vet Affairs Med Ctr, Durham, NC 27706 USA. Univ N Carolina, Chapel Hill, NC USA. RP Allen, KD (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev Serv 152, Durham Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA. EM kelli.allen@duke.edu FU U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR 04-016, 08-027, 91-408] FX By the U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (IIR 04-016 and Career Scientist Awards 08-027 [Dr. Bosworth] and 91-408 [Dr. Weinberger]). NR 42 TC 40 Z9 41 U1 2 U2 9 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 2 PY 2010 VL 153 IS 9 BP 570 EP 579 DI 10.7326/0003-4819-153-9-201011020-00006 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 673MH UT WOS:000283667000003 PM 21041576 ER PT J AU Arciniegas, DB Beresford, TP AF Arciniegas, David B. Beresford, Thomas P. TI Managing difficult interactions with patients in neurology practices A practical approach SO NEUROLOGY LA English DT Article ID PRIMARY-CARE; DEMENTIA; PSYCHOPATHOLOGY; PREVALENCE; OUTCOMES C1 [Arciniegas, David B.; Beresford, Thomas P.] Univ Colorado, Sch Med, Neurobehav Disorders Program, Dept Psychiat, Aurora, CO 80045 USA. [Arciniegas, David B.] Univ Colorado, Sch Med, Behav Neurol Sect, Dept Neurol, Aurora, CO 80045 USA. [Beresford, Thomas P.] Denver Vet Affairs Med Ctr, Psychiat Serv, Denver, CO USA. RP Arciniegas, DB (reprint author), Univ Colorado, Sch Med, Neurobehav Disorders Program, Dept Psychiat, 13001 E 17th Pl,Campus Box F546, Aurora, CO 80045 USA. EM David.Arciniegas@UCDenver.edu FU Neuropsychiatry; American Psychiatric Publishing, Inc.; Demos Medical Publishing; Orasi Medical, Inc.; National Institute of Mental Health (NIMH) [R01 MH081920-01A1]; National Institute of Child Health and Human Development (NICHD) [R01 HD047242-04, R01 HD047242-04S1]; Department of Defense [W81XWH-08-2-0652, A-15306]; National Institute on Aging (NIA) [R21 AG028609-01]; Henry M. Jackson Foundation; National Institute on Alcohol Abuse and Alcoholism [5R21AA016294] FX Dr. Arciniegas serves as an Associate Editor for Journal of Neuropsychiatry and Clinical Neurosciences and Neuropsychiatric Disease and Treatment, serves as an Editorial Board Member for The Open Psychiatry Journal, Brain Injury, Neurotrauma Letter, serves as Guest Editor for NeuroRehabilitation, and serves as International Editorial Board Member for Archivos de Neurociencias; receives publishing royalties from Neuropsychiatry: An Introductory Approach (Cambridge University Press, 2001), Clinical Manual for the Management of Adults with Traumatic Brain Injuries (American Psychiatric Publishing, Inc., 2010-prepublication royalties), and Brain Injury Medicine, 2nd edition (Demos Medical Publishing, 2010-prepublication royalties); receives research support from Orasi Medical, Inc.; receives research support from National Institute of Mental Health (NIMH R01 MH081920-01A1 [Coinvestigator]), National Institute of Child Health and Human Development (NICHD R01 HD047242-04 [Site Principal Investigator], NICHD R01 HD047242-04S1 [Site Principal Investigator]), Department of Defense (W81XWH-08-2-0652 [Consultant]), National Institute on Aging (NIA R21 AG028609-01 [Coinvestigator]); and receives research support from Henry M. Jackson Foundation. Dr. Beresford served as editorial board member for Alcohol & Alcoholism; received royalties from publishing Neuropsychiatry: An Introductory Approach, Cambridge University Press; received honoraria from speaking engagements or educational activities from Bristol Meyers Squibb; and receives research support from Department of Defense [A-15306 (Principal Investigator)] and National Institute on Alcohol Abuse and Alcoholism [5R21AA016294 (Principal Investigator)]. NR 21 TC 4 Z9 4 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 2 PY 2010 VL 75 IS 18 SU 1 BP S39 EP S44 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 690KH UT WOS:000285003200008 PM 21041770 ER PT J AU Corboy, JR Gross, RA AF Corboy, John R. Gross, Robert A. TI Clinical perspective for the practicing neurologist A new journal? SO NEUROLOGY LA English DT Editorial Material C1 [Corboy, John R.] Univ Colorado, Dept Neurol, Denver, CO 80202 USA. [Corboy, John R.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Gross, Robert A.] Univ Rochester, Med Ctr, Strong Epilepsy Ctr, Rochester, NY 14642 USA. RP Corboy, JR (reprint author), Univ Colorado, 12631 E 17th Ave,B185, Aurora, CO 80045 USA. EM john.corboy@ucdenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 2 PY 2010 VL 75 IS 18 SU 1 BP S1 EP S1 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 690KH UT WOS:000285003200001 ER PT J AU Miravalle, A Corboy, JR AF Miravalle, Augusto Corboy, John R. TI Therapeutic options in multiple sclerosis Five new things SO NEUROLOGY LA English DT Article ID CEREBROSPINAL VENOUS INSUFFICIENCY; STEM-CELL TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; AUTOIMMUNE ENCEPHALOMYELITIS; ORAL FINGOLIMOD; JC VIRUS; INTERFERON; DISEASE; FLUID; REMYELINATION C1 [Miravalle, Augusto; Corboy, John R.] Univ Colorado, Dept Neurol, Denver, CO 80202 USA. [Corboy, John R.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Miravalle, A (reprint author), 12631 E 17th Ave,B185, Aurora, CO 80045 USA. EM augusto.miravalle@ucdenver.edu FU Novartis; BioMS Medical; Orasi Medical Inc.; NIH/NINDS [1UO1NS4571901A1]; National MS Society FX Dr. Miravalle serves as a consultant for Bayer Schering Pharma, EMD Serono, Inc., Advanced Studies in Medicine (ASiM), and Novartis. Dr. Corboy serves as Editor for Neurology (R) Clinical Practice and as Section Editor for Neurology Today; serves as a consultant for Bayer Schering Pharma, EMD Serono, Inc., Advanced Studies in Medicine (ASiM), and Novartis; has received research support from Novartis, BioMS Medical, Orasi Medical Inc., the NIH/NINDS (1UO1NS4571901A1 [PI]), and the National MS Society; and has reviewed files and given expert testimony in medico-legal cases. He is a part-time employee of the Denver Veterans Medical Center. NR 35 TC 5 Z9 5 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 2 PY 2010 VL 75 IS 18 SU 1 BP S22 EP S26 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 690KH UT WOS:000285003200005 PM 21041767 ER PT J AU Zhou, Y Manka, JT Rodriguez, AL Weaver, CD Days, EL Vinson, PN Jadhav, S Hermann, EJ Jones, CK Conn, PJ Lindsley, CW Stauffer, SR AF Zhou, Ya Manka, Jason T. Rodriguez, Alice L. Weaver, C. David Days, Emily L. Vinson, Paige N. Jadhav, Satyawan Hermann, Elizabeth J. Jones, Carrie K. Conn, P. Jeffrey Lindsley, Craig W. Stauffer, Shaun R. TI Discovery of N-Aryl Piperazines as Selective mGluR(5) Potentiators with Improved In Vivo Utility SO ACS MEDICINAL CHEMISTRY LETTERS LA English DT Article DE mGluR; potentiator; positive allosteric modulator; schizophrenia; hyperlocomotion ID POSITIVE ALLOSTERIC MODULATOR; GLUTAMATE-RECEPTOR SUBTYPE-5; ANTIPSYCHOTIC-LIKE; SCHIZOPHRENIA; SERIES; SAR AB This letter describes the discovery, structure-activity relationship, and in vitro and in vivo pharmacological profile of a novel non-MPEP-derived mGluR(5) positive allosteric modulator (PAM) based upon an N-aryl piperazine chemotype. This mGluR(5) chemotyper exhibits the ability to act as either a noncompetitive antagonist/negative allosteric modulator or a potentiator of the glutamate response, depending on the identity of the amide substituent, that is, a molecular switch". A rapidly optimized PAM, 10e (VU0364289), was shown to be potent and specific for the rat mGluR(5) receptor and subsequently demonstrated to be efficacious in a clinically relevant rodent model predictive of antipsychotic activity, thus providing the first example of a centrally active mGluR(5) PAM optimized from an HTS-derived mGluR(5) noncompetitive antagonist. C1 [Zhou, Ya; Manka, Jason T.; Rodriguez, Alice L.; Weaver, C. David; Vinson, Paige N.; Jadhav, Satyawan; Hermann, Elizabeth J.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. [Lindsley, Craig W.] Vanderbilt Univ, Med Ctr, Dept Chem, Nashville, TN 37232 USA. [Zhou, Ya; Manka, Jason T.; Rodriguez, Alice L.; Weaver, C. David; Days, Emily L.; Vinson, Paige N.; Jadhav, Satyawan; Hermann, Elizabeth J.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Univ, Med Ctr, Vanderbilt Program Drug Discovery, Nashville, TN 37232 USA. [Jones, Carrie K.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37212 USA. [Weaver, C. David; Days, Emily L.] Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA. RP Stauffer, SR (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. EM shaun.stauffer@vanderbilt.edu RI Conn, Peter/D-7848-2012; Zhou, Ya/F-1220-2013 FU NIH National Institute of Neurological Disorders and Stroke (NINDS) [5R01 NS031373-15]; National Institute of Mental Health (NIMH) [R01 MH073676-04] FX We thank the NIH National Institute of Neurological Disorders and Stroke (NINDS #5R01 NS031373-15) and the National Institute of Mental Health (NIMH #R01 MH073676-04) for support of this program. NR 25 TC 29 Z9 29 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1948-5875 J9 ACS MED CHEM LETT JI ACS Med. Chem. Lett. PD NOV PY 2010 VL 1 IS 8 BP 433 EP 438 DI 10.1021/ml100181a PG 6 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 680AS UT WOS:000284203100013 PM 23308336 ER PT J AU Jablecki, CK Nuckols, TK Sandin, KJ Asch, SM AF Jablecki, Charles K. Nuckols, Teryl K. Sandin, Karl J. Asch, Steven M. TI CLINICAL QUALITY MEASURES FOR ELECTRODIAGNOSIS IN SUSPECTED CTS: COMMENTS REPLY SO MUSCLE & NERVE LA English DT Letter C1 [Jablecki, Charles K.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Nuckols, Teryl K.; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Nuckols, Teryl K.; Asch, Steven M.] RAND Corp, Santa Monica, CA USA. [Sandin, Karl J.] Sister Kenny Rehabil Inst, Minneapolis, MN USA. [Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. RP Jablecki, CK (reprint author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD NOV PY 2010 VL 42 IS 5 BP 843 EP 844 DI 10.1002/21850 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 675JW UT WOS:000283827700029 ER PT J AU Grudzen, CR Richardson, LD Morrison, M Cho, E Morrison, RS AF Grudzen, Corita R. Richardson, Lynne D. Morrison, Matthew Cho, Elizabeth Morrison, R. Sean TI Palliative Care Needs of Seriously Ill, Older Adults Presenting to the Emergency Department SO ACADEMIC EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT Annual Scientific Meeting of the Society-for-Academic-Emergency-Medicine CY JUN, 2010 CL Phoenix, AZ SP Soc Acad Emergency Med ID OF-LIFE QUESTIONNAIRE; COGNITIVE IMPAIRMENT; VALIDATION; MORTALITY; VALIDITY AB Objectives: The objective was to identify the palliative care needs of seriously ill, older adults in the emergency department (ED). Methods: The authors conducted a cross-sectional structured survey. A convenience sample of 50 functionally impaired adults 65 years or older with coexisting cancer, congestive heart failure, end-stage liver or renal disease, stroke, oxygen-dependent pulmonary disease, or dementia was recruited from an urban academic tertiary care ED. Face-to-face interviews were conducted using the Needs Near the End-of-Life Screening Tool (NEST), McGill Quality of Life Index (MQOL), and Edmonton Symptom Assessment Survey (ESAS) to assess 1) range and severity of symptoms, 2) goals of care, 3) psychological well-being, 4) health care utilization, 5) spirituality, 6) social connectedness, 7) financial burden, 8) the patient clinician relationship, and 9) overall quality of life (QOL). Results: Mean (+/- SD) age was 74.3 (+/- 6.5) years and cancer was the most common diagnosis. Mean (+/- SD) QOL on the MQOL was 3.6 (+/- 2.9). Over half of the patients exceeded intratest severity-of-needs cutoffs in four categories of the NEST: physical symptoms (47/50, 94%), finances (36/50, 72%), mental health (31/50, 62%), and access to care (29/50, 58%). The majority of patients reported moderate to severe fatigue, pain, dyspnea, and depression on the ESAS. Conclusions: Seriously ill, older adults in an urban ED have substantial palliative care needs. Future work should focus on the role of emergency medicine and the new specialty of palliative care in addressing these needs. C1 [Grudzen, Corita R.; Richardson, Lynne D.; Morrison, Matthew; Cho, Elizabeth] Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA. [Grudzen, Corita R.; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Morrison, R. Sean] James J Peters VA Hosp, Bronx, NY USA. RP Grudzen, CR (reprint author), Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA. EM corita.grudzen@mssm.edu OI Grudzen, Corita/0000-0003-3039-8497 FU NIA NIH HHS [K24 AG022345] NR 21 TC 37 Z9 39 U1 3 U2 11 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD NOV PY 2010 VL 17 IS 11 BP 1253 EP 1257 DI 10.1111/j.1553-2712.2010.00907.x PG 5 WC Emergency Medicine SC Emergency Medicine GA 676UW UT WOS:000283945100019 PM 21175525 ER PT J AU Henderson, C Jackson, C Slade, M Young, AS Strauss, JL AF Henderson, Claire Jackson, Carlos Slade, Mike Young, Alexander S. Strauss, Jennifer L. TI How Should we Implement Psychiatric Advance Directives? Views of Consumers, Caregivers, Mental Health Providers and Researchers SO ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH LA English DT Article DE Psychiatric advance directives; Consensus study; Implementation ID RANDOMIZED CONTROLLED-TRIAL; SERVICES; ILLNESS; CARE AB The aim of this study was to measure expert consensus on the implementation of Psychiatric Advance Directives (PADs) within the Veterans Health Administration. We conducted a two-round Delphi study with 55 panelists including consumers, caregivers, mental health providers and researchers. For a number of items where no positive or negative consensus was reached we found differences between the views of consumers and non-consumers, reflecting consumer's preferences for nonmedical settings for completion and assistance with completion independent of the treatment team. Thus, the principle of consumer choice that applies to MHAD content should also be applied to the process of completion offered. C1 [Henderson, Claire; Slade, Mike] Kings Coll London, Inst Psychiat, Hlth Serv, London SE5 8AF, England. [Henderson, Claire; Jackson, Carlos] James J Peters VA Med Ctr, Bronx, NY USA. [Young, Alexander S.] Greater Los Angeles VA, Los Angeles, CA USA. [Young, Alexander S.] Univ Calif Los Angeles, Los Angeles, CA USA. [Strauss, Jennifer L.] Durham VA Med Ctr, Durham, NC USA. [Strauss, Jennifer L.] Duke Univ, Med Ctr, Durham, NC USA. [Henderson, Claire; Slade, Mike] Kings Coll London, Inst Psychiat, Populat Res Dept, London SE5 8AF, England. RP Henderson, C (reprint author), Kings Coll London, Inst Psychiat, Hlth Serv, P029,Crespigny Pk, London SE5 8AF, England. EM Claire.Henderson@iop.kcl.ac.uk RI Henderson, Claire/E-4664-2010; Slade, Mike/C-1641-2010; Young, Alexander/A-1523-2009 OI Henderson, Claire/0000-0002-6998-5659; Slade, Mike/0000-0001-7020-3434; Young, Alexander/0000-0002-9367-9213 NR 30 TC 14 Z9 14 U1 3 U2 7 PU MAIK NAUKA/INTERPERIODICA/SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0894-587X J9 ADM POLICY MENT HLTH JI Adm. Policy. Ment. Health PD NOV PY 2010 VL 37 IS 6 BP 447 EP 458 DI 10.1007/s10488-010-0264-5 PG 12 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 711RW UT WOS:000286610100001 PM 20099077 ER PT J AU Fife, CE Yankowsky, KW Ayello, EA Capitulo, KL Fowler, E Krasner, DL Mulder, G Sibbald, RG AF Fife, Caroline E. Yankowsky, Kevin W. Ayello, Elizabeth A. Capitulo, Kathleen Leask Fowler, Evonne Krasner, Diane L. Mulder, Gerit Sibbald, R. Gary TI Legal Issues in the Care of Pressure Ulcer Patients: Key Concepts for Healthcare Providers-A Consensus Paper from the International Expert Wound Care Advisory Panel (c) SO ADVANCES IN SKIN & WOUND CARE LA English DT Article ID ELECTRONIC MEDICAL-RECORD; M SKIN CONDITIONS; LONG-TERM-CARE; BRADEN SCALE; RELIABILITY C1 [Fife, Caroline E.] Univ Texas Hlth Sci Ctr, Div Cardiol, Houston, TX USA. [Fife, Caroline E.] Mem Hermann Ctr Wound Healing, Houston, TX USA. [Yankowsky, Kevin W.] Fulbright & Jaworski LLP, Houston, TX USA. [Ayello, Elizabeth A.] John A Hartford Inst Geriatr Nursing, New York, NY USA. [Capitulo, Kathleen Leask] James J Peters VA Med Ctr, Bronx, NY USA. [Capitulo, Kathleen Leask] Case Western Univ, Cleveland, OH USA. [Capitulo, Kathleen Leask] Wenzhou Med Coll, Wenzhou, Peoples R China. [Fowler, Evonne] San Gorgonio Mem Hosp, Banning, CA USA. [Krasner, Diane L.] Rest Haven York, York, PA USA. [Mulder, Gerit] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Sibbald, R. Gary] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5S 1A1, Canada. RP Fife, CE (reprint author), Univ Texas Hlth Sci Ctr, Div Cardiol, Houston, TX USA. NR 35 TC 4 Z9 4 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1527-7941 J9 ADV SKIN WOUND CARE JI Adv. Skin Wound Care PD NOV PY 2010 VL 23 IS 11 BP 493 EP + DI 10.1097/01.ASW.0000390494.20964.a5 PG 14 WC Dermatology; Nursing; Surgery SC Dermatology; Nursing; Surgery GA 832ZF UT WOS:000295849100003 PM 20975333 ER PT J AU Ho, CH Powell, HL Collins, JF Bauman, WA Spungen, AM AF Ho, Chester H. Powell, Heather L. Collins, Joseph F. Bauman, William A. Spungen, Ann M. TI Poor Nutrition Is a Relative Contraindication to Negative Pressure Wound Therapy for Pressure Ulcers: Preliminary Observations in Patients with Spinal Cord Injury SO ADVANCES IN SKIN & WOUND CARE LA English DT Article ID VACUUM-ASSISTED CLOSURE; PREVALENCE AB OBJECTIVE: To assess the efficacy of negative-pressure wound therapy (NPWT) for healing of pressure ulcers (PrUs) in individuals with spinal-cord injury (SCI). DESIGN: Multicenter, 28-day observational study. SETTING: Ten Veterans Affairs Medical Center SCI centers. PATIENTS: Eighty-six SCI inpatients with Stage III/IV pelvic PrUs. INTERVENTIONS: Standard wound care with NPWT versus standard wound care alone (NoNPWT). MAIN OUTCOME MEASURES: Change in wound surface area (WSA) using the Verg Videometer Measurement Documentation software. MAIN RESULTS: The proportion of patients demonstrating a decrease in WSA (healing subgroup) was not significantly different between the NPWT (n = 33) and NoNPWT (n = 53) groups (67% vs 70%, respectively). In the healing subgroup, there was no significant difference between the NPWT versus NoNPWT groups in WSA decrease (-43 +/- 22% vs -50% +/- 26%, not statistically significant). Similarly, in the nonhealing subgroup, there was no significant difference between NPWT and NoNPWT groups (31% +/- 26% vs 32% +/- 34%). In the NPWT group, the nonhealing subgroup (11/33) had significantly lower serum albumin levels than the healing subgroup (22/33) (2.9 +/- 0.4 vs 3.3 +/- 0.5 mg/dL, P < .05). In the NoNPWT group, there was no significant difference in serum albumin levels between the healing versus nonhealing subgroups (3.2 +/- 0.3 vs 3.2 +/- 0.3 mg/dL). CONCLUSION: In SCI patients with Stage III/IV pelvic PrUs, NPWT did not significantly influence the rate of healing. Additionally, in malnourished individuals (albumin <3.0 mg/dL), NPWT was not efficacious. Healing outcomes in the NPWT group were significantly influenced by albumin levels, whereas no such disparity was noted between the healing and nonhealing PrUs for the NoNPWT group. Nutritional status appears to be important in the effectiveness of NPWT. C1 [Ho, Chester H.; Powell, Heather L.] Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Cleveland, OH USA. [Ho, Chester H.; Powell, Heather L.] Case Western Reserve Univ, Dept Phys Med & Rehabil, Cleveland, OH 44106 USA. [Collins, Joseph F.] VA Med Ctr, Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA. [Bauman, William A.; Spungen, Ann M.] James J Peters VA Med Ctr, RR&D Ctr Excellence Med Consequences Spinal Cord, Bronx, NY USA. [Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. FU Department of Veterans Affairs, VA Office of Research and Development, Clinical Sciences Service [535]; SCI Service and Rehabilitation Research and Development Center of Excellence for the Medical Consequences of SCI, VA Medical Center, Bronx, New York [B4162C] FX Funding for this study was provided by the Department of Veterans Affairs, VA Office of Research and Development, Clinical Sciences Service, Cooperative Studies Program, CS #535; SCI Service and Rehabilitation Research and Development Center of Excellence for the Medical Consequences of SCI #B4162C, James J. Peters VA Medical Center, Bronx, New York. The authors acknowledge Dr William Krol, as well as the following participating sites and site investigators for their effort and participation in this project: Charlie Norwood VA Medical Center (Augusta, Georgia)-Rose C. Trincher, MD; James J. Peters VA Medical Center (Bronx, New York)-George A. Deitrick, MD; Louis Stokes VA Medical Center (Cleveland, Ohio)-Chester H. Ho, MD; VA North Texas Healthcare System: Dallas VA Medical Center-Lance L. Goetz, MD; Edward Hines Jr VA Hospital (Hines, Illinois)-Bernard A. Nemchausky, MD; Michael E. Debakey VA Medical Center (Houston, Texas)-Sally A. Holmes, MD; VA Palo Alto Health Care System (Palo Alto, California)-Roy Sasaki, MD; Hunter Holmes McGuire VA Medical Center (Richmond, Virginia)-Meena Midha, MD; James A. Haley Veterans' Hospital (Tampa, Florida)-John L. Merritt, MD; and VA Boston Healthcare System, West Roxbury Campus (Boston, Massachusetts)-Sunil Sabharwal, MD. NR 21 TC 11 Z9 13 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1527-7941 J9 ADV SKIN WOUND CARE JI Adv. Skin Wound Care PD NOV PY 2010 VL 23 IS 11 BP 508 EP 516 DI 10.1097/01.ASW.0000390493.43835.ec PG 9 WC Dermatology; Nursing; Surgery SC Dermatology; Nursing; Surgery GA 832ZF UT WOS:000295849100004 PM 20975334 ER PT J AU Kim, MS Wang, TY Ou, FS Klein, AJ Hudson, PA Messenger, JC Masoudi, FA Rumsfeld, JS Ho, PM AF Kim, Michael S. Wang, Tracy Y. Ou, Fang-Shu Klein, Andrew J. Hudson, Paul A. Messenger, John C. Masoudi, Frederick A. Rumsfeld, John S. Ho, P. Michael TI Association of prior coronary artery bypass graft surgery with quality of care of patients with non-ST-segment elevation myocardial infarction: A report from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines SO AMERICAN HEART JOURNAL LA English DT Article ID RITA-3 RANDOMIZED-TRIAL; UNSTABLE ANGINA; FOLLOW-UP; GLYCOPROTEIN IIB/IIIA; NONINVASIVE STRATEGY; SURVIVAL; DISEASE; IMPROVEMENT AB Background The American College of Cardiology/American Health Association guidelines recommend both an early invasive strategy and administration of antiplatelet/anticoagulant therapy for high-risk patients in the absence of contraindications. Little is known about adherence to guideline recommendations in patients with prior coronary artery bypass graft (CABG) surgery presenting with non-ST-segment elevation myocardial infarction (NSTEMI). Methods We analyzed 47,557 patients with NSTEMI in the 2007-2008 National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. Treatment patterns were compared between patients with and without prior CABG surgery. Multivariable regression with generalized estimating equations evaluated the association between prior CABG and in-hospital outcomes. Results In this study, 8,790 NSTEMI patients (18.5%) had a history of CABG surgery. Prior CABG surgery was associated with a significantly lower adjusted likelihood of early cardiac catheterization (adjusted odds ratio [OR] 0.88, 95% CI 0.83-0.92), higher rates of short-term clopidogrel use (adjusted OR 1.08, 95% CI 1.02-1.14), and comparable use of anticoagulant therapy (adjusted OR 0.96, 95% CI 0.88-1.04). Adjusted risks of bleeding and in-hospital mortality did not differ significantly between the 2 groups (adjusted ORs 1.00, 95% CI 0.92-1.11 and 0.99, 95% CI 0.87-1.11, respectively). Conclusions Patients with prior CABG surgery presenting with NSTEMI are often felt to be at high risk for adverse outcomes and therefore require aggressive treatment. Our study indicates that they are less likely to undergo guideline-recommended early cardiac catheterization but equally or more likely to receive guideline-recommended antiplatelet and anticoagulant therapy. This risk-treatment paradox, however, does not appear to negatively influence short-term clinical outcomes. (Am Heart J 2010;160:951-7.) C1 [Kim, Michael S.] Univ Washington, Med Ctr, Sch Med, Seattle, WA 98195 USA. [Wang, Tracy Y.; Ou, Fang-Shu] Duke Clin Res Inst, Durham, NC USA. [Klein, Andrew J.] John Cochran VA Med Ctr, St Louis, MO USA. [Hudson, Paul A.; Messenger, John C.] Univ Colorado Denver, Aurora, CO USA. [Masoudi, Frederick A.] Denver Hlth Med Ctr, Denver, CO USA. [Rumsfeld, John S.; Ho, P. Michael] Denver VA Med Ctr, Denver, CO USA. RP Kim, MS (reprint author), Univ Washington, Med Ctr, Sch Med, 1959 NE Pacific St,Box 356116, Seattle, WA 98195 USA. EM mshkim@u.washington.edu NR 25 TC 9 Z9 10 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD NOV PY 2010 VL 160 IS 5 BP 951 EP 957 DI 10.1016/j.ahj.2010.07.025 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 683FX UT WOS:000284458700025 PM 21095285 ER PT J AU Lawson, N Thompson, K Saunders, G Saiz, J Richardson, J Brown, D Ince, N Caldwell, M Pope, D AF Lawson, Nancy Thompson, Kim Saunders, Gabrielle Saiz, Jaya Richardson, Jeannette Brown, Deborah Ince, Naomi Caldwell, Marc Pope, Diana TI SOUND INTENSITY AND NOISE EVALUATION IN A CRITICAL CARE UNIT SO AMERICAN JOURNAL OF CRITICAL CARE LA English DT Article ID ENVIRONMENTAL NOISE; SLEEP DISRUPTION; HOSPITAL WARDS; ICU; INTERVENTION; SETTINGS; NIGHT AB Background Sound levels in intensive care units can be high. Unfortunately, high levels of sound tend to result in poor sleep quality, which leads to slower healing, poorer immune response, and decreased cognitive function. Objectives To measure sound levels to which patients in intensive care units are typically exposed. Methods Peak sound pressure levels of alarms on medical devices set at different output levels were measured. Additionally, ambient sound pressure levels for durations of 10 to 24 hours were measured on 12 occasions in patients' rooms in the intensive care unit. Results Peak levels of equipment alarms measured inside a patient's room were high, and increased as the setting of the alarm level increased. The levels of these alarms when measured in an adjacent room did not increase with alarm output level. Mean sound levels inside the patient's room were generally less than 45 dB(A), but peak levels were often greater than 85 dB(C). Closing the door of the adjacent room did not decrease these peak levels. Peak and mean levels did not differ systematically during 24 hours of measurement. Conclusions High-intensity equipment alarms disturb patients' sleep but are critical in a medical emergency. However, nurses should not assume that raising the alarm output level will ensure that the alarm is audible from an adjacent room. Ambient noise measurements indicate high peak levels during both day and night. (American Journal of Critical Care. 2010; 19:e88-e99) C1 [Lawson, Nancy; Thompson, Kim; Saunders, Gabrielle; Brown, Deborah; Ince, Naomi] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA. [Caldwell, Marc] Seattle VA Med Ctr, Seattle, WA USA. RP Saunders, G (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Gabrielle.saunders@va.gov FU Department of Veterans Affairs, Veterans Health Administration Rehabilitation Research and Development [4844C] FX This study was supported in part by grant 4844C from the Department of Veterans Affairs, Veterans Health Administration Rehabilitation Research and Development. NR 40 TC 25 Z9 26 U1 1 U2 9 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 1062-3264 J9 AM J CRIT CARE JI Am. J. Crit. Care PD NOV 1 PY 2010 VL 19 IS 6 BP E88 EP E99 DI 10.4037/ajcc2010180 PG 12 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA 673LB UT WOS:000283662100003 PM 21041190 ER PT J AU Spiegel, BMR AF Spiegel, Brennan M. R. TI Treatment Strategies for Acid Reflux: EncomPASSing Practical Solutions for Primary Care SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID DISEASE; TRIALS AB Despite a steady diet of randomized controlled trials (RCTs) for over three decades, nearly all of our routine clinical decisions remain incompletely supported, or even totally unaddressed, by the burgeoning pile of RCT data. The biomedical literature tends to focus on explanatory RCTs that compare new agents with placebo; it is less common to find pragmatic clinical trials (PCTs) that test the risks, benefits, and costs of competing active therapies within the context of usual practice settings. In this issue of the American Journal of Gastroenterology, Moayeddi and colleagues report the results of the EncomPASS study-a novel PCT for the primary care management of reflux disease. In this editorial, the results of EncomPASS are discussed, and the study is highlighted as a model for investigators to follow as we continue to emphasize pragmatic trials that address everyday challenges in clinical care. C1 [Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Spiegel, Brennan M. R.] CURE Digest Dis Res Ctr, Los Angeles, CA USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu NR 9 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2010 VL 105 IS 11 BP 2347 EP 2349 DI 10.1038/ajg.2010.378 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 674UM UT WOS:000283775600003 PM 21048680 ER PT J AU Kvale, EA Woodby, L Williams, BR AF Kvale, Elizabeth A. Woodby, Lesa Williams, Beverly Rosa TI The Experience of Older Patients With Cancer in Phase 1 Clinical Trials: A Qualitative Case Series SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE aging; cancer psychosocial aspects; hope; illness and disease experiences; older people; pain; research participation; social support; symptom management ID RANDOMIZED CONTROLLED-TRIAL; OF-LIFE; I TRIALS; BODY-IMAGE; HOPE; PARTICIPATION; PERCEPTIONS; CHEMOTHERAPY; EXPECTATIONS; PERSPECTIVE AB This article explores the experiences of older patients with cancer in phase 1 clinical trials. Conducting a case series of face-to-face, in-depth, open-ended interviews and using qualitative methods of analysis, we find that the psychosocial process of social comparison is relevant for understanding older adults' phase 1 clinical trial participation. Social comparison influences decisions to enroll in a phase 1 clinical trial, shapes perceptions of supportive care needs, and encourages the utilization of hope. Additional research should develop strategies for addressing supportive care needs among this patient cohort whose use of social comparison can inhibit articulation of pain, suffering, and symptom burden as well as use of informal support systems. C1 [Kvale, Elizabeth A.; Woodby, Lesa; Williams, Beverly Rosa] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Birmingham, AL USA. [Kvale, Elizabeth A.; Woodby, Lesa; Williams, Beverly Rosa] Birmingham VA Med Ctr, Birmingham, AL USA. [Kvale, Elizabeth A.; Woodby, Lesa; Williams, Beverly Rosa] Univ Alabama, Ctr Aging, Birmingham, AL USA. [Kvale, Elizabeth A.; Woodby, Lesa; Williams, Beverly Rosa] Univ Alabama, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. RP Kvale, EA (reprint author), CH19 Room 219R, Birmingham, AL 35205 USA. EM ekvale@aging.uab.edu NR 61 TC 1 Z9 1 U1 1 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD NOV PY 2010 VL 27 IS 7 BP 474 EP 481 DI 10.1177/1049909110365072 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 669BV UT WOS:000283322300007 PM 20388935 ER PT J AU Choi, A Scherzer, R Bacchetti, P Tien, PC Saag, MS Gibert, CL Szczech, LA Grunfeld, C Shlipak, MG AF Choi, Andy Scherzer, Rebecca Bacchetti, Peter Tien, Phyllis C. Saag, Michael S. Gibert, Cynthia L. Szczech, Lynda A. Grunfeld, Carl Shlipak, Michael G. TI Cystatin C, Albuminuria, and 5-Year All-Cause Mortality in HIV-Infected Persons SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Kidney disease; mortality; human immunodeficiency virus (HIV) infection ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; STAGE RENAL-DISEASE; ANTIRETROVIRAL THERAPY; CARDIOVASCULAR EVENTS; SERUM CREATININE; ELDERLY PERSONS; RISK; OUTCOMES; DEATH AB Background: Compared with controls, human immunodeficiency virus (HIV)-infected persons have a greater prevalence of kidney disease, assessed according to high cystatin C level and albuminuria, but not according to creatinine level. However, the clinical importance of increased cystatin C level and albuminuria in the HIV-infected population has not been studied. Study Design: We conducted an observational cohort study to determine the association of kidney disease (measured according to albuminuria, cystatin C, and serum creatinine) with mortality. Setting & Participants: 922 HIV-infected persons enrolled in the FRAM (Fat Redistribution and Metabolic Change in HIV Infection) Study. Predictor: Serum cystatin C and serum creatinine levels were used to estimate glomerular filtration rates (eGFR(SCysC) and eGFR(SCr), respectively). Albuminuria was defined as a positive urine dipstick result (>= 1+) or urine albumin-creatinine ratio >30 mg/g. Outcome: 5-Year mortality. Results: At baseline, decreased kidney function (eGFR(SCysC) <60 mL/min/1.73 m(2)) or albuminuria was present in 28% of participants. After 5 years of follow-up, mortality was 48% in those with both eGFR(SCysC) <60 mL/min/1.73 m(2) and albuminuria, 23% in those with eGFR(SCysC) <60 mL/min/1.73 m(2) alone, 20% in those with albuminuria alone, and 9% in those with neither condition. After multivariable adjustment for demographics, cardiovascular risk factors, HIV-related factors, and inflammatory marker levels, eGFR(SCysC) <60 mL/min/1.73 m(2) and albuminuria were associated with a nearly 2-fold increase in mortality, whereas eGFR(SCr) <60 mL/min/1.73 m(2) did not appear to have a substantial association with mortality. Together, eGFR(SCysC) <60 mL/min/1.73 m(2) and albuminuria accounted for 17% of the population-level attributable risk of mortality. Limitations: Vital status was unknown in 261 participants from the original cohort. Conclusions: Kidney disease marked by albuminuria or increased cystatin C level appears to be an important risk factor for mortality in HIV-infected individuals. A substantial proportion of this risk may be unrecognized because of the current reliance on serum creatinine to estimate kidney function in clinical practice. Am J Kidney Dis 56: 872-882. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Grunfeld, Carl] Univ Calif San Francisco, FRAM Study, Off Principal Investigator, Vet Affairs Med Ctr,Metab Sect 111F, San Francisco, CA 94121 USA. [Choi, Andy; Scherzer, Rebecca; Tien, Phyllis C.; Grunfeld, Carl; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Saag, Michael S.] Univ Alabama, Birmingham, AL USA. [Gibert, Cynthia L.] DC VA Med Ctr, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ, Washington, DC USA. [Szczech, Lynda A.] Duke Univ, Med Ctr, Dept Med, Div Nephrol, Durham, NC 27710 USA. RP Grunfeld, C (reprint author), Univ Calif San Francisco, FRAM Study, Off Principal Investigator, Vet Affairs Med Ctr,Metab Sect 111F, 4150 Clement St, San Francisco, CA 94121 USA. EM carl.grunfeld@ucsf.edu FU National Institutes of Health (NIH) [R01 DK57508, R01 HL74814, R01 HL53359, K23 AI66943, K23 DK080645-01A1]; NIH center [P30 AI027767, M01 RR00036, M01 RR00051, M01 RR00052, M01 RR00054, M01 RR00083, M01 RR0636, M01 RR00865, KL2 RR024130, UL1 RR024131] FX Support: This study was supported by National Institutes of Health (NIH) grants R01 DK57508, R01 HL74814, R01 HL53359, K23 AI66943, and K23 DK080645-01A1 and NIH center grants P30 AI027767, M01 RR00036, M01 RR00051, M01 RR00052, M01 RR00054, M01 RR00083, M01 RR0636, M01 RR00865, KL2 RR024130, and UL1 RR024131. The funding agency had no role in the conduct of the study, collection of the data, management of the study, analysis of data, interpretation of the data, or preparation of the manuscript. A representative of the funding agent participated in planning the protocol. NR 45 TC 58 Z9 59 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD NOV PY 2010 VL 56 IS 5 BP 872 EP 882 DI 10.1053/j.ajkd.2010.05.019 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 668IL UT WOS:000283261700014 PM 20709438 ER PT J AU Fortney, JC Pyne, JM Steven, CA Williams, JS Hedrick, RG Lunsford, AK Raney, WN Ackerman, BA Ducker, LO Bonner, LM Smith, JL AF Fortney, John C. Pyne, Jeffrey M. Steven, Christopher A. Williams, J. Silas Hedrick, Richard G. Lunsford, Amanda K. Raney, William N. Ackerman, Betty A. Ducker, Loretta O. Bonner, Laura M. Smith, Jeffrey L. TI A Web-Based Clinical Decision Support System for Depression Care Management SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL AB Objective: To inform the design of future informatics systems that support the chronic care model. Study Design: We describe the development and functionality of a decision support system for the chronic care model of depression treatment, known as collaborative care. Dissemination of evidence-based collaborative care models has been slow, and fidelity to the evidence base has been poor during implementation initiatives. Implementation could be facilitated by a decision support system for depression care managers, the cornerstone of the collaborative care model. The Net Decision Support System (https://www.netdss.net/) is a free Web-based system that was developed to support depression care manager activities and to facilitate the dissemination of collaborative care models that maintain high fidelity to the evidence base. Methods: The NetDSS was based on intervention materials used for a randomized trial of depression care management that improved clinical outcomes compared with usual care. The NetDSS was developed jointly by a cross-functional design team of psychiatrists, depression care managers, information technology specialists, technical writers, and researchers. Results: The NetDSS has the following functional capabilities: patient registry, patient encounter scheduler, trial management, clinical decision support, progress note generator, and workload and outcomes report generator. The NetDSS guides the care manager through a self-documenting patient encounter using evidence-based scripts and self-scoring instruments. The NetDSS has been used to provide evidence-based depression care management to more than 1700 primary care patients. Conclusion: Intervention protocols can be successfully converted to Web-based decision support systems that facilitate the implementation of evidence-based chronic care models into routine care with high fidelity. (Am J Manag Care. 2070;76(17):849-854) C1 [Fortney, John C.; Pyne, Jeffrey M.; Steven, Christopher A.; Hedrick, Richard G.; Ducker, Loretta O.; Smith, Jeffrey L.] Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. [Fortney, John C.; Pyne, Jeffrey M.; Williams, J. Silas; Lunsford, Amanda K.; Raney, William N.; Ackerman, Betty A.; Smith, Jeffrey L.] Cent Arkansas Vet Healthcare Syst, HSR&D Ctr Mental Hlth & Outcomes Res, N Little Rock, AR USA. [Bonner, Laura M.] VA Puget Sound Healthcare Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA USA. RP Fortney, JC (reprint author), Univ Arkansas Med Sci, Dept Psychiat, 4301 W Markham St, Little Rock, AR 72205 USA. EM fortneyjohnc@uams.edu FU Department of Veterans Affairs [IMV 04-360, IIR 00-078-3, MNT 05-152, MHS-03-218, MNH 98-000]; National Institute of Mental Health [R01 MH076908-01]; Department of Psychiatry, University of Arkansas for Medical Sciences FX This study was funded by grants IMV 04-360, IIR 00-078-3, MNT 05-152, MHS-03-218, and MNH 98-000 from the Department of Veterans Affairs; by grant R01 MH076908-01 from the National Institute of Mental Health; and by a pilot grant from the Department of Psychiatry, University of Arkansas for Medical Sciences. NR 18 TC 10 Z9 11 U1 2 U2 7 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD NOV PY 2010 VL 16 IS 11 BP 849 EP 854 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 689GL UT WOS:000284915400005 PM 21348556 ER PT J AU Tantiwong, P Shanmugasundaram, K Monroy, A Ghosh, S Li, MY DeFronzo, RA Cersosimo, E Sriwijitkamol, A Mohan, S Musi, N AF Tantiwong, Puntip Shanmugasundaram, Karthigayan Monroy, Adriana Ghosh, Sangeeta Li, Mengyao DeFronzo, Ralph A. Cersosimo, Eugenio Sriwijitkamol, Apiradee Mohan, Sumathy Musi, Nicolas TI NF-kappa B activity in muscle from obese and type 2 diabetic subjects under basal and exercise-stimulated conditions SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE nuclear factor-kappa B; skeletal muscle; monocyte chemotactic protein-1; interleukin-6 ID INDUCED INSULIN-RESISTANCE; SKELETAL-MUSCLE; GLUCOSE; PATHWAY AB Tantiwong P, Shanmugasundaram K, Monroy A, Ghosh S, Li M, DeFronzo RA, Cersosimo E, Sriwijitkamol A, Mohan S, Musi N. NF-kappa B activity in muscle from obese and type 2 diabetic subjects under basal and exercise-stimulated conditions. Am J Physiol Endocrinol Metab 299: E794-E801, 2010. First published August 24, 2010; doi: 10.1152/ajpendo.00776.2009.-NF-kappa B is a transcription factor that controls the gene expression of several proinflammatory proteins. Cell culture and animal studies have implicated increased NF-kappa B activity in the pathogenesis of insulin resistance and muscle atrophy. However, it is unclear whether insulin-resistant human subjects have abnormal NF-kappa B activity in muscle. The effect that exercise has on NF-kappa B activity/signaling also is not clear. We measured NF-kappa B DNA-binding activity and the mRNA level of putative NF-kappa B-regulated myokines interleukin (IL)-6 and monocyte chemotactic protein-1 (MCP-1) in muscle samples from T2DM, obese, and lean subjects immediately before, during (40 min), and after (210 min) a bout of moderate-intensity cycle exercise. At baseline, NF-kappa B activity was elevated 2.1- and 2.7-fold in obese nondiabetic and T2DM subjects, respectively. NF-kappa B activity was increased significantly at 210 min following exercise in lean (1.9-fold) and obese (2.6-fold) subjects, but NF-kappa B activity did not change in T2DM. Exercise increased MCP-1 mRNA levels significantly in the three groups, whereas IL-6 gene expression increased significantly only in lean and obese subjects. MCP-1 and IL-6 gene expression peaked at the 40-min exercise time point. We conclude that insulin-resistant subjects have increased basal NF-kappa B activity in muscle. Acute exercise stimulates NF-kappa B in muscle from nondiabetic subjects. In T2DM subjects, exercise had no effect on NF-kappa B activity, which could be explained by the already elevated NF-kappa B activity at baseline. Exercise-induced MCP-1 and IL-6 gene expression precedes increases in NF-kappa B activity, suggesting that other factors promote gene expression of these cytokines during exercise. C1 [Musi, Nicolas] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. [Tantiwong, Puntip; Monroy, Adriana; Ghosh, Sangeeta; Li, Mengyao; DeFronzo, Ralph A.; Cersosimo, Eugenio; Sriwijitkamol, Apiradee; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Texas Diabet Inst, San Antonio, TX 78229 USA. [Shanmugasundaram, Karthigayan; Mohan, Sumathy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Ctr Healthy Aging, San Antonio, TX 78229 USA. RP Musi, N (reprint author), S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. FU American Diabetes Association; National Institutes of Health [AG-030979, DK-80157, DK-24092, CA-112175]; San Antonio Nathan Shock Center; UTHSCSA Executive Research Committee; South Texas Health Research Center; US Department of Veterans Affairs; Faculty of Medicine Siriraj Hospital Mahidol University of Thailand; Endocrine Fellows Foundation; Thai Ministry of Public Health and Maharat Nakhon Ratchasima Hospital; [T32-HL-04776] FX This study was supported by grants from the American Diabetes Association (N. Musi, E. Cersosimo, and R. A. DeFronzo), the National Institutes of Health (AG-030979 and DK-80157 to N. Musi, DK-24092 to R. A. DeFronzo, and CA-112175 to S. Mohan), the San Antonio Nathan Shock Center (N. Musi), the UTHSCSA Executive Research Committee (N. Musi), the South Texas Health Research Center (N. Musi), the US Department of Veterans Affairs (R. A. DeFronzo), the Faculty of Medicine Siriraj Hospital Mahidol University of Thailand (A. Sriwijitkamol), the Endocrine Fellows Foundation (A. Sriwijitkamol), and the Thai Ministry of Public Health and Maharat Nakhon Ratchasima Hospital (P. Tantiwong). S. Ghosh was funded by T32-HL-04776. NR 14 TC 39 Z9 42 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD NOV PY 2010 VL 299 IS 5 BP E794 EP E801 DI 10.1152/ajpendo.00776.2009 PG 8 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 673LX UT WOS:000283665600012 PM 20739506 ER PT J AU Scherz, N Labarere, J Mean, M Ibrahim, SA Fine, MJ Aujesky, D AF Scherz, Nathalie Labarere, Jose Mean, Marie Ibrahim, Said A. Fine, Michael J. Aujesky, Drahomir TI Prognostic Importance of Hyponatremia in Patients with Acute Pulmonary Embolism SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE hyponatremia; prognosis; pulmonary embolism ID ELEVATION MYOCARDIAL-INFARCTION; COMMUNITY-ACQUIRED PNEUMONIA; HEART-FAILURE; TOTAL HIP; OUTCOMES; HYPERTENSION; ADMISSION; HOSPITALIZATION; ARTHROPLASTY; MORTALITY AB Rationale: Although associated with adverse outcomes in other cardiopulmonary conditions, the prognostic value of hyponatremia, a marker of neurohormonal activation, in patients with acute pulmonary embolism (PE) is unknown. Objectives: To examine the associations between hyponatremia and mortality and hospital readmission rates for patients hospitalized with PE. Methods: We evaluated 13,728 patient discharges with a primary diagnosis of PE from 185 hospitals in Pennsylvania (January 2000 to November 2002). We used random-intercept logistic regression to assess the independent association between serum sodium levels at the time of presentation and mortality and hospital readmission within 30 days, adjusting for patient (race, insurance, severity of illness, use of thrombolytic therapy) and hospital factors (region, size, teaching status). Measurements and Main Results. Hyponatremia (sodium <= 135 mmol/L) was present in 2,907 patients (21.1%). Patients with a sodium level greater than 135, 130-135, and less than 130 mmol/L had a cumulative 30-day mortality of 8.0, 13.6, and 28.5% (P < 0.001), and a readmission rate of 11.8, 15.6, and 19.3% (P < 0.001), respectively. Compared with patients with a sodium greater than 135 mmol/L, the adjusted odds of dying were significantly greater for patients with a sodium 130-135 mmol/L (odds ratio [OR], 1.53; 95% confidence interval [Cl], 1.33-1.76) and a sodium less than 130 mmol/L (OR, 3.26; 95% Cl, 2.48-4.29). The adjusted odds of readmission were also increased for patients with a sodium of 130-135 mmol/L (OR, 1.28; 95% Cl, 1.12-1.46) and a sodium less than 130 mmol/L (OR, 1.44; 95% Cl, 1.02-2.02). Conclusions: Hyponatremia is common in patients presenting with PE, and is an independent predictor of short-term mortality and hospital readmission. C1 [Scherz, Nathalie; Mean, Marie] Univ Lausanne, Div Gen Internal Med, Lausanne, Switzerland. [Labarere, Jose] Univ Grenoble 1, CNRS, UMR 5525, TIMC, Grenoble, France. [Ibrahim, Said A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Ibrahim, Said A.] Philadelphia Vet Affairs VA Med Ctr, Philadelphia, PA USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Aujesky, Drahomir] Univ Bern, Div Gen Internal Med, Bern, Switzerland. RP Aujesky, D (reprint author), Univ Hosp Bern, Klin Allgemeine Innere Med, CH-3010 Bern, Switzerland. EM drahomir.aujesky@insel.ch RI Labarere, Jose/N-1688-2014 OI Labarere, Jose/0000-0001-7621-6586 FU National Heart, Lung, and Blood Institute [1 R21 HL075521-01A1]; Swiss National Science Foundation [33CSCO-122659]; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Zynx Health, Inc.; McQuaide Blasko; Up-To-Date; National Institutes of Health FX Supported in part by grant 1 R21 HL075521-01A1 from the National Heart, Lung, and Blood Institute, by grant 33CSCO-122659 from the Swiss National Science Foundation, and by a K24 career development award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (S.A.I.).; D.A. serves on the advisory board for Sanofi Aventis and Bayer for $1,001-$5,000 each; M.J.F. received consultancy fees from Zynx Health, Inc. for less than $1,000 and expert witness fees from McQuaide Blasko for $5,001-$10,000, and also receives royalties from Up-To-Date for less than $1,000; S.A.I. received a sponsored grant from the National Institutes of Health for more than $100,001; J.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; M.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; N.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. NR 27 TC 36 Z9 38 U1 1 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 1 PY 2010 VL 182 IS 9 BP 1178 EP 1183 DI 10.1164/rccm.201003-0481OC PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 677DQ UT WOS:000283969700014 PM 20595225 ER PT J AU Russell, JS Sawhney, R Monto, A Nanavati, S Ben Davoren, J Aslam, R Corvera, CU AF Russell, Jeffery S. Sawhney, Rajiv Monto, Alexander Nanavati, Sujal Ben Davoren, J. Aslam, Rizwan Corvera, Carlos U. TI Periprocedural complications by Child-Pugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular carcinoma at a VA medical center SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE Hepatitis C; Hepatocellular carcinoma; Transcatheter arterial embolization; Chemoembolization; Surgical complications AB BACKGROUND For patients with compensated cirrhosis transcatheter arterial embolization with and without additive chemotherapy has been shown to improve survival The aim of this study was to compare periprocedural complications in a population with hepatitis C virus related hepatocellular carcinoma to evaluate for differences in complications by severity of liver disease METHODS Patients with unresectable hepatocellular carcinoma treated by transcatheter arterial embolization with or without additive chemotherapy procedures from 2003 to 2006 were retrospectively reviewed and compared by Child Pugh (CP) class A total of 141 embolizations were done in 76 patients RESULTS Complication rates were seen in 27% of CP class A and 17% of CP class B patients There was no significant difference in the grade of complications between the 2 groups or between procedure types Survival rate was dependent on the degree of liver dysfunction (3-year CP class A, 49%, CP class B, 13%, P = 0048) CONCLUSION Embolization procedures to treat hepatitis C virus related hepatocellular carcinoma can be performed safely with low morbidity and mortality rates even in patients with a compromised hepatic reserve Published by Elsevier Inc C1 [Corvera, Carlos U.] San Francisco VA Med Ctr, Dept Surg, San Francisco, CA USA. [Russell, Jeffery S.] Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA. [Sawhney, Rajiv; Nanavati, Sujal; Aslam, Rizwan] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA. [Monto, Alexander] San Francisco VA Med Ctr, Dept Gastroenterol, San Francisco, CA USA. [Ben Davoren, J.] San Francisco VA Med Ctr, Dept Hematol Oncol, San Francisco, CA USA. RP Corvera, CU (reprint author), San Francisco VA Med Ctr, Dept Surg, San Francisco, CA USA. FU Veteran Health Administration; Northern California Institute for Research and Education FX Supported by a grant from the Veteran Health Administration and from the Northern California Institute for Research and Education (CUC) This manuscript was presented at the 2010 Association of VA Surgeons Conference on May 10 2010 NR 12 TC 3 Z9 3 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2010 VL 200 IS 5 BP 659 EP 664 DI 10.1016/j.amjsurg.2010.07.021 PG 6 WC Surgery SC Surgery GA 691LS UT WOS:000285081900021 PM 21056149 ER PT J AU Thirunavukarasu, P Brewster, LP Pecora, SM Hall, DE AF Thirunavukarasu, Pragatheeshwar Brewster, Luke P. Pecora, Stephanie M. Hall, Daniel E. TI Educational intervention is effective in improving knowledge and confidence in surgical ethics-a prospective study SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE Surgical ethics; Ethics education; ACGME; Core competency; Professionalism; Resident ethics education ID RESIDENCY PROGRAMS; RANDOMIZED-TRIAL; CLINICAL ETHICS; SURGERY; OUTCOMES AB BACKGROUND Professionalism and ethics are Accreditation Council for Graduate Medical Education (ACGME) core competencies but there is little evidence regarding the effectiveness of ethics education METHODS General surgery residents at the University of Pittsburgh completed questionnaires measuring attitudes and knowledge about surgical ethics before and after four 60-minute faculty-facilitated seminars implementing the American College of Surgeons ethics curriculum RESULTS Most residents experienced ethical challenges at least once every rotation competition of Interests (75%) professional obligations (75%) confidentiality (83%) truth telling (88%), surrogate decision making (91%) and end-of life issues (100%) The educational intervention increased both knowledge about surgical ethics (P = 013) and confidence in dealing with competition of interests (P = 001) professional obligations (P = 011), truth telling (P = 013) confidentiality (P = 011), end of-life issues (P = 007) and surrogate decision making (P = 052) Most residents recommended the American College of Surgeons text for future use (84%) considering ethics education a standard part of residency training (70%) CONCLUSIONS Focused instruction using the American College of Surgeons ethics curriculum can effectively Improve both knowledge and confidence about surgical ethics Published by Elsevier Inc C1 [Thirunavukarasu, Pragatheeshwar; Hall, Daniel E.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA. [Brewster, Luke P.] Emory Clin, Atlanta, GA 30322 USA. [Pecora, Stephanie M.; Hall, Daniel E.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Hall, DE (reprint author), Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA. RI Hall, Daniel/H-4843-2013 OI Hall, Daniel/0000-0001-6382-0522 FU Kamangar Foundation; Center for Study of Ethics and Human Values University of Washington St Louis FX This study was supported by funding through the Kamangar Foundation and Award Center for Study of Ethics and Human Values University of Washington St Louis NR 22 TC 6 Z9 6 U1 0 U2 4 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2010 VL 200 IS 5 BP 665 EP 669 DI 10.1016/j.amjsurg.2010.08.002 PG 5 WC Surgery SC Surgery GA 691LS UT WOS:000285081900022 PM 21056150 ER PT J AU Peniche, AG Osorio, EY Melby, PC Travi, BL AF Peniche, Alex G. Osorio, Elvia Y. Melby, Peter C. Travi, Bruno L. TI DEVELOPMENT OF A MEDIUM THROUGHPUT SYSTEM THAT USES LYMPH NODE EX VIVO EXPLANT CULTURES TO IDENTIFY COMPOUNDS AGAINST CUTANEOUS LEISHMANIASIS SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract CT 59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH) CY NOV 03-07, 2010 CL Atlanta, GA SP Amer Soc Trop Med & Hyg (ASTMH) C1 [Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2010 VL 83 IS 5 SU S MA 687 BP 205 EP 205 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 832QF UT WOS:000295819701056 ER PT J AU Kelly, JX Li, YX Forquer, I Melendez, V Hickman, M O'Neil, M Cooper, R Harris, E Pybus, B Sousa, J Li, QG Smilkstein, M Winter, R Hinrichs, D Riscoe, M AF Kelly, Jane X. Li, Yuexin Forquer, Isaac Melendez, Victor Hickman, Mark O'Neil, Michael Cooper, Roland Harris, Erin Pybus, Brandon Sousa, Jason Li, Qigui Smilkstein, Martin Winter, Rolf Hinrichs, Dave Riscoe, Mike TI NOVEL ACRIDONES AS BROAD-SPECTRUM ANTIMALARIALS SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract CT 59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH) CY NOV 03-07, 2010 CL Atlanta, GA SP Amer Soc Trop Med & Hyg (ASTMH) C1 [Kelly, Jane X.] Portland State Univ, Portland, OR 97207 USA. [Li, Yuexin; Forquer, Isaac; Winter, Rolf; Hinrichs, Dave; Riscoe, Mike] Portland VA Med Ctr, Portland, OR USA. [Melendez, Victor; Hickman, Mark; O'Neil, Michael; Harris, Erin; Pybus, Brandon; Sousa, Jason; Li, Qigui] Walter Reed Army Inst Res, Silver Spring, MD USA. [Cooper, Roland] Old Dominion Univ, Norfolk, VA USA. [Smilkstein, Martin] Oregon Translat Res & Drug Dev Inst, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2010 VL 83 IS 5 SU S MA 716 BP 213 EP 213 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 832QF UT WOS:000295819701084 ER PT J AU Wu, J Campuzano, S Halford, C Haake, DA Wang, J AF Wu, Jie Campuzano, Susana Halford, Colin Haake, David A. Wang, Joseph TI Ternary Surface Mono layers for Ultrasensitive (Zeptomole) Amperometric Detection of Nucleic Acid Hybridization without Signal Amplification SO ANALYTICAL CHEMISTRY LA English DT Article ID SELF-ASSEMBLED MONOLAYERS; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; ESCHERICHIA-COLI O157-H7; DNA HYBRIDIZATION; GOLD ELECTRODES; CHARGE-TRANSFER; IMMOBILIZATION; BIOSENSORS; SENSOR; DITHIOTHREITOL AB A ternary surface monolayer, consisting of coassembled thiolated capture probe, mercaptohexanol and dithiothreitol, is shown to offer dramatic improvements in the signal-to-noise characteristics of electrochemical DNA hybridization biosensors based on common self-assembled monolayers. Remarkably low detection limits down to 40 zmol (in 4 mu L samples) as well as only 1 CFU Escherichia coli per sensor are thus obtained without any additional amplification step in connection to the commonly used horseradish peroxidase/3,3',5,5'-tetramethylbenzidine system. Such dramatic improvements in the detection limits (compared to those of common binary alkanethiol interfaces and to those of most electrochemical DNA sensing strategies without target or signal amplification) are attributed primarily to the remarkably higher resistance to nonspecific adsorption. This reflects the highly compact layer (with lower pinhole density) produced by the coupling of the cyclic- and linear-configuration "backfillers" that leads to a remarkably low background noise even in the presence of complex sample matrixes. A wide range of surface compositions have been investigated, and the ternary mixed monolayer has been systematically optimized. Detailed impedance spectroscopy and cyclic voltammetric studies shed useful insights into the surface coverage. The impressive sensitivity and high specificity of the simple developed methodology indicate great promise for a wide range of nucleic acid testing, including clinical diagnostics, biothreat detection, food safety, and forensic analysis. C1 [Wu, Jie; Campuzano, Susana; Wang, Joseph] Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA. [Halford, Colin; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Halford, Colin; Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Wang, J (reprint author), Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA. EM josephwang@ucsd.edu RI Campuzano Ruiz, Susana/C-6448-2011; Wang, Joseph/C-6175-2011 FU National Institutes of Health [U01 AI075565]; National Science Foundation [CHE 0506529]; University Complutense of Madrid; Programa Becas Complutense del Amo FX Financial support from the National Institutes of Health (Award U01 AI075565) and National Science Foundation (Award CHE 0506529) is gratefully acknowledged. S.C. thanks the University Complutense of Madrid and Programa Becas Complutense del Amo (2010-2011). NR 39 TC 67 Z9 69 U1 1 U2 35 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD NOV 1 PY 2010 VL 82 IS 21 BP 8830 EP 8837 DI 10.1021/ac101474k PG 8 WC Chemistry, Analytical SC Chemistry GA 671SS UT WOS:000283531200014 PM 20883023 ER PT J AU Gaffo, AL Roseman, JM Jacobs, DR Lewis, CE Shikany, JM Mikuls, TR Jolly, PE Saag, KG AF Gaffo, Angelo L. Roseman, Jeffrey M. Jacobs, David R., Jr. Lewis, Cora E. Shikany, James M. Mikuls, Ted R. Jolly, Pauline E. Saag, Kenneth G. TI Serum urate and its relationship with alcoholic beverage intake in men and women: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; URIC-ACID; PURINE-BASES; CARDIOVASCULAR MORTALITY; PLASMA-CONCENTRATIONS; METABOLIC SYNDROME; LONG-TERM; CONSUMPTION; BEER AB Objective To investigate if beer, liquor (spirits), wine and total alcohol intakes have different associations with serum urate (SU) concentrations at different ages in a cohort of young men and women. Methods Data from 3123 participants at baseline and follow-up at 20 years were used, with balanced proportions of Caucasians and African Americans. The relationships of SU with categories of beer, liquor, wine and total alcohol intake referent to no intake were examined in sex-specific, cross-sectional analyses. Results Mean age (SD) at the beginning of follow-up was 25.1 (3.6) years. Compared with non-drinkers, significant associations between higher SU concentrations and greater beer intake were observed among men and women, with more pronounced and consistent associations for women. An association between greater liquor intake and higher SU concentrations was only seen for men at the year 20 evaluation. Wine intake was not associated with SU in either sex and total alcohol was associated with higher SU concentrations in both men and women. The magnitude of the associations between alcoholic beverages intake and SU was modest (<= 0.03 mg/dl/alcoholic beverage serving). Conclusion An association between higher SU concentrations and greater beer intake was consistent and pronounced among women, but also present in men. Despite the small magnitude of the increases in SU associated with alcohol intake, clinical implications in conditions such as cardiovascular disease and gout in young adults who are moderate and heavy drinkers cannot be ruled out. C1 [Gaffo, Angelo L.] Univ Alabama, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Gaffo, Angelo L.; Saag, Kenneth G.] Univ Alabama, Div Rheumatol, Birmingham, AL USA. [Roseman, Jeffrey M.; Jolly, Pauline E.] Univ Alabama, Dept Epidemiol, Birmingham, AL USA. [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Jacobs, David R., Jr.] Univ Oslo, Dept Nutr, Oslo, Norway. [Lewis, Cora E.; Shikany, James M.] Univ Alabama, Div Prevent Med, Birmingham, AL USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Sect Rheumatol & Clin Immunol, Omaha, NE USA. [Mikuls, Ted R.] Omaha Vet Affairs Med Ctr, Omaha, NE USA. RP Saag, KG (reprint author), FOT 820,1530 3rd Ave S, Birmingham, AL 35294 USA. EM ksaag@uab.edu FU NHLBI NIH HHS [N01 HC048047] NR 34 TC 24 Z9 25 U1 0 U2 4 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD NOV PY 2010 VL 69 IS 11 BP 1965 EP 1970 DI 10.1136/ard.2010.129429 PG 6 WC Rheumatology SC Rheumatology GA 665UI UT WOS:000283060600013 PM 20525839 ER PT J AU Mata, IF Shi, M Agarwal, P Chung, KA Edwards, KL Factor, SA Galasko, DR Ginghina, C Griffith, A Higgins, DS Kay, DM Kim, H Leverenz, JB Quinn, JF Roberts, JW Samii, A Snapinn, KW Tsuang, DW Yearout, D Zhang, J Payami, H Zabetian, CP AF Mata, Ignacio F. Shi, Min Agarwal, Pinky Chung, Kathryn A. Edwards, Karen L. Factor, Stewart A. Galasko, Douglas R. Ginghina, Carmen Griffith, Alida Higgins, Donald S. Kay, Denise M. Kim, Hojoong Leverenz, James B. Quinn, Joseph F. Roberts, John W. Samii, Ali Snapinn, Katherine W. Tsuang, Debby W. Yearout, Dora Zhang, Jing Payami, Haydeh Zabetian, Cyrus P. TI SNCA Variant Associated With Parkinson Disease and Plasma alpha-Synuclein Level SO ARCHIVES OF NEUROLOGY LA English DT Article ID GENOME-WIDE ASSOCIATION; LOCUS TRIPLICATION; RISK-FACTORS; GENE; SUSCEPTIBILITY; BLOOD; TRANSCRIPTION; VARIABILITY; EXPRESSION; BIOMARKERS AB Background: A functional repeat polymorphism in the SNCA promoter (REP1) conveys susceptibility for Parkinson disease (PD). There is also increasing evidence that single-nucleotide polymorphisms (SNPs) elsewhere in the gene are associated with PD risk. Objectives: To further explore the association of common SNCA SNPs with PD susceptibility, to determine whether evidence of allelic heterogeneity exists, and to examine the correlation between PD-associated variants and plasma alpha-synuclein levels. Design: Two-tiered analysis. Setting: Academic research. Patients: Patients and control subjects from the NeuroGenetics Research Consortium. Main Outcome Measures: We performed a 2-tiered analysis of 1956 patients with PD and 2112 controls from the NeuroGenetics Research Consortium using a comprehensive tag SNP approach. Previously published REP1 genotypes were also included. Plasma alpha-synuclein was assayed in 86 patients with PD and 78 controls using a highly sensitive Luminex assay. Results: Five of 15 SNPs genotyped were associated with PD under an additive model in tier 1 (alpha=.05). Of these, 4 were successfully replicated in tier 2. In the combined sample, the most significant marker was rs356219 (odds ratio, 1.41; 95% confidence interval, 1.28-1.55; P=1.6 x 10-12), located approximately 9 kilobases downstream from the gene. A regression model containing rs356219 alone best fit the data. The linkage disequilibrium correlation coefficient between this SNP and REP1 was low (r(2)=0.09). The risk-associated Callele of rs356219 was also correlated with higher transformed plasma alpha-synuclein levels in patients under an adjusted additive model (P=.005). Conclusions: Our data suggest that 1 or more unidentified functional SNCA variants modify risk for PD and that the effect is larger than and independent of REP1. This variant(s), tagged by rs356219, might act by upregulating SNCA expression in a dose-dependent manner. C1 [Mata, Ignacio F.; Yearout, Dora; Zabetian, Cyrus P.] Univ Washington, Geriatr Res Educ & Clin Ctr, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Leverenz, James B.; Tsuang, Debby W.] Univ Washington, Mental Illness Res Educ & Clin Ctr, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Leverenz, James B.; Samii, Ali; Zabetian, Cyrus P.] Univ Washington, Parkinsons Dis Res Educ & Clin Ctr, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Kim, Hojoong; Samii, Ali] Univ Washington, Neurol Sect, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Mata, Ignacio F.; Kim, Hojoong; Leverenz, James B.; Samii, Ali; Yearout, Dora; Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Sch Med, Seattle, WA 98108 USA. [Shi, Min; Ginghina, Carmen; Zhang, Jing] Univ Washington, Dept Pathol, Sch Med, Seattle, WA 98108 USA. [Edwards, Karen L.; Snapinn, Katherine W.] Univ Washington, Dept Epidemiol, Sch Med, Seattle, WA 98108 USA. [Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98108 USA. [Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Agarwal, Pinky; Griffith, Alida] Evergreen Hosp Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Chung, Kathryn A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Chung, Kathryn A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Higgins, Donald S.] Neurol Serv, Samuel Stratton Vet Affairs Med Ctr, Albany, NY USA. [Kay, Denise M.; Payami, Haydeh] New York State Dept Hlth, Genom Inst, Wadsworth Ctr, Albany, NY 12237 USA. RP Zabetian, CP (reprint author), Univ Washington, Geriatr Res Educ & Clin Ctr, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Mailstop S-182,1660 S Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu RI Shi, Min/G-6165-2012; Tsuang, Debby/L-7234-2016 OI Shi, Min/0000-0002-6901-2558; Tsuang, Debby/0000-0002-4716-1894 FU Ipsen; Schering Plough; Teva Neuroscience; Michael J. Fox Foundation; Parkinson's Disease Foundation; American Parkinson Disease Association; Department of Veterans Affairs [1101BX000531]; National Institutes of Health [P30 AG008017, P42 ES004696, P50 NS062684, R01 AG033398, R01 NS065070, R01 NS036960, R01 NS057567] FX Dr Agarwal serves on advisory boards for Ipsen and Merz Pharmaceuticals and has received compensation as a speaker for Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva Neuroscience. Dr Factor has received research grants from Ipsen, Schering Plough, and Teva Neuroscience and is a consultant for Allergan, Boehringer Ingelheim, Lundbeck, and UCB. Dr Samii has received compensation as a speaker for Boehringer Ingelheim, Ipsen, and Teva Neuroscience.; This work was supported by the Michael J. Fox Foundation, by the Parkinson's Disease Foundation, by the American Parkinson Disease Association, by grant 1101BX000531 from the Department of Veterans Affairs, and by grants P30 AG008017, P42 ES004696, P50 NS062684, R01 AG033398, R01 NS065070, R01 NS036960, and R01 NS057567 from the National Institutes of Health. NR 30 TC 70 Z9 74 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD NOV PY 2010 VL 67 IS 11 BP 1350 EP 1356 DI 10.1001/archneurol.2010.279 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 676RQ UT WOS:000283935300013 PM 21060011 ER PT J AU Wilde, EA Whiteneck, GG Bogner, J Bushnik, T Cifu, DX Dikmen, S French, L Giacino, JT Hart, T Malec, JF Millis, SR Novack, TA Sherer, M Tulsky, DS Vanderploeg, RD von Steinbuechel, N AF Wilde, Elisabeth A. Whiteneck, Gale G. Bogner, Jennifer Bushnik, Tamara Cifu, David X. Dikmen, Sureyya French, Louis Giacino, Joseph T. Hart, Tessa Malec, James F. Millis, Scott R. Novack, Thomas A. Sherer, Mark Tulsky, David S. Vanderploeg, Rodney D. von Steinbuechel, Nicole TI Recommendations for the Use of Common Outcome Measures in Traumatic Brain Injury Research SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Outcome assessment; health care; Brain injuries; Neurobehavioral manifestations; Research; Rehabilitation ID QUALITY-OF-LIFE; PORTLAND ADAPTABILITY INVENTORY; POST-CONCUSSION SYMPTOMS; FAMILY ASSESSMENT DEVICE; BEHAVIOR SCALE FRSBE; MINOR HEAD-INJURY; NOS-TBI; POSTCONCUSSION SYNDROME; ALCOHOL-CONSUMPTION; SIGNIFICANT OTHERS AB This article summarizes the selection of outcome measures by the interagency Traumatic Brain Injury (TBI) Outcomes Workgroup to address primary clinical research objectives, including documentation of the natural course of recovery from TBI, prediction of later outcome, measurement of treatment effects, and comparison of outcomes across studies. Consistent with other Common Data Elements Workgroups, the TBI Outcomes Workgroup adopted the standard 3-tier system in its selection of measures. In the first tier, core measures included valid, robust, and widely applicable outcome measures with proven utility in TBI from each identified domain, including global level of function, neuropsychological impairment, psychological status, TBI-related symptoms, executive functions, cognitive and physical activity limitations, social role participation, and perceived health-related quality of life. In the second tier, supplemental measures were recommended for consideration in TBI research focusing on specific topics or populations. In the third tier, emerging measures included important instruments currently under development, in the process of validation, or nearing the point of published findings that have significant potential to be superior to some older ("legacy") measures in the core and supplemental lists and may eventually replace them as evidence for their utility emerges. C1 [Wilde, Elisabeth A.; Sherer, Mark] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA. [Sherer, Mark] TIRR Mem Hermann, Houston, TX USA. [Wilde, Elisabeth A.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. [Sherer, Mark] Univ Texas Med Sch Houston, Houston, TX USA. [Whiteneck, Gale G.] Craig Hosp, Englewood, CO USA. [Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA. [Bushnik, Tamara] Rusk Inst Rehabil, Dept Rehabil Med, New York, NY USA. [Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, PM&R Serv, Hunter Holmes McGuire Vet Adm Med Ctr, Richmond, VA USA. [Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [French, Louis] Walter Reed Army Med Ctr, Dept Orthopaed & Rehabil, Washington, DC 20307 USA. [Giacino, Joseph T.] JFK Johnson Rehabil Inst, Edison, NJ USA. [Giacino, Joseph T.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA. [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA. [Malec, James F.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA. [Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA. [Millis, Scott R.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA. [Millis, Scott R.] Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI USA. [Novack, Thomas A.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA. [Tulsky, David S.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA. [Vanderploeg, Rodney D.] James A Haley Vet Hosp, Psychol Serv, Tampa, FL 33612 USA. [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA. [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL USA. [von Steinbuechel, Nicole] Univ Gottingen, Dept Med Psychol & Med Sociol, Univ Med Ctr, Gottingen, Germany. RP Wilde, EA (reprint author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA. EM ewilde@bcm.edu OI Bushnik, Tamara/0000-0003-3328-257X FU National Institutes of Health (NIH: National Institute of Neurological Disorders and Stroke); U.S. Department of Veterans Affairs (VA); U.S. Department of Defense (DoD); U.S. Department of Education/National Institute on Disability and Rehabilitation Research FX Supported by the National Institutes of Health (NIH: National Institute of Neurological Disorders and Stroke), U.S. Department of Veterans Affairs (VA), U.S. Department of Defense (DoD), and U.S. Department of Education/National Institute on Disability and Rehabilitation Research. NR 101 TC 124 Z9 126 U1 7 U2 29 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD NOV PY 2010 VL 91 IS 11 BP 1650 EP 1660 DI 10.1016/j.apmr.2010.06.033 PG 11 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 681UQ UT WOS:000284346400004 PM 21044708 ER PT J AU Yang, C Yuan, C Canton, G Hatsukami, T Tang, D AF Yang, Chun Yuan, Chun Canton, Gador Hatsukami, Thomas Tang, Dalin TI Advanced Human Carotid Plaque Progression Correlates Positively with Flow Shear Stress: An in Vivo MRI Multipatient 3D FSI Study SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Meeting Abstract CT Scientific Sessions on Arteriosclerosis, Thrombosis and Vascular Biology CY APR 08-10, 2010 CL San Francisco, CA C1 [Yang, Chun] Beijing Normal Univ, Beijing 100875, Peoples R China. [Yuan, Chun; Canton, Gador; Hatsukami, Thomas] Univ Washington, Seattle, WA 98195 USA. [Hatsukami, Thomas] VA Puget Sound HCS, Seattle, WA USA. [Tang, Dalin] Worcester Polytech Inst, Worcester, MA 01609 USA. RI Canton, Gador/H-4227-2016 OI Canton, Gador/0000-0002-0594-2764 NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD NOV PY 2010 VL 30 IS 11 BP E315 EP E315 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 667YS UT WOS:000283234800600 ER PT J AU Clancy, RM Marion, MC Kaufman, KM Ramos, PS Adler, A Harley, JB Langefeld, CD Buyon, JP AF Clancy, Robert M. Marion, Miranda C. Kaufman, Kenneth M. Ramos, Paula S. Adler, Adam Harley, John B. Langefeld, Carl D. Buyon, Jill P. CA Int Consortium Syst Lupus TI Identification of Candidate Loci at 6p21 and 21q22 in a Genome-Wide Association Study of Cardiac Manifestations of Neonatal Lupus SO ARTHRITIS AND RHEUMATISM LA English DT Article ID CONGENITAL HEART-BLOCK; PRIMARY SJOGRENS-SYNDROME; ANTI-SSA/RO; TNF-ALPHA; ATRIOVENTRICULAR-BLOCK; ENDOTHELIAL-CELLS; SSB/LA ANTIBODIES; RECURRENCE RATES; SS-A/RO; ERYTHEMATOSUS AB Objective. Cardiac manifestations of neonatal lupus, comprising atrioventricular conduction defects and cardiomyopathy, occur in fetuses exposed to anti-Ro/SSA antibodies, and carry substantial mortality. There is strong evidence of a genetic contribution to the risk. This study was undertaken to evaluate single-nucleotide polymorphisms (SNPs) for associations with cardiac neonatal lupus. Methods. Children of European ancestry with cardiac neonatal lupus (n = 116) were genotyped using the Illumina 370K SNP platform and merged with 3,351 controls. Odds ratios (ORs) and 95% confidence intervals (95% CIs) for association with cardiac neonatal lupus were determined. Results. The 17 most significant associations with cardiac neonatal lupus were found in the HLA region. The region near the MICB gene showed the strongest variant (rs3099844; P(dom) = 4.52 x 10(-10), OR 3.34 [95% CI 2.29-4.89]), followed by a missense variant within C6orf10 (rs7775397; P(dom) = 1.35 x 10(-9), OR 3.30), which lies between NOTCH4 and BTNL2, and several SNPs near the tumor necrosis factor alpha gene, including rs2857595 (P(add) = 1.96 x 10(-9), OR 2.37), rs2230365 (P(add) = 1.00 x 10(-3), OR 0.46), and rs3128982 (P(add) = 6.40 x 10(-6), OR 1.86). Outside the HLA region, an association was detected at 21q22, upstream of the transcription regulator ets-related isoform 1 (rs743446; P = 5.45 x 10(-6), OR 2.40). HLA notwithstanding, no individual locus previously implicated in autoimmune diseases achieved genome-wide significance. Conclusion. These results suggest that variation near genes related to inflammatory and apoptotic responses may promote cardiac injury initiated by passively acquired autoantibodies. C1 [Clancy, Robert M.] NYU, Langone Sch Med, New York, NY 10003 USA. [Marion, Miranda C.; Ramos, Paula S.; Langefeld, Carl D.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Harley, John B.] Univ Oklahoma, Oklahoma Med Res Fdn, Oklahoma City, OK USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Clancy, RM (reprint author), NYU, Langone Sch Med, 301 E 17th St, New York, NY 10003 USA. EM bobdclancy@aol.com FU NIH [AR-42455, N01-AR-42271, P01-AI-083194-01, P20-RR-020143-06, U19-AI-082714-01, P01-AR-049084-07, N01-AR-62277, R01-DE-018209-01A1, R37-AI-024717-21, R01-AR-042460-15]; American Heart Association [0655938T]; Wake Forest University Health Sciences Center for Public Health Genomics; Alliance for Lupus Research FX Supported by NIH grants AR-42455 and N01-AR-42271 and by American Heart Association grant-in-aid 0655938T. Ms Marion and Drs. Ramos and Langefeld's work was supported by the Wake Forest University Health Sciences Center for Public Health Genomics. Drs. Kaufman and Harley are recipients of US Department of Veterans Affairs Merit Awards. Dr. Harley's work was also supported by NIH grants P01-AI-083194-01, P20-RR-020143-06, U19-AI-082714-01, P01-AR-049084-07, N01-AR-62277, R01-DE-018209-01A1, R37-AI-024717-21, and R01-AR-042460-15. The International Consortium on Systemic Lupus Erythematosus Genetics was funded by the Alliance for Lupus Research. NR 50 TC 33 Z9 36 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD NOV PY 2010 VL 62 IS 11 BP 3415 EP 3424 DI 10.1002/art.27658 PG 10 WC Rheumatology SC Rheumatology GA 674UU UT WOS:000283776400033 PM 20662065 ER PT J AU Grossman, JM Gordon, R Ranganath, VK Deal, C Caplan, L Chen, WL Curtis, JR Furst, DE McMahon, M Patkar, NM Volkmann, E Saag, KG AF Grossman, Jennifer M. Gordon, Rebecca Ranganath, Veena K. Deal, Chad Caplan, Liron Chen, Weiling Curtis, Jeffrey R. Furst, Daniel E. McMahon, Maureen Patkar, Nivedita M. Volkmann, Elizabeth Saag, Kenneth G. TI American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID CORTICOSTEROID-INDUCED OSTEOPOROSIS; INDUCED BONE LOSS; INTERMITTENT CYCLICAL ETIDRONATE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; VERTEBRAL FRACTURE ASSESSMENT; INTRANASAL SALMON-CALCITONIN; CONNECTIVE-TISSUE DISEASE; HIGH-DOSE GLUCOCORTICOIDS AB Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice. C1 [Grossman, Jennifer M.; Gordon, Rebecca; Ranganath, Veena K.; Chen, Weiling; Furst, Daniel E.; McMahon, Maureen; Volkmann, Elizabeth] Univ Calif Los Angeles, Los Angeles, CA 90095 USA. [Gordon, Rebecca] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Deal, Chad] Cleveland Clin, Cleveland, OH 44106 USA. [Caplan, Liron] Univ Colorado, Denver, CO 80202 USA. [Curtis, Jeffrey R.; Patkar, Nivedita M.; Saag, Kenneth G.] Univ Alabama, Birmingham, AL USA. RP Grossman, JM (reprint author), Univ Calif Los Angeles, 1000 Vet Ave,Room 32-59,Rehabil Bldg, Los Angeles, CA 90095 USA. EM jgrossman@mednet.ucla.edu FU Lilly; Amgen; Genentech; Eli Lilly; Procter Gamble; Novartis; Roche/Genentech; Merck; Aventis; AstraZeneca; Pfizer; Horizon FX Dr. Deal has received consultant fees, speaking fees, and/or honoraria (more than $10,000 each) from Lilly, Amgen, and Genentech. Dr. Curtis has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Eli Lilly and Procter & Gamble, and (more than $10,000 each) from Novartis, Amgen, Roche/Genentech, and Merck. Dr. Saag has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Merck, Lilly, Novartis, Aventis, Genentech, AstraZeneca, Pfizer, and Horizon. NR 104 TC 319 Z9 346 U1 4 U2 20 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD NOV PY 2010 VL 62 IS 11 BP 1515 EP 1526 DI 10.1002/acr.20295 PG 12 WC Rheumatology SC Rheumatology GA 678BA UT WOS:000284041200001 PM 20662044 ER PT J AU Davis, LA Larson, MM Caplan, L AF Davis, Lisa A. Larson, Molly M. Caplan, Liron TI Observational Study to Determine Predictors of Rheumatology Clinic Visit Provider Contact Time SO ARTHRITIS CARE & RESEARCH LA English DT Article ID LENGTH AB Objective. To address perceived inefficiencies in an academic rheumatology practice, a timing/work-flow evaluation was initiated to determine the factors that predict the provider contact time (PCT), i.e., the amount of time that attending physicians spend with patients during an outpatient encounter. Methods. This prospective observational study was conducted at the University of Colorado Hospital Rheumatology Clinic for return patient visits in early 2008. Each patient encounter was subdivided into components, and the time for each component was recorded. Up to 20 return-visit encounters per provider were randomly selected for inclusion. Multivariate linear regression was used to predict the time, in minutes, that providers spent with patients, and logistic regression was used to determine the time intervals associated with the patient's perception that the visit ran on time. Results. Variables associated with increased PCT were whether a procedure was performed in the clinic (P = 0.037) and whether the visit occurred in the afternoon (P < 0.025). For every minute a provider was late in beginning to see a patient, the PCT decreased by 0.32 minutes (95% confidence interval [ 95% CI] 0.15, 0.49). Variables associated with the patient's perception that the visit ran on time included the check-in to vitals delay (odds ratio [ OR] 0.95; 95% CI 0.92, 0.99) and the provider delay (OR 0.92; 95% CI 0.86, 0.99). Conclusion. The patient's punctuality and the presence of a resident are not significantly associated with the time that a provider spends with a patient. However, the degree to which the provider runs late was associated with decreased PCT and diminishes the patient's perception that the visit is running on time. C1 [Davis, Lisa A.; Larson, Molly M.; Caplan, Liron] Univ Colorado, Sch Med, Denver, CO 80045 USA. [Caplan, Liron] Denver VAMC, Denver, CO USA. RP Caplan, L (reprint author), Univ Colorado, Sch Med, POB 6511,B115, Denver, CO 80045 USA. EM liron.caplan@ucdenver.edu FU NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases [T32-AR007534-24]; VA Health Services [CDP 09-388] FX Dr. Davis's work was supported by the NIH (grant T32-AR007534-24 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases). Dr. Caplan's work was supported by a VA Health Services Research and Development Award (CDP 09-388). NR 12 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD NOV PY 2010 VL 62 IS 11 BP 1650 EP 1654 DI 10.1002/acr.20281 PG 5 WC Rheumatology SC Rheumatology GA 678BA UT WOS:000284041200017 PM 20583104 ER PT J AU Lee, DBN Roberts, M Bluchel, CG Odell, RA AF Lee, David B. N. Roberts, Martin Bluchel, Christian G. Odell, Ross A. TI Zirconium: Biomedical and Nephrological Applications SO ASAIO JOURNAL LA English DT Article ID OSTEOBLAST-LIKE CELLS; STAGE RENAL-FAILURE; IN-VITRO; TRACE-ELEMENT; HEAVY-METALS; DIALYSIS OSTEOMALACIA; ORGANIC-SUBSTANCES; ENDOTHELIAL-CELLS; URINARY-EXCRETION; CLINICAL REPORT AB Recent years have witnessed a rapid increase in the use of zirconium (Zr)-containing compounds in artificial internal organs. Examples include dental implants and other restorative practices, total knee and hip replacement, and middle-ear ossicular chain reconstruction. In nephrological practice, Zr-containing sorbents have been used in hemofiltration, hemodialysis, peritoneal dialysis, and in the design and construction of wearable artificial kidneys. Zr compounds continue to be widely and extensively used in deodorant and antiperspirant preparations. In the public health arena, Zr compounds have been studied or used in controlling phosphorus pollution and in the reclamation of poison and bacteria-contaminated water. Experimental and clinical studies support the general consensus that Zr compounds are biocompatible and exhibit low toxicity. Reports on possible Zr-associated adverse reactions are rare and, in general, have not rigorously established a cause-and-effect relationship. Although publications on the use of Zr compounds have continued to increase in recent years, reports on Zr toxicity have virtually disappeared from the medical literature. Nevertheless, familiarity with, and continued vigilant monitoring of, the use of these compounds are warranted. This article provides an updated review on the biomedical use of Zr compounds. ASAIO Journal 2010; 56:550-556. C1 [Lee, David B. N.; Roberts, Martin] VA Greater Healthcare Syst, Nephrol Sect, Sepulveda Ambulatory Care Ctr & Nursing Home, North Hills, CA 91343 USA. [Lee, David B. N.; Roberts, Martin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Lee, David B. N.; Roberts, Martin; Bluchel, Christian G.] AWAK Technol Inc, Burbank, CA USA. [Lee, David B. N.; Roberts, Martin; Bluchel, Christian G.] AWAK Technol Inc, Singapore, Singapore. [Bluchel, Christian G.] Temasek Polytechn, Temasek Engn Sch, Singapore, Singapore. [Odell, Ross A.] Univ New S Wales, Grad Sch Biomed Engn, Sydney, NSW, Australia. RP Lee, DBN (reprint author), VA Greater Healthcare Syst, Nephrol Sect, Sepulveda Ambulatory Care Ctr & Nursing Home, Room 3526,Bldg 200,16111 Plummer St, North Hills, CA 91343 USA. EM dbnlee@ucla.edu NR 86 TC 25 Z9 25 U1 2 U2 23 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1058-2916 J9 ASAIO J JI Asaio J. PD NOV-DEC PY 2010 VL 56 IS 6 BP 550 EP 556 DI 10.1097/MAT.0b013e3181e73f20 PG 7 WC Engineering, Biomedical; Transplantation SC Engineering; Transplantation GA 674FH UT WOS:000283719600012 PM 21245802 ER PT J AU Vaid, M Sharma, SD Katiyar, SK AF Vaid, Mudit Sharma, Som D. Katiyar, Santosh K. TI Honokiol, a phytochemical from the Magnolia plant, inhibits photocarcinogenesis by targeting UVB-induced inflammatory mediators and cell cycle regulators: development of topical formulation SO CARCINOGENESIS LA English DT Article ID FACTOR-KAPPA-B; SKIN-CANCER; MOUSE SKIN; IN-VIVO; TUMOR-DEVELOPMENT; COX-2 EXPRESSION; HAIRLESS MICE; ACTIVATION; APOPTOSIS; CYCLOOXYGENASE-2 AB To develop newer and more effective chemopreventive agents for skin cancer, we assessed the effect of honokiol, a phytochemical from the Magnolia plant, on ultraviolet (UV) radiation-induced skin tumorigenesis using the SKH-1 hairless mouse model. Topical treatment of mice with honokiol in a hydrophilic cream-based topical formulation before or after UVB (180 mJ/cm(2)) irradiation resulted in a significant protection against photocarcinogenesis in terms of tumor multiplicity (28-60%, P < 0.05 to < 0.001) and tumor volume per tumor-bearing mouse (33-80%, P < 0.05 to 0.001, n = 20). Honokiol also inhibited and delayed the malignant progression of papillomas to carcinomas. To investigate the in vivo molecular targets of honokiol efficacy, tumors and tumor-uninvolved skin samples from the tumor-bearing mice were analyzed for inflammatory mediators, cell cycle regulators and survival signals using immunostaining, western blotting and enzyme-linked immunosorbent assay. Treatment with honokiol significantly inhibited UVB-induced expression of cyclooxygenase-2, prostaglandin E(2) (P < 0.001), proliferating cell nuclear antigen and proinflammatory cytokines, such as tumor necrosis factor-alpha (P < 0.001), interleukin (IL)-1 beta (P < 0.01) and IL-6 (P < 0.001) in the skin as well as in skin tumors. Western blot analysis revealed that honokiol: (i) inhibited the levels of cyclins D1, D2 and E and associated cyclin-dependent kinases (CDKs)2, CDK4 and CDK6, (ii) upregulated Cip/p21 and Kip/p27 and (iii) inhibited the levels of phosphatidylinositol 3-kinase and the phosphorylation of Akt at Ser(473) in UVB-induced skin tumors. Together, our results indicate that honokiol holds promise for the prevention of UVB-induced skin cancer by targeting inflammatory mediators, cell cycle regulators and cell survival signals in UVB-exposed skin. C1 [Vaid, Mudit; Sharma, Som D.; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration FX Veterans Administration Merit Review Award (S.K.K.). NR 47 TC 39 Z9 39 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD NOV PY 2010 VL 31 IS 11 BP 2004 EP 2011 DI 10.1093/carcin/bgq186 PG 8 WC Oncology SC Oncology GA 676OS UT WOS:000283922400014 PM 20823108 ER PT J AU Habib, SL Bhandari, BK Sadek, N Abboud-Werner, SL Abboud, HE AF Habib, Samy L. Bhandari, Besant K. Sadek, Nahed Abboud-Werner, Sherry L. Abboud, Hanna E. TI Novel mechanism of regulation of the DNA repair enzyme OGG1 in tuberin-deficient cells SO CARCINOGENESIS LA English DT Article ID HOGG1 SER326CYS POLYMORPHISM; TUMOR-SUPPRESSOR GENE; LUNG-CANCER RISK; EKER RAT MODEL; 3-KINASE/AKT PATHWAY; SCLEROSIS COMPLEX; DAMAGE; TSC2; KIDNEY; PHOSPHORYLATION AB Tuberin (protein encodes by tuberous sclerosis complex 2, Tsc2) deficiency is associated with the decrease in the DNA repair enzyme 8-oxoG-DNA glycosylase (OGG1) in tumour kidney of tuberous sclerosis complex (TSC) patients. The purpose of this study was to elucidate the mechanisms by which tuberin regulates OGG1. The partial deficiency in tuberin expression that occurs in the renal proximal tubular cells and kidney cortex of the Eker rat is associated with decreased activator protein 4 (AP4) and OGG1 expression. A complete deficiency in tuberin is associated with loss of AP4 and OGG1 expression in kidney tumour from Eker rats and the accumulation of significant levels of 8-oxo-deoxyguanosine. Knockdown of tuberin expression in human renal epithelial cells (HEK293) with small interfering RNA (siRNA) also resulted in a marked decrease in the expression of AP4 and OGG1. In contrast, overexpression of tuberin in HEK293 cells increased the expression of AP4 and OGG1 proteins. Downregulation of AP4 expression using siRNA resulted in a significant decrease in the protein expression of OGG1. Immunoprecipitation studies show that AP4 is associated with tuberin in cells. Gel shift analysis and chromatin immunoprecipitation identified the transcription factor AP4 as a positive regulator of the OGG1 promoter. AP4 DNA-binding activity is significantly reduced in Tsc2(-/-) as compared with Tsc2(+/+) cells. Transcriptional activity of the OGG1 promoter is also decreased in tuberin-null cells compared with wild-type cells. These data indicate a novel role for tuberin in the regulation of OGG1 through the transcription factor AP4. This regulation may be important in the pathogenesis of kidney tumours in patients with TSC disease. C1 [Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Abboud-Werner, Sherry L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Habib, Samy L.] S Texas Vet Healthcare Syst, Dept Geriatr Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Habib, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, MSC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM habib@uthscsa.edu FU American Diabetes Association; South Texas Veterans Healthcare System; The National Organization for Research FX American Diabetes Association Research Grant; Merit Review Award and New Investigator Award from the South Texas Veterans Healthcare System to S.L.H.; The authors would like to acknowledge Dr Daniel J.Riley and Dr Anthony Valente for helpful discussions and for critical reading of the manuscript, Dr P.Radicella at Radiobiologie Moleculaire et Cellulaire, France, for providing the OGG1 promoter construct and Dr S.Mitra at the University of Texas M. D. Anderson and Sealy Center for Molecular Science, Galveston, TX for providing the OGG1 antibody. N.S. is a recipient of the Research Fellowship Award from The National Organization for Research, Egypt. NR 44 TC 15 Z9 15 U1 1 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD NOV PY 2010 VL 31 IS 11 BP 2022 EP 2030 DI 10.1093/carcin/bgq189 PG 9 WC Oncology SC Oncology GA 676OS UT WOS:000283922400016 PM 20837600 ER PT J AU Afessa, B Anzueto, AR Craven, DE Kollef, MH AF Afessa, Bekele Anzueto, Antonio R. Craven, Donald E. Kollef, Marin H. TI Increased Mortality in Patients Without Ventilator-Associated Pneumonia Response SO CHEST LA English DT Letter ID COATED ENDOTRACHEAL-TUBES; BURDEN C1 [Afessa, Bekele] Mayo Clin, Div Pulm & Crit Care Med, Coll Med, Rochester, MN 55905 USA. [Anzueto, Antonio R.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Anzueto, Antonio R.] Univ Texas Hlth Sci Ctr San Antonio, Univ Hosp, San Antonio, TX 78229 USA. [Craven, Donald E.] Lahey Clin Med Ctr, Boston, MA USA. [Craven, Donald E.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Kollef, Marin H.] Washington Univ, Sch Med, St Louis, MO USA. RP Afessa, B (reprint author), Mayo Clin, Div Pulm & Crit Care Med, Coll Med, 200 1st St SW, Rochester, MN 55905 USA. EM Afessa.bekele@mayo.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD NOV PY 2010 VL 138 IS 5 BP 1275 EP 1275 DI 10.1378/chest.10-1724 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 681TH UT WOS:000284341700042 ER PT J AU Anderson, JA Willson, P Peterson, NJ Murphy, C Kent, TA AF Anderson, Jane A. Willson, Pamela Peterson, Nancy J. Murphy, Chris Kent, Thomas A. TI Prototype to Practice Developing and Testing a Clinical Decision Support System for Secondary Stroke Prevention in a Veterans Healthcare Facility SO CIN-COMPUTERS INFORMATICS NURSING LA English DT Article DE Advanced practice nursing; Clinical decision support systems; Electronic medical record; Evidence-based practice; Nursing; Secondary stroke prevention; Usability ID GUIDELINES AB A clinical decision support system that guides nurse practitioners and other healthcare providers in secondary stroke prevention was developed by a multidisciplinary team with funding received from the Veterans Health Administration Office of Nursing Services. This article presents alpha-testing results obtained while using an integrated model for clinical decision support system development that emphasizes end-user perspectives throughout the development process. Before-after and descriptive methods were utilized to evaluate functionality and usability of the prototype among a sample of multidisciplinary clinicians. The predominant functionality feature of the tool is automated prompting and documentation of secondary stroke prevention guidelines in the electronic medical record. Documentation of guidelines was compared among multidisciplinary providers (N = 15) using test case scenarios and two documentation systems, standard versus the prototype. Usability was evaluated with an investigator-developed questionnaire and one open-ended question. The prototype prompted a significant increase (P < .05) in provider documentation for six of 11 guidelines as compared with baseline documentation while using the standard system. Of a possible 56 points, usability was scored high (mean, 48.9 [SD, 6.8]). These results support that guideline prompting has been successfully engineered to produce a usable and useful clinical decision support system for secondary stroke prevention. C1 [Anderson, Jane A.; Murphy, Chris] Baylor Coll Med, Stroke Ctr, Houston, TX 77030 USA. [Anderson, Jane A.; Peterson, Nancy J.; Murphy, Chris; Kent, Thomas A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Anderson, Jane A.; Willson, Pamela; Peterson, Nancy J.; Murphy, Chris; Kent, Thomas A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Anderson, Jane A.; Willson, Pamela] Prairie View A&M Univ, Coll Nursing, Houston, TX USA. [Willson, Pamela] Elsevier, Review & Testing, Res, Houston, TX USA. RP Anderson, JA (reprint author), Baylor Coll Med, Stroke Ctr, Houston, TX 77030 USA. EM jane.anderson@med.va.gov OI Kent, Thomas/0000-0002-9877-7584 FU Veterans Health Administration Office of Nursing Services FX This project was funded by the Veterans Health Administration Office of Nursing Services. NR 23 TC 7 Z9 8 U1 2 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1538-2931 J9 CIN-COMPUT INFORM NU JI CIN-Comput. Inform. Nurs. PD NOV-DEC PY 2010 VL 28 IS 6 BP 353 EP 363 DI 10.1097/NCN.0b013e3181f69c5b PG 11 WC Computer Science, Interdisciplinary Applications; Medical Informatics; Nursing SC Computer Science; Medical Informatics; Nursing GA 675RL UT WOS:000283848300004 PM 20978406 ER PT J AU Maddox, TM Ho, PM Roe, M Dai, D Tsai, TT Rumsfeld, JS AF Maddox, Thomas M. Ho, P. Michael Roe, Matthew Dai, David Tsai, Thomas T. Rumsfeld, John S. TI Utilization of Secondary Prevention Therapies in Patients With Nonobstructive Coronary Artery Disease Identified During Cardiac Catheterization Insights From the National Cardiovascular Data Registry Cath-PCI Registry SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE prevention; coronary disease; epidemiology ID ACUTE MYOCARDIAL-INFARCTION; RISK STRATIFICATION; ANGIOGRAPHY; GUIDELINES; MECHANISMS; OUTCOMES; SITE AB Background-Secondary prevention therapies are indicated for patients with coronary artery disease (CAD). However, patients with nonobstructive CAD may be less likely to receive these therapies compared with patients with obstructive CAD. Therefore, we compared rates of secondary prevention medication prescription between patients with nonobstructive and obstructive CAD. Methods and Results-We conducted a retrospective cohort study of 1 489 745 CAD patients undergoing cardiac catheterization in 786 US centers between 2004 and 2007. We measured rates of aspirin, statin, beta-blocker, and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) prescription at hospital discharge among eligible patients; 237 167 (15.9%) patients had nonobstructive CAD and 1 252 578 (84.1%) had obstructive CAD. Compared with obstructive CAD patients, nonobstructive CAD patients had significantly lower rates of rates of aspirin (72.7% versus 90.9%), statin (60.0% versus 80.3%), beta-blocker (57.9% versus 79.4%), and ACEI/ARB (45.9% versus 58.6%; all probability values <0.0001) prescription at hospital discharge. After multivariable adjustment, nonobstructive CAD patients remained significantly less likely to receive prescriptions for aspirin (odds ratio, 0.37; 95% confidence interval, 0.35 to 0.39), statins (odds ratio, 0.45; 95% confidence interval, 0.43 to 0.48), beta-blockers (odds ratio, 0.46; 95% CI, 0.44 to 0.47), or ACEI/ARBs (odds ratio, 0.83; 95% confidence interval, 0.8 to 0.86) compared with obstructive CAD patients. Secondary analyses of selected subgroups supported the primary findings. Conclusions-Patients with nonobstructive CAD were significantly less likely to receive secondary prevention medication prescription at hospital discharge, as compared with patients with obstructive CAD. These findings highlight an opportunity to improve the quality of care for CAD patients with nonobstructive disease. (Circ Cardiovasc Qual Outcomes. 2010;3:632-641.) C1 [Maddox, Thomas M.] Univ Colorado, Denver VAMC, Cardiol Sect 111B, Denver, CO 80220 USA. [Roe, Matthew; Dai, David] Duke Clin Res Inst, Durham, NC USA. RP Maddox, TM (reprint author), Univ Colorado, Denver VAMC, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA. EM thomas.maddox@va.gov FU American College of Cardiology; Society for Coronary Angiography and Intervention; Department of Veterans Affairs Health Services Research and Developmen FX This study was supported by the American College of Cardiology and Society for Coronary Angiography and Intervention. The funders had no role in the design and conduct of the study nor collection, management, analysis, and interpretation of the data. The Research and Publications committee for the NCDR Cath-PCI registry reviewed and approved the final version of the manuscript. Drs Maddox and Ho were supported by Department of Veterans Affairs Health Services Research and Development Career Development Awards. NR 21 TC 29 Z9 33 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2010 VL 3 IS 6 BP 632 EP 641 DI 10.1161/CIRCOUTCOMES.109.906214 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 680VB UT WOS:000284262900011 PM 20923997 ER PT J AU Lambert-Kerzner, A Havranek, EP Plomondon, ME Albright, K Moore, A Gryniewicz, K Magid, D Ho, PM AF Lambert-Kerzner, Anne Havranek, Edward P. Plomondon, Mary E. Albright, Karen Moore, Ashley Gryniewicz, Kelsey Magid, David Ho, P. Michael TI Patients' Perspectives of a Multifaceted Intervention With a Focus on Technology A Qualitative Analysis SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE hypertension; qualitative; trials ID HEALTH-CARE; HYPERTENSION; MANAGEMENT AB Background-Few studies have investigated the effectiveness of multifaceted interventions from the study participants' perspective. We conducted qualitative interviews to understand patients' experiences with a multifaceted blood pressure (BP) control intervention involving interactive voice response technology, home BP monitoring, and pharmacist-led BP management. In the randomized study, the intervention resulted in clinically significant decreases in BP. Methods and Results-We used insights generated from in-depth interviews from all study participants randomly assigned to the multifaceted intervention or usual care (n = 146) to create a model explaining the observed improvements in health behavior and clinical outcomes. The data were analyzed using qualitative content analysis methods and consultative and reflexive team analysis. Six explanatory factors emerged from the patients' interviews: (1) improved relationships with medical personnel; (2) increased knowledge of hypertension; (3) increased participation in their health care and personal empowerment; (4) greater understanding of the impact of health behavior on BP; (5) high satisfaction with technology used in the intervention; and, for some patients, (6) increased health care utilization. Eighty-six percent of the intervention patients and 62% of the usual care patients stated that study participation had a positive effect on them. Of those expressing a positive effect, 68% (intervention) and 55% (usual care) reached their systolic BP goal. Conclusions-Establishing bidirectional conversations between patients and providers is a key element of successful hypertension management. Home BP monitoring coupled with interactive voice response technology reporting facilitates such conversations. (Circ Cardiovasc Qual Outcomes. 2010;3:668-674.) C1 [Lambert-Kerzner, Anne; Plomondon, Mary E.; Gryniewicz, Kelsey; Ho, P. Michael] Denver Vet Affairs Med Ctr, Denver, CO USA. [Lambert-Kerzner, Anne; Havranek, Edward P.; Plomondon, Mary E.; Albright, Karen; Moore, Ashley; Magid, David; Ho, P. Michael] Univ Colorado Denver, Aurora, CO USA. [Lambert-Kerzner, Anne; Havranek, Edward P.; Moore, Ashley] Denver Hlth Med Ctr, Denver, CO USA. [Magid, David] Kaiser Permanente, Inst Hlth Res, Denver, CO USA. RP Lambert-Kerzner, A (reprint author), DVAMC, 1055 Clermont St, Denver, CO 80220 USA. EM anne.lambert-kerzner@va.gov FU American Heart Association [0535086N]; Colorado Department of Public Health and Environment [99]; VA Health Services Research and Development Award [05-026] FX This work was funded in part by an award from the American Heart Association (0535086N) and from the Colorado Department of Public Health and Environment (CCPD No. 99).; Dr Ho was supported by a VA Health Services Research and Development Award (05-026) and serves as a consultant for Wellpoint, Inc. NR 29 TC 7 Z9 7 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2010 VL 3 IS 6 BP 668 EP 674 DI 10.1161/CIRCOUTCOMES.110.949800 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 680VB UT WOS:000284262900015 PM 20923992 ER PT J AU Mathenia, J Reyes-Cortes, E Williams, S Molano, I Ruiz, P Watson, DK Gilkeson, GS Zhang, XK AF Mathenia, J. Reyes-Cortes, E. Williams, S. Molano, I. Ruiz, P. Watson, D. K. Gilkeson, G. S. Zhang, X. K. TI Impact of Fli-1 transcription factor on autoantibody and lupus nephritis in NZM2410 mice SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY LA English DT Article DE animal model; autoantibody; Fli-1 transcription factor; lupus; nephritis ID ETS GENE FAMILY; RENAL-DISEASE; MARGINAL ZONE; MRL/LPR MICE; CELL-PROLIFERATION; B-CELLS; EXPRESSION; ERYTHEMATOSUS; MEMBER; GLOMERULONEPHRITIS AB P>The transcription factor Fli-1 is implicated in the pathogenesis of both murine and human lupus. Increased levels of Fli-1 mRNA were present in the peripheral blood lymphocytes from lupus patients; furthermore, transgenic overexpression of Fli-1 in normal mice resulted in the development of a lupus-like disease. Lupus nephritis is a major cause of death in both lupus patients as well as in animal models. In this study, we generated Fli-1 heterozygous knockout (Fli-1+/-) NZM2410 mice (of which the wild-type is a widely used lupus murine model) that expressed decreased levels of Fli-1 and investigated the impact of Fli-1 expression on lupus nephritis development and survival. Ninety-three per cent of the Fli-1+/- NZM2410 mice survived to the age of 52 weeks compared to only 35% of wild-type NZM2410 mice. Autoantibodies, including anti-dsDNA and anti-glomerular basement antigen, in Fli-1+/- NZM2410 mice were statistically significantly lower when compared to wild-type NZM2410 mice at the ages of 30 and 34 weeks. Total B cell and activated B cell populations in the spleens from Fli-1+/- NZM2410 mice were decreased significantly compared to wild-type NZM2410 mice. Fli-1+/- NZM2410 mice also had remarkably diminished proteinuria and decreased renal pathological scores when compared with wild-type NZM2410 mice. Expression of early growth response 1 (Egr-1) was decreased significantly in the kidneys from Fli-1+/- NZM2410 mice when compared to wild-type littermates. Our data indicate that expression of Fli-1 plays an important role in lupus disease development in NZM2410 mice. C1 [Mathenia, J.; Reyes-Cortes, E.; Molano, I.; Gilkeson, G. S.; Zhang, X. K.] Med Univ S Carolina, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA. [Watson, D. K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Mathenia, J.; Williams, S.; Gilkeson, G. S.; Zhang, X. K.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC USA. [Ruiz, P.] Univ Miami, Sch Med, Miami, FL USA. RP Zhang, XK (reprint author), Med Univ S Carolina, Div Rheumatol & Immunol, Dept Med, Suite 912,Jonathan Lucas St MSC637, Charleston, SC 29425 USA. EM zhangjo@musc.edu FU National Institutes of Health [AR054546]; Department of Veterans Affairs FX We thank Sarah Darley and William Zhang for providing excellent technical assistance. This study was supported by National Institutes of Health grants (AR054546 to X.K.Z.) and the Medical Research Service and Research Enhancement Award Programs, Department of Veterans Affairs (to X.K.Z and G. S. G.) NR 36 TC 14 Z9 16 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0009-9104 J9 CLIN EXP IMMUNOL JI Clin. Exp. Immunol. PD NOV PY 2010 VL 162 IS 2 BP 362 EP 371 DI 10.1111/j.1365-2249.2010.04245.x PG 10 WC Immunology SC Immunology GA 661AP UT WOS:000282694800017 PM 20731671 ER PT J AU Beste, LA Ioannou, GN Larson, MS Chapko, M Dominitz, JA AF Beste, Lauren A. Ioannou, George N. Larson, Meaghan S. Chapko, Michael Dominitz, Jason A. TI Predictors of Early Treatment Discontinuation Among Patients With Genotype 1 Hepatitis C and Implications for Viral Eradication SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Hepatology; Viral Hepatitis; Treatment Duration; Treatment Attrition ID PEGYLATED INTERFERON; VIRUS-INFECTION; ANTIVIRAL THERAPY; PLUS RIBAVIRIN; UNITED-STATES; PREVALENCE; VETERANS; COMPLETION; SYMPTOMS; USERS AB BACKGROUND & AIMS A significant proportion of patients with hepatitis C virus (HCV) infection discontinue anti viral treatment prematurely Risk factors for discontinuation before 48 weeks among patients with genotype 1 HCV vary over the course of therapy We investigated the rates and risk factors for treatment discontinuation within 12 weeks, 12-24 weeks, and 24-48 weeks METHODS We retrospectively evaluated data from all Veterans Affairs (VA) patients with genotype 1 HCV who initiated pegylated interferon and ribavirin therapy from 2002-2007 (n = 11,019) We accounted for appropriate discontinuation because of viral nonresponse RESULTS Overall, 53% of patients completed at least 38 4 weeks of therapy (80% of the projected 48 weeks), 16 5% discontinued early in the setting of viral nonresponse, and 30 9% discontinued de spite viral response or in the absence of virologic data Cirrhosis, diabetes, pretreatment substance use disorder, hemoglobin, and lack of hematopoietic growth factor use independently predicted discontinuation before 12 weeks (P < 05 for all) Among patients with documented early virologic responses, higher baseline levels of creatinine, depression, and lack of growth factor use predicted discontinuation from 12-24 weeks No factors independently predicted discontinuation from 24-48 weeks among patients responding to treatment at 24 weeks CONCLUSIONS Early discontinuation of antiviral therapy is common Use of growth factors was the strongest independent predictor of treatment retention be fore 24 weeks and should be evaluated prospectively Early interventions may also be warranted for other risk factors for early discontinuation, such as pre-existing substance use, depression, cirrhosis, or diabetes C1 VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Beste, Lauren A.; Larson, Meaghan S.; Chapko, Michael; Dominitz, Jason A.] VA Puget Sound Healthcare Syst, NW Hepatitis Resource Ctr C, Seattle, WA USA. [Beste, Lauren A.] VA Puget Sound Healthcare Syst, Div Gen Internal Med, Seattle, WA USA. [Ioannou, George N.; Dominitz, Jason A.] VA Puget Sound Healthcare Syst, Div Gastroenterol, Seattle, WA USA. [Ioannou, George N.; Dominitz, Jason A.] Univ Washington, Sch Med, Seattle, WA USA. [Chapko, Michael] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA. RP Beste, LA (reprint author), 1660 S Columbian Way, Seattle, WA 98108 USA. OI Dominitz, Jason/0000-0002-8070-7086 FU VA Puget Sound Health Care System, Seattle, Washington; Department of Veterans Affairs Health Services Research and Development [TPM 61-032]; Northwest Hepatitis C Resource Center Study FX This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington The study was supported by Department of Veterans Affairs Health Services Research and Development research and training funds (TPM 61-032) and the Northwest Hepatitis C Resource Center Study sponsors had no role in the study design, collection, analysis or interpretation of the data or in the writing of the report NR 24 TC 21 Z9 21 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD NOV PY 2010 VL 8 IS 11 BP 972 EP 978 DI 10.1016/j.cgh.2010.07.012 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 690UU UT WOS:000285034800018 PM 20692371 ER PT J AU Sun, HY Alexander, BD Lortholary, O Dromer, F Forrest, GN Lyon, GM Somani, J Gupta, KL del Busto, R Pruett, TL Sifri, CD Limaye, AP John, GT Klintmalm, GB Pursell, K Stosor, V Morris, MI Dowdy, LA Munoz, P Kalil, AC Garcia-Diaz, J Orloff, SL House, AA Houston, SH Wray, D Huprikar, S Johnson, LB Humar, A Razonable, RR Fisher, RA Husain, S Wagener, MM Singh, N AF Sun, Hsin-Yun Alexander, Barbara D. Lortholary, Olivier Dromer, Francoise Forrest, Graeme N. Lyon, G. Marshall Somani, Jyoti Gupta, Krishan L. del Busto, Ramon Pruett, Timothy L. Sifri, Costi D. Limaye, Ajit P. John, George T. Klintmalm, Goran B. Pursell, Kenneth Stosor, Valentina Morris, Michele I. Dowdy, Lorraine A. Munoz, Patricia Kalil, Andre C. Garcia-Diaz, Julia Orloff, Susan L. House, Andrew A. Houston, Sally H. Wray, Dannah Huprikar, Shirish Johnson, Leonard B. Humar, Atul Razonable, Raymund R. Fisher, Robert A. Husain, Shahid Wagener, Marilyn M. Singh, Nina CA Cryptococcal Collaborative TI Unrecognized Pretransplant and Donor-Derived Cryptococcal Disease in Organ Transplant Recipients SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID INVASIVE FUNGAL-INFECTIONS; HEMATOPOIETIC STEM-CELL; SOLID-ORGAN; NEOFORMANS INFECTION; IRON OVERLOAD; LIVER; TRANSMISSION; MENINGITIS; MORTALITY; VIRUS AB Background. Cryptococcosis occurring <= 30 days after transplantation is an unusual event, and its characteristics are not known. Methods. Patients included 175 solid-organ transplant (SOT) recipients with cryptococcosis in a multicenter cohort. Very early-onset and late-onset cryptococcosis were defined as disease occurring <= 30 days or 130 days after transplantation, respectively. Results. Very early-onset disease developed in 9 (5%) of the 175 patients at a mean of 5.7 days after transplantation. Overall, 55.6% (5 of 9) of the patients with very early-onset disease versus 25.9% (43 of 166) of the patients with late-onset disease were liver transplant recipients (Pp. 05). Very early cases were more likely to present with disease at unusual locations, including transplanted allograft and surgical fossa/site infections (55.6% vs 7.2%; P<.001). Two very early cases with onset on day 1 after transplantation (in a liver transplant recipient with Cryptococcus isolated from the lung and a heart transplant recipient with fungemia) likely were the result of undetected pretransplant disease. An additional 5 cases involving the allograft or surgical sites were likely the result of donor-acquired infection. Conclusions. A subset of SOT recipients with cryptococcosis present very early after transplantation with disease that appears to occur preferentially in liver transplant recipients and involves unusual sites, such as the transplanted organ or the surgical site. These patients may have unrecognized pretransplant or donor-derived cryptococcosis. C1 [Sun, Hsin-Yun; Singh, Nina] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA. [Husain, Shahid; Wagener, Marilyn M.; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA. [Alexander, Barbara D.] Duke Univ, Med Ctr, Durham, NC USA. [Forrest, Graeme N.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Lyon, G. Marshall; Somani, Jyoti] Emory Univ, Atlanta, GA 30322 USA. [del Busto, Ramon] Henry Ford Hosp, Detroit, MI 48202 USA. [Johnson, Leonard B.] St Johns Hosp, Detroit, MI USA. [Pruett, Timothy L.; Sifri, Costi D.] Univ Virginia, Charlottesville, VA USA. [Fisher, Robert A.] Virginia Commonwealth Univ, Richmond, VA USA. [Limaye, Ajit P.] Univ Washington, Seattle, WA 98195 USA. [Klintmalm, Goran B.] Baylor Univ, Med Ctr, Dallas, TX USA. [Pursell, Kenneth] Univ Chicago, Chicago, IL 60637 USA. [Stosor, Valentina] Northwestern Univ, Chicago, IL 60611 USA. [Morris, Michele I.; Dowdy, Lorraine A.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Houston, Sally H.] Tampa Gen Hosp, Tampa, FL 33606 USA. [Kalil, Andre C.] Univ Nebraska, Omaha, NE 68182 USA. [Garcia-Diaz, Julia] Ochsner Clin & Alton Ochsner Med Fdn, New Orleans, LA USA. [Orloff, Susan L.] Oregon Hlth & Sci Univ, Portland, OR USA. [Wray, Dannah] Med Univ S Carolina, Charleston, SC 29425 USA. [Huprikar, Shirish] Mt Sinai Med Ctr, New York, NY 10029 USA. [Razonable, Raymund R.] Mayo Clin, Rochester, MN USA. [Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan. [Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan. [Lortholary, Olivier] Hop Necker Enfants Malad, Fac Med Paris Descartes, Paris, France. [Dromer, Francoise] Inst Pasteur, Paris, France. [Gupta, Krishan L.] Postgrad Inst Med Educ & Res, Chandigarh 160012, India. [John, George T.] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India. [Munoz, Patricia] Hosp Gen Univ Gregorio Maranon, Madrid, Spain. [Munoz, Patricia] CIBER Enfermedades Resp, Madrid, Spain. [House, Andrew A.] Univ Western Ontario, London, ON, Canada. [Humar, Atul] Toronto Gen Hosp, Univ Hlth Network, Toronto, ON, Canada. RP Singh, N (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu RI Garcia-Diaz, Julia/D-3555-2011 OI SUN, HSIN-YUN/0000-0003-0074-7721; Munoz Garcia, Patricia Carmen/0000-0001-5706-5583 FU Astellas; Pfizer; Merck; Basilea; National Institutes of Health, National Institute of Allergy and Infectious Diseases [R01 AI 054719-01] FX B. D. A. has served on advisory boards for Abbott, Bristol Myers Squibb, bioMerieux, and has received investigator initiated grants from Astellas and Pfizer. O.L. has served on speaker's bureaus of Astellas, Gilead Sciences, Merck, Schering-Plough, and Pfizer and as a consultant for Astellas and Gilead Sciences. G. F. has received grant support from Astellas. G. M. L. has served on advisory boards for and received grants from Merck and Astellas and on speaker's bureaus of Astellas, Schering-Plough, and Wyeth. A. P. L. has served on consultant boards for Pfizer and Merck and has contracted research for Pfizer. M. I. M. has served on advisory boards for Astellas, Pfizer, and Merck; has received grants from Astellas, Basilea, and Pfizer; and has served on speaker's bureaus of Astellas and Pfizer. P. M. has served on speaker's bureaus of Merck and Novartis and on an advisory board for Pfizer. S. H. H. has served on speaker's bureaus of Astellas and Pfizer. L.B.J. has served on a speaker's bureau of Pfizer. S. H. has received grants from Pfizer, Astellas, and Merck. N.S. has received investigator-initiated grant support from Pfizer. All other authors: no conflicts.; National Institutes of Health, National Institute of Allergy and Infectious Diseases (R01 AI 054719-01 to N.S.) NR 29 TC 27 Z9 27 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2010 VL 51 IS 9 BP 1062 EP 1069 DI 10.1086/656584 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 669FC UT WOS:000283331300012 PM 20879857 ER PT J AU Spiegel, B Bolus, R Desai, AA Zagar, P Parker, T Moran, J Solomon, MD Khawar, O Gitlin, M Talley, J Nissenson, A AF Spiegel, Brennan Bolus, Roger Desai, Amar A. Zagar, Philip Parker, Tom Moran, John Solomon, Matthew D. Khawar, Osman Gitlin, Matthew Talley, Jennifer Nissenson, Allen TI Dialysis Practices That Distinguish Facilities with Below- versus Above-Expected Mortality SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID OUTCOMES; PATIENT; CARE; PHYSICIANS; RATIO AB Background and objectives: Mortality rates vary widely among dialysis facilities even after adjustment with standardized mortality ratios (SMRs). This variation may occur because top-performing facilities use practices not shared by others, because the SMR fails to capture key patient characteristics, or both. Practices were identified that distinguish top- from bottom-performing facilities by SMR. Design, setting, participants, & measurements: A cross-sectional survey was performed of staff across three organizations. Staff members rated the perceived quality of their units' patient-, provider-, and facility-level practices using a six-point Likert scale. Facilities were divided into those with above- versus below-expected mortality on the basis of SMRs from U.S. Renal Data Service facility reports. Mean Likert scores were computed for each practice using t tests. Practices that were statistically significant (P <= 0.05) and achieved at least a medium effect size of >= 0.4 were reported. Significant predictors were entered into a linear regression model. Results: Dialysis facilities with below-expected mortality reported that patients in their unit were more activated and engaged, physician communication and interpersonal relationships were stronger, dieticians were more resourceful and knowledgeable, and overall coordination and staff management were superior versus facilities with above-expected mortality. Staff ratings of these practices explained 31% of the variance in SMRs. Conclusions: Patient-, provider-, and facility-level practices partly explain SMR variation among facilities. Improving SMRs may require processes that reflect a coordinated, multidisciplinary environment (i.e., no one group, practice, or characteristic will drive facility-level SMRs). Understanding and improving SMRs will require a holistic view of the facility. Clin J Am Soc Nephrol 5: 2024-2033, 2010. doi: 10.2215/CJN.01620210 C1 [Spiegel, Brennan; Talley, Jennifer] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. [Spiegel, Brennan; Bolus, Roger; Khawar, Osman] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Spiegel, Brennan; Bolus, Roger; Solomon, Matthew D.; Talley, Jennifer] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA. [Desai, Amar A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Desai, Amar A.; Solomon, Matthew D.] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Zagar, Philip] Dialysis Clin Inc, Albuquerque, NM USA. [Parker, Tom] Renal Ventures Management LLC, Lakewood, CO USA. [Moran, John] Satellite Healthcare, Mountain View, CA USA. [Solomon, Matthew D.] Amgen Inc, Thousand Oaks, CA 91320 USA. [Nissenson, Allen] DaVita Inc, Denver, CO USA. RP Spiegel, B (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu FU Amgen, Inc.; Renal Physicians Association; American Nephrology Nurses Association FX Support for this investigator-initiated study was provided by a research grant from Amgen, Inc. Dr. Gitlin is an employee of Amgen, Inc. The principal investigator, Dr. Spiegel, maintained full control over all aspects of the study design, implementation, data collection, data analysis, data interpretation, and manuscript preparation. Dr. Spiegel had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The contributions of individual authors is as follows: AD. study design, study implementation, data collection, data interpretation, and manuscript preparation; R.B. study design, study implementation, data collection, data analysis, and manuscript review; AN study design, data interpretation, and manuscript review; P.Z. data collection/provision, data interpretation, and manuscript review; T.P. data collection/provision, data interpretation, and manuscript review; J.M. data collection/provision, data interpretation, and manuscript review; S.B. study design, data interpretation, and manuscript review; MS. study design, data interpretation, and manuscript review; O.K. study design, data interpretation, and manuscript review; M.G. data interpretation and manuscript preparation; J.T. study implementation and data collection; B.S. study design, study implementation, data collection, data analysis, data interpretation, manuscript preparation, manuscript approval, and guarantor of article. The opinions and assertions contained herein are the sole views of the authors and are not to be construed as official or as reflecting the views of the Department of Veteran Affairs. This study endorsed and supported by the Renal Physicians Association and the American Nephrology Nurses Association. Special thanks to the participating dialysis organizations-DCI; Renal Ventures Management LLC, and Satellite Healthcare. NR 12 TC 16 Z9 16 U1 1 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV PY 2010 VL 5 IS 11 BP 2024 EP 2033 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 677UX UT WOS:000284018500018 PM 20876677 ER PT J AU Kutner, NG Zhang, R Huang, YJ Johansen, KL AF Kutner, Nancy G. Zhang, Rebecca Huang, Yijian Johansen, Kirsten L. TI Depressed Mood, Usual Activity Level, and Continued Employment after Starting Dialysis SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; END; VALIDITY; WORK AB Background and objectives: When patients start dialysis, their employment rate declines and disability benefits are an option. With patient sociodemographic and clinical characteristics including disability income status controlled, we investigated the significance of depressed mood and usual activity level as predictors of patients' continued employment after dialysis start. Design, setting, participants, & measurements: Incident patients from 296 randomly selected dialysis clinics were surveyed in the Comprehensive Dialysis Study (CDS). Participants provided information about employment status, disability income status, education, depressive symptoms measured by the Patient Health Questionnaire-2 (PHQ-2), and usual activity level/energy expenditure measured by the Human Activity Profile. Age, gender, race, insurance, diabetes, inability to ambulate or transfer, chronic obstructive pulmonary disease, cardiovascular conditions, and hemoglobin and serum albumin values at treatment start were obtained from US Renal Data System files. Dialysis modality was defined at time of interview. Results: Among 585 CDS participants who worked in the previous year, 191 (32.6%) continued working after dialysis start. On the basis of the PHQ-2 cutoff score >= 3, 12.1% of patients who remained employed had possible or probable depression, compared with 32.8% of patients who were no longer employed. In adjusted analyses, higher Human Activity Profile scores were associated with increased likelihood of continued employment, and there was a borderline association between lower PHQ-2 scores and continued employment. Conclusions: Screening and management of depressive symptoms and support for increased activity level may facilitate patients' opportunity for continued employment after dialysis start, along with generally improving their overall quality of life. Clin J Am Soc Nephrol 5: 2040-2045, 2010. doi: 10.2215/CJN.03980510 C1 [Kutner, Nancy G.] Emory Univ, Dept Rehabil Med, Rehabil Qual Life Special Studies Ctr, Atlanta, GA 30322 USA. [Johansen, Kirsten L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Kutner, NG (reprint author), Emory Univ, Dept Rehabil Med, Rehabil Qual Life Special Studies Ctr, Atlanta, GA 30322 USA. EM nkutner@emory.edu FU National Institutes of Health [HHSN267200715004C, ADB N01-DK-7-5004] FX This study was supported by National Institutes of Health contract HHSN267200715004C, ADB N01-DK-7-5004 (N.G.K.). NR 37 TC 14 Z9 15 U1 0 U2 10 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV PY 2010 VL 5 IS 11 BP 2040 EP 2045 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 677UX UT WOS:000284018500020 PM 20884777 ER PT J AU Bryant, MS Rintala, DH Lai, EC Protas, EJ AF Bryant, M. S. Rintala, D. H. Lai, E. C. Protas, E. J. TI An investigation of two interventions for micrographia in individuals with Parkinson's disease SO CLINICAL REHABILITATION LA English DT Article ID VISUAL FEEDBACK AB Objective: This pilot study was designed to compare a change in micrographia between using grid lines and parallel horizontal lines as visual cues in individuals with Parkinson's disease. Design: Single group pre- and post-test. Setting: Research lab. Participants: Eleven males with Parkinson's disease. Interventions: Practice writing words with parallel and grid lines. The sequence of practising was randomized. Main outcome measures: Length of words. Results: The length of the words after practising with parallel lines was longer than in the initial free writing condition (17.83 +/- 3.93cm vs. 23.36 +/- 5.82 cm, P = 0.008). The length of the words after practising with grid lines was also longer than during free writing (17.83 +/- 3.93cm vs. 22.65 +/- 4.04 cm, P = 0.003). The length of the words after practising with parallel lines was not different from that after practising with grid lines. Conclusion: Improvements in letter size after practising with horizontal parallel lines and grid lines were not different. The addition of vertical lines to form a grid did not appear to improve the writing more than horizontal lines alone in persons with Parkinson's disease who experienced micrographia. C1 [Bryant, M. S.; Protas, E. J.] Univ Texas Med Branch, Sch Hlth Profess, Galveston, TX USA. [Bryant, M. S.; Rintala, D. H.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Lai, E. C.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Lai, E. C.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Bryant, MS (reprint author), 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mon.bryant@yahoo.com FU NICHD NIH HHS [K12 HD055929] NR 9 TC 14 Z9 14 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0269-2155 J9 CLIN REHABIL JI Clin. Rehabil. PD NOV PY 2010 VL 24 IS 11 BP 1021 EP 1026 DI 10.1177/0269215510371420 PG 6 WC Rehabilitation SC Rehabilitation GA 671UU UT WOS:000283537700006 PM 20554637 ER PT J AU Rubenstein, LZ Ganz, DA AF Rubenstein, Laurence Z. Ganz, David A. TI Falls and Their Prevention Preface SO CLINICS IN GERIATRIC MEDICINE LA English DT Editorial Material C1 [Rubenstein, Laurence Z.] Univ Oklahoma, Coll Med, Reynolds Dept Geriatr Med, Oklahoma City, OK 73104 USA. [Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90095 USA. RP Rubenstein, LZ (reprint author), Univ Oklahoma, Coll Med, Reynolds Dept Geriatr Med, 921 NE 13th St,VAMC 11G, Oklahoma City, OK 73104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD NOV PY 2010 VL 26 IS 4 BP XIII EP XIV DI 10.1016/j.cger.2010.07.007 PG 2 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 678MK UT WOS:000284079800001 PM 20934609 ER PT J AU Wu, SY Keeler, EB Rubenstein, LZ Maglione, MA Shekelle, PG AF Wu, Shinyi Keeler, Emmett B. Rubenstein, Laurence Z. Maglione, Margaret A. Shekelle, Paul G. TI A Cost-Effectiveness Analysis of a Proposed National Falls Prevention Program SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Falls; Fall prevention; Cost-effectiveness; Medicare; Health policy ID DWELLING OLDER PERSONS; ELDERLY-PEOPLE; RANDOMIZED TRIAL; NURSING-HOME; RISK-FACTORS; COMMUNITY; INJURIES; ADULTS; METAANALYSIS; POPULATION AB Falls are a major health concern for elderly people and cause substantial health care costs The authors used meta-analytic findings on the effectiveness of fall prevention interventions to determine cost-effectiveness of a proposed Medicare fall prevention program for people who experience a recent fall Using published clinical trial data the authors constructed a population-based economic model and estimated that in the base case, the program could prevent a half million people from falling again within a year From the model under most circumstances the cost-effectiveness ratio is less than $1500 per person prevented from experiencing a recurrent fall Paying for a fall prevention program to increase the use of evidence-based interventions would be a cost-effective use of Medicare dollars C1 [Wu, Shinyi] Univ So Calif, Epstein Dept Ind & Syst Engn, Los Angeles, CA 90089 USA. [Wu, Shinyi; Keeler, Emmett B.; Rubenstein, Laurence Z.; Maglione, Margaret A.; Shekelle, Paul G.] RAND Corp, So Calif Evidence Based Practice Ctr, Santa Monica, CA 90401 USA. [Rubenstein, Laurence Z.] Univ Calif Los Angeles, Div Geriatr, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rubenstein, Laurence Z.; Shekelle, Paul G.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Sepulveda Div, Los Angeles, CA 90073 USA. [Rubenstein, Laurence Z.; Shekelle, Paul G.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, W Los Angeles Div, Los Angeles, CA 90073 USA. RP Wu, SY (reprint author), Univ So Calif, Epstein Dept Ind & Syst Engn, 3715 McClintock Ave, Los Angeles, CA 90089 USA. FU National Institute on Aging as part of the UCLA Pepper Center [AG 10415] FX This research was performed by the Southern California Evidence Based Practice Center based at the RAND Corporation Santa Monica CA RAND is under contract with the Centers for Medicare and Medicaid Services (CMS) Dr Keeler was supported by the National Institute on Aging as part of the UCLA Pepper Center Grant AG 10415 NR 47 TC 13 Z9 13 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD NOV PY 2010 VL 26 IS 4 BP 751 EP + DI 10.1016/j.cger.2010.07.005 PG 17 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 678MK UT WOS:000284079800012 PM 20934620 ER PT J AU deFoneska, A Kaunitz, JD AF deFoneska, Arushi Kaunitz, Jonathan D. TI Gastroduodenal mucosal defense SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Article DE heat shock proteins; Helicobacter pylori; prostaglandins; proteinase-activated receptors; purinergic signalling; toll-like receptors; trefoil factors ID INTESTINAL ALKALINE-PHOSPHATASE; HELICOBACTER-PYLORI; GASTROINTESTINAL-DISEASES; ADAPTIVE CYTOPROTECTION; GASTRIC NECROSIS; RATS; EXPRESSION; RECEPTOR; CELLS; LIPOPOLYSACCHARIDE AB Purpose of review We have summarized recent findings related to gastroduodenal mucosal defense as well as factors contributing to defensive failure, highlighting findings that illuminate new pathophysiological mechanisms. Recent findings Gastroduodenal bicarbonate secretion is mediated by prostaglandin E receptors and stimulated by the prostone lubiprostone. Toll-like receptor (TLR)4 signaling is protective against gastric injury. Intestinal alkaline phosphatase (IAP) is a chemosensor that regulates the duodenal mucosal surface pH. Lipopolysaccharide (LPS) increases gastric permeability; IAP secreted during fat digestion may detoxify colonic LPS. NADPH oxidase activity mediates ischemia/reperfusion-related gastric mucosal damage. Heat shock protein 70 (HSP70) protects the gastric mucosa through inhibition of apoptosis, proinflammatory cytokines, and cell adhesion molecules (CAMs). HSP90 may be a contributing factor in impaired adaptive cytoprotection. Proteinase-activated receptor-1 (PAR-1) is protective against Helicobacter-induced gastritis, mediated by the suppression of proinflammatory pathways. IKK beta/NF-kappa B signaling decreases chronic Helicobacter-induced inflammation by inhibiting cellular apoptosis and necrosis. Activation of A(2A) adenosine receptors decreases inflammation and gastritis but leads to persistent Helicobacter pylori infection. Summary Enhanced understanding of the mechanisms of gastroduodenal defense and injury provides new insight into potential therapeutic targets, contributing towards the development of better tolerated and more effective therapies. C1 [deFoneska, Arushi; Kaunitz, Jonathan D.] UCLA Sch Med, W Los Angeles VA Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. [Kaunitz, Jonathan D.] UCLA Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. [Kaunitz, Jonathan D.] UCLA Sch Med, Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA. [Kaunitz, Jonathan D.] UCLA Sch Med, Dept Med, Los Angeles, CA 90073 USA. RP Kaunitz, JD (reprint author), UCLA Sch Med, W Los Angeles VA Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIH/NIDDK [RO1 DK54221, P30 DK0413] FX We thank Coleen Palileo for her editorial assistance. Supported by VA Merit Review funding, NIH/NIDDK RO1 DK54221, and NIH/NIDDK P30 DK0413. NR 40 TC 28 Z9 29 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0267-1379 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD NOV PY 2010 VL 26 IS 6 BP 604 EP 610 DI 10.1097/MOG.0b013e32833f1222 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 664SQ UT WOS:000282983200011 PM 20948371 ER PT J AU He, WJ Castiblanco, J Walter, EA Okulicz, JF Ahuja, SK AF He, Weijing Castiblanco, John Walter, Elizabeth A. Okulicz, Jason F. Ahuja, Sunil K. TI Mendelian randomization: potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes SO CURRENT OPINION IN HIV AND AIDS LA English DT Article DE biomarker; chemokine; gene; HIV; Mendelian randomization ID HUMAN-IMMUNODEFICIENCY-VIRUS; DUFFY ANTIGEN RECEPTOR; C-REACTIVE PROTEIN; COPY-NUMBER VARIATION; CD4(+) T-CELLS; DISEASE PROGRESSION; ANTIRETROVIRAL THERAPY; PROMOTER POLYMORPHISM; TYPE-1 INFECTION; AIDS SUSCEPTIBILITY AB Purpose of review It is unknown whether biomarkers simply correlate with or are causal for HIV-associated outcomes. Mendelian randomization is a genetic epidemiologic approach used to disentangle causation from association. Here, we discuss the potential use of Mendelian randomization for differentiating whether biomarkers are correlating with or causal for HIV-associated outcomes. Recent findings Mendelian randomization refers to the random allocation of alleles at the time of gamete formation. In observational epidemiology, this refers to the use of genetic variants to estimate a causal effect between a modifiable risk factor and an outcome of interest. A formal Mendelian randomization study using a genetic marker as a proxy for the biomarker has not been conducted in the HIV field. However, in the postgenomic era, this approach is being used increasingly. Examples are evidence for the causal role of BMI in blood pressure and noncausal role of C-reactive protein in coronary heart disease. We discuss the conceptual framework, uses, and limitations of Mendelian randomization in the context of HIV infection as well as specific biomarkers (IL-6, C-reactive protein) and genetic determinants (e. g., in CCR5, chemokine, and DARC genes) that associate with HIV-related outcomes. Summary Making the distinction between correlation and causality has particular relevance when a biomarker (e. g., IL-6) is potentially modifiable, in which case a biomarker-guided targeted treatment strategy may be feasible. Although the tenets of Mendelian randomization rest on strong assumptions, and conducting a Mendelian randomization study in HIV infection presents many challenges, it may offer the potential to identify causal biomarkers for HIV-associated outcomes. C1 [He, Weijing; Castiblanco, John; Ahuja, Sunil K.] S Texas Vet Healthcare Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA. [He, Weijing; Castiblanco, John; Walter, Elizabeth A.; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol Immunol & Biochem, San Antonio, TX 78229 USA. [Okulicz, Jason F.] Brooke Army Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA. RP Ahuja, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Vet Adm Ctr AIDS & HIV Infect, 7703 Floyd Curl Dr MC 7881,Rm 5-065R, San Antonio, TX 78229 USA. EM ahujas@uthscsa.edu OI CASTIBLANCO, JOHN/0000-0003-2556-3697; CASTIBLANCO, JOHN/0000-0002-7965-9822 FU Veterans Administration HIV/AIDS Center of the South Texas Veterans Healthcare System, NIH [R37046326]; Doris Duke Distinguished Clinical Scientist Award; VA MERIT award; Burroughs Wellcome Clinical Scientist Award in Translational Research FX The present work was supported by the Veterans Administration HIV/AIDS Center of the South Texas Veterans Healthcare System, NIH (R37046326), and the Doris Duke Distinguished Clinical Scientist Award to S. K. A. S. K. A. is also supported by a VA MERIT award and the Burroughs Wellcome Clinical Scientist Award in Translational Research. NR 137 TC 1 Z9 1 U1 3 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1746-630X EI 1746-6318 J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD NOV PY 2010 VL 5 IS 6 BP 545 EP 559 DI 10.1097/COH.0b013e32833f2087 PG 15 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 828NX UT WOS:000295509900014 PM 20978399 ER PT J AU Steven, DW Palevsky, PM AF Weisbord, Steven D. Palevsky, Paul M. TI Strategies for the prevention of contrast-induced acute kidney injury SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION LA English DT Review DE contrast-induced acute kidney injury; prevention; risk factors ID RANDOMIZED CONTROLLED-TRIAL; PERCUTANEOUS CORONARY INTERVENTION; RADIOCONTRAST-INDUCED NEPHROPATHY; INTRAVENOUS N-ACETYLCYSTEINE; ISOTONIC SODIUM-BICARBONATE; ATRIAL-NATRIURETIC-PEPTIDE; SEVERE RENAL-INSUFFICIENCY; MEDIA-INDUCED NEPHROPATHY; DIURESIS DVD TRIAL; HIGH-RISK PATIENTS AB Purpose of review The intravascular administration of iodinated contrast media for diagnostic imaging is a common cause of acute kidney injury and a leading cause of iatrogenic renal disease. The purpose of this review is to describe the principal risk factors for contrast-induced acute kidney injury and to summarize recent data describing the efficacy of various preventive interventions for this condition. Recent findings Whereas earlier studies suggested that certain low-osmolal contrast agents including iohexol and ioxaglate are more nephrotoxic than iso-osmolal iodixanol, recent clinical trials and meta-analyses comparing other low-osmolal contrast agents with iodixanol have found little difference in risk. The provision of prophylactic renal replacement therapy does not ameliorate the risk of contrast-induced acute kidney injury, and likely poses undue risk. Despite some research supporting a benefit of atrial natriuretic peptide, statins, and prostaglandin analogs, additional data from large, adequately powered studies are needed before these agents can be recommended. N-Acetylcysteine and isotonic intravenous bicarbonate have been investigated intensely, yet the data on these interventions are conflicting due to methodological limitations in past studies. Summary Prevention of contrast-induced acute kidney injury involves the identification of high-risk patients, consideration of alternative imaging procedures that do not involve the administration of iodinated contrast, and integration of the cumulative data available on preventive interventions in high-risk patients. C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Univ Drive Div, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Univ Drive Div, Room 7E123 111F-U, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 FU VA Health Services [RCD 03-176-2] FX The views expressed in this article are those of the authors and do not necessarily represent the views of the United States Department of Veterans Affairs. Dr Weisbord is supported by a VA Health Services Research and Development Career Development Transition Award (RCD 03-176-2). NR 111 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1062-4821 J9 CURR OPIN NEPHROL HY JI Curr. Opin. Nephrol. Hypertens. PD NOV PY 2010 VL 19 IS 6 BP 539 EP 549 DI 10.1097/MNH.0b013e32833d42e3 PG 11 WC Urology & Nephrology; Peripheral Vascular Disease SC Urology & Nephrology; Cardiovascular System & Cardiology GA 664RW UT WOS:000282981200005 ER PT J AU Szymusiak, R AF Szymusiak, Ronald TI Hypothalamic versus neocortical control of sleep SO CURRENT OPINION IN PULMONARY MEDICINE LA English DT Article DE adenosine; cytokines; preoptic hypothalamus; sleep homeostasis; synaptic homeostasis ID VENTROLATERAL PREOPTIC NEURONS; SLOW-WAVE ACTIVITY; EYE-MOVEMENT SLEEP; HORMONE-RELEASING-HORMONE; WAKING DISCHARGE PATTERNS; DORSAL RAPHE NUCLEUS; NERVE GROWTH-FACTOR; HOMEOSTATIC REGULATION; SEROTONERGIC NEURONS; PROSTAGLANDIN D-2 AB Purpose of review Regions of the neocortex most strongly activated during waking exhibit increased sleep intensity during subsequent sleep. The novel concept that aspects of sleep homeostasis are determined locally in the cortex contrasts with the established views that global changes in neocortical activity during sleep are achieved through inhibition of ascending arousal systems that originate in the brainstem and hypothalamus. Recent findings Experiments in animals and humans document asymmetries in neocortical electroencephalogram (EEG) slow-wave activity (SWA), a marker of homeostatic sleep need, as a result of functional activity during waking. In addition to local, use-dependent augmentation of EEG SWA and evoked potentials, expression of plasticity-related genes and of sleep-regulatory cytokines and neuromodulators have been shown to be elevated in a use-dependent manner in neocortex. The functional consequences of local sleep are hypothesized to involve regulation of synaptic plasticity, synaptic homeostasis and energy balance. Summary The evidence for use-dependent modulation of neocortical activity during sleep is compelling and provides novel insights into sleep function. However, local changes in neocortex are generally expressed on a background of global sleep. It remains to be determined if events initiated in the cortex have global sleep-promoting effects and how neocortical and hypothalamic mechanisms of sleep control interact. C1 [Szymusiak, Ronald] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 91343 USA. [Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. RP Szymusiak, R (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St,North Hills, Los Angeles, CA 91343 USA. EM rszym@ucla.edu FU Medical Research Service of the Department of Veterans Affairs; National Institute of Mental Health [MH63323] FX The author has no conflicts of interest relevant to the content of this article. Preparation of the article was supported by the U.S. Department of Veterans Affairs. The author has current grant support from the Medical Research Service of the Department of Veterans Affairs and the National Institute of Mental Health MH63323. NR 64 TC 11 Z9 11 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1070-5287 J9 CURR OPIN PULM MED JI Curr. Opin. Pulm. Med. PD NOV PY 2010 VL 16 IS 6 BP 530 EP 535 DI 10.1097/MCP.0b013e32833eec92 PG 6 WC Respiratory System SC Respiratory System GA 656UZ UT WOS:000282367400002 PM 20739890 ER PT J AU Luxton, DD Skopp, NA Maguen, S AF Luxton, David D. Skopp, Nancy A. Maguen, Shira TI GENDER DIFFERENCES IN DEPRESSION AND PTSD SYMPTOMS FOLLOWING COMBAT EXPOSURE SO DEPRESSION AND ANXIETY LA English DT Article DE depression; PTSD; combat exposure; gender; women ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; SCREEN PC-PTSD; PRIMARY-CARE; SEX-DIFFERENCES; IRAQ; AFGHANISTAN; MILITARY; SELF; PREVALENCE AB Background: This research examined gender as a moderator of the association between combat exposure (CE) and depression as well as CE and PTSD symptoms among a nonclinical sample of Soldiers following deployment in support of operations in Afghanistan and Iraq. Methods: Cases included 6,943 (516 women, 6,427 men) active duty Soldiers that were retrospectively analyzed from a pre- and post-deployment screening database at a large Army installation. Results: Gender moderated the association between CE and depressive and PTSD symptoms such that higher levels of CE were more strongly associated with depression and PTSD symptoms in women compared to men. Female Soldiers also reported higher severity of depressive symptoms compared to male Soldiers, whereas men reported higher levels of CE and a greater number of previous deployments compared to women. Conclusions: CE was a stronger predictor of post-deployment depression and PTSD symptoms for women compared to men. These results provide evidence for gender-based differences in depression and PTSD risk. Screening for degree of CE in addition to symptoms associated with depression and PTSD can help with the care for service members who are returning from deployments to combat zones. Depression and Anxiety 27:1027-1033, 2010. Published 2010 Wiley-Liss, Inc. C1 [Luxton, David D.; Skopp, Nancy A.] Natl Ctr Telehlth & Technol T2, Def Ctr Excellence DCoE Psychol Hlth & Traumat Br, Old Madigan Army Med Ctr, Tacoma, WA 98431 USA. [Maguen, Shira] San Francisco VA Med Ctr, San Francisco, CA USA. [Maguen, Shira] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Luxton, DD (reprint author), Natl Ctr Telehlth & Technol T2, Def Ctr Excellence DCoE Psychol Hlth & Traumat Br, Old Madigan Army Med Ctr, Old Madigan Army Med Ctr Bldg 9933A, Tacoma, WA 98431 USA. EM david.luxton@us.army.mil NR 39 TC 52 Z9 52 U1 1 U2 11 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD NOV PY 2010 VL 27 IS 11 BP 1027 EP 1033 DI 10.1002/da.20730 PG 7 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 676EI UT WOS:000283892500006 PM 20721909 ER PT J AU Custis, T Beynet, D Carranza, D Greco, J Lask, GP Kim, J AF Custis, Trenton Beynet, David Carranza, Dafnis Greco, Joseph Lask, Gary P. Kim, Jenny TI Comparison of Treatment of Melomental Fold Rhytides with Cross-Linked Hyaluronic Acid Combined with OnabotulinumtoxinA and Cross-Linked Hyaluronic Acid Alone SO DERMATOLOGIC SURGERY LA English DT Article ID TOXIN TYPE-A AB BACKGROUND Hyaluronic acid and onabotulinumtoxinA combination therapy has been shown to have greater clinical effectiveness than hyaluronic acid alone for glabellar furrowing, but this is not well documented for melomental fold rhytides. OBJECTIVE To compare the efficacy of intradermal cross-linked hyaluronic acid (HA) and onabotulinumtoxinA combination therapy with the efficacy of cross-linked HA monotherapy in patients with melomental fold rhytides. METHODS AND MATERIALS Twenty-two patients received combination therapy to a melomental fold area while also receiving cross-linked HA and a placebo saline injection to the contralateral side. Blinded physician evaluators and patient self-evaluators clinically and photographically assessed responses during standard intervals over 12 months. RESULTS The melomental folds treated with combination therapy had significantly greater aesthetic improvement than the monotherapy-treated side at 2 weeks and 1 month upon physician photographic review. Furthermore, the median time for return to pretreatment rhytides was 6.5 weeks longer in the combination therapy side. Patient assessment also revealed improvement over baseline for the combination therapy at 1 month. CONCLUSION Cross-linked HA and onabotulinumtoxinA combination therapy to melomental fold rhytides may provide better overall aesthetic results and longer duration of aesthetic improvement than cross-linked HA monotherapy. David Beynet, Gary P. Lask and Jenny Kim are consultants for Allergan. The authors received the cross-linked HA and onabotulinumtoxinA for the study from Allergan, Inc. (Irvine, CA). This was an investigator-initiated study and no scientific input was received from Allergan Inc. C1 [Custis, Trenton; Beynet, David; Carranza, Dafnis; Greco, Joseph; Lask, Gary P.; Kim, Jenny] Univ Calif Los Angeles, Div Dermatol, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Beynet, David; Kim, Jenny] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Dermatol, Los Angeles, CA USA. [Lask, Gary P.] Indianer Lask & Rosenzweig Dermatol Grp, Encino, CA USA. RP Kim, J (reprint author), Univ Calif Los Angeles, Div Dermatol, David Geffen Sch Med, 52-121 Ctr Hlth Sci,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM JeKim@mednet.ucla.edu NR 9 TC 10 Z9 10 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1076-0512 J9 DERMATOL SURG JI Dermatol. Surg. PD NOV PY 2010 VL 36 IS 3 SI SI BP 1852 EP 1858 DI 10.1111/j.1524-4725.2010.01741.x PG 7 WC Dermatology; Surgery SC Dermatology; Surgery GA 669UZ UT WOS:000283377000010 PM 20969662 ER PT J AU Nelson, KM Boyko, EJ Koepsell, T AF Nelson, Karin M. Boyko, Edward J. Koepsell, Thomas TI All-Cause Mortality Risk Among a National Sample of Individuals With Diabetes SO DIABETES CARE LA English DT Article ID CORONARY HEART-DISEASE; PHYSICAL-ACTIVITY; TIME-SCALE; FOLLOW-UP; ADULTS; HEALTH; WOMEN; PREDICTORS; MELLITUS; CHOICE AB OBJECTIVE- Little is known about the relative contributions of modifiable risk factors to overall diabetes mortality. The purpose of the current study is to 1) assess the association between modifiable risk factors and all-cause mortality among a nationally representative sample of individuals with diabetes and 2) determine the population-attributable risk percent (PAR%) for these factors. RESEARCH DESIGN AND METHODS- We analyzed data from a nationally representative sample of 1,507 adults over the age of 17 years with a self-reported diagnosis of diabetes from the Third National Health and Nutrition Examination Survey (NHANES III) mortality study. Our main outcome measures were all-cause mortality and PAR%. We used the Cox proportional hazard analysis to determine hazard ratios (HRs) for known diabetes risks and calculated PAR%. RESULTS- Among adults with diabetes, the HRs for all-cause mortality were significant for individuals who had an A1C >= 8% (HR 1.65, 95% CI 1.11-2.45) or reported no regular physical activity (1.58, 1.24-2.02) or current tobacco use (1.77, 1.15-2.73). The population-attributable risk was 15.3% for A1C value >= 8%, 16.4% for no regular physical activity, and 7.5% for current tobacco use. CONCLUSIONS- Health systems may consider prioritizing care to include smoking cessation, increasing physical activity, and moderate glycemic control among patients with diabetes. This study suggests that focusing on these areas may result in significant reductions in mortality in individuals with diabetes. C1 [Nelson, Karin M.; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA. [Nelson, Karin M.; Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA USA. [Nelson, Karin M.; Boyko, Edward J.; Koepsell, Thomas] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Nelson, Karin M.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Koepsell, Thomas] Univ Washington, Dept Epidemiol & Hlth Serv, Seattle, WA 98195 USA. RP Nelson, KM (reprint author), VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA. EM karin.nelson@va.gov OI Boyko, Edward/0000-0002-3695-192X FU Epidemiologic Research and Information Center VA Puget Sound Health Care System, Seattle, Washington FX This study was supported by the Epidemiologic Research and Information Center, VA Puget Sound Health Care System, Seattle, Washington. NR 24 TC 19 Z9 19 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD NOV PY 2010 VL 33 IS 11 BP 2360 EP 2364 DI 10.2337/dc10-0846 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 683ZI UT WOS:000284516400013 PM 20739687 ER PT J AU Osborn, CY Bains, SS Egede, LE AF Osborn, Chandra Y. Bains, Sujeev S. Egede, Leonard E. TI Health Literacy, Diabetes Self-Care, and Glycemic Control in Adults with Type 2 Diabetes SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Article ID SOCIAL SUPPORT; ELDERLY PERSONS; KNOWLEDGE; OUTCOMES; ASSOCIATION; MORTALITY; EDUCATION AB Background: Although limited health literacy is a barrier to disease management and has been associated with poor glycemic control, the mechanisms underlying the relationships between health literacy and diabetes outcomes are unknown. We examined the relationships between health literacy, determinants of diabetes self-care, and glycemic control in adults with type 2 diabetes. Methods: Patients with diabetes were recruited from an outpatient primary care clinic. We collected information on demographics, health literacy, diabetes knowledge, diabetes fatalism, social support, and diabetes self-care, and hemoglobin A1c values were extracted from the medical record. Structural equation models tested the predicted pathways linking health literacy to diabetes self-care and glycemic control. Results: No direct relationship was observed between health literacy and diabetes self-care or glycemic control. Health literacy had a direct effect on social support (r = -0.20, P < 0.05) and through social support had an indirect effect on diabetes self-care (r = -0.07) and on glycemic control (r = -0.01). More diabetes knowledge (r = 0.22, P < 0.05), less fatalism (r = -0.22, P < 0.05), and more social support (r = 0.27, P < 0.01) were independent, direct predictors of diabetes self-care and through self-care were related to glycemic control (r = -0.20, P < 0.05). Conclusions: Our findings suggest health literacy has an indirect effect on diabetes self-care and glycemic control through its association with social support. This suggests that for patients with limited health literacy, enhancing social support would facilitate diabetes self-care and improved glycemic control. C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Bains, Sujeev S.; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Osborn, Chandra Y.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. [Osborn, Chandra Y.] Vanderbilt Univ, Sch Med, Vanderbilt Eskind Diabet Ctr, Diabet Res & Training Ctr, Nashville, TN 37212 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu FU NIDDK [P60 DK020593] FX C.Y.O. is supported by a Diversity Supplement Award (NIDDK P60 DK020593). NR 35 TC 38 Z9 40 U1 4 U2 18 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD NOV PY 2010 VL 12 IS 11 BP 913 EP 919 DI 10.1089/dia.2010.0058 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 682IT UT WOS:000284395500009 PM 20879964 ER PT J AU Boyko, EJ Gerstein, HC Mohan, V Yusuf, S Sheridan, P Anand, S Shaw, JE AF Boyko, E. J. Gerstein, H. C. Mohan, V. Yusuf, S. Sheridan, P. Anand, S. Shaw, J. E. CA DREAM Trial Investigators TI Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial SO DIABETIC MEDICINE LA English DT Article DE Asian; ethnicity; Latino; prevention; rosiglitazone; thiazolidinedione ID IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE MODIFICATION; INSULIN-RESISTANCE; MELLITUS; RISK; AMERICANS; ATHEROSCLEROSIS; PREVALENCE; METFORMIN; WHITES AB P>Aims Risk of Type 2 diabetes varies by ethnicity, but whether ethnicity remains important among those who have impaired glucose tolerance or impaired fasting glucose is uncertain. Whether the effect of thiazolidinedione treatment on diabetes prevention in persons with non-diabetic dysglycaemia varies by ethnicity is also not known. We addressed these questions using data collected in the DREAM trial. Methods A 2-by-2 factorial double-blind randomized controlled trial to compare the effects of rosiglitazone and ramipril on the primary outcome of diabetes or death in persons meeting criteria for impaired glucose tolerance or impaired fasting glucose. The effect of these interventions by ethnicity was estimated using Cox regression analysis. Results Of 5269 adults, 2365 were randomly assigned to rosiglitzone and 2634 to placebo. South Asians showed a higher hazard for the primary outcome compared with Europeans (hazard ratio, 95% confidence interval 2.21, 1.41-3.47) adjusted for age, gender, BMI, waist-hip ratio and geographic region. A lesser increase in risk was seen in Black people (1.37, 1.04-1.81). A significant reduction in risk of the primary outcome with rosiglitazone treatment assignment was seen in all ethnic groups, but the treatment effect significantly differed by ethnicity (P = 0.0242), with South Asians experiencing a smaller, and Latinos a larger preventive effect. Conclusions Ethnicity is an important risk factor for Type 2 diabetes in dysglycaemic persons. All ethnic groups experienced a large significant reduction in diabetes risk because of rosiglitazone. The magnitude of this reduction differed by ethnicity. Given the post hoc nature of this analysis, further confirmation of these findings is needed. C1 [Boyko, E. J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Boyko, E. J.; Shaw, J. E.] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia. [Gerstein, H. C.; Yusuf, S.; Sheridan, P.] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada. [Mohan, V.] Madras Diabet Res Fdn & Dr Mohans Diabet Specialt, Madras, Tamil Nadu, India. [Anand, S.] McMaster Univ, Dept Med, Hamilton, ON, Canada. RP Boyko, EJ (reprint author), 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM eboyko@u.washington.edu RI Shaw, Jonathan/E-7388-2010 OI Shaw, Jonathan/0000-0002-6187-2203; Boyko, Edward/0000-0002-3695-192X FU Canadian Institutes of Health Research [MCT41548]; Sanofi-Aventis; Glaxo SmithKline; King Pharmaceuticals FX Support was provided by grants from the Canadian Institutes of Health Research (MCT41548), Sanofi-Aventis, Glaxo SmithKline and King Pharmaceuticals. SA holds the Michael G. DeGroote and Heart and Stroke Foundation of Ontario Chair in Population Health and the May Cohen Eli Lilly Endowed Chair in Women's Health Research, McMaster University. NR 22 TC 6 Z9 7 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0742-3071 J9 DIABETIC MED JI Diabetic Med. PD NOV PY 2010 VL 27 IS 11 BP 1226 EP 1232 DI 10.1111/j.1464-5491.2010.03064.x PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 666YX UT WOS:000283160200002 PM 20950379 ER PT J AU Akiba, Y Kaunitz, JD AF Akiba, Yasutada Kaunitz, Jonathan D. TI Lafutidine, a Protective H(2) Receptor Antagonist, Enhances Mucosal Defense in Rat Esophagus SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Esophageal blood flow; Interstitial pH; Capsaicin-sensitive afferent nerves; Pepsin; Interstitial acidification ID SENSITIVE AFFERENT NEURONS; CARBONIC-ANHYDRASES; REFLUX ESOPHAGITIS; ACID INJURY; BLOOD-FLOW; LOW PH; DUODENUM; MEDIATE; PEPSIN; NERVES AB Luminal acid or CO(2) induces a hyperemic response in the esophagus, via activation of acid sensors on capsaicin-sensitive afferent nerves (CSAN). Since disruption of the hyperemic response to luminal CO(2) acidifies the interstitium of the esophageal mucosa, the hyperemic response may maintain interstitial pH (pH(int)). We hypothesized that acid-related hyperemia maintains pH(int), preventing acid-induced injury in the esophageal mucosa. We examined the effects of capsaicin (Cap) or lafutidine (Laf), a mucosal protective H(2) antagonist, on the regulation of pH(int) and blood flow in rat esophagus using ratiometric microimaging and laser-Doppler measurements of the lower esophageal mucosa of living rats. The esophagus was topically superfused with pH 7.0 buffer, or a pH 1.0 or pH 1.0 + pepsin (1 mg/ml) solution with or without Laf. Cap (30 or 100 A mu M) or Laf (0.1 or 1 mM) dose-dependently increased blood flow, accompanied by increased pH(int). The pH 1.0 solution increased blood flow without pH(int) change, whereas Laf (1 mM) increased blood flow and pH(int) during acid exposure. The effects of Laf were abolished by ablation of CSAN. Perfusion of the acidified pepsin solution gradually decreased pH(int), inhibited by Laf perfusion. Activation of CSAN by Laf with or without acid, accompanied by hyperemia, increased pH(int), preventing acidified pepsin-induced interstitial acidification. Stimulation of the capsaicin pathway with compounds such as Laf enhances mucosal protection from acid-related injury in the upper gastrointestinal tract. C1 [Akiba, Yasutada; Kaunitz, Jonathan D.] W Los Angeles Vet Affairs Med Ctr, Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA. [Akiba, Yasutada; Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. [Akiba, Yasutada; Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Brentwood Biomed Res Inst, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU Taiho Pharmaceutical Co.; NIH-NIDDK [R01 DK54221]; Veterans Affairs FX We thank Coleen Palileo for her assistance with manuscript preparation. This work was supported by a research grant from Taiho Pharmaceutical Co., Veterans Affairs Merit Review Award, and NIH-NIDDK R01 DK54221 (J. Kaunitz). NR 25 TC 7 Z9 7 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD NOV PY 2010 VL 55 IS 11 BP 3063 EP 3069 DI 10.1007/s10620-010-1379-y PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 668VP UT WOS:000283300400009 PM 20824506 ER PT J AU Richardson, P Henderson, L Davila, JA Kramer, JR Fitton, CP Chen, GJ El-Serag, HB AF Richardson, Peter Henderson, Louise Davila, Jessica A. Kramer, Jennifer R. Fitton, Conar P. Chen, G. John El-Serag, Hashem B. TI Surveillance for Hepatocellular Carcinoma: Development and Validation of an Algorithm to Classify Tests in Administrative and Laboratory Data SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Algorithm; Liver cancer; Cirrhosis; Screening; Ultrasound; Alpha fetoprotein; VA ID MANAGEMENT; STAGE AB The purpose of alpha-fetoprotein (AFP) and abdominal ultrasound (US) cannot be discerned in administrative data. We developed an algorithm to identify AFP and US used as surveillance tests for hepatocellular carcinoma (HCC). We evaluated 300 AFP and 301 US tests from a VA database. Surveillance predictors in the administrative files (diagnoses, labs) were examined in logistic regression models. We calculated model-based probabilities of HCC surveillance status, and developed classification procedures using single and multiple imputation methods. The predictors of surveillance intent for AFP were absence of alcoholism, abdominal pain, ascites, diabetes and high AST levels. For US, the predictors of surveillance were prior AFP testing and HIV status and absence of abdominal pain, ascites, or drug dependence. For AFP classification, single imputation compared favorably with multiple imputation, both showing robustness in discrimination and calibration. For US both approaches were less robust in discrimination and calibration which was more moderate in multiple imputation than single imputation. Predictive algorithms in administrative files can be used to identify AFP performed for HCC surveillance, however, the intent of US is more difficult to identify. C1 [El-Serag, Hashem B.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Richardson, Peter; Davila, Jessica A.; Kramer, Jennifer R.; Fitton, Conar P.; Chen, G. John; El-Serag, Hashem B.] Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Richardson, Peter; Davila, Jessica A.; Kramer, Jennifer R.; Fitton, Conar P.; Chen, G. John; El-Serag, Hashem B.] Baylor Coll Med, Houston, TX 77030 USA. [El-Serag, Hashem B.] Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Henderson, Louise] Univ N Carolina, Dept Radiol, Chapel Hill, NC USA. RP El-Serag, HB (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu FU Houston VA HSR&D Center of Excellence [HFP90-020]; National Cancer Institute [R01-CA-125487] FX Financial support: This work was supported in part by the Houston VA HSR&D Center of Excellence (HFP90-020) and the National Cancer Institute (R01-CA-125487). NR 13 TC 12 Z9 12 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD NOV PY 2010 VL 55 IS 11 BP 3241 EP 3251 DI 10.1007/s10620-010-1387-y PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 668VP UT WOS:000283300400033 PM 20844957 ER PT J AU Hiemenz, JW Raad, II Maertens, JA Hachem, RY Saah, AJ Sable, CA Chodakewitz, JA Severino, ME Saddier, P Berman, RS Ryan, DM DiNubile, MJ Patterson, TF Denning, DW Walsh, TJ AF Hiemenz, J. W. Raad, I. I. Maertens, J. A. Hachem, R. Y. Saah, A. J. Sable, C. A. Chodakewitz, J. A. Severino, M. E. Saddier, P. Berman, R. S. Ryan, D. M. DiNubile, M. J. Patterson, T. F. Denning, D. W. Walsh, T. J. TI Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES LA English DT Article ID LIPOSOMAL AMPHOTERICIN-B; LIVER-TRANSPLANT RECIPIENTS; ALTERNATIVE TRIAL DESIGNS; STEM-CELL TRANSPLANTATION; FUNGAL-INFECTIONS; HEMATOLOGIC MALIGNANCIES; PULMONARY ASPERGILLOSIS; COLLOIDAL DISPERSION; ANTIFUNGAL THERAPY; PROGNOSTIC-FACTORS AB In a non-comparative study, caspofungin was effective salvage therapy for approximately half of the patients refractory to or intolerant of standard antifungal agents for invasive aspergillosis. To establish a frame of reference for these results, we compared the response to caspofungin with responses to other antifungal agents in a historical cohort of similar patients. The efficacy could be evaluated in 83 patients who received caspofungin 50 mg daily after a 70-mg loading dose. The historical control group, identified through a retrospective review of medical records, included 214 evaluable patients possibly refractory to or intolerant of a parts per thousand yen1 week of standard antifungal therapy. All patients had documented invasive aspergillosis. Favorable response was defined as a complete or partial response to therapy. Underlying diseases, baseline neutropenia, corticosteroid use, and sites of infection were similar in both studies. Most patients had received amphotericin B formulations and/or itraconazole, and were refractory to standard therapy. Favorable response rates were 45% with caspofungin and 16% with standard therapy. The unadjusted odds ratio for a favorable response (caspofungin/standard therapy) was 4.1 (95% confidence interval: 2.2, 7.5). After adjusting for potential imbalances in the frequency of disseminated infection, neutropenia, steroid use, and bone marrow transplantation between groups, the odds ratio remained at 4.1 (2.1, 7.9). Although only tentative conclusions about relative efficacy can be drawn from retrospective comparisons, caspofungin appeared to be at least as efficacious as an amphotericin B formulation and/or itraconazole for the treatment of invasive aspergillosis in patients refractory to or intolerant of their initial antifungal therapy. C1 [Hiemenz, J. W.] Univ Florida, Coll Med, Div Hematol Oncol, Gainesville, FL 32610 USA. [Raad, I. I.; Hachem, R. Y.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Maertens, J. A.] Univ Hosp Gasthuisberg, Leuven, Belgium. [Saah, A. J.; Sable, C. A.; Chodakewitz, J. A.; Severino, M. E.; Saddier, P.; Berman, R. S.; Ryan, D. M.; DiNubile, M. J.] Merck Res Labs, West Point, PA USA. [Patterson, T. F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Patterson, T. F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Denning, D. W.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England. [Walsh, T. J.] NCI, Bethesda, MD 20892 USA. RP Hiemenz, JW (reprint author), Univ Florida, Coll Med, Div Hematol Oncol, POB 100278, Gainesville, FL 32610 USA. EM john.hiemenz@medicine.ufl.edu OI Denning, David/0000-0001-5626-2251 FU Merck Co., Inc. FX Merck & Co., Inc., which markets caspofungin under the brand name Cancidas, sponsored and funded this study. Current and former employees of the sponsor (indicated on the title page) may own stock or stock options in the company. All non-Merck authors have served as investigators on Merck studies. The sponsor formally reviewed a penultimate draft. All co-authors approved an essentially final version of the manuscript. NR 45 TC 13 Z9 15 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0934-9723 J9 EUR J CLIN MICROBIOL JI Eur. J. Clin. Microbiol. Infect. Dis. PD NOV PY 2010 VL 29 IS 11 BP 1387 EP 1394 DI 10.1007/s10096-010-1013-0 PG 8 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 671LL UT WOS:000283507500009 PM 20703506 ER PT J AU Ponikowski, P Mitrovic, V O'Connor, CM Dittrich, H Cotter, G Massie, BM Givertz, MM Chen, E Murray, M Weatherley, BD Fujita, KP Metra, M AF Ponikowski, Piotr Mitrovic, Veselin O'Connor, Christopher M. Dittrich, Howard Cotter, Gad Massie, Barry M. Givertz, Michael M. Chen, Erluo Murray, Meredith Weatherley, Beth D. Fujita, Kenji P. Metra, Marco TI Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Haemodynamic effects; Heart failure; Renal failure ID A(1) RECEPTOR ANTAGONIST; SYSTOLIC DYSFUNCTION; PULMONARY-ARTERY; CONTROLLED TRIAL; KIDNEY-FUNCTION; BG9719 CVT-124; ADENOSINE; PRESSURE; FUROSEMIDE; TOLVAPTAN AB The direct effects of adenosine A1 receptor antagonists on haemodynamic parameters in patients with acute heart failure (HF) remain largely unknown. We evaluated the haemodynamic effects of the AA(1)RA rolofylline in 59 HF patients with concomitant renal impairment (estimated creatinine clearance 20-80 mL/min). Placebo or rolofylline 30 mg was administered as a 4 h infusion followed by intravenous (i.v.) loop diuretic administration. Haemodynamic measurements were carried out hourly up to 8 h post-dosing by pulmonary artery catheterization. Urine output, fractional excretion of sodium, potassium, urea, and uric acid, and blood urea nitrogen (BUN) and creatinine levels were also measured. In both groups, the changes from baseline in all haemodynamic indices except mean pulmonary artery pressure (PAP) were not clinically significant. Mean [95% confidence interval (CI)] PAP showed a placebo-adjusted decrease with rolofylline of -1.5 (-4.1, 1.1)mmHg at Hour 4 and -3.5 mmHg (95% CI: -6.2, -0.2) at Hour 8. There was a significant increase with rolofylline in diuresis [placebo-corrected mean (95% CI) change of 68 (20, 116)mL/h at Hour 2-4 and 103 (21, 185)mL/h at Hour 4-8] and in fractional excretion of sodium, potassium, and uric acid. Placebo-corrected changes in plasma levels of creatinine and BUN with rolofylline were non-significant. Single administration of rolofylline in patients with HF and impaired renal function produced a slight decrease in mean PAP and consistently increased diuresis and natriuresis without compromising renal function, both before and after administration of i.v. loop diuretics. C1 [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Dept Heart Dis, PL-50891 Wroclaw, Poland. [Mitrovic, Veselin] Max Planck Inst Physiol & Clin Res, Kerckhoff Klin, D-6350 Bad Nauheim, Germany. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, CA USA. [Dittrich, Howard] NovaCardia, San Diego, CA USA. [Cotter, Gad; Weatherley, Beth D.] Momentum Res, Durham, NC USA. [Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Chen, Erluo; Murray, Meredith] Merck & Co Inc, Upper Gwynedd, PA USA. [Fujita, Kenji P.] Merck & Co Inc, Rahway, NJ 07065 USA. [Metra, Marco] Univ Brescia, Div Cardiol, Dept Expt & Appl Med, Brescia, Italy. RP Ponikowski, P (reprint author), Med Univ, Clin Mil Hosp, Dept Heart Dis, Weigla 5, PL-50891 Wroclaw, Poland. EM piotrponikowski@4wsk.pl RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Metra, Marco/0000-0001-6691-8568 FU Merck; NovaCardia/Merck; Merck Co.; NovaCardia, Inc. FX P.P. has received honoraria from Merck and Biogen. V.M. has no conflicts. C.M.O'.C is a consultant and has received grant support from Merck. H.C.D. is/was a stockholder/consultant of the company (NovaCardia/Merck) that sponsored the study. G.C. is an employee of Momentum Research who received payments from Merck for the conduct of the study. B.M.M. has been a consultant to NovaCardia and Merck prior to and during the trial (payments from Merck<$ 10 000) and has received speaking honoraria for presentations during satellite symposia (<$ 10 000). M.M.G. has received research support from Merck & Co. E.C. and M. M. are employees of Merck and hold Merck stock options. B.D.W. is an employee of Momentum Research Inc., which has provided consulting services to Merck, Corthera, Celladon, Bio-heart, and Nile Therapeutics. K.P.F. is an employee of Merck & Co. M.M. has received honoraria for participation to meetings and as a member of the executive board from Cardiokine, Corthera, Merck, and Servier.; This study was funded by NovaCardia, Inc. As of September 2007, NovaCardia is a wholly owned subsidiary of Merck & Co, Inc. NR 35 TC 7 Z9 7 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1388-9842 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD NOV PY 2010 VL 12 IS 11 BP 1238 EP 1246 DI 10.1093/eurjhf/hfq137 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 673PB UT WOS:000283674300014 PM 20823097 ER PT J AU Solomon, VR Haq, W Smilkstein, M Srivastava, K Puri, SK Katti, SB AF Solomon, V. R. Haq, W. Smilkstein, M. Srivastava, Kumkum Puri, Sunil K. Katti, S. B. TI 4-Aminoquinoline derived antimalarials: Synthesis, antiplasmodial activity and heme polymerization inhibition studies SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article DE 4-Aminoquinoline; Thiourea; Antimalarial agents; Heme polymerization ID HEMATIN POLYMERIZATION; PLASMODIUM-FALCIPARUM; RETAIN ACTIVITY; IN-VITRO; CHLOROQUINE; DESIGN; DERIVATIVES; MECHANISM; BINDING; DRUGS AB A new series of 4-aminoquinoline derivatives have been synthesized and found to be active against both susceptible and resistant strains of Plasmodium falciparum in vitro. Compound 1-[3-(7-chloro-quinolin-4-ylamino)-propyl]-3-cyclopropyl-thiourea (7) exhibited superior in vitro activity against resistant strains of P. falciparum as compared to chloroquine (CQ). All the compounds showed resistance factor between 0.59 and 4.31 as against 5.05 for CQ. Spectroscopic studies suggested that this class of compounds act on heme polymerization target. (C) 2010 Elsevier Masson SAS. All rights reserved. C1 [Solomon, V. R.; Haq, W.; Katti, S. B.] Cent Drug Res Inst, Med & Proc Chem Div, Lucknow 226001, Uttar Pradesh, India. [Srivastava, Kumkum; Puri, Sunil K.] Cent Drug Res Inst, Div Parasitol, Lucknow 226001, Uttar Pradesh, India. [Smilkstein, M.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Katti, SB (reprint author), Cent Drug Res Inst, Med & Proc Chem Div, MG Rd, Lucknow 226001, Uttar Pradesh, India. EM setu_katti@yahoo.com RI Viswas, V. Raja Solomon/F-6654-2011 OI Viswas, V. Raja Solomon/0000-0002-9863-4452 FU CDRI; CSIR, New Delhi FX The authors thank the Director, CDRI for the support and the SAIF for the spectral data. One of the authors (V. R. Solomon) thanks the CSIR, New Delhi for Senior Research Fellowship. CDRI communication no. 7912 NR 31 TC 19 Z9 19 U1 0 U2 4 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0223-5234 J9 EUR J MED CHEM JI Eur. J. Med. Chem. PD NOV PY 2010 VL 45 IS 11 BP 4990 EP 4996 DI 10.1016/j.ejmech.2010.07.068 PG 7 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 676KZ UT WOS:000283911300035 PM 20805010 ER PT J AU Kosinski, MA Lipsky, BA AF Kosinski, Mark A. Lipsky, Benjamin A. TI Current medical management of diabetic foot infections SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY LA English DT Review DE empiric therapy; foot infections; multidrug-resistant organisms; osteomyelitis polymicrobial infections; severity of infection; soft-tissue infections ID RESISTANT-STAPHYLOCOCCUS-AUREUS; SKIN-STRUCTURE INFECTIONS; IN-VITRO ACTIVITY; GRAM-POSITIVE ORGANISMS; SOFT-TISSUE INFECTIONS; LENGTH-OF-STAY; COMPLICATED SKIN; RISK-FACTORS; LOWER-EXTREMITY; LINEZOLID THERAPY AB Foot infections are a serious complication of diabetes associated with substantial morbidity and occasional mortality. Antibiotic therapy for mild infections in patients who have not recently received antibiotic therapy can often be directed at just staphylococci and streptococci. Empiric therapy for infections that are chronic, moderate or severe, or that occur in patients who have failed previous antibiotic treatment, should usually be more broad spectrum. Bone infection also complicates a substantial percentage of diabetic foot wounds and increases the likelihood of treatment failure, requiring lower extremity amputation. An increasing body of evidence supports the effectiveness of nonsurgical treatment of diabetic foot osteomyelitis in selected patients, although the optimal choice of agent, route of administration and duration of therapy have yet to be defined. This article examines the potential role of standard and newer antibiotics that may be appropriate for treating diabetic foot infections, including ertapenem, vancomycin, moxifloxacin, daptomycin, telavancin and tigecycline, as well as several investigational agents, such as dalbavancin, ceftobiprole and nemonoxacin. C1 [Kosinski, Mark A.] New York Coll Podiatr Med, Div Med Sci, New York, NY 10035 USA. [Lipsky, Benjamin A.] VA Puget Sound Hlth Care Syst, Primary Care Clin & Antibiot Res, Seattle, WA 98108 USA. [Lipsky, Benjamin A.] Univ Washington, Sch Med, Seattle, WA 98108 USA. RP Kosinski, MA (reprint author), New York Coll Podiatr Med, Div Med Sci, 53 E 124th St, New York, NY 10035 USA. EM mkosins@nycpm.edu OI Lipsky, Benjamin A./0000-0001-9886-5114 FU Merck; Pfizer; Schering-Plough/Bayer; Cubist; Wyeth; TaiGen; Innocoll FX Mark Kosinski has received speaker fees from Merck. Benjamin Lipsky has received research funding consultant or speaker fees from Merck, Pfizer, Schering-Plough/Bayer, Cubist, Wyeth, TaiGen and Innocoll. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 113 TC 14 Z9 15 U1 0 U2 11 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1478-7210 J9 EXPERT REV ANTI-INFE JI Expert Rev. Anti-Infect. Ther. PD NOV PY 2010 VL 8 IS 11 BP 1293 EP 1305 DI 10.1586/ERI.10.122 PG 13 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 686GG UT WOS:000284684200016 PM 21073293 ER PT J AU Sano, M AF Sano, Mary TI ICAD 2010: detection may hold the key to treatment SO EXPERT REVIEW OF NEUROTHERAPEUTICS LA English DT Review AB The Alzheimer's Association International Conference on Alzheimer's Disease was held on July 10-15 in Honolulu (HI, USA). Over 3800 attendees participated, attending sessions that included more than 1700 posters and 200 oral presentations. The meeting, first organized in 1988 by Khalid Iqbal and Bengt Winblad, became an annual event in 2009, and under the current design includes not only well-established themes of interest, but investigator-initiated sessions also. The Alzheimer's Association started managing the conference in 2000 in partnership with the founders, and abstracts for the meeting are published in the association's journal, Alzheimer's & Dementia. Key themes of this year's conference included validation of biomarkers, drug development, the value of screening for cognitive loss and dementia and the proposal of a new criteria for Alzheimer's disease. C1 Mt Sinai Sch Med, James J Peters Vet Adm Med Ctr, Dept Psychiat, Alzheimer Dis Res Ctr, Bronx, NY 10468 USA. RP Sano, M (reprint author), Mt Sinai Sch Med, James J Peters Vet Adm Med Ctr, Dept Psychiat, Alzheimer Dis Res Ctr, 130 W Kingsbridge Rd,Code 150,Rm 1F01, Bronx, NY 10468 USA. EM mary.sano@mssm.edu NR 9 TC 1 Z9 1 U1 0 U2 0 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7175 J9 EXPERT REV NEUROTHER JI Expert Rev. Neurother. PD NOV PY 2010 VL 10 IS 11 BP 1659 EP 1661 DI 10.1586/ERN.10.150 PG 3 WC Clinical Neurology; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 686GJ UT WOS:000284684500010 PM 20977323 ER PT J AU George, MS AF George, Mark S. TI Transcranial magnetic stimulation for the treatment of depression SO EXPERT REVIEW OF NEUROTHERAPEUTICS LA English DT Review DE depression; TMS; transcranial magnetic stimulation; treatment-resistant ID TREATMENT-RESISTANT DEPRESSION; MOTOR CORTEX STIMULATION; HEALTHY-YOUNG MEN; RANDOMIZED CONTROLLED-TRIAL; DEEP BRAIN-REGIONS; MAJOR DEPRESSION; ELECTROCONVULSIVE-THERAPY; PREFRONTAL CORTEX; CORTICAL EXCITABILITY; BIPOLAR DEPRESSION AB Repeated daily left prefrontal transcranial magnetic stimulation (TMS) was first proposed as a potential treatment for depression in 1993. Multiple studies from researchers around the world since then have repeatedly demonstrated that TMS has antidepressant effects greater than sham treatment, and that these effects are clinically meaningful. A large industry-sponsored trial, published in 2007, resulted in US FDA approval in October 2008. Most recently, a large NIH-sponsored trial, with a more rigorous sham technique, found that a course of treatment (3-5 weeks) was statistically and clinically significant in reducing depression. However, consistently showing statistically and clinically significant antidepressant effects, and gaining regulatory approval, is merely the beginning for this new treatment. As with any new treatment involving a radically different approach, there are many unanswered questions about TMS, and the field is still rapidly evolving. These unanswered questions include the appropriate scalp location, understanding the mechanisms of action, refining the 'dose' (frequency, train, number of stimuli/day and pattern of delivery), understanding whether and how TMS can be combined with medications or talking/exposure therapy, or both, and how to deliver maintenance TMS. This article summarizes the available clinical information, and discusses key areas where more research is needed. TMS reflects a paradigm shift in treating depression. It is a safe, relatively noninvasive, focal brain stimulation treatment that does not involve seizures or implanted wires, and does not have drug-drug interactions or systemic side effects. C1 [George, Mark S.] Med Univ S Carolina, Inst Psychiat, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP George, MS (reprint author), Med Univ S Carolina, Inst Psychiat, 502 N,67 President St, Charleston, SC 29425 USA. EM georgem@musc.edu FU Glaxo-Smith-Kline; Jazz Pharmaceuticals; Brainsway FX Mark George reports no equity or other direct financial investment in any device or pharmaceutical firm. Within the past 3 years he has: served as a paid consultant to Glaxo-Smith-Kline, Jazz Pharmaceuticals, Cyberonics and Neuropace; received research grants from Glaxo-Smith-Kline, Jazz Pharmaceuticals and Brainsway; served as an unpaid consultant to Brainsonix, Brainsway, Neuronetics and NeoStim; and been the editor-in-chief of a journal published by Elsevier, entitled Brain Stimulation. The Medical University of South Carolina holds patents in the area of combining TMS with functional brain imaging. The total compensation from any company in a single year has been less than US$10,000. The total combined compensation from all consulting activities is less than 10% of his university salary. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 124 TC 38 Z9 39 U1 7 U2 21 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7175 J9 EXPERT REV NEUROTHER JI Expert Rev. Neurother. PD NOV PY 2010 VL 10 IS 11 BP 1761 EP 1772 DI 10.1586/ERN.10.95 PG 12 WC Clinical Neurology; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 686GJ UT WOS:000284684500020 PM 20977332 ER PT J AU Patel, SM Iqbal, N Kaul, S Ratcliffe, SJ Rickels, MR Reilly, MP Scattergood, T Basu, A Fuller, C Cappola, AR AF Patel, Shrita M. Iqbal, Nayyar Kaul, Shailja Ratcliffe, Sarah J. Rickels, Michael R. Reilly, Muredach P. Scattergood, Theresa Basu, Arpita Fuller, Carissa Cappola, Anne R. TI Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial SO FERTILITY AND STERILITY LA English DT Article DE Testosterone; insulin resistance; polycystic ovary syndrome; metabolic syndrome; aging; elderly; women ID POLYCYSTIC-OVARY-SYNDROME; CORONARY-ARTERY-DISEASE; METABOLIC SYNDROME; GLUCOSE DISPOSAL; ENDOGENOUS ANDROGENS; HORMONE AGONIST; HEART-DISEASE; SERUM; SUPPRESSION; SECRETION AB Objective: To determine whether insulin sensitizers lower androgen levels and whether androgen suppression improves insulin resistance in nondiabetic postmenopausal women. Design: Randomized, double-blind, placebo-controlled study. Setting: Clinical and Translational Research Center of a university hospital. Patient(s): Thirty-five postmenopausal women aged 50-79 years with insulin resistance and higher T levels. Intervention(s): Subjects were randomized to metformin plus leuprolide acetate (LA) placebo, LA plus metformin placebo, or LA placebo plus metformin placebo in a 1: 1: 1 fashion during a 12-week period. Main Outcome Measure(s): Insulin sensitivity (M) assessed by euglycemic hyperinsulinemic clamp and free T by equilibrium dialysis. Result(s): In those randomized to metformin, free T decreased by 19% compared with placebo, along with an expected improvement in M. Total Talso decreased significantly, whereas sex hormone-binding globulin (SHBG) did not change. In those randomized to LA, the percent change in M was not different from placebo, despite a 48% relative decrease in free T levels. Conclusion(s): These data are the first to establish a causal link between insulin resistance and T in postmenopausal women. They confirm that treatment of insulin resistance decreases T production in this population and demonstrate that pharmacologic lowering of T does not affect insulin resistance. (Fertil Steril (R) 2010; 94: 2161-6. (C) 2010 by American Society for Reproductive Medicine.) C1 [Patel, Shrita M.; Kaul, Shailja; Rickels, Michael R.; Scattergood, Theresa; Basu, Arpita; Fuller, Carissa; Cappola, Anne R.] Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA. [Patel, Shrita M.; Ratcliffe, Sarah J.; Cappola, Anne R.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Iqbal, Nayyar] Univ Penn, Sch Med, Sect Endocrinol Diabet & Metab, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Reilly, Muredach P.] Univ Penn, Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA. RP Cappola, AR (reprint author), Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, 764 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA. EM acappola@mail.med.upenn.edu RI Perez , Claudio Alejandro/F-8310-2010 OI Perez , Claudio Alejandro/0000-0001-9688-184X; Ratcliffe, Sarah/0000-0002-6644-8284 FU National Institute on Aging [K23 AG19161]; National Center for Research Resources [UL1RR024134]; National Institute of Diabetes and Digestive and Kidney Diseases [P30 DK19525]; John A. Hartford Foundation; University of Pennsylvania Institute for Diabetes, Obesity, and Metabolism FX Supported by K23 AG19161 from the National Institute on Aging, UL1RR024134 from the National Center for Research Resources, P30 DK19525 from the National Institute of Diabetes and Digestive and Kidney Diseases, the John A. Hartford Foundation, and the University of Pennsylvania Institute for Diabetes, Obesity, and Metabolism. The views expressed are those of the authors and do not necessarily represent the official views of the National Institutes of Health. NR 31 TC 12 Z9 12 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD NOV PY 2010 VL 94 IS 6 BP 2161 EP 2166 DI 10.1016/j.fertnstert.2010.01.064 PG 6 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 670QC UT WOS:000283441400042 PM 20226444 ER PT J AU Zhang, YQ Zhang, HM Shi, Y Lustgarten, M Li, Y Qi, WB Zhang, BX Van Remmen, H AF Zhang, Yiqiang Zhang, Hong-Mei Shi, Yun Lustgarten, Michael Li, Yan Qi, Wenbo Zhang, Bin-Xian Van Remmen, Holly TI Loss of manganese superoxide dismutase leads to abnormal growth and signal transduction in mouse embryonic fibroblasts SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE MnSOD; Oxidative stress; ROS; Signal transduction; Free radicals ID REACTIVE OXYGEN; OXIDATIVE STRESS; MITOCHONDRIAL-FUNCTION; KNOCKOUT MICE; MUTANT MICE; LIFE-SPAN; MAMMALIAN TARGET; FREE-RADICALS; CELLS; CA2+ AB Manganese superoxide dismutase (MnSOD) in the mitochondria plays an important role in cellular defense against oxidative damage. Homozygous MnSOD knockout (Sod2(-/-)) mice are neonatal lethal, indicating the essential role of MnSOD in early development. To investigate the potential cellular abnormalities underlying the aborted development of Sod2(-/-) mice, we examined the growth of isolated mouse embryonic fibroblasts (MEFs) from Sod2(-/-) mice. We found that the proliferation of Sod2(-/-) MEFs was significantly decreased compared with wild-type MEFs despite the absence of morphological differences. The Sod2(-/-) MEFs produced less cellular ATP, had lower O(2) consumption, generated more superoxide, and expressed less Prdx3 protein. Furthermore, the loss of MnSOD dramatically altered several markers involved in cell proliferation and growth, including decreased growth stimulatory function of mTOR signaling and enhanced growth inhibitory function of GSK-3 beta signaling. Interestingly, the G-protein-coupled receptor-mediated intracellular Ca(2+) signal transduction was also severely suppressed in Sod2(-/-) MEFs. Finally, the ratio of microtubule-associated protein light chain 3 (LC3)-II/LC3-I, an index of autophagic activity, was increased in Sod2(-/-)MEFs, consistent with a reduction in mTOR signal transduction. These data demonstrate that MnSOD deficiency results in alterations in several key signaling pathways, which may contribute to the lethal phenotype of Sod2(-/-) mice. Published by Elsevier Inc. C1 [Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Zhang, Yiqiang; Shi, Yun; Lustgarten, Michael; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Zhang, Yiqiang; Li, Yan; Qi, Wenbo; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Zhang, Yiqiang; Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Zhang, Hong-Mei; Zhang, Bin-Xian] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Zhang, Hong-Mei] Fourth Mil Med Univ, Dept Clin Oncol, Xijing Hosp, Xian 710032, Peoples R China. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. EM vanremmen@uthscsa.edu FU Department of Veterans Affairs FX The authors thank Corinne Price for help in editing the manuscript. This study was supported by a Department of Veterans Affairs Merit Grant to H.V.R. NR 65 TC 30 Z9 31 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD NOV 1 PY 2010 VL 49 IS 8 BP 1255 EP 1262 DI 10.1016/j.freeradbiomed.2010.07.006 PG 8 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 654YN UT WOS:000282207300001 PM 20638473 ER PT J AU Schreiner, MA Weiss, DG Lieberman, DA AF Schreiner, Mitchal A. Weiss, David G. Lieberman, David A. TI Proximal and Large Hyperplastic and Nondysplastic Serrated Polyps Detected by Colonoscopy Are Associated With Neoplasia SO GASTROENTEROLOGY LA English DT Article DE Serrated Polyps; Hyperplastic Polyps; Colon Surveillance; Advanced Neoplasia ID CPG ISLAND METHYLATION; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; KRAS MUTATIONS; RISK-FACTORS; ADENOMAS; BRAF; SURVEILLANCE; PREVALENCE; PATHWAYS AB BACKGROUND & AIMS: The family of serrated lesions includes hyperplastic polyps and sessile serrated adenomas without dysplasia, as well as traditional serrated adenoma with dysplasia. We investigated whether detection of proximal nondysplastic serrated polyps (ND-SP) at screening and surveillance colonoscopies is associated with advanced neoplasia. METHODS: The study included 3121 asymptomatic patients (aged 50-75 years) who had screening colonoscopies; 1371 had subsequent surveillance. The proximal colon was defined as segments proximal to the descending colon. Large ND-SP were defined as > 10 mm. We compared rates of detection of any neoplasia and advanced neoplasia at screening and surveillance colonoscopies (within 5.5 years) in patients with and without proximal or large ND-SP. RESULTS: At baseline screening, 248 patients (7.9%) had at least 1 proximal ND-SP. They were more likely than patients with no proximal ND-SP to have advanced neoplasia (17.3% vs 10.0%; odds ratio [OR], 1.90; 95% confidence interval [CI], 1.33-2.70). Patients with large ND-SP (n = 44) were also more likely to have synchronous advanced neoplasia (OR, 3.37; 95% CI, 1.71-6.65). During surveillance, 39 patients with baseline proximal ND-SP and no neoplasia were more likely to have neoplasia compared with subjects who did not have polyps (OR, 3.14; 95% CI, 1.59-6.20). Among patients with advanced neoplasia at baseline, those with proximal ND-SP (n = 43) were more likely to have advanced neoplasia during surveillance (OR, 2.17; 95% CI, 1.03-4.59). CONCLUSIONS: Detection of proximal and large ND-SP at a screening colonoscopy is associated with an increased risk for synchronous advanced neoplasia. Detection of proximal ND-SP in a baseline colonoscopy is associated with an increased risk for interval neoplasia during surveillance. C1 [Schreiner, Mitchal A.; Lieberman, David A.] Portland VA Med Ctr, Portland, OR 97239 USA. [Schreiner, Mitchal A.; Lieberman, David A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Weiss, David G.] Perry Point VA Med Ctr, Perry Point, MD USA. RP Lieberman, DA (reprint author), Portland VA Med Ctr, P3 GI,1037 SW Vet Hosp Rd, Portland, OR 97239 USA. EM lieberma@ohsu.edu FU Department of Veterans Affairs [380] FX Supported by the Department of Veterans Affairs Cooperative Study Program (#380) and the Department of Veterans Affairs with statistical support for the study (DGW). NR 29 TC 116 Z9 117 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD NOV PY 2010 VL 139 IS 5 BP 1497 EP 1502 DI 10.1053/j.gastro.2010.06.074 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 673HW UT WOS:000283651100024 PM 20633561 ER PT J AU Egede, LE Grubaugh, AL Ellis, C AF Egede, Leonard E. Grubaugh, Anouk L. Ellis, Charles TI The effect of major depression on preventive care and quality of life among adults with diabetes SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE Major depression; Preventive care; Quality of life; Adults with diabetes ID RISK-FACTOR SURVEY; SELF-CARE; MEDICATION ADHERENCE; COMORBID DEPRESSION; GLYCEMIC CONTROL; US ADULTS; TYPE-2; METAANALYSIS; INDIVIDUALS; SYMPTOMS AB Objective: To examine the association between major depression and preventive care practices and quality-of-life indices among adults with diabetes. Methods: Data from 16,754 participants with diabetes in the 2006 Behavioral Risk Factor Surveillance Survey were examined. Multiple logistic regression was used to assess the independent association between the presence of major depression and a range of (1) preventive care behaviors and (2) quality-of-life indices, after accounting for relevant covariates. Results: With regard to preventive care practices, women with major depression were less likely to have received a mammogram in the past 2 years [OR 0.60 (95% Cl 0.45-0.79) for women age 40 years and older and OR 0.52 (95% Cl 0.37-0.71) for women age 50 and older] relative to their counterparts without major depression. With regard to quality-of-life indices, individuals with major depression were less likely to perceive their health as good [OR 0.24 (95% Cl 0.19-0.31)], to report being satisfied with life [OR 0.10 (95% Cl 0.07-0.14)] and to report receiving needed social support [OR 0.29 (95% Cl 0.22-0.38)] relative to individuals without major depression. Individuals with major depression were also more likely to report one or more poor physical and poor mental health days in the past 30 days [OR 4.36 (95% Cl 3.33-5.72) and OR 9.77 (95% Cl 7.81-12.22), respectively] than those without major depression. Conclusions: Major depression in adults with diabetes is associated with decreases in a wide range of quality-of-life indices as well as preventive self-care practices that were not entirely limited to diabetes-specific disease management. (c) 2010 Elsevier Inc. All rights reserved. C1 [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Grubaugh, Anouk L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Ellis, Charles] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Egede, Leonard E.; Grubaugh, Anouk L.; Ellis, Charles] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. EM egedel@musc.edu FU SC HSRD [REA 08-261]; Veterans Health Administration Health Services Research and Development program [07-015-2, 07-012-3] FX This work represents work supported by the use of facilities at the Charleston, SC HSR&D Funded Center for Disease Prevention and Health Interventions for Diverse Populations (REA 08-261).; Dr. Grubaugh and Dr. Ellis are both supported by a career development award (CDA2 #07-015-2 and CDA #07-012-3, respectively) from the Veterans Health Administration Health Services Research and Development program. NR 42 TC 22 Z9 23 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD NOV-DEC PY 2010 VL 32 IS 6 BP 563 EP 569 DI 10.1016/j.genhosppsych.2010.08.002 PG 7 WC Psychiatry SC Psychiatry GA 693PC UT WOS:000285235000001 PM 21112446 ER PT J AU Scheuner, MT McNeel, TS Freedman, AN AF Scheuner, Maren T. McNeel, Timothy S. Freedman, Andrew N. TI Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview Survey SO GENETICS IN MEDICINE LA English DT Article DE family history; cancer; hereditary cancer syndrome; prevalence of familial risk ID NONPOLYPOSIS COLORECTAL-CANCER; LYNCH-SYNDROME; OVARIAN-CANCER; HISTORY; RISK; PREVENTION; REGISTRIES; CRITERIA AB Purpose: Family history guides cancer prevention and genetic testing. We sought to estimate the population prevalence of increased familial risk for breast, ovarian, endometrial, prostate, and colorectal cancers and hereditary cancer syndromes that include these cancers. Methods: Using the 2005 California Health Interview Survey data, a weak, moderate, or strong familial cancer risk was assigned to 33,187 respondents. Guidelines were applied to identify individuals with hereditary breast-ovarian cancer and hereditary nonpolyposis colon cancer. Results: Among respondents without a personal history of cancer, familial breast cancer was most prevalent; 7% had a moderate and 5% a strong familial risk. Older individuals and women were more likely to report family history of cancer. Generally, whites had the highest prevalence, and Asians and Latinos had the lowest prevalence. Among women without a personal history of breast or ovarian cancer, 2.5% met criteria for hereditary breast-ovarian cancer, and among individuals without a personal history of colorectal, endometrial or ovarian cancer, 1.1% met criteria for hereditary nonpolyposis colon cancer. Conclusions: We provide population-based prevalence estimates for moderate and strong familial risk for five common cancers and hereditary breast-ovarian cancer and hereditary nonpolyposis colon cancer. Such estimates are helpful in planning and evaluation of genetic services and prevention programs, and assessment of cancer surveillance and prevention strategies. Genet Med 2010:12(11):726-735. C1 [Scheuner, Maren T.] RAND Corp, Santa Monica, CA USA. [Scheuner, Maren T.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Scheuner, Maren T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [McNeel, Timothy S.] Informat Management Serv Inc, Silver Spring, MD USA. [Freedman, Andrew N.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. RP Scheuner, MT (reprint author), 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM scheuner@rand.org FU National Cancer Institute at the National Institutes of Health FX This work was supported by a contract from the National Cancer Institute at the National Institutes of Health. NR 25 TC 31 Z9 31 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD NOV PY 2010 VL 12 IS 11 BP 726 EP 735 DI 10.1097/GIM.0b013e3181f30e9e PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 678UD UT WOS:000284105800010 PM 20921897 ER PT J AU Paintlia, AS Paintlia, MK Singh, AK Orak, JK Singh, I AF Paintlia, Ajaib S. Paintlia, Manjeet K. Singh, Avtar K. Orak, John K. Singh, Inderjit TI Activation of PPAR-gamma and PTEN Cascade Participates in Lovastatin-Mediated Accelerated Differentiation of Oligodendrocyte Progenitor Cells SO GLIA LA English DT Article DE lovastatin; EAE/MS; oligodendrocyte progenitors; PPAR-gamma/PTEN; RhoA-ROCK; differentiation; remyelination ID CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; COA REDUCTASE INHIBITOR; MULTIPLE-SCLEROSIS; GENE-EXPRESSION; PROTEIN-KINASE; IN-VITRO; CYCLE PROGRESSION; GROWTH-ARREST; GLIAL-CELLS AB Previously, we and others documented that statins including-lovastatin (LOV) promote the differentiation of oligodendrocyte progenitor cells (OPCs) and remyelination in experimental autoimmune encephalomyelitis (EAE), an multiple sclerosis (MS) model. Conversely, some recent studies demonstrated that statins negatively influence oligodendrocyte (OL) differentiation in vitro and remyelination in a cuprizone-CNS demyelinating model. Therefore, herein, we first investigated the cause of impaired differentiation of OLs by statins in vitro settings. Our observations indicated that the depletion of cholesterol was detrimental to LOV treated OPCs under cholesterol/serum-deprived culture conditions similar to that were used in conflicting studies. However, the depletion of geranylgeranyl-pp under normal cholesterol homeostasis conditions enhanced the phenotypic commitment and differentiation of LOV-treated OPCs ascribed to inhibition of RhoA-Rho kinase. Interestingly, this effect of LOV was associated with increased activation and expression of both PPAR-g and PTEN in OPCs as confirmed by various pharmacological and molecular based approaches. Furthermore, PTEN was involved in an inhibition of OPCs proliferation via PI3K-Akt inhibition and induction of cell cycle arrest at G1 phase, but without affecting their cell survival. These effects of LOV on OPCs in vitro were absent in the CNS of normal rats chronically treated with LOV concentrations used in EAE indicating that PPAR-g induction in normal brain may be tightly regulated-providing evidences that statins are therapeutically safe for humans. Collectively, these data provide initial evidence that statin-mediated activation of the PPAR-gamma-PTEN cascade participates in OL differentiation, thus suggesting new therapeutic-interventions for MS or related CNS-demyelinating diseases. (C) 2010 Wiley-Liss, Inc. C1 [Paintlia, Ajaib S.; Paintlia, Manjeet K.; Orak, John K.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, 173 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu OI Paintlia, Ajaib/0000-0003-4525-5333 FU NIH [NS-22576, NS-34741, NS-37766, NS-038236]; Dialysis Clinic Inc. [C06-RR015455, C06-RR018823] FX Grant sponsor: NIH; Grant numbers: NS-22576, NS-34741, NS-37766, and NS-038236; Contract grant sponsor: Dialysis Clinic Inc.; Contract grant numbers: C06-RR015455 and C06-RR018823. NR 57 TC 24 Z9 25 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-1491 J9 GLIA JI Glia PD NOV PY 2010 VL 58 IS 14 BP 1669 EP 1685 DI 10.1002/glia.21039 PG 17 WC Neurosciences SC Neurosciences & Neurology GA 664VH UT WOS:000282990600003 PM 20578043 ER PT J AU Peterson, ED Roe, MT Chen, AY Fonarow, GC Lytle, BL Cannon, CP Rumsfeld, JS AF Peterson, Eric D. Roe, Matthew T. Chen, Anita Y. Fonarow, Gregg C. Lytle, Barbara L. Cannon, Christopher P. Rumsfeld, John S. TI The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care SO HEART LA English DT Database Review ID ACUTE CORONARY SYNDROMES; INTERVENTION OUTCOMES NETWORK; RAPID RISK STRATIFICATION; QUALITY IMPROVEMENT; ST-ELEVATION; EARLY IMPLEMENTATION; ACC/AHA GUIDELINES; WRITING COMMITTEE; AMERICAN-COLLEGE; ADVERSE OUTCOMES AB Aims The NCDR ACTION Registry-GWTG collects detailed in-hospital clinical, process-of-care and outcomes data for patients admitted with acute myocardial infarction (AMI) in the USA. The registry is a national AMI surveillance system that contributes to the scientific enquiry process of AMI care through the facilitation of local and national quality improvement efforts. Interventions No treatments are mandated, participating centres receive routine quality-of-care and outcomes performance feedback reports and access to quality of care tools, such as dosing algorithms and standing orders. Population AMI patients are retrospectively identified. No informed consent is required, as data are anonymised. From January 2007 to date, 147 165 records have been submitted from 383 participating US hospitals. Patients with a primary diagnosis of ST-segment elevation myocardial infarction or non-ST-segment elevation myocardial infarction are eligible for enrolment in the registry. These patients must have ischemic symptoms and electrocardiogram changes, and/or positive cardiac markers within 24 hours of initial presentation. Baseline data Approximately 350 fields encompassing patient demographics, medical history and risk factors, hospital presentation, initial cardiac status, medications and associated doses, reperfusion strategy, procedures, laboratory values, and outcomes. Data are manually entered by study personnel; there are non-financial incentives at the hospital level. Completeness within the registry is noteworthy with most fields at less than 5% missing. Endpoints Main outcome measures include American College of Cardiology/American Heart Association myocardial infarction performance indicators, as well as in-hospital patient outcomes. Data are available for research by application to: http://www.ncdr.com. C1 [Peterson, Eric D.; Roe, Matthew T.; Chen, Anita Y.; Lytle, Barbara L.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. [Cannon, Christopher P.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Peterson, ED (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA. EM peter016@mc.duke.edu FU Society of Chest Pain Centers; Society of Hospital Medicine; American College of Emergency Physicians; Bristol-Myers Squibb/Sanofi Pharmaceuticals; Schering-Plough Corporation; Agency for Healthcare Research and Quality (AHRQ) [U18HS016964] FX The ACTION Registry-GWTG is an initiative of the American College of Cardiology Foundation and the American Heart Association, with partnering support from the Society of Chest Pain Centers, the Society of Hospital Medicine and the American College of Emergency Physicians. The registry is sponsored by the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership and Schering-Plough Corporation. This project was supported by grant number U18HS016964 from the Agency for Healthcare Research and Quality (AHRQ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the AHRQ. The funding source had no role in the design or implementation of the study, or in the decision to seek publication. NR 17 TC 57 Z9 61 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1355-6037 J9 HEART JI Heart PD NOV PY 2010 VL 96 IS 22 BP 1798 EP 1802 DI 10.1136/hrt.2010.200261 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 668VC UT WOS:000283298700004 PM 20736202 ER PT J AU Golden-Mason, L Cox, AL Randall, JA Cheng, LL Rosen, HR AF Golden-Mason, Lucy Cox, Andrea L. Randall, Jessica A. Cheng, Linling Rosen, Hugo R. TI Increased Natural Killer Cell Cytotoxicity and NKp30 Expression Protects Against Hepatitis C Virus Infection in High-Risk Individuals and Inhibits Replication In Vitro SO HEPATOLOGY LA English DT Article ID CD56(+) T-CELLS; NK CELLS; ACTIVATING RECEPTOR; CYTOLYTIC FUNCTION; HUMAN HEPATOCYTES; PERIPHERAL-BLOOD; ENVELOPE PROTEIN; HCV INFECTION; CORE PROTEIN; FREQUENCY AB CD56(pos) natural killer (NK)/natural T (NT) cells are important innate effectors providing the first line of defense against viral infection. Enhanced NK activity has been shown to protect from human immunodeficiency virus-1 infection. However, the role played by these innate effectors in protection against or development of hepatitis C virus (HCV) infection is unknown. We characterized CD56(pos) populations in 11 injection drug users (IDUs) who remained uninfected despite being repeatedly exposed to HCV. NK profiles in exposed but uninfected (EU) individuals were compared with preinfection samples (median 90 days prior to HCV seroconversion) collected from 14 IDUs who were exposed and subsequently became infected (EI) and unexposed normal control subjects (n = 8). Flow cytometric analysis of CD56(pos) populations demonstrated that EUs had a higher proportion of CD56(low) mature (P = 0.0011) NK cells compared with El subjects. Bead-isolated NKs (>90% purity) from EUs had significantly higher interleukin-2 (IL-2) induced cytolytic activity against the NK-sensitive cell line K562 at an effector-to-target ratio of 10:1 (P < 0.0001). NKp30, a natural cytotoxicity receptor involved in NK activation, is highest on NK/NT cells in EUs relative to infected subjects. Using the JFH-1 infection system, we demonstrated that NKp30(high) cells in the absence of exogenous stimulation significantly reduce infection of hepatocytes. Conclusion: CD56(pos) populations in EUs are enriched for effector NKs displaying enhanced IL-2 induced cytolytic activity and higher levels of the natural cytotoxicity receptor NKp30-activating receptor. In addition, NKp30(high) cells are more effective in preventing infection of Huh-7.5 cells than their NKp30(low/neg) counterparts. These data support the hypothesis that NK cells contribute to anti-HCV defense in vivo in the earliest stages of infection, providing innate protection from HCV acquisition. (HEPATOLOGY 2010;52:1581-1589) C1 [Golden-Mason, Lucy; Randall, Jessica A.; Cheng, Linling; Rosen, Hugo R.] Univ Colorado, Dept Med, Div GI Hepatol, Aurora, CO 80045 USA. [Golden-Mason, Lucy; Rosen, Hugo R.] Univ Colorado, Integrated Dept Immunol, Denver, CO 80202 USA. [Golden-Mason, Lucy; Rosen, Hugo R.] Natl Jewish Hosp, Denver, CO USA. [Cox, Andrea L.] Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA. [Rosen, Hugo R.] Denver VA Med Ctr, Denver, CO USA. RP Rosen, HR (reprint author), Univ Colorado, Dept Med, Div GI Hepatol, Acad Off Bldg 1,12631 E 17th Ave B-158, Aurora, CO 80045 USA. EM hugo.rosen@ucdenver.edu FU National Institutes of Health [U19 AI40035, RO1 DK060590, U19 A 1066328] FX Supported by National Institutes of Health Grants U19 AI40035 (to A. L. C.) and RO1 DK060590 and U19 A 1066328 (HCV center grant; to H. R. R.). NR 43 TC 58 Z9 60 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD NOV PY 2010 VL 52 IS 5 BP 1581 EP 1589 DI 10.1002/hep.23896 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 674RH UT WOS:000283764800008 PM 20812318 ER PT J AU Lo, M Murray, GL Khoo, CA Haake, DA Zuerner, RL Adler, B AF Lo, Miranda Murray, Gerald L. Khoo, Chen Ai Haake, David A. Zuerner, Richard L. Adler, Ben TI Transcriptional Response of Leptospira interrogans to Iron Limitation and Characterization of a PerR Homolog SO INFECTION AND IMMUNITY LA English DT Article ID FERRIC CITRATE TRANSPORT; OUTER-MEMBRANE PROTEINS; ESCHERICHIA-COLI; PATHOGENIC LEPTOSPIRA; BACILLUS-SUBTILIS; FUR HOMOLOGS; SEROVAR LAI; NEISSERIA-MENINGITIDIS; BINDING PROTEIN; VIRULENCE GENES AB Leptospirosis is a globally significant zoonosis caused by Leptospira spp. Iron is essential for growth of most bacterial species. Since iron availability is low in the host, pathogens have evolved complex iron acquisition mechanisms to survive and establish infection. In many bacteria, expression of iron uptake and storage proteins is regulated by Fur. L. interrogans encodes four predicted Fur homologs; we have constructed a mutation in one of these, la1857. We conducted microarray analysis to identify iron-responsive genes and to study the effects of la1857 mutation on gene expression. Under iron-limiting conditions, 43 genes were upregulated and 49 genes were downregulated in the wild type. Genes encoding proteins with predicted involvement in inorganic ion transport and metabolism (including TonB-dependent proteins and outer membrane transport proteins) were overrepresented in the upregulated list, while 54% of differentially expressed genes had no known function. There were 16 upregulated genes of unknown function which are absent from the saprophyte L. biflexa and which therefore may encode virulence-associated factors. Expression of iron-responsive genes was not significantly affected by mutagenesis of la1857, indicating that LA1857 is not a global regulator of iron homeostasis. Upregulation of heme biosynthetic genes and a putative catalase in the mutant suggested that LA1857 is more similar to PerR, a regulator of the oxidative stress response. Indeed, the la1857 mutant was more resistant to peroxide stress than the wild type. Our results provide insights into the role of iron in leptospiral metabolism and regulation of the oxidative stress response, including genes likely to be important for virulence. C1 [Lo, Miranda; Murray, Gerald L.; Khoo, Chen Ai; Adler, Ben] Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. [Zuerner, Richard L.] USDA ARS, Infect Bacterial Dis Res Unit, Natl Anim Dis Ctr, Ames, IA 50010 USA. [Adler, Ben] Monash Univ, Australian Res Council, Ctr Excellence Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia. [Adler, Ben] Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia. RP Adler, B (reprint author), Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia. EM Ben.Adler@med.monash.edu.au FU National Health and Medical Research Council; Australian Research Council, Canberra, Australia; National Institute of Allergy and Infectious Diseases [AI-34431]; VA Medical Research Funds FX This work was supported by the National Health and Medical Research Council and the Australian Research Council, Canberra, Australia (to B.A.), by Public Health Service grant AI-34431 from the National Institute of Allergy and Infectious Diseases (to D.A.H.), and by VA Medical Research Funds (to D.A.H.). G.L.M. is the recipient of a NHMRC Peter Doherty Fellowship. NR 73 TC 30 Z9 31 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD NOV PY 2010 VL 78 IS 11 BP 4850 EP 4859 DI 10.1128/IAI.00435-10 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 665RB UT WOS:000283052100044 PM 20805337 ER PT J AU Lee, BY Wiringa, AE Bailey, RR Goyal, V Tsui, B Lewis, GJ Muder, RR Harrison, LM AF Lee, Bruce Y. Wiringa, Ann E. Bailey, Rachel R. Goyal, Vishal Tsui, Becky Lewis, G. Jonathan Muder, Robert R. Harrison, Lee M. TI The Economic Effect of Screening Orthopedic Surgery Patients Preoperatively for Methicillin-Resistant Staphylococcus aureus SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID HOSPITAL-ACQUIRED INFECTION; JOINT-REPLACEMENT SURGERY; NASAL CARRIAGE; COLONIZATION; MRSA; PNEUMONIA; MUPIROCIN; MORTALITY; EPIDEMIOLOGY; SURVEILLANCE AB BACKGROUND AND OBJECTIVE. Patients undergoing orthopedic surgery are susceptible to methicillin-resistant Staphylococcus aureus (MRSA) infections, which can result in increased morbidity, hospital lengths of stay, and medical costs. We sought to estimate the economic value of routine preoperative MRSA screening and decolonization of orthopedic surgery patients. METHODS. A stochastic decision-analytic computer simulation model was used to evaluate the economic value of implementing this strategy (compared with no preoperative screening or decolonization) among orthopedic surgery patients from both the third-party payer and hospital perspectives. Sensitivity analyses explored the effects of varying MRSA colonization prevalence, the cost of screening and decolonization, and the probability of decolonization success. RESULTS. Preoperative MRSA screening and decolonization was strongly cost-effective (incremental cost-effectiveness ratio less than $6,000 per quality-adjusted life year) from the third-party payer perspective even when MRSA prevalence was as low as 1%, decolonization success was as low as 25%, and decolonization costs were as high as $300 per patient. In most scenarios this strategy was economically dominant (ie, less costly and more effective than no screening). From the hospital perspective, preoperative MRSA screening and decolonization was the economically dominant strategy for all scenarios explored. CONCLUSIONS. Routine preoperative screening and decolonization of orthopedic surgery patients may under many circumstances save hospitals and third-party payers money while providing health benefits. Infect Control Hosp Epidemiol 2010; 31(11): 1130-1138 C1 [Lee, Bruce Y.] Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR Grp, Publ Hlth Computat & Operat Res PHICOR, Pittsburgh, PA 15213 USA. [Lee, Bruce Y.; Wiringa, Ann E.; Bailey, Rachel R.; Goyal, Vishal; Tsui, Becky; Lewis, G. Jonathan] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA 15213 USA. [Lee, Bruce Y.; Wiringa, Ann E.; Bailey, Rachel R.; Goyal, Vishal; Tsui, Becky; Lewis, G. Jonathan] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Harrison, Lee M.] Univ Pittsburgh, Infect Dis Epidemiol Res Unit, Sch Med, Pittsburgh, PA 15213 USA. [Muder, Robert R.] Vet Affairs Pittsburgh Hlth Syst, Div Infect Dis, Pittsburgh, PA USA. RP Lee, BY (reprint author), Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR Grp, Publ Hlth Computat & Operat Res PHICOR, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA. EM byl1@pitt.edu OI Slayton, Rachel/0000-0003-4699-8040 FU National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) [U01-GM070708-05]; Pennsylvania Department of Health FX National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) through grant U01-GM070708-05 and the Pennsylvania Department of Health. NR 62 TC 17 Z9 19 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD NOV PY 2010 VL 31 IS 11 BP 1130 EP 1138 DI 10.1086/656591 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 675OV UT WOS:000283840900006 PM 20923285 ER PT J AU Shi, Y Buffenstein, R Pulliam, DA Van Remmen, H AF Shi, Yun Buffenstein, Rochelle Pulliam, Daniel A. Van Remmen, Holly TI Comparative Studies of Oxidative Stress and Mitochondrial Function in Aging SO INTEGRATIVE AND COMPARATIVE BIOLOGY LA English DT Article; Proceedings Paper CT Annual Meeting of the Society-for-Integrative-and-Comparative-Biology CY JAN 03-07, 2010 CL Seattle, WA SP Soc Integrat & Comparat Biol ID HYDROGEN-PEROXIDE PRODUCTION; FREE-RADICAL PRODUCTION; LONGEST-LIVING RODENT; MAXIMUM LIFE-SPAN; NAKED MOLE-RAT; BUTYL-ALPHA-PHENYLNITRONE; HUMAN SKELETAL-MUSCLE; AGE-RELATED-CHANGES; SHORT-LIVED RAT; PROTEIN OXIDATION AB The oxidative stress theory and its correlate the mitochondrial theory of aging are among the most studied and widely accepted of all hypotheses of the mechanism of aging. To date, most of the supporting evidence for these theories has come from investigations using common model organisms such as Caenorhabditis elegans, Drosophila melanogaster, and laboratory rodents. However, comparative data from a wide range of endotherms provide equivocal support as to whether oxidative stress is merely a correlate, rather than a determinant, of species' maximum lifespan. The great majority of studies in this area have been devoted to the relationship between reactive oxygen species and maximal longevity in young adult organisms, with little emphasis on mitochondrial respiratory efficiency, age-related alterations in mitochondrial physiology or oxidative damage. The advantage of studying a broader spectrum of species is the broad range of virtually every biological phenotype/ trait, such as lifespan, body weight and metabolic rate. Here we summarize the results from a number of comparative studies in an effort to correlate oxidant production and oxidative damage among many species with their maximal lifespan and briefly discuss the pitfalls and limitations. Based on current information, it is not possible to accept or dispute the oxidative stress theory of aging, nor can we exclude the possibility that private mechanisms might offer an explanation for the longevity of exceptionally long-lived animal models. Thus, there is need for more thorough and controlled investigations with more unconventional animal models for a deeper understanding of the role of oxidative stress in longevity. C1 [Shi, Yun; Buffenstein, Rochelle; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Shi, Yun; Buffenstein, Rochelle; Pulliam, Daniel A.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Buffenstein, Rochelle; Pulliam, Daniel A.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Van Remmen, Holly] S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX USA. RP Shi, Y (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. EM vanremmen@uthscsa.edu NR 71 TC 10 Z9 10 U1 1 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1540-7063 J9 INTEGR COMP BIOL JI Integr. Comp. Biol. PD NOV PY 2010 VL 50 IS 5 BP 869 EP 879 DI 10.1093/icb/icq079 PG 11 WC Zoology SC Zoology GA 673QM UT WOS:000283678100016 PM 21558246 ER PT J AU Zhao, SJ Wang, YB Cao, L Ouellette, MM Freeman, JW AF Zhao, Shujie Wang, Yubao Cao, Lin Ouellette, Michel M. Freeman, James W. TI Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE pancreatic cancer; cell signaling; K-ras; EGFR; TGF-beta; Smad4 ID EPIDERMAL-GROWTH-FACTOR; TGF-BETA; CANCER CELLS; ADENOCARCINOMA; PROGRESSION; METASTASIS; MUTATIONS; PATHWAYS; TRANSFORMATION; INACTIVATION AB Activating mutation of K-ras and inactivation of DPC4 are two common genetic alterations that occur in the development and progression of pancreatic ductal adenocarcinomas (PDAC). A separate common event in PDAC progression is increased expression of phosphotyrosine kinase receptors (PTKRs). In our study, we examined whether activating mutations of K-ras and loss of Smad4 play a role in causing the aberrant expression of PTKRs. Immortalized human pancreas ductal cells (HPNE) were genetically modified by expressing oncogenic K-ras and/or by shRNA knockdown of Smad4. EGFR and erbB2 protein levels but not Ron or IGF-1R were substantially upregulated in HPNE cells that express K-ras((GD12)). The increased expression of EGFR in HPNE cells that expressed K-ras((GD12)) was mediated by both stabilizing EGFR protein and by increasing EGFR transcription. TGF-beta signaling partially suppressed K-ras((GD12)) induced EGFR transcription in Smad4 intact HPNE cells; whereas knockdown of Smad4 in cells expressing K-ras((GD12)) further enhanced expression of EGFR and erbB2. The upregulation of EGFR and erbB2 was associated with an increase of invasion, which was blocked by a kinase inhibitor of EGFR. Our study indicates for the first time, that oncogenic ras and loss of Smad signaling cooperate to upregulate EGFR and erbB2, which plays a role in promoting invasion. C1 [Zhao, Shujie; Wang, Yubao; Cao, Lin; Freeman, James W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hematol & Oncol, San Antonio, TX 78229 USA. [Zhao, Shujie; Cao, Lin; Freeman, James W.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA. [Ouellette, Michel M.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst, Omaha, NE USA. RP Freeman, JW (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hematol & Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM freemanjw@uthscsa.edu FU NIH [R21CA125713, RO1CA069122]; VA Merit Award FX Grant sponsor: NIH; Grant numbers: R21CA125713, RO1CA069122; Grant sponsor: VA Merit Award NR 38 TC 17 Z9 17 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD NOV 1 PY 2010 VL 127 IS 9 BP 2076 EP 2087 DI 10.1002/ijc.25412 PG 12 WC Oncology SC Oncology GA 659AO UT WOS:000282539600009 PM 20473902 ER PT J AU Woo, BKP Harwood, DG Melrose, RJ Mandelkern, MA Campa, OM Walston, A Sultzer, DL AF Woo, Benjamin K. P. Harwood, Dylan G. Melrose, Rebecca J. Mandelkern, Mark A. Campa, Olivia M. Walston, Amy Sultzer, David L. TI Executive deficits and regional brain metabolism in Alzheimer's disease SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Alzheimer's disease; positron emission tomography; executive function ID AMERICAN-NEUROPSYCHIATRIC-ASSOCIATION; FUNCTIONAL IMPAIRMENT; PREFRONTAL CORTEX; FDG-PET; DYSFUNCTION; HYPOMETABOLISM; INVOLVEMENT; COMMITTEE; MEMORY; APATHY AB Objective: Executive deficits are common in patients with Alzheimer's disease (AD), contribute prominently to clinical disability, and may be associated with frontal lobe pathology. This study examined regional brain hypometabolism associated with executive dysfunction in patients with AD. Methods: Forty-one patients with probable AD underwent [(18)F] fluorodeoxyglucose positron emission tomography (FDG-PET) imaging at rest. Neuropsychological measures of executive control included the Conceptualization (Conc) and Initiation/Perseveration (TIP) subscales of the Mattis Dementia Rating Scale (DRS), the Wechsler Adult Intelligence Scale (WAIS) Similarities subtest, the Tower test, and the Ruff Figural Fluency test (Ruff). Voxel-based analyses were conducted using statistical parametric mapping (SPM2) to measure the correlation between regional cerebral metabolism and executive measures. Correlations independent of global cognitive impairment were identified by including Mini-Mental State Examination (MMSE) score as a covariate in the model. Results: Executive deficits, as measured by poor performances on the DRS I/P and Conc subscales, were associated with hypometabolism in the bilateral mid-dorsolateral frontal region. Activity in posterior cortical regions also contributed uniquely to some aspects of executive functioning, as lower resting metabolism in parietal or temporal cortex was correlated with poor performance on four of the five executive measures. After controlling for global cognitive score, there were significant extra-frontal correlations with hypometabolism in insula, occipital lobe, and temporal cortex. Conclusions: Some but not all executive deficits in AD are associated with neural activity in the dorsolateral frontal cortex. Activities in distributed neural systems that include parietal and temporal cortex also contribute to some executive abilities. The pathophysiology of executive dysfunction is complex and includes abnormalities not limited to a single region. Copyright (C) 2010 John Wiley & Sons, Ltd. C1 [Woo, Benjamin K. P.; Harwood, Dylan G.; Melrose, Rebecca J.; Walston, Amy; Sultzer, David L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Woo, Benjamin K. P.; Harwood, Dylan G.; Melrose, Rebecca J.; Campa, Olivia M.; Walston, Amy; Sultzer, David L.] Vet Affairs Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA USA. [Mandelkern, Mark A.] Vet Affairs Greater Los Angeles Healthcare Syst, Nucl Med Serv, Los Angeles, CA USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. RP Woo, BKP (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. EM bkpwoo@gmail.com OI Woo, Benjamin/0000-0002-0127-4850 FU National Institute of Mental Health [R01 MH56031]; Department of Veterans Affairs FX This work was supported by the National Institute of Mental Health (R01 MH56031) and by the Department of Veterans Affairs. NR 43 TC 15 Z9 16 U1 2 U2 7 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD NOV PY 2010 VL 25 IS 11 BP 1150 EP 1158 DI 10.1002/gps.2452 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 674RM UT WOS:000283765300008 PM 20069587 ER PT J AU Li, HK Hubbard, LD Danis, RP Esquivel, A Florez-Arango, JF Ferrier, NJ Krupinski, EA AF Li, Helen K. Hubbard, Larry D. Danis, Ronald P. Esquivel, Adol Florez-Arango, Jose F. Ferrier, Nicola J. Krupinski, Elizabeth A. TI Digital versus Film Fundus Photography for Research Grading of Diabetic Retinopathy Severity SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article; Proceedings Paper CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology CY MAY, 2008 CL Ft Lauderdale, FL SP Assoc Res Vision & Opthalmol ID DIAGNOSIS; PROGRAM; SYSTEM; CAMERA AB PURPOSE. To assess agreement between digital and film photography for research classification of diabetic retinopathy severity. METHODS. Digital and film photographs from a 152-eye cohort with a full spectrum of Early Treatment Diabetic Retinopathy Study (ETDRS) severity levels were assessed for repeatability of grading within each image medium and for agreement on ETDRS discrete severity levels, ascending severity thresholds, and presence or absence of diabetic retinopathy index lesions, between digital and 35-mm slides (film). Digital photographs were color balanced to match film. RESULTS. There was substantial agreement (kappa = 0.61, kappa(w) [linear weighted] = 0.87) in classification of ETDRS diabetic retinopathy severity levels between digital images and film. Marginal homogeneity analyses found no significant difference in frequency distributions on the severity scale (P = 0.21, Bhapkar test). The kappa results ranged from 0.72 to 0.95 for presence or absence of eight ascending diabetic retinopathy severity thresholds. Repeatability of grading between readers viewing digital images was equal to or better than that obtained with film (pair-wise interreader kappa for digital images ranged from 0.47 to 0.57 and for film from 0.43 to 0.57. The kappa results for identifying diabetic retinopathy lesions ranged from moderate to almost perfect. Moderate agreement of intraretinal microvascular abnormalities and venous beading between digital images and film accounted for slightly lower concordance for severity thresholds >= 47 and for slightly lower interreader agreement within digital and film images at severity thresholds >= 43 and >= 47. CONCLUSIONS. Under controlled circumstances, digital photography can equal the reliability of 35-mm slides for research classification of ETDRS severity level. (Invest Ophthalmol Vis Sci. 2010;51:5846-5852) DOI:10.1167/iovs.09-4803 C1 [Li, Helen K.; Florez-Arango, Jose F.] Univ Texas Hlth Sci Ctr, Sch Biomed Informat, Houston, TX USA. [Li, Helen K.] Thomas Jefferson Univ, Dept Ophthalmol, Philadelphia, PA 19107 USA. [Hubbard, Larry D.; Danis, Ronald P.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA. [Ferrier, Nicola J.] Univ Wisconsin, Dept Mech Engn, Madison, WI 53706 USA. [Ferrier, Nicola J.] Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA. [Esquivel, Adol] Houston Vet Affairs Med Ctr, Houston, TX USA. [Esquivel, Adol] Baylor Coll Med, Houston, TX 77030 USA. [Florez-Arango, Jose F.] Univ De Antioquia, Medellin, Colombia. [Krupinski, Elizabeth A.] Univ Arizona, Dept Radiol, Tucson, AZ 85724 USA. RP Li, HK (reprint author), Community Retina Grp, 1400 Hermann Dr, Houston, TX 77004 USA. EM hlimed@mac.com OI Florez-Arango, Jose F/0000-0001-9083-0195 NR 31 TC 9 Z9 9 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD NOV PY 2010 VL 51 IS 11 BP 5846 EP 5852 DI 10.1167/iovs.09-4803 PG 7 WC Ophthalmology SC Ophthalmology GA 672BQ UT WOS:000283558400057 PM 20484593 ER PT J AU Tien, PC Choi, AI Zolopa, AR Benson, C Tracy, R Scherzer, R Bacchetti, P Shlipak, M Grunfeld, C AF Tien, Phyllis C. Choi, Andy I. Zolopa, Andrew R. Benson, Constance Tracy, Russell Scherzer, Rebecca Bacchetti, Peter Shlipak, Michael Grunfeld, Carl TI Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study Cohort SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; inflammation; C-reactive protein; fibrinogen; mortality ID HUMAN-IMMUNODEFICIENCY-VIRUS; C-REACTIVE PROTEIN; ANTIRETROVIRAL THERAPY; CARDIOVASCULAR-DISEASE; GENERAL-POPULATION; FAT REDISTRIBUTION; METABOLIC-CHANGE; DEATH; ASSOCIATION; SURVIVAL AB Objective: To determine the association of inflammatory markers, fibrinogen, and C-reactive protein (CRP), with 5-year mortality risk. Methods: Vital status was ascertained in 922 HIV-infected participants from the Study of Fat Redistribution and Metabolic Change in HIV infection. Multivariable logistic regression estimated odds ratios after adjustment for demographic, cardiovascular, and HIV-related factors. Results: Over a 5-year period, HIV-infected participants with fibrinogen levels in the highest tertile (>406 mg/dL) had 2.6-fold higher adjusted odds of death than those with fibrinogen in the lowest tertile (<319 mg/dL). Those with high CRP (>3 mg/L) had 2.7-fold higher adjusted odds of death than those with CRP <1 mg/L. When stratified by CD4 count category, fibrinogen (as a linear variable) remained independently associated [odds ratio (95% confidence intervals)] per 100 mg/dL increase in fibrinogen: 1.93 (1.57 to 2.37); 1.43 (1.14 to 1.79); 1.43 (1.14 to 1.81); and 1.30 (1.04 to 1.63) for CD4 <200, 200-350, >350 to 500, and >500 cells per microliter, respectively. Higher CRP also remained associated with higher odds of death overall and within each CD4 subgroup. Conclusions: Fibrinogen and CRP are strong and independent predictors of mortality in HIV-infected adults. Our findings suggest that even in those with relatively preserved CD4 counts >500 cells per microliter, inflammation remains an important risk factor for mortality. Further investigation should determine whether interventions to reduce inflammation might decrease mortality risk in HIV-infected individuals. C1 [Tien, Phyllis C.] Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, San Francisco, CA 94121 USA. [Tien, Phyllis C.; Choi, Andy I.; Scherzer, Rebecca; Shlipak, Michael; Grunfeld, Carl] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Zolopa, Andrew R.] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Benson, Constance] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Tracy, Russell] Univ Vermont, Dept Pathol & Biochem, Colchester, VT USA. [Bacchetti, Peter] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. RP Tien, PC (reprint author), Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, 111W,4150 Clement St, San Francisco, CA 94121 USA. EM ptien@ucsf.edu FU National Institutes of Health (NIH) [R01-DK57508, HL74814, HL53359, K23-AI66943, DK080645]; NIH center [M01-RR00036, RR00051, RR00052, RR00054, RR00083, RR0636, RR00865, UL1 RR024131] FX Supported by National Institutes of Health (NIH) grants R01-DK57508, HL74814, and HL53359; K23-AI66943 and DK080645, and NIH center grants M01-RR00036, RR00051, RR00052, RR00054, RR00083, RR0636, RR00865, and UL1 RR024131. The funding agency had no role in the collection or analysis of the data. NR 26 TC 127 Z9 129 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2010 VL 55 IS 3 BP 316 EP 322 DI 10.1097/QAI.0b013e3181e66216 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 675RE UT WOS:000283847400007 PM 20581689 ER PT J AU Chen, D Lei, L Lu, CX Galaleldeen, A Hart, PJ Zhong, GM AF Chen, Ding Lei, Lei Lu, Chunxue Galaleldeen, Ahmad Hart, P. John Zhong, Guangming TI Characterization of Pgp3, a Chlamydia trachomatis Plasmid-Encoded Immunodominant Antigen SO JOURNAL OF BACTERIOLOGY LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; HUMAN-ANTIBODY RESPONSES; OUTER-MEMBRANE PROTEIN; SECRETED PROTEASE; INFECTED CELLS; INHIBITION; ACTIVATION; DIFFERENTIATION; IDENTIFICATION; PURIFICATION AB Human antibody recognition of Chlamydia trachomatis plasmid-encoded Pgp3 protein is dependent on the native conformation of Pgp3. The structural basis for the conformation dependence and the function of Pgp3 remain unknown. Here, we report that Pgp3 trimerization is required for the recognition of Pgp3 by human antibodies. In a native polyacrylamide gel, Pgp3 purified from a bacterial expression system migrated as stable trimers that were dissociated into monomers only by treatment with urea or sodium dodecyl sulfate (SDS) but not nonionic detergents. Human antibodies recognized trimeric but not monomeric Pgp3, suggesting that Pgp3 is presented to the human immune system as trimers during C. trachomatis infection. The endogenous Pgp3 secreted into the chlamydial outer membrane complex or host cell cytosol is always trimerized. Intact Pgp3 trimers were eluted from the outer membrane complex by a combination of nonionic detergents with reducing agents but not by the presence of either alone. These observations have provided important information for further understanding the role of Pgp3 in chlamydial pathogenesis and potentially optimizing Pgp3 as a subunit vaccine candidate antigen. C1 [Chen, Ding; Lei, Lei; Lu, Chunxue; Zhong, Guangming] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Galaleldeen, Ahmad; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Hart, P. John] US Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Zhong, GM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM Zhongg@UTHSCSA.EDU RI Lei, Lei/I-3002-2013 FU U.S. National Institutes of Health; Robert A. Welch Foundation [AQ-1399]; Office of the Vice President for Research at the University of Texas Health Science Center FX This work was supported in part by grants (to G. Zhong) from the U.S. National Institutes of Health and from the Robert A. Welch Foundation (grant AQ-1399 to P. J. Hart). Support for the Center for Analytical Ultracentrifugation of Macromolecular Assemblies by the Office of the Vice President for Research at the University of Texas Health Science Center is also gratefully acknowledged. NR 47 TC 12 Z9 18 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD NOV PY 2010 VL 192 IS 22 BP 6017 EP 6024 DI 10.1128/JB.00847-10 PG 8 WC Microbiology SC Microbiology GA 672BZ UT WOS:000283559300018 PM 20851898 ER PT J AU Wijelath, E Kohler, TR Murray, J Namekata, M Yagi, M Sobel, M AF Wijelath, Errol Kohler, Ted R. Murray, Jacqueline Namekata, Mayumi Yagi, Mayumi Sobel, Michael TI Enhancement of capillary and cellular ingrowth in ePTFE implants with a proangiogenic recombinant construct derived from fibronectin SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A LA English DT Article DE expanded polytetrafluoroethylene; fibronectin; neovascularization; vascular endothelial growth factor; prostheses and implants; rats ID POLYTETRAFLUOROETHYLENE ARTERIAL GRAFTS; BIOLOGICAL-ACTIVITY; POROUS IMPLANTS; VASCULAR GRAFTS; ADIPOSE-TISSUE; SMALL-CALIBER; POROSITY; NEOVASCULARIZATION; GROWTH; VEGF AB Based on our discoveries of a unique, synergistic interplay between vascular endothelial growth factor (VEGF) and specific domains of the matrix protein fibronectin (FN), we used recombinant technology to create a new protein construct derived from the cell-binding and VEGF-binding domains of FN. We wished to test the hypothesis that this prototype recombinant FN (rFN) protein would enhance cellular and capillary ingrowth in vivo into expanded polytetrafluoroethylene (ePTFE) implants. ePTFE disks of high porosity (60 micron internodal distance) were embedded with fibrin gel and heparin, with/without mixtures of VEGF and rFN and were implanted subcutaneously in rats. Control implants embedded with fibrin glue and heparin alone showed an average of 8.5% (+/- 0.51% standard error mean (SEM)) cellular ingrowth. The addition of either VEGF or rFN caused a mod-est but significant increase in cellular ingrowth (12.7 +/- 1% and 11.8 +/- 0.98%, respectively, p < 0.004). However, the combination of rFN/VEGF/heparin dramatically increased cellular ingrowth (27.6 +/- 1.62%, p < 0.001), compared with all other treatments. Quantification of capillary ingrowth yielded the same pattern. These results suggest that the incorporation of such biological modulators into cardiovascular implants could offer new strategies for the design of a ready-made small diameter prosthetic graft with enhanced capacity for neovascularization and endothelialization. (C) 2010 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 95A: 641-648, 2010. C1 [Wijelath, Errol; Kohler, Ted R.; Murray, Jacqueline; Namekata, Mayumi; Yagi, Mayumi; Sobel, Michael] Univ Washington, Sch Med, Dept Surg, Div Vasc Surg,VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Wijelath, E (reprint author), Univ Washington, Sch Med, Dept Surg, Div Vasc Surg,VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM errolw@u.washington.edu FU NHLBI, National Institutes of Health [R01 HL079182]; Research Service of the Department of Veterans Affairs FX Contract grant sponsor: NHLBI, National Institutes of Health; contract grant number: R01 HL079182; Contract grant sponsor: Research Service of the Department of Veterans Affairs NR 26 TC 2 Z9 3 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1549-3296 J9 J BIOMED MATER RES A JI J. Biomed. Mater. Res. Part A PD NOV PY 2010 VL 95A IS 2 BP 641 EP 648 DI 10.1002/jbm.a.32871 PG 8 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA 660TF UT WOS:000282666600033 PM 20725965 ER PT J AU Ortqvist, E Brooks-Worrell, B Lynch, K Radtke, J Bekris, LM Kockum, I Agardh, CD Cilio, CM Lethagen, AL Persson, B Lernmark, A Reichow, J Oak, S Palmer, JP Hampe, CS AF Ortqvist, E. Brooks-Worrell, B. Lynch, K. Radtke, J. Bekris, L. M. Kockum, I. Agardh, C. -D. Cilio, C. M. Lethagen, A. L. Persson, B. Lernmark, A. Reichow, J. Oak, S. Palmer, J. P. Hampe, C. S. TI Changes in GAD65Ab-Specific Antiidiotypic Antibody Levels Correlate with Changes in C-Peptide Levels and Progression to Islet Cell Autoimmunity SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; JUVENILE DIABETES-MELLITUS; DNA ANTIBODIES; DISEASE-ACTIVITY; T-CELLS; ONSET; AUTOANTIBODIES; GAD65; DECARBOXYLASE; EPITOPE AB Context: The previously reported absence of 65-kDa glutamate decarboxylase antibody (GAD65Ab)-specific antiidiotypic antibodies (anti-Id) in type 1 diabetes (T1D) patients at clinical onset could be due to an inability to mount an antibody response to GAD65Ab or a longitudinal decline in anti-Id levels. Objective and Design: We investigated anti-Id levels in longitudinal samples obtained from T1D patients (n = 41) (clinical diagnosis- 12 months), and latent autoimmune diabetes in adults (LADA) patients (n = 32) who received alum-formulated human recombinant GAD65 (baseline -12 months). We also determined anti-Id levels in a small cohort of Type 2 diabetes patients during their development of autoimmune T cell responses. Results: At clinical onset T1D patients presented no or low anti-Id levels. However, 22/41 T1D patients showed >= 50% increase in GAD65Ab-specific anti-Id levels during follow-up; peaking at 3 (n = 1), 6 (n = 10), 9 (n = 10), or 12 (n = 1) months. Increasing anti-Id levels marked patients who experienced a temporary increase in C-peptide levels. Anti-Id levels correlated significantly with glycated hemoglobin and C-peptide levels at 6 and 9 months (P values ranged from < 0.001 to < 0.05). In LADA patients receiving placebo, anti-Id levels declined in seven of nine patients, whereas four of five patients receiving 20 mu g alum-formulated human recombinant GAD65 showed increasing anti-Id levels. Changes in anti-Id and C-peptide levels closely correlated (P < 0.0001). The significant decline in anti-Id levels (P = 0.03) in T2D patients developing T cell autoimmune responses supports our hypothesis that declining anti-Id levels are associated with developing islet autoimmunity. Conclusions: The close association between GAD65Ab-specific anti-Id levels and beta-cell function may provide a novel marker for the progression of autoimmune diabetes. (J Clin Endocrinol Metab 95: E310-E318, 2010) C1 [Reichow, J.; Palmer, J. P.; Hampe, C. S.] Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98109 USA. [Ortqvist, E.; Persson, B.] Karolinska Inst, Dept Woman & Child Hlth, SE-17177 Stockholm, Sweden. [Kockum, I.] Karolinska Inst, Dept Mol Med, SE-17177 Stockholm, Sweden. [Lynch, K.] Univ S Florida, Dept Pediat, Pediat Epidemiol Ctr, Tampa, FL 33620 USA. [Agardh, C. -D.; Cilio, C. M.; Lethagen, A. L.; Lernmark, A.] Lund Univ, Dept Clin Sci, Univ Hosp, SE-20502 Malmo, Sweden. [Reichow, J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Inst Biomed & Clin Res, Seattle, WA 98108 USA. RP Hampe, CS (reprint author), Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, SLU S-276,815 Mercer St, Seattle, WA 98109 USA. EM champe@u.washington.edu FU National Institutes of Health [DK26190, DK17047]; Swedish Diabetes Foundation; Swedish Diabetes Association; Swedish Child Diabetes Foundation; Jerring Foundation; Foundation of Queen Silvia's Jubilee Fund for Research on Children and Handicaps; American Diabetes Association; Medical Research Service of the Department of Veterans Affairs FX The study was performed as independent research sponsored by the National Institutes of Health (DK26190 and DK17047), the Swedish Diabetes Foundation, Swedish Diabetes Association, Swedish Child Diabetes Foundation, the Jerring Foundation, the Foundation of Queen Silvia's Jubilee Fund for Research on Children and Handicaps, and a Basic Science Award from the American Diabetes Association to (C.S.H.). The study also received support through the Medical Research Service of the Department of Veterans Affairs. NR 43 TC 4 Z9 6 U1 0 U2 3 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD NOV PY 2010 VL 95 IS 11 BP E310 EP E318 DI 10.1210/jc.2010-0785 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 675QB UT WOS:000283844400004 PM 20685858 ER PT J AU Fiorentino, L Martin, JL AF Fiorentino, Lavinia Martin, Jennifer L. TI Awake at 4 a.m.: Treatment of Insomnia With Early Morning Awakenings Among Older Adults SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE insomnia; circadian rhythms; advanced sleep phase syndrome; aging; cognitive-behavioral therapy; light therapy ID SLEEP DISORDERS; INTERVENTIONS; METAANALYSIS; EFFICACY AB Insomnia is a common problem among older adults. In particular, older adults experience insomnia coupled with early morning awakenings due to an interaction between age-related changes in circadian rhythm timing coupled with behavior changes that contribute to sustained poor sleep. Cognitive behavioral therapy for insomnia (CBT-I), at times coupled with circadian interventions (e.g., timed light exposure), are likely to be most successful in optimizing sleep quality. In delivering CBT-I to older adults, modifications are sometimes necessary to accommodate for medical problems, lifestyle, social factors, and patient preferences. Addition of circadian interventions can ameliorate the negative effects of inappropriately timed sleep as well. These treatment methods can be highly effective and benefits can be long-standing. A case example is used to illustrate these points. (C) 2010 Wiley Periodicals, Inc. J Clin Psychol: In Session 66:1161-1174, 2010. C1 [Fiorentino, Lavinia; Martin, Jennifer L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Martin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Martin, JL (reprint author), VA Greater Los Angeles Healthcare Syst Geriatr Re, Educ & Clin Ctr 11E, 16111 Plummer St, North Hills, CA 91343 USA. EM jennifer.martin@va.gov FU NIA NIH HHS [K23 AG028452-03, K23 AG028452, R01 AG026364]; NIMH NIH HHS [T32 MH 019925-1, T32 MH019925-10, T32 MH019925] NR 12 TC 2 Z9 3 U1 1 U2 12 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9762 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD NOV PY 2010 VL 66 IS 11 BP 1161 EP 1174 DI 10.1002/jclp.20734 PG 14 WC Psychology, Clinical SC Psychology GA 679TF UT WOS:000284183000004 PM 20845423 ER PT J AU Gehrman, PR Harb, GC AF Gehrman, Philip R. Harb, Gerlinde C. TI Treatment of Nightmares in the Context of Posttraumatic Stress Disorder SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE nightmares; sleep; PTSD; cognitive-behavioral therapy; REM; prazosin; imagery rehearsal ID SLEEP DISTURBANCE; COMBAT VETERANS; PRAZOSIN; SYMPTOMS; THERAPY; TRIAL; PTSD AB Nightmares are a common feature of posttraumatic stress disorder (PTSD) and are frequently resistant to treatment. Two emerging treatments for nightmares are pharmacotherapy with prazosin and psychotherapy using imagery rehearsal (IR). A case illustration demonstrates the application of these treatments with a client suffering from chronic, severe PTSD. The case illustrates the use of these strategies for managing PTSD-related nightmares, as well as the novel approach of scheduled awakenings following relapse. (C) 2010 Wiley Periodicals, Inc. J Clin Psychol: In Session 66:1185-1194, 2010. C1 [Gehrman, Philip R.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Gehrman, Philip R.; Harb, Gerlinde C.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Gehrman, PR (reprint author), Univ Penn, Dept Psychiat, 3535 Market St,Suite 670, Philadelphia, PA 19104 USA. EM gehrman@exchange.upenn.edu NR 17 TC 10 Z9 10 U1 1 U2 12 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9762 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD NOV PY 2010 VL 66 IS 11 BP 1185 EP 1194 DI 10.1002/jclp.20730 PG 10 WC Psychology, Clinical SC Psychology GA 679TF UT WOS:000284183000006 PM 20865767 ER PT J AU Bell, JF Johnson, ML Myers, K Patrick, DL AF Bell, Janice F. Johnson, M. Laura Myers, Kathleen Patrick, Donald L. TI Primary Health Care Quality in a National Sample of Children and Youth with Mental Health Impairment SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS LA English DT Article DE quality of care; mental health impairment; Medical Expenditures Panel Survey; children; adolescents ID MEDICAL HOME; PSYCHIATRIC-DISORDERS; UNMET NEED; CENTERED CARE; SERVICES; ADOLESCENTS; DEPRESSION; PERFORMANCE; PREVALENCE; BARRIERS AB Objective: To examine the general pediatric health care quality experiences of children and youth with mental health impairment. Methods: We conducted a cross-sectional analysis of 2006 Medical Expenditures Panel Survey data for children and youth aged 5 to 17 years (n = 7263). Mental health impairment was defined using the recommended cut-point (score >= 16) on the parent version of the Columbia Impairment Scale. Health care quality was measured with the Consumer Assessment of Healthcare Providers and Systems including parent ratings in 3 domains: provider communication, getting needed care, and getting care quickly. Logistic regression was used to test associations between mental health impairment and dichotomized Consumer Assessment of Healthcare Providers and Systems measures (poor vs good quality) adjusted for demographic characteristics, health insurance, and socioeconomic status. Analysis was conducted with Stata, Version 10.1 SE, and all estimates accounted for the Medical Expenditures Panel Survey complex sampling design. Results: In multivariable analysis, health care experiences of children with mental health impairment (versus those without) were consistently rated less favorably by parents, with greater odds of inferior quality of care ratings in all domains: getting needed care (odds ratio [OR] = 2.35), getting care quickly (OR = 1.41), physician communication (OR = 1.72), and overall health care quality (OR = 1.63). Conclusions: Further research is needed to identify specific aspects of care that families find problematic in relation to the organization and delivery of care within each quality domain. Interventions are needed to improve service systems for children and youth with mental health impairment, especially to support access to needed care. C1 [Bell, Janice F.] Univ Washington, Dept Hlth Serv, Maternal & Child Hlth Program, Seattle, WA 98195 USA. [Bell, Janice F.; Patrick, Donald L.] Seattle Qual Life Grp, Dept Hlth Serv, Seattle, WA USA. [Johnson, M. Laura] Vet Affairs Puget Sound Hlth Care Syst, NW Ctr Excellence Hlth Serv Res & Dev, Seattle, WA USA. [Myers, Kathleen] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Myers, Kathleen] Childrens Hosp, Med Ctr, Seattle, WA USA. RP Bell, JF (reprint author), Univ Washington, Dept Hlth Serv, Maternal & Child Hlth Program, Box 357230, Seattle, WA 98195 USA. EM jfbell@u.washington.edu NR 51 TC 4 Z9 4 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-206X J9 J DEV BEHAV PEDIATR JI J. Dev. Behav. Pediatr. PD NOV-DEC PY 2010 VL 31 IS 9 BP 694 EP 704 DI 10.1097/DBP.0b013e3181f17b09 PG 11 WC Behavioral Sciences; Psychology, Developmental; Pediatrics SC Behavioral Sciences; Psychology; Pediatrics GA 675NV UT WOS:000283838300002 PM 21057254 ER PT J AU Finley, EP Baker, M Pugh, MJ Peterson, A AF Finley, Erin P. Baker, Monty Pugh, Mary Jo Peterson, Alan TI Patterns and Perceptions of Intimate Partner Violence Committed by Returning Veterans with Post-Traumatic Stress Disorder SO JOURNAL OF FAMILY VIOLENCE LA English DT Article DE Partner violence; Veterans; PTSD; Patterns of abuse; Trauma ID MENTAL-HEALTH PROBLEMS; PERITRAUMATIC DISSOCIATION; MILITARY VETERANS; VIETNAM VETERANS; COMBAT VETERANS; TRAUMA; IRAQ; WAR; AFGHANISTAN; SLEEP AB Data from a recent mixed-methods study conducted among Veterans of Iraq and Afghanistan diagnosed with Post-Traumatic Stress Disorder (PTSD) raise important questions regarding the occurrence of Intimate Partner Violence (IPV) in this population. Three case studies illustrate two main findings. First, Veterans and family members participating in the study described three patterns of partner violence-violence committed in anger; dissociative violence; and parasomniac/hypnopompic violence-suggesting that distinct patterns of IPV may emerge in relation to PTSD symptoms. Second, participants' descriptions suggest that common ideas about PTSD and war-related suffering can play an important role in influencing how Veterans and their partners respond to episodes of partner violence. It is important for those providing care to PTSD-diagnosed Veterans and their partners to understand when and how partner violence may occur, and how both parties may perceive and respond to it, in order to aid in developing appropriate plans for coping and safety-seeking. C1 [Finley, Erin P.] S Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp Div, VERDICT Res Unit 1IC6, San Antonio, TX 78229 USA. [Peterson, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Div Behav Med, STRONG STAR Multidisciplinary PTSD Res Consortium, San Antonio, TX 78229 USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, Dept Med Geriatr & Gerontol, San Antonio, TX 78229 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Div Clin Epidemiol, Dept Med, San Antonio, TX 78229 USA. [Finley, Erin P.; Pugh, Mary Jo] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX 78229 USA. RP Finley, EP (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp Div, VERDICT Res Unit 1IC6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM finleye@uthscsa.edu OI Pugh, Mary Jo/0000-0003-4196-7763; Finley, Erin/0000-0003-4497-7721 NR 39 TC 18 Z9 18 U1 4 U2 20 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7482 J9 J FAM VIOLENCE JI J. Fam. Violence PD NOV PY 2010 VL 25 IS 8 BP 737 EP 743 DI 10.1007/s10896-010-9331-7 PG 7 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA 679SR UT WOS:000284181600004 ER PT J AU Gordon, WJ Polansky, JM Boscardin, WJ Fung, KZ Steinman, MA AF Gordon, William J. Polansky, Jesse M. Boscardin, W. John Fung, Kathy Z. Steinman, Michael A. TI Coronary Risk Assessment by Point-Based vs. Equation-Based Framingham Models: Significant Implications for Clinical Care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med DE risk assessment; cholesterol; heart diseases; practice guidelines as topic; prognosis ID ISCHEMIC-HEART-DISEASE; TREATMENT PANEL-III; CARDIOVASCULAR RISK; PRIMARY PREVENTION; CHOLESTEROL; GUIDELINES; PREDICTION; STATINS; SCORE; RECLASSIFICATION AB BACKGROUND: US cholesterol guidelines use original and simplified versions of the Framingham model to estimate future coronary risk and thereby classify patients into risk groups with different treatment strategies. We sought to compare risk estimates and risk group classification generated by the original, complex Framingham model and the simplified, point-based version. METHODS: We assessed 2,543 subjects age 20-79 from the 2001-2006 National Health and Nutrition Examination Surveys (NHANES) for whom Adult Treatment Panel III (ATP-III) guidelines recommend formal risk stratification. For each subject, we calculated the 10-year risk of major coronary events using the original and point-based Framingham models, and then compared differences in these risk estimates and whether these differences would place subjects into different ATP-III risk groups (<10% risk, 10-20% risk. or >20% risk). Using standard procedures, all analyses were adjusted for survey weights, clustering, and stratification to make our results nationally representative. RESULTS: Among 39 million eligible adults, the original Framingham model categorized 71% of subjects as having "moderate" risk (<10% risk of a major coronary event in the next 10 years), 22% as having "moderately high" (10-20%) risk, and 7% as having "high" (>20%) risk. Estimates of coronary risk by the original and point-based models often differed substantially. The point-based system classified 15% of adults (5.7 million) into different risk groups than the original model, with 10% (3.9 million) misclassified into higher risk groups and 5% (1.8 million) into lower risk groups, for a net impact of classifying 2.1 million adults into higher risk groups. These risk group misclassifications would impact guideline-recommended drug treatment strategies for 25-46% of affected subjects. Patterns of misclassifications varied significantly by gender. age. and underlying CHD risk. CONCLUSIONS: Compared to the original Framingham model, the point-based version misclassifies millions of Americans into risk groups for which guidelines recommend different treatment strategies. C1 [Fung, Kathy Z.; Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Gordon, William J.] Weill Cornell Med Coll, New York, NY USA. [Gordon, William J.; Steinman, Michael A.] Med Student Training Aging Res Program, San Francisco, CA USA. [Polansky, Jesse M.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. [Boscardin, W. John; Fung, Kathy Z.; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU NIA NIH HHS [K23-AG030999, K23 AG030999] NR 38 TC 7 Z9 7 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2010 VL 25 IS 11 BP 1145 EP 1151 DI 10.1007/s11606-010-1454-2 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 672YN UT WOS:000283624000005 PM 20824362 ER PT J AU Rosman, AS Korsten, MA AF Rosman, Alan S. Korsten, Mark A. TI Effect of Verification Bias on the Sensitivity of Fecal Occult Blood Testing: a Meta-Analysis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE fecal occult blood; guaiac; colorectal cancer; summary receiver operating characteristic curve: meta-analysis ID DIAGNOSTIC-TEST ACCURACY; AVERAGE-RISK POPULATION; COLORECTAL-CANCER; SYSTEMATIC REVIEWS; PROSPECTIVE MULTICENTER; SYMPTOMATIC PATIENTS; IMMUNOCHEMICAL TEST; HEMOCCULT TEST; TOTAL COLONOSCOPY; AMERICAN-COLLEGE AB OBJECTIVES: There is controversy regarding the sensitivity of fecal occult blood tests (FOBT) for detecting colorectal cancer. Many of the published studies failed to correct for verification bias which may have increased the sensitivity. METHODS: A meta-analysis of published studies evaluating the sensitivity and specificity of chemical-based FOBT for colorectal cancer was performed. Studies were included if both cancer and control subjects underwent confirmatory testing. We also included studies that attempted to correct for verification bias by either performing colonoscopy on all subjects regardless of the FOBT result or by using longitudinal follow-up. We then compared the sensitivity, specificity, and other diagnostic characteristics of the studies that attempted to correct for verification (n=10) vs. those that did not correct for this bias (n=19). RESULTS: The pooled sensitivity of guaiac-based FOBT for colorectal cancer of studies without verification bias was significantly lower than those studies with this bias [0.36 (95% CI 0.25-0.47) vs. 0.70 (95% CI 0.60-0.80), p=0.0011. The pooled specificity of the studies without verification bias was higher [0.96 (95% CI 0.94-0.97) vs. 0.88 (95% CI 0.84-0.91), p<0.005]. There was no significant difference in the area under the summary receiver operating characteristic curves. More sensitive chemical-based FOBT methods (e.g., Hemoccult (R) SENSA (R)) had a higher sensitivity but a lower specificity than standard guaiac methods. CONCLUSIONS: The sensitivity of guaiac-based FOBT for colorectal cancer has been overestimated as a result of verification bias. This test may not be sensitive enough to serve as an effective screening option for colorectal cancer. C1 [Rosman, Alan S.; Korsten, Mark A.] James J Peters Vet Affairs Med Ctr, Gastroenterol Sect, Bronx, NY 10468 USA. [Rosman, Alan S.; Korsten, Mark A.] James J Peters Vet Affairs Med Ctr, Program Med, Bronx, NY 10468 USA. [Rosman, Alan S.; Korsten, Mark A.] Mt Sinai Sch Med NYU, New York, NY USA. RP Rosman, AS (reprint author), James J Peters Vet Affairs Med Ctr, Gastroenterol Sect, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Alan.Rosman@VA.Gov FU Department of Veterans Affairs FX Funding Source: Department of Veterans Affairs. NR 74 TC 12 Z9 12 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2010 VL 25 IS 11 BP 1211 EP 1221 DI 10.1007/s11606-010-1375-0 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 672YN UT WOS:000283624000015 PM 20499198 ER PT J AU Widera, E Chang, A Chen, HL AF Widera, Eric Chang, Anna Chen, Helen L. TI Presenteeism: A Public Health Hazard SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE presenteeism; infection control; norovirus; long-term care; outbreak ID SICKNESS PRESENTEEISM; CARE WORKERS; INFLUENZA VACCINE; OUTBREAK; INFECTION; NOROVIRUS; IMPACT; STAFF; COST; GASTROENTERITIS AB "Presenteeism" occurs when an employee goes to work despite a medical illness that will prevent him or her from fully functioning at work. This problem has been well studied in the business and social science literature, and carries increased importance in the health care setting due to the risk of infectious disease transmission in vulnerable patient populations. In this manuscript, we discuss an outbreak of viral gastroenteritis in a long-term care facility and the role presenteeism played in disease transmission and extension of the outbreak. We use existing literature to point out the hazards of presenteeism in the health care sector. We will also discuss factors that may be involved in the decision to work while ill and propose policy changes that may reduce the incidence of presenteeism in health care organizations. C1 [Widera, Eric] VA Med Ctr 181G, San Francisco, CA 94121 USA. [Widera, Eric; Chang, Anna; Chen, Helen L.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Widera, Eric; Chang, Anna] San Francisco VA Med Ctr, San Francisco, CA USA. [Chen, Helen L.] Ctr Elders Independence, Oakland, CA USA. RP Widera, E (reprint author), VA Med Ctr 181G, 4150 Clement St, San Francisco, CA 94121 USA. EM Eric.Widera@ucsf.edu FU Health Resources and Services Administration FX Dr. Widera has received funding support from a Geriatrics Academic Career Award from the Health Resources and Services Administration. Dr. Chen has received funding support from a Geriatrics Education Center Grant from the Health Resources and Services Administration. NR 40 TC 34 Z9 38 U1 3 U2 23 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2010 VL 25 IS 11 BP 1244 EP 1247 DI 10.1007/s11606-010-1422-x PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 672YN UT WOS:000283624000021 PM 20549378 ER PT J AU Osborn, CY Amico, KR Fisher, WA Egede, LE Fisher, JD AF Osborn, Chandra Y. Amico, K. Rivet Fisher, William A. Egede, Leonard E. Fisher, Jeffrey D. TI An Information-Motivation-Behavioral Skills Analysis of Diet and Exercise Behavior in Puerto Ricans with Diabetes SO JOURNAL OF HEALTH PSYCHOLOGY LA English DT Article DE behavior; diabetes; glycemic control; Information-Motivation-Behavioral Skills (IMB) model; Puerto Rican ID AIDS-PREVENTIVE BEHAVIOR; PHYSICAL-ACTIVITY; ANTIRETROVIRAL THERAPY; GLYCEMIC CONTROL; HEALTH-BEHAVIOR; RISK BEHAVIOR; MODEL; INTERVENTION; CARE; ADHERENCE AB Frameworks are needed to inform diabetes self-care programs for diverse populations. We tested the Information-Motivation-Behavioral Skills (IMB) model in a sample of Puerto Ricans with Type 2 diabetes (N = 118). Structural equation models evaluated model fit and interrelations between IMB constructs. For diet behavior, information and motivation related to behavioral skills (r = 0.19, p < .05 and r = 0.39, p < .01, respectively); behavioral skills related to behavior (r = 0.42, p < .01 and r = 0.32, p < .05); and behavior related to glycemic control (r = -0.26, p < .05). For exercise, personal motivation related to behavioral skills (r = 0.53, p < .001), and behavioral skills related to behavior (r = 0.45, p < .001). The IMB model could inform interventions targeting these behaviors in diabetes. C1 [Osborn, Chandra Y.] Vanderbilt Univ, Sch Med, Vanderbilt Ctr Hlth Serv Res, Div Gen Internal Med & Publ Hlth, Nashville, TN 37232 USA. [Amico, K. Rivet; Fisher, Jeffrey D.] Univ Connecticut, Ctr Hlth Intervent & Prevent, Storrs, CT 06269 USA. [Fisher, William A.] Univ Western Ontario, Dept Psychol, London, ON N6A 3K7, Canada. [Fisher, William A.] Univ Western Ontario, Dept Obstet & Gynecol, London, ON N6A 3K7, Canada. [Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Osborn, CY (reprint author), Vanderbilt Univ, Sch Med, Vanderbilt Ctr Hlth Serv Res, Div Gen Internal Med & Publ Hlth, 1215 21st Ave S,Suite 6000,MCE N Tower, Nashville, TN 37232 USA. EM chandra.osborn@vanderbilt.edu FU NIDDK NIH HHS [P60 DK020593, F31 DK067022, F31 DK067022-01, F31 DK067022-02, P60 DK020593-30S2] NR 48 TC 13 Z9 13 U1 5 U2 16 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1359-1053 J9 J HEALTH PSYCHOL JI J. Health Psychol. PD NOV PY 2010 VL 15 IS 8 BP 1201 EP 1213 DI 10.1177/1359105310364173 PG 13 WC Psychology, Clinical SC Psychology GA 675RG UT WOS:000283847600008 PM 20453056 ER PT J AU Zorzi, P Aplin, AC Smith, KD Nicosia, RF AF Zorzi, Penelope Aplin, Alfred C. Smith, Kelly D. Nicosia, Roberto F. TI The rat aorta contains resident mononuclear phagocytes with proliferative capacity and proangiogenic properties SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE M-CSF; GM-CSF; IL-4; MHC II; dendritic cells; aortic ring; collagen ID MULTINUCLEATED GIANT-CELLS; ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; MACROPHAGE ACCUMULATION; INFLAMMATORY CYTOKINES; VESSEL FORMATION; DENDRITIC CELLS; ADIPOSE-TISSUE; IN-VITRO; ANGIOGENESIS AB Angiogenesis in the aortic ring model is preceded by activation of the immune system and impaired by ablation of adventitial macrophages. Treatment of aortic cultures with M-CSF induced extensive periaortic outgrowth of CD45(+) CD68(+) mononuclear cells with ultrastructural features of macrophages and DCs. Periaortic lysis of collagen caused many CD45(+) CD68(+) cells to attach to the bottom of the culture dish. Lifting the collagen gels left behind patches of CD45(+) CD68(+) cells, which focally organized into branching cords. These cells also expressed CD14, CD169, F4/80, and alpha-SMA but not CD31, vWF, desmin, or CD163. DNA synthesis studies showed that M-CSF-stimulated cells were actively proliferating. Aortic patch cells showed phagocytic properties and responded to IL-4 and GM-CSF by expressing MHC II, differentiating into DCs, and forming multinucleated giant cells. They also stimulated angiogenesis and VEGF production in aortic ring cultures. This study demonstrates that the rat aorta contains a distinct subset of immature immunocytes capable of proliferating, differentiating into macrophages and DCs, and stimulating angiogenesis. Isolation of these cells in patches from M-CSF-stimulated aortic rings provides a reproducible system to study the biology and angiogenic role of the resident immune system of the aortic wall. J. Leukoc. Biol. 88: 1051-1059; 2010. C1 [Nicosia, Roberto F.] Vet Adm Puget Sound Hlth Care syst, Pathol & Lab Med Serv, Seattle, WA USA. [Zorzi, Penelope; Aplin, Alfred C.; Smith, Kelly D.; Nicosia, Roberto F.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. RP Nicosia, RF (reprint author), VA Puget Sound Hlth Care Syst, Pathol & Lab Med Serv S 113, 1660 S Columbian Way, Seattle, WA 98108 USA. EM roberto.nicosia@va.gov FU National Heart Lung and Blood Institute [HL-52585]; Department of Veterans Affairs Medical Research Services FX This study was supported by the National Heart Lung and Blood Institute grant HL-52585 and a Merit Review grant from the Department of Veterans Affairs Medical Research Services. We gratefully acknowledge Ms. Debbie Jones for her excellent technical assistance with the electron microscopy studies. NR 41 TC 12 Z9 12 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD NOV PY 2010 VL 88 IS 5 BP 1051 EP 1059 DI 10.1189/jlb.0310178 PG 9 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 692YG UT WOS:000285191200024 PM 20628067 ER PT J AU Shugarman, LR Goebel, JR Lanto, A Asch, SM Sherbourne, CD Lee, ML Rubenstein, LV Wen, L Meredith, L Lorenz, KA AF Shugarman, Lisa R. Goebel, Joy R. Lanto, Andy Asch, Steven M. Sherbourne, Cathy D. Lee, Martin L. Rubenstein, Lisa V. Wen, Li Meredith, Lisa Lorenz, Karl A. TI Nursing Staff, Patient, and Environmental Factors Associated with Accurate Pain Assessment SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Pain measurement; veterans; outpatients ID CANCER PAIN; NURSES ASSESSMENT; PRIMARY-CARE; REPRESENTATIVE SAMPLE; ANXIETY DISORDERS; DECISION-MAKING; MANAGEMENT; QUESTIONNAIRE; DEPRESSION; IMPAIRMENT AB Context Although pain ranks highly among reasons for seeking care, routine pain assessment is often inaccurate Objectives This study evaluated factors associated with nurses (e g, registered) and other nursing support staff (e g, licensed vocational nurses and health technicians) discordance with patients in estimates of pain in a health system where routine pain screening using a 0-10 numeric rating scale (NRS) is mandated Methods This was a cross-sectional, visit-based, cohort study that included surveys of clinic outpatients (n = 465) and nursing staff (n = 94) who screened for pain as part of routine vital sign measurement during intake These data were supplemented by chart review We compared patient pain levels documented by the nursing staff (N-NRS) with those reported by the patient during the study survey (S-NRS) Results Pain underestimation (N-NRS < S-NRS) occurred in 25% and overestimation (N-NRS > S-NRS) in 7% of the cases Nursing staff used informal pain-screening techniques that did not follow established NRS protocols in half of the encounters Pain underestimation was positively associated with more years of nursing staff work experience and patient anxiety or post-traumatic stress disorder and negatively associated with better patient-reported health status Pain overestimation was positively associated with nursing staffs use of the full NRS protocol and with a distracting environment in which patient vitals were taken Conclusion Despite a long-standing mandate, pain-screening implementation falls short, and informal screening is common J Pain Symptom Manage 2010,40 723-733 (C) 2010 US Cancer Pain Relief Committee Published by Elsevier Inc All rights reserved C1 [Lanto, Andy; Asch, Steven M.; Lee, Martin L.; Rubenstein, Lisa V.; Lorenz, Karl A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Asch, Steven M.; Rubenstein, Lisa V.; Lorenz, Karl A.] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA. [Wen, Li] Vet Adm Long Beach Healthcare Syst, Long Beach, CA USA. [Goebel, Joy R.] Calif State Univ Long Beach, Sch Nursing, Dept Nursing, Long Beach, CA 90840 USA. [Shugarman, Lisa R.; Asch, Steven M.; Sherbourne, Cathy D.; Rubenstein, Lisa V.; Meredith, Lisa; Lorenz, Karl A.] RAND Corp, Santa Monica, CA USA. RP Lorenz, KA (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Code 111 G, Los Angeles, CA 90073 USA. FU Veterans Administration [IIR-030150] FX Dr Karl Lorenz was supported by a VA HSR&D Career Development Award This study was funded by The Veterans Administration (IIR-030150) The funder was not involved in the conduct of the study or development of the submission The authors declare no conflicts of interest NR 45 TC 11 Z9 12 U1 2 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD NOV PY 2010 VL 40 IS 5 BP 723 EP 733 DI 10.1016/j.jpainsymman.2010.02.024 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 686BI UT WOS:000284671400009 PM 20692807 ER PT J AU Anderson, WG Goldstein, NE AF Anderson, Wendy G. Goldstein, Nathan E. TI Update in Hospice and Palliative Care SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID ADVANCED CANCER; ASSOCIATION; DIALYSIS; DEATH C1 [Anderson, Wendy G.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA. [Anderson, Wendy G.] Univ Calif San Francisco, Palliat Care Program, San Francisco, CA 94143 USA. [Goldstein, Nathan E.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Goldstein, Nathan E.] James J Peters VA Med Ctr, Bronx, NY USA. RP Anderson, WG (reprint author), Univ Calif San Francisco, Div Hosp Med, 521 Parnassus Ave,Box 0903, San Francisco, CA 94143 USA. EM anderson.wg@gmail.com FU University of California San Francisco Clinical and Translational Science Institute by National Institutes of Health [5KL2 RR024130-04]; National Institute of Aging [K23 AG025933] FX Dr. Anderson was supported by the University of California San Francisco Clinical and Translational Science Institute Career Development Program, which is supported by National Institutes of Health grant number 5KL2 RR024130-04. Dr. Goldstein was supported by a Mentored Patient-Oriented Research Career Development Award from the National Institute of Aging (K23 AG025933). Drs. Anderson and Goldstein presented these articles for the State of the Science Plenary Session at the Annual Assembly of the American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses Association on March 6, 2010 in Boston, Massachusetts. NR 16 TC 1 Z9 1 U1 1 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD NOV PY 2010 VL 13 IS 11 BP 1305 EP 1310 DI 10.1089/jpm.2010.0253 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 682JD UT WOS:000284397000002 ER PT J AU Carlson, MDA Bradley, EH Du, QL Morrison, RS AF Carlson, Melissa D. A. Bradley, Elizabeth H. Du, Qingling Morrison, R. Sean TI Geographic Access to Hospice in the United States SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID FOR-PROFIT; CARE; NONPROFIT; HOSPITALS; PATTERNS; CANCER; LIFE; HOME AB Background: Despite a 41% increase in the number of hospices since 2000, more than 60% of Americans die without hospice care. Given that hospice care is predominantly home based, proximity to a hospice is important in ensuring access to hospice services. We estimated the proportion of the population living in communities within 30 and 60 minutes driving time of a hospice. Methods: We conducted a cross-sectional study of geographic access to U. S. hospices using the 2008 Medicare Provider of Services data, U. S. Census data, and ArcGIS software. We used multivariate logistic regression to identify gaps in hospice availability by community characteristics. Results: As of 2008, 88% of the population lived in communities within 30 minutes and 98% lived in communities within 60 minutes of a hospice. Mean time to the nearest hospice was 15 minutes and the range was 0 to 403 minutes. Community characteristics independently associated with greater geographic access to hospice included higher population density, higher median income, higher educational attainment, higher percentage of black residents, and the state not having a Certificate of Need policy. The percentage of each state's population living in communities more than 30 minutes from a hospice ranged from 0% to 48%. Conclusions: Recent growth in the hospice industry has resulted in widespread geographic access to hospice care in the United States, although state and community level variation exists. Future research regarding variation and disparities in hospice use should focus on barriers other than geographic proximity to a hospice. C1 [Carlson, Melissa D. A.; Du, Qingling; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Bradley, Elizabeth H.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. [Morrison, R. Sean] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Carlson, MDA (reprint author), Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM melissa.carlson@mssm.edu FU National Institute of Nursing Research [1K99NR010495-01]; Patrick and Catherine Weldon Donaghue Medical Research Foundation [02-102]; National Institute on Aging [K24 AG022345] FX Funding sources: Brookdale Leadership in Aging Fellowship, National Institute of Nursing Research Career Development Award (1K99NR010495-01); Patrick and Catherine Weldon Donaghue Medical Research Foundation Investigator Award (Grant #02-102); National Institute on Aging Mid-Career Investigator Award in Patient Oriented Research (K24 AG022345). NR 30 TC 26 Z9 26 U1 3 U2 11 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD NOV PY 2010 VL 13 IS 11 BP 1331 EP 1338 DI 10.1089/jpm.2010.0209 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 682JD UT WOS:000284397000007 PM 20979524 ER PT J AU Pierre, JM AF Pierre, Joseph M. TI The Borders of Mental Disorder in Psychiatry and the DSM: Past, Present, and Future SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Article DE Diagnostic and Statistical Manual of Mental Disorders (DSM); DSM-5; diagnosis; normality; spectrum; categorical diagnosis; dimensional diagnosis; personality disorders; neuroethics; neuroenhancement ID NATIONAL COMORBIDITY SURVEY; HARMFUL DYSFUNCTION ANALYSIS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED-TRIAL; BIPOLAR DISORDER; PERSONALITY-DISORDERS; DIAGNOSTIC CRITERIA; LIFETIME PREVALENCE; COGNITIVE DEFICITS; SURVEY REPLICATION AB Over the past 60 years, the Diagnostic and Statistical Manual of Mental Disorders (DSM) has evolved from early efforts to collect statistical information to a modern compendium of mental disorders that can be reliably diagnosed, but have not been validated. Throughout this history, DSM architects have struggled with the seemingly fundamental, but complex question of how to define a mental disorder. Current proposals indicate that a spectrum model of mental illness will be embraced in DSM-5, prompting renewed concern and debate about pathologizing normal existence. While a spectrum view of mental illness may reflect biologic reality and help pave the path towards validated models of psychiatric disorder, diagnostic expansion does have important practical implications and could give rise to problems in clinical work and society at large, including the further sanctioning of a shift from psychiatric treatment to neuroenhancement. Debates about what should or should not be considered a mental illness in DSM-5 are likely to remain unresolved and, in the future, must be framed according to contextual utility. Diagnosis and thresholds of pathology are ultimately value-based so that careful analysis and perhaps even different definitions of disorder may be required to guide decision-making in research, clinical work, and public policy. (Journal of Psychiatric Practice 2010;16:375-386) C1 [Pierre, Joseph M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Pierre, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Pierre, JM (reprint author), 11301 Wilshire Blvd,Bldg 210,Room 15, Los Angeles, CA 90073 USA. EM joseph.pierre2@va.gov NR 117 TC 7 Z9 7 U1 4 U2 18 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1527-4160 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD NOV PY 2010 VL 16 IS 6 BP 375 EP 386 DI 10.1097/01.pra.0000390756.37754.68 PG 12 WC Psychiatry SC Psychiatry GA 685CC UT WOS:000284601000002 PM 21107142 ER PT J AU Perez-Rodriguez, MM Weinstein, S New, AS Bevilacqua, L Yuan, QP Zhou, ZF Hodgkinson, C Goodman, M Koenigsberg, HW Goldman, D Siever, LJ AF Perez-Rodriguez, M. Mercedes Weinstein, Shauna New, Antonia S. Bevilacqua, Laura Yuan, Qiaoping Zhou, Zhifeng Hodgkinson, Colin Goodman, Marianne Koenigsberg, Harold W. Goldman, David Siever, Larry J. TI Tryptophan-hydroxylase 2 haplotype association with borderline personality disorder and aggression in a sample of patients with personality disorders and healthy controls SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Borderline personality disorder; TPH2; Suicidal behavior; Affective instability; Impulsive aggression ID CENTRAL SEROTONERGIC FUNCTION; ISOFORM TPH2 GENE; IMPULSIVE-AGGRESSION; PROLACTIN RESPONSE; D-FENFLURAMINE; CEREBROSPINAL-FLUID; VIOLENT OFFENDERS; MAJOR DEPRESSION; TRANSMISSION DISEQUILIBRIUM; POLYMORPHIC VARIANTS AB Background There is a decreased serotonergic function in impulsive aggression and borderline personality disorder (BPD) and genetic association studies suggest a role of serotonergic genes in impulsive aggression and BPD Only one study has analyzed the association between the tryptophan-hydroxylase 2 (TPH2) gene and BPD A TPH2 "risk" haplotype has been described that is associated with anxiety depression and suicidal behavior Methods We assessed the relationship between the previously identified risk" haplotype at the TPH2 locus and BPD diagnosis impulsive aggression affective lability and suicidal/parasuicidal behaviors in a well-characterized clinical sample of 103 healthy controls (HCs) and 251 patients with personality disorders (109 with BPD) A logistic regression including measures of depression affective lability and aggression scores in predicting risk" haplotype was conducted Results The prevalence of the "risk" haplotype was significantly higher in patients with BPD compared to HCs Those with the "risk" haplotype have higher aggression and affect lability scores and more suicidal/parasuicidal behaviors than those without it In the logistic regression model affect lability was the only significant predictor and it correctly classified 83 1% of the subjects as risk or non-risk haplotype carriers Conclusions We found an association between the previously described TPH2 risk haplotype and BPD diagnosis affective lability suicidal/parasuicidal behavior and aggression scores (C) 2010 Elsevier Ltd All rights reserved C1 [Perez-Rodriguez, M. Mercedes; Weinstein, Shauna; New, Antonia S.; Goodman, Marianne; Koenigsberg, Harold W.; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Weinstein, Shauna; New, Antonia S.; Goodman, Marianne; Koenigsberg, Harold W.; Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, Bronx, NY 10468 USA. [Bevilacqua, Laura; Yuan, Qiaoping; Zhou, Zhifeng; Hodgkinson, Colin; Goldman, David] NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA. RP Siever, LJ (reprint author), James J Peters Vet Adm Med Ctr, 3rd Floor,Room 3B,20 130 W Kingsbridge Rd, Bronx, NY 10468 USA. RI Perez Rodriguez, Maria/B-9410-2013; Goldman, David/F-9772-2010 OI Perez Rodriguez, Maria/0000-0001-5137-1993; Goldman, David/0000-0002-1724-5405 FU National Institute of Mental Health [MH56140, MH63875]; Veterans Affairs [7609-028, 9001-03-0051]; Veterans Affairs VISN 3 Mental Illness Research Education & Clinical Center; National Center for Research Resources (NCRR) [MO1-RR-00071] FX This research was supported by Grants MH56140 & MH63875 from the National Institute of Mental Health to Larry J Siever by a Veterans Affairs Merit Review Grant (7609-028) to Larry J Siever and by the Veterans Affairs VISN 3 Mental Illness Research Education & Clinical Center; This publication was made possible by Grant Number MO1-RR-00071 from the National Center for Research Resources (NCRR) a component of the National Institutes of Health (NIH) Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NIH; This work was supported in part by a VA Merit award to Dr New (9001-03-0051) New (PI)- Intermediate Phenotypes for Borderline Personality Disorder and a VA Career Development Award to Dr Goodman NR 78 TC 30 Z9 34 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD NOV PY 2010 VL 44 IS 15 BP 1075 EP 1081 DI 10.1016/j.jpsychires.2010.03.014 PG 7 WC Psychiatry SC Psychiatry GA 684RJ UT WOS:000284566700013 PM 20451217 ER PT J AU Chen, DC Xiu, MH Liu, H Zhang, BS Wang, Y Kosten, TR Zhang, XY AF Chen, Da Chun Xiu, Mei Hong Liu, Hong Zhang, Ben Shu Wang, Yu Kosten, Thomas R. Zhang, Xiang Yang TI Reduced status of plasma total antioxidant capacity in schizophrenia with tardive dyskinesia SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Letter C1 [Zhang, Xiang Yang] Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Chen, Da Chun; Xiu, Mei Hong; Zhang, Xiang Yang] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing, Peoples R China. [Liu, Hong; Zhang, Ben Shu; Wang, Yu] TianJin Med Univ, Dept Neurol, Tianjin, Peoples R China. RP Zhang, XY (reprint author), Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. NR 11 TC 5 Z9 5 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD NOV PY 2010 VL 44 IS 15 BP 1111 EP 1112 DI 10.1016/j.jpsychires.2010.03.008 PG 2 WC Psychiatry SC Psychiatry GA 684RJ UT WOS:000284566700019 PM 20398909 ER PT J AU Singh, JA Mahowald, ML Noorbaloochi, S AF Singh, Jasvinder A. Mahowald, Maren L. Noorbaloochi, Siamak TI Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE TOTAL KNEE ARTHROPLASTY; INTRAARTICULAR; BOTULINUM TOXIN A; RANDOMIZED CONTROLLED TRIAL; PAIN; FUNCTION ID DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; NEUROPATHIC PAIN; OUTCOME MEASURES; CLINICAL-TRIAL; SUBSTANCE-P; RAT BLADDER; JOINT PAIN; OSTEOARTHRITIS; INJECTIONS AB Objective. To assess short-term efficacy of single intraarticular botulinum toxin (IA-BoNT/A) injection in patients with chronically painful total knee arthroplasty (TKA) in a randomized, placebo-controlled, triple-blind study. Methods. Patients with chronic TKA pain (pain > 6 on 0-10 scale and > 6 months post-TKA) evaluated in and referred from orthopedic surgery clinics were recruited. The primary outcome, proportion of patients with clinically meaningful decrease of at least 2 points on 0-10 visual analog scale (VAS) for pain, was compared between treatment groups at 2 months using comparison of proportions test and for all efficacy timepoints (2, 3, and 4 months) using generalized estimating equations (GEE). Secondary outcomes of global assessment, function, and quality of life were compared using GEE, duration of pain relief by t-test, and adverse events by chi-square test. Results. In total, 54 patients with 60 painful TKA were randomized, with main analyses restricted to one TKA per patient (49 TKA in 49 patients). Mean age was 67 years, 84% were men, and mean duration of TKA pain was 4.5 years. A significantly greater proportion of patients (71%) in the IA-BoNT/A group compared to IA-placebo (35%) achieved clinically meaningful reduction in VAS pain at 2 months (p = 0.028) and at all efficacy timepoints (p = 0.019). Duration of meaningful pain relief was significantly greater after IA-BoNT/A, 39.6 days (SD 50.4) compared to IA-placebo, 15.7 days (SD 22.6; p = 0.045). Statistically significantly better scores were seen in IA-BoNT/A vs IA-placebo for all efficacy timepoints for the following outcomes: "very much improved" on physician global assessment of change (p = 0.003); Western Ontario McMaster Osteoarthritis Index physical function (p = 0.026), stiffness (p = 0.004), and total scores (p = 0.024); and Short-Form 36 pain subscale score (p = 0.049). Number of total and serious adverse events was similar between groups, with no patients in either group with new objective motor or sensory deficits during followup. Conclusion. In this single-center randomized trial, single IA-BoNT/A injection provided clinically meaningful short-term improvements in pain, global assessment, and function in patients with chronic painful TKA. A multicenter trial is needed to confirm these findings. (First Release September I 2010; J Rheumatol 2010;37:2377-86; doi:10.3899/jrheum.100336) C1 [Singh, Jasvinder A.; Mahowald, Maren L.] Univ Minnesota, Vet Affairs Med Ctr, Rheumatol Sect, Med Serv, Minneapolis, MN USA. Univ Minnesota, Vet Affairs Med Ctr, Div Rheumatol, Dept Med, Minneapolis, MN USA. Univ Minnesota, Vet Affairs Med Ctr, Dept Med, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Hlth Sci Res, Rochester, MN USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped, Rochester, MN USA. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, MN USA. [Singh, Jasvinder A.] Univ Alabama, Fac Off Tower 805B, Birmingham, AL 35294 USA. RP Singh, JA (reprint author), Univ Alabama, Fac Off Tower 805B, 510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com RI teng, yj/C-4440-2011 OI singh, jasvinder/0000-0003-3485-0006 FU NIH CTSA [1 KL2 RR024151-01]; Arthritis Foundation North Central Chapter Grant; University of Minnesota Academic Health Center; Minnesota Medical Foundation; Allergan Pharmaceuticals, Irvine, CA FX Supported by the NIH CTSA Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Thanslational Research), Arthritis Foundation North Central Chapter Grant, University of Minnesota Academic Health Center Seed Grant, and Minnesota Medical Foundation Grant. Dr. Singh and Dr Mahowald have received research and travel grants from Allergan Pharmaceuticals, Irvine, CA, for other research projects. Dr. Mahowald served as a consultant to Allergan Pharmaceuticals. NR 57 TC 17 Z9 18 U1 1 U2 5 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD NOV PY 2010 VL 37 IS 11 BP 2377 EP 2386 DI 10.3899/jrheum.100336 PG 10 WC Rheumatology SC Rheumatology GA 681HL UT WOS:000284301900030 PM 20810509 ER PT J AU Raval, MV Bilimoria, KY Bentrem, DJ Stewart, AK Ko, CY Reynolds, M Wayne, JD AF Raval, Mehul V. Bilimoria, Karl Y. Bentrem, David J. Stewart, Andrew K. Ko, Clifford Y. Reynolds, Marleta Wayne, Jeffrey D. TI Use of Sentinel Lymph Node Biopsy for Melanoma in Children and Adolescents SO JOURNAL OF SURGICAL ONCOLOGY LA English DT Article DE melanoma; sentinel lymph node biopsy; pediatric oncology; pediatric surgery; National Cancer Data Base ID CANCER-DATA-BASE; UNITED-STATES; PEDIATRIC MELANOMA; MELANOCYTIC LESIONS; MALIGNANT-MELANOMA; SINGLE-INSTITUTION; POPULATION; EPIDEMIOLOGY; EXPERIENCE; SURVIVAL AB Background: Though sentinel lymph node biopsy (SLNB) is an integral component of melanoma staging, little is known about its use in children Methods: Patients (0-18 years) with melanoma diagnosed from 2003 to 2007 in the National Cancer Data Base were assessed Logistic regression models were used to identify clinicopathologic, socioeconomic, and hospital factors associated with SLNB use and lymph node metastases (LNM) Results: 01 671 children, 68 7% underwent SLNB SLNB utilization rates were 39 9% for T1a patients and 87 6% for T1b-T3 patients T1b-T3 patients were more likely to undergo SLNB if they were older (OR 4 86 95% Cl 1 88-12 59) or cared for at Children's hospitals (OR 2 43 95% CI 1 09-5 40) T1b-T3 patients were less likely to undergo SLNB if uninsured (OR 0 25 95% CI 0 08-0 76) Of those with SLNB, 1 I 8 (25 6%) had pathologically confirmed LNM Patients were more likely to have LNM if younger (OR 3 19 95% Cl 1 20-8 51) or having higher T stage. (OR 10 38 95% CI 4 59-23 47) Conclusions: SI,NB use for children with melanoma was associated with clinicopathologic. socioeconomic, and hospital factors Younger patients have a higher likelihood of LNM but are the least likely to undergo SLNB Though overall adherence appears high. there remains an opportunity for improved care for children with melanoma J. Surg Oncol 2010,102 634-639 (C) 2010 Wiley-Liss, Inc C1 [Raval, Mehul V.; Bilimoria, Karl Y.; Stewart, Andrew K.; Ko, Clifford Y.] Amer Coll Surg, Canc Programs, Div Res & Optimal Patient Care, Chicago, IL USA. [Raval, Mehul V.; Reynolds, Marleta] Childrens Mem Hosp, Div Pediat Surg, Chicago, IL 60614 USA. [Raval, Mehul V.; Bilimoria, Karl Y.; Bentrem, David J.; Wayne, Jeffrey D.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Div Gastrointestinal & Oncol Surg, Chicago, IL 60611 USA. [Bentrem, David J.] Jesse Brown VA Med Ctr, Chicago, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Raval, MV (reprint author), 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. OI Raval, Mehul/0000-0002-1527-2661 FU John Gray Research Fellowship; Daniel F and Ada L Rice Foundation; Northwestern University; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service; American College of Surgeons, Commission on Cancer; American Cancer Society FX M V R participates in the American College of Surgeons Clinical Scholars in Residence Program M V R is supported by the John Gray Research Fellowship and the Daniel F and Ada L Rice Foundation. K Y B is supported by a Priority Grant from Northwestern University D J B is supported by a Career Development Award from the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service The National Cancer Data Base is supported by the American College of Surgeons, Commission on Cancer, and the American Cancer Society NR 43 TC 3 Z9 3 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0022-4790 J9 J SURG ONCOL JI J. Surg. Oncol. PD NOV 1 PY 2010 VL 102 IS 6 BP 634 EP 639 DI 10.1002/jso.21683 PG 6 WC Oncology; Surgery SC Oncology; Surgery GA 674OZ UT WOS:000283758300018 PM 20721965 ER PT J AU Friedlander, AH AF Friedlander, Arthur H. TI Untitled SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Letter ID DENTAL PROCEDURES; ARTHROPLASTY C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD NOV PY 2010 VL 141 IS 11 BP 1295 EP 1296 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 680OK UT WOS:000284244100002 PM 21037183 ER PT J AU Alley, DE Koster, A Mackey, D Cawthon, P Ferrucci, L Simonsick, EM Yu, BB Hardy, S Goodpaster, B Sarkisian, C Houston, DK Kritchevsky, SB Cummings, S Lee, JS Tylavsky, FA Newman, A Harris, T AF Alley, Dawn E. Koster, Annemarie Mackey, Dawn Cawthon, Peggy Ferrucci, Luigi Simonsick, Eleanor M. Yu, Binbing Hardy, Susan Goodpaster, Bret Sarkisian, Catherine Houston, Denise K. Kritchevsky, Stephen B. Cummings, Steven Lee, Jung-Sun Tylavsky, Frances A. Newman, Anne Harris, Tamara CA Hlth Aging & Body Composition Stud TI Hospitalization and Change in Body Composition and Strength in a Population-Based Cohort of Older Persons SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE lean mass; weight loss; function; hospitalization; strength ID BED REST; WEIGHT CHANGE; MUSCLE MASS; ADULTS; FRAILTY; HEALTH; WOMEN; DISABILITY; MORTALITY; RECOVERY AB OBJECTIVES: To examine the association between hospitalization and annual changes in body composition and strength in older adults. DESIGN: Cohort study. SETTING: Clinic examinations in Pittsburgh, Pennsylvania, or Memphis, Tennessee. PARTICIPANTS: Well-functioning adults aged 70 to 79 who participated in the Health, Aging and Body Composition Study. MEASUREMENTS: Hospitalizations were reported at annual clinic visits and in semiannual phone interviews. In the event of death or reported hospitalization, hospitalizations were adjudicated according to medical record review. Dual X-ray absorptiometry (DXA) assessments of total, lean, and fat mass were conducted in six annual examinations, and measures of knee extensor strength were conducted in two annual examinations. RESULTS: DXA assessments followed 2,309 hospitalizations. In men and women, hospitalization in the previous year was associated with greater declines in total mass (- 0.76 and -0.81 kg, respectively), fat mass (-0.41 and -0.54 kg), and lean mass (-0.33 and -0.25 kg) (P < .001 for all) than in nonhospitalized participants, after adjustment for demographics and baseline values. Hospitalization was associated with strength declines in men (-4.02 Nm, P = .046) but not in women. Relationships were similar after adjusting for health behaviors and chronic conditions, although the association between hospitalization and strength was attenuated. Associations increased with number of days hospitalized; hospitalizations totaling 8 days or more in the previous year were associated with significantly greater loss of total, lean, and fat mass and loss of strength in both sexes than in nonhospitalized participants. CONCLUSION: Hospitalization is associated with significant changes in body composition and strength in older persons. These effects appear particularly important in persons hospitalized for 8 or more days per year. J Am Geriatr Soc 58:2085-2091, 2010. C1 [Alley, Dawn E.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA. [Koster, Annemarie; Yu, Binbing; Harris, Tamara] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Mackey, Dawn; Cawthon, Peggy; Cummings, Steven] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Ferrucci, Luigi; Simonsick, Eleanor M.] NIA, Longitudinal Studies Sect, Baltimore, MD 21224 USA. [Hardy, Susan; Goodpaster, Bret; Newman, Anne] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Newman, Anne] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA. [Sarkisian, Catherine] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Houston, Denise K.; Kritchevsky, Stephen B.] Wake Forest Univ, Bowman Gray Sch Med, Sticht Ctr Aging, Winston Salem, NC USA. [Lee, Jung-Sun] Univ Georgia, Coll Publ Hlth, Athens, GA 30602 USA. [Tylavsky, Frances A.] Univ Tennessee, Dept Epidemiol, Memphis, TN USA. RP Alley, DE (reprint author), Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA. EM dalley@epi.umaryland.edu RI Koster, Annemarie/E-7438-2010; Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Kritchevsky, Stephen/0000-0003-3336-6781 FU National Institutes of Health, National Institute on Aging (NIA); Organized Research Center on Aging at the University of Maryland, Baltimore; NIA [N01-AG-6-2101, N01-AG-6-2103, N01-AG-2106] FX D. Houston received a speaker honorarium from Abbott Nutrition Health Institute. All other authors have no financial disclosure to report. This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute on Aging (NIA) and by the Organized Research Center on Aging at the University of Maryland, Baltimore. The Health ABC Study is funded under NIA Contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-2106. NR 25 TC 22 Z9 23 U1 4 U2 9 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2010 VL 58 IS 11 BP 2085 EP 2091 DI 10.1111/j.1532-5415.2010.03144.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 676WT UT WOS:000283950100005 PM 21054288 ER PT J AU Hwang, U Richardson, LD Harris, B Morrison, RS AF Hwang, Ula Richardson, Lynne D. Harris, Ben Morrison, R. Sean TI The Quality of Emergency Department Pain Care for Older Adult Patients SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE emergency department; pain; quality of care; geriatrics ID ELDERLY-PATIENTS; MEDICAL-RECORD; CANCER PAIN; MANAGEMENT; ANALGESIA; DEMENTIA; FRACTURE AB OBJECTIVES: To determine whether there are differences in emergency department (ED) pain assessment and treatment for older and younger adults. DESIGN: Retrospective observational cohort. SETTING: Urban, academic tertiary care ED during July and December 2005. PARTICIPANTS: Adult patients with conditions warranting ED pain care. MEASUREMENTS: Age, Charlson comorbidity score, number of prior medications, sex, race and ethnicity, triage severity, degree of pain, treating clinician, and final ED diagnosis. Pain care process measures were pain assessment and treatment and time of activities. RESULTS: One thousand thirty-one ED visits met inclusion criteria; 92% of these had a documented pain assessment. Of those reporting pain, 41% had follow-up pain assessments, and 59% received analgesic medication (58% of these as opioids, 24% as nonsteroidal anti-inflammatory drugs (NSAIDs)). In adjusted analyses, there were no differences according to age in pain assessment and receiving any analgesic. Older patients (65-84) were less likely than younger patients (18-64) to receive opioid analgesics for moderate to severe (odds ratio (OR) 50.44, 95% confidence interval (CI) 50.22-0.88) and were more likely to more likely to receive NSAIDs for mild pain (OR = 3.72, 95% CI = 0.97-14.24). Older adults had a lower reduction of initial to final recorded pain scores (P = .002). CONCLUSION: There appear to be differences in acute ED pain care for older and younger adults. Lower overall reduction of pain scores and less opioid use for the treatment of painful conditions in older patients highlight disparities of concern. Future studies should determine whether these differences represent inadequate ED pain care. J Am Geriatr Soc 58:2122-2128, 2010. C1 [Hwang, Ula; Richardson, Lynne D.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA. [Hwang, Ula; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Hwang, Ula; Morrison, R. Sean] James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Harris, Ben] Univ Illinois, Dept Emergency Med, Advocate Christ Med Ctr, Oak Lawn, IL USA. RP Hwang, U (reprint author), Mt Sinai Sch Med, Dept Emergency Med, 1 Gustave L Levy Pl,Box 1620, New York, NY 10029 USA. EM ula.hwang@mountsinai.org FU National Institute on Aging [K24 AG022345]; Jahnigen Career Development Award FX Ula Hwang was a recipient of a Jahnigen Career Development Award administered by the American Geriatrics Society. R. Sean Morrison is a recipient of a Mid-Career Investigator Award in Patient-Oriented Research (K24 AG022345) from the National Institute on Aging. NR 31 TC 33 Z9 33 U1 3 U2 8 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2010 VL 58 IS 11 BP 2122 EP 2128 DI 10.1111/j.1532-5415.2010.03152.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 676WT UT WOS:000283950100010 PM 21054293 ER PT J AU Espinoza, SE Jung, I Hazuda, H AF Espinoza, Sara E. Jung, Inkyung Hazuda, Helen TI Lower Frailty Incidence in Older Mexican Americans than in Older European Americans: The San Antonio Longitudinal Study of Aging SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE frailty; ethnic differences; older adults ID MINI-MENTAL-STATE; WOMENS HEALTH; ADULTS; ASSOCIATION; PHENOTYPE; MORTALITY; PARADOX; INDEX; ADL AB OBJECTIVES: To directly compare frailty incidence of older Mexican American (MA) and European American (EA) adults. DESIGN: Longitudinal, observational cohort study. SETTING: Socioeconomically diverse neighborhoods in San Antonio, Texas. PARTICIPANTS: Three hundred one older MA and 305 older EA adults in the San Antonio Longitudinal Study of Aging (SALSA) who were nonfrail at baseline. MEASUREMENTS: Frailty was assessed at baseline, and three follow-ups conducted over an average of 9.9 years using well-established criteria from the Cardiovascular Health Study. Covariates were baseline age, sex, socioeconomic status (SES), prefrailty status, diabetes mellitus, and comorbidity. The adjusted ethnic odds (MA vs EA) of incident frailty were estimated using generalized estimating equations. RESULTS: There was no ethnic difference in the unadjusted incidence of frailty over the three follow-up examinations (odds ratio (OR) 50.97, 95% confidence interval (CI) 50.62-1.52), even though baseline SES was significantly lower in MAs than EAs. After covariate adjustment, the odds of incident frailty were significantly lower for MAs than EAs (OR = 0.40, 95% CI = 0.23-0.72). Other significant predictors of frailty in the adjusted model were prefrailty (present vs absent OR = 3.19, 95% CI = 1.86-5.47), education (1-year increment OR = 0.89, 95% CI = 0.83-0.96), and income (1-year increment OR = 0.88, 95% CI = 0.79-2.04). CONCLUSION: These findings lend support to the Hispanic Paradox and suggest that MAs who live to older ages are less likely than similarly aged EAs to become frail. Further research is needed to identify the underlying biological and social mechanisms that explain this finding to enhance the development of interventions for the prevention and treatment of this clinical geriatric syndrome. J Am Geriatr Soc 58:2142-2148, 2010. C1 [Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA. [Espinoza, Sara E.; Hazuda, Helen] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Jung, Inkyung] Yonsei Univ, Coll Med, Dept Biostat, Seoul, South Korea. [Espinoza, Sara E.; Hazuda, Helen] S Texas Vet Healthcare Syst, San Antonio, TX USA. RP Espinoza, SE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Div Geriatr Gerontol & Palliat Med, 7703 Floyd Curl Dr,Mail Code 7875, San Antonio, TX 78229 USA. EM espinozas2@uthscsa.edu FU National Institute on Aging [R01-AG10444, R01-AG16518]; National Center for Research Resources (NCRR) [M01-RR01345, KL2 RR025766] FX Research support was received from National Institute on Aging Grants R01-AG10444 and R01-AG16518 and National Center for Research Resources (NCRR) Grant M01-RR01345. This work was also supported by Clinical and Translational Science Awards Award KL2 RR025766 from NCRR. NR 29 TC 18 Z9 21 U1 3 U2 7 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2010 VL 58 IS 11 BP 2142 EP 2148 DI 10.1111/j.1532-5415.2010.03153.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 676WT UT WOS:000283950100013 PM 21054295 ER PT J AU Al-Aly, Z Zeringue, A Fu, J Rauchman, MI McDonald, JR El-Achkar, TM Balasubramanian, S Nurutdinova, D Xian, H Stroupe, K Abbott, KC Eisen, S AF Al-Aly, Ziyad Zeringue, Angelique Fu, John Rauchman, Michael I. McDonald, Jay R. El-Achkar, Tarek M. Balasubramanian, Sumitra Nurutdinova, Diaria Xian, Hong Stroupe, Kevin Abbott, Kevin C. Eisen, Seth TI Rate of Kidney Function Decline Associates with Mortality SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; NONTRADITIONAL RISK-FACTORS; CORONARY-HEART-DISEASE; REVERSE EPIDEMIOLOGY; RENAL-DISEASE; UNITED-STATES; CARDIOVASCULAR OUTCOMES; VASCULAR CALCIFICATION; DIABETES-MELLITUS; SERUM CREATININE AB The effect of rate of decline of kidney function on risk for death is not well understood Using the Department of Veterans Affairs national databases, we retrospectively studied a cohort of 4171 patients who had rheumatoid arthritis and early stage 3 chronic kidney disease (CKD, estimated GFR 45 to 60 ml/min) and followed them longitudinally to characterize predictors of disease progression and the effect of rate of kidney function decline on mortality After a median of 2 6 years, 1604 (38%) maintained stable kidney function, 426 (10%), 1147 (28%), and 994 (24%) experienced mild moderate, and severe progression of CKD, respectively (defined as estimated GFR decline of 0 to 1, 1 to 4, and >4 ml/min per yr) Peripheral artery disease predicted moderate progression of CKD progression Black race, hypertension, diabetes, cardiovascular disease, and peripheral artery disease predicted severe progression of CKD After a median of 5 7 years, patients with severe progression had a significantly increased risk for mortality (hazard ratio 1 54 95% confidence interval 1 30 to 1 82) compared with those with mild progression, patients with moderate progression exhibited a similar trend (hazard ratio 1 10 95% confidence interval 0 98 to 1 30) Our results demonstrate an independent and graded association between the rate of kidney function decline and mortality Incorporating the rate of decline into the definition of CKD may transform a static definition into a dynamic one that more accurately describes the potential consequences of the disease for an individual C1 [Al-Aly, Ziyad; Rauchman, Michael I.; El-Achkar, Tarek M.] St Louis Vet Affairs Med Ctr, Div Nephrol, St Louis, MO 63106 USA. [Al-Aly, Ziyad; Zeringue, Angelique; Fu, John; McDonald, Jay R.; Balasubramanian, Sumitra; Nurutdinova, Diaria; Xian, Hong; Eisen, Seth] St Louis Vet Affairs Clin Res & Epidemiol Ctr, St Louis, MO USA. [Fu, John] St Louis Univ, Div Biostat, Sch Publ Hlth, St Louis, MO 63103 USA. [McDonald, Jay R.; Nurutdinova, Diaria] Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA. [Stroupe, Kevin] Edward Hines Vet Affairs Med Ctr, Ctr Management Complex Chron Care, Hines, IL USA. [Abbott, Kevin C.] Walter Reed Army Med Ctr, Div Nephrol, Washington, DC 20307 USA. [Eisen, Seth] US Dept Vet Affairs, Washington, DC USA. RP Al-Aly, Z (reprint author), St Louis Vet Affairs Med Ctr, Div Nephrol, 915 N Grand Blvd,111B JC, St Louis, MO 63106 USA. RI Zeringue, Angelique/I-1755-2012; Al-Aly, Ziyad/S-4439-2016 OI Al-Aly, Ziyad/0000-0002-2600-0434; Abbott, Kevin/0000-0003-2111-7112 FU Department of Veterans Affairs [VISN 15] FX This work was funded by a Department of Veterans Affairs VISN 15 Career Development Award to Ziyad Al-Aly, M D NR 48 TC 88 Z9 89 U1 1 U2 5 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD NOV PY 2010 VL 21 IS 11 BP 1961 EP 1969 DI 10.1681/ASN.2009121210 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 689ZL UT WOS:000284969500020 PM 20947634 ER PT J AU Victor, TL Boone, KB Kulick, AD AF Victor, Tara L. Boone, Kyle B. Kulick, Alexis D. TI My head hurts just thinking about it SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Letter ID EXAGGERATION C1 [Victor, Tara L.] Calif State Univ Dominguez Hills, Dept Psychol, Carson, CA 90747 USA. [Victor, Tara L.; Boone, Kyle B.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Boone, Kyle B.] Alliant Int Univ, Calif Sch Forens Studies, Alhambra, CA USA. [Victor, Tara L.; Kulick, Alexis D.] Greater Los Angeles Vet Healthcare Syst, Dept Phys Med & Rehabil, Los Angeles, CA USA. RP Victor, TL (reprint author), Calif State Univ Dominguez Hills, Dept Psychol, 1000 E Victoria St,SBS G305, Carson, CA 90747 USA. NR 6 TC 3 Z9 3 U1 1 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD NOV PY 2010 VL 16 IS 6 BP 1151 EP 1152 DI 10.1017/S1355617710000858 PG 2 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 690RL UT WOS:000285023200023 PM 20673382 ER PT J AU Stelzner, F Stelzner, M AF Stelzner, Friedrich Stelzner, Matthias TI Manometry data support a novel concept of the lower esophageal sphincter system SO LANGENBECKS ARCHIVES OF SURGERY LA English DT Article DE Esophagus; Sphincter; Manometry; Anatomy ID IMPEDANCE CHARACTERISTICS; PARTIAL FUNDOPLICATION; ANTIREFLUX PROCEDURE; MOTOR FUNCTION; ACHALASIA; NISSEN; DISTENSION; DIAPHRAGM; CARDIA; REFLUX AB Purpose Detailed understanding of the functional anatomy of the lower esophageal sphincter (LES) is germane to successful surgical treatment of esophageal disorders. However, a comprehensive concept of the structure-function relationship of the LES is currently lacking. Methods We reviewed published anatomic evidence, medical imaging, and impedance manometry data sets and developed a novel functional concept of the LES. Results Morphologic evidence accumulated over the past three decades indicates that the LES is an anatomic structure that differs markedly from typical ring sphincters of the gastrointestinal tract (e.g., upper esophageal sphincter or anal sphincters). Recent impedance manometry investigations shed new light on the functional anatomy of the LES. These data corroborate a concept of this sphincter as a double-layer, twisted stretch sphincter. This sphincter requires tissue tension for optimal function. Retightening of the longitudinal stretch of the esophagus provides an effective therapy if this tension is lost, e.g., for patients with hiatal hernias. Paralysis of the muscle fibers of this sphincter system results in functional obstruction, and this explains the pathophysiology of "achalasia". Conclusions Based on available data, we propose a novel concept that better explains the structure-function relationship of the LES. Improved knowledge of the biomechanical factors of esophageal disorders can be expected to advance surgical treatment for these diseases. C1 [Stelzner, Friedrich] Univ Klinikum Bonn, Zentrum Chirurg, D-53105 Bonn, Germany. [Stelzner, Friedrich] Univ Bonn, Med Ctr, Dept Surg, D-5300 Bonn, Germany. [Stelzner, Matthias] Univ Calif Los Angeles, Surg Serv, VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Stelzner, Matthias] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. RP Stelzner, F (reprint author), Univ Klinikum Bonn, Zentrum Chirurg, Sigmund Freud Str 25, D-53105 Bonn, Germany. EM Stel33345@aol.com NR 32 TC 5 Z9 5 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1435-2443 J9 LANGENBECK ARCH SURG JI Langenbecks Arch. Surg. PD NOV PY 2010 VL 395 IS 8 BP 1083 EP 1091 DI 10.1007/s00423-010-0662-x PG 9 WC Surgery SC Surgery GA 679ZW UT WOS:000284200300013 PM 20614132 ER PT J AU Marzo, SJ Moeller, CW Sharma, N Cunningham, K Jones, KJ Foecking, EM AF Marzo, Sam J. Moeller, Carl W. Sharma, Nijee Cunningham, Kelly Jones, Kathryn J. Foecking, Eileen M. TI Facial Motor Nuclei Cell Loss With Intratemporal Facial Nerve Crush Injuries in Rats SO LARYNGOSCOPE LA English DT Article DE Facial nerve; facial motor nucleus; facial injury; facial crush injury; rat facial nerve ID POOR FUNCTIONAL RECOVERY; QUALITY-OF-LIFE; PERIPHERAL-NERVE; ELECTRICAL-STIMULATION; CONTRIBUTING FACTORS; GONADAL-STEROIDS; ADULT-RAT; REPAIR; MOTONEURONS; TRANSECTION AB Objectives/Hypothesis: Injuries of cranial nerves that are distal to but near the motor nucleus might result in retrograde motoneuron cell death. The hypothesis of this article is that an intratemporal crush injury of the facial nerve in rats can cause facial motor nuclei cell death. Study Design: Prospective, randomized, controlled animal study. Methods: Sprague-Dawley rats were randomly divided into four groups: intratemporal sham, intratemporal crush injury, extratemporal crush injury, and extratemporal sham. The intratemporal (n = 9) and extratemporal crush injury (n = 4) groups underwent a 60-second crush of the nerve at the facial nerve tympanic segment or main facial nerve trunk distal to the stylomastoid foramen, respectively. The intratemporal sham group (n = 4) underwent identical exposure to the intratemporal crush without subsequent injury. Both sham groups and the extratemporal crush group were sacrificed at 4 weeks. The intratemporal crush group was subdivided into 4(n = 4) and 8-week (n = 5) postinjury groups. Brain sections were stained with thionin and facial motor nuclei were counted under magnification. The contralateral uninjured facial motor nucleus was used to compare motor nucleus cell survival. Results: Intratemporal crush injury resulted in increased cell loss at 4 (89.43% +/- 8.57% standard error of mean) and 8 weeks (85.78% +/- 3.15%) after injury compared to sham injury (119.09% +/- 13.35%) (P < .05). No significant change in cell survival was noted between the distal crush (103.29% +/- 6.34%) and sham group (111.71% +/- 3.24%) (P > .05). Conclusions: A rat intratemporal crush injury resulted in approximately 15% facial motor nuclei cell loss compared to an intratemporal sham injury. An extratemporal crush injury did not lead to any significant facial motor nuclei cell loss. This might have future translational implications in humans with intratemporal facial nerve injuries. C1 [Marzo, Sam J.; Moeller, Carl W.; Cunningham, Kelly; Jones, Kathryn J.; Foecking, Eileen M.] Loyola Univ Chicago, Stritch Sch Med, Dept Otolaryngol Head & Neck Surg, Maywood, IL USA. [Sharma, Nijee] Loyola Univ Chicago, Stritch Sch Med, Dept Neurosci, Maywood, IL USA. [Jones, Kathryn J.] Loyola Univ Chicago, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL USA. [Jones, Kathryn J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev Serv, Hines, IL 60141 USA. RP Marzo, SJ (reprint author), Loyola Univ Hlth Syst, Div Otol Neurotol & Skull Base Surg, Dept Otolaryngol Head & Neck Surg, 2160 S 1st Ave, Maywood, IL 60153 USA. EM smarzo@lumc.edu FU Loyola Otolaryngology Research Fund [B6175R] FX The work was supported by the VA Pilot Grant (No. B6175R), Loyola Otolaryngology Research Fund. The authors have no other funding, financial relationships, or conflicts of interest to disclose. NR 50 TC 4 Z9 4 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD NOV PY 2010 VL 120 IS 11 BP 2264 EP 2269 DI 10.1002/lary.21077 PG 6 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 673FI UT WOS:000283644100024 PM 20830757 ER PT J AU Maciejewski, ML Smith, VA Livingston, EH Kavee, AL Kahwati, LC Henderson, WG Arterburn, DE AF Maciejewski, Matthew L. Smith, Valerie A. Livingston, Edward H. Kavee, Andrew L. Kahwati, Leila C. Henderson, William G. Arterburn, David E. TI Health Care Utilization and Expenditure Changes Associated With Bariatric Surgery SO MEDICAL CARE LA English DT Article DE bariatric; surgery; expenditures; cost; utilization; veterans; weight loss ID LONG-TERM MORTALITY; MORBIDLY OBESE-PATIENTS; GASTRIC BYPASS-SURGERY; OF-VETERANS-AFFAIRS; RISK ADJUSTMENT; SURGICAL CARE; COSTS; OUTCOMES; QUALITY; IMPACT AB Context: Bariatric surgery provides significant reductions in weight and comorbidity, and has the potential to reduce health care utilization. It is unknown whether health care utilization and expenditures are reduced for veterans after bariatric surgery. Objectives: To examine health care utilization and expenditures of severely obese individuals before and after bariatric surgery within the Veterans Health Administration. Design, Setting, and Patients: We conducted a retrospective, longitudinal cohort study of health care use and expenditures among all veterans who underwent bariatric surgery in 1 of 12 approved Department of Veterans Affairs bariatric centers from 2000 to 2006. Bariatric patients were identified via Current Procedural Terminology-4 codes from a database of major surgical procedures maintained by the National Surgical Quality Improvement Program. Main Outcome Measure: The main outcomes of interest for our analysis were multivariable adjusted inpatient and outpatient health care utilization and expenditures in the 3 years prior to surgery and in the 3 years after surgery. Results: Between 2000 and 2006, 846 veterans had bariatric surgery, 25% of whom underwent a laparoscopic procedure. The mean initial body mass index was 48.5, the mean age was 51; and 73% were male. In multivariable models including all years of data, outpatient, inpatient, and overall expenditures significantly decreased in the years after surgery because of higher clinical resources required in the months before and during surgery. When excluding the 6 months leading up to surgery and the 6 months just after surgery, outpatient expenditures remained lower in the post-surgical period, but inpatient and overall expenditures were significantly higher. Conclusion: Our analyses indicate that this cohort of older, male bariatric surgery patients does not achieve a reduction in health care expenditures 3 years after their procedure. These results are at variance from other, similar published studies and may reflect differences in study populations or systems of care. C1 [Maciejewski, Matthew L.; Smith, Valerie A.; Kavee, Andrew L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA. [Maciejewski, Matthew L.] Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA. [Livingston, Edward H.] Univ Texas SW Med Ctr Dallas, Div Gastrointestinal & Endocrine Surg, Dallas, TX 75390 USA. [Livingston, Edward H.] Vet Adm N Texas Hlth Care Syst, Dallas, TX USA. [Livingston, Edward H.] Univ Texas Arlington, Arlington, TX 76019 USA. [Kahwati, Leila C.] Natl Ctr Hlth Promot & Dis Prevent, Dept Vet Affairs, Off Patient Care Serv, Durham, NC USA. [Henderson, William G.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Henderson, William G.] Univ Colorado, Sch Publ Hlth, Dept Biostat, Aurora, CO USA. [Henderson, William G.] Univ Colorado, Colorado Hlth Outcomes Program, Aurora, CO USA. [Arterburn, David E.] Grp Hlth Res Inst Seattle, Seattle, WA USA. [Arterburn, David E.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA. RP Maciejewski, ML (reprint author), Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care 152, 411 W Chapel Hill St,Suite 600, Durham, NC 27705 USA. EM matthew.maciejewski@va.gov FU Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs [IIR 05-201]; Takeda Pharmaceuticals; Surgical Review Corporation; Amgen; Texas Instruments FX Supported by the Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs, project number IIR 05-201. Supported by Takeda Pharmaceuticals and the Surgical Review Corporation, and owns stock in Amgen (to M. L. M.) and from Texas Instruments, and he serves as a contributing editor to JAMA (to E. H. L.). NR 34 TC 15 Z9 15 U1 4 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD NOV PY 2010 VL 48 IS 11 BP 989 EP 998 DI 10.1097/MLR.0b013e3181ef9cf7 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 671HB UT WOS:000283490600007 PM 20940651 ER PT J AU Stallard, E Kinosian, B Zbrozek, AS Yashin, AI Glick, HA Stern, Y AF Stallard, Eric Kinosian, Bruce Zbrozek, Arthur S. Yashin, Anatoliy I. Glick, Henry A. Stern, Yaakov TI Estimation and Validation of a Multiattribute Model of Alzheimer Disease Progression SO MEDICAL DECISION MAKING LA English DT Article DE clinical assessment; outcomes; staging of dementia ID GLOBAL DETERIORATION SCALE; COST-EFFECTIVENESS; DEMENTIA; PREDICTORS; MEMBERSHIP; SELECTION; FEATURES; GRADE; TIME; CARE AB Objectives. To estimate and validate a multiattribute model of the clinical course of Alzheimer disease (AD) from mild AD to death in a high-quality prospective cohort study, and to estimate the impact of hypothetical modifications to AD progression rates on costs associated with Medicare and Medicaid services. Data and Methods. The authors estimated sex-specific longitudinal Grade of Membership (GoM) models for AD patients (103 men, 149 women) in the initial cohort of the Predictors Study (1989-2001) based on 80 individual measures obtained every 6 mo for 10 y. These models were replicated for AD patients (106 men, 148 women) in the 2nd Predictors Study cohort (1997-2007). Model validation required that the disease-specific transition parameters be identical for both Predictors Study cohorts. Medicare costs were estimated from the National Long Term Care Survey. Results. Sex-specific models were validated using the 2nd Predictors Study cohort with the GoM transition parameters constrained to the values estimated for the 1st Predictors Study cohort; 57 to 61 of the 80 individual measures contributed significantly to the GoM models. Simulated, cost-free interventions in the rate of progression of AD indicated that large potential cost offsets could occur for patients at the earliest stages of AD. Conclusions. AD progression is characterized by a small number of parameters governing changes in large numbers of correlated indicators of AD severity. The analysis confirmed that the progression of AD represents a complex multidimensional physiological process that is similar across different study cohorts. The estimates suggested that there could be large cost offsets to Medicare and Medicaid from the slowing of AD progression among patients with mild AD. The methodology appears generally applicable in AD modeling. C1 [Stallard, Eric; Yashin, Anatoliy I.] Duke Univ, Dept Sociol, Durham, NC 27706 USA. [Stallard, Eric; Yashin, Anatoliy I.] Duke Univ, Ctr Populat Hlth & Aging, Durham, NC USA. [Kinosian, Bruce; Glick, Henry A.] Univ Penn Hlth Syst, Div Gen Internal Med, Philadelphia, PA USA. [Kinosian, Bruce] Philadelphia VA Med Ctr, CHERP, Philadelphia, PA USA. [Zbrozek, Arthur S.] Wyeth Pharmaceut, Global Hlth Outcomes Assessment, Collegeville, PA USA. [Stern, Yaakov] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA. [Stern, Yaakov] Columbia Univ Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY 10032 USA. [Stern, Yaakov] Columbia Univ Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA. RP Kinosian, B (reprint author), Ralston House,Rm226,3615 Chestnut St, Philadelphia, PA 19104 USA. EM brucek@mail.med.upenn.edu FU Elan Pharmaceuticals; Wyeth Pharmaceuticals; National Institute on Aging [R01-AG028259, R01-AG030612, R01-AG07370] FX The primary financial support for this study was provided by a grant jointly funded by Elan Pharmaceuticals and Wyeth Pharmaceuticals. Funding for supplemental analysis of the National Long Term Care Survey was provided by the National Institute on Aging through grants R01-AG028259 and R01-AG030612. The Predictors Study is supported by a grant to Dr. Stern from the National Institute on Aging, grant R01-AG07370. The funding agreements ensured the authors' independence in designing the study, interpreting the data, and writing and publishing the report. The following author is employed by a primary sponsor: Arthur S. Zbrozek, Wyeth Pharmaceuticals. The helpful comments of Trent McLaughlin, PhD, Elan Pharmaceuticals, on this article are acknowledged. David L. Straley provided programming support at Duke University. Revision accepted for publication 6 January 2010. NR 35 TC 9 Z9 9 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD NOV-DEC PY 2010 VL 30 IS 6 BP 625 EP 638 DI 10.1177/0272989X10363479 PG 14 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 698FU UT WOS:000285580100001 PM 21183754 ER PT J AU Hickam, DH AF Hickam, David H. TI Decision Aids: Evolving From Novelties to Effective Communication Tools SO MEDICAL DECISION MAKING LA English DT Editorial Material ID CHRONIC ILLNESS; MANAGEMENT C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. RP Hickam, DH (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM hickam@ohsu.edu NR 8 TC 0 Z9 0 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD NOV-DEC PY 2010 VL 30 IS 6 BP 699 EP 700 DI 10.1177/0272989X10387782 PG 2 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 698FU UT WOS:000285580100009 PM 21183757 ER PT J AU Naik, AD Singh, H AF Naik, Aanand D. Singh, Hardeep TI Electronic Health Records to Coordinate Decision Making for Complex Patients: What Can We Learn from Wiki? SO MEDICAL DECISION MAKING LA English DT Article DE decision making; communication; electronic health records; disease management; reviews; quality and safety ID PRIMARY-CARE; EFFECTIVE COMMUNICATION; INFORMATION-TECHNOLOGY; SURVIVORSHIP CARE; MANAGEMENT; OUTCOMES; TRIALS; ERRORS AB Background. Processes of communication that guide decision making among clinicians collaboratively caring for complex patients are poorly understood and vary based on local contexts. In this paper, the authors characterize these processes and propose a wiki-style communication model to improve coordination of decision making among clinicians using an integrated electronic health record (EHR). Methods. A narrative review of current patterns of communication among clinicians sharing medical decisions focusing on the emerging and potential roles of EHRs to enhance communication among clinicians caring for complex patients. Results. The authors present the taxonomy of decision making and communication among clinicians caring for complex patients. They then adapt wiki-style communication to propose a novel model of communication among clinicians for decision making within multidisciplinary disease management programs. Future innovations using wiki-style communication among clinicians are also described and placed in the context of medical decisions by clinicians working together in disease management programs. Conclusions. EHR-based wiki-style applications may have the potential to improve communication and care coordination among clinicians caring for complex patients. This could lead to improved quality and safety within multidisciplinary disease management programs. C1 [Naik, Aanand D.] Baylor Coll Med, Hlth Decis Making & Commun Program, Houston Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Naik, Aanand D.; Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Hlth Policy & Qual Program, Houston Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Naik, Aanand D.; Singh, Hardeep] Baylor Coll Med, John M Eisenberg Ctr Clin Decis & Commun Sci, Houston, TX 77030 USA. RP Naik, AD (reprint author), Houston HSR& Ctr Excellence, Michael E DeBakey VA 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM anaik@bcm.tmc.edu FU NCI NIH HHS [K23CA125585]; NIA NIH HHS [K23AG027144] NR 36 TC 16 Z9 16 U1 4 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD NOV-DEC PY 2010 VL 30 IS 6 BP 722 EP 731 DI 10.1177/0272989X10385846 PG 10 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 698FU UT WOS:000285580100012 PM 21183759 ER PT J AU Weisbord, SD Palevsky, PM AF Weisbord, Steven D. Palevsky, Paul M. TI ACUTE KIDNEY INJURY Kidney injury after contrast media: marker or mediator? SO NATURE REVIEWS NEPHROLOGY LA English DT News Item ID ACUTE-RENAL-FAILURE; CORONARY INTERVENTION; INDUCED NEPHROPATHY; CYSTATIN-C; MORTALITY C1 [Weisbord, Steven D.; Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. RP Weisbord, SD (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Univ Dr, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 10 TC 6 Z9 6 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5061 J9 NAT REV NEPHROL JI Nat. Rev. Nephrol. PD NOV PY 2010 VL 6 IS 11 BP 634 EP 636 DI 10.1038/nrneph.2010.129 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 671VQ UT WOS:000283539900002 PM 20981117 ER PT J AU Handforth, A Homanics, GE Covey, DF Krishnan, K Lee, JY Sakimura, K Martin, FC Quesada, A AF Handforth, Adrian Homanics, Gregg E. Covey, Douglas F. Krishnan, Kathiresan Lee, Jae Yeol Sakimura, Kenji Martin, Fredricka C. Quesada, Arnulfo TI T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor SO NEUROPHARMACOLOGY LA English DT Article DE Essential tremor; Harmaline; Ethosuximide; Zonisamide; Calcium channel; Cerebellum; Inferior olive ID HARMALINE-INDUCED TREMOR; RAT SENSORY NEURONS; ABSENCE SEIZURES; GABA(A) RECEPTOR; CEREBELLAR NEURONS; CA2+ CURRENT; ZONISAMIDE; ANTICONVULSANT; BLOCKADE; MICE AB Essential tremor is a common disorder that lacks molecular targets for therapeutic development. 1-type calcium channel activation has been postulated to underlie rhythmicity in the olivo-cerebellar system that is implicated in essential tremor. We therefore tested whether compounds that antagonize T-type calcium channel currents suppress tremor in two mouse models that possess an essential tremor-like pharmacological response profile. Tremor was measured using digitized spectral motion power analysis with harmaline-induced tremor and in the GABA(A) receptor alpha 1 subunit-null model. Mice were given ethosuximide, zonisamide, the neuroactive steroid (3 beta,5 alpha,17 beta)-17-hydroxyestrane-3-carbonitrile (ECN), the 3,4-dihydroquinazoline derivative KYS05064, the mibefradil derivative NNC 55-0396, or vehicle. In non-sedating doses, each compound reduced harmaline-induced tremor by at least 50% (range of maximal suppression: 53-81%), and in the GABA(A) alpha 1-null model by at least 70% (range 70-93%). Because the 1-type calcium channel Cav3.1 is the dominant subtype expressed in the inferior olive, we assessed the tremor response of Cav3.1-deficient mice to harmaline, and found that null and heterozygote mice exhibit as much tremor as wild-type mice. In addition, ECN and NNC 55-0396 suppressed harmaline tremor as well in Cav3.1-null mice as in wild-type mice. The finding that five 1-type calcium antagonists suppress tremor in two animal tremor models suggests that 1-type calcium channels may be an appropriate target for essential tremor therapy development. It is uncertain whether medications developed to block only the Cav3.1 subtype would exhibit efficacy. Published by Elsevier Ltd. C1 [Handforth, Adrian] Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv W127, Los Angeles, CA 90073 USA. [Homanics, Gregg E.] Univ Pittsburgh, Dept Anesthesiol & Pharmacol, Pittsburgh, PA USA. [Homanics, Gregg E.] Univ Pittsburgh, Dept Biol Chem, Pittsburgh, PA USA. [Covey, Douglas F.; Krishnan, Kathiresan] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO USA. [Lee, Jae Yeol] Kyung Hee Univ, Coll Sci, Res Inst Basic Sci, Seoul, South Korea. [Lee, Jae Yeol] Kyung Hee Univ, Coll Sci, Dept Chem, Seoul, South Korea. [Sakimura, Kenji] Niigata Univ, Brain Res Inst, Dept Cellular Neurobiol, Niigata, Japan. [Martin, Fredricka C.; Quesada, Arnulfo] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Quesada, Arnulfo] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. RP Handforth, A (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv W127, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM charles.handforth@va.gov OI Homanics, Gregg/0000-0003-3641-8153; Lee, Jae Yeol/0000-0001-6622-6692 FU International Essential Tremor Foundation; Ralph M. Parsons Foundation; Veterans Affairs; NIH [AA10422, GM47969]; Korea Institute of Science and Technology FX Cav3.1 mice embryos were provided by the Riken BRC through the National Bio-Resource Project of the MEXT, Japan. This work was supported by the International Essential Tremor Foundation (AQ), The Ralph M. Parsons Foundation, Veterans Affairs (AH), NIH AA10422 (GEH), NIH GM47969 (DFC), and Vision 21 Program, Korea Institute of Science and Technology (JYL). We are grateful for the technical assistance of Brandon Bunker, Ana Artero, and Christopher Shin. NR 42 TC 21 Z9 21 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD NOV PY 2010 VL 59 IS 6 BP 380 EP 387 DI 10.1016/j.neuropharm.2010.05.012 PG 8 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 670UR UT WOS:000283453300003 PM 20547167 ER PT J AU Harner, H Hanlon, AL Garfinkel, M AF Harner, Holly Hanlon, Alexandra L. Garfinkel, Marian TI Effect of Iyengar Yoga on Mental Health of Incarcerated Women: A Feasibility Study SO NURSING RESEARCH LA English DT Article DE incarcerated women; mental health; prison; yoga ID PSYCHIATRIC-DISORDERS; STRESS REDUCTION; DEPRESSION; OSTEOARTHRITIS; INTERVENTION; PREVALENCE; INVENTORY; SYMPTOMS AB Background: Incarcerated women share a disproportionate burden of mental illness. Although psychotropic medications are available to women in prison, adjunctive treatment modalities, such as Iyengar yoga, may increase psychological well-being. Objectives: The purposes of this study were (a) to address the feasibility of providing a gender-responsive exercise intervention within a correctional institution and (b) to observe the effect of a group-format Iyengar yoga program that met two sessions a week for 12 weeks on levels of depression symptoms, anxiety symptoms, and perceived stress among incarcerated women. Methods: A repeated measures design, in which each participant served as her own control, was used. Participants completed three self-administered instruments: the Beck Depression Inventory, the Beck Anxiety Inventory, and the Perceived Stress Scale before treatment (baseline) and during treatment (Weeks 4, 8, and 12). Linear mixed effects models were used to examine statistically significant changes in mental health measures over time, taking advantage of all available data. Results: Although 21 women initially participated in the intervention, 6 women completed the 12-week intervention. A significant linear decrease was demonstrated in symptoms of depression over time, with mean values changing from 24.90 at baseline to 5.67 at Week 12. There was a marginally significant decrease in anxiety over time (12.00 at baseline to 7.33 at Week 12) and a nonlinear change in stress over time, with decreases from baseline to Week 4 and subsequent increases to Week 12. Discussion: Women who participated in this program experienced fewer symptoms of depression and anxiety over time. Findings from this study may be used to improve future interventions focusing on the health outcomes of incarcerated women. C1 [Harner, Holly] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [Garfinkel, Marian] Temple Sch Med, Philadelphia, PA USA. [Garfinkel, Marian] Temple Univ, Sch Podiatr Med, Philadelphia, PA 19122 USA. RP Harner, H (reprint author), La Salle Univ, Sch Nursing & Hlth Sci, Philadelphia, PA 19141 USA. EM harner@lasalle.edu FU Boston College; Center for Health Equity Research at the University of Pennsylvania School of Nursing FX This research was supported by a research incentive grant from Boston College. The authors acknowledge the guidance of Iyengar yoga instructor Ms. Louise Colby and the research assistance from Angela Hou Liang, MSN, WHCNP-BC, and Meggie Gavin Galligan RN, BSN. The authors also thank the Center for Health Equity Research at the University of Pennsylvania School of Nursing for supporting the preparation of this manuscript. NR 35 TC 12 Z9 13 U1 3 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-6562 J9 NURS RES JI Nurs. Res. PD NOV-DEC PY 2010 VL 59 IS 6 BP 389 EP 399 DI 10.1097/NNR.0b013e3181f2e6ff PG 11 WC Nursing SC Nursing GA 675CH UT WOS:000283802200004 PM 20842067 ER PT J AU Madison, DL Lundblad, JR AF Madison, D. L. Lundblad, J. R. TI C-terminal binding protein and poly(ADP)ribose polymerase 1 contribute to repression of the p21(waf1/cip1) promoter SO ONCOGENE LA English DT Article DE Poly(ADP)ribose Polymerase; p21; CtBP; PARP inhibitor ID POLY(ADP-RIBOSE) POLYMERASE-1; GENE-EXPRESSION; ADENOVIRUS E1A; CELLULAR PHOSPHOPROTEIN; COREPRESSOR FUNCTION; NEGATIVE MODULATION; IONIZING-RADIATION; CANCER-CELLS; DNA-DAMAGE; TRANSCRIPTION AB Transcriptional repression by the C-terminal binding protein (CtBP) is proposed to require nicotinamide adenine dinucleotide dehydrogenase (NAD(H). Previous studies have implicated CtBP in transcriptional repression of the p21(waf1/cip1) gene. Similarly, the NAD-dependent poly(adenosine diphosphate) ribose polymerase 1 (PARP1) may affect p21 expression via its NAD-dependent enzymatic activity; we therefore asked if PARP1 and CtBP were functionally linked in regulating p21 transcription. We found that restraint of basal p21 transcription requires both CtBP and PARP1. PARP inhibition attenuated activation of p21 transcription by both p53-independent and p53-dependent processes, in a CtBP-dependent manner. CtBP1 + 2 or PARP1 + 2 knockdown partially activated p21 gene expression, suggesting relief of a corepressor function dependent on both proteins. We localized CtBP-responsive repression elements to the proximal promoter region, and found ZBRK1 overexpression could also overcome DNA damage-dependent, but not p53-dependent activation through this region. By chromatin immunoprecipitation we find dismissal of CtBP from the proximal promoter following DNA-damage, and that PARP1 associates with a CtBP corepressor complex in nuclear extracts. We propose a model in which both CtBP and PARP functionally interact in a corepressor complex as components of a molecular switch necessary for p21 repression, and following DNA damage signals activation of p21 transcription by corepressor dismissal and coactivator recruitment. Oncogene (2010) 29, 6027-6039; doi:10.1038/onc.2010.338; published online 16 August 2010 C1 [Madison, D. L.; Lundblad, J. R.] Oregon Hlth & Sci Univ, Div Endocrinol, Dept Med, Portland, OR 97239 USA. [Madison, D. L.] Portland VA Med Ctr, Endocrine Sect, Dept Hosp & Specialty Med, Portland, OR USA. RP Madison, DL (reprint author), Oregon Hlth & Sci Univ, Div Endocrinol, Dept Med, L-604,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM Madisond@ohsu.edu FU [NIDDK R01DK060133]; [NCI K08CA109158] FX This work as supported by Grants (NIDDK R01DK060133) to JRL and DLM (NCI K08CA109158). We thank J Hildebrand (University of Pittsburgh) for the CtBP MEFs, R Klein (OHSU) for access to and assistance with real time PCR, R Kwok (University of Michigan) for the p53 expression construct and Madeleine Pham and Loren Brown for technical assistance. NR 52 TC 10 Z9 10 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD NOV PY 2010 VL 29 IS 45 BP 6027 EP 6039 DI 10.1038/onc.2010.338 PG 13 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 678VA UT WOS:000284108700005 PM 20711239 ER PT J AU George, M Margolis, ML AF George, Maureen Margolis, Mitchell L. TI Race and Lung Cancer Surgery-A Qualitative Analysis of Relevant Beliefs and Management Preferences SO ONCOLOGY NURSING FORUM LA English DT Article ID ALTERNATIVE MEDICINE USE; AFRICAN-AMERICAN ADULTS; FOCUS GROUPS; LOW-INCOME; BREAST-CANCER; COMPLEMENTARY THERAPIES; RACIAL DISPARITIES; PROSTATE-CANCER; ASTHMA; WOMEN AB Purpose/Objectives: To gain a better understanding of beliefs about the utility of lung cancer resection surgery and preferences for lung cancer management among African American and Caucasian adults. Research Approach: Qualitative. Setting: The Philadelphia Veterans Affairs Medical Center. Participants: 21 participants (9 African Americans and 12 Caucasians; 11 with chronic obstructive pulmonary disease and 10 with lung-cancer). Methodologic Approach: Three focus groups were conducted. Transcripts and field notes were coded, grouped into thematic categories, and explored in later focus groups. Main Research Variables: Beliefs about lung cancer resection surgery and management preferences. Findings: African Americans doubted that surgery was needed, questioned its efficacy, and preferred complementary and alternative medicine (CAM). African Americans and Caucasians believed that exposure to air during surgery could cause tumor spread and were skeptical that smoking caused lung cancer. Therefore, they had a sense of treatment futility. Conversely, Caucasians were impatient with forced waiting for surgery. Both groups believed that surgery would be better accepted if current patients met past surgical patients, obtained second opinions, and had trusting patient-provider relationships. Conclusions: Suspicion about surgeons' motives and perceived ineffectiveness of surgery, as well as support for CAM among African Americans, may contribute to key racial disparities in lung cancer care. Interpretation: If providers understand more clearly the beliefs and preferences that impede acceptance of surgical resection, then they can formulate educational interventions directed at overcoming patient resistance. The clinical utility of such individualized interventions could be evaluated in future studies. C1 [George, Maureen] Univ Penn, Sch Nursing, Ctr Hlth Dispar Res, Family & Community Hlth Div, Philadelphia, PA 19104 USA. [Margolis, Mitchell L.] Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA. RP George, M (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Dispar Res, Family & Community Hlth Div, Philadelphia, PA 19104 USA. EM mgeorge@nursing.upenn.edu FU Center for Health Equity Research and Promotion [LIP 72-011] FX Maureen George, PhD, RN, AE-C, is an assistant professor in the Family and Community Health Division, Center for Health Disparities Research, in the School of Nursing at the University of Pennsylvania, and Mitchell L. Margolis, MD, is a clinical associate professor of medicine in the Pulmonary, Allergy, and Critical Care Division of the Philadelphia Veterans Affairs Medical Center at the University of Pennsylvania Medical Center, both in Philadelphia. This study was supported by a grant from the Center for Health Equity Research and Promotion [LIP 72-011]. George can be reached at mgeorge@nursing.upenn.edu, with copy to editor at ONEEditor@ons.org. (Submitted August 2009. Accepted for publication October, 21, 2009.) NR 46 TC 14 Z9 14 U1 2 U2 6 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD NOV PY 2010 VL 37 IS 6 BP 740 EP 748 DI 10.1188/10.ONF.740-748 PG 9 WC Oncology; Nursing SC Oncology; Nursing GA 680SR UT WOS:000284255200009 PM 21059585 ER PT J AU Mukherjee, R Huang, W Tepikin, AV Gukovskaya, A Criddle, DN Sutton, R AF Mukherjee, R. Huang, W. Tepikin, A. V. Gukovskaya, A. Criddle, D. N. Sutton, R. TI Alisporivir (Deb025) Prevents Necrosis in and Decreases the Severity of Experimental Pancreatitis SO PANCREAS LA English DT Meeting Abstract C1 [Mukherjee, R.; Huang, W.; Tepikin, A. V.; Criddle, D. N.] Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England. [Mukherjee, R.; Huang, W.; Sutton, R.] Royal Liverpool Univ Hosp, NIHR Pancreas Biomed Res Unit, Liverpool, Merseyside, England. [Gukovskaya, A.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Gukovskaya, A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD NOV PY 2010 VL 39 IS 8 BP 1335 EP 1335 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 664FU UT WOS:000282946600160 ER PT J AU Rakonczay, Z Biczo, G Dosa, S Shalbuyeva, N Hracsko, Z Kukor, Z Venglovecz, V Varga, IS Ivanyi, B Wittmann, T Gukovskaya, A Takacs, T Hegyi, P AF Rakonczay, Z., Jr. Biczo, G. Dosa, S. Shalbuyeva, N. Hracsko, Z. Kukor, Z. Venglovecz, V. Varga, I. S. Ivanyi, B. Wittmann, T. Gukovskaya, A. Takacs, T. Hegyi, P. TI Mitochondial Injury Precedes NF-kappa B and Premature Trypsinogen Activation in L-lysine-induced Acute Pancreatitis in Rats SO PANCREAS LA English DT Meeting Abstract C1 [Rakonczay, Z., Jr.; Biczo, G.; Wittmann, T.; Takacs, T.; Hegyi, P.] Univ Szeged, Dept Med 1, Szeged, Hungary. [Dosa, S.; Ivanyi, B.] Univ Szeged, Dept Pathol, Szeged, Hungary. [Hracsko, Z.; Varga, I. S.] Univ Szeged, Dept Biochem & Mol Biol, Szeged, Hungary. [Venglovecz, V.] Univ Szeged, Dept Pharmacol & Pharmacotherapy, Szeged, Hungary. [Shalbuyeva, N.; Gukovskaya, A.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kukor, Z.] Semmelweis Univ, Dept Med Chem Mol Biol & Pathobiochem, H-1085 Budapest, Hungary. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD NOV PY 2010 VL 39 IS 8 BP 1342 EP 1342 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 664FU UT WOS:000282946600188 ER PT J AU Mukherjee, R McQuinn, TC Dugan, MA Saul, JP Spinale, FG AF Mukherjee, Rupak McQuinn, Tim C. Dugan, Melissa A. Saul, J. Philip Spinale, Francis G. TI Cardiac Function and Circulating Cytokines After Endotoxin Exposure in Neonatal Mice SO PEDIATRIC RESEARCH LA English DT Article ID FLOW CARDIOPULMONARY BYPASS; ARTERIAL SWITCH OPERATION; INDUCED ORGAN DAMAGE; N-ACETYLCYSTEINE; OXIDATIVE STRESS; INFLAMMATORY RESPONSE; CARDIOPLEGIC ARREST; INNATE IMMUNITY; CONSCIOUS RATS; SHOCK AB Complications after cardiac surgery in neonates can occur because of activation of the inflammatory system. This study used lipopolysaccharide (LPS) endotoxin exposure to cause cytokine activation in neonatal mice and examine left ventricular (LV) function and the effects of antioxidant treatment on cytokine levels. Neonatal mice (6 d old) were injected with either 25 mg/kg LPS (n = 13) or PBS (n = 14), and LV function (echocardiography) was measured at 4 h. Plasma levels of TNF-alpha, IL-4, IL-6, and IL-10 were measured at 30 min, I, 2, and 4 h after injection (a = 5 mice per group). Effects of pretreatment with N-acetylcysteine (NAC, 50 mg/kg) on cytokine levels were examined at 2 and 4 h after PBS or LPS (n = 5 mice per group). Four hours after LPS, heart rate was increased (434 +/- 14 versus 405 +/- 14 bpm, p < 0.05). LV end-diastolic dimension and ejection time were reduced with LPS (both p < 0.05). LPS exposure increased plasma TNF-alpha IL-6, and IL-10 levels. NAC pretreatment attenuated the increases in TNF-alpha and IL-6 levels, but augmented IL-10 levels at 2 h post-LPS. LPS exposure altered cardiac performance and activated cytokines in neonatal mice, which may be ameliorated using antioxidants. (Pediatr Res 68: 381-386, 2010) C1 [Mukherjee, Rupak; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA. [Mukherjee, Rupak; McQuinn, Tim C.; Dugan, Melissa A.; Saul, J. Philip] Med Univ S Carolina, Div Pediat Cardiol, Charleston, SC 29425 USA. [Spinale, Francis G.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Mukherjee, R (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Strom Thurmond Res Bldg,770 MUSC Complex,Suite 62, Charleston, SC 29425 USA. EM mukherr@musc.edu FU National Heart, Lung, and Blood Institute [HL-45024, HL-97012, PO1-48788]; VA; Division of Pediatric Cardiology FX Supported, in part, by Grants HL-45024, HL-97012, and PO1-48788 from National Heart, Lung, and Blood Institute, a VA Merit Award [to F.G.S.], and departmental funds from the Division of Pediatric Cardiology. NR 40 TC 9 Z9 10 U1 0 U2 1 PU INT PEDIATRIC RESEARCH FOUNDATION, INC PI BALTIMORE PA 351 W CAMDEN ST, BALTIMORE, MD 21201-2436 USA SN 0031-3998 J9 PEDIATR RES JI Pediatr. Res. PD NOV PY 2010 VL 68 IS 5 BP 381 EP 386 PG 6 WC Pediatrics SC Pediatrics GA 670GR UT WOS:000283409700003 PM 20613681 ER PT J AU Figlewicz, DP Sipols, AJ AF Figlewicz, Dianne P. Sipols, Alfred J. TI Energy regulatory signals and food reward SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR LA English DT Review DE Insulin; Leptin; Ghrelin; Motivation; Food intake; Reward; Dopamine ID VENTRAL TEGMENTAL AREA; BLOOD-BRAIN-BARRIER; MELANIN-CONCENTRATING HORMONE; HYPOTHALAMIC NEUROPEPTIDE-Y; CENTRAL-NERVOUS-SYSTEM; HIGH-FAT DIET; LEPTIN-RESPONSIVE NEURONS; OPIOID RECEPTOR-BINDING; NUCLEUS-ACCUMBENS SHELL; AGOUTI-RELATED PEPTIDE AB The hormones insulin leptin and ghrelin have been demonstrated to act in the central nervous system (CNS) as regulators of energy homeostasis acting at medial hypothalamic sites Here we summarize research demonstrating that in addition to direct homeostatic actions at the hypothalamus CNS circuitry that subserves reward and is also a direct and indirect target for the action of these endocrine regulator, of energy homeostasis Specifically insulin and leptin can decrease food reward behaviors and modulate the function of neurotransmitter systems and neural circuitry that mediate food reward the midbrain dopamine (DA) and opioidergic pathways Ghrelin can increase food reward behaviors and support midbrain DA neuronal function We summarize discussion of behavioral systems and cellular evidence in support of the contributions of reward circuitry to the homeostatic roles of these hormones in the CNS The understanding of neuroendocrine modulation of food reward as well as food reward modulation by diet and obesity may point to new directions for therapeutic approaches to overeating or eating disorders Published by Elsevier Inc C1 [Figlewicz, Dianne P.] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98108 USA. [Figlewicz, Dianne P.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Sipols, Alfred J.] Univ Latvia, Fac Med, LV-1586 Riga, Latvia. [Sipols, Alfred J.] Univ Latvia, Inst Expt & Clin Med, LV-1586 Riga, Latvia. RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, 1660 S Columbian Way, Seattle, WA 98108 USA. FU Dept of Veterans Affairs; NIH [DK40963]; University of Latvia [Y2-ZP84-003] FX This work is supported by a Career Scientist Award from the Dept of Veterans Affairs and NIH Grant DK40963 (DPF) and a University of Latvia Grant Y2-ZP84-003 (AJS) NR 249 TC 64 Z9 65 U1 2 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0091-3057 J9 PHARMACOL BIOCHEM BE JI Pharmacol. Biochem. Behav. PD NOV PY 2010 VL 97 IS 1 SI SI BP 15 EP 24 DI 10.1016/j.pbb.2010.03.002 PG 10 WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy GA 689YA UT WOS:000284965800003 PM 20230849 ER PT J AU Lee, TJ AF Lee, Timothy J. TI Pharmacologic Treatment for Low Back Pain: One Component of Pain Care SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Article DE Low back pain; Acetaminophen; Nonsteroidal anti-inflammatory drugs; Muscle relaxants; Antidepressants; Antiepileptics; Opioids ID OPIOID PRESCRIPTIONS; PROGNOSIS; THERAPY; TRIAL; COST AB Analgesic medications are commonly used for low back pain (LBP) Evidence on the efficacy of pharmacologic therapy for LBP comes from clinical trials that have many limitations including short-term studies and selective trial populations Evidence currently supports the use of short-term pharmacologic treatment for LBP However the safety and efficacy of long-term pharmacologic therapy for LBP is uncertain and therefore best used with caution monitoring and as one component of a comprehensive paincare approach emphasizing rehabilitation C1 VA Puget Sound, Seattle, WA 98108 USA. RP Lee, TJ (reprint author), VA Puget Sound, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 20 TC 5 Z9 5 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 J9 PHYS MED REH CLIN N JI Phys. Med. Rehabil. Clin. N. Am. PD NOV PY 2010 VL 21 IS 4 BP 793 EP + DI 10.1016/j.pmr.2010.06.013 PG 9 WC Rehabilitation SC Rehabilitation GA 687PJ UT WOS:000284790100009 PM 20977961 ER PT J AU Stout, A AF Stout, Alison TI Interventions for Low Back Pain Conclusions SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Editorial Material C1 [Stout, Alison] Univ Washington, Dept Rehabil, Spine & Musculoskeletal Med Rehabil Care Serv, Vet Adm Puget Sound, Seattle, WA 98195 USA. [Stout, Alison] VA Puget Sound HCS, Dept Rehabil, Seattle, WA 98108 USA. RP Stout, A (reprint author), Univ Washington, Dept Rehabil, Spine & Musculoskeletal Med Rehabil Care Serv, Vet Adm Puget Sound, Seattle, WA 98195 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 J9 PHYS MED REH CLIN N JI Phys. Med. Rehabil. Clin. N. Am. PD NOV PY 2010 VL 21 IS 4 BP 817 EP 817 DI 10.1016/j.pmr.2010.08.003 PG 1 WC Rehabilitation SC Rehabilitation GA 687PJ UT WOS:000284790100011 PM 20977963 ER PT J AU Stout, A AF Stout, Alison TI Epidural Steroid Injections for Low Back Pain SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Article DE Epidural steroid; Spine intervention; Lumbar; Transforaminal; Interlaminar; Caudal; Low back pain; Low back pain treatment ID SPINAL STENOSIS; RADICULAR PAIN; LUMBOSACRAL RADICULOPATHY; NITRIC-OXIDE; DOUBLE-BLIND; SCIATICA; INTERLAMINAR; EFFICACY; DISC; HERNIATIONS AB Epidural steroid injection (ESI) has been used as a treatment for low back pain for over 50 years In the last 10 to 15 years, there has been a significant increase in the use of ESIs for the treatment of low back pain and radicular pain without clear improvements in outcomes Recent literature has focused on the use of ESIs as treatment for radicular pain associated with low back pain with some studies showing benefit over control groups for limb symptoms There is a lack of literature, however, to support the use of ESIs for the treatment of axial low back pain The theoretical basis for their use technical considerations and the literature available for different approaches of access to the epidural space as pertaining to the treatment for low back pain without radiculopathy are reviewed C1 [Stout, Alison] Univ Washington, Dept Rehabil, Seattle, WA 98195 USA. RP Stout, A (reprint author), VA Puget Sound HCS, Rehabil Care Serv, 117 RCS,1660 S Columbian Way, Seattle, WA 98108 USA. NR 51 TC 10 Z9 12 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 J9 PHYS MED REH CLIN N JI Phys. Med. Rehabil. Clin. N. Am. PD NOV PY 2010 VL 21 IS 4 BP 825 EP + DI 10.1016/j.pmr.2010.08.001 PG 11 WC Rehabilitation SC Rehabilitation GA 687PJ UT WOS:000284790100013 PM 20977965 ER PT J AU Stout, A AF Stout, Alison TI Discography SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Article DE Discography; Spine intervention; Lumbar disc; Low back pain; Low back pain treatment ID LOW-BACK-PAIN; LUMBAR DISCOGRAPHY; ASYMPTOMATIC SUBJECTS; PROVOCATIVE DISCOGRAPHY; INTERVERTEBRAL DISC; SYMPTOMS; SPINE; DEGENERATION; FUSION; RATES AB Discography is a purely diagnostic interventional procedure performed to confirm or refute the hypothesis that a specific lumbar disc is the predominant source of a patient's low back pain In patients with severe low back pain, unresponsive to conservative care discography is used when clinical evaluation suggests that the pain is emanating from the intervertebral disc and other sources of pain have been ruled out The evidence for its use remains controversial There is variability and subjectivity in discography techniques and diagnostic criteria making some investigators question its validity When standardized diagnostic criteria are used, however, the specificity of discography improves dramatically Recently long-term side effects have been studied and lumbar discography seems to increase disc degeneration and herniation as detected on magnetic resonance imaging Although the clinical significance is unclear it is an important risk to consider prior to performing discography and changes in discography techniques may be indicated Discography remains the only technique, however that can be used to determine whether a patient's low back pain is emanating from the intervertebral disc and is a valid test when coupled with careful patient selection strict adherence to standardized technique and diagnostic criteria and consideration of possible long-term sequelae C1 [Stout, Alison] Vet Affairs Puget Sound Hlth Care Syst, Dept Rehabil, Rehabil Care Serv, Seattle, WA 98108 USA. [Stout, Alison] Univ Washington, Dept Rehabil, Seattle, WA 98195 USA. [Stout, Alison] Univ Washington, Spine & Musculoskeletal Med Rehabil Care Serv, Vet Adm Puget Sound, Dept Rehabil, Seattle, WA 98195 USA. RP Stout, A (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Rehabil, Rehabil Care Serv, 117 RCS,1660 S Columbian Way, Seattle, WA 98108 USA. NR 29 TC 7 Z9 8 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 J9 PHYS MED REH CLIN N JI Phys. Med. Rehabil. Clin. N. Am. PD NOV PY 2010 VL 21 IS 4 BP 859 EP + DI 10.1016/j.pmr.2010.07.002 PG 10 WC Rehabilitation SC Rehabilitation GA 687PJ UT WOS:000284790100017 PM 20977969 ER PT J AU Stineman, MG Streim, JE AF Stineman, Margaret Grace Streim, Joel E. TI The Biopsycho-ecological Paradigm: A Foundational Theory for Medicine SO PM&R LA English DT Review AB The current biomedical and psychosocial frameworks that form the conceptual basis of medicine today are insufficient to address the needs of the medically complex and environmentally challenged populations of patients often cared for by physical medicine and rehabilitation specialists. The expanded biopsycho-ecological model of health, illness, injury, and disability operating through mechanisms of Health Environmental Integration (HEI) encourages a more complete understanding of illness, injury, activity limitation, and participation restriction as arising at the interface between the person and the environment. HEI recognizes complex interacting multilevel functional hierarchies beginning at the cellular level and ending at the individual's experience of the environment. Although the foci of illness and injury are within the body and mind, the physical and social environments contain elements that can cause or exacerbate disease and barriers that interact in ways that lead to injuries and disabilities. Furthermore, these environments hold the elements from which treating agents, facilitators, and social supports must be fashioned. The highly integrative biopsycho-ecological framework provides an expanded basis for understanding the objective causes and subjective meanings of disabilities. Disabilities are reduced through HEI by seeking to maximally integrate the body and mind (the self) with both the surrounding physical environment and other people in society. HEI offers mechanisms for interdisciplinary research, an expanded framework for education and empowerment, and a blueprint for optimizing day-to-day clinical care at both the individual patient and treatment population levels in the ever-changing scientific, political, and policy environments. PM R 2010;2:1035-1045 C1 [Stineman, Margaret Grace] Ctr Clin Epidemiol & Biostat, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA. [Streim, Joel E.] Univ Penn, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA. [Streim, Joel E.] Philadelphia Vet Affairs Med Ctr, VISN Mental Illness Res Clin & Educ Ctr 4, Philadelphia, PA USA. RP Stineman, MG (reprint author), Ctr Clin Epidemiol & Biostat, Dept Phys Med & Rehabil, 904 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM mstinema@mail.med.upenn.edu FU NIH [R01-AG032420] FX This work was supported in part by grant R01-AG032420 from the NIH. NR 93 TC 19 Z9 20 U1 2 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 J9 PM&R JI PM&R PD NOV PY 2010 VL 2 IS 11 BP 1035 EP 1045 DI 10.1016/j.pmrj.2010.06.013 PG 11 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA V24LS UT WOS:000208412500008 PM 21093839 ER PT J AU Rotondi, AJ Anderson, CM Haas, GL Eack, SM Spring, MB Ganguli, R Newhill, C Rosenstock, J AF Rotondi, Armando J. Anderson, Carol M. Haas, Gretchen L. Eack, Shaun M. Spring, Michael B. Ganguli, Rohan Newhill, Christina Rosenstock, Jason TI Web-Based Psychoeducational Intervention for Persons With Schizophrenia and Their Supporters: One-Year Outcomes SO PSYCHIATRIC SERVICES LA English DT Article ID PSYCHIATRIC-INPATIENTS; FAMILY MANAGEMENT; FEASIBILITY; RELAPSE; METAANALYSIS; PREVENTION; ILLNESS; CARE AB Objective: This study examined the use of a uniquely designed Web site and home computers to deliver online multifamily psychoeducational therapy to persons with schizophrenia and their informal supports (family and friends). Web site usage and outcome benefits are reported. Methods: Thirty-one persons with schizophrenia or schizoaffective disorder and 24 support persons were randomly assigned to the online intervention (telehealth) or treatment as usual (usual care) condition. At three, six, and 12 months, interviewer-administered assessments were conducted with participants. Intention-to-treat analyses compared persons with schizophrenia in the two study conditions on severity of positive symptoms and knowledge of schizophrenia. Support persons in the two study conditions were compared on knowledge of schizophrenia. Each participant's usage of the Web site was logged. Results: Persons with schizophrenia in the telehealth condition had a large and significant reduction in positive symptoms (p=.042, d=-.88) and a large and significant increase in knowledge of schizophrenia compared with their counterparts in the usual care condition. Support persons in the telehealth condition showed a large and significant increase in knowledge about prognosis compared with those in the usual care condition (p=.036, d=1.94). Persons with schizophrenia used the Web site to a much greater extent (pages viewed and time spent) than support persons. Conclusions: These findings suggest that online delivery of psychotherapeutic treatment and educational resources to consumers' homes has considerable potential to improve consumer well-being and offers several advantages over standard clinic-based delivery models. (Psychiatric Services 61: 1099-1105, 2010) C1 [Rotondi, Armando J.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA. [Eack, Shaun M.; Newhill, Christina] Univ Pittsburgh, Dept Social Work, Pittsburgh, PA 15260 USA. [Spring, Michael B.] Univ Pittsburgh, Dept Informat Sci, Pittsburgh, PA 15260 USA. [Anderson, Carol M.; Haas, Gretchen L.; Ganguli, Rohan; Rosenstock, Jason] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA. [Rotondi, Armando J.; Haas, Gretchen L.] Vet Affairs Pittsburgh Healthcare Syst, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Rotondi, AJ (reprint author), Univ Pittsburgh, Dept Crit Care Med, 644 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15260 USA. EM rotondi@pitt.edu RI lyp, maggie/G-1471-2011 FU National Institute of Mental Health [R01 MH63484]; Abbott Laboratories; Bristol Myers-Squibb FX This project was supported by grant R01 MH63484 from the National Institute of Mental Health.; Dr. Eack receives consulting fees from Abbott Laboratories. Dr. Ganguli is a consultant for Janssen Pharmaceuticals, Johnson & Johnson, and Eli Lilly and Company, and he works under a research grant funded by Bristol MyersSquibb. The other authors report no competing interests. NR 38 TC 57 Z9 57 U1 6 U2 25 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD NOV PY 2010 VL 61 IS 11 BP 1099 EP 1105 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 673IA UT WOS:000283651500010 PM 21041348 ER PT J AU Herbst, E Metzler, TJ Lenoci, M McCaslin, SE Inslicht, S Marmar, CR Neylan, TC AF Herbst, Ellen Metzler, Thomas J. Lenoci, Maryann McCaslin, Shannon E. Inslicht, Sabra Marmar, Charles R. Neylan, Thomas C. TI Adaptation effects to sleep studies in participants with and without chronic posttraumatic stress disorder SO PSYCHOPHYSIOLOGY LA English DT Article DE Posttraumatic stress disorder; Adaptation effects; First night effect; Ambulatory polysomnography ID ADMINISTERED PTSD SCALE; PITUITARY-ADRENAL AXIS; LABORATORY ADAPTATION; VIETNAM VETERANS; NIGHT; HOME; DISTURBANCES; VARIABILITY; PARAMETERS; INSOMNIACS AB The "first night effect" (FNE) is the alteration of sleep architecture observed on the first night of polysomnographic (PSG) studies. It is unclear whether the FNE reflects adaptation to the equipment, sleeping environment, or both. Moreover, it is possible that certain patient populations, such as those with posttraumatic stress disorder (PTSD), demonstrate greater adaptation effects that are highly context dependent. We assessed FNE in participants with PTSD and healthy controls in a cross-sectional study consisting of PSG testing at home and in the hospital. Contrary to our expectations, the PTSD group showed no adaptation effects in either setting. Only the control group assigned to the "hospital first" condition showed significant decreases in total sleep time on night 1 versus night 2 of the study. The results suggest that the FNE is related to adaptation to the combination of the hospital environment and the recording equipment. C1 [Herbst, Ellen; Metzler, Thomas J.; McCaslin, Shannon E.; Inslicht, Sabra; Marmar, Charles R.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Herbst, Ellen; Metzler, Thomas J.; Lenoci, Maryann; McCaslin, Shannon E.; Inslicht, Sabra; Marmar, Charles R.; Neylan, Thomas C.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA USA. RP Neylan, TC (reprint author), VA Med Ctr, Psychiat Serv 116P, PTSD Program, 4150 Clement St, San Francisco, CA 94121 USA. EM Thomas.Neylan@ucsf.edu FU National Institutes of Health [MH057157, MH73978]; Sierra Pacific Mental Illness and Education Clinical Center (MIRECC); NIH/NCRRUCSF-CTSI [UL1 RR024131] FX This work was supported by the National Institutes of Health (TCN: MH057157 & MH73978), the Sierra Pacific Mental Illness and Education Clinical Center (MIRECC), and from the NIH/NCRRUCSF-CTSI Grant Number UL1 RR024131. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 36 TC 11 Z9 12 U1 1 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0048-5772 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PD NOV PY 2010 VL 47 IS 6 BP 1127 EP 1133 DI 10.1111/j.1469-8986.2010.01030.x PG 7 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 663HU UT WOS:000282874800016 PM 20456661 ER PT J AU Li, HK Florez-Arango, JF Hubbard, LD Esquivel, A Danis, RP Krupinski, EA AF Li, Helen K. Florez-Arango, Jose F. Hubbard, Larry D. Esquivel, Adol Danis, Ronald P. Krupinski, Elizabeth A. TI GRADING DIABETIC RETINOPATHY SEVERITY FROM COMPRESSED DIGITAL RETINAL IMAGES COMPARED WITH UNCOMPRESSED IMAGES AND FILM SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE classification; diabetic retinopathy; digital; film; fundus photography; image compression; JND; JPEG2000; just-noticeable difference; reproducibility; telemedicine ID VISUAL-SYSTEM MODEL; COPY MAMMOGRAPHY DISPLAY; OBSERVER PERFORMANCE; PHOTOGRAPHY; DIAGNOSIS; JPEG; TELEOPHTHALMOLOGY; TELEMEDICINE; CRT AB Purpose: To compare research grading of diabetic retinopathy (DR) severity level from compressed digital images versus uncompressed images and film. Methods: Compressed (JPEG2000, 37:1) digital images (C) were compared with uncompressed digital (U) and film (F) stereoscopic photographs from a 152-eye cohort with full-spectrum Early Treatment Diabetic Retinopathy Study severity levels for agreement on severity level, DR presence with ascending severity threshold, presence of DR index lesions, and repeatability of grading. Results: Classification of Early Treatment Diabetic Retinopathy Study severity levels from C images agreed substantially with results from F images (kappa = 0.60, kappa(w) [linear weighted] = 0.86) and uncompressed digital images (kappa = 0.76, kappa(w) = 0.92). For agreement of uncompressed digital versus F images, kappa = 0.62 and kappa(w) = 0.86. Distribution of Early Treatment Diabetic Retinopathy Study levels was not significantly different between C and F images (P = 0.09, Bhapkar's test for marginal homogeneity). For presence/absence of DR at 8 ascending severity thresholds, agreement between C and F was "almost perfect'' (kappa >= 0.8). Agreement on severity level between readers with C images was at least as good as that with uncompressed digital image or F. Repeatability of severity threshold grading between readers was similar using C or F images. For identifying individual DR lesions, agreement between C and F ranged from "moderate'' to "perfect.'' Agreement of grading venous beading from C was slightly lower than from F. Conclusion: Full Early Treatment Diabetic Retinopathy Study scale DR severity level grading using C images is comparable to that using U images or film. RETINA 30:1651-1661, 2010 C1 [Li, Helen K.] Thomas Jefferson Univ, Dept Ophthalmol, Philadelphia, PA 19107 USA. [Li, Helen K.; Florez-Arango, Jose F.] Univ Texas Hlth Sci Ctr, Sch Biomed Informat, Houston, TX USA. [Florez-Arango, Jose F.] Univ Antioquia, Sch Med, Medellin, Colombia. [Hubbard, Larry D.; Danis, Ronald P.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA. [Esquivel, Adol] Baylor Coll Med, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. [Krupinski, Elizabeth A.] Univ Arizona, Dept Radiol, Tucson, AZ 85724 USA. RP Li, HK (reprint author), Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, 301 Univ Blvd, Galveston, TX 77555 USA. EM hlimed@mac.com OI Florez-Arango, Jose F/0000-0001-9083-0195 FU Juvenile Diabetes Foundation Research International, New York, NY; Research to Prevent Blindness FX Supported by a grant from Juvenile Diabetes Foundation Research International, New York, NY (H.K.L.) and by unrestricted grants from the Research to Prevent Blindness (Department of Ophthalmology and Visual Sciences, The University of Texas Medical Branch and the Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health). NR 42 TC 5 Z9 5 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0275-004X J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD NOV-DEC PY 2010 VL 30 IS 10 BP 1651 EP 1661 DI 10.1097/IAE.0b013e3181e3790b PG 11 WC Ophthalmology SC Ophthalmology GA 678HL UT WOS:000284064600014 PM 20921928 ER PT J AU Wylie, KP Tregellas, JR AF Wylie, Korey P. Tregellas, Jason R. TI The role of the insula in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Review DE Insula; Schizophrenia; Neuroimaging; Faces; Prosody; Acetylcholine ID AUDITORY-VERBAL HALLUCINATIONS; FUNCTIONAL MAGNETIC-RESONANCE; MATTER VOLUME ABNORMALITIES; FACIAL AFFECT RECOGNITION; VOXEL-BASED MORPHOMETRY; SELF-FACE RECOGNITION; COMMON NEURAL BASIS; OLD-WORLD MONKEY; HUMAN BRAIN; EMOTIONAL PROSODY AB Involvement of the insular cortex is a common finding in neuroanatomical studies of schizophrenia, yet its contribution to disease pathology remains unknown. This review describes the normal function of the insula and examines pathology of this region in schizophrenia. The insula is a cortical structure with extensive connections to many areas of the cortex and limbic system. It integrates external sensory input with the limbic system and is integral to the awareness of the body's state (interoception). Many deficits observed in schizophrenia involve these functions and may relate to insula pathology. Furthermore, reports describing deficits caused by lesions of the insula parallel deficits observed in schizophrenia. Examples of insula-related functions that are altered in schizophrenia include the processing of both visual and auditory emotional information, pain, and neuronal representations of the self. The last of these functions, processing representations of the self, plays a key role in discriminating between self-generated and external information, suggesting that insula dysfunction may contribute to hallucinations, a cardinal feature of schizophrenia. Published by Elsevier B.V. C1 [Wylie, Korey P.; Tregellas, Jason R.] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA. [Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA. RP Tregellas, JR (reprint author), Univ Colorado Denver, Dept Psychiat, Mail Stop F546,13001 E 17th Pl, Aurora, CO 80045 USA. EM Jason.Tregellas@ucdenver.edu RI Tregellas, Jason/J-3637-2015 FU NIMH NIH HHS [P50 MH086383] NR 166 TC 95 Z9 96 U1 6 U2 25 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV PY 2010 VL 123 IS 2-3 BP 93 EP 104 DI 10.1016/j.schres.2010.08.027 PG 12 WC Psychiatry SC Psychiatry GA 687RN UT WOS:000284795700001 PM 20832997 ER PT J AU Iyer, RS Bhargava, P Medverd, JR AF Iyer, Ramesh S. Bhargava, Puneet Medverd, Jonathan R. TI A 65-year-old man presents with pelvic pain SO SKELETAL RADIOLOGY LA English DT Editorial Material C1 [Bhargava, Puneet; Medverd, Jonathan R.] Univ Washington, Dept Radiol, Body Imaging Sect, Seattle, WA 98108 USA. [Bhargava, Puneet; Medverd, Jonathan R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Iyer, Ramesh S.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA. RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, Body Imaging Sect, 1660 S Columbian Way, Seattle, WA 98108 USA. EM bhargp@uw.edu RI Bhargava, Puneet /F-1330-2011 OI Bhargava, Puneet/0000-0002-3849-9666 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2348 J9 SKELETAL RADIOL JI Skeletal Radiol. PD NOV PY 2010 VL 39 IS 11 BP 1129 EP 1129 DI 10.1007/s00256-010-0898-0 PG 1 WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging GA 650PF UT WOS:000281861100011 ER PT J AU Iyer, R Bhargava, P Medverd, J AF Iyer, Ramesh S. Bhargava, Puneet Medverd, Jonathan R. TI A 65-year-old man presents with pelvic pain SO SKELETAL RADIOLOGY LA English DT Editorial Material DE Tophaceous gout; Symphysis pubis ID TOPHACEOUS GOUT; SYMPHYSIS C1 [Bhargava, Puneet; Medverd, Jonathan R.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Bhargava, Puneet; Medverd, Jonathan R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Iyer, Ramesh S.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA. RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, 1660 S Columbian Way, Seattle, WA 98195 USA. EM bhargp@uw.edu RI Bhargava, Puneet /F-1330-2011 NR 9 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2348 J9 SKELETAL RADIOL JI Skeletal Radiol. PD NOV PY 2010 VL 39 IS 11 BP 1151 EP 1152 DI 10.1007/s00256-010-0899-z PG 2 WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging GA 650PF UT WOS:000281861100015 PM 20405125 ER PT J AU Boyd, JE Katz, EP Link, BG Phelan, JC AF Boyd, Jennifer E. Katz, Emerald P. Link, Bruce G. Phelan, Jo C. TI The relationship of multiple aspects of stigma and personal contact with someone hospitalized for mental illness, in a nationally representative sample SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY LA English DT Article DE Stigma; Mental illness; Survey; Personal experience; Contact ID SOCIAL DISTANCE; PERCEIVED STIGMA; PEOPLE; ILL; DISCRIMINATION; CONSEQUENCES; SEVERITY AB The stigma of mental illness has been shown to be affected by personal contact with mental illness and by a belief in the genetic heritability of mental illness. We use data from a nationally representative survey to test whether the relationship of stigma with contact remains after taking into account the effects of genetic beliefs and other background characteristics. Contact was defined as a history of psychiatric hospitalization among respondents themselves, their family members, or their friends. Respondents answered questions about a vignette character with a mental illness. We found that respondents with contact felt less anger and blame toward the character, thought that the character had a more serious problem, and would want less social distance from the character, including both casual and intimate aspects of social distance. Respondents with contact were not significantly different from the general population in the degree to which they expressed sympathy, thought the problem would last a lifetime, or wanted to restrict reproduction. Thus, contact is associated with having a less ostracizing, critical attitude toward a stranger with mental illness. The results underscore the importance of this experienced group as a resource in fighting stigma in society. Since many people who have had a psychiatric hospitalization have not told their friends or family members about it, this lower-stigma group could be enlarged. C1 [Boyd, Jennifer E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Katz, Emerald P.] San Francisco VA Med Ctr, Psychosocial Rehabil & Recovery Ctr, San Francisco, CA 94121 USA. [Link, Bruce G.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA. [Link, Bruce G.; Phelan, Jo C.] Columbia Univ, Dept Sociomed Sci, Mailman Sch Publ Hlth, New York, NY USA. [Link, Bruce G.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. RP Boyd, JE (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St 116A, San Francisco, CA 94121 USA. EM jennifer.boyd@ucsf.edu RI Link, Bruce/N-9087-2013 OI Link, Bruce/0000-0001-9980-7450 NR 29 TC 30 Z9 31 U1 4 U2 13 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0933-7954 J9 SOC PSYCH PSYCH EPID JI Soc. Psychiatry Psychiatr. Epidemiol. PD NOV PY 2010 VL 45 IS 11 BP 1063 EP 1070 DI 10.1007/s00127-009-0147-9 PG 8 WC Psychiatry SC Psychiatry GA 666LY UT WOS:000283117900005 PM 19823756 ER PT J AU Taghavi, CE Lee, KB He, WB Keorochana, G Murray, SS Brochmann, EJ Uludag, H Behnam, K Wang, JC AF Taghavi, Cyrus E. Lee, Kwang-Bok He, Wubing Keorochana, Gun Murray, Samuel S. Brochmann, Elsa J. Uludag, Hasan Behnam, Keyvan Wang, Jeffrey C. TI Bone Morphogenetic Protein Binding Peptide Mechanism and Enhancement of Osteogenic Protein-1 Induced Bone Healing SO SPINE LA English DT Article DE bone morphogenetic protein; bone morphogenetic protein binding peptide; osteogenic protein; bone graft alternative ID ANTERIOR CERVICAL DISKECTOMY; LUMBAR SPINE FUSION; ILIAC-CREST AUTOGRAFT; POLYETHERETHERKETONE SPACER; LIGAMENTUM-FLAVUM; SAFETY PROFILE; MARROW-CELLS; GRAFT; RHBMP-2; MODEL AB Study Design. In vitro and in vivo evaluation of BBP interactions with BMP. Objective. To explore bone morphogenetic protein-binding peptide (BBP)'s mechanism of action, investigate an extended repertoire for BBP applications, and evaluate the usefulness of BBP as a surgical adjuvant when used with recombinant human osteogenic protein-1 (rhOP-1). Summary of Background Data. Bone morphogenetic proteins (BMPs) are osteoinductive proteins that provide a potential alternative to autograft. Their utility is limited by cost, and potential dose-dependent risks, such as local inflammatory reactions and ectopic bone formation. BBP, a cyclized synthetic peptide, avidly binds recombinant human BMP-2 (rhBMP-2) and has been shown to accelerate and enhance its osteogenic qualities. Methods. BBP binding with 4 growth factors from the transforming growth factor -beta family were assessed using surface plasmon resonance. The in vivo retention of rhBMP-2 was quantified by comparing the percentage of retained [(125)I]-labeled rhBMP-2 in absorbable collagen sponge implants with or without BBP at 1, 3, and 7 days postimplantation. The adjunctive effect of BBP with rhOP-1-induced bone growth was evaluated by comparing time to fusion and fusion rates in a rodent posterolateral fusion model with 2 different doses of rhOP-1 with or without BBP. Results. BBP bound all 4 growth factors with an intermediate affinity. The in vivo retention of rhBMP-2 alone ranged from about 40% on day 1 to about 30% on day 7, whereas, the retention of rhBMP-2 in the presence of BBP was about 85% on day 1 and about 55% on day 7. The addition of BBP to rhOP-1 resulted in significantly earlier and greater fusion rates than achieved with rhOP-1 alone. Conclusion. The mechanism of the BBP enhanced osteoinductive properties of BMPs involves the binding and retention of the growth factor, resulting in a prolonged exposure of BMP to the desired fusion site. The use of BBP in conjunction with BMPs may prove to provide satisfactory fusion outcomes, while reducing the costs and side effects associated with BMP use. C1 [Taghavi, Cyrus E.; Lee, Kwang-Bok; He, Wubing; Keorochana, Gun; Wang, Jeffrey C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthopaed Surg, Los Angeles, CA 90095 USA. [Murray, Samuel S.; Brochmann, Elsa J.] VA Greater Los Angeles Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA USA. [Murray, Samuel S.; Brochmann, Elsa J.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Murray, Samuel S.] Univ Calif Los Angeles, Interdept Program Biomed Engn, Los Angeles, CA 90024 USA. [Uludag, Hasan] Univ Alberta, Edmonton, AB, Canada. [Behnam, Keyvan] VA Greater Los Angeles Hlth Care Syst, Res Serv, Sepulveda, CA USA. [Behnam, Keyvan] Lanx Inc, Broomfield, CO USA. RP Wang, JC (reprint author), UCLA Comprehens Spine Ctr, Orthopaed Spine Serv, 1250 16th St,Suite 745, Santa Monica, CA 90404 USA. EM jwang@mednet.ucla.edu FU Department of Veterans Affairs, Lanx Inc.; Canadian Institutes of Health Research FX Department of Veterans Affairs, Lanx Inc., and Canadian Institutes of Health Research funds were received in support of this work. Although one or more of the author(s) has/have received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this manuscript, benefits will be directed solely to a research fund, foundation, educational institution, or other nonprofit organization which the author(s) has/have been associated. NR 51 TC 17 Z9 18 U1 3 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 J9 SPINE JI SPINE PD NOV 1 PY 2010 VL 35 IS 23 BP 2049 EP 2056 DI 10.1097/BRS.0b013e3181cc0220 PG 8 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 671GX UT WOS:000283490100023 PM 20581758 ER PT J AU Stetler, RA Chen, J Cao, GD AF Stetler, R. Anne Chen, Jun Cao, Guodong TI White Matter Protection by Erythropoietin: An Emerging Matter in the Treatment of Neonatal Hypoxic-Ischemic Brain Injury Response SO STROKE LA English DT Letter ID STROKE C1 [Stetler, R. Anne; Chen, Jun; Cao, Guodong] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Stetler, R. Anne; Chen, Jun; Cao, Guodong] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. RP Stetler, RA (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. NR 9 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD NOV PY 2010 VL 41 IS 11 BP E596 EP E596 DI 10.1161/STROKEAHA.110.593574 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 670QX UT WOS:000283443500014 ER PT J AU Pollak, KI Arnold, R Alexander, SC Jeffreys, AS Olsen, MK Abernethy, AP Rodriguez, KL Tulsky, JA AF Pollak, Kathryn I. Arnold, Robert Alexander, Stewart C. Jeffreys, Amy S. Olsen, Maren K. Abernethy, Amy P. Rodriguez, Kari L. Tulsky, James A. TI Do patient attributes predict oncologist empathic responses and patient perceptions of empathy? SO SUPPORTIVE CARE IN CANCER LA English DT Article DE Empathy; Oncologist; Advanced cancer; Socioeconomic status; Negative emotion ID QUALITY-OF-LIFE; PSYCHOLOGICAL ADJUSTMENT; PHYSICIAN COMMUNICATION; CANCER COMMUNICATION; RACIAL-DIFFERENCES; SCOPE TRIAL; INTERVENTION; DISTRUST; PATTERNS; ANXIETY AB Purpose Most patients with advanced cancer experience negative emotion. When patients express emotions, oncologists rarely respond empathically. Oncologists may respond more empathically to some patients, and patients may perceive different levels of empathy and trust given past documentation of disparities in cancer care. Methods We audio-recorded 264 outpatient encounters between oncologists and patients with advanced cancer at three sites. We examined whether patient gender, age, race, marital status, education, economic security, and length of relationship with oncologist were related to oncologist empathic responses to patient's negative emotion and patient's perceptions of oncologist empathy and trust. Results Half (51%) of the patients expressed a negative emotion. Oncologists sometimes responded with empathy (29%). Oncologists were equally empathic with all patients, except they were more empathic with patients with low economic security compared with those reporting high economic security (p=.002). Patients with low economic security viewed oncologists as more empathic (p=.06) compared with those with moderate security. Married patients also viewed oncologists as more empathic (p=.04). Patients who knew their oncologist for more than a year had more trust than patients who knew their oncologists for less time (p=.02). Conclusions Oncologists, in general, did not respond empathically to patient's negative emotion, and did this equally for most patients. Oncologists responded more empathically to patients who were less economically advantaged. In turn, patients with lower economic security perceived more empathy. Although oncologists need more education in responding empathically, they may not need to correct many biases in care. C1 [Pollak, Kathryn I.] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA. [Pollak, Kathryn I.; Abernethy, Amy P.; Tulsky, James A.] Duke Univ, Med Ctr, Duke Comprehens Canc Ctr, Canc Prevent Detect & Control Res Program, Durham, NC 27710 USA. [Arnold, Robert; Rodriguez, Kari L.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Arnold, Robert; Rodriguez, Kari L.] Univ Pittsburgh, Sch Med, Inst Doctor Patient Commun, Pittsburgh, PA USA. [Arnold, Robert] Univ Pittsburgh, Sch Med, Inst Enhance Palliat Care, Pittsburgh, PA USA. [Alexander, Stewart C.; Abernethy, Amy P.; Tulsky, James A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Alexander, Stewart C.; Abernethy, Amy P.; Tulsky, James A.] Duke Univ, Med Ctr, Ctr Palliat Care, Durham, NC 27710 USA. [Alexander, Stewart C.; Jeffreys, Amy S.; Olsen, Maren K.; Tulsky, James A.] Durham VA Med Ctr, Ctr Hlth Serv Res, Durham, NC USA. [Olsen, Maren K.] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA. [Rodriguez, Kari L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Rodriguez, Kari L.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Pollak, KI (reprint author), Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA. EM kathryn.pollak@duke.edu OI Abernethy, Amy/0000-0001-6930-8722 FU [R01CA100387] FX This work was supported by R01CA100387. The authors have no financial disclosures. NR 29 TC 7 Z9 7 U1 3 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD NOV PY 2010 VL 18 IS 11 BP 1405 EP 1411 DI 10.1007/s00520-009-0762-8 PG 7 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 654QG UT WOS:000282182500006 PM 19838742 ER PT J AU Maciejewski, ML Livingston, EH Kahwati, LC Henderson, WG Kavee, AL Arterburn, DE AF Maciejewski, Matthew L. Livingston, Edward H. Kahwati, Leila C. Henderson, William G. Kavee, Andrew L. Arterburn, David E. TI Discontinuation of diabetes and lipid-lowering medications after bariatric surgery at Veterans Affairs medical centers SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Article DE Bariatric; Medication; Discontinuation; Diabetes; Dyslipidemia; Veterans ID LAPAROSCOPIC GASTRIC BYPASS; RISK ADJUSTMENT; SURGICAL CARE; OBESITY; COSTS; IMPROVEMENT; QUALITY; EXPENDITURES; METAANALYSIS; PERFORMANCE AB Background: Bariatric surgery has largely been performed on middle-age female populations and been associated with significant medication discontinuation; however, it is unknown whether similar medication discontinuation rates could be achieved in men. The purpose of the present analysis was to examine the discontinuation rate of diabetes or lipid-lowering medications and the patient factors associated with medication discontinuation among veterans undergoing bariatric surgery. Methods: We identified the demographic and health status information for 284 veterans with diabetes and 298 veterans with hyperlipidemia who had undergone bariatric surgery at 1 of 12 Veterans Affairs bariatric centers in 2000 to 2006 from the Veterans Affairs National Surgical Quality Improvement Program data. We also identified the medications that had been prescribed and discontinued using the Veterans Affairs administrative data. Medication discontinuation was estimated using a logistic regression model. Results: Of the 284 veterans with diabetes and 298 with hyperlipidemia, 52% and 40% had discontinued their medications at 1 year, respectively. The veterans with diabetes were more likely to discontinue medication if they had been taking oral hypoglycemic agents alone (odds ratio 2.77, P < .001) than were those taking insulin or oral hypoglycemic agents and insulin. The veterans with hyperlipidemia were more likely to discontinue medication if they had only been taking fibrates (odds ratio 6.15, P < .01) than were those veterans taking statins and fibrates. Conclusion: Bariatric surgery led to significant medication discontinuation within 1 year for high-risk veterans with diabetes or hyperlipidemia. (Surg Obes Relat Dis 2010;6:601-607.) Published by Elsevier Inc. C1 [Maciejewski, Matthew L.; Kavee, Andrew L.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA. [Maciejewski, Matthew L.] Duke Univ, Dept Med, Div Gen Internal Med, Durham, NC USA. [Livingston, Edward H.] Univ Texas SW Med Ctr Dallas, Div Gastrointestinal & Endocrine Surg, Dallas, TX 75390 USA. [Livingston, Edward H.] Vet Affairs N Texas Hlth Care Syst, Dallas, TX USA. [Livingston, Edward H.] Univ Texas Arlington, Arlington, TX 76019 USA. [Kahwati, Leila C.] Natl Ctr Hlth Promot & Dis Prevent, Off Patient Care Serv, Vet Hlth Adm, Dept Vet Affairs, Durham, NC USA. [Henderson, William G.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Henderson, William G.] Univ Colorado, Dept Biostat, Sch Publ Hlth, Aurora, CO USA. [Henderson, William G.] Univ Colorado, Colorado Hlth Outcomes Program, Aurora, CO USA. [Arterburn, David E.] Grp Hlth Res Inst, Seattle, WA USA. [Arterburn, David E.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA. RP Maciejewski, ML (reprint author), Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, 508 Fulton St,Mail Stop 152, Durham, NC 27705 USA. EM matthew.maciejewski@va.gov FU Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs [IIR 05-201]; Takeda Pharmaceuticals; Surgical Review Corporation FX Supported by the Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs (IIR 05-201) and has been reviewed and approved by the Surgical Quality Data Use Group (SQDUG), Office of Patient Care Services.; Dr. Maciejewski has received consultation funds from Takeda Pharmaceuticals and the Surgical Review Corporation, and owns stock in Amgen. NR 25 TC 12 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD NOV-DEC PY 2010 VL 6 IS 6 BP 601 EP 607 DI 10.1016/j.soard.2010.07.005 PG 7 WC Surgery SC Surgery GA 694UG UT WOS:000285323900003 PM 20965791 ER PT J AU Beer, TM Benavides, M Emmons, SL Hayes, M Liu, GH Garzotto, M Donovan, D Katovic, N Reeder, C Eilers, K AF Beer, Tomasz M. Benavides, Maria Emmons, Sandra L. Hayes, Margaret Liu, Guohui Garzotto, Mark Donovan, Deirdre Katovic, Nina Reeder, Caron Eilers, Kristine TI Acupuncture for Hot Flashes in Patients With Prostate Cancer SO UROLOGY LA English DT Article ID GENE-RELATED PEPTIDE; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; BREAST-CANCER; VASOMOTOR SYMPTOMS; POSTMENOPAUSAL WOMEN; LUTEINIZING-HORMONE; MEGESTROL-ACETATE; PILOT EVALUATION; BLOOD-FLOW AB OBJECTIVES To determine the effect of acupuncture on hot flash frequency and intensity, quality of life, and sleep quality in patients undergoing hormonal therapy for prostate cancer. Hot flashes are a common adverse effect of hormonal therapy for prostate cancer. METHODS Men who had a hot flash score > 4 who were receiving androgen deprivation therapy for prostate cancer underwent acupuncture with electrostimulation biweekly for 4 weeks, then weekly for 6 weeks, using a predefined treatment plan. The primary endpoint was a 50% reduction in the hot flash score after 4 weeks of therapy, calculated from the patients' daily hot flash diaries. The hot flash-related quality of life and sleep quality and biomarkers potentially related to hot flashes, including serotonin, calcitonin gene-related peptide, and urinary 5-hydroxyindoleacetic acid, were examined. RESULTS A total of 25 men were enrolled from September 2003 to April 2007. Of these, 22 were eligible and evaluable. After 4 weeks, 9 (41%, 95% confidence interval 21%-64%) of 22 patients had had a > 50% reduction in the hot flash score. Of the 22 patients, 12 (55%, 95% confidence interval 32%-76%) met this response definition at any point during the therapy course. No patient had a significant increase in hot flash score during therapy. A reduced hot flash score was associated with improvement in the hot flash-related quality of life and sleep quality. CONCLUSIONS Multiple placebo-controlled trials have demonstrated a 25% response rate to placebo treatment for hot flashes. Of the 22 patients, 41% had responded by week 4 and 55% overall in the present pilot study, providing evidence of a potentially meaningful benefit. Additional studies of acupuncture for hot flashes in this population are warranted. UROLOGY 76: 1182-1188, 2010. (C) 2010 Elsevier Inc. C1 [Beer, Tomasz M.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA. Goodlife Acupuncture, Bend, OR USA. Oregon Coll Oriental Med, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. RP Beer, TM (reprint author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, 3303 SW Bond Ave,CII14R, Portland, OR 97201 USA. EM beert@ohsu.edu FU Oregon Health and Science University General Clinical Research Center [M01 RR000334]; Oregon Clinical and Translational Research Institute [UL1RR024140]; National Institutes of Health, Bethesda, Maryland [R21 CA098406] FX This study was supported in part by grant M01 RR000334 from the Oregon Health and Science University General Clinical Research Center, grant UL1RR024140 from the Oregon Clinical and Translational Research Institute, and grant R21 CA098406 from the National Institutes of Health, Bethesda, Maryland. NR 41 TC 14 Z9 15 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD NOV PY 2010 VL 76 IS 5 BP 1182 EP 1188 DI 10.1016/j.urology.2010.03.033 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 675QD UT WOS:000283844600043 PM 20494414 ER PT J AU Federman, AD Woodward, M Keyhani, S AF Federman, Alex D. Woodward, Mark Keyhani, Salomeh TI Physicians' Opinions About Reforming Reimbursement Results of a National Survey SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID PAY-FOR-PERFORMANCE; CARE-SPECIALTY INCOME; HEALTH-CARE; PAYMENT POLICY; US PHYSICIANS; INSURANCE; VIEWS; PERSPECTIVE; QUALITY; OPTIONS AB Background: Several strategies have been proposed to reform physician reimbursement while improving quality of care. Despite much debate, physicians' opinions regarding reimbursement reform proposals have not been objectively assessed. Methods: We conducted a national survey of randomly selected physicians between June 25 and October 31, 2009. Physicians rated their support for several reimbursement reform proposals: rewarding quality with financial incentives, bundling payments for episodes of care, shifting payments from procedures to management and counseling services, increasing pay to generalists, and offsetting increased pay to generalists with a reduction in pay for other specialties. Support for the different reform options was compared with physician practice characteristics. Results: The response rate was 48.5% (n = 1222). Four of 5 physicians (78.4%) indicated that under Medicare, some procedures are compensated too highly and others are compensated at rates insufficient to cover costs. Incentives were the most frequently supported reform option (49.1%), followed by shifting payments (41.6%) and bundling (17.2%). Shifting payments and bundling were more commonly supported by generalists than by other specialists. There was broad support for increasing pay for generalists (79.8%), but a proposal to offset the increase with a 3% reduction in specialist reimbursement was supported by only 39.1% of physicians. Conclusions: Physicians are dissatisfied with Medicare reimbursement and show little consensus for major proposals to reform reimbursement. The successful adoption of payment reform proposals may require a better understanding of physicians' concerns and their willingness to make tradeoffs. Arch Intern Med. 2010;170(19):1735-1742 C1 [Federman, Alex D.; Woodward, Mark; Keyhani, Salomeh] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA. [Keyhani, Salomeh] Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA. [Keyhani, Salomeh] James J Peters Vet Adm Med Ctr, Bronx, NY USA. RP Federman, AD (reprint author), Mt Sinai Sch Med, Div Gen Internal Med, POB 1087,1 Gustave L Levy Pl, New York, NY 10029 USA. EM alex.federman@mssm.edu FU Robert Wood Johnson Foundation; National Institute on Aging; National Heart, Lung, and Blood Institute; Veterans Administration Health Services Research and Development Service FX This project was supported by a grant from the Robert Wood Johnson Foundation and also by grants from the National Institute on Aging; the National Heart, Lung, and Blood Institute; and the Veterans Administration Health Services Research and Development Service (Drs Federman and Keyhani). NR 33 TC 4 Z9 4 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD OCT 25 PY 2010 VL 170 IS 19 BP 1735 EP 1742 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 670PT UT WOS:000283440500009 PM 20975020 ER PT J AU Saban, KL Bryant, FB Reda, DJ Stroupe, KT Hynes, DM AF Saban, Karen L. Bryant, Fred B. Reda, Domenic J. Stroupe, Kevin T. Hynes, Denise M. TI Measurement invariance of the kidney disease and quality of life instrument (KDQOL-SF) across Veterans and non-Veterans SO HEALTH AND QUALITY OF LIFE OUTCOMES LA English DT Article ID STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; DIALYSIS OUTCOMES; PRACTICE PATTERNS; FIT INDEXES; FACTORIAL INVARIANCE; PSYCHOMETRIC PROPERTIES; COVARIANCE-STRUCTURES; PERITONEAL-DIALYSIS; HEALTH AB Background: Studies have demonstrated that perceived health-related quality of life (HRQOL) of patients receiving hemodialysis is significantly impaired. Since HRQOL outcome data are often used to compare groups to determine health care effectiveness it is imperative that measures of HRQOL are valid. However, valid HRQOL comparisons between groups can only be made if instrument invariance is demonstrated. The Kidney Disease Quality of Life Short Form (KDQOL-SF) is a widely used HRQOL measure for patients with chronic kidney disease (CKD) however, it has not been validated in the Veteran population. Therefore, the purpose of this study was to examine the measurement invariance of the KDQOL-SF across Veterans and non-Veterans with CKD. Methods: Data for this study were from two large prospective observational studies of patients receiving hemodialysis: 1) Veteran End-Stage Renal Disease Study (VETERAN) (N = 314) and 2) Dialysis Outcomes and Practice Patterns Study (DOPPS) (N = 3,300). Health-related quality of life was measured with the KDQOL-SF, which consists of the SF-36 and the Kidney Disease Component Summary (KDCS). Single-group confirmatory factor analysis was used to evaluate the goodness-of-fit of the hypothesized measurement model for responses to the subscales of the KDCS and SF-36 instruments when analyzed together; and given acceptable goodness-of-fit in each group, multigroup CFA was used to compare the structure of this factor model in the two samples. Pattern of factor loadings (configural invariance), the magnitude of factor loadings (metric invariance), and the magnitude of item intercepts (scalar invariance) were assessed as well as the degree to which factors have the same variances, covariances, and means across groups (structural invariance). Results: CFA demonstrated that the hypothesized two-factor model (KDCS and SF-36) fit the data of both the Veteran and DOPPS samples well, supporting configural invariance. Multigroup CFA results concerning metric and scalar invariance suggested partial strict invariance for the SF-36, but only weak invariance for the KDCS. Structural invariance was not supported. Conclusions: Results suggest that Veterans may interpret the KDQOL-SF differently than non-Veterans. Further evaluation of measurement invariance of the KDQOL-SF between Veterans and non-Veterans is needed using large, randomly selected samples before comparisons between these two groups using the KDQOL-SF can be done reliably. C1 [Saban, Karen L.; Stroupe, Kevin T.; Hynes, Denise M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Chron Complex Care, Hines, IL 60141 USA. [Saban, Karen L.] Loyola Univ Chicago, Marcella Niehoff Sch Nursing, Maywood, IL USA. [Bryant, Fred B.] Loyola Univ Chicago, Dept Psychol, Chicago, IL USA. [Reda, Domenic J.] Vet Affairs Cooperat Studies Program Coordinating, Hines, IL USA. [Stroupe, Kevin T.; Hynes, Denise M.] Vet Affairs Informat Resource Ctr, Hines, IL USA. [Stroupe, Kevin T.] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA. [Hynes, Denise M.] Univ Illinois, Coll Med, Chicago, IL USA. RP Saban, KL (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Chron Complex Care, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. EM Ksaban@luc.edu OI Saban, Karen/0000-0001-5767-5453 FU U.S. Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service - "Cost and Effectiveness of End-Stage Renal Disease Care" [ECI 20 016]; Veterans Affairs Health Services Research and Development Service [TPN 42-001]; Amgen; Kyowa Hakko Kirin, Japan; Genzyme; Abbott FX This research was supported by the U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service - "Cost and Effectiveness of End-Stage Renal Disease Care" (D. Hynes, Principal Investigator) (ECI 20 016). Dr. Hynes is supported by a five-year Veterans Affairs Health Services Research and Development Service Research Career Scientist Award. Dr. Saban is supported by a three-year Veterans Affairs Health Services Research and Development Service Postdoctoral Fellowship (TPN 42-001). DOPPS data were provided by Arbor Research Collaborative for Health which administers and coordinates the Dialysis Outcomes and Practice Study. DOPPS is supported by scientific research from Amgen (since 1996), Kyowa Hakko Kirin (since 1999, in Japan), Genzyme (since 2009), and Abbott (since 2009), without restrictions on publications. We would like to thank Jenny Huo for her statistical assistance in performing multiple imputations. In addition, we would like to express our sincere gratitude to Dr. Albert Satorra (Departament d'Economia i Empresa, Universitat Pompeu Fabra) for his expert statistical guidance. Finally, we would like to acknowledge the anonymous reviewers for their insightful comments and suggestions concerning an earlier draft of this manuscript. NR 89 TC 9 Z9 9 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1477-7525 J9 HEALTH QUAL LIFE OUT JI Health Qual. Life Outcomes PD OCT 25 PY 2010 VL 8 AR 120 DI 10.1186/1477-7525-8-120 PG 16 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 724QC UT WOS:000287590300001 PM 20973987 ER PT J AU Helfrich, CD Damschroder, LJ Hagedorn, HJ Daggett, GS Sahay, A Ritchie, M Damush, T Guihan, M Ullrich, PM Stetler, CB AF Helfrich, Christian D. Damschroder, Laura J. Hagedorn, Hildi J. Daggett, Ginger S. Sahay, Anju Ritchie, Mona Damush, Teresa Guihan, Marylou Ullrich, Philip M. Stetler, Cheryl B. TI A critical synthesis of literature on the promoting action on research implementation in health services (PARIHS) framework SO IMPLEMENTATION SCIENCE LA English DT Review ID CONCEPTUAL-FRAMEWORK; PRACTICE GUIDELINES; CARE; CONTEXT; BEHAVIOR; FACILITATION; EXPLORATION; IMPROVEMENT; MANAGEMENT; OUTCOMES AB Background: The Promoting Action on Research Implementation in Health Services framework, or PARIHS, is a conceptual framework that posits key, interacting elements that influence successful implementation of evidence-based practices. It has been widely cited and used as the basis for empirical work; however, there has not yet been a literature review to examine how the framework has been used in implementation projects and research. The purpose of the present article was to critically review and synthesize the literature on PARIHS to understand how it has been used and operationalized, and to highlight its strengths and limitations. Methods: We conducted a qualitative, critical synthesis of peer-reviewed PARIHS literature published through March 2009. We synthesized findings through a three-step process using semi-structured data abstraction tools and group consensus. Results: Twenty-four articles met our inclusion criteria: six core concept articles from original PARIHS authors, and eighteen empirical articles ranging from case reports to quantitative studies. Empirical articles generally used PARIHS as an organizing framework for analyses. No studies used PARIHS prospectively to design implementation strategies, and there was generally a lack of detail about how variables were measured or mapped, or how conclusions were derived. Several studies used findings to comment on the framework in ways that could help refine or validate it. The primary issue identified with the framework was a need for greater conceptual clarity regarding the definition of sub-elements and the nature of dynamic relationships. Strengths identified included its flexibility, intuitive appeal, explicit acknowledgement of the outcome of 'successful implementation,' and a more expansive view of what can and should constitute 'evidence.' Conclusions: While we found studies reporting empirical support for PARIHS, the single greatest need for this and other implementation models is rigorous, prospective use of the framework to guide implementation projects. There is also need to better explain derived findings and how interventions or measures are mapped to specific PARIHS elements; greater conceptual discrimination among sub-elements may be necessary first. In general, it may be time for the implementation science community to develop consensus guidelines for reporting the use and usefulness of theoretical frameworks within implementation studies. C1 [Helfrich, Christian D.] VA Puget Sound Healthcare Syst, NW HSR&D Ctr Excellence, Seattle, WA USA. [Helfrich, Christian D.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Damschroder, Laura J.] VA Ann Arbor Healthcare Syst, HSR&D Ctr Clin Management Res & Diabet QUERI, Ann Arbor, MI USA. [Hagedorn, Hildi J.] Minneapolis VA Med Ctr, VA Substance Use Disorders Qual Enhancement Res I, Minneapolis, MN USA. [Hagedorn, Hildi J.] Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55455 USA. [Daggett, Ginger S.; Damush, Teresa] Richard L Roudebush VA Med Ctr, VA Stroke QUERI, HSR&D Ctr Excellence, Indianapolis, IN USA. [Sahay, Anju] VA Palo Alto Hlth Care Syst, Chron Heart Failure QUERI Ctr, Palo Alto, CA USA. [Ritchie, Mona] Cent Arkansas Vet Healthcare Syst, Mental Hlth Qual Enhancement Res Initiat, N Little Rock, AR USA. [Damush, Teresa] Indiana Univ, Ctr Aging Res, Regenstrief Inc, Indianapolis, IN 46204 USA. [Guihan, Marylou] Jr VA Hosp, Spinal Cord Injury QUERI Res Coordinating Ctr, Ctr Management Complex Chron Care CMC3, Hines, IL USA. [Ullrich, Philip M.] VA Puget Sound Hlth Care Syst, Spinal Cord Injury QUERI, Seattle, WA USA. [Stetler, Cheryl B.] Boston Univ, Sch Publ Hlth, Dept Hlth Serv, Boston, MA USA. RP Helfrich, CD (reprint author), VA Puget Sound Healthcare Syst, NW HSR&D Ctr Excellence, Seattle, WA USA. EM christian.helfrich@va.gov RI Helfrich, Christian/D-2382-2016 OI Helfrich, Christian/0000-0002-9827-4768; Damschroder, Laura/0000-0002-3657-8459 FU U.S. Department of Veterans Affairs, Office of Research and Development Health Services FX This material is based upon work supported by the U.S. Department of Veterans Affairs, Office of Research and Development Health Services R&D Program. We wish to acknowledge the important contributions of Jeffrey Smith to the paper, and the important administrative assistance of Jared LeClerc and Rachel Smith. Also, our thanks to Corrine Voils for providing invaluable feedback on a draft of the paper, and to Lars Wallin and Jacqueline Tetroe for their excellent reviews and suggestions. The views expressed in this article are the authors' and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 61 TC 89 Z9 91 U1 3 U2 42 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD OCT 25 PY 2010 VL 5 AR 82 DI 10.1186/1748-5908-5-82 PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 680KT UT WOS:000284231500001 PM 20973988 ER PT J AU Qin, WP Pan, JP Bauman, WA Cardozo, CP AF Qin, Weiping Pan, Jiangping Bauman, William A. Cardozo, Christopher P. TI Differential alterations in gene expression profiles contribute to time-dependent effects of nandrolone to prevent denervation atrophy SO BMC GENOMICS LA English DT Article ID SKELETAL-MUSCLE ATROPHY; FOXO TRANSCRIPTION FACTORS; ANDROGEN RECEPTOR; MAMMALIAN TARGET; CARDIAC-HYPERTROPHY; RAPAMYCIN PATHWAY; UBIQUITIN LIGASES; KNOCKOUT MICE; FIBER-TYPE; F-BOX AB Background: Anabolic steroids, such as nandrolone, slow muscle atrophy, but the mechanisms responsible for this effect are largely unknown. Their effects on muscle size and gene expression depend upon time, and the cause of muscle atrophy. Administration of nandrolone for 7 days beginning either concomitantly with sciatic nerve transection (7 days) or 29 days later (35 days) attenuated denervation atrophy at 35 but not 7 days. We reasoned that this model could be used to identify genes that are regulated by nandrolone and slow denervation atrophy, as well as genes that might explain the time-dependence of nandrolone effects on such atrophy. Affymetrix microarrays were used to profile gene expression changes due to nandrolone at 7 and 35 days and to identify major gene expression changes in denervated muscle between 7 and 35 days. Results: Nandrolone selectively altered expression of 124 genes at 7 days and 122 genes at 35 days, with only 20 genes being regulated at both time points. Marked differences in biological function of genes regulated by nandrolone at 7 and 35 days were observed. At 35, but not 7 days, nandrolone reduced mRNA and protein levels for FOXO1, the mTOR inhibitor REDD2, and the calcineurin inhibitor RCAN2 and increased those for ApoD. At 35 days, correlations between mRNA levels and the size of denervated muscle were negative for RCAN2, and positive for ApoD. Nandrolone also regulated genes for Wnt signaling molecules. Comparison of gene expression at 7 and 35 days after denervation revealed marked alterations in the expression of 9 transcriptional coregulators, including Ankrd1 and 2, and many transcription factors and kinases. Conclusions: Genes regulated in denervated muscle after 7 days administration of nandrolone are almost entirely different at 7 versus 35 days. Alterations in levels of FOXO1, and of genes involved in signaling through calcineurin, mTOR and Wnt may be linked to the favorable action of nandrolone on denervated muscle. Marked changes in the expression of genes regulating transcription and intracellular signaling may contribute to the time-dependent effects of nandrolone on gene expression. C1 [Qin, Weiping; Pan, Jiangping; Bauman, William A.; Cardozo, Christopher P.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Qin, Weiping; Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. RP Cardozo, CP (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM chris.cardozo@mssm.edu FU Veterans Health Administration, Rehabilitation Research and Development Service [B4162C, B3347K, B3522R] FX The research reported here was supported by the Veterans Health Administration, Rehabilitation Research and Development Service (B4162C, B3347K, B3522R), which had no role in study design, data collection and interpretation, manuscript preparation or decisions to submit the manuscript. Microarray analysis was performed by the Microarray Core at the Mount Sinai School of Medicine. NR 78 TC 13 Z9 13 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2164 J9 BMC GENOMICS JI BMC Genomics PD OCT 22 PY 2010 VL 11 AR 596 DI 10.1186/1471-2164-11-596 PG 17 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 679PG UT WOS:000284172700001 PM 20969782 ER PT J AU Neily, J Mills, PD Young-Xu, YN Carney, BT West, P Berger, DH Mazzia, LM Paull, DE Bagian, JP AF Neily, Julia Mills, Peter D. Young-Xu, Yinong Carney, Brian T. West, Priscilla Berger, David H. Mazzia, Lisa M. Paull, Douglas E. Bagian, James P. TI Association Between Implementation of a Medical Team Training Program and Surgical Mortality SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID PROPENSITY SCORE; OPERATING-ROOM; RISK ADJUSTMENT; CARE; COMMUNICATION; MORBIDITY; SURGERY; QUALITY; SAFETY; BRIEFINGS AB Context There is insufficient information about the effectiveness of medical team training on surgical outcomes. The Veterans Health Administration (VHA) implemented a formalized medical team training program for operating room personnel on a national level. Objective To determine whether an association existed between the VHA Medical Team Training program and surgical outcomes. Design, Setting, and Participants A retrospective health services study with a contemporaneous control group was conducted. Outcome data were obtained from the VHA Surgical Quality Improvement Program (VASQIP) and from structured interviews in fiscal years 2006 to 2008. The analysis included 182 409 sampled procedures from 108 VHA facilities that provided care to veterans. The VHA's nationwide training program required briefings and debriefings in the operating room and included checklists as an integral part of this process. The training included 2 months of preparation, a 1-day conference, and 1 year of quarterly coaching interviews Main Outcome Measure The rate of change in the mortality rate 1 year after facilities enrolled in the training program compared with the year before and with non-training sites. Results The 74 facilities in the training program experienced an 18% reduction in annual mortality (rate ratio [RR], 0.82; 95% confidence interval [CI], 0.76-0.91; P=.01) compared with a 7% decrease among the 34 facilities that had not yet undergone training (RR, 0.93; 95% CI, 0.80-1.06; P=.59). The risk-adjusted mortality rates at baseline were 17 per 1000 procedures per year for the trained facilities and 15 per 1000 procedures per year for the nontrained facilities. At the end of the study, the rates were 14 per 1000 procedures per year for both groups. Propensity matching of the trained and nontrained groups demonstrated that the decline in the risk-adjusted surgical mortality rate was about 50% greater in the training group (RR, 1.49; 95% CI, 1.10-2.07; P=.01) than in the nontraining group. A dose-response relationship for additional quarters of the training program was also demonstrated: for every quarter of the training program, a reduction of 0.5 deaths per 1000 procedures occurred (95% CI, 0.2-1.0; P=.001). Conclusion Participation in the VHA Medical Team Training program was associated with lower surgical mortality. JAMA. 2010; 304(15): 1693-1700 C1 [Neily, Julia; Mills, Peter D.; Young-Xu, Yinong; Carney, Brian T.; West, Priscilla; Mazzia, Lisa M.; Paull, Douglas E.; Bagian, James P.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Vet Affairs,Natl Ctr Patient Safety, Hanover, NH 03756 USA. [Mills, Peter D.; Young-Xu, Yinong] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Hanover, NH 03756 USA. [Berger, David H.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA. [Berger, David H.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Bagian, James P.] Univ Texas Med Branch, Galveston, TX USA. [Bagian, James P.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Bethesda, MD 20814 USA. RP Neily, J (reprint author), 215 N Main St, White River Jct, VT 05009 USA. EM Julia.Neily@va.gov NR 32 TC 330 Z9 336 U1 3 U2 19 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 20 PY 2010 VL 304 IS 15 BP 1693 EP 1700 DI 10.1001/jama.2010.1506 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 666PZ UT WOS:000283129700023 PM 20959579 ER PT J AU Keyhani, S Woodward, M Federman, AD AF Keyhani, Salomeh Woodward, Mark Federman, Alex D. TI Physician Views on the Use of Comparative Effectiveness Research: A National Survey SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Keyhani, Salomeh] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Woodward, Mark] George Inst, Camperdown, NSW 2050, Australia. [Federman, Alex D.] Mt Sinai Sch Med, New York, NY 10029 USA. RP Keyhani, S (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. RI Woodward, Mark/D-8492-2015 NR 4 TC 6 Z9 7 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 19 PY 2010 VL 153 IS 8 BP 551 EP 552 DI 10.7326/0003-4819-153-8-201010190-00023 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 665SA UT WOS:000283054600016 PM 20956718 ER PT J AU Chan, ED Keane, J Iseman, MD AF Chan, Edward D. Keane, Joseph Iseman, Michael D. TI Should Cigarette Smoke Exposure Be a Criterion to Treat Latent Tuberculous Infection? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID TOBACCO SMOKING; PULMONARY TUBERCULOSIS; COLLIDING EPIDEMICS; PASSIVE SMOKING; RISK-FACTOR; ASSOCIATION; METAANALYSIS; MORTALITY; COPD C1 [Chan, Edward D.] Univ Colorado, Denver Vet Affairs Med Ctr, Natl Jewish Hlth, Denver, CO 80202 USA. [Keane, Joseph] Trinity Coll Dublin, Dublin, Ireland. [Keane, Joseph] St James Hosp, Dublin 8, Ireland. RP Chan, ED (reprint author), Univ Colorado, Denver Vet Affairs Med Ctr, Natl Jewish Hlth, Anschutz Med Campus, Denver, CO 80202 USA. OI Keane, Joseph/0000-0001-5313-385X NR 23 TC 5 Z9 5 U1 0 U2 6 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD OCT 15 PY 2010 VL 182 IS 8 BP 990 EP 992 DI 10.1164/rccm.201006-0861ED PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 669XR UT WOS:000283384000002 PM 20947905 ER PT J AU Wu, X Chen, KW Yao, L Ayutyanont, N Langbaum, JBS Fleisher, A Reschke, C Lee, W Liu, XF Alexander, GE Bandy, D Foster, NL Thompson, PM Harvey, DJ Weiner, MW Koeppe, RA Jagust, WJ Reiman, EM AF Wu, Xia Chen, Kewei Yao, Li Ayutyanont, Napatkamon Langbaum, Jessica B. S. Fleisher, Adam Reschke, Cole Lee, Wendy Liu, Xiaofen Alexander, Gene E. Bandy, Dan Foster, Norman L. Thompson, Paul M. Harvey, Danielle J. Weiner, Michael W. Koeppe, Robert A. Jagust, William J. Reiman, Eric M. CA Alzheimer's Dis Neuroimaging Initi TI Assessing the reliability to detect cerebral hypometabolism in probable Alzheimer's disease and amnestic mild cognitive impairment SO JOURNAL OF NEUROSCIENCE METHODS LA English DT Article DE Alzheimer's disease; MCI; FDG-PET; Reproducibility of results; Reliability; Bootstrap resampling; Family-wise error; SPM ID POSITRON-EMISSION-TOMOGRAPHY; APOLIPOPROTEIN-E; DEMENTIA; ABNORMALITIES AB Fluorodeoxyglucose positron emission tomography (FDG-PET) studies report characteristic patterns of cerebral hypometabolism in probable Alzheimer's disease (pAD) and amnestic mild cognitive impairment (aMCI). This study aims to characterize the consistency of regional hypometabolism in pAD and aMCI patients enrolled in the AD neuroimaging initiative (ADNI) using statistical parametric mapping (SPM) and bootstrap resampling, and to compare bootstrap-based reliability index to the commonly used type-I error approach with or without correction for multiple comparisons. Batched SPM5 was run for each of 1000 bootstrap iterations to compare FDG-PET images from 74 pAD and 142 aMCI patients, respectively, to 82 normal controls. Maps of the hypometabolic voxels detected for at least a specific percentage of times over the 1000 runs were examined and compared to an overlap of the hypometabolic maps obtained from 3 randomly partitioned independent sub-datasets. The results from the bootstrap derived reliability of regional hypometabolism in the overall data set were similar to that observed in each of the three non-overlapping sub-sets using family-wise error. Strong but non-linear association was found between the bootstrap-based reliability index and the type-I error. For threshold p = 0.0005, pAD was associated with extensive hypometabolic voxels in the posterior cingulate/precuneus and parietotemporal regions with reliability between 90% and 100%. Bootstrap analysis provides an alternative to the parametric family-wise error approach used to examine consistency of hypometabolic brain voxels in pAD and aMCI patients. These results provide a foundation for the use of bootstrap analysis characterize statistical ROIs or search regions in both cross-sectional and longitudinal FDG-PET studies. This approach offers promise in the early detection and tracking of AD, the evaluation of AD-modifying treatments, and other biologically or clinical important measurements using brain images and voxel-based data analysis techniques. (C) 2010 Elsevier B.V. All rights reserved. C1 [Chen, Kewei; Ayutyanont, Napatkamon; Langbaum, Jessica B. S.; Fleisher, Adam; Reschke, Cole; Lee, Wendy; Liu, Xiaofen; Bandy, Dan; Reiman, Eric M.] Banner Alzheimers Inst, Phoenix, AZ USA. [Wu, Xia; Yao, Li] Beijing Normal Univ, Sch Informat Sci & Technol, Beijing 100875, Peoples R China. [Chen, Kewei] Univ Arizona, Dept Radiol, Tucson, AZ 85724 USA. [Chen, Kewei] Arizona State Univ, Sch Math & Stat, Tempe, AZ USA. [Fleisher, Adam] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Thompson, Paul M.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Alexander, Gene E.] Univ Arizona, Dept Psychol, Phoenix, AZ USA. [Alexander, Gene E.] Univ Arizona, Evelyn F McKnight Brain Inst, Phoenix, AZ USA. [Foster, Norman L.] Univ Utah, Ctr Alzheimers Care Imaging & Res, Salt Lake City, UT 84112 USA. [Foster, Norman L.] Univ Utah, Dept Neurol, Salt Lake City, UT 84112 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Med Radiol Psychiat & Neurol, San Francisco, CA 94143 USA. [Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging & Neurodegenerat Dis, San Francisco, CA USA. [Koeppe, Robert A.] Univ Michigan, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA. [Jagust, William J.] Univ Calif Berkeley, Sch Publ Hlth, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. [Chen, Kewei; Yao, Li] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China. [Harvey, Danielle J.] Univ Calif Davis, Davis, CA 95616 USA. [Chen, Kewei; Ayutyanont, Napatkamon; Langbaum, Jessica B. S.; Fleisher, Adam; Reschke, Cole; Lee, Wendy; Liu, Xiaofen; Alexander, Gene E.; Bandy, Dan; Reiman, Eric M.] Arizona Alzheimers Consortium, Phoenix, AZ USA. RP Chen, KW (reprint author), Banner Alzheimers Inst, Phoenix, AZ USA. EM kewei.chen@bannerhealth.com RI Scharre, Douglas/E-4030-2011; Chen, kewei/P-6304-2015 OI Chen, kewei/0000-0001-8497-3069 FU National Natural Science Foundation of China [60931003, 60905063, 60805040, 90820019]; National Institute of Mental Health, US [R01 MH57899]; National Institute on Aging, US [9R01AG031581-10, P30 AG19610, k23 AG24062]; State of Arizona; Alzheimer's Disease Neuroimaging Initiative (ADNI; National Institutes of Health) [U01 AG024904]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; NIH [P30 AG010129, K01 AG030514]; Dana Foundation FX This work was supported by the Key Program of National Natural Science Foundation of China (60931003) and National Natural Science Foundation of China (60905063, 60805040, and 90820019). It is also supported by the National Institute of Mental Health, US (R01 MH57899), the National Institute on Aging, US (9R01AG031581-10 and P30 AG19610, k23 AG24062) and the state of Arizona.; Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI; National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., and Wyeth, as well as non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for NeuroImaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129, K01 AG030514, and the Dana Foundation. NR 14 TC 8 Z9 8 U1 2 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0270 J9 J NEUROSCI METH JI J. Neurosci. Methods PD OCT 15 PY 2010 VL 192 IS 2 BP 277 EP 285 DI 10.1016/j.jneumeth.2010.07.030 PG 9 WC Biochemical Research Methods; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 663YK UT WOS:000282925900014 PM 20678521 ER PT J AU Heinrich, MC Corless, CL AF Heinrich, Michael C. Corless, Christopher L. TI CANCER Oncogenes in context SO NATURE LA English DT Editorial Material ID GASTROINTESTINAL STROMAL TUMORS C1 [Heinrich, Michael C.] Portland VA Med Ctr, Dept Med, Portland, OR 97239 USA. [Corless, Christopher L.] Portland VA Med Ctr, Dept Pathol, Portland, OR 97239 USA. OHSU Knight Canc Inst, Portland, OR 97239 USA. RP Heinrich, MC (reprint author), Portland VA Med Ctr, Dept Med, Portland, OR 97239 USA. EM heinrich@ohsu.edu NR 11 TC 5 Z9 5 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD OCT 14 PY 2010 VL 467 IS 7317 BP 796 EP 797 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 663PB UT WOS:000282898700053 PM 20944735 ER PT J AU Steinman, MA Hanlon, JT AF Steinman, Michael A. Hanlon, Joseph T. TI Managing Medications in Clinically Complex Elders "There's Got to Be a Happy Medium" SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID ADVERSE DRUG EVENTS; RANDOMIZED-CONTROLLED-TRIALS; EMERGENCY-DEPARTMENT VISITS; OLDER-ADULTS; PRIMARY-CARE; AMBULATORY-CARE; RISK-FACTORS; DISCONTINUING MEDICATIONS; PHARMACIST INTERVENTION; GENERAL-PRACTITIONERS AB Multiple medication use is common in older adults and may ameliorate symptoms, improve and extend quality of life, and occasionally cure disease. Unfortunately, multiple medication use is also a major risk factor for prescribing and adherence problems, adverse drug events, and other adverse health outcomes. Using the case of an older patient taking multiple medications, this article summarizes the evidence-based literature about improving medication use and withdrawing specific drugs and drug classes. It also describes a systematic approach for how health professionals can assess and improve medication regimens to benefit patients and their caregivers and families. JAMA. 2010;304(14):1592-1601 www.jama.com C1 [Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Dept Med, Div Geriatr Med, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU National Institute on Aging and the American Federation for Aging Research [K23 AG030999]; Department of Veterans Affairs [IIR 06-080]; National Institute of Aging [R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056]; National Institute of Mental Health [R34 MH082682]; National Institute of Nursing Research [R01 NR010135]; Agency for Healthcare Research and Quality [HS017695, HS018721]; Veterans Administration Health Services [IIR06-062]; SCAN Foundation FX Dr Steinman was supported by the National Institute on Aging and the American Federation for Aging Research (K23 AG030999) and by the Department of Veterans Affairs (IIR 06-080). Dr Hanlon was supported by grants from the National Institute of Aging (R01AG027017, P30AG024827, T32 AG021885, K07AG033174, and R01AG034056), the National Institute of Mental Health (R34 MH082682), the National Institute of Nursing Research (R01 NR010135), the Agency for Healthcare Research and Quality (HS017695 and HS018721), and a Veterans Administration Health Services research grant (IIR06-062). The Care of the Aging Patient series is made possible by funding from The SCAN Foundation. NR 97 TC 134 Z9 137 U1 3 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 13 PY 2010 VL 304 IS 14 BP 1592 EP 1601 DI 10.1001/jama.2010.1482 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 662OE UT WOS:000282816500024 PM 20940385 ER PT J AU Shabani, S Foster, R Gubner, N Phillips, TJ Mark, GP AF Shabani, S. Foster, R. Gubner, N. Phillips, T. J. Mark, G. P. TI MUSCARINIC TYPE 2 RECEPTORS IN THE LATERAL DORSAL TEGMENTAL AREA MODULATE COCAINE AND FOOD SEEKING BEHAVIOR IN RATS SO NEUROSCIENCE LA English DT Article DE cocaine; addiction; acetylcholine; muscarinic; self-administration; motivation ID ACCUMBAL DOPAMINE RELEASE; NUCLEUS-ACCUMBENS; CHOLINERGIC NEURONS; ACETYLCHOLINE-RECEPTORS; GLUTAMATE RECEPTORS; RETICULAR-FORMATION; GABAERGIC NEURONS; IN-VITRO; STIMULATION; LATERODORSAL AB The cholinergic input from the lateral dorsal tegmental area (LDTg) modulates the dopamine cells of the ventral tegmental area (VTA) and plays an important role in cocaine taking. Specific pharmacological agents that block or stimulate muscarinic receptors in the LDTg change acetylcholine (ACh) levels in the VTA. Furthermore, manipulations of cholinergic input in the VTA can change cocaine taking. In the current study, the ACh output from the LDTg was attenuated by treatment with the selective muscarinic type 2 (M2) autoreceptor agonist oxotremorine . sesquifumarate (OxoSQ). We hypothesized that OxoSQ would reduce the motivation of rats to self-administer both natural and drug rewards. Animals were tested on progressive ratio (PR) schedules of reinforcement for food pellets and cocaine. On test days, animals on food and on cocaine schedules were bilaterally microinjected prior to the test. Rats received either LDTg OxoSQ infusions or LDTg artificial cerebrospinal fluid (aCSF) infusions in a within-subjects design. In addition, infusions were delivered into a dorsal brain area above the LDTg as an anatomical control region. OxoSQ microinjection in the LDTg, compared to aCSF, significantly reduced both the number of self-administered pellets and cocaine infusions during the initial half of the session; this reduction was dose-dependent. OxoSQ microinjections into the area just dorsal to the LDTg had no significant effect on self-administration of food pellets or cocaine. Animals were also tested in locomotor activity chambers for motor effects following the above microinjections. Locomotor activity was mildly increased by OxoSQ microinjection into the LDTg during the initial half of the session. Overall, these data suggest that LDTg cholinergic neurons play an important role in modifying the reinforcing value of natural and drug rewards. These effects cannot be attributed to significant alterations of locomotor behavior and are likely accomplished through LDTg muscarinic autoreceptors. Published by Elsevier Ltd on behalf of IBRO. C1 [Shabani, S.; Foster, R.; Gubner, N.; Phillips, T. J.; Mark, G. P.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Phillips, T. J.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Shabani, S (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk,Rd L470, Portland, OR 97239 USA. EM shabanis@ohsu.edu FU NIH [RO1 DA14639, T32 DA07262, P50 DA018165]; Department of Veterans Affairs FX We would like to thank Dr. Stephen T. Hansen for providing training on all the surgical procedures mentioned in this study, Dr. Ted Benice for his help with Med Associates software, and Tamie Painter for her technical support. We would also like to thank Dr. Suzanne Mitchell for her advice and generous support with lab space and equipment during the locomotor activity experiment. This work was supported by NIH grants RO1 DA14639 and T32 DA07262, and P50 DA018165, and by the Department of Veterans Affairs. NR 59 TC 8 Z9 10 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD OCT 13 PY 2010 VL 170 IS 2 BP 559 EP 569 DI 10.1016/j.neuroscience.2010.07.028 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 651PH UT WOS:000281939100018 PM 20667466 ER PT J AU Reite, M Reite, E Collins, D Teale, P Rojas, DC Sandberg, E AF Reite, Martin Reite, Erik Collins, Dan Teale, Peter Rojas, Donald C. Sandberg, Elliot TI Brain size and brain/intracranial volume ratio in major mental illness SO BMC PSYCHIATRY LA English DT Article ID SCHIZOAFFECTIVE DISORDER; BIPOLAR DISORDER; SCHIZOPHRENIA; METAANALYSIS; ENDOPHENOTYPES; MRI; CSF; AGE AB Background: This paper summarizes the findings of a long term study addressing the question of how several brain volume measure are related to three major mental illnesses in a Colorado subject group. It reports results obtained from a large N, collected and analyzed by the same laboratory over a multiyear period, with visually guided MRI segmentation being the primary initial analytic tool. Methods: Intracerebral volume (ICV), total brain volume (TBV), ventricular volume (W), ventricular/brain ratio (VBR), and TBV/ICV ratios were calculated from a total of 224 subject MRIs collected over a period of 13 years. Subject groups included controls (C, N = 89), and patients with schizophrenia (SZ, N = 58), bipolar disorder (BD, N = 51), and schizoaffective disorder (SAD, N = 26). Results: ICV, TBV, and W measures compared favorably with values obtained by other research groups, but in this study did not differ significantly between groups. TBV/ICV ratios were significantly decreased, and VBR increased, in the SZ and BD groups compared to the C group. The SAD group did not differ from C on any measure. Conclusions: In this study TBV/ICV and VBR ratios separated SZ and BD patients from controls. Of interest however, SAD patients did not differ from controls on these measures. The findings suggest that the gross measure of TBV may not reliably differ in the major mental illnesses to a degree useful in diagnosis, likely due to the intrinsic variability of the measures in question; the differences in VBR appear more robust across studies. Differences in some of these findings compared to earlier reports from several laboratories finding significant differences between groups in W and TBV may relate to phenomenological drift, differences in analytic techniques, and possibly the "file drawer problem". C1 [Reite, Martin; Collins, Dan; Teale, Peter; Rojas, Donald C.] Univ Colorado Denver, Dept Psychiat, Aurora, CO USA. [Reite, Erik] Eglin AFB Hosp, Ft Walton Beach, FL USA. [Sandberg, Elliot] Denver VAMC, Dept Radiol, Denver, CO USA. RP Reite, M (reprint author), Univ Colorado Denver, Dept Psychiat, Aurora, CO USA. EM martin.reite@ucdenver.edu RI Rojas, Don/F-4296-2012 OI Rojas, Don/0000-0001-6560-9616 FU USPHS [MH47476, MH64502, MH 088623]; NIH FX This research was supported by USPHS grants No. MH47476, MH64502, and 088623; MR was Principal Investigator on the NIH grants that funded this research, and was responsible for the overall design and interpretation of the findings. ER personally segmented all MRI structures over the course of the study, and contributed to the literature review and discussion of how these findings relate to previously published findings by other laboratories. DC initiated and performed those computer analytic techniques used to clarify and improve resolution of several of the brain volume variable, and maintained the final data base contributing to the manuscript. PT supervised overall accuracy and comparability of imaging across the several MRI laboratories, and contributed to the final data analysis and manuscript preparation. DR was responsible for supervision of experimental design and final data analysis. ES was responsible for training in neuroanatomy and monitoring accuracy of image outlines. All authors have read and approved the final manuscript.. NR 36 TC 6 Z9 6 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-244X J9 BMC PSYCHIATRY JI BMC Psychiatry PD OCT 11 PY 2010 VL 10 AR 79 DI 10.1186/1471-244X-10-79 PG 9 WC Psychiatry SC Psychiatry GA 668ZJ UT WOS:000283315400001 PM 20937136 ER PT J AU Das, F Ghosh-Choudhury, N Kasinath, BS Choudhury, GG AF Das, Falguni Ghosh-Choudhury, Nandini Kasinath, Balakuntalam S. Choudhury, Goutam Ghosh TI TGF beta enforces activation of eukaryotic elongation factor-2 (eEF2) via inactivation of eEF2 kinase by p90 ribosomal S6 kinase (p90Rsk) to induce mesangial cell hypertrophy SO FEBS LETTERS LA English DT Article DE Diabetic nephropathy; Receptor serine/threonine kinase; mRNA translation ID MESSENGER-RNA TRANSLATION; DIABETIC-NEPHROPATHY; HIGH GLUCOSE; FIBRONECTIN EXPRESSION; PROTEIN-SYNTHESIS; PROGRESSION; MECHANISMS; SIGNAL; ROLES; MAPK AB eEF2 phosphorylation is under tight control to maintain mRNA translation elongation. We report that TGF beta activates eEF2 by decreasing eEF2 phosphorylation and simultaneously increasing eEF2 kinase phosphorylation. Remarkably, inhibition of Erk1/2 blocked the TGF beta-induced dephosphorylation and phosphorylation of eEF2 and eEF2 kinase. TGF beta increased phosphorylation of p90Rsk in an Erk1/2-dependent manner. Inactive p90Rsk reversed TGF beta-inhibited phosphorylation of eEF2 and suppressed eEF2 kinase activity. Finally, inactive p90Rsk significantly attenuated TGF beta-induced protein synthesis and hypertrophy of mesangial cells. These results present the first evidence that TGF beta utilizes the two layered kinase module Erk/p90Rsk to activate eEF2 for increased protein synthesis during cellular hypertrophy. Published by Elsevier B. V. on behalf of the Federation of European Biochemical Societies. C1 [Das, Falguni; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, VA Res, San Antonio, TX USA. [Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Res, San Antonio, TX USA. [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU NIH [RO1 DK50190, RO1 AR52425, DK 077295, RC2A 036613]; Juvenile Diabetes Research Foundation [1-2008-185]; VA; VA Research Service FX NIH RO1 DK50190 and The Juvenile Diabetes Research Foundation 1-2008-185 Grants to GGC supported this work. GGC is a recipient of VA Senior Research Career Scientist Award and is supported by VA Research Service Merit Review grant. NGC is supported by VA Merit Review and NIH RO1 AR52425 Grants. BSK is supported by Grants from NIH (DK 077295 and RC2A 036613) and VA Research Service. NR 27 TC 10 Z9 10 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-5793 J9 FEBS LETT JI FEBS Lett. PD OCT 8 PY 2010 VL 584 IS 19 BP 4268 EP 4272 DI 10.1016/j.febslet.2010.09.010 PG 5 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 656TU UT WOS:000282360800025 PM 20837011 ER PT J AU Massie, BM O'Connor, CM Metra, M Ponikowski, P Teerlink, JR Cotter, G Weatherley, BD Cleland, JGF Givertz, MM Voors, AA DeLucca, P Mansoor, GA Salerno, CM Bloomfield, DM Dittrich, HC AF Massie, Barry M. O'Connor, Christopher M. Metra, Marco Ponikowski, Piotr Teerlink, John R. Cotter, Gad Weatherley, Beth Davison Cleland, John G. F. Givertz, Michael M. Voors, Adriaan A. DeLucca, Paul Mansoor, George A. Salerno, Christina M. Bloomfield, Daniel M. Dittrich, Howard C. CA PROTECT Investigators Comm TI Rolofylline, an Adenosine A(sub 1)-Receptor Antagonist, in Acute Heart Failure. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID WORSENING RENAL-FUNCTION; A(1) RECEPTOR ANTAGONIST; RISK STRATIFICATION; CLINICAL-TRIALS; KIDNEY-FUNCTION; IMPAIRMENT; OUTCOMES; DIAGNOSIS; KW-3902; IMPACT AB Background: Worsening renal function, which is associated with adverse outcomes, often develops in patients with acute heart failure. Experimental and clinical studies suggest that counterregulatory responses mediated by adenosine may be involved. We tested the hypothesis that the use of rolofylline, an adenosine A(sub 1)-receptor antagonist, would improve dyspnea, reduce the risk of worsening renal function, and lead to a more favorable clinical course in patients with acute heart failure. Methods: We conducted a multicenter, double-blind, placebo-controlled trial involving patients hospitalized for acute heart failure with impaired renal function. Within 24 hours after presentation, 2033 patients were randomly assigned, in a 2:1 ratio, to receive daily intravenous rolofylline (30 mg) or placebo for up to 3 days. The primary end point was treatment success, treatment failure, or no change in the patient's clinical condition; this end point was defined according to survival, heart-failure status, and changes in renal function. Secondary end points were the post-treatment development of persistent renal impairment and the 60-day rate of death or readmission for cardiovascular or renal causes. Results: Rolofylline, as compared with placebo, did not provide a benefit with respect to the primary end point (odds ratio, 0.92; 95% confidence interval, 0.78 to 1.09; P=0.35). Persistent renal impairment developed in 15.0% of patients in the rolofylline group and in 13.7% of patients in the placebo group (P=0.44). By 60 days, death or readmission for cardiovascular or renal causes had occurred in similar proportions of patients assigned to rolofylline and placebo (30.7% and 31.9%, respectively; P=0.86). Adverse-event rates were similar overall; however, only patients in the rolofylline group had seizures, a known potential adverse effect of A(sub 1)-receptor antagonists. Conclusions: Rolofylline did not have a favorable effect with respect to the primary clinical composite end point, nor did it improve renal function or 60-day outcomes. It does not show promise in the treatment of acute heart failure with renal dysfunction. (Funded by NovaCardia, a subsidiary of Merck; ClinicalTrials.gov numbers, NCT00328692 and NCT00354458.) N Engl J Med 2010;363:1419-28. C1 [Massie, Barry M.; Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Massie, Barry M.; Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA. [Cotter, Gad; Weatherley, Beth Davison] Momentum Res, Durham, NC USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Cleland, John G. F.] Univ Hull, Kingston Upon Hull, Yorks, England. [Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Voors, Adriaan A.] Univ Groningen, Groningen, Netherlands. [DeLucca, Paul; Salerno, Christina M.] Merck Res Labs, N Wales, PA USA. [Mansoor, George A.; Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard C.] NovaCardia, San Diego, CA USA. RP Massie, BM (reprint author), San Francisco VA Med Ctr 111C, Div Cardiol, 4150 Clement St, San Francisco, CA 94121 USA. EM barry.massie@va.gov RI ; Teerlink, John/D-2986-2012; Zateyshchikov, Dmitry/D-6575-2012; Vasilieva, Elena/B-2137-2016; Zadionchenko, Vladimir/A-7445-2016; Ponikowski, Piotr/O-6454-2015 OI Cleland, John/0000-0002-1471-7016; Zateyshchikov, Dmitry/0000-0001-7065-2045; Metra, Marco/0000-0001-6691-8568; Zadionchenko, Vladimir/0000-0003-2377-5266; Ponikowski, Piotr/0000-0002-3391-7064 FU NovaCardia, a subsidiary of Merck FX Supported by NovaCardia, a subsidiary of Merck. NR 28 TC 244 Z9 250 U1 2 U2 17 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 7 PY 2010 VL 363 IS 15 BP 1419 EP 1428 DI 10.1056/NEJMoa0912613 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 659NV UT WOS:000282575100007 PM 20925544 ER PT J AU Chung, KA Lobb, BM Nutt, JG Horak, FB AF Chung, Kathryn A. Lobb, Brenna M. Nutt, John G. Horak, Fay B. TI Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease SO NEUROLOGY LA English DT Article ID PEDUNCULOPONTINE TEGMENTAL NUCLEUS; NURSING-HOME RESIDENTS; BASALIS MAGNOCELLULARIS; POSTURAL CONTROL; DEMENTIA; RISK; ATTENTION; BALANCE; ANTIDEPRESSANTS; NEURONS AB Objective: To investigate if a central cholinesterase inhibitor will reduce falling frequency in subjects with Parkinson disease (PD) with advanced postural instability. Background: Falling due to postural instability is a significant problem in advancing PD, and is minimally impacted by dopaminergic therapy. Anticholinergic medications increase falling in the elderly. Further, CNS cholinergic neuron loss occurs in PD. We hypothesized that acetylcholine augmentation may reduce frequent falling in subjects with PD. Methods: We enrolled 23 subjects with PD who reported falling or nearly falling more than 2 times per week. In a randomized, placebo-controlled, crossover design, subjects were given 6 weeks of donepezil or placebo with a 3-week washout between phases. The primary outcomes were daily falls and near falls reported on postcards. Secondary outcomes included scores on the Activities of Balance Confidence Scale, Berg Balance Scale, Clinical Global Impression of Change, Folstein Mini-Mental State Examination, and the motor section of the Unified Parkinson's Disease Rating Scale. Results: Fall frequency per day on placebo was 0.25 +/- 0.08 (SEM) compared with 0.13 +/- 0.03 on donepezil (p < 0.05). The frequency of near falls was not significantly different between phases. The secondary outcomes did not differ; however, there was a trend to improvement on the subject-completed Global Impression of Change scale. Conclusions: Subjects with PD fell approximately half as often during the 6 weeks on donepezil than on placebo. Larger trials of cholinergic augmentation are warranted in subjects with PD with frequent falls. Classification of evidence: This study provides Class II evidence that donepezil (maximum 10 mg per day) significantly reduced the number of falls in patients with PD (0.13 falls/day, SEM = 0.03) than when taking placebo (0.25 falls/day, SEM = 0.08, p = 0.049). Neurology (R) 2010;75:1263-1269 C1 [Chung, Kathryn A.; Nutt, John G.; Horak, Fay B.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Lobb, Brenna M.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA. RP Chung, KA (reprint author), OP 32,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM chungka@ohsu.edu FU Veterans Administration; US Public Health Service [ULIRR024140-02]; NIH [R01-NS21062, NIA AG006457, NINDS R01 NS 21062, UL1-RR024140, NIDCD R01 DC004082-07, NIA R37 AG006457, RC1 NS068678]; Pfizer Inc.; Department of Veterans Affairs; Novartis; Teva Pharmaceutical Industries Ltd.; Schering-Plough Corp; National Parkinson Foundation; National MS Society; Parkinson's Alliance; Kinetics Foundation FX This was an investigator-initiated project funded with an unrestricted grant from Pfizer Inc., who did not design or monitor the study or receive the data or influence the writing of the manuscript. Supported by a Veterans Administration Career Development Award, US Public Health Service Grant (ULIRR024140-02), and the NIH (R01-NS21062 and NIA AG006457). Pfizer Inc. provided drug and matched placebo.; Dr. Chung has received research support from a VA Career Development Award. B. M. Lobb receives support from the Department of Veterans Affairs. Dr. Nutt has received funding for travel from Novartis and Teva Pharmaceutical Industries Ltd.; has received speaker honoraria from Novartis; has served as a consultant for XenoPort Inc., IMPAX Laboratories, Inc., Neurogen Inc., Synosia Therapeutics, and NeuroDerm, Ltd.; and has received research support from Schering-Plough Corp, the NIH (NINDS R01 NS 21062 [PI] and UL1-RR024140 [PI]), the Veterans Administration (PADRECC [Co-PI]), and the National Parkinson Foundation. Dr. Horak serves on scientific advisory boards for the Movement Disorders Society, Novartis, and the MS Society; serves as an Associate Editor for Cerebellum and on the editorial boards of Gait and Posture and the Journal of Biomechanics; holds/has filed patents re: Device for conditioning balance and motor coordination and instrumented mobility system to objectively measure balance and gait; serves as Chief Scientific Officer and member of the board of APDM, Inc.; and receives research support from the NIH (NIDCD R01 DC004082-07 [PI], NIA R37 AG006457 [PI], and RC1 NS068678 [PI]), the National MS Society, Parkinson's Alliance, and the Kinetics Foundation. NR 39 TC 89 Z9 92 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD OCT 5 PY 2010 VL 75 IS 14 BP 1263 EP 1269 DI 10.1212/WNL.0b013e3181f6128c PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 663JW UT WOS:000282883900011 PM 20810998 ER PT J AU Canolty, RT Ganguly, K Kennerley, SW Cadieu, CF Koepsell, K Wallis, JD Carmena, JM AF Canolty, Ryan T. Ganguly, Karunesh Kennerley, Steven W. Cadieu, Charles F. Koepsell, Kilian Wallis, Jonathan D. Carmena, Jose M. TI Oscillatory phase coupling coordinates anatomically dispersed functional cell assemblies SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE neuronal oscillations; neuronal ensembles; spike timing; local field potentials; brain rhythms ID NEURONAL OSCILLATIONS; NEOCORTICAL NEURONS; THETA-OSCILLATIONS; AUDITORY-CORTEX; MOTOR CORTEX; BEHAVING RAT; IN-VITRO; GAMMA; NETWORK; SYNCHRONIZATION AB Hebb proposed that neuronal cell assemblies are critical for effective perception, cognition, and action. However, evidence for brain mechanisms that coordinate multiple coactive assemblies remains lacking. Neuronal oscillations have been suggested as one possible mechanism for cell assembly coordination. Prior studies have shown that spike timing depends upon local field potential (LFP) phase proximal to the cell body, but few studies have examined the dependence of spiking on distal LFP phases in other brain areas far from the neuron or the influence of LFP-LFP phase coupling between distal areas on spiking. We investigated these interactions by recording LFPs and single-unit activity using multiple microelectrode arrays in several brain areas and then used a unique probabilistic multivariate phase distribution to model the dependence of spike timing on the full pattern of proximal LFP phases, distal LFP phases, and LFP-LFP phase coupling between electrodes. Here we show that spiking activity in single neurons and neuronal ensembles depends on dynamic patterns of oscillatory phase coupling between multiple brain areas, in addition to the effects of proximal LFP phase. Neurons that prefer similar patterns of phase coupling exhibit similar changes in spike rates, whereas neurons with different preferences show divergent responses, providing a basic mechanism to bind different neurons together into coordinated cell assemblies. Surprisingly, phase-coupling-based rate correlations are independent of interneuron distance. Phase-coupling preferences correlate with behavior and neural function and remain stable over multiple days. These findings suggest that neuronal oscillations enable selective and dynamic control of distributed functional cell assemblies. C1 [Canolty, Ryan T.; Ganguly, Karunesh; Kennerley, Steven W.; Cadieu, Charles F.; Koepsell, Kilian; Wallis, Jonathan D.; Carmena, Jose M.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. [Ganguly, Karunesh] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Cadieu, Charles F.; Koepsell, Kilian] Univ Calif Berkeley, Redwood Ctr Theoret Neurosci, Berkeley, CA 94720 USA. [Wallis, Jonathan D.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA. [Carmena, Jose M.] Univ Calif Berkeley, Program Cognit Sci, Berkeley, CA 94720 USA. RP Carmena, JM (reprint author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. EM carmena@eecs.berkeley.edu OI Wallis, Joni/0000-0001-7262-7417 FU National Institutes of Health [R01DA-19028, P01NS-040813, F32MH-081521]; National Science Foundation [IIS-0941343, IIS-0917342, IIS-1010239]; US Department of Veterans Affairs and American Heart Association; Defense Advanced Research Projects Agency [N66001-10-C-2008]; Multiscale Systems Center FX This work was funded by National Institutes of Health Grants R01DA-19028 and P01NS-040813 (to J.D.W.), National Institutes of Health Grant F32MH-081521 (to S.W.K.), National Science Foundation Grants IIS-0941343 (to J.M.C.), IIS-0917342 (to K.K.) and IIS-1010239 (to C.F.C. and K.K.), the US Department of Veterans Affairs and American Heart Association (to K.G.), the Defense Advanced Research Projects Agency Contract N66001-10-C-2008, and the Multiscale Systems Center (to J.M.C.). NR 48 TC 115 Z9 116 U1 0 U2 17 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD OCT 5 PY 2010 VL 107 IS 40 BP 17356 EP 17361 DI 10.1073/pnas.1008306107 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 658TJ UT WOS:000282512000056 PM 20855620 ER PT J AU Lomonaco, R Ortiz-Lopez, C Orsak, B Finch, J King, J Cusi, K AF Lomonaco, Romina Ortiz-Lopez, Carolina Orsak, Beverly Finch, Joan King, James Cusi, Kenneth TI PREVALENCE OF NAFLD BY MRS AND ROLE OF INSULIN RESISTANCE AND T2DM IN THE DEVELOPMENT OF NASH IN A PREDOMINANTLY HISPANIC POPULATION SO HEPATOLOGY LA English DT Meeting Abstract CT 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 29-NOV 02, 2010 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Lomonaco, Romina; Ortiz-Lopez, Carolina; Orsak, Beverly; King, James; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78229 USA. [Finch, Joan; Cusi, Kenneth] Vet Adm Med Ctr, Diabet Div, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2010 VL 52 IS 4 SU S MA 624 BP 619A EP 620A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 740EY UT WOS:000288775600623 ER PT J AU Ortiz-Lopez, C Webb, A Lomonaco, R Orsak, B Darland, CM Finch, J Diaz, N Cusi, K AF Ortiz-Lopez, Carolina Webb, Amy Lomonaco, Romina Orsak, Beverly Darland, Celia M. Finch, Joan Diaz, Norma Cusi, Kenneth TI ABNORMAL GLUCOSE METABOLISM IS FREQUENTLY OVERLOOKED IN PATIENTS WITH NASH AND ASSOCIATED WITH SEVERE HEPATIC AND ADIPOSE TISSUE INSULIN RESISTANCE SO HEPATOLOGY LA English DT Meeting Abstract CT 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 29-NOV 02, 2010 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Ortiz-Lopez, Carolina; Webb, Amy; Lomonaco, Romina; Orsak, Beverly; Finch, Joan; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78229 USA. [Webb, Amy; Darland, Celia M.; Finch, Joan; Diaz, Norma; Cusi, Kenneth] Audie L Murphy Vet Affairs Hosp, Diabet Div, San Antonio, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2010 VL 52 IS 4 SU S MA 628 BP 621A EP 622A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 740EY UT WOS:000288775600627 ER PT J AU Vermehren, J Yu, ML Monto, A Yao, JD Anderson, C Bertuzis, R Schneider, G Sarrazin, C AF Vermehren, Johannes Yu, Ming-Lung Monto, Alexander Yao, Joseph D. Anderson, Christopher Bertuzis, Rasa Schneider, George Sarrazin, Christoph TI CLINICAL UTILITY OF THE REALTIME HCV ASSAY (ABBOTT MOLECULAR) FOR RESPONSE-GUIDED THERAPY IN PATIENTS INFECTED WITH HCV GENOTYPES 1, 2, OR 3 AND TREATED WITH PEGINTERFERON-ALFA PLUS RIBAVIRIN (PEGIFN/RBV) SO HEPATOLOGY LA English DT Meeting Abstract CT 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 29-NOV 02, 2010 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Vermehren, Johannes; Sarrazin, Christoph] Klinikum JW Goethe Univ, Med Klin 1, Frankfurt, Germany. [Yu, Ming-Lung] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan. [Monto, Alexander] San Francisco VA Med Ctr, San Francisco, CA USA. [Yao, Joseph D.] Mayo Med Labs, Rochester, MN USA. [Anderson, Christopher; Bertuzis, Rasa; Schneider, George] Abbott Mol, Des Plaines, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2010 VL 52 IS 4 SU S MA 972 BP 789A EP 790A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 740EY UT WOS:000288775601290 ER PT J AU Enestvedt, B Enestvedt, CK Faigel, DO Orloff, SL AF Enestvedt, Brintha Enestvedt, C. Kristian Faigel, Douglas O. Orloff, Susan L. TI RISK FACTORS FOR BILIARY STRICTURE POST ORTHOTOPIC LIVER TRANSPLANTATION: A SINGLE CENTER EXPERIENCE SO HEPATOLOGY LA English DT Meeting Abstract CT 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 29-NOV 02, 2010 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Enestvedt, Brintha; Enestvedt, C. Kristian; Faigel, Douglas O.; Orloff, Susan L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Orloff, Susan L.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2010 VL 52 IS 4 SU S MA 1073 BP 838A EP 838A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 740EY UT WOS:000288775601391 ER PT J AU Kim, CW Torrey, K Valiga, ME Cho, H Lee, CD Chang, KM AF Kim, Chang Wook Torrey, Keith Valiga, Mary E. Cho, Hyosun Lee, Chang Don Chang, Kyong-Mi TI HBV-SPECIFIC T CELL RESPONSE OF HCV-INFECTED PATIENTS WITH ISOLATED ANTI-HBC AND COMBINED ANTI-HBC/ANTI-HBS ANTIBODY RESPONSE SO HEPATOLOGY LA English DT Meeting Abstract CT 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 29-NOV 02, 2010 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Torrey, Keith; Valiga, Mary E.; Cho, Hyosun; Chang, Kyong-Mi] Philadelphia VA Med Ctr, GI Hepatol Res Ctr, Philadelphia, PA USA. [Kim, Chang Wook; Torrey, Keith; Valiga, Mary E.; Cho, Hyosun; Chang, Kyong-Mi] Univ Penn, Philadelphia, PA 19104 USA. [Kim, Chang Wook; Lee, Chang Don] Catholic Univ Korea, Seoul, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2010 VL 52 IS 4 SU S MA 1372 BP 980A EP 981A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 740EY UT WOS:000288775601702 ER PT J AU Kaplan, DE Daruich, J Jalali, Z Rafiullah Nunez, M Vogel, M Vispo, E Barreiro, P Rockstroh, JK Mauss, S Brau, N AF Kaplan, David E. Daruich, Jorge Jalali, Ziba Rafiullah Nunez, Marina Vogel, Martin Vispo, Eugenia Barreiro, Pablo Rockstroh, Juergen K. Mauss, Stefan Braeu, Norbert TI AGE AND HEPATOCELLULAR CARCINOMA IN HIV-INFECTED PATIENTS SO HEPATOLOGY LA English DT Meeting Abstract CT 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 29-NOV 02, 2010 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kaplan, David E.] Univ Penn, Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA. [Daruich, Jorge] Univ Buenos Aires, Secc Hepatol, Buenos Aires, DF, Argentina. [Jalali, Ziba] Univ Nebraska Med Ctr, Div Infect Dis, Omaha, NE USA. [Rafiullah; Braeu, Norbert] Bronx VA Med Ctr, Bronx, NY USA. [Nunez, Marina] Wake Forest Univ, Div Infect Dis, Winston Salem, NC 27109 USA. [Vogel, Martin; Rockstroh, Juergen K.] Univ Klinikum Bonn, Bonn, Germany. [Vispo, Eugenia; Barreiro, Pablo] Hosp Carlos III, Madrid, Spain. [Mauss, Stefan] Dusseldorf Ctr HIV & HepatoGastroenterol, Dusseldorf, Germany. [Braeu, Norbert] Mt Sinai Sch Med, Div Infect Dis, New York, NY USA. [Braeu, Norbert] Mt Sinai Sch Med, Div Liver Dis, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2010 VL 52 IS 4 SU S MA 1795 BP 1174A EP 1175A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 740EY UT WOS:000288775602413 ER PT J AU Kramer, B Jouldjian, S Wang, M Mitchell, M Finke, B AF Kramer, B. Jouldjian, S. Wang, M. Mitchell, M. Finke, B. TI A MODEL FOR THE USE OF VETERANS HEALTH AFFAIRS AND/OR INDIAN HEALTH SERVICE BY OLDER AMERICAN INDIAN AND ALASKA NATIVE VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kramer, B.; Jouldjian, S.; Wang, M.; Mitchell, M.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Kramer, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Finke, B.] Indian Hlth Serv, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 16 EP 16 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006701076 ER PT J AU Spira, AP Stone, KL Redline, S Ensrud, K Yaffe, K AF Spira, A. P. Stone, K. L. Redline, S. Ensrud, K. Yaffe, K. TI ACTIGRAPHIC SLEEP AND NEUROPSYCHOLOGICAL TEST PERFORMANCE IN VERY OLD WOMEN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Spira, A. P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Stone, K. L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Redline, S.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Ensrud, K.] Univ Minnesota, Minneapolis, MN USA. [Ensrud, K.] Minnepolis VA Med Ctr, Minneapolis, MN USA. [Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 37 EP 37 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006701178 ER PT J AU Yaffe, K Laffan, A Harrison, SL Spira, AP Ensrud, K Ancoli-Israel, S Redline, S Stone, KL AF Yaffe, K. Laffan, A. Harrison, S. Litwack Spira, A. P. Ensrud, K. Ancoli-Israel, S. Redline, S. Stone, K. L. TI SLEEP DISORDERED BREATHING, HYPOXIA, AND RISK OF MILD COGNITIVE IMPAIRMENT & DEMENTIA IN OLDER WOMEN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Laffan, A.; Harrison, S. Litwack; Stone, K. L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Spira, A. P.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Ensrud, K.] Univ Minnesota, Minneapolis, MN USA. [Ensrud, K.] Minneapolis VA Med Ctr, Minneapolis, MN USA. [Ancoli-Israel, S.] Univ Calif San Diego, San Diego, CA 92103 USA. [Redline, S.] Case Western Reserve Univ, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 37 EP 37 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006701179 ER PT J AU Laffan, A Stone, KL Blackwell, T Ancoli-Israel, S Ensrud, K Redline, S Slinin, Y Yaffe, K AF Laffan, A. Stone, K. L. Blackwell, T. Ancoli-Israel, S. Ensrud, K. Redline, S. Slinin, Y. Yaffe, K. TI SLEEP DURATION AND DISRUPTION: ASSOCIATIONS WITH COGNITIVE DECLINE IN OLDER MEN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Laffan, A.; Stone, K. L.; Blackwell, T.] Calif Pacific Med Ctr, San Francisco, CA USA. [Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ancoli-Israel, S.] Univ Calif San Diego, San Diego, CA 92103 USA. [Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ensrud, K.; Slinin, Y.] Vet Affairs Med Ctr, Minneapolis, MN USA. [Redline, S.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Ensrud, K.; Slinin, Y.] Univ Minnesota, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 38 EP 38 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006701181 ER PT J AU Lee, CG Boyko, EJ Strotmeyer, ES Cawthon, PM Hoffman, AR Everson-Rose, S Barrett-Connor, E Orwoll, E AF Lee, C. G. Boyko, E. J. Strotmeyer, E. S. Cawthon, P. M. Hoffman, A. R. Everson-Rose, S. Barrett-Connor, E. Orwoll, E. TI INCREASED RISK OF LEAN MASS LOSS ASSOCIATED WITH INSULIN RESISTANCE IN OLDER MEN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Lee, C. G.; Orwoll, E.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Boyko, E. J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Strotmeyer, E. S.] Univ Pittsburgh, Pittsburgh, PA USA. [Cawthon, P. M.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Hoffman, A. R.] Stanford Sch Med, Palo Alto, CA USA. [Everson-Rose, S.] Univ Minnesota, Minneapolis, MN USA. [Barrett-Connor, E.] Univ Calif San Diego, San Diego, CA 92103 USA. RI Strotmeyer, Elsa/F-3015-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 41 EP 41 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006701195 ER PT J AU Shrestha, S Bradford, A Snow, A Wilson, N Stanley, M Kunik, ME AF Shrestha, S. Bradford, A. Snow, A. Wilson, N. Stanley, M. Kunik, M. E. TI PREVENTING AGGRESSION IN VETERANS WITH DEMENTIA SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Shrestha, S.; Bradford, A.; Wilson, N.; Stanley, M.; Kunik, M. E.] Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. [Stanley, M.; Kunik, M. E.] Michael E Debakey Vet Affair Med Ctr, Houston, TX USA. [Snow, A.] Univ Alabama, Tuscaloosa, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 66 EP 66 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006701315 ER PT J AU Ahluwalia, S Leos, R Goebel, JR Lorenz, K AF Ahluwalia, S. Leos, R. Goebel, J. R. Lorenz, K. TI A USER-CENTERED DESIGN APPROACH TO THE DEVELOPMENT OF A CLINICAL INFORMATICS SYMPTOM ASSESSMENT TOOL SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Ahluwalia, S.; Leos, R.; Goebel, J. R.; Lorenz, K.] Vet Adm Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 132 EP 132 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006701630 ER PT J AU Tsukuda, R AF Tsukuda, R. TI INTERDISCIPLINARY TEAMWORK: LESSONS HISTORY CAN TEACH US FOR THE FUTURE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Tsukuda, R.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 141 EP 141 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006701674 ER PT J AU Menon, S McCullough, LB Espadas, D Braun, U AF Menon, S. McCullough, L. B. Espadas, D. Braun, U. TI FEASIBILITY OF USING A VALUES INVENTORY AS A DISCUSSION AID ABOUT END-OF-LIFE CARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Menon, S.; McCullough, L. B.; Espadas, D.; Braun, U.] VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Braun, U.] Baylor Coll Med, Dept Med, Sect Geriatr, Houston, TX 77030 USA. [McCullough, L. B.; Braun, U.] Baylor Coll Med, Ctr Eth & Hlth Policy, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 211 EP 211 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006702131 ER PT J AU Espinoza, SE Hazuda, HP AF Espinoza, S. E. Hazuda, H. P. TI FRAILTY IN MEXICAN AMERICANS: WHERE THEY LIVE MAKES A DIFFERENCE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Espinoza, S. E.] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr & Gerontol, San Antonio, TX 78229 USA. [Hazuda, H. P.] Univ Texas Hlth Sci Ctr San Antonio Med, Div Clin Epidemiol, San Antonio, TX USA. [Espinoza, S. E.; Hazuda, H. P.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 212 EP 213 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006702137 ER PT J AU Espinoza, SE Pierce, A Halade, D Richardson, A AF Espinoza, S. E. Pierce, A. Halade, D. Richardson, A. TI PLASMA HAPTOGLOBIN IN PRE-FRAIL OLDER ADULTS: A PILOT STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Espinoza, S. E.; Pierce, A.; Halade, D.; Richardson, A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Espinoza, S. E.; Pierce, A.; Halade, D.; Richardson, A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 213 EP 213 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006702138 ER PT J AU Ahluwalia, S Gross, CP Chaudhry, S Fried, TR AF Ahluwalia, S. Gross, C. P. Chaudhry, S. Fried, T. R. TI THE IMPACT OF COMORBIDITY ON MORTALITY AMONG OLDER PERSONS WITH ADVANCED HEART FAILURE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Ahluwalia, S.] Vet Adm Greater Los Angeles, Los Angeles, CA USA. [Gross, C. P.; Chaudhry, S.; Fried, T. R.] Yale Univ, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 215 EP 215 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006702147 ER PT J AU Hutt, E Ho, M Pointer, L Shahan, E AF Hutt, E. Ho, M. Pointer, L. Shahan, E. TI EFFECTIVENESS OF ACEI/ARBS IN VA NURSING HOME RESIDENTS WITH HEART FAILURE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hutt, E.; Ho, M.; Pointer, L.; Shahan, E.] Univ Colorado, Denver VAMC, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 215 EP 215 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006702148 ER PT J AU Ahluwalia, S Gross, CP Chaudhry, S Fried, TR AF Ahluwalia, S. Gross, C. P. Chaudhry, S. Fried, T. R. TI A LONGITUDINAL ANALYSIS OF COMORBIDITY BURDEN AMONG OLDER ADULTS WITH HEART FAILURE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Ahluwalia, S.] Vet Adm Greater Los Angeles, Los Angeles, CA USA. [Gross, C. P.; Chaudhry, S.; Fried, T. R.] Yale Univ, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 216 EP 216 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006702150 ER PT J AU Griffith, JL AF Griffith, J. L. TI SOCIAL SUPPORT AND SEXUAL INTEREST IN OLDER ADULTHOOD: A PROFILE FROM THE NATIONAL SOCIAL LIFE, HEALTH AND AGING PROJECT (NSHAP) SO GERONTOLOGIST LA English DT Meeting Abstract C1 Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. Ctr Geriatr Res Educ & Clin, James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 240 EP 241 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006702273 ER PT J AU Lane, D AF Lane, D. TI "POINTS TO CONSIDER IN PLANNING FOR A SUCCESSFUL CAREER PROVIDING PSYCHOLOGICAL CARE TO OLDER ADULTS" SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Lane, D.] VA Puget Sound Healthcare Syst, Geriatr & Extended Care Serv, Tacoma, WA USA. [Lane, D.] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 243 EP 243 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006702285 ER PT J AU Bass, DM Looman, WJ McCarthy, C Walder, A Morgan, RO AF Bass, D. M. Looman, W. J. McCarthy, C. Walder, A. Morgan, R. O. TI OUTCOMES FOR CAREGIVERS AFTER SIX-MONTHS IN PARTNERS IN DEMENTIA CARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Bass, D. M.; Looman, W. J.; McCarthy, C.] Benjamin Rose Inst, Margaret Blenkner Res Inst, Cleveland, OH USA. [Walder, A.] Michael E DeBakey Vet Med Ctr, Houston, TX USA. [Morgan, R. O.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 322 EP 323 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006702661 ER PT J AU Kramer, B AF Kramer, B. TI THE GERIATRIC SCHOLARS PROGRAM: AN OVERVIEW SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kramer, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kramer, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 341 EP 341 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006702747 ER PT J AU Adamson, MM Weinstein, H Cherrier, M Diep, H Taylor, J AF Adamson, M. M. Weinstein, H. Cherrier, M. Diep, H. Taylor, J. TI SPATIAL NAVIGATION ABILITIES IN OLDER PILOTS AND NON-PILOTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Adamson, M. M.; Weinstein, H.; Diep, H.; Taylor, J.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Cherrier, M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 355 EP 355 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006702813 ER PT J AU Alessi, C AF Alessi, C. TI HS PRESIDENTIAL SYMPOSIUM: CHANGES IN LATITUDES, CHANGES IN ATTITUDES: TRANSITIONS OF CARE IN TIMES OF DISASTER AND POVERTY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Alessi, C.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Alessi, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 368 EP 368 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006703003 ER PT J AU Bates-Jensen, B AF Bates-Jensen, B. TI WOUND CARE IN HAITI 1 MONTH POST EARTHQUAKE: INFECTION, REPAIR, AND REHABILITATION SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Bates-Jensen, B.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Bates-Jensen, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 368 EP 368 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006703005 ER PT J AU Kramer, B AF Kramer, B. TI INSTEP (INCREASING STABILITY THROUGH EVALUATION AND PRACTICE): PROCESS EVALUATION SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kramer, B.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 385 EP 385 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006703083 ER PT J AU Rubenstein, L Kramer, B Vivrette, R AF Rubenstein, L. Kramer, B. Vivrette, R. TI STAYING INDEPENDENT: VALIDATING A FALL RISK SCREENER SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Rubenstein, L.; Kramer, B.; Vivrette, R.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 385 EP 385 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006703085 ER PT J AU Rubenstein, L AF Rubenstein, L. TI INSTEP (INCREASING STABILITY THROUGH EVALUATION AND PRACTICE): OUTCOME ANALYSIS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Rubenstein, L.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 385 EP 385 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006703084 ER PT J AU Payne, KL AF Payne, K. L. TI TIPS, TRICKS, AND ADVICE FOR LANDING A POSTDOCTORAL FELLOWSHIP IN GEROPSYCHOLOGY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Payne, K. L.] Milwaukee VA, Milwaukee, WI USA. [Payne, K. L.] Portland VA Med Ctr, Portland, OR USA. [Payne, K. L.] Univ Alabama, Tuscaloosa, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 394 EP 394 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006703129 ER PT J AU Alessi, C Martin, J Fiorentino, L Chung, C Josephson, K Jouldjian, S AF Alessi, C. Martin, J. Fiorentino, L. Chung, C. Josephson, K. Jouldjian, S. TI DEVELOPMENT OF A NONPHARMACOLOGICAL INTERVENTION TO IMPROVE SLEEP PATTERNS AMONG OLDER ADULTS UNDERGOING INPATIENT POST-ACUTE REHABILITATION SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Alessi, C.; Martin, J.; Josephson, K.; Jouldjian, S.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Alessi, C.; Martin, J.; Fiorentino, L.; Chung, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 482 EP 482 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006703551 ER PT J AU Byers, AL Arean, PA Yaffe, K AF Byers, A. L. Arean, P. A. Yaffe, K. TI PREVALENCE AND CHARACTERISTICS OF MENTAL HEALTH SERVICES USE IN OLDER AMERICANS WITH AND WITHOUT MOOD AND ANXIETY DISORDERS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Byers, A. L.; Arean, P. A.; Yaffe, K.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Byers, A. L.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Yaffe, K.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, K.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 496 EP 496 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006703619 ER PT J AU Moreno, G Mangione, CM Wang, P Trejo, L Butch, A Sarkisian, C AF Moreno, G. Mangione, C. M. Wang, P. Trejo, L. Butch, A. Sarkisian, C. TI ARE PHYSICAL ACTIVITY AND PHYSICAL PERFORMANCE ASSOCIATED WITH BIO-MARKERS AMONG ELDERLY LATINOS? SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Moreno, G.] UCLA Dept Family Med, Los Angeles, CA USA. [Mangione, C. M.] UCLA Dept Med, Div Gen Internal Med & Hlth Serv, Los Angeles, CA USA. [Mangione, C. M.; Wang, P.; Sarkisian, C.] UCLA Dept Med, Div Geriatr, Los Angeles, CA USA. [Trejo, L.] Dept Aging, Los Angeles, CA USA. [Butch, A.] UCLA Pathol Lab Med, Los Angeles, CA USA. [Sarkisian, C.] VA Greater Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 517 EP 517 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006703711 ER PT J AU Chodosh, J Miller-Martinez, D Aneshensel, C Wight, RG Karlamangla, AS AF Chodosh, J. Miller-Martinez, D. Aneshensel, C. Wight, R. G. Karlamangla, A. S. TI DEPRESSIVE SYMPTOMS, CHRONIC DISEASE, AND PHYSICAL DISABILITY AS PREDICTORS OF COGNITIVE FUNCTIONING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Chodosh, J.; Miller-Martinez, D.; Karlamangla, A. S.] UCLA Div Geriatr, Los Angeles, CA USA. [Chodosh, J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Aneshensel, C.; Wight, R. G.] Community Hlth Sci UCLA, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2010 VL 50 SU 1 BP 525 EP 526 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 703UL UT WOS:000286006703747 ER PT J AU Gallun, FJ Saunders, GH AF Gallun, Frederick J. Saunders, Gabrielle H. TI The Ear-Brain System: Approaches to the Study and Treatment of Hearing Loss SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Editorial Material ID SPECTRAL SHAPE-DISCRIMINATION; LISTENERS; ADULTS; SPEECH; NOISE C1 [Gallun, Frederick J.; Saunders, Gabrielle H.] Rehabil Res & Dev Serv RR&D, US Dept Vet Affairs, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA. RP Gallun, FJ (reprint author), Rehabil Res & Dev Serv RR&D, US Dept Vet Affairs, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. RI Gallun, Frederick/G-3792-2012 OI Gallun, Frederick/0000-0002-4145-2199 NR 12 TC 0 Z9 0 U1 2 U2 3 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD OCT PY 2010 VL 21 IS 9 SI SI DI 10.3766/jaaa.21.9.1 PG 3 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 704YF UT WOS:000286090900001 ER PT J AU Zuleger, CL Macklin, MD Newton, MA Albertini, MR AF Zuleger, Cindy L. Macklin, Michael D. Newton, Michael A. Albertini, Mark R. TI In Vivo 6-thioguanine-resistant T Cells from Melanoma Patients Contain T Cells with Melanoma Specificity as well as T Cells with Suppressive Function SO JOURNAL OF IMMUNOTHERAPY LA English DT Meeting Abstract C1 [Zuleger, Cindy L.; Macklin, Michael D.; Newton, Michael A.; Albertini, Mark R.] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Comprehens Canc Ctr, Madison, WI 53706 USA. [Albertini, Mark R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1524-9557 J9 J IMMUNOTHER JI J. Immunother. PD OCT PY 2010 VL 33 IS 8 BP 889 EP 889 PG 1 WC Oncology; Immunology; Medicine, Research & Experimental SC Oncology; Immunology; Research & Experimental Medicine GA 653XQ UT WOS:000282131800107 ER PT J AU Campbell, J Prochazka, AV Yamashita, T Gopal, R AF Campbell, Jessica Prochazka, Allan V. Yamashita, Traci Gopal, Ravi TI Predictors of Persistent Burnout in Internal Medicine Residents: A Prospective Cohort Study SO ACADEMIC MEDICINE LA English DT Article ID PATIENT-CARE; PROGRAM AB Purpose Resident burnout continues to be a major problem despite work hours restrictions. The authors conducted a longitudinal study to determine whether burnout in internal medicine residents is persistent and what factors predispose residents to persistent burnout. Method The authors mailed a survey to internal medicine residents at the University of Colorado Denver Health Science Center each May, from 2003 through 2008. The survey measures included the Maslach Burnout Inventory organized into three subscales: emotional exhaustion (EE), depersonalization (DP), and personal accomplishment. The authors defined burned-out residents as having a high EE or DP score and persistent burnout as being burned out during all three years of residency. Results Of the 179 eligible residents, 86 (48%) responded to the survey during all three years of their residency. Sixty-seven residents (78%) were burned out at least once: 58 residents (67%) were burned out during their internship, 58 (67%) during their second year, and 50 (58%) during their third year (P <.08). Of the 58 burned-out interns, 42 (72%) continued to be burned out through their three years of training. Persistent burnout was more likely to occur in men (OR = 3.31, P <.01) and was associated with screening positive for depression as an intern (OR = 4.4, P <.002). Conclusions Once present, burnout tends to persist through residency. Men and residents who screened positive for depression as interns are at the highest risk for persistent burnout. Interventions to prevent burnout during internship may significantly decrease burnout throughout residency. C1 [Campbell, Jessica; Prochazka, Allan V.; Gopal, Ravi] Univ Colorado Denver, Sch Med, Dept Med, Aurora, CO USA. [Campbell, Jessica] Denver Hlth Med Ctr, Div Hosp Med, Denver, CO USA. [Prochazka, Allan V.; Gopal, Ravi] Denver VA Med Ctr, Denver, CO USA. [Yamashita, Traci] Univ Colorado Denver, Sch Med, Div Gen Internal Med, Aurora, CO USA. RP Campbell, J (reprint author), 660 Bannock St,MC 4000, Denver, CO 80204 USA. EM jessica.campbell@dhha.org FU University of Colorado FX This study was funded in part by the University of Colorado Denver Division of General Internal Medicine Small Grant Program. NR 15 TC 34 Z9 37 U1 0 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD OCT PY 2010 VL 85 IS 10 BP 1630 EP 1634 DI 10.1097/ACM.0b013e3181f0c4e7 PG 5 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 656UN UT WOS:000282365000021 PM 20881685 ER PT J AU Lugea, A Gong, J Nguyen, J Nieto, J French, SW Pandol, SJ AF Lugea, Aurelia Gong, Jun Nguyen, Janie Nieto, Jose French, Samuel W. Pandol, Stephen J. TI Cholinergic Mediation of Alcohol-Induced Experimental Pancreatitis SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Pancreas; Alcohol Feeding; Cerulein; Cholinergic Pathways; Acetylcholinesterase ID CERULEIN-INDUCED PANCREATITIS; KAPPA-B ACTIVATION; ACINAR-CELLS; ACETYLCHOLINESTERASE ACTIVITY; EXOCRINE SECRETION; ETHANOL; RATS; CHOLECYSTOKININ; KINASE; INJURY AB Objectives: The mechanisms initiating pancreatitis in patients with chronic alcohol abuse are poorly understood. Although alcohol feeding has been previously suggested to alter cholinergic pathways, the effects of these cholinergic alterations in promoting pancreatitis have not been characterized. For this study, we determined the role of the cholinergic system in ethanol-induced sensitizing effects on cerulein pancreatitis. Methods: Rats were pair-fed control and ethanol-containing Lieber-DeCarli diets for 6 weeks followed by parenteral administration of 4 hourly intraperitoneal injections of the cholecystokinin analog, cerulein at 0.5 mu g/kg. This dose of cerulein was selected because it caused pancreatic injury in ethanol-fed but not in control-fed rats. Pancreatitis was preceded by treatment with the muscarinic receptor antagonist atropine or by bilateral subdiaphragmatic vagotomy. Measurement of pancreatic pathology included serum lipase activity, pancreatic trypsin, and caspase-3 activities, and markers of pancreatic necrosis, apoptosis, and autophagy. In addition, we measured the effects of ethanol feeding on pancreatic acetylcholinesterase activity and pancreatic levels of the muscarinic acetylcholine receptors m1 and m3. Finally, we examined the synergistic effects of ethanol and carbachol on inducing acinar cell damage. Results: We found that atropine blocked almost completely pancreatic pathology caused by cerulein administration in ethanol-fed rats, while vagotomy was less effective. Ethanol feeding did not alter expression levels of cholinergic muscarinic receptors in the pancreas but significantly decreased pancreatic acetylcholinesterase activity, suggesting that acetylcholine levels and cholinergic input within the pancreas can be higher in ethanol-fed rats. We further found that ethanol treatment of pancreatic acinar cells augmented pancreatic injury responses caused by the cholinergic agonist, carbachol. Conclusion: These results demonstrate key roles for the cholinergic system in the mechanisms of alcoholic pancreatitis. C1 [Lugea, Aurelia; Gong, Jun; Nguyen, Janie; Nieto, Jose; Pandol, Stephen J.] Vet Affairs Greater Los Angeles Healthcare Syst, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA USA. [French, Samuel W.] Harbor UCLA Med Ctr, Dept Pathol, Torrance, CA 90509 USA. RP Lugea, A (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, Bldg 258,Room 339,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM alugea@ucla.edu FU National Institute on Alcohol Abuse and Alcoholism (NIAAA) [P50-A11999, 08,116] FX This work was supported by the Department of Veterans Affairs and Research Center for Alcoholic Liver and Pancreatic Diseases (NIAAA P50-A11999) funded by the National Institute on Alcohol Abuse and Alcoholism. We also acknowledge the Animal Core and Morphology Core facilities of the NIAAA-supported Research Center for Alcoholic Liver and Pancreatic Diseases (NIAAA P50-A11999 and NIAAA 08,116 to SW French) for providing assistance with animal alcohol feeding and morphological analyses of pancreatic tissues. NR 66 TC 8 Z9 8 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2010 VL 34 IS 10 BP 1768 EP 1781 DI 10.1111/j.1530-0277.2010.01264.x PG 14 WC Substance Abuse SC Substance Abuse GA 656FW UT WOS:000282313600014 PM 20626730 ER PT J AU Teng, E Becker, BW Woo, E Knopman, DS Cummings, JL Lu, PH AF Teng, Edmond Becker, Brian W. Woo, Ellen Knopman, David S. Cummings, Jeffrey L. Lu, Po H. TI Utility of the Functional Activities Questionnaire for Distinguishing Mild Cognitive Impairment From Very Mild Alzheimer Disease SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE mild cognitive impairment; dementia; Alzheimer disease; activities of daily living; standardized assessment ID UNIFORM DATA SET; INSTRUMENTAL ACTIVITIES; OLDER-ADULTS; DEMENTIA; DIAGNOSIS; MCI; INDIVIDUALS; COMMUNITY; DEFICITS; SUBTYPES AB Current criteria for mild cognitive impairment (MCI) require "essentially intact" performance of activities of daily living (ADLs), which has proven difficult to operationalize. We sought to determine how well the Functional Activities Questionnaire (FAQ), a standardized assessment of instrumental ADLs, delineates the clinical distinction between MCI and very mild Alzheimer disease (AD). We identified 1801 individuals in the National Alzheimer's Coordinating Center Uniform Data Set with MCI (n = 1108) or very mild AD (n = 693) assessed with the FAQ and randomized them to the development or test sets. Receiver-operator curve (ROC) analysis of the development set identified optimal cut-points that maximized the sensitivity and specificity of FAQ measures for differentiating AD from MCI and were validated with the test set. ROC analysis of total FAQ scores in the development set produced an area under the curve of 0.903 and an optimal cut-point of 5/6, which yielded 80.3% sensitivity, 87.0% specificity, and 84.7% classification accuracy in the test set. Bill paying, tracking current events, and transportation (P's < 0.005) were the FAQ items of greatest diagnostic utility. These data suggest that the FAQ exhibits adequate sensitivity and specificity when used as a standardized assessment of instrumental ADLs in the diagnosis of AD versus MCI. C1 [Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA. [Teng, Edmond; Becker, Brian W.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Teng, Edmond; Woo, Ellen; Cummings, Jeffrey L.; Lu, Po H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Cummings, Jeffrey L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Knopman, David S.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA. RP Teng, E (reprint author), W Los Angeles VA Healthcare Ctr, Neurobehav Unit, Bldg 500 116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM eteng@ucla.edu FU National Institute on Aging [P50 AG16570, U01 AG016976]; National Alzheimer's Coordinating Center; Alzheimer's Disease Research Centers of California; Sidell-Kagan Foundation FX This research was supported by the National Institute on Aging (P50 AG16570 U01 AG016976), the National Alzheimer's Coordinating Center, the Alzheimer's Disease Research Centers of California, and the Sidell-Kagan Foundation. NR 33 TC 26 Z9 27 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD OCT-DEC PY 2010 VL 24 IS 4 BP 348 EP 353 DI 10.1097/WAD.0b013e3181e2fc84 PG 6 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 681JN UT WOS:000284308100007 PM 20592580 ER PT J AU Al-Khatib, SM Calkins, H Eloff, BC Kowey, P Hammill, SC Ellenbogen, KA Marinac-Dabic, D Waldo, AL Brindis, RG Wilbur, DJ Jackman, WM Yaross, MS Russo, AM Prystowsky, E Varosy, PD Gross, T Pinnow, E Turakhia, MP Krucoff, MW AF Al-Khatib, Sana M. Calkins, Hugh Eloff, Benjamin C. Kowey, Peter Hammill, Stephen C. Ellenbogen, Kenneth A. Marinac-Dabic, Danica Waldo, Albert L. Brindis, Ralph G. Wilbur, David J. Jackman, Warren M. Yaross, Marcia S. Russo, Andrea M. Prystowsky, Eric Varosy, Paul D. Gross, Thomas Pinnow, Ellen Turakhia, Mintu P. Krucoff, Mitchell W. TI Developing the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a collaborative pan-stakeholder critical path registry model: A Cardiac Safety Research Consortium "Incubator" Think Tank SO AMERICAN HEART JOURNAL LA English DT Article ID ANTIARRHYTHMIC-DRUG THERAPY; PULMONARY-VEIN ABLATION; RADIOFREQUENCY ABLATION; CATHETER ABLATION; RANDOMIZED-TRIAL AB Although several randomized clinical trials have demonstrated the safety and efficacy of catheter ablation of atrial fibrillation (AF) in experienced centers, the outcomes of this procedure in routine clinical practice and in patients with persistent and long-standing persistent AF remain uncertain. Brisk adoption of this therapy by physicians with diverse training and experience highlights potential concerns regarding the safety and effectiveness of this procedure. Some of these concerns could be addressed by a national registry of AF ablation procedures such as the Safety of Atrial Fibrillation Ablation Registry Initiative that was initially proposed at a Cardiac Safety Research Consortium Think Tank meeting in April 2009. In January 2010, the Cardiac Safety Research Consortium, in collaboration with the Duke Clinical Research Institute, the US Food and Drug Administration, the American College of Cardiology, and the Heart Rhythm Society, held a follow-up meeting of experts in the field to review the construct and progress to date. Other participants included the National Heart, Lung, and Blood Institute; the Centers for Medicare and Medicaid Services; the Agency for Healthcare Research and Quality; the AdvaMed AF working group; and additional industry representatives. This article summarizes the discussions that occurred at the meeting of the state of the Safety of Atrial Fibrillation Ablation Registry Initiative, the identification of a clear pathway for its implementation, and the exploration of solutions to potential issues in the execution of this registry. (Am Heart J 2010; 160: 619-626.e1.) C1 [Al-Khatib, Sana M.; Krucoff, Mitchell W.] Duke Univ, Duke Clin Res Inst, Med Ctr, Durham, NC 27715 USA. [Calkins, Hugh] Johns Hopkins Univ, Baltimore, MD USA. [Eloff, Benjamin C.; Marinac-Dabic, Danica; Gross, Thomas; Pinnow, Ellen] US FDA, Silver Spring, MD USA. [Kowey, Peter] Main Line Hlth Heart Ctr, Philadelphia, PA USA. [Hammill, Stephen C.] Mayo Clin, Rochester, MN USA. [Ellenbogen, Kenneth A.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA. [Waldo, Albert L.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Brindis, Ralph G.] Amer Coll Cardiol, Washington, DC USA. [Brindis, Ralph G.] Oakland Kaiser Permanente, Oakland, CA USA. [Wilbur, David J.] Loyola Univ, Med Ctr, Chicago, IL 60611 USA. [Jackman, Warren M.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Yaross, Marcia S.] Biosense Webster, Diamond Bar, CA USA. [Russo, Andrea M.] Cooper Univ Hosp, Robert Wood Johnson Med Sch, Camden, NJ USA. [Prystowsky, Eric] Care Grp, Indianapolis, IN USA. [Varosy, Paul D.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Varosy, Paul D.] Univ Colorado, Denver, CO 80202 USA. [Turakhia, Mintu P.] Palo Alto VA Hlth Care Syst, Palo Alto, CA USA. [Turakhia, Mintu P.] Stanford Univ, Stanford, CA 94305 USA. RP Al-Khatib, SM (reprint author), Duke Univ, Duke Clin Res Inst, Med Ctr, POB 17969, Durham, NC 27715 USA. EM alkha001@mc.duke.edu FU CSRC, DCRI, ACC, HRS; FDA; AdvaMed FX This conference was funded by the CSRC, DCRI, ACC, HRS; registration fees and in-kind support from the FDA and AdvaMed. NR 16 TC 10 Z9 10 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD OCT PY 2010 VL 160 IS 4 BP 619 EP U249 DI 10.1016/j.ahj.2010.06.044 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 660WN UT WOS:000282677300010 PM 20934554 ER PT J AU Samlowski, WE Moon, J Tuthill, RJ Heinrich, MC Balzer-Haas, NS Merl, SA DeConti, RC Thompson, JA Witter, MT Flaherty, LE Sondak, VK AF Samlowski, Wolfram E. Moon, James Tuthill, Ralph J. Heinrich, Michael C. Balzer-Haas, Naomi S. Merl, Stuart A. DeConti, Ronald C. Thompson, John A. Witter, Merle T. Flaherty, Lawrence E. Sondak, Vernon K. TI A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin) A Southwest Oncology Group Study (S0331) SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS LA English DT Article DE Merkel cell carcinoma; neuroendocrine carcinoma of the skin; imatinib mesylate; c-KIT ID CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; CLINICAL BEHAVIOR; CD117 EXPRESSION; KIT; CHEMOTHERAPY; TUMORS; 5-FLUOROURACIL; POLYOMAVIRUS; INHIBITOR AB Background: Imatinib mesylate (Gleevec) was evaluated as a treatment for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) based on the identification of strong c-KIT staining of these neoplasms. Methods: Eligibility included patients with measurable metastatic or unresectable MCC, c-KIT (CD117) expression and a Zubrod performance status of 0 to 2. Imatinib 400 mg daily was administered orally in 28-day cycles to 23 patients. Results: Overall, imatinib was well tolerated with grade 1 or 2 nausea, diarrhea, and hematologic toxicity as the most frequent side effects. A partial response was seen in 1 patient (4%; 95% CI: 0%-22%). Median progression-free survival was 1 month (95% CI: 1-2 months). Median overall survival was 5 months (95% CI: 2-8 months). One patient achieved a partial response and another had prolonged disease stabilization while receiving treatment. Conclusions: The majority of patients progressed rapidly within 1 to 2 cycles of treatment. The observed progression-free survival and overall survival were not adequate to conclude that this agent was active in advanced MCC, and thus the planned second stage of patient accrual was not opened. C1 [Samlowski, Wolfram E.; Witter, Merle T.; Sondak, Vernon K.] Nevada Canc Inst, Las Vegas, NV USA. [Moon, James] SW Oncol Grp, Ctr Stat, Seattle, WA USA. [Tuthill, Ralph J.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Balzer-Haas, Naomi S.] Univ Penn ECOG, Abramson Canc Ctr, Philadelphia, PA USA. [Merl, Stuart A.] Dayton Clin Oncol Program, Dayton, OH USA. [DeConti, Ronald C.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Thompson, John A.] Puget Sound Oncol Consortium, Seattle, WA USA. [Flaherty, Lawrence E.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. RP Samlowski, WE (reprint author), SW Oncol Grp, Chairs Off S0331, 24 Frank Lloyd Wright Dr,POB 483, Ann Arbor, MI 48106 USA. EM arlauska@med.umich.edu OI Samlowski, Wolfram/0000-0002-0713-914X FU National Cancer Institute, DHHS [CA32102, CA38926, CA35090, CA073590, CA20319), CA45377, A35178, CA35176, CA46113, CA46441, CA42777, CA86780, CA58861, CA46282, CA35119, CA15488, CA21115] FX Supported, in part, by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA32102, CA38926, CA35090, CA073590, CA20319), CA45377, CA35178, CA35176, CA46113, CA46441, CA42777, CA86780, CA58861, CA46282, CA35119, CA15488, CA21115. NR 35 TC 32 Z9 32 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-3732 J9 AM J CLIN ONCOL-CANC JI Am. J. Clin. Oncol.-Cancer Clin. Trials PD OCT PY 2010 VL 33 IS 5 BP 495 EP 499 DI 10.1097/COC.0b013e3181b9cf04 PG 5 WC Oncology SC Oncology GA 659WT UT WOS:000282598700013 PM 20019577 ER PT J AU Kessler, C Chen, J Dill, C Tyndall, G Olszyk, MD AF Kessler, Chad Chen, Jennifer Dill, Curt Tyndall, Gary Olszyk, Mark D. TI State of affairs of emergency medicine in the Veterans Health Administration SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID QUALITY-OF-CARE; CENTERS; SYSTEM AB Background: The Veterans Health Administration (VHA) has reformed its emergency medical services. Objectives: This study updates an overview of emergency medicine within VHA. Methods: This is a cross-sectional survey of VHA medical facilities offering emergency medical care. Results: Sixty-eight percent (95/140) of facilities had emergency departments (EDs) only, 12% (16/140) had both ED and urgent care centers (UCCs), and 16% (23/140) had only UCCs. The mean (SD) ED/UCC census was 13 371 (7664). A mean (SD) of 53% (27%) of facility admissions were admitted through ED/UCCs. The median of all ED/UCC admissions admitted to intensive care unit level care was 11% (interquartile range, 7-16). Of physicians with any board certification, 16% (209/1331) of physicians had emergency medicine board certification. Conclusions: Emergency medical care is now available at most VHA facilities. The specialty of emergency medicine has an important but minority presence within clinical emergency medical care at VHA. Published by Elsevier Inc. C1 [Chen, Jennifer] W Los Angeles VA Med Ctr, David Geffen UCLA Sch Med, Dept Med, Los Angeles, CA 90073 USA. [Kessler, Chad] Univ Illinois, Jesse Brown VA Hosp, Dept Internal Med, Chicago, IL 60612 USA. [Kessler, Chad] Univ Illinois, Jesse Brown VA Hosp, Dept Emergency Med, Chicago, IL 60612 USA. [Dill, Curt] NYU, Sch Med, VA New York Harbor Healthcare Ctr, Dept Emergency Serv, Brooklyn, NY 11209 USA. [Tyndall, Gary] Syracuse VAMC, Emergency Serv, Syracuse, NY 13210 USA. [Olszyk, Mark D.] VA Maryland Healthcare Syst, Emergency Serv, Baltimore, MD 21201 USA. RP Chen, J (reprint author), W Los Angeles VA Med Ctr, David Geffen UCLA Sch Med, Dept Med, Los Angeles, CA 90073 USA. EM jen.chencn@gmail.com OI Chen, Jennifer/0000-0002-4801-5397; Tyndall, Gary/0000-0001-9984-4809 NR 10 TC 8 Z9 8 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD OCT PY 2010 VL 28 IS 8 BP 947 EP 951 DI 10.1016/j.ajem.2009.08.008 PG 5 WC Emergency Medicine SC Emergency Medicine GA 660TV UT WOS:000282669300019 PM 20887913 ER PT J AU Whitcomb, DC Muddana, V Langmead, CJ Houghton, FD Guenther, A Eagon, PK Mayerle, J Aghdassi, AA Weiss, FU Evans, A Lamb, J Clermont, G Lerch, MM Papachristou, GI AF Whitcomb, David C. Muddana, Venkata Langmead, Christopher J. Houghton, Frank D., Jr. Guenther, Annett Eagon, Patricia K. Mayerle, Julia Aghdassi, Ali A. Weiss, F. Ulrich Evans, Anna Lamb, Janette Clermont, Gilles Lerch, Markus M. Papachristou, Georgios I. TI Angiopoietin-2, a Regulator of Vascular Permeability in Inflammation, Is Associated With Persistent Organ Failure in Patients With Acute Pancreatitis From the United States and Germany SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID CIRCULATING ANGIOPOIETIN-2; SEPSIS; MULTICENTER; POPULATION; MORTALITY; SEVERITY; MEDIATOR; INJURY; SCORE; LEAK AB OBJECTIVES: Patients with severe acute pancreatitis (AP) typically develop vascular leak syndrome, resulting in hemoconcentration, hypotension, pulmonary edema, and renal insufficiency. Angiopoietin-1 (Ang-1) and 2 (Ang-2) are autocrine peptides that reduce or increase endothelial permeability, respectively. The aim of this study was to determine whether Ang-1 and/or Ang-2 levels are predictive biomarkers of persistent organ failure (>48h) and prolonged hospital course. METHODS: Banked serum from 28 patients enrolled in the Severity of Acute Pancreatitis Study at the University of Pittsburgh Medical Center (UPMC) and 58 controls was analyzed for Ang-1 and Ang-2 levels. Separately, serum from 123 patients and 103 controls at Greifswald University (GU), Germany was analyzed for Ang-2 levels. Angiopoietin levels were measured by enzyme-linked immunosorbent assay. RESULTS: In all, 6 out of 28 UPMC patients (21%) and 14 out of 123 GU patients (13%) developed persistent organ failure and were classified as severe AP. Ang-2 was significantly higher on admission in patients who developed persistent organ failure compared with those who did not in UPMC (3,698 pg/ml vs. 1,001 pg/ml; P=0.001) and GU (4,945 pg/ml vs. 2,631 pg/ml; P=0.0004) cohorts. After data scaling, admission Ang-2 levels showed a receiver-operator curve of 0.81, sensitivity 90%, and specificity 67% in predicting persistent organ failure. In addition, Ang-2 levels remained significantly higher in severe AP compared with mild AP patients until day 7 (days 2-4: P<0.005; day 7: P<0.02). Ang-1 levels were not significantly different between mild and severe AP patients on admission. CONCLUSIONS: Elevated serum Ang-2 levels on admission are associated with and may be a useful biomarker of predicting persistent organ failure and ongoing endothelial cell activation in AP. C1 [Whitcomb, David C.; Muddana, Venkata; Houghton, Frank D., Jr.; Eagon, Patricia K.; Evans, Anna; Lamb, Janette; Papachristou, Georgios I.] Univ Pittsburgh, Dept Med, Div Gastroenterol Hepatol & Nutr, Med Ctr, Pittsburgh, PA 15213 USA. [Whitcomb, David C.] Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA 15213 USA. [Whitcomb, David C.] Univ Pittsburgh, Sch Med, Dept Physiol, Pittsburgh, PA 15213 USA. [Whitcomb, David C.] Univ Pittsburgh, Sch Med, Dept Human Genet, Pittsburgh, PA 15213 USA. [Langmead, Christopher J.] Carnegie Mellon Univ, Dept Comp Sci, Pittsburgh, PA 15213 USA. [Guenther, Annett; Mayerle, Julia; Aghdassi, Ali A.; Weiss, F. Ulrich; Lerch, Markus M.] Ernst Moritz Arndt Univ Greifswald, Dept Med A, Greifswald, Germany. [Clermont, Gilles] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA. [Clermont, Gilles; Papachristou, Georgios I.] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA. RP Whitcomb, DC (reprint author), Univ Pittsburgh, Dept Med, Div Gastroenterol Hepatol & Nutr, Med Ctr, Room 401-4,3708 5th Ave, Pittsburgh, PA 15213 USA. EM whitcomb@pitt.edu RI Lerch, Markus M./E-2206-2016; Weiss, Frank/A-6386-2009 OI Lerch, Markus M./0000-0002-9643-8263; Weiss, Frank Ulrich/0000-0003-3369-6369 FU National Pancreas Foundation; VA Stars Competitive Pilot Project Fund (CPPF); DFG [LE 625/8-1, 9-1, GRK 840 E3, E4]; Alfried-Krupp Foundation; [BMBF-NBL3 01 ZZ 0403] FX This study was funded by the National Pancreas Foundation (D. C. W.), the VA Stars Competitive Pilot Project Fund (CPPF), DFG LE 625/8-1 and 9-1, the Alfried-Krupp Foundation, DFG GRK 840 E3 and E4, and BMBF-NBL3 01 ZZ 0403. NR 20 TC 28 Z9 29 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2010 VL 105 IS 10 BP 2287 EP 2292 DI 10.1038/ajg.2010.183 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 659US UT WOS:000282593000023 PM 20461065 ER PT J AU Chavalitdhamrong, D Giri, B Luthra, M AF Chavalitdhamrong, Disaya Giri, Badri Luthra, Munish TI Acute Autoimmune Hepatitis Mimicking an Acute Abdomen SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 15-20, 2010 CL San Antonio, TX SP Amer Coll Gastroenterol C1 [Chavalitdhamrong, Disaya; Giri, Badri; Luthra, Munish] Mt Sinai Sch Med Bronx Program, James J Peters Vet Affairs Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2010 VL 105 SU 1 MA 731 BP S264 EP S264 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 663VG UT WOS:000282917700725 ER PT J AU Cheifetz, A Melmed, G Spiegel, B Talley, J Devlin, S Harrell, L Irving, P Jones, J Kaplan, G Kozuch, P Sparrow, M Velayos, F Baidoo, L Bressler, B Siegel, C AF Cheifetz, Adam Melmed, Gil Spiegel, Brennan Talley, Jennifer Devlin, Shane Harrell, Laura Irving, Peter Jones, Jennifer Kaplan, Gil Kozuch, Patricia Sparrow, Miles Velayos, Fernando Baidoo, Leonard Bressler, Brian Siegel, Corey TI Setting Priorities for Comparative Effectiveness Research in Inflammatory Bowel Disease: Results of an International Provider Survey, Expert RAND Panel, and Patient Focus Groups SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 15-20, 2010 CL San Antonio, TX SP Amer Coll Gastroenterol C1 [Cheifetz, Adam] Beth Israel Deaconess Med Ctr, Med GI, Boston, MA 02215 USA. [Melmed, Gil] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Spiegel, Brennan] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Talley, Jennifer] CURE Digest Dis Res Ctr, Los Angeles, CA USA. [Devlin, Shane; Kaplan, Gil] Univ Calgary, Calgary, AB, Canada. [Harrell, Laura] Univ Chicago, Chicago, IL 60637 USA. [Irving, Peter] Guys & St Thomas Hosp, London SE1 9RT, England. [Jones, Jennifer] Univ Saskatchewan, Saskatoon, SK, Canada. [Kozuch, Patricia] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Sparrow, Miles] Alfred Hosp, Melbourne, Vic, Australia. [Velayos, Fernando] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Baidoo, Leonard] Univ Pittsburgh, Pittsburgh, PA USA. [Bressler, Brian] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Siegel, Corey] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2010 VL 105 SU 1 MA 1147 BP S415 EP S416 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 663VG UT WOS:000282917701337 ER PT J AU Sun, S Spiegel, B Mody, R Dabbous, F Dabbous, O Chey, W AF Sun, Shawn Spiegel, Brennan Mody, Reema Dabbous, Firas Dabbous, Omar Chey, William TI Economic and Humanistic Burden of Chronic Constipation SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 15-20, 2010 CL San Antonio, TX SP Amer Coll Gastroenterol C1 [Sun, Shawn; Mody, Reema; Dabbous, Firas; Dabbous, Omar] Takeda Pharmaceut N Amer, Deerfield, IL USA. [Spiegel, Brennan] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chey, William] Univ Michigan Hlth Syst, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2010 VL 105 SU 1 MA 1081 BP S391 EP S391 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 663VG UT WOS:000282917701271 ER PT J AU Copeland, LA Parchman, ML Zeber, JE Lawrence, VA Downs, JR Miller, AL AF Copeland, Laurel A. Parchman, Michael L. Zeber, John E. Lawrence, Valerie A. Downs, John R. Miller, Alexander L. TI Prediabetes Assessment and Follow-up in Older Veterans With Schizophrenia SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Mortality; prediabetes; schizophrenia; veterans ID ANTIPSYCHOTIC-DRUGS; DIABETES-MELLITUS; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; GLUCOSE-TOLERANCE; EXCESS MORTALITY; HEALTH-SERVICES; PRIMARY-CARE; RISK; WEIGHT AB Objectives: Assess glycemic monitoring and follow-up. Design: Retrospective study using administrative data (October 2001-September 2005). Setting: Veterans Health Administration. Participants: A nationwide sample of 39,226 outpatients aged 50 years or older with schizophrenia. Patients had no diagnosis or medications for diabetes at baseline. Measurements: Hemoglobin A1c tests; blood glucose tests with same-day low-density lipoprotein to approximate fasting glucose. Glycemic tests were combined to indicate a) prediabetic dysglycemia (100-125 mg/dL proxy fasting glucose or 5.8%-6.4% hemoglobin A1c) and b) diabetic dysglycemia (>= 126 proxy fasting glucose or >= 6.5% A1c). Results: Approximately one-third of patients (32%; 12,587) had proxy fasting blood glucose or A1c tests in 2002; multiple tests were rare. The proportion tested increased to 40% by 2005. Test results suggested prediabetic dysglycemia for 5,345 tested patients (42% of those tested) and diabetic dysglycemia for 1,287 tested patients (10%) at baseline. In multivariate regression models, glycemic testing was associated with dyslipidemia, hypertension, and younger age. Dysglycemia was associated with hypertension, dyslipidemia, and older age. Follow-up treatment/diagnosis of diabetes occurred for 8% of patients (11% of those tested) and was associated with baseline dysglycemia, hypertension, and younger age. Mortality (15% during the 4-year study) was higher among untested and untreated patients. Conclusions: Dysglycemia was prevalent among older patients with schizophrenia, although monitoring and follow-up were uncommon. Follow-up treatment correlated with survival. Despite evident utility of testing, few at-risk patients with schizophrenia were adequately monitored, diagnosed, or treated for dysglycemia. (Am J Geriatr Psychiatry 2010; 18:887-896) C1 [Copeland, Laurel A.; Zeber, John E.; Miller, Alexander L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Parchman, Michael L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Lawrence, Valerie A.; Downs, John R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Copeland, LA (reprint author), VERDICT Res, S Texas Vet HCS, 7400 Merton Minter 11C6, San Antonio, TX 78229 USA. EM LaurelACopeland@gmail.com OI Parchman, Michael/0000-0001-7129-2889; Copeland, Laurel/0000-0002-9478-0209 FU Department of Veterans Affairs [IIR-05-326]; VERDICT Research Center; University of Texas Health Science Center at San Antonio; Copeland as PI: VA HSRD; Hogg Fndn/UT-Austin; Copeland as co-I: VA HSRD; VA VISN 17; NIH; Dept of Defense; Parchman as PI: VA/HSRD; NIDDK; Parchman as co-I: VA HSRD; Lawrence as PI: VA/HSRD; Lawrence as co-I: VHA; Zeber as PI: VA HSRD; PhRMA Fndn; UTHSCSA Training Pgm; Zeber as co-I: VA HSRD; Downs as PI: none Downs as co-I: VA/HSRD; NINR; Miller as PI: AstraZeneca; Pfizer Organon; UNC/NIMH; Glaxo Smith Kline; Pfizer; Sanofi Aventis; Janssen; Miller as co-I: VA HSRD; Research Foundation for Mental Hygiene New York; CME, Inc. Orlando, FL; France Foundation Atlanta, GA; Organon (Advisory Board) Parsippany, NJ; Dainippon Sumitomo (Advisory Board) Chicago; Eli Lilly (Advisory Board) Scottsdale, AZ; AstraZeneca (Advisory Board) Baltimore; CME Outfitters Washington, DC; Research Foundation for Mental Hygiene; VA San Antonio, TX; Comprehensive Neuroscience online survey; NCME, Inc. French Camp, CA; State of Maryland Baltimore; NCME, Inc. Smithville, TX; NCME, Inc. Reno, NV; International Congress on Schizophrenia Research San Diego, CA; VA HSRD FX This work was supported by the Department of Veterans Affairs (Grant # IIR-05-326; PI: Copeland) with additional support from VERDICT Research Center and the University of Texas Health Science Center at San Antonio.; Funding Details: Copeland as PI: VA HSR&D 2009-2010 $50,300; VA HSR&D 2006-2008 $300,000; VA HSR&D 2006-2009 $273,200; VA HSR&D 2008 $35,600; Hogg Fndn/UT-Austin 2009-2010 $14,995; Copeland as co-I: VA HSR&D 2009-2010 $223,600; VA HSR&D 2006-2010 $725,500; VA HSR&D 2003-2008 $735,400; VA VISN 17 2005-2008 $586,422; VA VISN 17 20052008 $736,990; VA HSR&D 2006-2009 $518,100; NIH 2007-2010 $323,538; Dept of Defense 2008-2013 $25,000,000.; Parchman as PI: VA/HSR&D 2009-2012 $834,600; NIH 2007-2012 $2,050,750; NIDDK 2004-2007 $301,500; Parchman as co-I: VA HSR&D 2008 to 2009 $146,500; VA/HSR&D 2006-2009 $271,300; VA/HSR&D 2003-2008 $735,400; NIH 2008-2013 $1,500,000; VA/HSR&D 2007-2008 $74,500; NIH 2006-2011 400,000; Lawrence as PI: VA/HSR&D 2007-2012 $734,050; VA/HSR&D 2003-2008 $735,400; Lawrence as co-I: VHA 2007-2009 $90,000; VA/HSR&D 2006-2009 $273,200; VA/HSR&D 2008-2008 $84,800; VA/HSR&D 2008-2008 $35,600; Zeber as PI: VA HSR&D 2009 $50,000; VA VISN 17 2008-2009 $100,000; PhRMA Fndn 2007-2008 $60,000; UTHSCSA Training Pgm 50% salary support 2006-2008; Zeber as co-I: VA HSR&D 2008 $35,600; VA HSR&D 2009-2010 $141,000; VA HSR&D 2009-2010 $50,300; VA HSR&D 2009-2010 $223,600; VA HSR&D 2006-2010 $725,500; VA HSR&D 2003-2008 $735,400; VA HSR&D 2006-2009 $273,200.; Downs as PI: none Downs as co-I: VA/HSR&D 2007-2010 $468,300; VA/HSR&D 2008-2008 $84,800; NINR 2007-2010 $788,497; Miller as PI: AstraZeneca 2007-2009 $35,256; Pfizer Organon 2007-2009 $36,988; UNC/NIMH 2007-2009 $150,030; UNC/NIMH 2007-2009 $33,750; UNC/NIMH 2007-2009 $80,360; UNC/NIMH 2009 $20,090; Glaxo Smith Kline 2007 $9,582; Pfizer 2007-2009 $160,000; Sanofi Aventis 2009 $89,916; Janssen 2008 $9,036; NIMH 2006-2011 $2,297,435; Miller as co-I: VA HSR&D 20062009 $273,200; Janssen 2008 $35,000; NIMH 2006-2011 $2,251,596; NIMH 2008-2013 $2,523,247; Miller Honoraria: Research Foundation for Mental Hygiene New York 08-30-07 $1,000; CME, Inc. Orlando, FL 10-12-07 $2,500; France Foundation Atlanta, GA 10-09-07 $1,500; Organon (Advisory Board) Parsippany, NJ 10-25-07 $3,000; Dainippon Sumitomo (Advisory Board) Chicago 10-26-07 $3,000; Eli Lilly (Advisory Board) Scottsdale, AZ 11-01-07$1,500; AstraZeneca (Advisory Board) Baltimore 11-02-07 $2,750 CME Outfitters Washington, DC 11-07-07 $5,000; Research Foundation for Mental Hygiene 09-07-08 to 10-21-08 $2,500; VA San Antonio, TX 03-18-08 $300; Comprehensive Neuroscience online survey 05-30-08 $250; NCME, Inc. French Camp, CA 10-22-08 $2,000; State of Maryland Baltimore 11-12-08 $200; NCME, Inc. Smithville, TX 11-18-08 $2,000; NCME, Inc. Reno, NV 12-17-08 $2,000; International Congress on Schizophrenia Research San Diego, CA 03-31-09 $1,000. NR 36 TC 14 Z9 14 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD OCT PY 2010 VL 18 IS 10 BP 887 EP 896 DI 10.1097/JGP.0b013e3181e56cdc PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 653WP UT WOS:000282128900004 PM 20808110 ER PT J AU Gellad, WF Good, CB Lowe, JC Donohue, JM AF Gellad, Walid F. Good, Chester B. Lowe, John C. Donohue, Julie M. TI Variation in Prescription Use and Spending for Lipid-Lowering and Diabetes Medications in the Veterans Affairs Healthcare System SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID GEOGRAPHIC-VARIATION; UNITED-STATES; DRUG PRICES; QUALITY; PREVALENCE; HOSPITALS; DECISION; TRIALS; SAFETY; SAMPLE AB Objectives: To examine variation in outpatient prescription use and spending for hyperlipidemia and diabetes mellitus in the Veterans Affairs Healthcare System (VA) and its association with quality measures for these conditions. Study Design: Cross-sectional. Methods: We compared outpatient prescription use, spending, and quality of care across 135 VA medical centers (VAMCs) in fiscal year 2008, including 2.3 million patients dispensed lipid-lowering medications and 981,031 patients dispensed diabetes medications. At each facility, we calculated VAMC-level cost per patient for these medications, the proportion of patients taking brand-name drugs, and Healthcare Effectiveness Data and Information Set (HEDIS) scores for hyperlipidemia (low-density lipoprotein cholesterol level <100 mg/dL) and for diabetes (glycosylated hemoglobin level >9% or not measured). Results: The median cost per patient for lipid-lowering agents in fiscal year 2008 was $49.60 and varied from $39.68 in the least expensive quartile of VAMCs to $69.57 in the most expensive quartile (P < .001). For diabetes agents, the median cost per patient was $158.34 and varied from $123.34 in the least expensive quartile to $198.31 in the most expensive quartile (P < .001). The proportion of patients dispensed brand-name oral drugs among these classes in the most expensive quartile of VAMCs was twice that in the least expensive quartile (P < .001). There was no correlation between VAMC-level prescription spending and performance on HEDIS measures for lipid-lowering drugs (r = 0.12 and r = 0.07) or for diabetes agents (r = -0.10). Conclusions: Despite the existence of a closely managed formulary, significant variation in prescription spending and use of brand-name drugs exists in the VA. Although we could not explicitly risk-adjust, there appears to be no relationship between prescription spending and quality of care. (Am J Manag Care. 2010;16(10):741-750) C1 [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Dept Vet Affairs Med Ctr, Pittsburgh, PA 15206 USA. [Good, Chester B.] VA Pittsburgh Healthcare Syst, Ctr Medicat Safety, Pittsburgh, PA 15206 USA. [Gellad, Walid F.; Good, Chester B.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Lowe, John C.] Univ Pittsburgh, Dept Pharm, Pittsburgh, PA USA. [Donohue, Julie M.] Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA. [Gellad, Walid F.] RAND Corp, Pittsburgh, PA USA. [Lowe, John C.] Vet Hlth Adm, Pharm Benefits Mangement Serv, Washington, DC USA. RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Dept Vet Affairs Med Ctr, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM walid.gellad@va.gov OI Donohue, Julie/0000-0003-2418-6017 FU VA Pittsburgh Healthcare System; National Center for Research Resources, National Institutes of Health Roadmap for Medical Research [KL2 RR024154] FX This study is the result of work supported by resources from the VA Pittsburgh Healthcare System. Dr Donohue was supported by grant KL2 RR024154 from the National Center for Research Resources, a component of the National Institutes of Health Roadmap for Medical Research. NR 38 TC 7 Z9 7 U1 0 U2 5 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD OCT PY 2010 VL 16 IS 10 BP 741 EP 750 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 678SO UT WOS:000284100900006 PM 20964470 ER PT J AU Kim, H Ross, JS Melkus, GD Zhao, ZL Boockvar, K AF Kim, Hongsoo Ross, Joseph S. Melkus, Gail D. Zhao, Zhonglin Boockvar, Kenneth TI Scheduled and Unscheduled Hospital Readmissions Among Patients With Diabetes SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID REHOSPITALIZATIONS; MEDICINE; QUALITY; RATES; CARE AB Objectives: To describe rates of scheduled and unscheduled readmissions among midlife and older patients with diabetes and to examine associated socioeconomic and clinical factors. Study Design: Population-based data set study. Methods: Using the 2006 California State Inpatient Dataset, we identified 124,967 patients 50 years or older with diabetes who were discharged from acute care hospitals between April and September 2006 and examined readmissions in the 3 months following their index hospitalizations. Results: About 26.3% of patients were readmitted within the 3-month period following their index hospitalizations, 87.2% of which were unscheduled readmissions. Patients with unscheduled readmissions were more likely to have a higher comorbidity burden, be members of racial/ethnic minority groups with public insurance, and live in lower-income neighborhoods. Having a history of hospitalization in the 3 months preceding the index hospitalization was also a strong predictor of unscheduled readmissions. Almost one-fifth of unscheduled readmissions (constituting approximately 27,500 inpatient days and costing almost $72.7 million) were potentially preventable based on definitions of Prevention Quality Indicators by the Agency for Healthcare Research and Quality. Scheduled readmissions were less likely to occur among patients 80 years or older, the uninsured, and those with an unscheduled index hospitalization. Conclusions: The predictors of scheduled and unscheduled readmissions are different. Transition care to prevent unscheduled readmissions in acutely ill patients with diabetes may help reduce rates, improving care. Further studies are needed on potential disparities in scheduled readmissions. (Am J Manag Care. 2010;16(10):760-767) C1 [Kim, Hongsoo] Seoul Natl Univ, Grad Sch Publ Hlth, Seoul 151742, South Korea. [Kim, Hongsoo] Seoul Natl Univ, Inst Hlth & Environm, Seoul 151742, South Korea. [Ross, Joseph S.; Boockvar, Kenneth] James J Peters VA Med Ctr, Bronx, NY USA. [Ross, Joseph S.; Boockvar, Kenneth] Mt Sinai Sch Med, New York, NY USA. [Melkus, Gail D.] NYU, Coll Nursing, New York, NY USA. [Zhao, Zhonglin] NYU, Coll Dent, New York, NY USA. RP Kim, H (reprint author), Seoul Natl Univ, Grad Sch Publ Hlth, 599 Kwanak Ro, Seoul 151742, South Korea. EM hk65.snu@gmail.com OI Boockvar, Kenneth/0000-0003-1165-5558 FU NIA NIH HHS [K08 AG032886] NR 24 TC 23 Z9 23 U1 1 U2 4 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD OCT PY 2010 VL 16 IS 10 BP 760 EP 767 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 678SO UT WOS:000284100900008 PM 20964472 ER PT J AU Singh, H Petersen, LA Thomas, EJ Wilson, L Sittig, DF AF Singh, Hardeep Petersen, Laura A. Thomas, Eric J. Wilson, Lindsey Sittig, Dean F. TI Notification of Abnormal and Critical Values: The Road Ahead Reply SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter C1 [Singh, Hardeep; Petersen, Laura A.; Wilson, Lindsey] Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. [Singh, Hardeep; Petersen, Laura A.; Wilson, Lindsey] Baylor Coll Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep; Petersen, Laura A.; Wilson, Lindsey] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA. [Thomas, Eric J.] Univ Texas Houston, Mem Hermann Ctr Healthcare Qual & Safety, Div Gen Med, Univ Texas Med Sch Houston,Dept Med, Houston, TX USA. [Sittig, Dean F.] Univ Texas Sch Biomed Informat, Houston, TX USA. [Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. RP Singh, H (reprint author), Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD OCT PY 2010 VL 123 IS 10 BP E21 EP E21 DI 10.1016/j.amjmed.2010.06.008 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 656WR UT WOS:000282372300014 ER PT J AU Hua, P Feng, WG Ji, SN Raij, L Jaimes, EA AF Hua, Ping Feng, Wenguang Ji, Shaonin Raij, Leopoldo Jaimes, Edgar A. TI Nicotine worsens the severity of nephropathy in diabetic mice: implications for the progression of kidney disease in smokers SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE reactive oxygen species; tobacco ID SMOOTH-MUSCLE-CELLS; STAGE RENAL-FAILURE; NADPH OXIDASE; NAD(P)H OXIDASE; ACETYLCHOLINE-RECEPTORS; ENDOTHELIAL-CELLS; CIGARETTE-SMOKING; ANGIOTENSIN-II; FIBRONECTIN EXPRESSION; ESSENTIAL-HYPERTENSION AB Hua P, Feng W, Ji S, Raij L, Jaimes EA. Nicotine worsens the severity of nephropathy in diabetic mice: implications for the progression of kidney disease in smokers. Am J Physiol Renal Physiol 299: F732-F739, 2010. First published August 4, 2010; doi:10.1152/ajprenal.00293.2010.-Epidemiological studies have established the role of cigarette smoking as a risk factor in the progression of chronic kidney disease, including diabetic nephropathy. We have previously reported that nicotine promotes mesangial cell proliferation and hypertrophy via activation of non-neuronal nicotinic acetylcholine receptors and that nicotine worsens renal injury in a model of acute glomerulonephritis (Jaimes E, Tian RX, Raij L. Am J Physiol Heart Circ Physiol 292: H76-H82, 2007; Jaimes EA, Tian RX, Joshi M, Raij L. Am J Nephrol 29: 319-326, 2009). These studies were designed to test the hypothesis that nicotine worsens renal injury in db/db mice, a well-established model of diabetic nephropathy, and that reactive oxygen species play an important as mediators of these effects. For these studies, nicotine (100 mu g/ml) was administered in the drinking water to control and db/db mice for 10 wk. Blood pressure was measured by the tail-cuff method, and urine was collected for proteinuria. At death, kidneys were collected for histology and molecular biology. The administration of nicotine did not result in significant changes in blood pressure or blood glucose and resulted in cotinine levels similar to those found in the plasma of smokers. In diabetic mice, the administration of nicotine significantly increased urinary protein excretion (1-fold), glomerular hypertrophy, and mesangial area (similar to 20%). These changes were accompanied by significant increases in NADPH oxidase 4 (similar to 30%) and increased nitrotyrosine and Akt expression. In vitro, we determined that nicotine has additive effects to high glucose on reactive oxygen species generation and Akt phosphorylation in human mesangial cells. These findings unveil novel mechanisms that may result in the development of novel strategies in the treatment and prevention of diabetic nephropathy in smokers. C1 [Hua, Ping; Feng, Wenguang; Ji, Shaonin; Jaimes, Edgar A.] Univ Alabama, Div Nephrol, Birmingham, AL USA. [Jaimes, Edgar A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Raij, Leopoldo] Univ Miami, Div Renal, Miami, FL USA. [Raij, Leopoldo] Miami Vet Affairs Med Ctr, Miami, FL USA. RP Jaimes, EA (reprint author), ZRB 637,1530 3rd Ave S, Birmingham, AL 35294 USA. EM ejaimes@uab.edu FU National Institutes of Health [ES014948]; Flight Attendants Research Institute; Florida Department of Health FX These studies were funded by National Institutes of Health Grant ES014948 (to E. A. Jaimes), a Clinical Investigator Award from the Flight Attendants Research Institute (to E. A. Jaimes), and a Team Science Project of the Florida Department of Health (to E. A. Jaimes and L. Raij.) NR 48 TC 30 Z9 30 U1 0 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD OCT PY 2010 VL 299 IS 4 BP F732 EP F739 DI 10.1152/ajprenal.00293.2010 PG 8 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 658IP UT WOS:000282484000006 PM 20685820 ER PT J AU Soneji, S Lyer, SS Armstrong, K Asch, DA AF Soneji, Samir Lyer, Shally Shalini Armstrong, Katrina Asch, David A. TI Racial Disparities in Stage-Specific Colorectal Cancer Mortality: 1960-2005 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; COLON-CANCER; WHITES; SURVIVAL; BLACKS; HEALTH; CARE; RACE; CONSEQUENCES; CARCINOMA AB Objectives. We examined whether racial disparities in stage-specific colorectal cancer survival changed between 1960 and 2005. Methods. We used US Mortality Multiple-Cause-of-Death Data Files and intercensal estimates to calculate standardized mortality rates by gender and race from 1960 to 2005. We used Surveillance, Epidemiology, and End Results (SEER) data to estimate stage-specific colorectal cancer survival. To account for SEER sampling uncertainty, we used a bootstrap resampling procedure and fit a Cox proportional hazards model. Results. Between 1960-2005, patterns of decline in mortality rate as a result of colorectal cancer differed greatly by gender and race: 54% reduction for White women, 14% reduction for Black women, 39% reduction for White men, and 28% increase for Black men. Blacks consistently experienced worse rates of stage-specific survival and life expectancy than did Whites for both genders, across all age groups, and for localized, regional, and distant stages of the disease. Conclusions. The rates of stage-specific colorectal cancer survival differed among Blacks when compared with Whites during the 4-decade study period. Differences in stage-specific life expectancy were the result of differences in access to care or quality of care. More attention should be given to racial disparities in colorectal cancer management. (Am J Public Health. 2010;100: 1912-1916. doi:10.2105/AJPH.2009.184192) C1 [Soneji, Samir; Asch, David A.] Univ Penn, Robert Wood Johnson Hlth & Soc Scholars Program, Philadelphia, PA 19104 USA. [Lyer, Shally Shalini] Univ Penn, Grad Program Publ Hlth Studies, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Armstrong, Katrina; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Soneji, S (reprint author), Univ Penn, Robert Wood Johnson Hlth & Soc Scholars Program, 3641 Locust Walk, Philadelphia, PA 19104 USA. EM soneji@wharton.upenn.edu OI Asch, David/0000-0002-7970-286X FU Robert Wood Johnson Foundation FX We thank the Robert Wood Johnson Foundation Health & Society Scholars and Robert Wood Johnson Clinical Scholars programs for their financial support. NR 34 TC 48 Z9 48 U1 1 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2010 VL 100 IS 10 BP 1912 EP 1916 DI 10.2105/AJPH.2009.184192 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 656SC UT WOS:000282355900022 PM 20724684 ER PT J AU Mehta, KM Fung, KZ Kistler, CE Chang, A Walter, LC AF Mehta, Kala M. Fung, Kathy Z. Kistler, Christine E. Chang, Anna Walter, Louise C. TI Impact of Cognitive Impairment on Screening Mammography Use in Older US Women SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID ALZHEIMERS-DISEASE; HEALTH-STATUS; SURVIVAL; DEMENTIA; PREVALENCE; PREDICTORS; DIAGNOSIS; MORTALITY; PEOPLE AB Objectives. We evaluated mammography rates for cognitively impaired women in the context of their life expectancies, given that guidelines do not recommend screening mammography in women with limited life expectancies because harms outweigh benefits. Methods. We evaluated Medicare claims for women aged 70 years or older from the 2002 wave of the Health and Retirement Study to determine which women had screening mammography. We calculated population-based estimates of 2-year screening mammography prevalence and 4-year survival by cognitive status and age. Results. Women with severe cognitive impairment had lower rates of mammography (18%) compared with women with normal cognition (45%). Nationally, an estimated 120000 screening mammograms were performed among women with severe cognitive impairment despite this group's median survival of 3.3 years (95% confidence interval=2.8, 3.7). Cognitively impaired women who had high net worth and were married had screening rates approaching 50%. Conclusions. Although severe cognitive impairment is associated with lower screening mammography rates, certain subgroups with cognitive impairment are often screened despite lack of probable benefit. Given the limited life expectancy of women with severe cognitive impairment, guidelines should explicitly recommend against screening these women. (Am J Public Health. 2010;100:1917-1923. doi:10.2105/AJPH.2008.158485) C1 [Mehta, Kala M.; Kistler, Christine E.; Chang, Anna; Walter, Louise C.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA. [Fung, Kathy Z.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Mehta, KM (reprint author), Univ Calif San Francisco, Div Geriatr, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA. EM kala.mehta@ucsf.edu FU National Institute on Aging [NIA-K-01AG025444-01A1, NIA U01AG009740]; Department of Veterans Affairs Merit Review grant [IIR 04-427]; Robert Wood Johnson Physician Faculty Scholar; University of Michigan FX K M. Mehta is currently supported by a Research Career Scientist Award from the National Institute on Aging (NIA-K-01AG025444-01A1). She is currently an affiliate of the Center for Aging in Diverse Communities at University of California, San Francisco, a part of the P30 AG 15272 350 Resource Centers for Minority Aging Research Program (NIA, National Institute of Nursing Research, and the National Center for Minority Health and Health Disparities). L.C. Walter was supported by a Department of Veterans Affairs Merit Review grant (IIR 04-427) and is a Robert Wood Johnson Physician Faculty Scholar. The Health and Retirement Study is sponsored by the MA (grant NIA U01AG009740) and is conducted by the University of Michigan. NR 37 TC 20 Z9 21 U1 1 U2 3 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2010 VL 100 IS 10 BP 1917 EP 1923 DI 10.2105/AJPH.2008.158485 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 656SC UT WOS:000282355900023 PM 20075325 ER PT J AU Chan, ED Bai, XY Kartalija, M Ormes, IM Ordways, DJ AF Chan, Edward D. Bai, Xiyuan Kartalija, Marinka Ormes, Ian M. Ordways, Diane J. TI Host Immune Response to Rapidly Growing Mycobacteria, an Emerging Cause of Chronic Lung Disease SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Review DE Mycobacterium abscessus; immune responses; rapidly growing mycobacteria; host defense ID TUMOR-NECROSIS-FACTOR; MACROPHAGE TNF-ALPHA; GROWTH-FACTOR-BETA; NONTUBERCULOUS MYCOBACTERIA; PULMONARY-DISEASE; AVIUM COMPLEX; INTERFERON-GAMMA; TGF-BETA; TUBERCULOSIS INFECTION; ABSCESSUS INFECTION AB Rapidly growing mycobacteria (RGM) are environmental organisms classified under the broader category of nontuberculous mycobacteria. The most common RGM to cause human diseases are Mycobacterium abscessus, Mycobacterium chelonae, Mycobacterium fortuitum, and Mycobacterium massiliense. Infections due to the RGM are an emerging health problem in the United States. Chronic pulmonary disease and skin/soft-tissue infections are the two most common disorders due to these organisms. Clinical outcomes in the treatment of M. abscessus infections are generally disappointing. Because less is known about the nature of the immune response to M. abscessus than for tuberculosis, we herein highlight the major clinical features associated with infections due to M. abscessus and other RGM, and review the known host immune response to RGM, drawing from experimental animal and clinical studies. Based on in vitro and in vivo murine models, Toll-like receptor 2, dectin-1, tumor necrosis factor (TNF)-alpha, IFN-gamma, leptin, T cells, and possibly neutrophils are important components in the host defense against RGM infections. However, excessive induction of TNF-alpha by the R morphotype of M. abscessus may allow it to be more pathogenic than the S morphotype. Clinical observations and/or genetic studies in humans corroborate many of the findings in animals in that those with cell-mediated immunodeficiency, genetic defects in IFN-gamma-IL-12 axis, and those individuals on TNF-alpha blockers are at increased risk for nontuberculous mycobacteria infections, including the RGM. However, much remains to be discovered on why seemingly healthy individuals, particularly slender postmenopausal women with thoracic cage anomalies, appear to be at increased risk. C1 [Chan, Edward D.; Bai, Xiyuan] Natl Jewish Hlth, Div Mycobacterial & Resp Infect, Denver, CO 80206 USA. [Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Chan, Edward D.; Bai, Xiyuan] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Denver, CO USA. [Kartalija, Marinka] Univ Colorado Denver, Div Infect Dis, Denver, CO USA. [Ormes, Ian M.; Ordways, Diane J.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. RP Chan, ED (reprint author), Natl Jewish Hlth, Div Mycobacterial & Resp Infect, D509,Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA. EM chane@njhealth.org FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development (E.D.C.). NR 73 TC 33 Z9 33 U1 1 U2 3 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1044-1549 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD OCT PY 2010 VL 43 IS 4 BP 387 EP 393 DI 10.1165/rcmb.2009-0276TR PG 7 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA 660UY UT WOS:000282673100001 PM 20081053 ER PT J AU Livhits, M Mercado, C Yermilov, I Parikh, JA Dutson, E Mehran, A Ko, CY Gibbons, MM AF Livhits, Masha Mercado, Cheryl Yermilov, Irina Parikh, Janak A. Dutson, Erik Mehran, Amir Ko, Clifford Y. Gibbons, Melinda Maggard TI Behavioral Factors Associated with Successful Weight Loss after Gastric Bypass SO AMERICAN SURGEON LA English DT Article ID BARIATRIC SURGERY; FOLLOW-UP; QUESTIONNAIRE; ATTENDANCE; OBESITY AB Patients undergoing bariatric surgery lose substantial weight (>= 50% excess weight loss [EWL]), but an estimated 20 per cent fail to achieve this goal. Our objective was to identify behavioral predictors of weight loss after laparoscopic Roux-en-Y gastric bypass. We retrospectively surveyed 148 patients using validated instruments for factors predictive of weight loss. Success was defined as >= 50 per cent EWL and failure as <50 per cent EWL. Mean follow-up after laparoscopic Roux-en-Y gastric bypass was 40.1 +/- 15.3 months, with 52.7 per cent of patients achieving successful weight loss. After controlling for age, gender, and preoperative body mass index, predictors of successful weight loss included surgeon follow-up (odds ratio [OR] 8.2, P < 0.01), attendance of postoperative support groups (OR 3.7, P = 0.02), physical activity (OR 3.5, P < 0.01), single or divorced marital status (OR 3.2, P = 0.03), self-esteem (OR 0.3, P = 0.02), and binge eating (OR 0.9, P < 0.01). These factors should be addressed in prospective studies of weight loss after bariatric surgery, as they may identify patients at risk for weight loss failure who may benefit from early tailored interventions. C1 [Livhits, Masha; Mercado, Cheryl; Yermilov, Irina; Parikh, Janak A.; Dutson, Erik; Mehran, Amir; Ko, Clifford Y.; Gibbons, Melinda Maggard] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Livhits, Masha; Yermilov, Irina; Parikh, Janak A.; Ko, Clifford Y.; Gibbons, Melinda Maggard] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Gibbons, Melinda Maggard] Olive View Univ Calif, Dept Surg, Sylmar, CA USA. RP Livhits, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 LeConte Ave,72 215 CHS, Los Angeles, CA 90095 USA. EM mlivhits@mednet.ucla.edu FU VA Department of Surgery; Robert Wood Johnson Physician Faculty FX We would like to acknowledge the generous contribution of Paul G. Shekelle to the design of our project and critical review of the analysis. The VA Department of Surgery provided support for Dr. Livhits and Dr. Maggard Gibbons. Dr. Maggard Gibbons's time was supported in part by a grant from the Robert Wood Johnson Physician Faculty Scholars program. NR 15 TC 44 Z9 45 U1 0 U2 7 PU SOUTHEASTERN SURGICAL CONGRESS PI ATLANTA PA 141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA SN 0003-1348 J9 AM SURGEON JI Am. Surg. PD OCT PY 2010 VL 76 IS 10 BP 1139 EP 1142 PG 4 WC Surgery SC Surgery GA 663AO UT WOS:000282855600027 PM 21105629 ER PT J AU Raval, MV Bentrem, DJ Stewart, AK Ko, CY Reynolds, M AF Raval, Mehul V. Bentrem, David J. Stewart, Andrew K. Ko, Clifford Y. Reynolds, Marleta TI Utilization of Total Thyroidectomy for Differentiated Thyroid Cancer in Children SO ANNALS OF SURGICAL ONCOLOGY LA English DT Article ID TERM-FOLLOW-UP; DATA-BASE; UNITED-STATES; YOUNG-ADULTS; CARCINOMA; DISEASE; ADOLESCENTS; RECURRENCE; MANAGEMENT; CHILDHOOD AB Purpose. Recent recommendations suggest that total thyroidectomy (TT) is the surgical management of choice for differentiated thyroid cancer in children. The objective of this study is to assess trends in extent of surgical resection for differentiated thyroid cancer in children over the past two decades and to identify patient, tumor or hospital factors associated with use of TT. Patients and Methods. Of 8,013 patients (aged 0-21 years) with differentiated thyroid cancer from the National Cancer Data Base (1985-2007), 5,933(74%) underwent TT. Trends in extent of surgery were examined. Logistic regression was used to identify factors that predict use of TT. Results. Use of TT increased from 50.6% in 1985 to 84% in 2007 (P < 0.001). Patients were more likely to undergo TT if they had higher household income or had private insurance (P = 0.002 and P = 0.037). Patients were more likely to undergo TT if they had larger tumors or if there were nodal metastases present at time of resection (both P < 0.001). After adjusting for patient and tumor factors, patients treated at high-volume or Children's Oncology Group hospitals were more likely to undergo TT than patients treated at low-volume or non-Children's Oncology Group hospitals (P < 0.001). Conclusions. Overall utilization of TT in children with differentiated thyroid cancer has steadily increased over the past 23 years in the USA. Variations in use of TT are not only related to tumor factors including size and nodal involvement, but also are also related to socioeconomic and hospital factors, demonstrating disparities in care. C1 [Raval, Mehul V.; Stewart, Andrew K.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, Chicago, IL USA. [Raval, Mehul V.; Reynolds, Marleta] Childrens Mem Hosp, Div Pediat Surg, Chicago, IL 60614 USA. [Raval, Mehul V.; Bentrem, David J.] Northwestern Univ, Div Gastrointestinal & Oncol Surg, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. [Bentrem, David J.] Jesse Brown VA Med Ctr, Chicago, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Raval, MV (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, Chicago, IL USA. EM mehulvraval@gmail.com OI Raval, Mehul/0000-0002-1527-2661 FU John Gray Research Fellowship; Daniel F. and Ada L. Rice Foundation; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service; American College of Surgeons Commission on Cancer; American Cancer Society FX M.V.R. participates in the American College of Surgeons Clinical Scholars in Residence Program. M.V.R. is supported by the John Gray Research Fellowship and the Daniel F. and Ada L. Rice Foundation. D.J.B. is supported by a career development award from the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service. The National Cancer Data Base is supported by the American College of Surgeons, Commission on Cancer, and the American Cancer Society. NR 53 TC 10 Z9 11 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD OCT PY 2010 VL 17 IS 10 BP 2545 EP 2553 DI 10.1245/s10434-010-1083-3 PG 9 WC Oncology; Surgery SC Oncology; Surgery GA 669ZP UT WOS:000283389200003 PM 20429037 ER PT J AU Ge, PS Ishaque, BM Bonilla, J de Virgilio, C AF Ge, Phillip S. Ishaque, Brandon M. Bonilla, Janet de Virgilio, Christian TI Popliteal Artery Pseudoaneurysm After Isolated Hyperextension of the Knee SO ANNALS OF VASCULAR SURGERY LA English DT Article ID VASCULAR INJURIES; ARTERIOGRAPHY ALWAYS; DISLOCATIONS; REPAIR AB We report an unusual case of a traumatic pseudoaneurysm of the popliteal artery after an isolated blunt hyperextension injury to the knee. A 56-year-old man presented with a 1-month history of left knee pain that occurred after a fall onto his buttocks with hyperextension of the knee while transferring a relative out of a wheelchair. A large pulsatile mass in the posterior aspect of the left knee was palpated on physical examination, although he had warm distal extremities and 2+ distal pulses bilaterally. Magnetic resonance angiography revealed a 7.6 x 6.2 x 4.9 cm left popliteral artery pseudoaneurysm, which was subsequently treated with aneurysm exclusion with end to end reverse saphenous vein graft bypass. The development of a popliteal artery pseudoaneurysm after blunt knee injury without dislocation, fracture, or ligament injury is extremely unusual, but requires prompt treatment to avoid the potential complications of permanent functional impairment and limb loss. C1 [Ge, Phillip S.; Ishaque, Brandon M.; Bonilla, Janet] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [de Virgilio, Christian] W Los Angeles VA Med Ctr, Dept Surg, Los Angeles, CA USA. RP de Virgilio, C (reprint author), Harbor UCLA Med Ctr, Dept Surg, 1000 W Carson St, Torrance, CA 90309 USA. EM cdevirgilio@labiomed.org NR 22 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0890-5096 J9 ANN VASC SURG JI Ann. Vasc. Surg. PD OCT PY 2010 VL 24 IS 7 AR 950.e7 DI 10.1016/j.avsg.2010.01.014 PG 5 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 647YC UT WOS:000281655700018 PM 20471789 ER PT J AU Weiner, M Peloquin, C Burman, W Luo, CC Engle, M Prihoda, TJ Mac Kenzie, WR Bliven-Sizemore, E Johnson, JL Vernon, A AF Weiner, Marc Peloquin, Charles Burman, William Luo, Chi-Cheng Engle, Melissa Prihoda, Thomas J. Mac Kenzie, William R. Bliven-Sizemore, Erin Johnson, John L. Vernon, Andrew TI Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID PULMONARY TUBERCULOSIS; ANTIMYCOBACTERIAL DRUGS; PHARMACOKINETICS; RIFABUTIN; BIOAVAILABILITY; MOXIFLOXACIN; RESISTANCE; REGIMENS; ATORVASTATIN; RIFAPENTINE AB Rifampin has concentration-dependent activity against Mycobacterium tuberculosis. However, marked intersubject variation of rifampin concentrations occurs. In this study, we evaluated rifampin pharmacokinetics in relation to tuberculosis, geographic region, race, and single nucleotide polymorphisms of the human transporter genes SLCO1B1, SLCO1B3, and MDR1. Seventy-two adults with pulmonary tuberculosis from Africa, North America, and Spain were evaluated during multidrug intensive-phase therapy, and their results were compared to those from 16 healthy controls from North America. Rifampin pharmacokinetic values were similar between tuberculosis patients and controls (geometric mean [GM] area under the concentration-time curve from 0 to 24 h [AUC(0-24)] of 40.2 versus 40.9 mu g . h/ml; P = 0.9). However, in multivariable analyses, the rifampin AUC(0-24) was significantly affected by rifampin dosage (in mg/kg of body weight), polymorphisms in the SLCO1B1 gene, and the presence of tuberculosis by geographic region. The adjusted rifampin AUC(0-24) was lowest in patients with tuberculosis from Africa compared to that in non-African patients or control subjects. The adjusted rifampin AUC(0-24) was also 36% lower among participants with SLCO1B1 genotype c.463CA than that among participants with SLCO1B1 genotype c.463CC (adjusted GM, 29.8 versus 46.7 mu g . h/ml; P = 0.001). Polymorphisms in the SLCO1B1 gene associated with lower rifampin exposure were more frequent among black subjects. In conclusion, marked intersubject variation of the rifampin AUC(0-24) values was observed, but the mean values of the AUC(0-24) did not significantly vary between patients with tuberculosis and healthy controls. Lower rifampin exposure was associated with the polymorphism of the SLCO1B1 c. 463C>A gene. When adjusted for the patient mg/kg dosage and transporter gene polymorphisms, rifampin exposure was lower in patients with tuberculosis, which suggests that additional absorption or metabolic processes affect rifampin exposure with tuberculosis disease. C1 [Weiner, Marc] S Texas Vet Hlth Care Syst, Div Infect Dis 111, San Antonio, TX 78229 USA. [Weiner, Marc; Engle, Melissa; Prihoda, Thomas J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Peloquin, Charles] Univ Florida, Coll Pharm, Gainesville, FL 32610 USA. [Burman, William] Denver Publ Hlth, Denver, CO 80204 USA. [Luo, Chi-Cheng; Mac Kenzie, William R.; Bliven-Sizemore, Erin; Vernon, Andrew] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Johnson, John L.] Uganda Case Western Reserve Univ Res Collaborat, Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. RP Weiner, M (reprint author), S Texas Vet Hlth Care Syst, Div Infect Dis 111, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM weiner@uthscsa.edu RI Mac Kenzie, William /F-1528-2013 OI Mac Kenzie, William /0000-0001-7723-0339 FU Centers for Disease Control and Prevention; Global Alliance for TB Drug Development; Veterans Administration; NIH [MO1-RR-01346]; Tuberculosis Trials Consortium FX This work was supported by the Centers for Disease Control and Prevention, the Global Alliance for TB Drug Development, and the Veterans Administration. Assistance in evaluation of patients was provided by the Frederic C. Bartter General Clinical Research Center at the VAMC San Antonio (supported by NIH grant MO1-RR-01346). This study was sponsored by the Tuberculosis Trials Consortium. NR 33 TC 51 Z9 54 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD OCT PY 2010 VL 54 IS 10 BP 4192 EP 4200 DI 10.1128/AAC.00353-10 PG 9 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 651EI UT WOS:000281907200021 PM 20660695 ER PT J AU Morganroth, PA Kreider, ME Werth, VP AF Morganroth, Pamela A. Kreider, Mary Elizabeth Werth, Victoria P. TI Mycophenolate Mofetil for Interstitial Lung Disease in Dermatomyositis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID RHEUMATOID-ARTHRITIS; PULMONARY-FUNCTION; METHOTREXATE AB Objective. To report our experience using mycophenolate mofetil as first-line treatment for dermatomyositis-associated interstitial lung disease. Methods. We examined the medical records of all 16 dermatomyositis patients with interstitial lung disease seen in our outpatient university hospital dermatology clinic between May 26, 2006, and May 25, 2009. In this retrospective case series, we describe the clinical course of the 4 patients with definitive evidence of interstitial lung disease on radiologic imaging who were treated with mycophenolate mofetil and had pulmonary data available to document their outcome. All of the patients also received prednisone. Results. All 3 patients with at least 1 year of followup receiving mycophenolate mofetil experienced complete normalization of pulmonary function tests (including diffusing capacity for carbon monoxide) and resolution of dyspnea. They were also able to reduce their prednisone doses. The only patient with pre- and posttreatment chest computed tomography imaging had total resolution of her interstitial opacities. The patient with only 5 months of posttreatment followup experienced an improvement in diffusing capacity for carbon monoxide from 44% to 77% predicted, but no change in dyspnea. Conclusion. These promising data indicate that mycophenolate mofetil may be a useful therapy for interstitial lung disease in patients with dermatomyositis, but larger studies are needed to more definitively evaluate the role of this medication in therapy. C1 [Morganroth, Pamela A.; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Morganroth, Pamela A.; Kreider, Mary Elizabeth; Werth, Victoria P.] Univ Penn, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Hosp Univ Penn, Dept Dermatol, PCAM Suite 1-330S,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU NIH [K24-AR-02207]; Department of the VA, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX Based on work supported by the NIH and by a Merit Review Grant from the Department of the VA, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. Dr. Werth's work was supported by grants from the NIH (K24-AR-02207). NR 15 TC 37 Z9 39 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD OCT PY 2010 VL 62 IS 10 BP 1496 EP 1501 DI 10.1002/acr.20212 PG 6 WC Rheumatology SC Rheumatology GA 667IA UT WOS:000283185300019 PM 20506189 ER PT J AU Wu, Y Bauman, WA Blitzer, RD Cardozo, C AF Wu, Yong Bauman, William A. Blitzer, Robert D. Cardozo, Christopher TI Testosterone-induced hypertrophy of L6 myoblasts is dependent upon Erk and mTOR SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Muscle; Hypertrophy; Testosterone; mTOR; Erk ID ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE; YOUNG MEN; MAMMALIAN TARGET; PATHWAY; STRENGTH; RECEPTOR; CELLS; TRANSLATION; MACHINERY AB Testosterone increases the size and strength of skeletal muscle. This study further characterized the molecular mechanisms of the anabolic actions of testosterone on a rat myoblast cell line (L6 cells). Testosterone did not induce hypertrophy in L6 cells lacking the androgen receptor (AR). Hypertrophy was prevented by the AR antagonist bicalutamide and the mTOR inhibitor rapamycin. Testosterone induced Erk phosphorylation by 2 h, and mTOR autophosphorylation was elevated within 20 min; phosphorylation of p70S6 kinase was increased by 2 h. Inhibitors of Erk or PI3K blocked tesotosterone-induced hypertrophy. Erk phosphorylation returned to baseline when media containing testosterone was replaced at 16 h with fresh media lacking testosterone; when bicalutamide was added to testosterone-enriched media at 16 h, Erk phosphorylation remained elevated. Autophosphorylation of the IGF-1 receptor was minimally altered by testosterone at 20 min and unaffected at later time points; PI3K/PDK1-dependent phosphorylation of Akt was not altered by testosterone. These findings indicate that testosterone stimulates hypertrophy of L6 myoblasts through a mechanism that requires its binding to the AR and involves a signaling cascade dependent upon Erk and mTOR which is likely activated by substances released into the extracellular space which are not IGF-1 or other ligands for receptor tyrosine kinases. Published by Elsevier Inc. C1 [Wu, Yong; Bauman, William A.; Cardozo, Christopher] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Dept Vet Affairs, Bronx, NY 10468 USA. [Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. [Blitzer, Robert D.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. RP Cardozo, C (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Dept Vet Affairs, Room 1E-02,W Kingsbridge Rd, Bronx, NY 10468 USA. EM Chris.Cardozo@mssm.edu FU VA RRD [B4162C, B3347K, B4616R]; NIH [R01-GM054508, R21-DA029298] FX Supported by VA RR&D Grants B4162C to W.A.B. and B3347K and B4616R to C.C., respectively. R.D.B. is supported by NIH Grants R01-GM054508 and R21-DA029298. The study sponsors had no role in the design of the studies, collection, analysis or interpretation of the data, writing the manuscript or the decision to submit the manuscript for publication. NR 21 TC 23 Z9 24 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD OCT 1 PY 2010 VL 400 IS 4 BP 679 EP 683 DI 10.1016/j.bbrc.2010.08.127 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 662YP UT WOS:000282850500039 PM 20816664 ER PT J AU Cowart, LA Gandy, JL Tholanikunnel, B Hannun, YA AF Cowart, L. Ashley Gandy, Jason L. Tholanikunnel, Baby Hannun, Yusuf A. TI Sphingolipids mediate formation of mRNA processing bodies during the heat-stress response of Saccharomyces cerevisiae SO BIOCHEMICAL JOURNAL LA English DT Article DE heat-stress response; phytosphingosine; processing body; Saccharomyces cerevisiae; sphingolipid; translation ID BUDDING YEAST; DE-NOVO; SPHINGOID BASE; P-BODIES; CERAMIDE; GRANULES; BIOSYNTHESIS; TRANSLATION; METABOLISM; PROGRAMS AB Recent work, especially in the yeast Saccharomyces cerevisiae, has demonstrated that mRNA movement from active translation to cytoplasmic granules, termed mRNA'p-bodies' (processing bodies), occurs in concert with the regulation of translation during cell stress. However, the signals regulating p-body formation are poorly defined. Recent results have demonstrated a function for sphingolipids in regulating translation during heat stress, which led to the current hypothesis that p-bodies may form during heat stress in a sphingolipid-dependent manner. In the present study, we demonstrate that mild-heat-stress-induced formation of p-bodies, as determined by localization of a GFP (green fluorescent protein)-tagged Dcp2p and RFP (red fluorescent protein)-tagged Edc3p to discrete cytoplasmic foci. Sphingoid base synthesis was required for this effect, as inhibition of sphingoid base synthesis attenuated formation of these foci during heat stress. Moreover, treatment of yeast with the exogenous sphingoid bases phyto- and dihydro-sphingosine promoted formation of p-bodies in the absence of heat stress, and the lcb4/lcb5 double-deletion yeast, which accumulates high intracellular levels of sphingoid bases, had large clearly defined p-bodies under non-stress conditions. Functionally, inhibition of sphingolipid synthesis during heat stress did not prevent translation stalling, but extended translation arrest, indicating that sphingolipids mediate translation initiation. These results are consistent with the notion that p-bodies serve not only in mRNA degradation, but also for re-routing transcripts back to active translation, and that sphingolipids play a role in this facet of the heat-stress response. Together, these results demonstrate a critical and novel role for sphingolipids in mediating p-body formation during heat stress. C1 [Cowart, L. Ashley; Gandy, Jason L.; Tholanikunnel, Baby; Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29423 USA. [Cowart, L. Ashley] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29401 USA. RP Hannun, YA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29423 USA. EM hannun@musc.edu FU National Institutes of Health [GM63625]; American Heart Association [0555470U]; Center of Biomedical Research Excellence in Lipidomics and Pathobiology; VA Merit Award FX This work was supported by the National Institutes of Health [grant number GM63625 (to Y.A.H.)]; the American Heart Association [grant number 0555470U (to B.G.T.)]; the Center of Biomedical Research Excellence in Lipidomics and Pathobiology (to L.A.C.); and by a VA Merit Award (to L.A.C). NR 35 TC 18 Z9 18 U1 0 U2 4 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0264-6021 J9 BIOCHEM J JI Biochem. J. PD OCT 1 PY 2010 VL 431 BP 31 EP 38 DI 10.1042/BJ20100307 PN 1 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 662ZM UT WOS:000282852800004 PM 20629639 ER PT J AU Morley, JF Duda, JE AF Morley, James F. Duda, John E. TI Olfaction as a biomarker in Parkinson's disease SO BIOMARKERS IN MEDICINE LA English DT Review DE diagnosis; dopaminergic functional imaging; neuropathology; olfaction; olfactory bulb; Parkinson's disease; parkinsonian disorders; pathophysiology; smell ID SLEEP BEHAVIOR DISORDER; PROGRESSIVE SUPRANUCLEAR PALSY; SMELL IDENTIFICATION TEST; LEWY BODY DISORDERS; ODOR IDENTIFICATION; TRANSCRANIAL SONOGRAPHY; ALPHA-SYNUCLEINOPATHY; COGNITIVE IMPAIRMENT; CLINICAL-DIAGNOSIS; AUTONOMIC FAILURE AB Olfactory dysfunction in Parkinson's disease is common and of interest, both as a clinical finding and potential biomarker. In this article, we discuss studies characterizing the olfactory deficit in Parkinson's disease and pathological analysis that suggests the olfactory system is a likely induction site of the neurodegenerative process. These studies have enabled research to explore the potential of olfactory dysfunction as a key component in early diagnostic strategies, as a biomarker for diagnostic purposes, a predictor of clinical outcomes and a potential therapy-independent marker of disease progression. C1 [Morley, James F.; Duda, John E.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Morley, James F.; Duda, John E.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. RP Duda, JE (reprint author), Univ Penn, Sch Med, Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. EM john.duda@va.gov NR 95 TC 19 Z9 19 U1 2 U2 9 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1752-0363 J9 BIOMARK MED JI Biomark. Med. PD OCT PY 2010 VL 4 IS 5 BP 661 EP 670 DI 10.2217/BMM.10.95 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 673DD UT WOS:000283638000003 PM 20945979 ER PT J AU Vedeniapin, A Cheng, L George, MS AF Vedeniapin, Andrei Cheng, Laura George, Mark S. TI Feasibility of simultaneous cognitive behavioral therapy and left prefrontal rTMS for treatment resistant depression SO BRAIN STIMULATION LA English DT Article ID TRANSCRANIAL MAGNETIC STIMULATION; CORTEX C1 [Vedeniapin, Andrei] Med Univ S Carolina, IOP, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Cheng, Laura] Med Univ S Carolina, Coll Med, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Vedeniapin, A (reprint author), Med Univ S Carolina, IOP, Dept Psychiat & Behav Sci, 519 N,67 President St, Charleston, SC 29425 USA. EM vedeniap@musc.edu FU National Institute on Drug Abuse [R25 DA020537]; Neuronetics; Brainsway; Principal Investigator for a Veterans Affairs [VA CSP 556] FX Partial funding to Dr. Vedeniapin was provided by National Institute on Drug Abuse grant R25 DA020537.; Mark George is an unpaid consultant to several TMS manufacturers (Neuronetics. Brainsway, Neostim, Neosync). Neuronetics loaned the TMS equipment for a recent National Institutes of Health-sponsored TMS trial in depression that Dr. George chaired. The brain stimulation laboratory is conducting a depression clinical trial funded by Brainsway. Dr. George is on the executive committee and is a site Principal Investigator for a Veterans Affairs funded multisite cooperative studies trial of TMS to treat depressed veterans (VA CSP 556). NR 14 TC 11 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X J9 BRAIN STIMUL JI Brain Stimul. PD OCT PY 2010 VL 3 IS 4 BP 207 EP 210 DI 10.1016/j.brs.2010.03.005 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 675GG UT WOS:000283814200004 PM 20965449 ER PT J AU Morrow, PK Divers, S Provencher, L Luoh, SW Petrella, TM Giurescu, M Schmelter, T Wang, Y Hortobagyi, GN Vahdat, LT AF Morrow, Phuong K. Divers, Stephen Provencher, Louise Luoh, Shiuh-Wen Petrella, Teresa M. Giurescu, Marius Schmelter, Thomas Wang, Yao Hortobagyi, Gabriel N. Vahdat, Linda T. TI Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Phase II; Sagopilone; Epothilones; Breast cancer; Metastatic ID IXABEPILONE BMS-247550; OVARIAN-CANCER; SOLID TUMORS; NEUROPATHY; TAXANE; ANTHRACYCLINE; CAPECITABINE; CISPLATIN; RESISTANT; AGENT AB Sagopilone is a novel, fully synthetic epothilone that has shown promising preclinical activity in a range of tumor models, including platinum-resistant ovarian cancer and metastatic breast cancer (MBC). This open-label, multicenter, Phase II study investigated the efficacy, safety, and tolerability of sagopilone administered to patients with MBC. Women with MBC whose previous chemotherapy regimen included a taxane and an anthracycline received sagopilone 16 or 22 mg/m(2) as a 3-h intravenous infusion every 21 days. Efficacy (using modified Response Evaluation Criteria in Solid Tumors), safety, and tolerability were assessed in this population. A total of 65 patients received sagopilone at either 16 mg/m(2) (N = 39) or 22 mg/m(2) (N = 26). Patients received a median of two cycles of sagopilone. Among the 65 patients who were evaluable for efficacy, there were three confirmed tumor responses over both treatment arms; however, the primary target of the study was not reached. The main treatment-related adverse events were sensory neuropathy (81.5%) and fatigue (44.6%). There were no deaths related to the study drug. Sagopilone was moderately tolerated in both treatment arms and showed limited activity in heavily pre-treated patients with MBC. C1 [Morrow, Phuong K.; Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA. [Divers, Stephen] Genesis Canc Ctr, Hot Springs, AR USA. [Provencher, Louise] CHA Laval Univ, Ctr Malad Sein Deschenes Fabia, Quebec City, PQ, Canada. [Luoh, Shiuh-Wen] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Luoh, Shiuh-Wen] Portland VA Med Ctr, Portland, OR USA. [Petrella, Teresa M.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. [Giurescu, Marius; Schmelter, Thomas] Bayer Schering Pharma AG, Berlin, Germany. [Wang, Yao] Bayer HealthCare Pharmaceut, Wayne, NJ USA. [Vahdat, Linda T.] Weill Cornell Med Coll, New York, NY USA. RP Morrow, PK (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, 1515 Holcombe,Box 1354, Houston, TX 77030 USA. EM pmorrow@mdanderson.org OI Vahdat, Linda/0000-0002-3522-7382 FU Bayer HealthCare Pharmaceuticals; Glaxo Smith Kline; Pfizer; Novartis FX The authors would like to thank Tanya Chaudry, Ph.D., at Complete HealthVizion for assistance in the preparation and revision of the draft manuscript, based on detailed discussion and feedback from the authors. Editorial assistance was supported by a grant from Bayer HealthCare Pharmaceuticals. We would also like to thank all investigators who participated in this study.; Dr. Shiuh-Wen Luoh receives research support from Glaxo Smith Kline and serves as an Institute PA for clinical trials sponsored by Glaxo Smith Kline. Dr. Teresa M. Petrella is a consultant for Glaxo Smith Kline, Merck, and Pfizer. She has received research funds from Pfizer. Dr. Marius Giurescu is an employee of Bayer Schering Pharma. Dr. Thomas Schmelter is an employee of Bayer Schering Pharma. Dr. Yao Wang is an employee of Bayer HealthCare Pharmaceuticals and owns company stocks in Bayer HealthCare Pharmaceuticals Dr. Gabriel N. Hortobagyi is a consultant for Novartis, Merck and Sanofi Aventis; he has received research support from Novartis. Dr. Linda T. Vahdat is a consultant for Bayer. NR 22 TC 10 Z9 10 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD OCT PY 2010 VL 123 IS 3 BP 837 EP 842 DI 10.1007/s10549-010-1102-x PG 6 WC Oncology SC Oncology GA 651BQ UT WOS:000281900000023 PM 20697802 ER PT J AU Tsai, TT AF Tsai, Thomas T. TI No Free Lunch: Transradial Access in Patients on Coumadin SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material ID PERCUTANEOUS CORONARY INTERVENTION C1 [Tsai, Thomas T.] Univ Colorado, Denver VA Med Ctr, Denver, CO 80202 USA. RP Tsai, TT (reprint author), 1055 Clermont St, Denver, CO 80220 USA. EM thomas.tsai@ucdenver.edu NR 7 TC 0 Z9 0 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD OCT 1 PY 2010 VL 76 IS 4 BP 500 EP 501 DI 10.1002/ccd.22785 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 658FN UT WOS:000282476000008 PM 20882652 ER PT J AU Tsai, TT Maddox, TM Rumsfeld, JS Ho, PM Magid, DJ Xu, S Powers, JD Carroll, NM Shetterly, SM Margolis, K Go, AS AF Tsai, Thomas T. Maddox, Thomas M. Rumsfeld, John S. Ho, P. Michael Magid, David J. Xu, Stanley Powers, J. David Carroll, Nikki M. Shetterly, Susan M. Margolis, Karen Go, Alan S. TI Response to Letter Regarding Article, "Increased Risk of Bleeding in Patients on Clopidogrel Therapy After Drug-Eluting Stents Implantation: Insights From the HMO Research Network-Stent Registry (HMORN-Stent)" SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Letter ID LONG-TERM OUTCOMES; THROMBOSIS C1 [Tsai, Thomas T.; Maddox, Thomas M.; Rumsfeld, John S.; Ho, P. Michael; Magid, David J.] Univ Colorado, Denver VA Med Ctr, Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80202 USA. [Margolis, Karen] HealthPartners Res Fdn, Minneapolis, MN USA. [Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Go, Alan S.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Go, Alan S.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Go, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Tsai, TT (reprint author), Univ Colorado, Denver VA Med Ctr, Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80202 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7640 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD OCT PY 2010 VL 3 IS 5 BP E25 EP E25 DI 10.1161/CIRCINTERVENTIONS.110.958587 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 666ZA UT WOS:000283160500005 ER PT J AU Eickhoff, JC Kim, K Beach, J Kolesar, JM Gee, JR AF Eickhoff, Jens C. Kim, KyungMann Beach, Jason Kolesar, Jill M. Gee, Jason R. TI A Bayesian adaptive design with biomarkers for targeted therapies SO CLINICAL TRIALS LA English DT Article; Proceedings Paper CT Annual Conference on Statistical Issues on Clinical Trials - Statistical Issues in Developing Targeted Therapies CY APR 29, 2009 CL Univ Pennsylvania, Philadelphia, PA SP Amer Stat Assoc, Soc Clinical Trials HO Univ Pennsylvania ID CLINICAL-TRIAL DESIGNS; PARTIAL LEAST-SQUARES; CANCER; CLASSIFICATION; RANDOMIZATION; VALIDATION; REGRESSION; EFFICIENCY AB Background Targeted therapies are becoming increasingly important for the treatment of various diseases. Biomarkers are a critical component of a targeted therapy as they can be used to identify patients who are more likely to benefit from a treatment. Targeted therapies, however, have created major challenges in the design, conduct, and analysis of clinical trials. In traditional clinical trials, treatment effects for various biomarkers are typically evaluated in an exploratory fashion and only limited information about the predictive values of biomarkers obtained. Purpose New study designs are required, which effectively evaluate both the diagnostic and the therapeutic implication of biomarkers. Methods The Bayesian approach provides a useful framework for optimizing the clinical trial design by directly integrating information about biomarkers and clinical outcomes as they become available. We propose a Bayesian covariate-adjusted response-adaptive randomization design, which utilizes individual biomarker profiles and patient's clinical outcomes as they become available during the course of the trial, to assign the most efficacious treatment to individual patients. Predictive biomarker subgroups are determined adaptively using a partial least squares regression approach. Results A series of simulation studies were conducted to examine the operating characteristics of the proposed study design. The simulation studies show that the proposed design efficiently identifies patients who benefit most from a targeted therapy and that there are substantial savings in the sample size requirements when compared to alternative designs. Limitations The design does not control for the type I error in the traditional sense and a positive result should be confirmed by conducting an independent phase III study focusing on the selected biomarker profile groups. Conclusions We conclude that the proposed design may serve a useful role in the early efficacy phase of targeted therapy development. Clinical Trials 2010; 7: 546-556. http://ctj.sagepub.com C1 [Eickhoff, Jens C.; Kim, KyungMann; Beach, Jason] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA. [Eickhoff, Jens C.; Kim, KyungMann; Kolesar, Jill M.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI USA. [Gee, Jason R.] William S Middleton Mem Vet Adm Med Ctr, Urol Sect, Madison, WI USA. [Gee, Jason R.] Lahey Clin Med Ctr, Sophia Gordon Canc Ctr, Inst Urol, Burlington, MA 01803 USA. RP Eickhoff, JC (reprint author), Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA. EM eickhoff@biostat.wisc.edu FU NCI NIH HHS [P30 CA14520, P30 CA014520] NR 27 TC 13 Z9 14 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 J9 CLIN TRIALS JI Clin. Trials PD OCT PY 2010 VL 7 IS 5 BP 546 EP 556 DI 10.1177/1740774510372657 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 653KK UT WOS:000282089800005 PM 20571131 ER PT J AU Young, KY Laird, A Zhou, XH AF Young, K. Y. Laird, A. Zhou, X. H. TI The efficiency of clinical trial designs for predictive biomarker validation SO CLINICAL TRIALS LA English DT Article; Proceedings Paper CT Annual Conference on Statistical Issues on Clinical Trials - Statistical Issues in Developing Targeted Therapies CY APR 29, 2009 CL Univ Pennsylvania, Philadelphia, PA SP Amer Stat Assoc, Soc Clinical Trials HO Univ Pennsylvania ID BREAST-CANCER; CHEMOTHERAPY AB Background The rapid advance of molecular genetic technology and of molecular diagnostics companies have set the stage for a new era in personalized treatments. Biomarkers such as gene expressions may be integrated into the anatomically based tumor-node-metastasis staging system to provide information for risk stratification and treatment selection. With the assumption that preliminary results show evidence that a biomarker has predictive value, the marker-based designs are geared to assess the purported predictive value in a clinical trial. Purpose In this article, we compared the efficiency of the traditional design, which does not involve a biomarker, to several alternative designs in terms of the sample size required in each trial. Methods We first derived the variance formulas for the two-sample t-tests under the various designs when the biomarker assay is imperfect, and then conducted numerical and simulation studies to evaluate the performance of the various designs. Results Based on numerical and simulation studies, we conclude that the marker-based strategy designs are less efficient than the traditional design in general. Since the biomarker assay is imperfect in a realistic setting, the estimated sample size for each alternative design is influenced by the sensitivity and specificity of the assay and the prevalence of the biomarker in the population of interest as well as the parameters involved in a standard sample size calculation. Limitations Due to limitations of a simulation study, it is not clear whether our results can be generalized to other parameter settings that are different from the ones used in the simulation study. Conclusions The marker-based strategy designs are less efficient than the traditional design in general. If there is no treatment effect among marker-negative patients, it is still feasible to use the marker-based strategy design I if the assay sensitivity is high. If the treatment effect among marker-negative patients is half of the effect among marker-positive patients, the marker prevalence must be relatively high and the sensitivity of the assay must be very high for the marker-based strategy design I to approximate the efficiency of the traditional design. The efficiency of the marker-based strategy design II relative to the traditional design is low in all scenarios considered under the current study. Clinical Trials 2010; 7: 557-566. http://ctj.sagepub.com C1 [Young, K. Y.; Laird, A.; Zhou, X. H.] Univ Washington, Dept Biostat, Seattle, WA 98198 USA. [Zhou, X. H.] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98101 USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, HSB Box 357232, Seattle, WA 98198 USA. EM azhou@u.washington.edu NR 12 TC 14 Z9 14 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 J9 CLIN TRIALS JI Clin. Trials PD OCT PY 2010 VL 7 IS 5 BP 557 EP 566 DI 10.1177/1740774510370497 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 653KK UT WOS:000282089800006 PM 20571132 ER PT J AU Kalapatapu, RK Patil, U Goodman, MS AF Kalapatapu, Raj K. Patil, Uday Goodman, Marianne S. TI Using the Internet to Assess Perceptions of Patients with Borderline Personality Disorder: What Do Patients Want in the DSM-V? SO CYBERPSYCHOLOGY BEHAVIOR AND SOCIAL NETWORKING LA English DT Article ID CLASSIFICATION; FAMILIES; STIGMA AB Objectives: This study was an anonymous Internet survey of individuals currently diagnosed with borderline personality disorder (BPD), where participants gave opinions about BPD criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR), and suggested modifications for BPD criteria to appear in the DSM-V (5th edition). Methods: Survey links were posted on 24 websites/Internet blogs that offered advice, education, or treatment of BPD. Demographic and clinical data pertaining to each participant were collected. Free-text responses were analyzed by frequencies of keywords and key phrases. Results: A total of 1,832 responses were downloaded between March 7 and June 6, 2009, and 646 responses were analyzable. Results indicated that the majority of the DSM-IV-TR criteria appeared to capture what participants were experiencing, even though a significant percentage of participants felt that something was missing from the current criteria. A significant percentage of participants felt that BPD should be renamed in the DSM-V; some combination of "emotion(al)'' and "(dys)regulation'' was most commonly suggested to include in an alternative name. Conclusions: This Internet study highlighted the enthusiasm of individuals diagnosed with BPD to share their opinions on the DSM criteria with mental-health professionals. A significant percentage of participants in this study felt that BPD should be renamed in the DSM-V. Patient involvement during the DSM-V revision process remains controversial. C1 [Kalapatapu, Raj K.] Columbia Univ, New York State Psychiat Inst, Subst Use Res Ctr, Unit 120, New York, NY 10032 USA. [Patil, Uday] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Goodman, Marianne S.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Goodman, Marianne S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Kalapatapu, RK (reprint author), Columbia Univ, New York State Psychiat Inst, Subst Use Res Ctr, Unit 120, 1051 Riverside Dr, New York, NY 10032 USA. EM kalapat@pi.cpmc.columbia.edu NR 33 TC 2 Z9 2 U1 1 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2152-2715 EI 2152-2723 J9 CYBERPSYCH BEH SOC N JI Cyberpsychology Behav. Soc. Netw. PD OCT PY 2010 VL 13 IS 5 BP 483 EP 494 DI 10.1089/cyber.2009.0351 PG 12 WC Psychology, Social SC Psychology GA 665PR UT WOS:000283048400001 PM 20950172 ER PT J AU Lazo, M Solga, SF Horska, A Bonekamp, S Diehl, AM Brancati, FL Wagenknecht, LE Pi-Sunyer, FX Kahn, SE Clark, JM AF Lazo, Mariana Solga, Steven F. Horska, Alena Bonekamp, Susanne Diehl, Anna Mae Brancati, Frederick L. Wagenknecht, Lynne E. Pi-Sunyer, F. Xavier Kahn, Steven E. Clark, Jeanne M. CA Fatty Liver Subgrp Look AHEAD Res TI Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes SO DIABETES CARE LA English DT Article ID NONALCOHOLIC FATTY LIVER; WEIGHT-LOSS; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; CRYPTOGENIC CIRRHOSIS; CALORIE RESTRICTION; NATURAL-HISTORY; RISK-FACTORS; STEATOHEPATITIS; EXERCISE AB OBJECTIVE - Weight loss through lifestyle changes is recommended for nonalcoholic fatty liver disease (NAFLD). However, its efficacy in patients with type 2 diabetes is unproven. RESEARCH DESIGN AND METHODS - Look AHEAD (Action for Health in Diabetes) is a 16-center clinical trial with 5,145 overweight or obese adults with type 2 diabetes, who were randomly assigned to an intensive lifestyle intervention (ILI) to induce a minimum weight loss of 7% or a control group who received diabetes support and education (DSE). In the Fatty Liver Ancillary Study, 96 participants completed proton magnetic resonance spectroscopy to quantify hepatic steatosis and tests to exclude other causes of liver disease at baseline and 12 months. We defined steatosis >5.5% as NAFLD. RESULTS - Participants were 49% women and 68% white. The mean age was 61 years, mean BMI was 35 kg/m(2), mean steatosis was 8.0%, and mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were 20.5 and 24.2 units/l, respectively. After 12 months, participants assigned to ILI (n = 46) lost more weight (-8.5 vs. -0.05%; P<0.01) than those assigned to DSE and had a greater decline in steatosis (-50.8 vs. -22.8%, P=0.04) and in AI C (-0.7 vs. -0.2%, P=0.04). There were no significant 12-month changes in AST or ALT levels. At 12 months, 26% of DSE participants and 3% (1 of 31) of ILI participants without NAFLD at baseline developed NAFLD (P<0.05). CONCLUSIONS - A 12-month intensive lifestyle intervention in patients with type 2 diabetes reduces steatosis and incident NAFLD. C1 [Lazo, Mariana; Brancati, Frederick L.; Clark, Jeanne M.] Welch Ctr Prevent Epidemiol & Clin Res, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Horska, Alena] Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Baltimore, MD USA. [Diehl, Anna Mae] Duke Univ, Med Ctr, Durham, NC USA. [Wagenknecht, Lynne E.] Wake Forest Univ, Div Publ Hlth Sci, Winston Salem, NC 27109 USA. [Pi-Sunyer, F. Xavier] Columbia Univ, St Lukes Roosevelt Hosp Ctr, Coll Phys & Surg, Div Endocrinol Diabet & Nutr, New York, NY USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. RP Lazo, M (reprint author), Welch Ctr Prevent Epidemiol & Clin Res, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. EM mlazo@jhsph.edu OI Bonekamp, Susanne/0000-0001-5847-5656; Kahn, Steven/0000-0001-7307-9002 FU National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK-060427, U01-DK-57149]; Johns Hopkins University School of Medicine General Clinical Research Center [M01-RR-00052]; Department of Veterans Affairs FX The study was supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (grants R01-DK-060427 and U01-DK-57149), The Johns Hopkins University School of Medicine General Clinical Research Center (grant M01-RR-00052), and the Department of Veterans Affairs. NR 24 TC 104 Z9 110 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2010 VL 33 IS 10 BP 2156 EP 2163 DI 10.2337/dc10-0856 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 667PD UT WOS:000283205100005 PM 20664019 ER PT J AU Kahn, SE AF Kahn, S. E. TI Beta-cell loss in type 2 diabetes SO DIABETES OBESITY & METABOLISM LA English DT Meeting Abstract C1 [Kahn, S. E.] Univ Washington, Seattle, WA 98195 USA. [Kahn, S. E.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1462-8902 J9 DIABETES OBES METAB JI Diabetes Obes. Metab. PD OCT PY 2010 VL 12 SU 1 BP 12 EP 12 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 656XE UT WOS:000282373600017 ER PT J AU Lynch, CP Strom, JL Egede, LE AF Lynch, Cheryl P. Strom, Joni L. Egede, Leonard E. TI Variation in Quality of Care Indicators for Diabetes in a National Sample of Veterans and Non-Veterans SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Article ID AFFAIRS HEALTH-CARE; PREVALENCE; ADULTS; SYSTEM AB Background: Veterans have a disproportionately higher burden of type 2 diabetes. It is unclear whether veterans with diabetes have better self-care behaviors or receive better quality of care than non-veterans. The objective was to examine differences in diabetes care between veterans and non-veterans. Methods: Data analysis was performed with respondents from the 2003 Behavioral Risk Factor Surveillance Survey (n-21,111 with diabetes). Veterans were those who reported U. S. military service and no longer on active duty. Self-care behaviors included daily fruit and vegetable intake, physical activity level, self-foot checks, and home glucose testing. Quality of care indicators included provider actions over the past 12 months (2+ office visits, 2+ glycosylated hemoglobin checks, 1+ foot exams, 1+ dilated eye exams, daily aspirin use, receiving flu or pneumonia vaccine). Multiple logistic regression using STATA version 10 (Stata Corp., College Station, TX) analyzed differences by veteran status on each quality indicator, controlling for sociodemographics and diabetes education. Results: Veterans comprised 14.2% of the sample, and 12.4% had diabetes compared to 6.7% of non-veterans. In final adjusted models, veterans were significantly more likely to check their feet (odds ratio [OR] 1.33, 95% confidence interval [CI] 1.09, 1.64), get a dilated eye exam (OR 1.36, 95% CI 1.11, 1.66), receive aspirin (OR 1.31, 95% CI 1.04, 1.65), get a flu shot (OR 1.32, 95% CI 1.09, 1.61), and ever get a pneumonia shot (OR 1.38, 95% CI 1.12, 1.70). Conclusions: Veterans appear to have better self-care behaviors and receive better preventive care than non-veterans. However, future efforts need to focus on boosting self-care to improve diabetes outcomes. C1 [Lynch, Cheryl P.; Strom, Joni L.; Egede, Leonard E.] Med Univ S Carolina, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Lynch, Cheryl P.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC 29425 USA. RP Lynch, CP (reprint author), Med Univ S Carolina, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Ctr Hlth Dispar Res, 135 Rutledge Ave,MSC 250593, Charleston, SC 29425 USA. EM lynchcp@musc.edu FU Center for Disease Prevention and Health Interventions for Diverse Populations [REA 08-261] FX This work was supported by the use of facilities at the Charleston VA Health Services Research & Development-funded Center for Disease Prevention and Health Interventions for Diverse Populations (REA 08-261). NR 25 TC 5 Z9 5 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD OCT PY 2010 VL 12 IS 10 BP 785 EP 790 DI 10.1089/dia.2010.0040 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 659UC UT WOS:000282591400006 PM 20809677 ER PT J AU Amorosa, V MacNeil, A McConnell, R Patel, A Dillon, KE Hamilton, K Erickson, BR Campbell, S Knust, B Cannon, D Miller, D Manning, C Rollin, PE Nichol, ST AF Amorosa, Valerianna MacNeil, Adam McConnell, Ryan Patel, Ami Dillon, Katherine E. Hamilton, Keith Erickson, Bobbie Rae Campbell, Shelley Knust, Barbara Cannon, Deborah Miller, David Manning, Craig Rollin, Pierre E. Nichol, Stuart T. TI Imported Lassa Fever, Pennsylvania, USA, 2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID EPIDEMIC; LIBERIA AB We report a case of Lassa fever in a US traveler who visited rural Liberia, became ill while in country, sought medical care upon return to the United States, and subsequently had his illness laboratory confirmed. The patient recovered with supportive therapy. No secondary cases occurred. C1 [Amorosa, Valerianna; McConnell, Ryan; Dillon, Katherine E.; Hamilton, Keith] Univ Penn, Philadelphia, PA 19104 USA. [Amorosa, Valerianna] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [MacNeil, Adam; Patel, Ami; Erickson, Bobbie Rae; Campbell, Shelley; Knust, Barbara; Cannon, Deborah; Miller, David; Manning, Craig; Rollin, Pierre E.; Nichol, Stuart T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Patel, Ami] Philadelphia Dept Hlth, Philadelphia, PA USA. RP Amorosa, V (reprint author), Philadelphia VAMC Med, Philadelphia, PA 19104 USA. EM valerianna.amorosa@uphs.upenn.edu OI Cameron, Katherine/0000-0002-0859-0741 NR 14 TC 25 Z9 27 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2010 VL 16 IS 10 BP 1598 EP 1600 DI 10.3201/eid1610.100774 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 657EA UT WOS:000282394800014 PM 20875288 ER PT J AU Ramsay, E Faught, E Krumholz, A Naritoku, D Privitera, M Schwarzman, L Mao, L Wiegand, F Hulihan, J AF Ramsay, Eugene Faught, Edward Krumholz, Allan Naritoku, Dean Privitera, Michael Schwarzman, Lesley Mao, Lian Wiegand, Frank Hulihan, Joseph CA Capss-272 Study Group TI Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: A randomized double-blind clinical trial SO EPILEPSIA LA English DT Article DE Complex partial seizures; Epilepsy; Generalized tonic-clonic seizures; Phenytoin; Rapid-initiation; Topiramate ID NEWLY-DIAGNOSED EPILEPSY; 1ST UNPROVOKED SEIZURE; TONIC CLONIC SEIZURES; UNTREATED EPILEPSY; CARBAMAZEPINE; LAMOTRIGINE; MONOTHERAPY; RISK; VALPROATE; ADULTS AB P>Purpose: To evaluate topiramate (TPM) and phenytoin (PHT) monotherapy following rapid oral initiation in new-onset epilepsy. Methods: Randomized, double-blind, 28-day trial of TPM (100 mg/day beginning on day 1) versus PHT (1,000 mg on day 1 followed by 300 mg/day maintenance dosing) in 261 patients with new-onset epilepsy. The primary end point was time to seizure, and the primary objective was to establish noninferiority of TPM to PHT in the risk of seizure. Results: At day 28, the estimated seizure-free rate was 81.1% for TPM treatment in comparison with 90.3% for PHT treatment. Noninferiority of TPM to PHT (primary objective) could not be established [hazard ratio (HR) 2.0, 95% confidence interval (CI), 0.98 to 4.12, p = 0.366), and PHT could not be shown to be superior to TPM. A higher percentage discontinued with PHT compared to TPM for all reasons (21.1 vs. 12.8%) and due to adverse events (13.4 vs. 6.8%). The most common treatment-related adverse events in both groups were dizziness, paresthesia, and somnolence. A post hoc analysis showed that TPM was superior to PHT in time to discontinuation (retention rate) for all causes (89.4% vs. 80.3%, p = 0.047). Conclusion: This study was inconclusive in establishing noninferiority of TPM 100 mg/day compared to a standard regimen of oral PHT in seizure risk in this population of patients with new-onset epilepsy. Given the superiority of TPM in overall retention and favorable tolerability without titration, it may nonetheless be an appropriate option in some patients with new-onset epilepsy requiring rapid treatment initiation. C1 [Ramsay, Eugene] Ochsner Baptist Med Ctr, Epilepsy Inst, New Orleans, LA 70115 USA. [Faught, Edward] Univ Alabama, Sch Med, Birmingham, AL USA. [Faught, Edward] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Krumholz, Allan] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Naritoku, Dean] So Illinois Univ, Springfield, IL USA. [Privitera, Michael] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Schwarzman, Lesley; Mao, Lian; Wiegand, Frank; Hulihan, Joseph] LLC, Ortho McNeil Janssen Sci Affairs, Titusville, NJ USA. RP Ramsay, E (reprint author), Ochsner Baptist Med Ctr, Epilepsy Inst, 4299 Clara St,MacFarland Bldg,Suite 440, New Orleans, LA 70115 USA. EM eramsay@epiworld.com RI Ramsay, R. Eugene/D-4491-2011 FU Ortho-McNeil Janssen Scientific Affairs, LLC.; Abbott Laboratories; Bertex; Carter-Wallace; Cephalon; Cyberonics; Eisai; GlaxoSmithKline; IVAX; Marion Merrell Dow; Novartis; Ortho-McNeil Pharmaceuticals; Ovation Pharmaceuticals; Pfizer; RW Johnson; Schwarz Pharma; SmithKline Beecham; UCB Pharma; X-cel Pharma; Ortho-McNeil/JohnsonJohnson; Schwarz Pharma/UCB; American Epilepsy Society; EpiFellows Foundation; Janssen-Cilag; National Institutes of Health; Pfizer Inc FX Funding for this study was provided by Ortho-McNeil Janssen Scientific Affairs, LLC.; Eugene Ramsay has received support from, and/or has served as a paid consultant for Abbott Laboratories, Bertex, Carter-Wallace, Cephalon, Cyberonics, Eisai, GlaxoSmithKline, IVAX, Marion Merrell Dow, Novartis, Ortho-McNeil Pharmaceuticals, Ovation Pharmaceuticals, Pfizer, RW Johnson, Schwarz Pharma, SmithKline Beecham, UCB Pharma, and X-cel Pharma.; Edward Faught has received support from, and/or has served as a paid consultant for Ortho-McNeil/Johnson&Johnson.; Allan Krumholz has received support from, and/or has served as a paid consultant for Ortho-McNeil Pharmaceuticals, Ovation Pharmaceuticals, and UCB Pharma.; Dean Naritoku has received support from, and/or has served as a paid consultant for Abbott Laboratories, Eisai, GlaxoSmithKline, Ortho-McNeil Pharmaceuticals, and Schwarz Pharma/UCB.; Michael Privitera has received support from, and/or has served as a paid consultant for the American Epilepsy Society, epiFellows Foundation, GlaxoSmithKline, Janssen-Cilag, National Institutes of Health, Ortho-McNeil Pharmaceuticals, Pfizer Inc, and UCB Pharma. NR 35 TC 17 Z9 17 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD OCT PY 2010 VL 51 IS 10 BP 1970 EP 1977 DI 10.1111/j.1528-1167.2010.02670.x PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 660KE UT WOS:000282639700006 PM 20633037 ER PT J AU de Molina, RM Mortensen, EM Restrepo, MI Copeland, LA Pugh, MJV Anzueto, A AF de Molina, R. Malo Mortensen, E. M. Restrepo, M. I. Copeland, L. A. Pugh, M. J. V. Anzueto, A. TI Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article DE Chronic obstructive pulmonary disease; inhaled corticosteroids; mortality; pneumonia ID OBSTRUCTIVE PULMONARY-DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; SALMETEROL/FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE; UNITED-STATES; RISK-FACTORS; PROPENSITY SCORE; LUNG-DISEASE; SALMETEROL; EXACERBATIONS AB Recent studies suggest that use of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) may be associated with a higher incidence of pneumonia. However, it is unclear whether COPD subjects on ICS who develop pneumonia have worse outcomes. Therefore, our aim was to examine the association of prior outpatient ICS therapy with mortality in hospitalised COPD subjects with pneumonia. We included subjects >= 64 yrs of age, hospitalised with pneumonia in US Veterans Affairs hospitals, and assessed the association of ICS exposure with mortality for hospitalised COPD subjects with pneumonia in a covariate-adjusted regression model. We identified 6,353 subjects with a diagnosis of pneumonia and prior COPD, of whom 38% were on ICS. Mortality was 9% at 30 days and 16% at 90 days. In regression analyses, outpatient ICS therapy was associated with lower mortality at both 30 days (OR 0.76, 95% CI 0.70-0.83), and 90 days (OR 0.80, 95% CI 0.75-0.86). Outpatient therapy with ICS was associated with a significantly lower 30- and 90-day mortality in hospitalised COPD patients with pneumonia. C1 [Restrepo, M. I.] UTHSCSA, ALMD, VERDICT Res Programme,S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX 78229 USA. [de Molina, R. Malo; Restrepo, M. I.; Anzueto, A.] UTHSCSA, Div Pulm & Crit Care Med, Dept Med, San Antonio, TX 78229 USA. [Mortensen, E. M.] UTHSCSA, Div Gen Internal Med, Dept Med, San Antonio, TX 78229 USA. [Copeland, L. A.] UTHSCSA, Dept Psychiat, San Antonio, TX 78229 USA. [Pugh, M. J. V.] UTHSCSA, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. RP Restrepo, MI (reprint author), UTHSCSA, ALMD, VERDICT Res Programme,S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, 11C6,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu OI Mortensen, Eric/0000-0002-3880-5563; Copeland, Laurel/0000-0002-9478-0209 FU Spanish Pulmonary Society (SEPAR) [757]; Dept of Veterans Affairs [IIR 02-076, MREP 02-267] FX R. Malo de Molina received funding from the Spanish Pulmonary Society (SEPAR), project 757. M.J. Pugh received funding from the Dept of Veterans Affairs IIR 02-076 and MREP 02-267. L. A. Copeland was supported by the Dept of Veterans Affairs MREP 05-145. M. I. Restrepo is supported by a Dept of Veteran Affairs Veterans Integrated Service Network 17 new faculty grant and National Health Institute KL2 Grant 9CTSA Award Number (KL2 RR025766). This material is the result of work supported with resources and the use of facilities at the South Texas Veterans Health Care System. The funding agencies had no role in conducting the study, or role in the preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 52 TC 39 Z9 39 U1 0 U2 0 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 J9 EUR RESPIR J JI Eur. Resp. J. PD OCT PY 2010 VL 36 IS 4 BP 751 EP 757 DI 10.1183/09031936.00077509 PG 7 WC Respiratory System SC Respiratory System GA 658ER UT WOS:000282473700014 ER PT J AU Stengel, A Tache, Y AF Stengel, Andreas Tache, Yvette TI Corticotropin-releasing factor signaling and visceral response to stress SO EXPERIMENTAL BIOLOGY AND MEDICINE LA English DT Article; Proceedings Paper CT Annual FASEB Experimental Biology Meeting CY APR 21, 2009 CL San Diego, CA DE cardiovascular system; corticotropin-releasing factor (CRF); irritable bowel syndrome (IBS); stress; urocortin (Ucn) ID IRRITABLE-BOWEL-SYNDROME; ENTERIC NERVOUS-SYSTEM; EXPERIMENTAL HEART-FAILURE; MESSENGER-RNA EXPRESSION; FUNCTIONAL GASTROINTESTINAL DISORDERS; HORMONE-RECEPTOR ANTAGONIST; WATER-AVOIDANCE STRESS; COLONIC MOTOR RESPONSE; TYPE-2 CRF RECEPTORS; ISOLATED RAT-HEART AB Stress may cause behavioral and/or psychiatric manifestations such as anxiety and depression and also impact on the function of different visceral organs, namely the gastrointestinal and cardiovascular systems. During the past years substantial progress has been made in the understanding of the underlying mechanisms recruited by stressors. Activation of the corticotropin-releasing factor (CRF) signaling system is recognized to be involved in a large number of stress-related behavioral and somatic disorders. This review will outline the present knowledge on the distribution of the CRF system (ligands and receptors) expressed in the brain and peripheral viscera and its relevance in stress-induced alterations of gastrointestinal and cardiovascular functions and the therapeutic potential of CRF(1) receptor antagonists. C1 [Tache, Yvette] VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Div Digest Dis, Los Angeles, CA 90095 USA. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU NIDDK NIH HHS [R01 DK033061, R01 DK 33061, R01 DK 57238, R01 DK057238, R37 DK033061] NR 171 TC 54 Z9 59 U1 0 U2 7 PU SOC EXPERIMENTAL BIOLOGY MEDICINE PI MAYWOOD PA 195 WEST SPRING VALLEY AVE, MAYWOOD, NJ 07607-1727 USA SN 1535-3702 J9 EXP BIOL MED JI Exp. Biol. Med. PD OCT PY 2010 VL 235 IS 10 BP 1168 EP 1178 DI 10.1258/ebm.2010.009347 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 670VN UT WOS:000283455500005 PM 20881321 ER PT J AU Mukherjee, R Colbath, GP Justus, CD Bruce, JA Allen, CM Hewett, KW Saul, JP Gourdie, RG Spinale, FG AF Mukherjee, Rupak Colbath, Gregory P. Justus, Charles D. Bruce, James A. Allen, Claire M. Hewett, Kenneth W. Saul, J. Philip Gourdie, Robert G. Spinale, Francis G. TI Spatiotemporal induction of matrix metalloproteinase-9 transcription after discrete myocardial injury SO FASEB JOURNAL LA English DT Article DE myocardial injury; structure; remodeling ID MATRIX-METALLOPROTEINASE INHIBITION; LEFT-VENTRICULAR ENLARGEMENT; GAP-JUNCTION; HEART-FAILURE; ATRIAL-FIBRILLATION; TARGETED DELETION; TISSUE INHIBITOR; CARDIAC-FUNCTION; INFARCTION; EXPRESSION AB Radiofrequency (RF) ablation of the myocardium causes discrete sites of injury. RF scars can expand, altering the extracellular matrix (ECM) structure and the continuity of the electrical syncytium of the adjacent myocardium. Matrix metalloproteinases (MMPs), such as MMP-9, contribute to ECM remodeling. However, whether and to what degree transcriptional induction of MMP-9 occurs after myocardial RF injury and the association with electrical conduction patterns after RF injury remains unexplored. This study examined MMP-9 gene promoter (M9PROM) activation after myocardial RF injury using mice in which the M9PROM was fused to a beta-galactosidase (beta-gal) reporter. RF lesions (0.5-mm probe, 80 degrees C, 30 s) were created on the left ventricular (LV) epicardium of M9PROM mice (n=62) and terminally studied at 1 h, 1 d, 3 d, 7 d, 14 d, and 28 d after RF injury. M9PROM activation was localized through beta-gal staining. The RF scar area and the area of beta-gal staining were measured and normalized to LV area (planimetry). RF scar size increased from 1 h post-RF-injury values by 7 d and remained higher at 28 d. M9PROM activation became evident at 3 d and peaked at 7 d. Electrical conduction was measured (potentiometric dye mapping) at 7 d after RF injury. Heterogeneities in action potentials and electrical impulse propagation coincident with M9PROM activation were observed after RF injury. For example, conduction proximal to the RF site was slower than that in the remote myocardium (0.15+/-0.02 vs. 0.83+/-0.08 mm/ms, P<0.05). Thus, a unique spatiotemporal pattern of MMP-9 transcriptional activation occurred after discrete myocardial injury, which was associated with the development of electrical heterogeneity. Therefore, these findings suggest that changes in a key determinant of extracellular matrix remodeling, in addition to changes in myocardial structure, can contribute to arrhythmogenesis around the region of myocardial injury.-Mukherjee, R., Colbath, G. P., Justus, C. D., Bruce, J. A., Allen, C. M., Hewett, K. W., Saul, J. P., Gourdie, R. G., Spinale, F. G. Spatiotemporal induction of matrix metalloproteinase-9 transcription following discrete myocardial injury. FASEB J. 24, 3819-3828 (2010). www.fasebj.org C1 [Mukherjee, Rupak; Colbath, Gregory P.; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA. [Mukherjee, Rupak; Bruce, James A.; Allen, Claire M.; Saul, J. Philip; Spinale, Francis G.] Med Univ S Carolina, Div Pediat Cardiol, Charleston, SC 29425 USA. [Justus, Charles D.; Hewett, Kenneth W.; Gourdie, Robert G.] Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA. [Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Mukherjee, R (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Strom Thurmond Res Bldg,770 MUSC Complex,Ste 625, Charleston, SC 29425 USA. EM mukherr@musc.edu FU U.S. National Institutes of Health [HL-66029, HL-45024, HL-97012, P01-48788, HL-56728] FX This study was supported by U.S. National Institutes of Health grants HL-66029 (to R.M.), HL-45024, HL-97012, and P01-48788 (to F.G.S.), and HL-56728 (to R.G.G.). NR 41 TC 6 Z9 6 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD OCT PY 2010 VL 24 IS 10 BP 3819 EP 3828 DI 10.1096/fj.10-155531 PG 10 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 690LI UT WOS:000285005900020 PM 20530752 ER PT J AU Leung, FW Harker, JO Jackson, G Okamoto, KE Behbahani, OM Jamgotchian, NJ Aharonian, HS Guth, PH Mann, SK Leung, JW AF Leung, Felix W. Harker, Judith O. Jackson, Guy Okamoto, Kate E. Behbahani, Omid M. Jamgotchian, Nora J. Aharonian, H. Steven Guth, Paul H. Mann, Surinder K. Leung, Joseph W. TI A proof-of-principle, prospective, randomized, controlled trial demonstrating improved outcomes in scheduled unsedated colonoscopy by the water method SO GASTROINTESTINAL ENDOSCOPY LA English DT Article; Proceedings Paper CT Digestive Disease Week/111th Annual Meeting of the American-Gastroenterological-Association CY MAY 01-06, 2010 CL New Orleans, LA SP Amer Gastroenterol Assoc ID SEDATION-FREE COLONOSCOPY; SCREENING COLONOSCOPY; COLORECTAL-CANCER; PATIENT; VETERANS; PERFORMANCE; POPULATION; DISCOMFORT; ENDOSCOPY; TIME AB Background: An observational study in veterans showed that a novel water method (water infusion in lieu of air insufflation) enhanced cecal intubation and willingness to undergo a repeat scheduled unsedated colonoscopy. Objective: To confirm these beneficial effects and significant attenuation of discomfort in a randomized, controlled trial (RCT). Design: Prospective RCT, intent-to-treat analysis. Setting: Veterans Affairs ambulatory care facility. Patients: Veterans undergoing scheduled unsedated colonoscopy. Interventions: During insertion, the water and traditional air methods were compared. Main Outcome Measurements: Discomfort and procedure-related outcomes. Results: Eighty-two veterans were randomized to the air (n = 40) or water (n = 42) method. Cecal intubation (78% vs 98%) and willingness to repeat (78% vs 93%) were significantly better with the water method (P < .05; Fisher exact test). The mean (standard deviation) of maximum discomfort (0 = none, 10 = most severe) during colonoscopy was 5.5 (3.0) versus 3.6 (2.1) P = .002 (Student t test), and the median overall discomfort after colonoscopy was 3 versus 2, P = .052 (Mann-Whitney U test), respectively. The method, but not patient characteristics, was a predictor of discomfort (t = -1.998, P = .049, R(2) = 0.074). The odds ratio for failed cecal intubation was 2.09 (95% CI, 1.49-2.93) for the air group. Fair/poor previous experience increased the risk of failed cecal intubation in the air group only. The water method numerically increased adenoma yield. Limitations: Single site, small number of elderly men, unblinded examiner, possibility of unblinded subjects, restricted generalizability. Conclusions: The RCT data confirmed that the water method significantly enhanced cecal intubation and willingness to undergo a repeat colonoscopy. The decrease in maximum discomfort was significant; the decrease in overall discomfort approached significance. The method, but not patient characteristics, was a predictor of discomfort. (Clinical trial registration number NCT00747084). (Gastrointest Endosc 2010;72:693-700.) C1 [Leung, Felix W.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, David Geffen Sch Med,Div Gastroenterol 111G, Res Serv,Sepulveda Ambulatory Care Ctr, North Hills, CA 91343 USA. [Leung, Felix W.; Aharonian, H. Steven; Guth, Paul H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Mann, Surinder K.; Leung, Joseph W.] Vet Affairs No Calif Healthcare Syst, Sacramento VAMC, Mather, CA USA. [Mann, Surinder K.; Leung, Joseph W.] UC Davis Med Ctr, Sacramento, CA USA. [Leung, Felix W.; Harker, Judith O.; Jackson, Guy; Okamoto, Kate E.; Behbahani, Omid M.; Jamgotchian, Nora J.; Aharonian, H. Steven; Guth, Paul H.] Vet Affairs Greater Los Angeles Healthcare Syst, Med Serv, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. RP Leung, FW (reprint author), Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, David Geffen Sch Med,Div Gastroenterol 111G, Res Serv,Sepulveda Ambulatory Care Ctr, 16111 Plummer St, North Hills, CA 91343 USA. EM felix.leung@va.gov NR 42 TC 50 Z9 51 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD OCT PY 2010 VL 72 IS 4 BP 693 EP 700 DI 10.1016/j.gie.2010.05.020 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 663ZB UT WOS:000282927600004 PM 20619405 ER PT J AU Becker, PS Taylor, JA Trobridge, GD Zhao, X Beard, BC Chien, S Adair, J Kohn, DB Wagner, JE Shimamura, A Kiem, HP AF Becker, P. S. Taylor, J. A. Trobridge, G. D. Zhao, X. Beard, B. C. Chien, S. Adair, J. Kohn, D. B. Wagner, J. E. Shimamura, A. Kiem, H-P TI Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector SO GENE THERAPY LA English DT Article DE gene therapy; mitomycin C; reducing agent; hypoxia ID HEMATOPOIETIC STEM-CELLS; NATURAL GENE-THERAPY; FUNCTIONAL CORRECTION; REPOPULATING CELLS; REVERSE MOSAICISM; PROGENITOR CELLS; ENGRAFTMENT; VIRUS AB One of the major hurdles for the development of gene therapy for Fanconi anemia (FA) is the increased sensitivity of FA stem cells to free radical-induced DNA damage during ex vivo culture and manipulation. To minimize this damage, we have developed a brief transduction procedure for lentivirus vector-mediated transduction of hematopoietic progenitor cells from patients with Fanconi anemia complementation group A (FANCA). The lentiviral vector FancA-sW contains the phosphoglycerate kinase promoter, the FANCA cDNA, and a synthetic, safety-modified woodchuck post transcriptional regulatory element (sW). Bone marrow mononuclear cells or purified CD34(+) cells from patients with FANCA were transduced in an overnight culture on recombinant fibronectin peptide CH-296, in low (5%) oxygen, with the reducing agent, N-acetyl-L-cysteine (NAC), and a combination of growth factors, granulocyte colony-stimulating factor (G-CSF), Flt3 ligand, stem cell factor, and thrombopoietin. Transduced cells plated in methylcellulose in hypoxia with NAC showed increased colony formation compared with 21% oxygen without NAC (P<0.03), showed increased resistance to mitomycin C compared with green fluorescent protein (GFP) vector-transduced controls (P<0.007), and increased survival. Thus, combining short transduction and reducing oxidative stress may enhance the viability and engraftment of gene-corrected cells in patients with FANCA. Gene Therapy (2010) 17, 1244-1252; doi:10.1038/gt.2010.62; published online 20 May 2010 C1 [Becker, P. S.; Zhao, X.; Chien, S.] Univ Washington, Div Hematol, Dept Med, Seattle, WA 98109 USA. [Taylor, J. A.] Oregon Hlth & Sci Univ, Div Hematol Oncol, Dept Med, Portland, OR USA. [Taylor, J. A.] Portland VA Med Ctr, Portland, OR USA. [Trobridge, G. D.; Beard, B. C.; Adair, J.; Shimamura, A.; Kiem, H-P] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Trobridge, G. D.; Kiem, H-P] Univ Washington, Div Med Oncol, Dept Med, Seattle, WA 98109 USA. [Kohn, D. B.] Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90024 USA. [Kohn, D. B.] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA. [Wagner, J. E.] Univ Minnesota, Dept Pediat, Div Pediat Hematol Oncol, Minneapolis, MN 55455 USA. [Shimamura, A.] Seattle Childrens Hosp, Dept Pediat, Div Pediat Hematol Oncol, Seattle, WA USA. [Kiem, H-P] Univ Washington, Dept Pathol, Seattle, WA 98109 USA. RP Becker, PS (reprint author), Univ Washington, Div Hematol, Dept Med, Campus Box 358056,815 Mercer St N415, Seattle, WA 98109 USA. EM pbecker@u.washington.edu RI Kohn, Donald/N-5085-2016 OI Kohn, Donald/0000-0003-1840-6087 FU NIH [HL085693, DK56465, DK47754]; National Institutes of Health FX This work was supported by NIH Grants HL085693, DK56465 and DK47754 to HPK. We thank Helen Crawford and Bonnie Larson for help with the preparation of the article. HPK is a Molecular Medicine Investigator and the recipient of the Jose Carreras/E. Donnall Thomas Endowed Chair for Cancer Research. We received grant support from National Institutes of Health. NR 27 TC 15 Z9 15 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0969-7128 J9 GENE THER JI Gene Ther. PD OCT PY 2010 VL 17 IS 10 BP 1244 EP 1252 DI 10.1038/gt.2010.62 PG 9 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 664GO UT WOS:000282948600008 PM 20485382 ER PT J AU Chen, G Buck, KJ AF Chen, G. Buck, K. J. TI Rostroventral caudate putamen involvement in ethanol withdrawal is influenced by a chromosome 4 locus SO GENES BRAIN AND BEHAVIOR LA English DT Article DE c-Fos; lesion; Mpdz; MUPP1 seizure; striatum ID PDZ DOMAIN PROTEIN; C-FOS EXPRESSION; ACUTE ALCOHOL-WITHDRAWAL; BASAL GANGLIA; STRIATOPALLIDAL NEURONS; INDUCED CONVULSIONS; NMDA RECEPTORS; NERVOUS-SYSTEM; C57BL/6J MICE; NR2B SUBUNIT AB Physiological dependence and associated withdrawal episodes are thought to constitute a motivational force that sustains alcohol use and abuse and may contribute to relapse in dependent individuals. Although no animal model duplicates alcoholism, models for specific factors, like withdrawal, are useful for identifying potential genetic and neural determinants of liability in humans. Previously, we identified a quantitative trait locus (QTL) and gene (Mpdz, which encodes the multi-PDZ domain protein) on chromosome 4 with a large effect on alcohol withdrawal in mice. Using congenic mice that confirm this QTL and c-Fos expression as a high-resolution marker of neuronal activation, we report that congenic mice show significantly less neuronal activity associated with alcohol withdrawal in the rostroventral caudate putamen (rvCP), but not other parts of the striatum, compared with background strain mice. Moreover, bilateral rvCP lesions significantly increase alcohol withdrawal severity. Using retrograde (fluorogold) and anterograde (Texas Red conjugated dextran amine) tract tracing, we found that similar to 25% of c-Fos immunoreactive rvCP neurons project to caudolateral substantia nigra pars reticulata (clSNr), which we previously found is crucially involved in withdrawal following acute and repeated alcohol exposure. Our results expand upon work suggesting that this QTL impacts alcohol withdrawal via basal ganglia circuitry associated with limbic function, and indicate that an rvCP-clSNr projection plays a critical role. Given the growing body of evidence that the syntenic region of human chromosome 9p and human MPDZ gene are associated with alcohol abuse, our results may facilitate research on alcohol dependence and associated withdrawal in clinical populations. C1 [Buck, K. J.] Portland VA Med Ctr, Dept Behav Neurosci, Portland, OR 97239 USA. Portland VA Med Ctr, Portland Alcohol Res Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland, OR 97239 USA. RP Buck, KJ (reprint author), Portland VA Med Ctr, Dept Behav Neurosci, Portland, OR 97239 USA. EM buckk@ohsu.edu FU VA; [AA011114]; [AA10760]; [DA05228] FX Supported by AA011114, AA10760, DA05228, and the VA. We are grateful to Drs. Laura Kozell, Robert Hitzemann, Charles Meshul, John Belknap and John Crabbe for helpful discussions of these experiments and their comments on a draft of this manuscript. NR 60 TC 6 Z9 6 U1 1 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1601-1848 J9 GENES BRAIN BEHAV JI Genes Brain Behav. PD OCT PY 2010 VL 9 IS 7 BP 768 EP 776 DI 10.1111/j.1601-183X.2010.00611.x PG 9 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 660IT UT WOS:000282634300011 PM 20608999 ER PT J AU Silber, JH Rosenbaum, PR Brachet, TJ Ross, RN Bressler, LJ Even-Shoshan, O Lorch, SA Volpp, KG AF Silber, Jeffrey H. Rosenbaum, Paul R. Brachet, Tanguy J. Ross, Richard N. Bressler, Laura J. Even-Shoshan, Orit Lorch, Scott A. Volpp, Kevin G. TI The Hospital Compare Mortality Model and the Volume-Outcome Relationship SO HEALTH SERVICES RESEARCH LA English DT Article DE Hospital Compare; mortality; acute myocardial infarction; random effects model ID ACUTE MYOCARDIAL-INFARCTION; REPORT CARDS; HEALTH-CARE; QUALITY; SURVIVAL AB Objective We ask whether Medicare's Hospital Compare random effects model correctly assesses acute myocardial infarction (AMI) hospital mortality rates when there is a volume-outcome relationship. Data Sources/Study Setting Medicare claims on 208,157 AMI patients admitted in 3,629 acute care hospitals throughout the United States. Study Design We compared average-adjusted mortality using logistic regression with average adjusted mortality based on the Hospital Compare random effects model. We then fit random effects models with the same patient variables as in Medicare's Hospital Compare mortality model but also included terms for hospital Medicare AMI volume and another model that additionally included other hospital characteristics. Principal Findings Hospital Compare's average adjusted mortality significantly underestimates average observed death rates in small volume hospitals. Placing hospital volume in the Hospital Compare model significantly improved predictions. Conclusions The Hospital Compare random effects model underestimates the typically poorer performance of low-volume hospitals. Placing hospital volume in the Hospital Compare model, and possibly other important hospital characteristics, appears indicated when using a random effects model to predict outcomes. Care must be taken to insure the proper method of reporting such models, especially if hospital characteristics are included in the random effects model. C1 [Silber, Jeffrey H.; Brachet, Tanguy J.; Ross, Richard N.; Bressler, Laura J.; Even-Shoshan, Orit; Lorch, Scott A.] Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.; Brachet, Tanguy J.] Univ Penn, Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.; Rosenbaum, Paul R.; Brachet, Tanguy J.; Even-Shoshan, Orit; Lorch, Scott A.; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Rosenbaum, Paul R.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA. [Lorch, Scott A.] Childrens Hosp Philadelphia, Dept Pediat, Div Neonatol, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Vet Adm Hosp, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. RP Silber, JH (reprint author), Childrens Hosp Philadelphia, Ctr Outcomes Res, 3535 Market St,Suite 1029, Philadelphia, PA 19104 USA. EM silberj@wharton.upenn.edu RI Rosenbaum, Paul/H-8687-2012 FU NHLBI [R01 HL082637, R01 HL094593]; NSF [0849370] FX This work was supported by NHLBI grants R01 HL082637 and R01 HL094593 and NSF grant 0849370. Portions of this work were presented at the 2009 Academy Health Annual Meeting. We thank Traci Frank, A. A., for her assistance with preparing this manuscript. NR 33 TC 39 Z9 39 U1 1 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD OCT PY 2010 VL 45 IS 5 BP 1148 EP 1167 DI 10.1111/j.1475-6773.2010.01130.x PN 1 PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 648RU UT WOS:000281712400002 PM 20579125 ER PT J AU Meterko, M Wright, S Lin, H Lowy, E Cleary, PD AF Meterko, Mark Wright, Steven Lin, Hai Lowy, Elliott Cleary, Paul D. TI Mortality among Patients with Acute Myocardial Infarction: The Influences of Patient-Centered Care and Evidence-Based Medicine SO HEALTH SERVICES RESEARCH LA English DT Article DE Patient assessment; satisfaction; patient outcomes; functional status; ADLs; IADLs; quality of care; patient safety (measurement) ID MEDICARE MANAGED CARE; HEALTH-CARE; HOSPITAL-CARE; OUTCOMES; QUALITY; SATISFACTION; ADHERENCE; CAHPS(R); PERFORMANCE; PHYSICIAN AB Background Recent studies have suggested that there is a positive impact of patient-centered care (PCC) on both the patient-physician relationship and subsequent patient health-related behaviors. One recent prospective study reported a significant relationship between the degree of PCC experienced by patients during their hospitalization for acute myocardial infarction (AMI) and their postdischarge cardiac symptoms. A limitation of this study, however, was a lack of information regarding the technical quality of the AMI care, which might have explained at least part of the differences in outcomes. The present study was undertaken to test the influence of both PCC and technical care quality on outcomes among AMI patients. Methods We analyzed data from a national sample of 1,858 veterans hospitalized for an initial AMI in a Department of Veterans Affairs medical center during fiscal years 2003 and 2004 for whom data had been compiled on evidence-based treatment and who had also completed a Picker questionnaire assessing perceptions of PCC. Cox proportional hazards models were used to estimate the relationship between PCC and survival 1-year postdischarge, controlling for technical quality of care, patient clinical condition and history, admission process characteristics, and patient sociodemographic characteristics. We hypothesized that better PCC would be associated with a lower probability of death 1-year postdischarge, even after controlling for patient characteristics and the technical quality of care. Results Better PCC was associated with a significantly but modestly lower hazard of death over the 1-year study period (hazard ratio 0.992, 95 percent confidence interval 0.986-0.999). Conclusions Providing PCC may result in important clinical benefits, in addition to meeting patient needs and expectations. C1 [Meterko, Mark] VA Boston Healthcare Syst 152 M, HSR&D Ctr Org Leadership & Management Res, Boston, MA USA. [Meterko, Mark] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Wright, Steven] VA Off Qual & Performance, Washington, DC USA. [Lin, Hai] Women & Infants Hosp Rhode Isl, Brown Ctr Study Children Risk, Providence, RI 02908 USA. [Lowy, Elliott] VA Puget Sound Healthcare Syst, HSR&D NW Ctr Excellence, Seattle, WA USA. [Cleary, Paul D.] Yale Univ, Sch Med, Sch Publ Hlth, New Haven, CT 06520 USA. RP Cleary, PD (reprint author), Yale Univ, Sch Med, Sch Publ Hlth, 60 Coll St,LEPH 210,POB 208034, New Haven, CT 06520 USA. EM paul.cleary@yale.edu FU Picker Institute FX This research was supported by a grant from the Picker Institute. Marjorie Nealon-Seibert, M.B.A., Survey Administrator at COLMR, assisted with preparation and submission of the study for IRB review by the VA Boston Healthcare System. There are no financial or other disclosures. NR 46 TC 61 Z9 62 U1 5 U2 13 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD OCT PY 2010 VL 45 IS 5 BP 1188 EP 1204 DI 10.1111/j.1475-6773.2010.01138.x PN 1 PG 17 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 648RU UT WOS:000281712400004 PM 20662947 ER PT J AU Liu, CF Chapko, M Bryson, CL Burgess, JF Fortney, JC Perkins, M Sharp, ND Maciejewski, ML AF Liu, Chuan-Fen Chapko, Michael Bryson, Chris L. Burgess, James F., Jr. Fortney, John C. Perkins, Mark Sharp, Nancy D. Maciejewski, Matthew L. TI Use of Outpatient Care in Veterans Health Administration and Medicare among Veterans Receiving Primary Care in Community-Based and Hospital Outpatient Clinics SO HEALTH SERVICES RESEARCH LA English DT Article DE Access; demand; utilization of services; Medicare; VA health care system; cohort analysis ID PERFORMANCE-MEASURES; DUAL-USE; VA; AFFAIRS; SERVICES; QUALITY; ACCESS; COVERAGE; SYSTEM AB Objective To examine differences in use of Veterans Health Administration (VA) and Medicare outpatient services by VA primary care patients. Data Sources/Study Setting VA administrative and Medicare claims data from 2001 to 2004. Study Design Retrospective cohort study of outpatient service use by 8,964 community-based and 6,556 hospital-based VA primary care patients. Principal Findings A significant proportion of VA patients used Medicare-reimbursed primary care (> 30 percent) and specialty care (> 60 percent), but not mental health care (3-4 percent). Community-based patients had 17 percent fewer VA primary care visits (p <.001), 9 percent more Medicare-reimbursed visits (p <.001), and 6 percent fewer total visits (p <.05) than hospital-based patients. Community-based patients had 22 percent fewer VA specialty care visits (p <.0001) and 21 percent more Medicare-reimbursed specialty care visits (p <.0001) than hospital-based patients, but no difference in total visits (p=.80). Conclusions Medicare-eligible VA primary care patients followed over 4 consecutive years used significant primary care and specialty care outside of VA. Community-based patients offset decreased VA use with increased service use paid by Medicare, suggesting that increasing access to VA primary care via community clinics may fragment veteran care in unintended ways. Coordination of care between VA and non-VA providers and health care systems is essential to improve the quality and continuity of care. C1 [Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, HSR&D, Dept Vet Affairs, NW Ctr Outcomes Res Older Adults, Seattle, WA 98101 USA. [Liu, Chuan-Fen; Chapko, Michael; Sharp, Nancy D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Bryson, Chris L.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA. [Burgess, James F., Jr.] Ctr Org Leadership & Management Res, Dept Vet Affairs, Boston, MA USA. [Burgess, James F., Jr.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Fortney, John C.] S Cent Mental Hlth Illness Res & Educ & Clin Ctr, N Little Rock, AR USA. [Fortney, John C.] Cent Arkansas Vet Healthcare Syst, HSR&D Ctr Mental Healthcare & Outcomes Res, N Little Rock, AR USA. [Fortney, John C.] Univ Arkansas Med Sci, Dept Psychiat & Behav Sci, Div Hlth Serv Res, N Little Rock, AR USA. [Maciejewski, Matthew L.] Vet Adm Med Ctr, Ctr Hlth Serv Res Primary Care, Dept Vet Affairs, Durham, NC 27705 USA. [Maciejewski, Matthew L.] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27710 USA. RP Liu, CF (reprint author), VA Puget Sound Hlth Care Syst, HSR&D, Dept Vet Affairs, NW Ctr Outcomes Res Older Adults, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM chuan-fen.liu@va.gov OI Burgess, James/0000-0002-6646-7071 FU Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs [IIR 04-292] FX This work was supported by the Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs, project number IIR 04-292. Drs. Liu, Chapko, Bryson, Sharp, and Perkins are at the Northwest Center for Outcomes Research in Older Adults at the Seattle VA. Dr. Burgess is at the Center for Organization, Leadership & Management Research at the Boston VA. Dr. Fortney is at the Center for Mental Healthcare and Outcomes Research at the Little Rock VA. Dr. Maciejewski is at the Center for Health Services Research in Primary Care at the Durham VA. The authors are grateful for helpful comments from Will Manning. The views expressed herein are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs and other affiliated institutions. NR 31 TC 25 Z9 25 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD OCT PY 2010 VL 45 IS 5 BP 1268 EP 1286 DI 10.1111/j.1475-6773.2010.01123.x PN 1 PG 19 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 648RU UT WOS:000281712400008 PM 20831716 ER PT J AU Blosser, CD Ayehu, G Wu, S Lomagro, RM Malone, E Brunelli, SM Itkin, M Golden, M McCombs, P Lipschutz, JH AF Blosser, Christopher D. Ayehu, Gashu Wu, Sam Lomagro, Ruth M. Malone, Ellen Brunelli, Steven M. Itkin, Max Golden, Michael McCombs, Peter Lipschutz, Joshua H. TI High rate of fistula placement in a cohort of dialysis patients in a single payer system SO HEMODIALYSIS INTERNATIONAL LA English DT Article DE Fistula; hemodialysis; health care economics ID VEIN ARTERIOVENOUS-FISTULAS; VASCULAR ACCESS; HEMODIALYSIS-PATIENTS; OUTCOMES; TRANSPOSITION; PATENCY; IMPACT; CARE C1 [Blosser, Christopher D.; Ayehu, Gashu; Wu, Sam; Lipschutz, Joshua H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Lomagro, Ruth M.; Lipschutz, Joshua H.] Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. [Malone, Ellen; Golden, Michael; McCombs, Peter] Vet Affairs Med Ctr, Dept Surg, Vasc Surg Sect, Philadelphia, PA USA. [Brunelli, Steven M.] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA USA. [Itkin, Max] Vet Affairs Med Ctr, Dept Radiol, Intervent Radiol Sect, Philadelphia, PA USA. RP Lipschutz, JH (reprint author), 431 Hill Pavilion,380 S Univ Ave, Philadelphia, PA 19104 USA. EM jhlipsch@mail.med.upenn.edu FU National Institutes of Health [DK069909, DK070980, K23DK079056]; Satellite Healthcare FX The authors and this work were supported in part by the National Institutes of Health (DK069909 and DK070980 to J.H.L.; K23DK079056 to S.M.B.) and Satellite Healthcare (Norman S. Coplon Extramural Research Grant to J.H.L). NR 25 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1492-7535 J9 HEMODIAL INT JI Hemodial. Int. PD OCT PY 2010 VL 14 IS 4 BP 393 EP 397 DI 10.1111/j.1542-4758.2010.00479.x PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 667DY UT WOS:000283174100009 PM 20812959 ER PT J AU Cusi, K Lomonaco, R Ortiz-Lopez, C Webb, A Orsak, B Darland, CM Finch, J Kaminski-Graham, R AF Cusi, Kenneth Lomonaco, Romina Ortiz-Lopez, Carolina Webb, Amy Orsak, Beverly Darland, Celia M. Finch, Joan Kaminski-Graham, Rosemarie TI ASSESSMENT OF ETHNIC AND METABOLIC FACTORS IN THE DEVELOPMENT OF NASH IN A PREDOMINANTLY HISPANIC POPULATION: THE UNIVERSITY OF TEXAS AT SAN ANTONIO NASH TRIAL SO HEPATOLOGY LA English DT Meeting Abstract CT 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 29-NOV 02, 2010 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Cusi, Kenneth; Lomonaco, Romina; Ortiz-Lopez, Carolina; Orsak, Beverly] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Cusi, Kenneth; Lomonaco, Romina; Webb, Amy; Darland, Celia M.; Finch, Joan; Kaminski-Graham, Rosemarie] Vet Adm Med Ctr, Diabet Div, San Antonio, TX USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2010 VL 52 IS 4 SU S MA 698 BP 653A EP 654A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 740EY UT WOS:000288775601017 ER PT J AU Louvet, A Artru, F Wartel, F O'Grady, JG Carithers, RL Phillips, M Mendenhall, CL Naveau, S Canva-Delcambre, V Morgan, TR Mathurin, P AF Louvet, Alexandre Artru, Florent Wartel, Faustine O'Grady, John G. Carithers, Robert L. Phillips, Martin Mendenhall, Charles L. Naveau, Sylvie Canva-Delcambre, Valerie Morgan, Timothy R. Mathurin, Philippe TI A RESPONSE-GUIDED THERAPY FOR A BETTER MANAGEMENT OF PATIENTS SEVERE ALCOHOLIC HEPATITIS TREATED WITH CORTICOSTEROIDS SO HEPATOLOGY LA English DT Meeting Abstract CT 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 29-NOV 02, 2010 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Louvet, Alexandre; Artru, Florent; Wartel, Faustine; Canva-Delcambre, Valerie; Mathurin, Philippe] Ctr Hosp Reg & Univ Lille, Hop Huriez, F-59037 Lille, France. [O'Grady, John G.; Phillips, Martin] Kings Coll London, London WC2R 2LS, England. [Mendenhall, Charles L.] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA. [Carithers, Robert L.] Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol, Seattle, WA USA. [Naveau, Sylvie] Hop Antoine Beclere, Clamart, France. [Morgan, Timothy R.] Vet Affairs Long Beach Healthcare Syst, Gastroenterol Sect, Long Beach, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2010 VL 52 IS 4 SU S MA 1652 BP 1109A EP 1109A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 740EY UT WOS:000288775602272 ER PT J AU Chirinos, JA Segers, P AF Chirinos, Julio A. Segers, Patrick TI Noninvasive Evaluation of Left Ventricular Afterload Part 1: Pressure and Flow Measurements and Basic Principles of Wave Conduction and Reflection SO HYPERTENSION LA English DT Article DE afterload; noninvasive; input impedance; arterial load ID MIDDLE-AGED MEN; ARTERIAL STIFFNESS; AUGMENTATION INDEX; INPUT IMPEDANCE; PULSE; VELOCITY; QUANTIFICATION; AMPLIFICATION; HYPERTENSION; VALIDATION AB The mechanical load imposed by the systemic circulation to the left ventricle is an important determinant of normal and abnormal cardiovascular function. Left ventricular afterload is determined by complex time-varying phenomena, which affect pressure and flow patterns generated by the pumping ventricle and cannot be expressed as a single numeric measure or described in terms of pressure alone. Left ventricular afterload is best described in terms of pressure-flow relations. High-fidelity arterial applanation tonometry can be used to record time-resolved central pressure noninvasively, whereas contemporary noninvasive imaging techniques, such as Doppler echocardiography and phase-contrast MRI, allow for accurate assessments of aortic flow. Central pressure and flow can be analyzed using simplified biomechanical models to characterize various components of afterload, with great potential for mechanistic understanding of the role of central hemodynamics in cardiovascular disease and the effects of therapeutic interventions. In the first part of this tutorial, we review noninvasive techniques for central pressure and flow measurements and basic concepts of wave conduction and reflection as they relate to the interpretation of central pressure-flow relations. Conceptual descriptions of various models and methods are emphasized over mathematical ones. Our review is aimed at helping researchers and clinicians apply and interpret results obtained from analyses of left ventricular afterload in clinical and epidemiological settings. (Hypertension. 2010;56:555-562.) C1 [Chirinos, Julio A.] Univ Penn, Dept Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Segers, Patrick] Univ Ghent, IBiTech, B-9000 Ghent, Belgium. RP Chirinos, JA (reprint author), Room 8B-111,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM julio.chirinos@uphs.upenn.edu NR 23 TC 43 Z9 45 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD OCT PY 2010 VL 56 IS 4 BP 555 EP U30 DI 10.1161/HYPERTENSIONAHA.110.157321 PG 18 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 650VL UT WOS:000281881400001 PM 20733089 ER PT J AU Chirinos, JA Segers, P AF Chirinos, Julio A. Segers, Patrick TI Noninvasive Evaluation of Left Ventricular Afterload Part 2: Arterial Pressure-Flow and Pressure-Volume Relations in Humans SO HYPERTENSION LA English DT Article DE afterload; noninvasive; input impedance; arterial load ID HEART-FAILURE; HYPERTENSION; WINDKESSEL; LOAD AB The mechanical load imposed by the systemic circulation to the left ventricle is an important determinant of normal and abnormal cardiovascular function. Left ventricular afterload is determined by complex time-varying phenomena, which affect pressure and flow patterns generated by the pumping ventricle. Left ventricular afterload is best described in terms of pressure-flow relations, allowing for quantification of various components of load using simplified biomechanical models of the circulation, with great potential for mechanistic understanding of the role of central hemodynamics in cardiovascular disease and the effects of therapeutic interventions. In the second part of this tutorial, we review analytic methods used to characterize left ventricular afterload, including analyses of central arterial pressure-flow relations and windkessel modeling (pressure-volume relations). Conceptual descriptions of various models and methods are emphasized over mathematical ones. Our review is aimed at helping researchers and clinicians obtain and interpret results from analyses of left ventricular afterload in clinical and epidemiological settings. (Hypertension. 2010;56:563-570.) C1 [Chirinos, Julio A.] Univ Penn, Dept Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Segers, Patrick] Univ Ghent, IBiTech, B-9000 Ghent, Belgium. RP Chirinos, JA (reprint author), Room 8B-111,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM julio.chirinos@uphs.upenn.edu NR 24 TC 48 Z9 51 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD OCT PY 2010 VL 56 IS 4 BP 563 EP 570 DI 10.1161/HYPERTENSIONAHA.110.157339 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 650VL UT WOS:000281881400002 PM 20733088 ER PT J AU Chirinos, JA Townsend, R AF Chirinos, Julio A. Townsend, Raymond TI Sodium, Potassium, and Target Organ Damage A Case for Central Hemodynamics SO HYPERTENSION LA English DT Editorial Material ID ESSENTIAL-HYPERTENSION; RATS C1 [Chirinos, Julio A.; Townsend, Raymond] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Chirinos, JA (reprint author), Room 8B-111,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM julio.chirinos@uphs.upenn.edu NR 11 TC 1 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD OCT PY 2010 VL 56 IS 4 BP 578 EP 580 DI 10.1161/HYPERTENSIONAHA.110.159046 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 650VL UT WOS:000281881400006 PM 20733084 ER PT J AU Selby, JV Lee, J Swain, BE Tavel, HM Ho, PM Margolis, KL O'Connor, PJ Fine, L Schmittdiel, JA Magid, DJ AF Selby, Joe V. Lee, Janelle Swain, Bix E. Tavel, Heather M. Ho, P. Michael Margolis, Karen L. O'Connor, Patrick J. Fine, Lawrence Schmittdiel, Julie A. Magid, David. J. TI Trends in Time to Confirmation and Recognition of New-Onset Hypertension, 2002-2006 SO HYPERTENSION LA English DT Article DE hypertension; electronic health records; registries; early detection; screening ID AMBULATORY BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; RISK; MANAGEMENT; CARE; VARIABILITY; POPULATION; ADULTS; TRIAL AB Achieving full benefits of blood pressure control in populations requires prompt recognition of previously undetected hypertension. In 2003, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure provided definitions of hypertension and recommended that single elevated readings be confirmed within 1 to 2 months. We sought to determine whether the time required to confirm and recognize (ie, diagnose and/or treat) new-onset hypertension decreased from 2002 to 2006 for adult members of 2 large integrated healthcare delivery systems, Kaiser Permanente Northern California and Colorado. Using electronically stored office blood pressure readings, physician diagnoses, and pharmacy prescriptions, we identified 200 587 patients with new-onset hypertension (2002-2006) marked by 2 consecutive elevated blood pressure readings in previously undiagnosed, untreated members. Mean confirmation intervals (time from the first to second consecutive elevated reading) declined steadily from 103 to 89 days during this period. For persons recognized within 12 months after confirmation, the mean interval to recognition declined from 78 to 61 days. However, only 33% of individuals were recognized within 12 months. One third were never recognized during observed follow-up. For these patients, most subsequent blood pressure recordings were not elevated. Higher initial blood pressure levels, history of previous cardiovascular disease, and older age were associated with shorter times to recognition. Times to confirmation and recognition of new-onset hypertension have become shorter in recent years, especially for patients with higher cardiovascular disease risk. Variability in office-based blood pressure readings suggests that further improvements in recognition and treatment may be achieved with more specific automated approaches to identifying hypertension. (Hypertension. 2010;56:605-611.) C1 [Selby, Joe V.; Lee, Janelle; Swain, Bix E.; Schmittdiel, Julie A.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Tavel, Heather M.; Magid, David. J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Ho, P. Michael] Denver Vet Affairs Med Ctr, Denver, CO USA. [Ho, P. Michael] Univ Colorado, Denver, CO 80202 USA. [Margolis, Karen L.; O'Connor, Patrick J.] HealthPartners Res Fdn, Minneapolis, MN USA. [Fine, Lawrence] NHLBI, NIH, Bethesda, MD 20892 USA. RP Selby, JV (reprint author), Kaiser Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA. EM joe.selby@kp.org FU National Heart, Lung, and Blood Institute [U19HL091179]; Office of Research in Women's Health Building Interdisciplinary Careers [K12HD052163]; Veterans' Affairs Research and Development [05-026-2] FX This study was supported by the National Heart, Lung, and Blood Institute (award No. U19HL091179). J.A.S. is supported by the Office of Research in Women's Health Building Interdisciplinary Careers in Women's Health K12 Career Development Award (K12HD052163). P.M.H. is supported by a Veterans' Affairs Research and Development Career Development Award (05-026-2). NR 27 TC 21 Z9 21 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD OCT PY 2010 VL 56 IS 4 BP 605 EP 611 DI 10.1161/HYPERTENSIONAHA.110.153528 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 650VL UT WOS:000281881400011 PM 20733092 ER PT J AU Heliot, R Ganguly, K Jimenez, J Carmena, JM AF Heliot, Rodolphe Ganguly, Karunesh Jimenez, Jessica Carmena, Jose M. TI Learning in Closed-Loop Brain-Machine Interfaces: Modeling and Experimental Validation SO IEEE TRANSACTIONS ON SYSTEMS MAN AND CYBERNETICS PART B-CYBERNETICS LA English DT Article DE Brain-machine interfaces (BMIs); internal model; macaque monkey; motor learning ID DIRECT CORTICAL CONTROL; PRIMATE MOTOR CORTEX; ARM MOVEMENTS; PROSTHETIC DEVICES; INTERNAL-MODELS; TETRAPLEGIA; FEEDFORWARD; KINEMATICS; DIRECTION; NETWORKS AB Closed-loop operation of a brain-machine interface (BMI) relies on the subject's ability to learn an inverse transformation of the plant to be controlled. In this paper, we propose a model of the learning process that undergoes closed-loop BMI operation. We first explore the properties of the model and show that it is able to learn an inverse model of the controlled plant. Then, we compare the model predictions to actual experimental neural and behavioral data from nonhuman primates operating a BMI, which demonstrate high accordance of the model with the experimental data. Applying tools from control theory to this learning model will help in the design of a new generation of neural information decoders which will maximize learning speed for BMI users. C1 [Heliot, Rodolphe; Carmena, Jose M.] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Program Cognit Sci, Berkeley, CA 94720 USA. [Heliot, Rodolphe; Ganguly, Karunesh; Carmena, Jose M.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. [Ganguly, Karunesh] San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA 94121 USA. [Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Heliot, R (reprint author), Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Program Cognit Sci, Berkeley, CA 94720 USA. EM carmena@eecs.berkeley.edu FU French "Delegation generale pour l'armement' [PDE 07C0067]; American Heart Association; Graduate Assistance in Areas of National Need Fellowship; Christopher and Dana Reeve Foundation FX The work of R. Heliot was supported by the French "Delegation generale pour l'armement' under Grant PDE 07C0067. The work of K. Ganguly was supported by the American Heart Association. The work of J. Jimenez was supported by the Graduate Assistance in Areas of National Need Fellowship. The work of J. M. Carmena was supported by the Christopher and Dana Reeve Foundation. This paper was recommended by Associate Editor J. D. R. Millan. NR 42 TC 26 Z9 26 U1 1 U2 6 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1083-4419 J9 IEEE T SYST MAN CY B JI IEEE Trans. Syst. Man Cybern. Part B-Cybern. PD OCT PY 2010 VL 40 IS 5 BP 1387 EP 1397 DI 10.1109/TSMCB.2009.2036931 PG 11 WC Automation & Control Systems; Computer Science, Artificial Intelligence; Computer Science, Cybernetics SC Automation & Control Systems; Computer Science GA 668TI UT WOS:000283292800014 PM 20007050 ER PT J AU Durazzo, TC Meyerhoff, DJ Nixon, SJ AF Durazzo, Timothy C. Meyerhoff, Dieter J. Nixon, Sara Jo TI Chronic Cigarette Smoking: Implications for Neurocognition and Brain Neurobiology SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article DE chronic cigarette smoking; neurocognition; neurobiology; neuroimaging; genetics ID CEREBRAL-BLOOD-FLOW; MAGNETIC-RESONANCE SPECTROSCOPY; MIDDLE-AGED ADULTS; BODY-MASS INDEX; MILD COGNITIVE IMPAIRMENT; WHITE-MATTER LESIONS; YOUNG-WOMEN SMOKE; RISK TASK BART; NICOTINE DEPENDENCE; CARDIOVASCULAR HEALTH AB Compared to the substantial volume of research on the general health consequences associated with chronic smoking, little research has been specifically devoted to the investigation of its effects on human neurobiology and neurocognition. This review summarizes the peer-reviewed literature on the neurocognitive and neurobiological implications of chronic cigarette smoking in cohorts that were not seeking treatment for substance use or psychiatric disorders. Studies that specifically assessed the neurocognitive or neurobiological (with emphasis on computed tomography and magnetic resonance-based neuroimaging studies) consequences of chronic smoking are highlighted. Chronic cigarette smoking appears to be associated with deficiencies in executive functions, cognitive flexibility, general intellectual abilities, learning and/or memory processing speed, and working memory. Chronic smoking is related to global brain atrophy and to structural and biochemical abnormalities in anterior frontal regions, subcortical nuclei and commissural white matter. Chronic smoking may also be associated with an increased risk for various forms of neurodegenerative diseases. The existing literature is limited by inconsistent accounting for potentially confounding biomedical and psychiatric conditions, focus on cross-sectional studies with middle aged and older adults and the absence of studies concurrently assessing neurocognitive, neurobiological and genetic factors in the same cohort. Consequently, the mechanisms promoting the neurocognitive and neurobiological abnormalities reported in chronic smokers are unclear. Longitudinal studies are needed to determine if the smoking-related neurobiological and neurocognitive abnormalities increase over time and/or show recovery with sustained smoking cessation. C1 [Durazzo, Timothy C.; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Durazzo, Timothy C.; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. [Nixon, Sara Jo] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA. [Nixon, Sara Jo] Univ Florida, Dept Psychol, Gainesville, FL 32611 USA. RP Durazzo, TC (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 505 Parnassus Ave,M-391, San Francisco, CA 94143 USA. EM timothy.durazzo@ucsf.edu; dieter.meyerhoff@ucsf.edu; sjnixon@ufl.edu RI Nixon, Sara/L-1369-2014 OI Nixon, Sara/0000-0003-1179-2851 FU NIH [DA 024136, AA10788, DA 13677, U54 RR025208] FX This material is the result of work supported by NIH DA 024136 (TCD), AA10788 (DJM) and DA 13677 and U54 RR025208 (Nelson, PI; SJN, Co-Investigator) with resources and the use of facilities at the San Francisco Veterans Administration Medical Center, San Francisco, CA, USA. NR 195 TC 69 Z9 71 U1 2 U2 18 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD OCT PY 2010 VL 7 IS 10 BP 3760 EP 3791 DI 10.3390/ijerph7103760 PG 32 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 672IO UT WOS:000283576600011 PM 21139859 ER PT J AU Ford, JM Roach, BJ Miller, RM Duncan, CC Hoffman, RE Mathalon, DH AF Ford, Judith M. Roach, Brian J. Miller, Ryan M. Duncan, Connie C. Hoffman, Ralph E. Mathalon, Daniel H. TI When it's time for a change: Failures to track context in schizophrenia SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Article DE P300; Schizophrenia; Context ID CONTINGENT NEGATIVE-VARIATION; EVENT-RELATED POTENTIALS; AUDITORY EVOKED-RESPONSE; LATE POSITIVE WAVE; STIMULUS SEQUENCE; P300 AMPLITUDE; MISMATCH NEGATIVITY; BRAIN POTENTIALS; SCALP TOPOGRAPHY; CNV AB Introduction: Reduction of P300 event-related potential amplitude in schizophrenia is perhaps the most replicated biological reflection of the illness. P300 is typically elicited by infrequent deviant events that are imbedded in a series of identical frequent standard events. Deviants have features that explicitly distinguish them from standards, whereas standards can be distinguished from each other based on their local sequential probabilities within the stimulus series. The improbable occurrence of a standard should generate a P300, but only if the implicit local context generated by the recent stimulus history is processed. Method: To assess the ability of schizophrenia patients to process this implicit contextual information, ERPs were elicited from 22 controls and 16 schizophrenia patients during an auditory oddball task containing infrequent target tones (15%) and novel distracter sounds (15%) imbedded pseudo-randomly in a series of standard tones (70%). Consecutively presented standards following deviant stimuli varied in sequential probability from p = 1.0 for the 1st standard to p = 0.16 for the 4th consecutive standard. Results: Patients compared to controls demonstrated smaller P300 (P3a) to the fourth consecutive standard. However, in controls but not patients a contingent negative variation (CNV) was observed prior to the fourth standard, and an N2b/mismatch negativity (MMN) was observed following it. Conclusions: These outcomes suggest that patients are deficient in using the implicit context established by recent stimulus history to anticipate that an otherwise standard stimulus was unlikely and its occurrence unexpected. (C) 2010 Published by Elsevier B.V. C1 [Ford, Judith M.; Roach, Brian J.; Miller, Ryan M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA. [Ford, Judith M.; Roach, Brian J.; Miller, Ryan M.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Duncan, Connie C.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA. [Hoffman, Ralph E.] Yale Univ, Dept Psychiat, Sch Med, New Haven, CT 06520 USA. RP Ford, JM (reprint author), San Francisco VA Med Ctr, Psychiat Serv, 116D,4150 Clement St, San Francisco, CA 94121 USA. EM judith.ford@ucsf.edu OI Roach, Brian/0000-0002-3264-1465; Mathalon, Daniel/0000-0001-6090-4974 FU VA Schizophrenia Biological Research Center; Research Career Scientist; VA Merit Review; NIMH; NARSAD; VA Career Award FX This work was supported by the VA Schizophrenia Biological Research Center (JMF), Research Career Scientist (JMF), VA Merit Review (JMF), NIMH (JMF, DHM, REH), NARSAD (JMF, DHM, REH), VA Career Award (DHM). NR 69 TC 19 Z9 19 U1 4 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD OCT PY 2010 VL 78 IS 1 SI SI BP 3 EP 13 DI 10.1016/j.ijpsycho.2010.05.005 PG 11 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 657IR UT WOS:000282406900002 PM 20580752 ER PT J AU Estrella, MM Parekh, RS Abraham, A Astor, BC Szczech, LA Anastos, K Dehovitz, JA Merenstein, DJ Pearce, CL Tien, PC Cohen, MH Gange, SJ AF Estrella, Michelle M. Parekh, Rulan S. Abraham, Alison Astor, Brad C. Szczech, Lynda A. Anastos, Kathryn Dehovitz, Jack A. Merenstein, Daniel J. Pearce, C. Leigh Tien, Phyllis C. Cohen, Mardge H. Gange, Stephen J. TI The Impact of Kidney Function at Highly Active Antiretroviral Therapy Initiation on Mortality in HIV-Infected Women SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE kidney disease; mortality; HIV; WIHS; antiretroviral therapy ID DISEASE; DEATH; OUTCOMES; LEVEL; RATES; RISK AB Background: In the early highly active antiretroviral therapy (HAART) era, kidney dysfunction was strongly associated with death among HIV-infected individuals. We re-examined this association in the later HAART period to determine whether chronic kidney disease remains a predictor of death after HAART initiation. Methods: To evaluate the effect of kidney function at the time of HAART initiation on time to all-cause mortality, we evaluated 1415 HIV-infected women initiating HAART in the Women's Interagency HIV Study. Multivariable proportional hazards models with survival times calculated from HAART initiation to death were constructed; participants were censored at the time of the last available visit or December 31, 2006. Results: Chronic kidney disease (estimated glomerular filtration rate less than 60 mL/min/1.73 m(2)) at HAART initiation was associated with higher mortality risk adjusting for age, race, hepatitis C serostatus, AIDS history, and CD4(+) cell count (hazard ratio 2.23, 95% confidence interval: 1.45-3.43). Adjustment for hypertension and diabetes history attenuated this association (hazard ratio = 1.89, confidence interval: 0.94-3.80). Lower kidney function at HAART initiation was weakly associated with increased mortality risk in women with prior AIDS (hazard ratio = 1.09, confidence interval: 1.00-1.19, per 20% decrease in estimated glomerular filtration rate). Conclusions: Kidney function at HAART initiation remains an independent predictor of death in HIV-infected individuals, especially in those with a history of AIDS. Our study emphasizes the necessity of monitoring kidney function in this population. Additional studies are needed to determine mechanisms underlying the increased mortality risk associated with chronic kidney disease in HIV-infected persons. C1 [Estrella, Michelle M.] Johns Hopkins Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA. [Parekh, Rulan S.] Univ Toronto, Div Nephrol, Toronto, ON, Canada. [Parekh, Rulan S.; Abraham, Alison; Astor, Brad C.; Gange, Stephen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Szczech, Lynda A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Anastos, Kathryn] Montefiore Med Ctr, Dept Med, Washington, DC USA. [Dehovitz, Jack A.] SUNY Hlth Sci Ctr, Sch Publ Hlth, Dept Prevent Med & Community Hlth, Washington, DC USA. [Dehovitz, Jack A.] SUNY Hlth Sci Ctr, Sch Publ Hlth, Dept Med, Washington, DC USA. [Merenstein, Daniel J.] Georgetown Univ, Med Ctr, Dept Family Med, Washington, DC 20007 USA. [Pearce, C. Leigh] Univ So Calif, Norris Comprehens Canc Ctr, Dept Prevent Med, Keck Sch Med, San Francisco, CA USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge H.] Rush Univ, Chicago, IL 60612 USA. RP Estrella, MM (reprint author), Johns Hopkins Sch Med, Dept Med, Div Nephrol, 1830 E Monument St,Suite 416, Baltimore, MD 21205 USA. EM mestrel1@jhmi.edu OI Gange, Stephen/0000-0001-7842-512X FU [UO1-AI-35004]; [UO1-AI-31834]; [UO1-AI-34994]; [UO1-AI-34989]; [UO1-AI-34993]; [UO1-AI-42590]; [UO1-HD-32632]; [UL1 RR024131]; [1K23-DK-081317-01A1]; [5U01DK070657-03]; [1R01-DK-072367]; [R01-DK-07677001]; [R21-DK078218-01A1]; [R01-DK-080094-02] FX The WIHS is funded by UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590, UO1-HD-32632, and UL1 RR024131. Additional support came from 1K23-DK-081317-01A1 to MME, 5U01DK070657-03 and 1R01-DK-072367 to RSP, R01-DK-07677001 and R21-DK078218-01A1 to BCA, and R01-DK-080094-02 to LAS. NR 17 TC 25 Z9 27 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD OCT 1 PY 2010 VL 55 IS 2 BP 217 EP 220 DI 10.1097/QAI.0b013e3181e674f4 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 658QI UT WOS:000282504100018 PM 20581688 ER PT J AU Ghotb, A Noworolski, SM Madden, E Scherzer, R Qayyum, A Pannell, J Ferrell, L Peters, M Tien, PC AF Ghotb, Alireza Noworolski, Susan M. Madden, Erin Scherzer, Rebecca Qayyum, Aliya Pannell, Jane Ferrell, Linda Peters, Marion Tien, Phyllis C. TI Adipose Tissue and Metabolic Factors Associated With Steatosis in HIV/HCV Coinfection: Histology Versus Magnetic Resonance Spectroscopy SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE adipose tissue; HIV; HCV; insulin resistance; magnetic resonance spectroscopy; steatosis ID HEPATITIS-C-VIRUS; HIV-INFECTED PATIENTS; HCV GENOTYPE; LIVER; PREVALENCE; FIBROSIS AB Background: Hepatic steatosis is common in persons with HIV and hepatitis C virus (HCV); yet biopsy measurement of steatosis is prone to sampling error. We compared magnetic resonance spectroscopy (MRS) measurement of steatosis to histology in HIV/HCV-coinfected patients and explored the associated adipose tissue and metabolic factors. Methods: Cross-sectional analysis of 42 HIV/HCV-coinfected men and women. Logistic regression analysis identified factors (MRI-measured visceral adipose tissue and abdominal subcutaneous adipose tissue and Homeostasis Model Assessment-estimated insulin resistance) associated with histologic steatosis (>= 5% of hepatocytes with fat) and MRS steatosis (>= 5% of hepatic fat). Results: MRS steatosis was strongly associated with histologic steatosis, when measured continuously (odds ratio: 10.2 per doubling of MRS-measured hepatic fat; 95% confidence interval: 2.9 to 69.3) and dichotomously (Kappa coefficient = 0.52; P = 0.0007). Four of the 10 with MRS-measured steatosis did not have histologic steatosis; 3 of 9 with histologic steatosis did not have MRS-measured steatosis (67% sensitivity; 88% specificity). Associations of visceral adipose tissue and abdominal subcutaneous adipose tissue were associated with both histologic and MRS-measured steatosis. Insulin resistance was also associated with both. Conclusions: When compared with histology, MRS was similarly associated with adipose tissue and metabolic factors. MRS is a useful noninvasive alternative to biopsy in HIV/HCV coinfection. C1 [Tien, Phyllis C.] Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, San Francisco, CA 94121 USA. [Scherzer, Rebecca; Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ghotb, Alireza] Calif Pacific Med Ctr, Dept Med, San Francisco, CA USA. [Noworolski, Susan M.; Qayyum, Aliya] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94121 USA. [Madden, Erin] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94121 USA. [Pannell, Jane] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94121 USA. [Ferrell, Linda] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94121 USA. RP Tien, PC (reprint author), Univ Calif San Francisco, VAMC, Infect Dis Sect, Dept Med, 111W,4150 Clement St, San Francisco, CA 94121 USA. EM ptien@ucsf.edu FU UCSF Hellman Early Career Faculty Award; National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources [UL1 RR024131]; [K23 AI-66943]; [P01 HD-40543]; [UO1 AI-34989]; [M01 RR-00083] FX Supported in part by grants K23 AI-66943, P01 HD-40543, UO1 AI-34989, M01 RR-00083, and the UCSF Hellman Early Career Faculty Award.; The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the National Institute of Child Health and Human Development (UO1-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). NR 15 TC 7 Z9 7 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD OCT 1 PY 2010 VL 55 IS 2 BP 228 EP 231 DI 10.1097/QAI.0b013e3181e1d963 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 658QI UT WOS:000282504100021 PM 20512045 ER PT J AU Goodrich, DE Lai, ZS Lasky, E Burghardt, AR Kilbourne, AM AF Goodrich, David E. Lai, Zongshan Lasky, Elaine Burghardt, Amy R. Kilbourne, Amy M. TI Access to weight loss counseling services among patients with bipolar disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Bipolar disorder; Weight loss; Physical activity; Nutritional counseling; Atypical; Antipsychotics; Service access ID CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; UNITED-STATES; SCHIZOPHRENIA; HEALTH; RISK; COMORBIDITY; OBESITY; CARE; INDIVIDUALS AB Background: Cardiovascular disease is the leading cause of mortality in persons with bipolar disorder but little is known about utilization of services for risk reduction. We assessed determinants of access to weight counseling in a sample of patients with bipolar disorder. Methods: Patients enrolled in the Continuous Improvement for Veterans in Care: Mood Disorders (CIVIC-MD), a prospective study conducted from July 2004-July 2006. Patient data were obtained from a baseline questionnaire and chart review. Results: Out of 298 patients, 73% received some weight counseling, with utilization more likely for those with higher BMI (OR = 1.12, p<0.001) or prescribed a second generation antipsychotic (SGA) (OR = 1.80, p = 0.05). About 41% received 2 >= dietary consultations with consults more likely for those reporting illicit substance use (OR = 1.9, p<0.05) or SGA treatment (OR = 2.4, p<0.05). In approximately 25% of patients, increased BMI (OR = 1.06, p = 0.04) and SGA treatment (OR = 2.13, p = 0.04) were associated with greater likelihood of receiving >= 2 exercise consultations. Zero-inflated Poisson regression found SGA treatment was associated with more diet consultations (beta = 35, p<0.05) while SGA treatment (beta = 29, p<0.05) and women (beta = 76, p<0.001) were associated with more exercise consultations. Illicit substance use (beta = -0.36, p<0.05), binge drinking (beta = 32, p<0.05) and other ethnicity (beta = -0.57, p<0.05) were associated with fewer exercise consults. Limitations: Single-site study and limited chart detail. Conclusion: The majority of patients received some weight counseling, with obesity and SGA predicting service use over time. However, low utilization patterns underscore the need for research into determinants of long-term counseling utilization to improve patient health outcomes. Published by Elsevier B.V. C1 [Goodrich, David E.; Kilbourne, Amy M.] VA Ann Arbor Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA. [Lasky, Elaine] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Lai, Zongshan; Burghardt, Amy R.; Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Kilbourne, AM (reprint author), VA Ann Arbor HSR&D 11H,2215 Fuller Rd, Ann Arbor, MI 48105 USA. EM amykilbo@umich.edu OI Goodrich, David/0000-0003-3232-2189 FU Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service [IIR 02-283-2, 02-283]; National Institutes of Health [R34 MH74509] FX This research was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (IIR 02-283-2; A. Kilbourne, PI) and the National Institutes of Health (R34 MH74509; A. Kilbourne, PI). The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.; This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (02-283) and the National Institute of Mental Health (MH 74509). NR 26 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD OCT PY 2010 VL 126 IS 1-2 BP 75 EP 79 DI 10.1016/j.jad.2010.02.138 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 658KD UT WOS:000282488000009 PM 20381155 ER PT J AU Black, HL Priolo, C Akinyemi, D Gonzalez, R Jackson, DS Garcia, L George, M Apter, AJ AF Black, Heather L. Priolo, Chantel Akinyemi, D'Jahna Gonzalez, Rodalyn Jackson, Danielle S. Garcia, Laura George, Maureen Apter, Andrea J. TI Clearing Clinical Barriers: Enhancing Social Support Using a Patient Navigator for Asthma Care SO JOURNAL OF ASTHMA LA English DT Article DE Asthma; barriers; communication; control; patient navigator; self-management ID DISPARITIES; ADULTS; INTERVENTION; MANAGEMENT; ADHERENCE; NUMERACY; OUTCOMES; QUALITY; SYSTEM; WOMEN AB Background. Patients with moderate or severe asthma, particularly those who are minority or poor, often encounter significant personal, clinical practice, and health system barriers to accessing care. Objective. To explore the ideas of patients and providers for potentially feasible, individualized, cost-effective ways to reduce obstacles to care by providing social support using a patient advocate or navigator. Methods. The authors conducted four focus groups of adults with moderate or severe asthma. Participants were recruited from clinics serving low-income and minority urban neighborhoods. Data from these patient focus groups were shared with two additional focus groups, one of nurses and one of physicians. Researchers independently coded and agreed upon themes from all focus groups, which were categorized by types of social support: instrumental (physical aid), informational (educational), emotional (empathizing), validation (comparisons to others). Results. Patients and providers agreed that a patient navigator could help patients manage asthma by giving social support. Both groups found instrumental and informational support most important. However, patients desired more instrumental help whereas providers focused on informational support. Physicians stressed review of medical information whereas patients wanted information to complete administrative tasks. Providers and patients agreed that the patient navigator's role in asthma would need to address both short-term care of exacerbations and enhance long-term chronic self-management by working with practice personnel. Conclusions. Along with medical information, there is a need for providers to connect patients to instrumental support relevant to acute and long-term asthma-self-management. C1 [Black, Heather L.; Priolo, Chantel; Akinyemi, D'Jahna; Gonzalez, Rodalyn; Jackson, Danielle S.; Garcia, Laura; Apter, Andrea J.] Univ Penn, Div Pulm Allergy & Crit Care Med, Sect Allergy & Immunol, Philadelphia, PA 19104 USA. [George, Maureen] Univ Penn, Sch Nursing, Family & Community Hlth Div, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. RP Apter, AJ (reprint author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA. EM apter@mail.med.upenn.edu FU [HL073932]; [HL088469]; [HL099612]; [K23AT003907] FX This work is support by grants HL073932, HL088469, and HL099612 (A. Apter); HL073932, HL099612 (C. Priolo, L. Garcia, R. Gonzalez, D. Jackson); and K23AT003907 (M. George). NR 33 TC 11 Z9 12 U1 0 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0277-0903 J9 J ASTHMA JI J. Asthma PD OCT PY 2010 VL 47 IS 8 BP 913 EP 919 DI 10.3109/02770903.2010.506681 PG 7 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 658VB UT WOS:000282516400012 PM 20846085 ER PT J AU Takahashi, TA Maciejewski, ML Bradley, K AF Takahashi, Traci A. Maciejewski, Matthew L. Bradley, Katharine TI US Hospitalizations and Costs for Illicit Drug Users with Soft Tissue Infections SO JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; SAN-FRANCISCO; INJECTION; CARE; EMERGENCY; ABSCESSES; ABUSE; SKIN; ACCIDENT AB Skin and soft tissue infections (SSTIs) are common complications of illicit drug use. Studies at single, urban hospitals demonstrate high rates of emergency department visits and hospitalizations for these infections. This study sought to estimate nationwide and regional incidence and costs of hospitalizations for illicit drug users with SSTIs in the US. AHRQ's Nationwide Inpatient Sample was used to conduct a retrospective cross-sectional, time-series study. Hospitalizations of illicit drug users with SSTIs were identified using International Classification of Diseases, 9th Revision Clinical Modification codes. An estimated 106,126 hospitalizations for illicit drug users with SSTIs represented 0.07% of all US non-Federal hospitalizations from 1998 to 2001 and cost over 193 million dollars in 2001. Higher rates of hospitalization were found in the West, Northeast, and urban teaching hospitals. Hospitalization rates for illicit drug users with SSTIs vary significantly according to US region. Resources to reduce the incidence and severity of these infections should be targeted accordingly. C1 [Takahashi, Traci A.; Bradley, Katharine] VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA 98108 USA. [Maciejewski, Matthew L.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Bradley, Katharine] Univ Washington, Sch Med, Seattle, WA USA. RP Takahashi, TA (reprint author), VA Puget Sound Hlth Care Syst, HSR&D, 1660 S ColumbianWay,S-111 PCC, Seattle, WA 98108 USA. EM traci@u.washington.edu; matthew.maciejewski@va.gov; katharine.bradley@va.gov FU NIDA NIH HHS [R03DA14518] NR 27 TC 9 Z9 9 U1 2 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1094-3412 J9 J BEHAV HEALTH SER R JI J. Behav. Health Serv. Res. PD OCT PY 2010 VL 37 IS 4 BP 508 EP 518 DI 10.1007/s11414-009-9177-z PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 652YA UT WOS:000282047300008 PM 19381818 ER PT J AU Matlock, DD Nowels, CT Bekelman, DB AF Matlock, Dan D. Nowels, Carolyn T. Bekelman, David B. TI Patient Perspectives on Decision Making in Heart Failure SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Heart failure; patient-centered care; decision making; qualitative ID CARE; DEPRESSION; LIFE; PARTICIPATION; INVOLVEMENT; PREFERENCES; QUALITY AB Background: Patients with heart failure (HF) face an array of challenging decisions involving medications, devices, and transplants. The goal of this qualitative study was to describe patients' perceptions surrounding difficult decisions along with factors that influenced their decisions. Methods and Results: We studied 22 patients with symptomatic HF from the University of Colorado Hospital using in-depth, semistructured interviews. We used descriptive theme analysis in an iterative process to analyze responses to the question: "Can you tell me about any important or difficult decisions you have had to make about your heart condition?" Two distinct decision-making styles emerged: active (55%) and passive (45%). Active decision makers identified interventions such as implantable cardioverter-defibrillators, medications, and transplants to be the most difficult decisions and weighed concerns for side effects, family, and quality of life. Passive decision makers generally did not identify a difficult decision and described factors such as trust in God, trust in the physician, and power of the physician as reasons for their passivity. Conclusions: Patients with HF use active and passive decision styles in their approach to medical decision making. Future work should investigate communication techniques to assure that passive decision makers receive health care that is concordant with their values. (J Cardiac Fail 2010;16:823-826) C1 [Matlock, Dan D.; Nowels, Carolyn T.; Bekelman, David B.] Univ Colorado Denver, Div Gen Internal Med, Acad Off 1, Sch Med, Aurora, CO 80045 USA. [Matlock, Dan D.; Bekelman, David B.] Colorado Cardiovasc Outcomes Res Grp, Denver, CO USA. [Bekelman, David B.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Matlock, DD (reprint author), Univ Colorado Denver, Div Gen Internal Med, Acad Off 1, Sch Med, 12631 E 17th Ave,Campus Box B-180, Aurora, CO 80045 USA. EM daniel.matlock@ucdenver.edu FU University of Colorado Denver (UCD) Hartford/Jahnigen Center for Excellence in Geriatric Medicine; UCD FX This research was conducted while Dan Matlock, MD, was a Hartford Geriatrics Health Outcomes Scholar. This research was funded by the University of Colorado Denver (UCD) Hartford/Jahnigen Center for Excellence in Geriatric Medicine and the UCD Mordecai Palliative Care Grants Fund. NR 19 TC 11 Z9 11 U1 3 U2 6 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD OCT PY 2010 VL 16 IS 10 BP 823 EP 826 DI 10.1016/j.cardfail.2010.06.003 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 664XO UT WOS:000282997500004 PM 20932464 ER PT J AU Wijelath, E Namekata, M Murray, J Furuyashiki, M Zhang, SY Coan, D Wakao, M Harris, RB Suda, Y Wang, LC Sobel, M AF Wijelath, Errol Namekata, Mayumi Murray, Jacqueline Furuyashiki, Mai Zhang, Siyuan Coan, Daniel Wakao, Masahiro Harris, Robert B. Suda, Yasuo Wang, Lianchun Sobel, Michael TI Multiple Mechanisms for Exogenous Heparin Modulation of Vascular Endothelial Growth Factor Activity SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE VEGF-A; VEGFR2; HEPARIN; ENDOTHELIAL CELL; Ndst ID VEGF RECEPTOR; EXTRACELLULAR DOMAIN; BIOLOGICAL-ACTIVITY; BINDING PEPTIDE; SUGAR CHIPS; SULFATE; CELLS; ANGIOGENESIS; NEUROPILIN-1; MIGRATION AB Heparin and heparin-like molecules are known to modulate the cellular responses to vascular endothelial growth factor-A (VEGF-A). In this study, we investigated the likely mechanisms for heparin's influence on the biological activity of VEGF-A. Previous studies have shown that exogenous heparin's effects on the biological activity of VEGF-A are many and varied, in part due to the endogenous cell-surface heparan sulfates. To circumvent this problem, we used mutant endothelial cells lacking cell-surface heparan sulfates. We showed that VEGF-induced cellular responses are dependent in part on the presence of the heparan sulfates, and that exogenous heparin significantly augments VEGF's cellular effects especially when endogenous heparan sulfates are absent. Exogenous heparin was also found to play a cross-bridging role between VEGF-A165 and putative heparin-binding sites within its cognate receptor, VEGFR2 when they were examined in isolation. The cross-bridging appears to be more dependent on molecular weight than on a specific heparin structure. This was confirmed by surface plasmon resonance binding studies using sugar chips immobilized with defined oligosaccharide structures, which showed that VEGF-A165 binds to a relatively broad range of sulfated glycosaminoglycan structures. Finally, studies of the far-UV circular dichroism spectra of VEGF-A165 showed that heparin can also modulate the conformation and secondary structure of the protein. J. Cell. Biochem. 111: 461-468, 2010. (C) 2010 Wiley-Liss, Inc. C1 [Wijelath, Errol; Namekata, Mayumi; Murray, Jacqueline; Coan, Daniel; Sobel, Michael] VA Puget Sound Hlth Care Syst, Dept Surg, Div Vasc Surg, Seattle, WA 98108 USA. [Wijelath, Errol; Namekata, Mayumi; Murray, Jacqueline; Coan, Daniel; Sobel, Michael] Univ Washington, Sch Med, Seattle, WA USA. [Furuyashiki, Mai; Suda, Yasuo] SUDx Biotec Corp, Kobe, Hyogo, Japan. [Zhang, Siyuan; Wang, Lianchun] Univ Georgia, Complex Carbohydrate Res Ctr, Dept Biochem & Mol Biol, Athens, GA 30602 USA. [Wakao, Masahiro; Suda, Yasuo] Kagoshima Univ, Dept Nanostruct & Adv Mat, Grad Sch Sci & Engn, Kagoshima 890, Japan. [Harris, Robert B.] Commonwealth Biotechnol Inc, Richmond, VA USA. RP Wijelath, E (reprint author), VA Puget Sound Hlth Care Syst, Dept Surg, Div Vasc Surg, S151,1660 S Columbian Way, Seattle, WA 98108 USA. EM errolw@u.washington.edu FU NIH [RO1HL097182, P41RR005351]; Japan Science and Technology Agency FX Grant sponsor: NIH; Grant numbers: RO1HL097182, P41RR005351; Grant sponsor: Japan Science and Technology Agency. NR 34 TC 12 Z9 13 U1 1 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD OCT 1 PY 2010 VL 111 IS 2 BP 461 EP 468 DI 10.1002/jcb.22727 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 658HZ UT WOS:000282482400022 PM 20524207 ER PT J AU Dey, N Ghosh-Choudhury, N Das, F Li, XN Venkatesan, B Barnes, JL Kasinath, BS Choudhury, GG AF Dey, Nirmalya Ghosh-Choudhury, Nandini Das, Falguni Li, Xiaonan Venkatesan, Balachandar Barnes, Jeffrey L. Kasinath, Balakuntalam S. Choudhury, Goutam Ghosh TI PRAS40 Acts as a Nodal Regulator of High Glucose-Induced TORC1 Activation in Glomerular Mesangial Cell Hypertrophy SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID RICH AKT-SUBSTRATE; MESSENGER-RNA TRANSLATION; GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR PTEN; INDUCED DNA-SYNTHESIS; 40 KDA PRAS40; DIABETIC-NEPHROPATHY; MAMMALIAN TARGET; RENAL HYPERTROPHY; PHOSPHATIDYLINOSITOL 3-KINASE AB Diabetic nephropathy manifests aberrant activation of TORC1, which senses key signals to modulate protein synthesis and renal hypertrophy. PRAS40 has recently been identified as a raptor-interacting protein and is a component and a constitutive inhibitor of TORC1. The mechanism by which high glucose stimulates TORC1 activity is not known. PRAS40 was identified in the mesangial cells in renal glomeruli and in tubulointerstitium of rat kidney. Streptozotocin-induced diabetic renal hypertrophy was associated with phosphorylation of PRAS40 in the cortex and glomeruli. In vitro, high glucose concentration increased PRAS40 phosphorylation in a PI 3 kinase- and Akt-dependent manner, resulting in dissociation of raptor PRAS40 complex in mesangial cells. High glucose augmented the inactivating and activating phosphorylation of 4EBP-I and S6 kinase, respectively, with concomitant induction of protein synthesis and hypertrophy. Expression of TORC1-nonphosphorylatable mutant of 4EBP-I and dominant-negative S6 kinase significantly inhibited high glucose-induced protein synthesis and hypertrophy. PRAS40 knockdown mimicked the effect of high glucose on phosphorylation of 4EBP-I and S6 kinase, protein synthesis, and hypertrophy. To elucidate the role of PRAS40 phosphorylation, we used phosphorylation-deficient mutant of PRAS40, which in contrast to PRAS40 knockdown inhibited phosphorylation of 4EBP-I and S6 kinase, leading to reduced mesangial cell hypertrophy. Thus, our data identify high glucose-induced phosphorylation and inactivation of PRAS40 as a central node for mesangial cell hypertrophy in diabetic nephropathy. J. Cell. Physiol. 225: 27-41, 2010. (C) 2010 Wiley-Liss, Inc. C1 [Dey, Nirmalya; Das, Falguni; Li, Xiaonan; Venkatesan, Balachandar; Barnes, Jeffrey L.; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Barnes, Jeffrey L.; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, VA Res, San Antonio, TX USA. [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU NIH [ROI DK50190, ROI AR52425]; Juvenile Diabetes Research Foundation [1-2008-185]; Department of Veterans Affairs; VA Merit Review; VA Research Service; VA Research Service Merit Review FX The authors thank Dr. L. Mahimainathan for his help in animal experiments. The authors wish to acknowledge the University of Texas Health Science Center FACS Core Facility for FACS analysis provided in this article. This work was supported by NIH ROI DK50190, The Juvenile Diabetes Research Foundation 1-2008-185, and VA Research Service Merit Review grants to G.G.C., who is a recipient of Senior Research Career Scientist Award from the Department of Veterans Affairs. N.G.C. is supported by NIH ROI AR52425 and VA Merit Review grants. B.S.K. is supported by grants from NIH, VA Research Service. NR 87 TC 26 Z9 26 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD OCT PY 2010 VL 225 IS 1 BP 27 EP 41 DI 10.1002/jcp.22186 PG 15 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 643KK UT WOS:000281295100005 PM 20629086 ER PT J AU Brooks, AC Comer, SD Sullivan, MA Bisaga, A Carpenter, KM Raby, WM Yu, E O'Brien, CP Nunes, EV AF Brooks, Adam C. Comer, Sandra D. Sullivan, Maria A. Bisaga, Adam Carpenter, Kenneth M. Raby, Wilfrid M. Yu, Elmer O'Brien, Charles P. Nunes, Edward V. TI Long-Acting Injectable Versus Oral Naltrexone Maintenance Therapy With Psychosocial Intervention for Heroin Dependence: A Quasi-Experiment SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID OPIOID DEPENDENCE; CONTINGENCY MANAGEMENT; EFFICACY; IMPLANTS; GUIDE AB Objective: To conduct a quasi-experimental comparison of early clinical outcomes between injectable, sustained-release, depot naltrexone formulation versus oral naltrexone maintenance therapy in individuals with opiate dependence. Method: Early retention in treatment and urine-confirmed opiate use in the first 8 weeks postdetoxification were compared between patients (diagnosed as opiate-dependent according to DSM-IV criteria) participating in 2 concurrently run randomized clinical trials of oral (n = 69; patients treated from September 1999 to May 2002) and long-acting injectable (n = 42; patients treated from November 2000 to June 2003) naltrexone maintenance therapy with psychosocial therapy. Results: Long-acting injectable naltrexone produced significantly better outcome than oral naltrexone on days retained in treatment (F(1,106) = 6.49, P = .012) and for 1 measure of opiate use (F(1,106) = 5.26, P = .024); other measures were not significantly different, but differences were in the same direction. In subanalyses, there were interaction effects between baseline heroin use severity and type of treatment. In subanalyses, heroin users with more severe baseline use showed better retention with oral naltrexone maintenance therapy combined with intensive psychotherapy (behavioral naltrexone therapy) as compared to retention shown by severe heroin users treated with long-acting naltrexone injections combined with standard cognitive-behavioral therapy (chi(2)(1) = 9.31, P = .002); less severe heroin users evidenced better outcomes when treated with long-acting injectable naltrexone. Conclusions: This quasi-experimental analysis provides tentative indications of superior outcomes for heroin-dependent patients treated with long-acting injectable naltrexone compared to oral naltrexone. The finding that heroin users with more severe baseline use achieved better outcomes with oral naltrexone is most probably attributable to the intensive nature of the psychosocial treatments provided and points to the opportunity for continued research in augmenting injectable naltrexone with psychosocial strategies to further improve outcome, especially in individuals with more severe use. The results should be considered exploratory given the quasi-experimental nature of the study. J Clin Psychiatry 2010;71(10): 1371-1378 (C) Copyright 2010 Physicians Postgraduate Press, Inc, C1 [Brooks, Adam C.] Treatment Res Inst, Philadelphia, PA 19106 USA. [Brooks, Adam C.; Comer, Sandra D.; Sullivan, Maria A.; Bisaga, Adam; Carpenter, Kenneth M.; Raby, Wilfrid M.; Nunes, Edward V.] New York State Psychiat Inst & Hosp, Div Subst Abuse, New York, NY 10032 USA. [Comer, Sandra D.; Sullivan, Maria A.; Bisaga, Adam; Carpenter, Kenneth M.; Raby, Wilfrid M.; Nunes, Edward V.] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Yu, Elmer; O'Brien, Charles P.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Yu, Elmer; O'Brien, Charles P.] Philadelphia Vet Affairs Med Ctr, Dept Behav Hlth, Philadelphia, PA USA. RP Brooks, AC (reprint author), Treatment Res Inst, 600 Publ Ledger Bldg,150 S Independence Mall W, Philadelphia, PA 19106 USA. EM abrooks@tresearch.org FU Schering-Plough; Grunenthal GmbH; Reckitt Benckiser; Johnson Johnson; Alkermes; National Institute on Drug Abuse; [P50 DA09236]; [P60 DA05186]; [R01 DA10746]; [K02 DA00288] FX Dr Corner has been a consultant to Purdue Pharma, Alpharma, King, Inflexxion, Shire, BioDelivery Services, and Analgesics Research; has received grant/research support from Schering-Plough, Grunenthal GmbH, Reckitt Benckiser, and Johnson & Johnson; has received honoraria from the Rehabilitation Institute of Chicago, Yale University, Wake Forest University, and the University of Michigan at Ann Arbor; and has served on the speakers or advisory boards of Alpharma and King. Dr Bisaga has received a grant from Alkermes to conduct a study of depot naltrexone in a clinical trial; Alkermes is providing the medication. Dr O'Brien has an ongoing intermittent consulting relationship with Alkermes. Dr Nunes served on the board of Alkermes/Cephalon until he resigned from that position in November of 2007. Alkermes/Cephalon makes a comparable product to Depotrex, the product used in this study. Drs Brooks, Sullivan, Carpenter, Baby, and Yu have no conflicts to disclose that could affect the reporting of this study.; The authors gratefully acknowledge the support of the National Institute on Drug Abuse. Support for original data collection was drawn from center grants P50 DA09236 and P60 DA05186, as well as R01 DA10746 and K02 DA00288 (Dr Nunes). NR 23 TC 11 Z9 11 U1 1 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2010 VL 71 IS 10 BP 1371 EP 1378 DI 10.4088/JCP.09m05080ecr PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 696LY UT WOS:000285444100014 PM 20673549 ER PT J AU Long, JA Field, S Armstrong, K Chang, VW Metlay, JP AF Long, Judith A. Field, Sam Armstrong, Katrina Chang, Virginia W. Metlay, Joshua P. TI Social Capital and Glucose Control SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Diabetes; Veterans; African Americans; Residence characteristics ID CARDIOVASCULAR-DISEASE; RACIAL-DIFFERENCES; DIABETES-MELLITUS; GLYCEMIC CONTROL; HEALTH; MORTALITY; DISPARITIES; POPULATION; COMMUNITIES; POVERTY AB There is a growing diabetes epidemic in the United States and if we are to halt its progress we need to better understand the social determinants of this disease and its control. Social capital, which has been associated with general health and mortality, may be one important mediator of glucose control. In this study we determine if neighborhood social capital is associated with glucose control, independent of individual factors. We performed a cross-sectional study of Black veterans with diabetes living in Philadelphia. We merged individual-level data from surveys and charts with six area-level social capital descriptors. Holding all other variables constant, patients who lived in neighborhoods that scored near the 5th percentile of working together to improve the neighborhood were estimated to have glycosylated hemoglobin (HbA1c) values that were at least one point above a conservative clinical definition of "diabetes control" (HbA1c a parts per thousand currency sign 8%). If these same patients were to live in neighborhoods in the 95th percentile, their expected HbA1c would be over A1/2 a point below the cut-off value 8%. No other measure of social capital was associated with HbA1c. In this study of black veterans with diabetes we observed that living in neighborhoods where people work together is associated with better glucose control. C1 [Long, Judith A.; Chang, Virginia W.; Metlay, Joshua P.] Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, Philadelphia, PA 19104 USA. [Long, Judith A.; Armstrong, Katrina; Chang, Virginia W.; Metlay, Joshua P.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Long, Judith A.; Armstrong, Katrina; Chang, Virginia W.; Metlay, Joshua P.] Univ Penn, Dept Med, Sch Med, Philadelphia, PA 19104 USA. [Long, Judith A.] Univ Penn, Sch Med, Metab & Diabet Endocrinol Res Ctr, Philadelphia, PA 19104 USA. [Field, Sam] Univ N Carolina, FPG Child Dev Inst, Chapel Hill, NC USA. [Metlay, Joshua P.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Long, JA (reprint author), Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, 1201 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jalong@mail.med.upenn.edu NR 41 TC 8 Z9 8 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 J9 J COMMUN HEALTH JI J. Community Health PD OCT PY 2010 VL 35 IS 5 BP 519 EP 526 DI 10.1007/s10900-010-9222-0 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 661DK UT WOS:000282703000010 PM 20143139 ER PT J AU Onishi, Y Hayashi, T Sato, KK Ogihara, T Kuzuya, N Anai, M Tsukuda, K Boyko, EJ Fujimoto, WY Kikuchi, M AF Onishi, Yukiko Hayashi, Tomoshige Sato, Kyoko Kogawa Ogihara, Takehide Kuzuya, Nobuaki Anai, Motonobu Tsukuda, Katsunori Boyko, Edward J. Fujimoto, Wilfred Y. Kikuchi, Masatoshi TI Fasting tests of insulin secretion and sensitivity predict future prediabetes in Japanese with normal glucose tolerance SO JOURNAL OF DIABETES INVESTIGATION LA English DT Article DE Glucose intolerance; Insulin resistance; Epidemiology ID BETA-CELL FUNCTION; VISCERAL ADIPOSITY; DIABETES-MELLITUS; PLASMA-GLUCOSE; RISK-FACTOR; PROGRESSION; PREVALENCE; PROJECTIONS; POPULATION; AMERICANS AB Aims/Introduction: Reduced insulin sensitivity and secretion are important in the pathogenesis of type 2 diabetes. Their relationships to prediabetes, impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have been previously studied with the oral glucose tolerance test (OGTT). We investigated whether or not baseline measures of insulin secretion and sensitivity obtained from fasting blood specimens were related to the development of prediabetes and how these measures compared with those based on the OGTT. Materials and Methods: In 152 Japanese subjects with normal glucose tolerance, we measured baseline plasma glucose and insulin after an overnight fast and during a 75 g OGTT, insulin resistance index (homeostasis model assessment [HOMA-IR]), and insulin secretion (insulinogenic index [30 min insulin - fasting insulin] divided by [30 min glucose - fasting glucose] or HOMA-beta). Results: At a 5-6 year (mean 5.7 years) follow-up examination, we confirmed 36 cases of prediabetes. After adjusting for age, sex, family history of diabetes, body mass index, and 2-h plasma glucose, the odds ratio comparing the lowest tertile (<= 0.82) of insulinogenic index with the highest tertile (>= 1.43) was 6.98 (95% confidence interval, 1.96-24.85) and was 10.72 (2.08-55.3) comparing the lowest tertile (<= 76.3) of HOMA-beta with the highest tertile (>= 122.1), whereas the respective odds ratios of HOMA-IR were 3.74 (1.03-13.57) and 10.89 (1.93-61.41) comparing the highest tertile (>= 1.95) with the lowest tertile (<= 1.25). Conclusions: Lower insulin secretion and sensitivity are independent risk factors for prediabetes. Clinically practical identification of those at risk for prediabetes is obtainable from HOMA-beta and HOMA-IR, both of which are measured in fasting state. (J Diabetes Invest, doi: 10.1111.j.2040-1124.2010.00041.x, 2010) C1 [Onishi, Yukiko; Tsukuda, Katsunori; Kikuchi, Masatoshi] Asahi Life Fdn, Inst Adult Dis, Dept Diabet & Metab, Tokyo, Japan. [Anai, Motonobu] Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo, Japan. [Hayashi, Tomoshige; Sato, Kyoko Kogawa] Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Osaka 558, Japan. [Ogihara, Takehide] Hitachi Gen Hosp, Div Internal Med, Ibaraki, Japan. [Kuzuya, Nobuaki] Yokohama Sakae Kyosai Hosp, Dept Endocrinol & Metab, Yokohama, Kanagawa, Japan. [Hayashi, Tomoshige; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Hayashi, Tomoshige; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res Informat Ctr, Seattle, WA USA. [Boyko, Edward J.; Fujimoto, Wilfred Y.] Univ Washington, Dept Med, Seattle, WA USA. RP Onishi, Y (reprint author), Asahi Life Fdn, Inst Adult Dis, Dept Diabet & Metab, Tokyo, Japan. EM y-ohnishi@asahi-life.or.jp RI Hayashi, Tomoshige/N-8508-2015 OI Boyko, Edward/0000-0002-3695-192X NR 22 TC 5 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 2040-1116 J9 J DIABETES INVEST JI J. Diabetes Investig. PD OCT PY 2010 VL 1 IS 5 BP 191 EP 195 DI 10.1111/j.2040-1124.2010.00041.x PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 755DN UT WOS:000289907000006 PM 24843431 ER PT J AU Bilimoria, KY Cohen, ME Merkow, RP Wang, X Bentrem, DJ Ingraham, AM Richards, K Hall, BL Ko, CY AF Bilimoria, Karl Y. Cohen, Mark E. Merkow, Ryan P. Wang, Xue Bentrem, David J. Ingraham, Angela M. Richards, Karen Hall, Bruce L. Ko, Clifford Y. TI Comparison of Outlier Identification Methods in Hospital Surgical Quality Improvement Programs SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article DE Surgery; Hospital; Quality; Morbidity; Mortality; Morbidity; Complications; Deaths; National surgery quality improvement program; Outlier ID RISK-ADJUSTMENT; PATIENT SAFETY; HEALTH-CARE; OF-CARE; SURGERY; PERFORMANCE AB Surgeons and hospitals are being increasingly assessed by third parties regarding surgical quality and outcomes, and much of this information is reported publicly. Our objective was to compare various methods used to classify hospitals as outliers in established surgical quality assessment programs by applying each approach to a single data set. Using American College of Surgeons National Surgical Quality Improvement Program data (7/2008-6/2009), hospital risk-adjusted 30-day morbidity and mortality were assessed for general surgery at 231 hospitals (cases = 217,630) and for colorectal surgery at 109 hospitals (cases = 17,251). The number of outliers (poor performers) identified using different methods and criteria were compared. The overall morbidity was 10.3% for general surgery and 25.3% for colorectal surgery. The mortality was 1.6% for general surgery and 4.0% for colorectal surgery. Programs used different methods (logistic regression, hierarchical modeling, partitioning) and criteria (P < 0.01, P < 0.05, P < 0.10) to identify outliers. Depending on outlier identification methods and criteria employed, when each approach was applied to this single dataset, the number of outliers ranged from 7 to 57 hospitals for general surgery morbidity, 1 to 57 hospitals for general surgery mortality, 4 to 27 hospitals for colorectal morbidity, and 0 to 27 hospitals for colorectal mortality. There was considerable variation in the number of outliers identified using different detection approaches. Quality programs seem to be utilizing outlier identification methods contrary to what might be expected, thus they should justify their methodology based on the intent of the program (i.e., quality improvement vs. reimbursement). Surgeons and hospitals should be aware of variability in methods used to assess their performance as these outlier designations will likely have referral and reimbursement consequences. C1 [Bilimoria, Karl Y.; Cohen, Mark E.; Merkow, Ryan P.; Wang, Xue; Ingraham, Angela M.; Richards, Karen] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Bilimoria, Karl Y.; Bentrem, David J.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Bilimoria, Karl Y.] Univ Texas Houston, MD Anderson Canc Ctr, Div Surg Oncol, Houston, TX 77030 USA. [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. [Hall, Bruce L.] St Louis & Barnes Jewish Hosp, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO 63110 USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO 63110 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. RP Bilimoria, KY (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM kbilimoria@facs.org NR 27 TC 10 Z9 10 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD OCT PY 2010 VL 14 IS 10 BP 1600 EP 1606 DI 10.1007/s11605-010-1316-6 PG 7 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 653OM UT WOS:000282101500025 PM 20824379 ER PT J AU Bradley, KA Williams, EC AF Bradley, Katharine A. Williams, Emily C. TI What Can General Medical Providers Do for Hospitalized Patients with Alcohol Dependence After Discharge? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID RANDOMIZED-CONTROLLED-TRIAL; DOUBLE-BLIND; BRIEF INTERVENTION; USE DISORDERS; DRINKING; OUTCOMES; CARE; INDIVIDUALS; TOPIRAMATE; SEEKING C1 [Bradley, Katharine A.; Williams, Emily C.] Vet Affairs Puget Sound Hlth Care Syst, HSR&D, Seattle, WA 98101 USA. [Bradley, Katharine A.] Vet Affairs Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA 98101 USA. [Bradley, Katharine A.; Williams, Emily C.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98101 USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. RP Bradley, KA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, HSR&D, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Katharine.bradley@va.gov NR 31 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2010 VL 25 IS 10 BP 1000 EP 1002 DI 10.1007/s11606-010-1441-7 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 652ZN UT WOS:000282051400003 PM 20632122 ER PT J AU Vig, EK Starks, H Taylor, JS Hopley, EK Fryer-Edwards, K AF Vig, Elizabeth K. Starks, Helene Taylor, Janelle S. Hopley, Elizabeth K. Fryer-Edwards, Kelly TI Why Don't Patients Enroll in Hospice? Can We Do Anything About It? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE hospice; decision making; terminally ill; terminal care ID MENTAL STATUS QUESTIONNAIRE; OF-LIFE-CARE; TREATMENT PREFERENCES; BARRIERS; END; DISCUSSIONS; ELIGIBILITY; PHYSICIANS; AMERICAN; SERVICES AB United States hospice organizations aim to provide quality, patient-centered end-of-life care to patients in the last 6 months of life, yet some of these organizations observe that some hospice-eligible patients who are referred to hospice do not initially enroll. Primary objective: To identify reasons that eligible patients do not enroll in hospice (phase 1). Secondary objective: To identify strategies used by hospice providers to address these reasons (phase 2). Semi-structured interviews analyzed using content analysis. In phase 1, we interviewed 30 patients and/or family members of patients who had a hospice admissions visit, but who did not enroll. In phase 2, we interviewed 19 hospice staff and national experts. In phase 1, we asked participants to describe the patient's illness, the hospice referral, and why they had not enrolled. We performed a content analysis to characterize their reasons for not enrolling in hospice. In phase 2, we enrolled hospice admissions staff and hospice experts. We asked them to describe how they would respond to each reason (from phase 1) during an admissions visit with a potential new hospice patient. We identified key phrases, and summarized their recommendations. Reasons that patients hadn't enrolled fell into three broad categories: patient/family perceptions (e.g., "not ready"), hospice specific issues (e.g., variable definitions of hospice-eligible patients), and systems issues (e.g., concerns about continuity of care). Hospice staff/experts had encountered each reason, and offered strategies at the individual and organizational level for responding. In hopes of increasing hospice enrollment among hospice-eligible patients, non-hospice and hospice clinicians may want to adopt some of the strategies used by hospice staff/experts for talking about hospice with patients/families and may want to familiarize themselves with the differences between hospice organizations in their area. Hospices may want to reconsider their admission policies and procedures in light of patients' and families' perceptions and concerns. C1 [Vig, Elizabeth K.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr & Extended Care, Seattle, WA 98108 USA. [Vig, Elizabeth K.; Hopley, Elizabeth K.] Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Starks, Helene; Fryer-Edwards, Kelly] Univ Washington, Dept Bioeth & Humanities, Seattle, WA 98195 USA. [Starks, Helene] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Taylor, Janelle S.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. RP Vig, EK (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr & Extended Care, 1660 S Columbian Way S-182 Eth, Seattle, WA 98108 USA. EM vigster@u.washington.edu FU National Institute on Aging [K23 AG19635] FX This work was supported by the National Institute on Aging (K23 AG19635). This material was presented in part at the Annual Assembly of the American Academy of Hospice and Palliative Medicine in New Orleans, LA in January 2005, and at the Annual Meeting of the Society of General Internal Medicine in Toronto, Ontario, Canada in April 2007. NR 42 TC 23 Z9 23 U1 3 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2010 VL 25 IS 10 BP 1009 EP 1019 DI 10.1007/s11606-010-1423-9 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 652ZN UT WOS:000282051400005 PM 20535577 ER PT J AU Williams, BA McGuire, J Lindsay, RG Baillargeon, J Cenzer, IS Lee, SJ Kushel, M AF Williams, Brie A. McGuire, James Lindsay, Rebecca G. Baillargeon, Jacques Cenzer, Irena Stijacic Lee, Sei J. Kushel, Margot TI Coming Home: Health Status and Homelessness Risk of Older Pre-release Prisoners SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE health status; homelessness risk; pre-release prisoners; older prisoners ID FORMER INMATES; ADULTS; POPULATION; DEATH; CARE; SYSTEM; BOSTON; ILL AB Older adults comprise an increasing proportion of the prison and homeless populations. While older age is associated with adverse post-release health events and incarceration is a risk factor for homelessness, the health status and homelessness risk of older pre-release prisoners are unknown. Moreover, most post-release services are geared towards veterans; it is unknown whether the needs of non-veterans differ from those of veterans. To assess health status and risk of homelessness of older pre-release prisoners, and to compare veterans with non-veterans. Cross-sectional study of 360 prisoners (a parts per thousand yen55 years of age) within 2 years of release from prison using data from the 2004 Survey of Inmates in State and Federal Correctional Facilities. Veteran status, health status (based on self-report), and risk of homelessness (homelessness before arrest). Mean age was 61 years; 93.8% were men and 56.5% were white. Nearly 40% were veterans, of whom 77.2% reported likely VA service eligibility. Veterans were more likely to be white and to have obtained a high school diploma or GED. Overall, 79.1% reported a medical condition and 13.6% reported a serious mental illness. There was little difference in health status between veterans and non-veterans. Although 1 in 12 prisoners reported a risk factor for homelessness, the risk factors did not differ according to veteran status. Older pre-release prisoners had a high burden of medical and mental illness and were at risk for post-release homelessness regardless of veteran status. Reentry programs linking pre-release older prisoners to medical and psychiatric services and to homelessness prevention programs are needed for both veterans and non-veterans. C1 [Williams, Brie A.; Cenzer, Irena Stijacic; Lee, Sei J.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA. [Williams, Brie A.; Cenzer, Irena Stijacic; Lee, Sei J.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA USA. [McGuire, James] Vet Hlth Adm, Healthcare Reentry Vet Program, Durham, NC USA. [Lindsay, Rebecca G.] Univ Calif San Francisco, San Francisco Sch Med, San Francisco, CA 94121 USA. [Lindsay, Rebecca G.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Baillargeon, Jacques] Univ Texas Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX USA. [Baillargeon, Jacques] Univ Texas Med Branch, Div Epidemiol, Galveston, TX USA. [Kushel, Margot] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. RP Williams, BA (reprint author), Univ Calif San Francisco, Div Geriatr, 4150 Clement St,Box 181-G, San Francisco, CA 94121 USA. EM brie.williams@ucsf.edu; mkushel@medsfgh.ucsf.edu FU Brookdale Leadership in Aging Fellowship; National Institute of Aging [K23AG033102]; Hellman Family Award; UCSF FX Brie Williams was supported in part by the Brookdale Leadership in Aging Fellowship, the National Institute of Aging (K23AG033102), and the Hellman Family Award. Rebecca Lindsay was supported by the UCSF Dean's Summer Fellowship. Drs. Williams, McGuire, and Lee are employees of the Department of Veterans Affairs. The opinions expressed in this manuscript may not represent those of the VA. NR 58 TC 23 Z9 23 U1 2 U2 19 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2010 VL 25 IS 10 BP 1038 EP 1044 DI 10.1007/s11606-010-1416-8 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 652ZN UT WOS:000282051400009 PM 20532651 ER PT J AU Lynch, CP Gebregziabher, M Echols, C Gilbert, GE Zhao, YM Egede, LE AF Lynch, Cheryl P. Gebregziabher, Mulugeta Echols, Carrae Gilbert, Gregory E. Zhao, Yumin Egede, Leonard E. TI Racial Disparities in All-Cause Mortality Among Veterans with Type 2 Diabetes SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE race; all-cause mortality; diabetes; veterans ID HEALTH-CARE-SYSTEM; US ADULTS; CARDIOVASCULAR-DISEASE; ADMINISTRATIVE DATA; MEN; METAANALYSIS; HEMOGLOBIN; MELLITUS; OUTCOMES; BLACKS AB Racial differences in mortality among veterans with diabetes are less well characterized than those in the general population. To examine racial differences in all-cause mortality in a large sample of veterans with diabetes. A retrospective cohort. Participants comprised 8,812 veterans with type 2 diabetes. The main outcome measure was time to death. The main predictor was race/ethnicity. Other risk factors (or covariates) included age, gender, marital status, employment, glycosylated hemoglobin (HgbA1c), and several ICD-9 coded physical and mental health comorbidities. Average follow-up was 4.5 years; 64% of veterans were non-Hispanic whites (NHW), 97% male, and 84% at least 50 years old. The overall mortality rate was 15% and was significantly lower for non-Hispanic blacks (NHB). Baseline HgbA1c values also differed for NHW (mean = 7.05) and NHB (mean = 7.65) (p < 0.001). In sequentially-built models NHB race was associated with a lower risk of mortality with HR ranging 0.80-0.92. After adjusting for all significant covariates, the risk of mortality remained lower for NHB (HR = 0.84, 95% CI: 0.75, 0.94). Increased mortality risk was associated with age, not being employed or retired, poor glycemic control, cancer, Coronary Heart Disease (CHD), and anxiety disorder; while a lower risk was associated with being female and ever being married. The risk of death among NHB veterans with diabetes remained significantly lower than that of NHW after controlling for important confounding variables. Future studies in the VA need to examine detailed contributions of patient, provider and system-level factors on racial differences in mortality in adults with diabetes, especially if the findings of this study are replicated at other sites or using national VA data. C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Lynch, Cheryl P.; Zhao, Yumin; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Ralph H Johnson Vet Affairs Med Ctr, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM Egedel@musc.edu RI Gilbert, Gregory/C-7735-2016 OI Gilbert, Gregory/0000-0003-0879-5496; Gebregziabher, Mulugeta/0000-0002-4826-481X FU VA HSRD [REA 08-261] FX This study represents work supported by the use of resources at the VA HSR&D Funded Center for Disease Prevention and Health Interventions for Diverse Populations (REA 08-261) in Charleston, SC. NR 33 TC 8 Z9 8 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2010 VL 25 IS 10 BP 1051 EP 1056 DI 10.1007/s11606-010-1405-y PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 652ZN UT WOS:000282051400011 PM 20532659 ER PT J AU Bishop, TF Federman, AD Ross, JS AF Bishop, Tara F. Federman, Alex D. Ross, Joseph S. TI Laboratory Test Ordering at Physician Offices with and without On-Site Laboratories SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE physician self-referral; reimbursement/incentive; laboratories/economics; laboratories/utilization ID REFERRING PHYSICIANS; OWNERSHIP; CHARGES; GROWTH; COSTS AB Physician self-referral, ordering a test or procedure or referring to a facility in which a physician has a financial interest, has been associated with increased utilization of health care services. To examine the association between on-site laboratories and laboratory test ordering among visits to group-practice physicians. Cross-sectional study using data from the 2005 and 2006 National Ambulatory Medical Care Surveys. Visits by adults to non-federally-funded, non-hospital-based group practices. Primary analyses focused on visits to physician owners; secondary analyses focused on visits to non-owners. Ordering of five laboratory tests: complete blood count (CBC), electrolytes, glycoslyated hemoglobin A1c (HbA1c), cholesterol, and prostate-specific antigen (PSA). There were 19,163 visits to group-practice owners with 51.9% to a practice with an on-site laboratory. Visits to primary care physicians were more likely to be to a practice with an on-site laboratory when compared with visits to specialists (64.4% vs. 34.0%, p < 0.001). Among visits to specialist group owners, all five tests were ordered more often if there was an on-site laboratory, even after accounting for patient and practice characteristics: CBC: adjusted odds ratio[OR] = 8.01, 95% Confidence Interval [CI], 5.00-12.82, p < 0.001; electrolytes: aOR = 3.51, 95% CI, 1.93-6.40, p < 0.001; HbA1c: aOR = 4.91, 95% CI, 1.75-13.78, p = 0.003; cholesterol: aOR = 3.32, 95% CI, 1.85-5.93, p < 0.001; and PSA: aOR = 3.84, 95% CI, 1.93-7.65, p < 0.001. This association was not found among visits to primary care physician owners and all practice non-owners (both primary care and specialists). The estimated excess spending on these five tests by specialist owners with on-site laboratories was $75 million per 100 million visits. In a nationally representative sample of visits to physician-owned group practices, specialist owners with on-site laboratories were more likely to order five common laboratory tests, potentially resulting in millions in excess healthcare spending. C1 [Bishop, Tara F.; Federman, Alex D.] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, HSR&D Res Enhancement Award Program, Bronx, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Bishop, TF (reprint author), Mt Sinai Sch Med, Div Gen Internal Med, 1 Gustave L Levy Pl,Box 1087, New York, NY 10029 USA. EM taraf@alum.mit.edu FU National Institute on Aging [K08 AG032886, K23 AG028955-01]; American Federation of Aging Research FX This project was not directly supported with external funds. Drs. Ross and Federman are both currently supported by the National Institute on Aging (K08 AG032886 and K23 AG028955-01, respectively) and by the American Federation of Aging Research through the Paul B. Beeson Career Development Award Program. NR 23 TC 6 Z9 6 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2010 VL 25 IS 10 BP 1057 EP 1063 DI 10.1007/s11606-010-1409-7 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 652ZN UT WOS:000282051400012 PM 20532656 ER PT J AU Henderson, MC Dhaliwal, G Jones, SR Culbertson, C Bowen, JL AF Henderson, Mark C. Dhaliwal, Gurpreet Jones, Stephen R. Culbertson, Charles Bowen, Judith L. TI RE: Doing What Comes Naturally (vol 25, pg 84, 2010) SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Correction C1 [Henderson, Mark C.; Bowen, Judith L.] UC Davis Med Ctr, Dept Internal Med, Sacramento, CA USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA. [Jones, Stephen R.; Culbertson, Charles] Legacy Hlth Syst, Dept Internal Med, Portland, OR USA. [Jones, Stephen R.; Culbertson, Charles] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Henderson, MC (reprint author), UC Davis Med Ctr, Dept Internal Med, Sacramento, CA USA. EM MCHenderson@ucdavis.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2010 VL 25 IS 10 BP 1138 EP 1138 DI 10.1007/s11606-010-1339-4 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 652ZN UT WOS:000282051400028 ER PT J AU Trombetta, JM Bradshaw, AD AF Trombetta, Jessica M. Bradshaw, Amy D. TI SPARC/Osteonectin Functions to Maintain Homeostasis of the Collagenous Extracellular Matrix in the Periodontal Ligament SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY LA English DT Article DE SPARC; periodontal ligament; collagen; BM-40; osteonectin; extracellular matrix; matricellular; periodontium; aging ID ALVEOLAR BONE LOSS; MATRICELLULAR PROTEIN; SECRETED PROTEIN; CELL-MATRIX; SPARC; FIBROBLASTS; DISEASE; TISSUES; FIBRILLOGENESIS; REGENERATION AB Expression of secreted protein acidic and rich in cysteine (SPARC)/osteonectin, a collagen-binding matricellular protein, is frequently associated with tissues with high rates of collagen turnover, such as bone. In the oral cavity, expression of SPARC/osteonectin has been localized to the periodontal ligament (PDL), a collagen-rich tissue with high rates of collagen turnover. The PDL is critical for tooth position within the alveolar bone and for absorbing forces generated by chewing. To characterize the function of SPARC/osteonectin in PDL, SPARC/osteonectin expression in murine PDL was evaluated by immunochemistry at 1, 4, 6, and >18 months. Highest levels of SPARC/osteonectin were detected at 1 and >18 months, with decreased levels associated with adult (4-6 months) PDL. To determine whether the absence of SPARC/osteonectin expression influenced cellular and fibrillar collagen content in PDL, PDL of SPARC-null mice was evaluated using histological stains and compared with that of wild-type (WT). Our results demonstrated decreased numbers of nuclei in PDL of SPARC-null mice at 1 month. In addition, decreased collagen volume fractions were found at 1 and >18 months and decreases in thick collagen fiber volume fraction were detected at 4, 6, and >18 months in SPARC-null PDL. The greatest differences in cell number and in collagen content between SPARC-null and WT PDL coincided with ages at which levels of SPARC/osteonectin expression were highest in WT PDL, at 1 and >18 months. These results support the hypothesis that SPARC/osteonectin is critical in the control of tissue collagen content and indicate that SPARC/osteonectin is necessary for PDL homeostasis. (J Histochem Cytochem 58:871-879, 2010) C1 [Bradshaw, Amy D.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Craniofacial Biol, Charleston, SC 29425 USA. [Trombetta, Jessica M.; Bradshaw, Amy D.] Med Univ S Carolina, Div Cardiol, Dept Med, Charleston, SC 29425 USA. [Bradshaw, Amy D.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Bradshaw, AD (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Craniofacial Biol, 114 Doughty St,Rm 223, Charleston, SC 29425 USA. EM bradshad@musc.edu RI Self, Casey/B-6871-2011 FU National Institutes of Health [T32 DE-017551, 2P20RR017696, HL-094517]; Veterans Administration FX This work was supported by National Institutes of Health Grants T32 DE-017551 (to JMT), 2P20RR017696 (to ADB), and HL-094517 (to ADB) and by a Veterans Administration Merit Award (to ADB). NR 33 TC 18 Z9 19 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0022-1554 J9 J HISTOCHEM CYTOCHEM JI J. Histochem. Cytochem. PD OCT PY 2010 VL 58 IS 10 BP 871 EP 879 DI 10.1369/jhc.2010.956144 PG 9 WC Cell Biology SC Cell Biology GA 652BK UT WOS:000281975100002 PM 20566756 ER PT J AU Crum-Cianflone, NF Hullsiek, KH Roediger, M Ganesan, A Patel, S Landrum, ML Weintrob, A Agan, BK Medina, S Rahkola, J Hale, BR Janoff, EN AF Crum-Cianflone, Nancy F. Hullsiek, Katherine Huppler Roediger, Mollie Ganesan, Anuradha Patel, Sugat Landrum, Michael L. Weintrob, Amy Agan, Brian K. Medina, Sheila Rahkola, Jeremy Hale, Braden R. Janoff, Edward N. CA Infect Dis Clinical Res Program HI TI A Randomized Clinical Trial Comparing Revaccination with Pneumococcal Conjugate Vaccine to Polysaccharide Vaccine among HIV-Infected Adults SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID IMMUNODEFICIENCY-VIRUS-INFECTION; PROTECTIVE ANTIBODY-RESPONSES; CELL TRANSPLANTATION; DOUBLE-BLIND; DISEASE; CHILDREN; IMMUNOGENICITY; IMMUNIZATION; BACTEREMIA; TYPE-1 AB Background. The risk of pneumococcal disease persists, and antibody responses to revaccination with the 23-valent polysaccharide vaccine (PPV) are low among human immunodeficiency virus (HIV)-infected adults. We determined whether revaccination with the 7-valent pneumococcal conjugate vaccine (PCV) would enhance these responses. Methods. In a randomized clinical trial, we compared the immunogenicity of revaccination with PCV (np) or PPV (n = 73) among HIV-infected adults (median CD4 cell count, 533 cells/mm(3)) who had been vaccinated with PPV 3-8 years earlier. HIV-uninfected adults (n = 25) without prior pneumococcal vaccination received 1 dose of PCV. A positive response was defined as a >= 2-fold increase (from baseline to day 60) in capsule-specific immunoglobulin G, with a postvaccination level >= 1000 ng/mL for at least 2 of the 4 serotypes. Results. HIV-infected persons demonstrated a higher frequency of positive antibody responses to PCV than to PPV (57% vs 36%) (Pp. 004) and greater mean changes in the immunoglobulin G concentration from baseline to day 60 for serotypes 4, 9V, and 19F (P<.05, for all), but not for serotype 14. However, by day 180, both outcomes were similar. Responses to PCV were greater in frequency and magnitude for all serotypes in HIV-uninfected adults, compared with those in HIV-infected adults. Conclusions. Among persons with HIV infection, revaccination with PCV was only transiently more immunogenic than PPV, and responses were inferior to those in HIV-uninfected subjects with primary vaccination. Pneumococcal vaccines with more robust and sustained immunogenicity are needed for HIV-infected adults. C1 [Crum-Cianflone, Nancy F.] USN, San Diego Med Ctr, Clin Invest Dept KCA, Infect Dis Clin, San Diego, CA 92134 USA. [Crum-Cianflone, Nancy F.; Hullsiek, Katherine Huppler; Roediger, Mollie; Ganesan, Anuradha; Landrum, Michael L.; Weintrob, Amy; Agan, Brian K.; Medina, Sheila; Hale, Braden R.] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA. [Ganesan, Anuradha] USN, Med Ctr, Infect Dis Clin, Bethesda, MD 20814 USA. [Hullsiek, Katherine Huppler; Roediger, Mollie] Univ Minnesota, Div Biostat, Minneapolis, MN USA. [Patel, Sugat] USN, Med Ctr Portsmouth, Infect Dis Clin, Portsmouth, VA USA. [Landrum, Michael L.] San Antonio Mil Med Ctr, Infect Dis Serv, San Antonio, TX USA. [Weintrob, Amy] Walter Reed Army Med Ctr, Infect Dis Clin, Washington, DC 20307 USA. [Rahkola, Jeremy; Janoff, Edward N.] Univ Colorado, Div Infect Dis, Mucosal & Vaccine Res Program Colorado, Denver, CO 80202 USA. [Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Crum-Cianflone, NF (reprint author), USN, San Diego Med Ctr, Clin Invest Dept KCA, Infect Dis Clin, 34800 Bob Wilson Dr,Ste 5, San Diego, CA 92134 USA. EM nancy.crum@med.navy.mil; braden.hale@med.navy.mil OI Polis, Michael/0000-0002-9151-2268; Agan, Brian/0000-0002-5114-1669 FU NIAID NIH HHS [Y01 AI005072, Y1-AI-5072] NR 35 TC 42 Z9 44 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2010 VL 202 IS 7 BP 1114 EP 1125 DI 10.1086/656147 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 651FR UT WOS:000281912100016 PM 20795819 ER PT J AU Pang, YG Greisler, HP AF Pang, Yonggang Greisler, Howard P. TI Using a Type 1 Collagen-Based System to Understand Cell-Scaffold Interactions and to Deliver Chimeric Collagen-Binding Growth Factors for Vascular Tissue Engineering SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Article DE type 1 collagen; growth factor; confocal microscopy; local delivery; scaffold ID SMOOTH-MUSCLE-CELLS; DRUG-DELIVERY; BLOOD-VESSEL; IN-VITRO; MIGRATION; MATRIX; REORGANIZATION; CONSTRUCTION; BIOMATERIALS; VEHICLE AB Vascular tissue engineering should provide more biocompatible and functional conduits than synthetic vascular grafts. Understanding cell-scaffold interactions and developing an efficient delivery system for growth factors and other biomolecules to control the signaling between the cells and the scaffold are fundamental issues in a wide range of tissue engineering research fields. Type 1 collagen is a natural scaffold extensively used in vascular tissue engineering and is a widely used vehicle in biomolecule delivery. In this article, we will discuss type 1 collagen as a vascular tissue engineering scaffold, describe strategies for elucidating the interaction between cells and type 1 collagen scaffolds using various imaging techniques, and summarize our work on the development of a chimeric collagen-binding growth factor-based local delivery system. C1 [Pang, Yonggang; Greisler, Howard P.] Loyola Univ, Dept Surg, Med Ctr, Maywood, IL 60153 USA. [Pang, Yonggang; Greisler, Howard P.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Pang, Yonggang] IIT, Dept Biomed Engn, Chicago, IL 60616 USA. [Greisler, Howard P.] Loyola Univ, Med Ctr, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA. RP Greisler, HP (reprint author), Loyola Univ, Dept Surg, Med Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA. EM hgreisl@lumc.edu RI Pang, Yonggang/B-2843-2011 FU NIH [R01-HL41272]; Department of Veteran's Affairs; Chicago Association for Research and Education in Science; National Center for Research Resources [R13 RR023236] FX Supported by grants from the NIH R01-HL41272 (HPG), Department of Veteran's Affairs (HPG), and Chicago Association for Research and Education in Science (HPG). This symposium was supported in part by a grant from the National Center for Research Resources (R13 RR023236). NR 33 TC 6 Z9 11 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD OCT PY 2010 VL 58 IS 7 BP 845 EP 848 PG 4 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 653WD UT WOS:000282127700010 PM 20683346 ER PT J AU Kaczorowski, DJ Afrazi, A Scott, MJ Kwak, JH Gill, R Edmonds, RD Liu, YJ Fan, J Billiar, TR AF Kaczorowski, David J. Afrazi, Amin Scott, Melanie J. Kwak, Joon H. Gill, Roop Edmonds, Rebecca D. Liu, Yujian Fan, Jie Billiar, Timothy R. TI Pivotal Advance: The pattern recognition receptor ligands lipopolysaccharide and polyinosine-polycytidylic acid stimulate factor B synthesis by the macrophage through distinct but overlapping mechanisms SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE Toll-like receptors; complement; inflammation ID TOLL-LIKE RECEPTORS; INNATE IMMUNITY; ENDOTHELIAL-CELLS; MOUSE MACROPHAGES; 3RD COMPONENT; EARLY EVENTS; IFN-GAMMA; TNF-ALPHA; COMPLEMENT; PATHWAY AB TLRs and complement are critical to the host response in sepsis, trauma, and ischemia/reperfusion. We hypothesize that TLR stimulation leads to synthesis and release of complement components by macrophages, an important source of extrahepatic complement. RAW264.7 macrophages or peritoneal macrophages from WT and TLR4-, TLR3-, TRIF-, or MyD88-deficient mice were cultured under standard conditions. In some experiments, cells were pretreated with inhibitors of MAPKs or a NF-kappa B inhibitor. Cells were stimulated with TLR ligands at known stimulatory concentrations. Intratracheal and i.p. injections were also performed in mice. RT-PCR, Western blotting, and immunocytochemistry were used for analysis. Using a RT-PCR-based panel, we demonstrate that of 18 complement components tested, factor B of the alternative pathway is the most robustly up-regulated complement component in macrophages in response to LPS. This up-regulation results in release of factor B into the media. Upregulation of factor B by LPS is dependent on TLR4, TRIF, JNK, and NF-kappa B. A screen of other TLR ligands demonstrated that stimulation with poly I: C (dsRNA analog) also results in up-regulation of factor B, which is dependent on JNK and NF-kappa B but independent of TLR3 and TRIF. Up-regulation of factor B is also observed after intratracheal and i.p. injection of LPS or poly I: C in vivo. PRR stimulation profoundly influences production and release of factor B by macrophages. Understanding the mechanisms of PRR-mediated complement production may lead to strategies aimed at preventing tissue damage in diverse settings, including sepsis, trauma, and ischemia/reperfusion. J. Leukoc. Biol. 88: 609-618; 2010. C1 [Kaczorowski, David J.; Afrazi, Amin; Scott, Melanie J.; Kwak, Joon H.; Gill, Roop; Edmonds, Rebecca D.; Liu, Yujian; Fan, Jie; Billiar, Timothy R.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA. [Liu, Yujian; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Surg Res, Pittsburgh, PA USA. RP Billiar, TR (reprint author), Univ Pittsburgh, Presbyterian Univ Hosp, Dept Surg F1281, Med Ctr, POB 7533,200 Lothrop St, Pittsburgh, PA 15213 USA. EM billiartr@upmc.edu FU National Institutes of Health [P50-GM-53789, R01-HL-079669]; VA Merit Award; American College of Surgeons FX This work was supported by National Institutes of Health grant P50-GM-53789 (T. R. B. and J.F.), National Institutes of Health grant R01-HL-079669 (J. F.), and VA Merit Award (J. F.). D. J. K. and R. D. E. are each recipients of American College of Surgeons Resident Research Scholarships. We thank Meihua Bo, Hong Liao, and Danielle Reiser for technical assistance. NR 33 TC 14 Z9 14 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD OCT PY 2010 VL 88 IS 4 BP 609 EP 618 DI 10.1189/jlb.0809588 PG 10 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 692ZW UT WOS:000285195400002 PM 20413727 ER PT J AU Hammad, SM Pierce, JS Soodavar, F Smith, KJ Al Gadban, MM Rembiesa, B Klein, RL Hannun, YA Bielawski, J Bielawska, A AF Hammad, Samar M. Pierce, Jason S. Soodavar, Farzan Smith, Kent J. Al Gadban, Mohammed M. Rembiesa, Barbara Klein, Richard L. Hannun, Yusuf A. Bielawski, Jacek Bielawska, Alicja TI Blood sphingolipidomics in healthy humans: impact of sample collection methodology SO JOURNAL OF LIPID RESEARCH LA English DT Article DE sphingolipid metabolome; sphingomyelin; ceramide; sphingosine ID TANDEM MASS-SPECTROMETRY; APOLIPOPROTEIN-A-I; SPHINGOSINE 1-PHOSPHATE; DENSITY-LIPOPROTEIN; SIGNAL-TRANSDUCTION; SPHINGOSINE-1-PHOSPHATE; CERAMIDE; PLASMA; METABOLISM; CELLS AB We used a HPLC-MS/MS methodology for determination of a basic metabolomic profile (18:1,18:0 sphingoid backbone, C(14)-C(26) N-acyl part) of "normal" sphingolipid levels in human serum and plasma. Blood was collected from healthy males and nonpregnant females under fasting and nonfasting conditions with and without anticoagulants. Sphingolipids analyzed included sphingoid bases, sphingosine and dihydrosphingosine, their 1-phosphates (S1P and dhS1P), molecular species (C(n)-) of ceramide (Cer), sphingomyelin (SM), hexosylceramide (HexCer), lactosylceramide (LacCer), and Cer 1-phosphate (Cer1P). SM, LacCer, HexCer, Cer, and Cer1P constituted 87.7, 5.8, 3.4, 2.8, and 0.15% of total sphingolipids, respectively. The abundant circulating SM was C(16)-SM (64.0 mu M), and it increased with fasting (100 mu M). The abundant LacCer was C(16)-LacCer (10.0 mu M) and the abundant HexCer was C(24)-HexCer (2.5 mu M). The abundant Cer, C(24)-Cer (4.0 mu M), was not influenced by fasting; however, levels of C(16)-C(20) Cers were decreased in response to fasting. S1P levels were higher in serum than plasma (0.68 mu M vs. 0.32 mu M). We also determined levels of sphingoid bases and SM species in isolated lipoprotein classes. HDL(3) was the major carrier of S1P, dhS1P, and Sph, and LDL was the major carrier of Cer and dhSph. Per particle, VLDL contained the highest levels of SM, Cer, and S1P. HPLC-MS/MS should provide a tool for clinical testing of circulating bioactive sphingolipids in human blood.-Hammad, S. M., J. S. Pierce, F. Soodavar, K. J. Smith, M. M. Al Gadban, B. Rembiesa, R. L. Klein, Y. A. Hannun, J. Bielawski, and A. Bielawska. Blood sphingolipidomics in healthy humans:impact of sample collection methodology. J. Lipid Res. 2010. 51: 3074-3087. C1 [Hammad, Samar M.; Soodavar, Farzan; Smith, Kent J.; Al Gadban, Mohammed M.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Pierce, Jason S.; Rembiesa, Barbara; Hannun, Yusuf A.; Bielawski, Jacek; Bielawska, Alicja] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Klein, Richard L.] Med Univ S Carolina, Div Endocrinol, Dept Med, Charleston, SC 29425 USA. [Klein, Richard L.] Ralph H Johnson Vet Affairs Med Ctr, Dept Vet Affairs, Charleston, SC 29401 USA. RP Hammad, SM (reprint author), Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. EM hammadsm@musc.edu FU National Institutes of Health [HL-079274, R0-1HL079274-04S1]; Southeastern Clinical and Translational Research Institute; South Carolina Center of Biomedical Research Excellence (COBRE) in Lipidomics and Pathobiology; National Center for Research Resources (NCCR) [P20 RR17677, CO6RR018823]; Department of Veterans Affairs FX This work was supported by National Institutes of Health Grants HL-079274 and R0-1HL079274-04S1 (American Recovery and Reinvestment Act), The Southeastern Clinical and Translational Research Institute to S.M.H., the South Carolina Center of Biomedical Research Excellence (COBRE) in Lipidomics and Pathobiology (P20 RR17677 from National Center for Research Resources (NCCR) to S.M.H., Y.A.H., A.B., and J.B., the Department of Veterans Affairs Merit Review Program to R.L.K., and NCRR Grant CO6RR018823 for the facility. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or other granting agencies. NR 56 TC 98 Z9 99 U1 4 U2 22 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD OCT PY 2010 VL 51 IS 10 BP 3074 EP 3087 DI 10.1194/jlr.D008532 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 649GS UT WOS:000281756800021 PM 20660127 ER PT J AU Walker, RH Davies, G Koch, RJ Haack, AK Moore, C Meshul, CK AF Walker, Ruth H. Davies, Georgia Koch, Rick J. Haack, Andrew K. Moore, Cynthia Meshul, Charles K. TI Effects of Zona Incerta Lesions on Striatal Neurochemistry and Behavioral Asymmetry in 6-Hydroxydopamine-Lesioned Rats SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE microdialysis; 6-hydroxydopamine; glutamate; dopamine ID DEEP BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS LESIONS; HIGH-FREQUENCY STIMULATION; ACTIVE ELECTRODE CONTACTS; MEDIAL FRONTAL-CORTEX; PARKINSONS-DISEASE; BASAL GANGLIA; DOPAMINE NEUROTRANSMISSION; NIGROSTRIATAL PATHWAY; 6-OHDA LESION AB Analysis of optimal sites for neurosurgical interventions in patients with Parkinson's disease (PD) suggests that significant clinical benefits may be achieved by involvement of the zona incerta (ZI). Unilateral electrolytic ZI lesions were made in intact and ipsilaterally 6-hydroxydopamine (60HDA)-lesioned rats. Extracellular levels of glutamate, dopamine, and its metabolites in the ipsilateral striatum of awake rats were measured by using microdialysis, and tests of behavioral asymmetry were performed. In intact rats, ZI lesions had no effect on striatal extracellular glutamate or absolute levels of dopamine or metabolites, but dopamine metabolism decreased. After ZI lesions, contralateral forepaw use decreased in the forepaw adjusting steps test, but there was no change in response to vibrissa stimulation or cylinder exploration. There was no development of rotational asymmetry with amphetamine. In 60HDA-lesioned rats, striatal extracellular glutamate levels were elevated compared with controls. ZI lesions reduced the increased levels of glutamate back to normal values. ZI lesions reduced dopamine and homovanillic acid levels and showed a trend toward a decrease in dopamine metabolism. 60HDA-lesioned rats demonstrated the expected asymmetry of motor behaviors. After ZI lesions, ipsilateral turns following amphetamine injection were reduced, and there was a trend toward improved symmetry of forepaw use as determined with the forepaw adjusting steps test. There was no change in forepaw use with vibrissa stimulation or cylinder exploration. These data indicate that lesions of the ZI can affect striatal neurochemistry and motor behavioral asymmetry and suggest potential mechanisms by which ZI lesions may improve symptoms in PD. (C) 2010 Wiley-Liss, Inc. C1 [Walker, Ruth H.; Davies, Georgia; Koch, Rick J.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA. [Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Haack, Andrew K.; Moore, Cynthia; Meshul, Charles K.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Neurocytol Lab, Res Serv, Portland, OR 97201 USA. [Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci & Pathol, Portland, OR 97201 USA. RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol 127, Bronx, NY 10468 USA. EM ruth.walker@mssm.edu FU U.S. Department of Veterans Affairs FX Contract grant sponsor: U.S. Department of Veterans Affairs (to R.H.W., C.K.M.). NR 52 TC 3 Z9 3 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD OCT PY 2010 VL 88 IS 13 BP 2964 EP 2975 DI 10.1002/jnr.22446 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 642OK UT WOS:000281225100019 PM 20544826 ER PT J AU Vo, NV Sowa, GA Kang, JD Seidel, C Studer, RK AF Vo, Nam V. Sowa, Gwendolyn A. Kang, James D. Seidel, Christopher Studer, Rebecca K. TI Prostaglandin E2 and Prostaglandin F2 alpha Differentially Modulate Matrix Metabolism of Human Nucleus Pulposus Cells SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE nucleus pulposus cells; prostaglandins; PGE(2); PGF(2 alpha); intervertebral disc matrix ID INTERVERTEBRAL DISC DEGENERATION; NECROSIS-FACTOR-ALPHA; HUMAN ARTICULAR CHONDROCYTES; IN-VITRO; NITRIC-OXIDE; EXPRESSION; CYCLOOXYGENASE-2; ACTIVATION; HERNIATION; MEDIATORS AB Prostaglandin (PG) actions on disc metabolism are unclear even though certain PGs are highly expressed by disc cells under inflammatory conditions and nonsteroidal anti-inflammatory drugs (NSAI Ds) are frequently used to block PG production to treat back pain. Hence this study aimed to (1) quantify gene expression of arachiclonic acid cascade components responsible for PG synthesis and (2) examine the effects of key PGs on disc matrix homeostasis Microarray analysis revealed that inflammatory stress increases expression of synthases and receptors for prostaglandin E2 (PGE(2)) and prostaglandin F2 alpha (PGF(2 alpha)), resulting in elevated PGE(2) and PGF(2 alpha) production in conditioned mocha of disc cells PGE(2) diminished disc cell proteoglycan synthesis, in a dose-dependent manner Semiquantitative RT-PGR revealed differential effects of PGE(2) and PGF(2 alpha) on disc cell expression of key matrix structural genes. aggrecan, versican, collagens type I and II PGE(2) and PGF(2 alpha) also decreased message for the anabolic factor, IGF-1 PGE2 decreased mRNA expression for the anti-catabolic factor TIMP-1 while PGF(2 alpha) increased mRNAs for catabolic factors MMP-1 and MMP-3 Thus, PGE(2) and PGF(2 alpha) may have an overall negative impact on disc matrix homeostasis, and the use of NSAIDs may impact disc metabolism is well as treat back pain (C) 2010 Orthopaedic Research Society Published by Wiley Periodicals, Inc J Orthop Res 28 1259-1266, 2010 C1 [Vo, Nam V.; Sowa, Gwendolyn A.; Kang, James D.; Studer, Rebecca K.] Univ Pittsburgh, Sch Med, Ferguson Lab Orthopaed Res, Pittsburgh, PA 15260 USA. [Vo, Nam V.; Sowa, Gwendolyn A.; Kang, James D.; Studer, Rebecca K.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Pittsburgh, PA 15261 USA. [Sowa, Gwendolyn A.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15261 USA. [Studer, Rebecca K.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Seidel, Christopher] Stowers Inst Med Res, Kansas City, MO USA. RP Vo, NV (reprint author), Univ Pittsburgh, Sch Med, Ferguson Lab Orthopaed Res, Pittsburgh, PA 15260 USA. FU VA Rehabilitation Research and Development [B4-3894RA]; Pittsburgh Foundation; Ferguson Laboratory FX This work supported by VA Rehabilitation Research and Development Grant B4-3894RA and the Albert B. Ferguson, Jr, MD Orthopaedic Fund of the Pittsburgh Foundation. The work was approved by the IRB of the University of Pittsburgh The authors gratefully acknowledge the technical support of SuLan Huang, Elizabeth Christian, Geoffrey Sirockman, and the staff of the Ferguson Laboratory NR 40 TC 8 Z9 9 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD OCT PY 2010 VL 28 IS 10 BP 1259 EP 1266 DI 10.1002/joi.21157 PG 8 WC Orthopedics SC Orthopedics GA 647YQ UT WOS:000281657200001 PM 20839316 ER PT J AU Rabow, MW Pantilat, SZ Kerr, K Enguidanos, S Ferrell, B Goldstein, R Pankratz, C Picchi, T Rosenfeld, KE Stone, SC AF Rabow, Michael W. Pantilat, Steven Z. Kerr, Kathleen Enguidanos, Susan Ferrell, Bruce Goldstein, Rebecca Pankratz, Charles Picchi, Tina Rosenfeld, Kenneth E. Stone, Susan C. TI The Intersection of Need and Opportunity: Assessing and Capitalizing on Opportunities To Expand Hospital-Based Palliative Care Services SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID METRICS CONSENSUS RECOMMENDATIONS; UNITED-STATES; PROGRAMS; LIFE AB Background: To develop and grow most effectively, palliative care programs must consider how best to align their mission with that of their institution. To do so, programs must identify their institutional mission and needs, what palliative care can do to address those needs given available resources, and how the palliative care team can measure and document its value. Such an approach encourages the palliative care team to think strategically and to see themselves and their service as a solution to issues and concerns within the institution. It also helps a palliative care team decide which, among many potential opportunities and possible initiatives, is the one most likely to be supported by the institution and have a recognized and significant impact. Subjects and Methods: We present five case studies to demonstrate how successful programs identify and address institutional needs to create opportunities for palliative care program growth. These case studies can serve as models for other programs seeking to develop or expand their palliative care services. C1 [Rabow, Michael W.; Pantilat, Steven Z.; Kerr, Kathleen] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Enguidanos, Susan] Univ So Calif, Leonard Davis Sch Gerontol, Los Angeles, CA USA. [Ferrell, Bruce] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Goldstein, Rebecca] Downey Med Ctr Kaiser Downey, Dept Med, Downey, CA USA. [Pankratz, Charles] St Johns Reg Med Ctr, Dept Med, Oxnard, CA USA. [Pankratz, Charles] St Johns Pleasant Valley Hosp, Dept Med, Camarillo, CA USA. [Picchi, Tina] St Johns Reg Med Ctr, Dept Spiritual Care, Oxnard, CA USA. [Picchi, Tina] St Johns Pleasant Valley Hosp, Dept Spiritual Care, Camarillo, CA USA. [Rosenfeld, Kenneth E.] VA Greater Angeles Hlth Syst, Dept Med, Los Angeles, CA USA. [Stone, Susan C.] Univ So Calif, Dept Emergency Med, Los Angeles, CA USA. RP Rabow, MW (reprint author), Univ Calif San Francisco, Dept Med, 1701 Divisadero St 500, San Francisco, CA 94143 USA. EM mrabow@medicine.ucsf.edu OI Enguidanos, Susan/0000-0002-5112-288X FU Archstone Foundation Hospital-Based Palliative Care Service Innovation Initiative FX All authors have received support from the Archstone Foundation Hospital-Based Palliative Care Service Innovation Initiative. NR 13 TC 4 Z9 5 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD OCT PY 2010 VL 13 IS 10 BP 1205 EP 1210 DI 10.1089/jpm.2010.0112 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 664IP UT WOS:000282953900008 PM 20831435 ER PT J AU Raval, MV Sturgeon, C Bentrem, DJ Elaraj, DM Stewart, AK Winchester, DJ Ko, CY Reynolds, M AF Raval, Mehul V. Sturgeon, Cord Bentrem, David J. Elaraj, Dina M. Stewart, Andrew K. Winchester, David J. Ko, Clifford Y. Reynolds, Marleta TI Influence of lymph node metastases on survival in pediatric medullary thyroid cancer SO JOURNAL OF PEDIATRIC SURGERY LA English DT Article DE Medullary thyroid cancer; Thyroid neoplasm; Pediatric surgery; Pathology; Epidemiology; National cancer data base ID MULTIPLE ENDOCRINE NEOPLASIA; STANDARDIZED SURGICAL APPROACH; 80 CONSECUTIVE PATIENTS; DATA-BASE REPORT; CLINICAL-CHARACTERISTICS; CONTEMPORARY SERIES; PROGNOSTIC-FACTORS; RET PROTOONCOGENE; BIOCHEMICAL CURE; UNITED-STATES AB Purpose: Lymph node metastases (LNM) from medullary thyroid cancer (MTC) are common in adults and are a poor prognostic factor. Less is known about LNM in children, who often have hereditary forms of MTC. Guidelines recommend prophylactic thyroidectomy in early childhood, but randomized prospective trials are not feasible. We hypothesized that LNM is associated with poor prognosis in children. Methods: Patients with MTC 21 years or younger from the National Cancer Data Base from 1985 to 2007 were studied. Multivariable logistic regression was used to identify factors associated with lymph node evaluation. Survival was estimated using the Kaplan-Meier method. Results: Of 430 patients, 276 (64.2%) had nodal evaluation with LNM present in 121 (28.1%). Older patients, those with tumors larger than 2 cm, and those with involved margins were more likely to have LNM (all P < .05). Patients undergoing total thyroidectomy, those with involved margins, and older patients were more likely to undergo lymph node evaluation after controlling for patient, tumor, and hospital factors (all P < .05). Over time an increasing number of patients with MTC have undergone total thyroidectomy. Patients 16 to 21 years of age had lower 10-year overall survival compared to patients 0 to 15 years old (88.7% vs 98.1%, P = .005). Lymph node metastases were also associated with decreased 10-year overall survival (84.4% vs 100%, P < .001). Conclusions: In pediatric MTC, LNM predict poorer overall survival. Adequate lymph node assessment can provide valuable prognostic information for the pediatric MTC patient. Lymph node assessment should be considered for older pediatric patients undergoing surgery for hereditary MTC or biopsy confirmed MTC. (C) 2010 Elsevier Inc. All rights reserved. C1 [Raval, Mehul V.; Stewart, Andrew K.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, Chicago, IL 60611 USA. [Raval, Mehul V.; Reynolds, Marleta] Childrens Mem Hosp, Div Pediat Surg, Chicago, IL 60614 USA. [Raval, Mehul V.; Sturgeon, Cord; Bentrem, David J.; Elaraj, Dina M.] Northwestern Univ, Feinberg Sch Med, Div Gastrointestinal & Oncol Surg, Dept Surg, Chicago, IL 60611 USA. [Bentrem, David J.] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA. [Winchester, David J.] NorthShore Univ HealthSyst, Dept Surg, Evanston, IL 60201 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90073 USA. [Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Raval, MV (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, Chicago, IL 60611 USA. EM m-raval@md.northwestern.edu OI Raval, Mehul/0000-0002-1527-2661 FU John Gray Research Fellowship; Daniel F and Ada L Rice Foundation; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service; American College of Surgeons, Commission on Cancer; American Cancer Society FX MVR participates in the American College of Surgeons Clinical Scholars in Residence Program and is supported by the John Gray Research Fellowship and the Daniel F and Ada L Rice Foundation. DJB is supported by a career development award from the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service. The National Cancer Data Base is supported by the American College of Surgeons, Commission on Cancer, and the American Cancer Society. NR 42 TC 9 Z9 9 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0022-3468 J9 J PEDIATR SURG JI J. Pediatr. Surg. PD OCT PY 2010 VL 45 IS 10 BP 1947 EP 1954 DI 10.1016/j.jpedsurg.2010.06.013 PG 8 WC Pediatrics; Surgery SC Pediatrics; Surgery GA 656WC UT WOS:000282370800010 PM 20920711 ER PT J AU Ross, JH Hardy, DC Schuyler, CA Slate, EH Mize, TW Huang, Y AF Ross, J. H. Hardy, D. C. Schuyler, C. A. Slate, E. H. Mize, T. W. Huang, Y. TI Expression of periodontal interleukin-6 protein is increased across patients with neither periodontal disease nor diabetes, patients with periodontal disease alone and patients with both diseases SO JOURNAL OF PERIODONTAL RESEARCH LA English DT Article DE periodontal diseases; diabetes mellitus; interleukin-6 (IL-6); gene expression ID MATRIX METALLOPROTEINASE-1 EXPRESSION; CARDIOVASCULAR-DISEASE; IL-6; LIPOPOLYSACCHARIDE; INFLAMMATION; TISSUE; RISK; POLYMORPHISMS; FIBROBLASTS; MELLITUS AB Background and Objective: Epidemiological studies have established that patients with diabetes have an increased prevalence and severity of periodontal disease. Interleukin (IL)-6, a multifunctional cytokine, plays a role in the tissue inflammation that characterizes periodontal disease. Our recent study has shown a trend of increase in periodontal IL-6 expression at the mRNA level across patients with neither periodontal disease nor diabetes, patients with periodontal disease alone and patients with both diseases. However, the periodontal IL-6 expression at the protein level in these patients has not been investigated. Material and Methods: Periodontal tissue specimens were collected from eight patients without periodontal disease and diabetes (group 1), from 17 patients with periodontal disease alone (group 2) and from 10 patients with both periodontal disease and diabetes (group 3). The frozen sections were prepared from these tissue specimens and IL-6 protein expression was detected and quantified. Results: The nonparametric Kruskal-Wallis test showed that the difference in IL-6 protein levels among the three groups was statistically significant (p = 0.035). Nonparametric analysis using the Jonckheere-Terpstra test showed a tendency of increase in periodontal IL-6 protein levels across group 1 to group 2 to group 3 (p = 0.006). Parametric analysis of variance (ANOVA) on IL-6 protein levels showed that neither age nor gender significantly affected the difference of IL-6 levels among the groups. Conclusion: Periodontal IL-6 expression at the protein level is increased across patients with neither periodontal disease nor diabetes, patients with periodontal disease alone and patients with both diseases. C1 [Huang, Y.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. [Ross, J. H.; Hardy, D. C.; Mize, T. W.] Med Univ S Carolina, Div Periodont, Dept Stomatol, Coll Dent Med, Charleston, SC 29403 USA. [Slate, E. H.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29403 USA. [Huang, Y.] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Charleston, SC 29403 USA. RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU NIH [DE16353]; Department of Veterans Affairs; COBRE, NIH [P20RR017696] FX This work was supported by NIH grant DE16353 and by a Merit Review Grant from the Department of Veterans Affairs (to Y.H.). This work was also partially supported by COBRE grant P20RR017696 from NIH. NR 29 TC 11 Z9 12 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3484 J9 J PERIODONTAL RES JI J. Periodont. Res. PD OCT PY 2010 VL 45 IS 5 BP 688 EP 694 DI 10.1111/j.1600-0765.2010.01286.x PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 641PR UT WOS:000281141500013 PM 20682019 ER PT J AU Petri, M Naqibuddin, M Carson, KA Wallace, DJ Weisman, MH Holliday, SL Sampedro, M Padilla, PA Brey, RL AF Petri, Michelle Naqibuddin, Mohammad Carson, Kathryn A. Wallace, Daniel J. Weisman, Michael H. Holliday, Stephen L. Sampedro, Margaret Padilla, Patricia A. Brey, Robin L. TI Depression and Cognitive Impairment in Newly Diagnosed Systemic Lupus Erythematosus SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE SYSTEMIC LUPUS ERYTHEMATOSUS; DEPRESSION; AUTOMATED NEUROPSYCHOLOGICAL ASSESSMENT METRICS ID RATING-SCALE; DISEASE-ACTIVITY; PSYCHIATRIC-SYMPTOMS; REVISED CRITERIA; FATIGUE; CLASSIFICATION; SCHIZOPHRENICS; ANTIBODIES; DISORDERS; MOOD AB Objective. Cognitive impairment is present in 80% of patients with systemic lupus erythematosus (SLE) 10 years after diagnosis. The natural history of cognitive dysfunction in newly diagnosed SLE is unknown. We examined the association of depression and cognitive performance in newly diagnosed SLE. Methods. A multicenter cohort of 111 patients newly diagnosed (within 9 months) with SLE underwent cognitive function testing using an automated battery [Automated Neuropsychological Assessment Metrics (ANAM)] with 9 subtests. Depression was measured using the Calgary Depression Scale (CDS). Results. The patient cohort was 97.3% female, 55.9% white, 15.3% African American, 20.7% Hispanic, mean age 37.8 years, mean education 15.2 years. CDS score ranged from 0 to 18 (mean 5.0 +/- 4.6). CDS score did not differ by age, sex, ethnicity, or prednisone dose. Higher Krupp Fatigue Severity Scale scores and presence of fibromyalgia were significantly associated with higher CDS score (p < 0.001 p = 0.006, respectively). Depressed patients, defined by a CDS score > 6, had significantly poorer performance on 5 ANAM throughput measures: code substitution (p = 0.03), continuous performance (p = 0.02), matching-to-sample (p = 0.04), simple reaction time (p = 0.02), and the Sternberg memory test (p = 0.04). Adjusting for age, sex, ethnicity, education, and prednisone dose, a higher CDS score remained significantly associated with poorer performance on 3 measures, but the association was slightly attenuated for code substitution and matching-to-sample. Depression was not associated with mathematical or spatial processing. Conclusion. Depression, a modifiable risk factor, is associated with significantly poorer function in several cognitive domains in patients newly diagnosed with SLE. Treatment of depression when the CDS score is greater than 6 may improve cognitive functioning and should be further studied. (First Release July 15 2010; J Rheumatol 2010;37:2032-8; doi:10.3899/jrheum.091366) C1 [Petri, Michelle; Naqibuddin, Mohammad; Carson, Kathryn A.; Sampedro, Margaret] Johns Hopkins Univ, Baltimore, MD 21205 USA. [Wallace, Daniel J.; Weisman, Michael H.] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA 90095 USA. [Holliday, Stephen L.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Padilla, Patricia A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Petri, M (reprint author), Johns Hopkins Univ, 1830 E Monument St,Suite 7500, Baltimore, MD 21205 USA. EM mpetri@jhmi.edu FU NIH [RO1 AR049125]; Johns Hopkins Institute for Clinical and Translational Research [UL1 RR 025005]; University of Texas Health Science Center at San Antonio Frederic C. Bartter General Clinical Research Center [MO1-RR-01346] FX The Brain CONECTIONS study is supported by NIH RO1 AR049125 and the Johns Hopkins Institute for Clinical and Translational Research (K. Carson is supported by UL1 RR 025005) and the University of Texas Health Science Center at San Antonio Frederic C. Bartter General Clinical Research Center (MOI-RR-01346). NR 46 TC 35 Z9 37 U1 3 U2 8 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD OCT PY 2010 VL 37 IS 10 BP 2032 EP 2038 DI 10.3899/jrheum.091366 PG 7 WC Rheumatology SC Rheumatology GA 663DY UT WOS:000282864400010 PM 20634244 ER PT J AU Emmons, RR Garber, CE Cirnigliaro, CM Moyer, JM Kirshblum, SC Galea, MD Spungen, AM Bauman, WA AF Emmons, Racine R. Garber, Carol Ewing Cirnigliaro, Christopher M. Moyer, Jeremy M. Kirshblum, Steven C. Galea, Marinella D. Spungen, Ann M. Bauman, William A. TI The Influence of Visceral Fat on the Postprandial Lipemic Response in Men with Paraplegia SO JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION LA English DT Article DE spinal cord injury; postprandial lipemia; triglyceride clearance; abdominal adiposity ID DENSITY-LIPOPROTEIN CHOLESTEROL; SPINAL-CORD-INJURY; METABOLIC SYNDROME; ULTRASONOGRAPHY; ATHEROGENESIS; OBESITY; PLASMA AB Background: Postprandial lipemia (PPL) is associated with vascular dysfunction and may be an etiologic factor in the progression of atherogenic cardiovascular disease. Objective: In 10 men with paraplegia and 10 able-bodied men, the magnitude of the PPL responses and the relationship of abdominal adiposity and the PPL responses were determined. Methods: Anthropometrics, dual energy x-ray absorptiometry, and abdominal ultrasonography were performed to determine visceral fat and total body fat. A fasting lipid profile was performed. A high-fat milkshake (1.3 g fat/kg body mass) was administered with serum collected at baseline and at 2, 4, and 6 hours after the test meal for subsequent measurement of triglyceride. The triglyceride response was determined by the area under the triglyceride curve. Results: No significant differences were noted between the groups in fasting lipid values or in measures of visceral fat. Total body fat tended to be higher in men with paraplegia than in able-bodied men (34.9 +/- 10.0 vs. 27.3 +/- 6.7%, p = 0.07). No significant difference between the groups was observed in triglyceride response. In men with paraplegia, visceral fat was strongly associated with the triglyceride (r = 0.8, p = 0.005), fasting low-density lipoprotein (r = 0.66, p = 0.04), and triglyceride responses (r = 0.80, p = 0.005); a significant relationship was not found between fasting high-density lipoprotein and any measure of adiposity. In men with paraplegia, triglyceride response was positively related to all measures of abdominal adiposity. Conclusion: Visceral abdominal fat was related to delayed triglyceride clearance after a fat load, which may contribute to coronary heart disease (CHD) risk and progression of vascular disease in men with paraplegia. C1 [Emmons, Racine R.; Cirnigliaro, Christopher M.; Moyer, Jeremy M.; Galea, Marinella D.; Spungen, Ann M.; Bauman, William A.] US Dept Vet Affairs, Rehabil Res & Dev Ctr Excellence Med Consequences, James J Peters VA Med Ctr, Bronx, NY USA. [Emmons, Racine R.; Garber, Carol Ewing] Columbia Univ Teachers Coll, New York, NY 10027 USA. [Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, Steven C.] Univ Med Sch New Jersey, Dept Phys Med & Rehabil, Newark, NJ USA. RP Emmons, RR (reprint author), James J Peters VA Med Ctr, VA Ctr Excellence Med Consequences SCI, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM racine.emmons@va.gov OI Garber, Carol/0000-0002-1268-576X FU Department of Veterans Affairs Rehabilitation Research and Development Center of Excellence for the Medical Consequences of Spinal Cord Injury [B4162C] FX This work was supported by the Department of Veterans Affairs Rehabilitation Research and Development Center of Excellence for the Medical Consequences of Spinal Cord Injury (#B4162C). NR 25 TC 8 Z9 8 U1 0 U2 2 PU AMER COLLEGE NUTRITION PI CLEARWATER PA 300 SOUTH DUNCAN AVENUE, STE 225, CLEARWATER, FL 33755 USA SN 0731-5724 J9 J AM COLL NUTR JI J. Am. Coll. Nutr. PD OCT PY 2010 VL 29 IS 5 BP 476 EP 481 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 716YX UT WOS:000287010500005 PM 21504974 ER PT J AU Hempton, TJ Dominici, JT AF Hempton, Timothy J. Dominici, John T. TI MORE ABOUT CROWN LENGTHENING Response SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Letter C1 [Hempton, Timothy J.] Tufts Univ, Sch Dent Med, Boston, MA 02111 USA. [Dominici, John T.] Michael E DeBakey Vet Adm Med Ctr, Prosthodont Residency Programs, Houston, TX USA. RP Hempton, TJ (reprint author), Tufts Univ, Sch Dent Med, Boston, MA 02111 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD OCT PY 2010 VL 141 IS 10 BP 1184 EP 1185 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 662XJ UT WOS:000282847300009 ER PT J AU Duru, OK Sarkisian, CA Leng, M Mangione, CM AF Duru, O. Kenrik Sarkisian, Catherine A. Leng, Mei Mangione, Carol M. TI Sisters in Motion: A Randomized Controlled Trial of a Faith-Based Physical Activity Intervention SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE physical activity; African Americans; randomized controlled trial ID AMERICAN-HEART-ASSOCIATION; OLDER-ADULTS; CARDIOVASCULAR-DISEASE; HEALTH-PROMOTION; PUBLIC-HEALTH; WOMEN; EXERCISE; OUTCOMES; RECOMMENDATIONS; QUESTIONNAIRE AB OBJECTIVES To evaluate a faith-based intervention (Sisters in Motion) intended to increase walking in older, sedentary African-American women. DESIGN Randomized controlled trial using within-church randomization. SETTING Three Los Angeles churches. PARTICIPANTS Sixty-two African-American women aged 60 and older who reported being active less than 30 minutes three times per week and walked less than 35,000 steps per week as measured using a baseline pedometer reading. INTERVENTION Intervention participants received a multicomponent curriculum including scripture readings, prayer, goal-setting, a community resource guide, and walking competitions. Intervention and control participants both participated in physical activity sessions. MEASUREMENTS The primary outcome was change in weekly steps walked as measured using the pedometer. Secondary outcomes included change in systolic blood pressure (SBP). Outcomes were assessed at baseline and 6 months after the intervention. RESULTS Eighty-five percent of participants attended at least six of eight sessions. Intervention participants averaged 12,727 steps per week at baseline, compared with 13,089 steps in controls. Mean baseline SBP was 156 mmHg for intervention participants and 147 mmHg for controls (P=.10). At 6 months, intervention participants had increased their weekly steps by 9,883 on average, compared with an increase of 2,426 for controls (P=.02); SBP decreased on average by 12.5 mmHg in intervention participants and only 1.5 mmHg in controls (P=.007). CONCLUSION The Sisters in Motion intervention led to an increase in walking and a decrease in SBP at 6 months. This is the first randomized controlled trial of a faith-based physical activity program to increase physical activity in older African-American women and represents an attractive approach to stimulate lifestyle change in this population. C1 [Duru, O. Kenrik; Leng, Mei; Mangione, Carol M.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Sarkisian, Catherine A.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Div Geriatr, Los Angeles, CA 90095 USA. RP Duru, OK (reprint author), Univ Calif Los Angeles, Div Gen Internal Med Hlth Serv Res, 911 Broxton Plaza, Los Angeles, CA 90095 USA. EM kduru@mednet.ucla.edu FU Institute for Health and Aging, University of California at San Francisco; National Institutes on Aging [R01-AG024460]; University of California at Los Angeles (UCLA); National Center on Minority Health and Health Disparities [2P20MD000182]; UCLA Center for Health Improvement of Minority Elderly/Resource Centers for Minority Aging Research; National Institutes of Health (NIH); NIA [2P30AG021684, P30-AG028748] FX The authors gratefully acknowledge the support and guidance of Dr. Anita Stewart and Ms. Dawn Gillis at the Institute for Health and Aging, University of California at San Francisco, who graciously shared their experiences in developing a physical activity intervention for translation in a community setting. The authors would also like to thank the program participants in the Seniors in Motion for Health program in San Francisco, sponsored by the Network for Elders.; This study was funded by a diversity supplement awarded to Dr. Duru by the National Institutes on Aging, to Grant R01-AG024460. Dr. Mangione was supported by University of California at Los Angeles (UCLA)/Drew Project Export, National Center on Minority Health and Health Disparities, 2P20MD000182. Dr. Mangione also received support from the UCLA Center for Health Improvement of Minority Elderly/Resource Centers for Minority Aging Research, National Institutes of Health (NIH), NIA under Grant 2P30AG021684. Drs. Duru, Sarkisian, and Mangione received support from the UCLA Older Americans Independence Center, NIH, NIA Grant P30-AG028748. The content of this article does not necessarily represent the official views of the NIA or the NIH. NR 33 TC 43 Z9 44 U1 2 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2010 VL 58 IS 10 BP 1863 EP 1869 DI 10.1111/j.1532-5415.2010.03082.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 660ZP UT WOS:000282690900005 PM 20929464 ER PT J AU Palmer, RF Royall, DR AF Palmer, Raymond F. Royall, Donald R. TI Missing Data? Plan on It! SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE missing data methods; statistical measurement; longitudinal aging research ID FREEDOM HOUSE; MODELS; GROWTH; ASSOCIATION; DECLINE; TIME AB Longitudinal study designs are indispensable for investigating age-related functional change. There now are well-established methods for addressing missing data in longitudinal studies. Modern missing data methods not only minimize most problems associated with missing data (e.g., loss of power and biased parameter estimates), but also have valuable new applications such as research designs that use modern missing data methods to plan missing data purposefully. This article describes two state-of-the-art statistical methodologies for addressing missing data in longitudinal research: growth curve analysis and statistical measurement models. How the purposeful planning of missing data in research designs can reduce subject burden, improve data quality and statistical power, and manage costs is then described. J Am Geriatr Soc 58:S343-S348, 2010. C1 [Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78284 USA. [Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat & Epidemiol, San Antonio, TX 78284 USA. [Royall, Donald R.] S Texas Vet Hlth Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, Dept Family & Community Med, San Antonio, TX USA. [Royall, Donald R.] S Texas Vet Hlth Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, Dept Psychiat, San Antonio, TX USA. [Royall, Donald R.] S Texas Vet Hlth Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, Dept Med, San Antonio, TX USA. [Royall, Donald R.] S Texas Vet Hlth Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, Dept Pharmacol, San Antonio, TX USA. RP Palmer, RF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. EM palmerr@uthscsa.edu FU Robert Wood Johnson Foundation FX This paper is based on a January 2009 conference on Longitudinal Studies in Aging, Boca Raton, Florida, supported by a grant from the Robert Wood Johnson Foundation. NR 44 TC 23 Z9 24 U1 0 U2 12 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2010 VL 58 SU 2 BP S343 EP S348 DI 10.1111/j.1532-5415.2010.03053.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 656YJ UT WOS:000282376700014 PM 21029065 ER PT J AU Hanlon, JT Perera, S Sevick, MA Rodriguez, KL Jaffe, EJ AF Hanlon, Joseph T. Perera, Subashan Sevick, Mary Ann Rodriguez, Keri L. Jaffe, Emily J. TI Pain and Its Treatment in Older Nursing Home Hospice/Palliative Care Residents SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Aged; nursing home; hospice; palliative care; analgesics ID NONMALIGNANT PAIN; HOSPICE CARE; MANAGEMENT; ADULTS AB Objectives: The objectives of this study were to determine the prevalence of pain, describe its treatment, and determine factors associated with any pain in older residents assigned to a hospice specialty unit bed or receiving services from a hospice/palliative care/end-of-life special program in US nursing homes. Design: Cross-sectional study of data from the 2004 National Nursing Home Survey. Setting: The setting was 1174 US nursing homes. Participants: Participants were 303 sampled patients, 65 years or older, representing 33,413 individuals receiving hospice/palliative care. Measurements: Facility staff was asked if, in the past 7 days, the resident had reported or shown evidence of pain. Medication use data were derived from medication administration records. Information about demographics and health status was derived from Minimum Data Set records. Results: Cancer was the primary diagnosis in only 11.4% of residents. Overall 36.6% had any pain in the previous week. Among those with any pain, 86.4% received some analgesic; specifically, 65.5% received opioids, whereas 31.7% received acetaminophen. Those with any pain compared with those without pain had shorter lengths of stay in hospice/palliative care (mean 123 days versus 161 days, P < .01), were more likely to be incontinent of bowel (76.2%, versus 60.3%, P < 0.01) and bladder (84.5% versus 71.8%, P = 0.01). Conclusions: Pain symptoms were present in more than one third of older nursing home hospice/palliative care residents despite the use of opioids in two thirds of those who had reported or shown evidence of any pain. Additional future studies are needed to improve the management of pain in older residents receiving hospice/palliative care in US nursing homes. (J Am Med Dir Assoc 2010; 11: 579-583) C1 [Hanlon, Joseph T.; Perera, Subashan] Univ Pittsburgh, Dept Med, Div Geriatr Med, Sch Med, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm & Therapeut, Sch Pharm, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.; Sevick, Mary Ann; Rodriguez, Keri L.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Hanlon, Joseph T.; Sevick, Mary Ann; Rodriguez, Keri L.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Perera, Subashan] Univ Pittsburgh, Dept Biostat, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. [Sevick, Mary Ann; Rodriguez, Keri L.; Jaffe, Emily J.] Univ Pittsburgh, Div Gen Internal Med, Dept Med, Sch Med, Pittsburgh, PA 15213 USA. [Sevick, Mary Ann] Univ Pittsburgh, Dept Behav & Community Hlth Sci, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Med, Div Geriatr Med, Sch Med, Kaufman Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu RI Perera, Subashan/D-7603-2014 FU National Institute of Aging [R01AG027017, P30AG024827]; VA Health Services Research grant [IIR-06-062] FX This study was supported by National Institute of Aging grants (R01AG027017; P30AG024827), and a VA Health Services Research grant (IIR-06-062). NR 21 TC 16 Z9 18 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD OCT PY 2010 VL 11 IS 8 BP 579 EP 583 DI 10.1016/j.jamda.2009.11.014 PG 5 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 669FO UT WOS:000283333500007 PM 20889094 ER PT J AU Jonker, MA Sano, Y Hermsen, JL Lan, JG Kudsk, KA AF Jonker, Mark A. Sano, Yoshifumi Hermsen, Joshua L. Lan, Jinggang Kudsk, Kenneth A. TI Proinflammatory Cytokine Surge After Injury Stimulates an Airway Immunoglobulin A Increase SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT Annual Meeting of the Surgical-Infection-Society CY MAY09, 2009 CL Chicago, IL SP Surg Infection Soc DE Pro-inflammatory cytokines; Mucosal immunity; Airway; Injury; Kinetics; Intraperitoneal ID TUMOR-NECROSIS-FACTOR; VENTILATOR-ASSOCIATED PNEUMONIA; CRITICALLY-ILL PATIENTS; EPITHELIAL-CELL LINE; FACTOR-KAPPA-B; NOSOCOMIAL PNEUMONIA; FACTOR-ALPHA; SECRETORY COMPONENT; TRAUMA PATIENTS; MUCOSAL IMMUNITY AB Background: Injury stimulates an innate airway IgA response in severely injured patients, which also occurs in mice. Tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 beta stimulate the production of polymeric immunoglobulin receptor, the protein required to transport immunoglobulin A (IgA) to mucosal surfaces. Blockade of TNF-alpha and IL-1 beta eliminates the airway IgA response to injury. IL-6 stimulates differentiation of B cells into IgA-secreting plasma cells at mucosal sites. We investigated the local and systemic kinetics of TNF-alpha, IL-1 beta, and IL-6 after injury in mice. We also hypothesized that injection of exogenous TNF-alpha, IL-1 beta, and IL-6 would replicate the airway IgA response to injury. Methods: Experiment 1: male Institute of Cancer Research mice were randomized to uninjured controls (n = 8) or to surgical stress with laparotomy and neck incisions, with killing at 1, 2, 3, 5, or 8 hours after injury (n = 8/group). Bronchoalveolar lavage (BAL) and serum levels of TNF-alpha, IL-1 beta, and IL-6 were analyzed by enzyme-linked immunosorbent assay. Experiment 2: male Institute of Cancer Research mice were randomized to uninjured controls (n = 6), injury (surgical stress that was similar to experiment 1 except the peritoneum was left intact, n = 6), or cytokine injection with intraperitoneal injection of recombinant TNF-alpha, IL-1 beta, and IL-6. Animals were killed at 2 hours after injury, and nasal airway lavage and BAL IgA were analyzed by enzyme-linked immunosorbent assay. Results: Experiment 1: BAL TNF-alpha, IL-1 beta, and IL-6 levels increased in bimodal pattern after injury at 3 hours and 8 hours versus controls (p < 0.05). Serum IL-6 did not increase at 3 hours, but did show a significant increase by 5 hours versus control (p < 0.05). Serum levels of TNF-alpha and IL-1 beta did not change. Experiment 2: both Injury and combination TNF-alpha, IL-1 beta, and IL-6 cytokine injection significantly increased IgA levels in airway lavage (BAL + nasal airway lavage) compared with control (p < 0.01 for both). Conclusions: Airway levels of TNF-alpha, IL-1 beta, and IL-6 increase in a bimodal pattern after injury with peaks at 3 hours and 8 hours, which do not correspond to serum changes. The peak at 8 hours is consistent with the known increase in airway IgA after injury. Intraperitoneal injection of a combination exogenous TNF-alpha, IL-1 beta, and IL-6 replicates the airway IgA increase after injury. This effect is not seen with individual cytokine injections. C1 [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Jonker, Mark A.; Sano, Yoshifumi; Hermsen, Joshua L.; Lan, Jinggang; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA. RP Kudsk, KA (reprint author), 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU NIGMS NIH HHS [R01 GM53439, R01 GM053439-03, R01 GM053439-06A1, R01 GM053439-13, R01 GM053439-04, R01 GM053439-11, R01 GM053439-10A2, R01 GM053439-05, R01 GM053439-09, R01 GM053439-07, R01 GM053439-12, R01 GM053439, R01 GM053439-02, R01 GM053439-08] NR 51 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD OCT PY 2010 VL 69 IS 4 BP 843 EP 848 DI 10.1097/TA.0b013e3181c45284 PG 6 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 664KP UT WOS:000282959100036 PM 20173656 ER PT J AU Kalantar, BS Hipp, JA Reitman, CA Dreiangel, N Ben-Galim, P AF Kalantar, Babak S. Hipp, John A. Reitman, Charles A. Dreiangel, Niv Ben-Galim, Peleg TI Diagnosis of Unstable Cervical Spine Injuries: Laboratory Support for the Use of Axial Traction to Diagnose Cervical Spine Instability SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article DE Cervical spine; Trauma; Instability; Diagnosis; Traction ID COMPUTED-TOMOGRAPHY SCAN; BLUNT TRAUMA PATIENTS; INTERVERTEBRAL MOTION; PLAIN RADIOGRAPHY; JACKSON TABLE; DISLOCATIONS; CLEARANCE; PATIENT; SERIES; HEAD AB Background: The ability to detect damage to the intervertebral structures is critical in the management of patients after blunt trauma. A practical and inexpensive method to identify severe structural damage not clearly seen on computed tomography would be of benefit. The objective of this study was to assess whether ligamentous injury in the subaxial cervical spine can be reliably detected by analysis of lateral radiographs taken with and without axial traction. Methods: Twelve fresh, whole, postrigor-mortis cadavers were used for this study. Lateral cervical spine radiographs were obtained during the application of 0 N, 89 N, and 178 N of axial traction applied to the head. Progressive incremental sectioning of posterior structures was then performed at C4 C5 with traction imaging repeated after each intervention. Intervertebral distraction was analyzed using computer-assisted software. Results: Almost imperceptible intervertebral separation was found when traction was applied to intact spines. In the subaxial cervical spine, the average posterior disc height consistently increased under traction in severely injured spines. The average disc height increase was 14% of the C4 upper endplate width, compared with an average of 2% in the noninjured spines. A change of more than 5% in posterior disc height under traction was above the 95% confidence interval for intact spines, with sensitivity of 83% and specificity of 80%. Applied force of 89 N (20 lb) was sufficient to demonstrate injury. The combination of assessing alignment and distraction under traction increased both the sensitivity and specificity to nearly 100%. Conclusion: This study supports further clinical investigations to determine whether low-level axial traction may be a useful adjunct for detecting unstable subaxial cervical spine injuries in an acute setting. C1 [Hipp, John A.] Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA. Michael E DeBakey Vet Adm Med Ctr, Spine Res Lab, Houston, TX USA. RP Hipp, JA (reprint author), Baylor Coll Med, Dept Orthoped Surg, 6620 Main St,11th Floor, Houston, TX 77030 USA. EM jhipp@bcm.edu NR 34 TC 1 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD OCT PY 2010 VL 69 IS 4 BP 889 EP 895 DI 10.1097/TA.0b013e3181bbd660 PG 7 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 664KP UT WOS:000282959100047 PM 20130489 ER PT J AU Forbes, D Creamer, M Bisson, JI Cohen, JA Crow, BE Foa, EB Friedman, MJ Keane, TM Kudler, HS Ursano, RJ AF Forbes, David Creamer, Mark Bisson, Jonathan I. Cohen, Judith A. Crow, Bruce E. Foa, Edna B. Friedman, Mathew J. Keane, Terence M. Kudler, Harold S. Ursano, Robert J. TI A Guide to Guidelines for the Treatment of PTSD and Related Conditions SO JOURNAL OF TRAUMATIC STRESS LA English DT Article AB In recent years, several practice guidelines have appeared to inform clinical work in the assessment and treatment of posttraumatic stress disorder. Although there is a high level of consensus across these documents, there are also areas of apparent difference that may lead to confusion among those to whom the guidelines are targeted providers, consumers, ant/purchasers of mental health services for people affected by trauma. The authors have been responsible for developing guidelines across three continents (North America, Europe, and Australia). The aim of this article is to examine the various guidelines and to compare and contrast their methodologies and recommendations to aid clinicians in making decisions about their use. C1 [Forbes, David; Creamer, Mark] Univ Melbourne, ACPMH, Melbourne, Vic 3002, Australia. [Bisson, Jonathan I.] Cardiff Univ, Dept Psychol Med, Cardiff, S Glam, Wales. [Cohen, Judith A.] Allegheny Gen Hosp, Dept Psychiat, Pittsburgh, PA 15212 USA. [Cohen, Judith A.] Drexel Univ, Coll Med, Philadelphia, PA USA. [Foa, Edna B.] Univ Penn, Dept Psychiat, Ctr Treatment & Study Anxiety, Philadelphia, PA 19104 USA. [Friedman, Mathew J.] Dartmouth Med Sch, Dept Psychiat, Hanover, NH USA. [Friedman, Mathew J.] Dartmouth Med Sch, Dept Pharmacol, Hanover, NH USA. [Keane, Terence M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA. [Kudler, Harold S.] US Dept Vet Affairs, Mid Atlantic Mental Illness Res Educ & Clin Ctr, Washington, DC USA. [Ursano, Robert J.] Uniformed Serv Univ Hlth Sci, Ctr Study Traumat Stress, Bethesda, MD USA. RP Forbes, D (reprint author), Univ Melbourne, ACPMH, Level 1,340 Albert St, Melbourne, Vic 3002, Australia. EM dforbes@unimelb.edu.au RI turton, miranda/F-4682-2011 NR 14 TC 95 Z9 96 U1 4 U2 27 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD OCT PY 2010 VL 23 IS 5 BP 537 EP 552 DI 10.1002/jts.20565 PG 16 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 674PF UT WOS:000283758900001 PM 20839310 ER PT J AU Calohan, J Peterson, K Peskind, ER Raskind, MA AF Calohan, Jess Peterson, Kris Peskind, Elaine R. Raskind, Murray A. TI Prazosin Treatment of Trauma Nightmares and Sleep Disturbance in Soldiers Deployed in Iraq SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; COMBAT VETERANS; PTSD; SYMPTOMS; BRAIN AB Trauma nightmares and sleep disturbance impair combat soldiers' functioning. The alpha-1 adrenoreceptor antagonist prazosin has been demonstrated effective for these symptoms in Vietnam veterans. Thirteen soldiers seeking relief from distressing trauma nightmares impairing military function in northern Iraq in 2006 received prazosin alone or in combination with other psychotropics. Mean prazosin dose was 4.1 (SD = 2.2) mg before bed. Six soldiers improved markedly and 3 moderately on the Clinical Global Impression of Change Ratings of distressing dreams decreased from an average of 7.0 (SD = 0.7) to 2.9 (SD = 3.0, p < .001) and those of disturbed sleep from 67 (SD = 0.9) to 3.7 (SD = 2.4, p < .001). Prazosin appears effective and well tolerated in the desert warfare environment. RP Raskind, MA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S116 6 E, Seattle, WA 98108 USA. EM murray.raskind@va.gov NR 10 TC 18 Z9 19 U1 0 U2 6 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD OCT PY 2010 VL 23 IS 5 BP 645 EP 648 DI 10.1002/jts.20570 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 674PF UT WOS:000283758900014 PM 20931662 ER PT J AU Churchill, BM Bergman, J Kristo, B Gore, JL AF Churchill, Bernard M. Bergman, Jonathan Kristo, Blaine Gore, John L. TI Improved Continence in Patients With Neurogenic Sphincteric Incompetence With Combination Tubularized Posterior Urethroplasty and Fascial Wrap: The Lengthening, Narrowing and Tightening Procedure SO JOURNAL OF UROLOGY LA English DT Article DE urethra; urinary bladder, neurogenic; meningomyelocele; urinary incontinence; reconstructive surgical procedures ID BLADDER NECK REPAIR; URINARY-INCONTINENCE; CHILDREN; 10-YEAR AB Purpose: We evaluated the outcome in 19 patients who underwent bladder neck reconstruction by lengthening, narrowing and tightening the bladder neck with a combined tubularized posterior urethroplasty and circumferential fascial wrap. Materials and Methods: We reviewed the records of all patients who underwent bladder neck lengthening, narrowing and tightening between April 1996 and November 2002. Preoperative urodynamic and radiographic data were available on all patients. The surgical technique involved retroperitoneal exposure of the bladder neck with a tubularized posterior urethroplasty over a urethral catheter. The reconstructed urethra was then circumferentially wrapped with a fitted piece of cadaveric fascia. Results: Of the 19 patients 15 remain completely continent at a mean +/- SD followup of 35.5 +/- 29.1 months. Three patients underwent secondary reconstruction, including bladder neck ligation in all 3 and secondary enterocystoplasty in 2. No patient experienced difficult intermittent catheterization via the urethra postoperatively. Conclusions: Bladder neck lengthening, narrowing and tightening is effective for managing neurogenic sphincteric incontinence. Outcomes are comparable with those of other reconstructive procedures. C1 [Gore, John L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Gore, JL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Box 951738,CHS 66-124, Los Angeles, CA 90095 USA. EM jgore@mednet.ucla.edu OI Gore, John/0000-0002-2847-5062 NR 13 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD OCT PY 2010 VL 184 IS 4 SU 1 BP 1763 EP 1767 DI 10.1016/j.juro.2010.03.080 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 660DC UT WOS:000282618600065 PM 20728163 ER PT J AU Marsh, L AF Marsh, Laura TI Treatment of Lewy-body dementias and psychopathology SO LANCET NEUROLOGY LA English DT Editorial Material ID PARKINSONS-DISEASE; BODIES; SYSTEM C1 [Marsh, Laura] Baylor Coll Med, Dept Psychiat, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Marsh, Laura] Baylor Coll Med, Dept Neurol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Marsh, L (reprint author), Baylor Coll Med, Dept Psychiat, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. EM laura.marsh2@va.gov NR 9 TC 1 Z9 1 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 J9 LANCET NEUROL JI Lancet Neurol. PD OCT PY 2010 VL 9 IS 10 BP 943 EP 945 DI 10.1016/S1474-4422(10)70208-8 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 672WC UT WOS:000283616700003 PM 20729149 ER PT J AU Heinrich, MC AF Heinrich, Michael C. TI Imatinib treatment of metastatic GIST: don't stop (believing) SO LANCET ONCOLOGY LA English DT Editorial Material ID GASTROINTESTINAL STROMAL TUMORS; STEM-CELLS; LEUKEMIA C1 Portland VA Med Ctr, Portland, OR USA. [Heinrich, Michael C.] OHSU Knight Canc Inst, Portland, OR USA. RP Heinrich, MC (reprint author), Portland VA Med Ctr, Portland, OR USA. EM heinrich@ohsu.edu NR 6 TC 6 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 J9 LANCET ONCOL JI Lancet Oncol. PD OCT PY 2010 VL 11 IS 10 BP 910 EP 911 DI 10.1016/S1470-2045(10)70225-4 PG 2 WC Oncology SC Oncology GA 667RE UT WOS:000283210600004 PM 20864404 ER PT J AU Naugler, WE Sonnenberg, A AF Naugler, Willscott E. Sonnenberg, Amnon TI Survival and Cost-Effectiveness Analysis of Competing Strategies in the Management of Small Hepatocellular Carcinoma SO LIVER TRANSPLANTATION LA English DT Article ID HEPATITIS-C VIRUS; RADIOFREQUENCY ABLATION; COMPUTED-TOMOGRAPHY; NATURAL-HISTORY; GROWTH-RATE; COMPENSATED CIRRHOSIS; CLINICAL-TRIALS; UNITED-STATES; LIVER-TUMORS; COMPLICATIONS AB The aim of the present study is to compare the survival rates and cost-effectiveness of different treatment strategies for small (<2 cm) hepatocellular carcinoma (HCC). Markov chains are developed to model different management strategies for patients with compensated cirrhosis and small HCC. Probabilities of progression and survival and the likelihood of orthotopic liver transplantation are taken from the literature and incorporated into the models. As a starting population, 1000 patients are followed over a period of 10 years. Patients treated immediately with transarterial chemoembolization (TACE) or radiofrequency ablation (RFA) live as long as or longer than patients who are monitored expectantly with the intention of liver transplantation once the HCC has grown larger than 2 cm and a higher transplant priority score becomes available. With TACE, immediate treatment results in an average survival time of 4.269 years versus 4.324 years with the monitoring strategy. With RFA, immediate treatment results in an average survival time of 5.273 years versus 5.236 years with the monitoring strategy. In addition, the cost analysis shows that immediate treatment with either TACE or RFA is less expensive than monitoring. The better cost-effectiveness of immediate therapy versus the monitoring strategy remains robust and unaffected by variations of the assumptions built into the model. In conclusion, in patients with compensated cirrhosis and small HCC, a strategy of immediate treatment with either TACE or RFA prevails over a strategy of expectant monitoring with the intention of transplantation. Liver Transpl 16: 1186-1194, 2010. (C) 2010 AASLD. C1 [Naugler, Willscott E.] Oregon Hlth & Sci Univ, Div Gastroenterol, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Naugler, WE (reprint author), Oregon Hlth & Sci Univ, Div Gastroenterol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM nauglers@ohsu.edu NR 39 TC 27 Z9 28 U1 0 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1527-6465 J9 LIVER TRANSPLANT JI Liver Transplant. PD OCT PY 2010 VL 16 IS 10 BP 1186 EP 1194 DI 10.1002/lt.22129 PG 9 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA 665XH UT WOS:000283070000009 PM 20879017 ER PT J AU Keith, RL Karoor, V Mozer, AB Hudish, TM Le, M Miller, YE AF Keith, Robert L. Karoor, Vijaya Mozer, Anthony B. Hudish, Tyler M. Le, Mysan Miller, York E. TI Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression SO LUNG CANCER LA English DT Article DE Chemoprevention; Lung cancer; Transgenic mice; Src; EGFR; Gefitinib; Prostacyclin ID GROWTH-FACTOR RECEPTOR; PULMONARY PROSTACYCLIN; TRANSGENIC MICE; TUMOR-GROWTH; CELL-LINES; EXPRESSION; ADENOCARCINOMA; INHIBITION; SRC; TUMORIGENESIS AB Introduction: We hypothesized that the combination of the EGFR tyrosine kinase inhibitor (TKI) gefitinib with the powerful chemopreventive manipulation of lung-specific transgenic prostacyclin synthase (PGIS) overexpression on tumorigenesis in FVB/N mice would result in augmented chemoprevention. Materials and methods: Wildtype and littermate PGIS overexpressors (OE) were given urethane, 1 mg/kg i.p. followed by thrice weekly i.p. injections of gefitinib, 50 mg/kg or 100 mg/kg, or vehicle. Pulmonary adenomas were enumerated and measured. Results: Gefitinib at either 50 mg/kg or 100 mg/kg administered i.p. three times weekly was effective in inhibiting EGF induced EGFR tyrosine phosphorylation and downstream signaling. The PGIS overexpressors showed significant decreases in tumor multiplicity consistent with prior studies. Gefitinib had no effect on tumor multiplicity or volume in wildtype mice. Among the PGIS overexpressors, a significant reduction in tumor multiplicity was shown in the 50 mg/kg, but not the 100 mg/kg, gefitinib treatment group vs. vehicle control animals (1.13 +/- 0.29 vs. 2.29 +/- 0.32 tumors/mouse, p = 0.015). We examined the phosphorylation status in selected downstream effectors of EGFR (Erk, Akt, Src, PTEN). The major difference in the 50 mg/kg vs. 100 mg/kg group was an increase in p-Src in the PGIS OE mice receiving the higher dose. Conclusion: We conclude that gefitinib alone has no chemopreventive efficacy in this model; it augmented the effect of PGIS overexpression at 50 mg/kg but not 100 mg/kg. Increased p-Src is correlated with loss of efficacy at the higher dose, suggesting the potential for combined EGFR and Src inhibition strategies in chemoprevention. (C) 2010 Published by Elsevier Ireland Ltd. C1 [Keith, Robert L.; Mozer, Anthony B.; Hudish, Tyler M.; Le, Mysan; Miller, York E.] Vet Adm Med Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80220 USA. [Keith, Robert L.; Karoor, Vijaya; Miller, York E.] Univ Colorado, Dept Med, Denver, CO 80262 USA. RP Miller, YE (reprint author), Denver VA Med Ctr, Dept Med, 1055 Clermont St,Pulm 111A, Denver, CO 80220 USA. EM york.miller@ucdenver.edu FU Department of Veterans Affairs; NCI [P50 CA58187] FX Supported by Department of Veterans Affairs Merit Review Grants (YEM and RLK) and NCI P50 CA58187 (SPORE in Lung Cancer, YEM and RLK). NR 26 TC 6 Z9 6 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 J9 LUNG CANCER JI Lung Cancer PD OCT PY 2010 VL 70 IS 1 BP 37 EP 42 DI 10.1016/j.lungcan.2010.01.004 PG 6 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 658QE UT WOS:000282503700006 PM 20116128 ER PT J AU Cedfeldt, AS Bower, EA English, C Grady-Weliky, TA Girard, DE Choi, D AF Cedfeldt, Andrea S. Bower, Elizabeth A. English, Clea Grady-Weliky, Tana A. Girard, Donald E. Choi, Dongseok TI Personal time off and residents' career satisfaction, attitudes and emotions SO MEDICAL EDUCATION LA English DT Article ID INTERNAL-MEDICINE RESIDENTS; HEALTH-CARE; BURNOUT; PHYSICIANS; PROGRAMS; STRESS; PREDICTORS; STUDENTS AB OBJECTIVES Doctors who are satisfied with their careers have less stress and burnout and are less likely to make medical errors and more likely to provide a higher quality of patient care. In response to reports that residents experienced barriers to taking time off, Oregon Health and Science University designed a survey to evaluate residents' awareness of their programmes' policies for time off, their ability to find time for personal needs, and associations of both with career satisfaction, emotions and training experience. METHODS All 675 residents in a large, urban, tertiary care academic medical centre located in the USA were invited to participate in a confidential, web-based, cross-sectional survey in 2008; 66% completed the survey. The survey instrument consisted of a variety of items including yes/no, multiple choice, Likert scale and narrative response types. RESULTS Only 41% of respondents were aware of their programmes' policies regarding time off. Residents who reported awareness of a policy were more able to find time to take care of personal needs (odds ratio = 1.553, p = 0.026). These respondents reported more positive experiences and emotions, fewer negative experiences and emotions, higher levels of career satisfaction and relatively less perceived stress than those who were unaware of a time-off policy. In addition, these respondents reported, on average, fewer work and more sleep hours. CONCLUSIONS Our results highlight the importance of ensuring mechanisms for residents to find time to fulfil personal needs in order to enhance resident well-being and career satisfaction. Ensuring resident awareness of time-off policies is one way to do this. Our study demonstrates that ensuring residents are able to find time for personal needs has significant consequences with respect to resident perceptions of well-being and may be an effective strategy to promote career satisfaction and prevent burnout. C1 [Cedfeldt, Andrea S.; Girard, Donald E.] Oregon Hlth & Sci Univ, Div Grad Med Educ, Portland, OR 97239 USA. [Cedfeldt, Andrea S.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR USA. [Bower, Elizabeth A.; Girard, Donald E.] Oregon Hlth & Sci Univ, Div Continuing Med Educ, Portland, OR 97239 USA. [Bower, Elizabeth A.; Girard, Donald E.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. [English, Clea] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97239 USA. [Grady-Weliky, Tana A.] Oregon Hlth & Sci Univ, Off Educ & Student Affairs, Portland, OR 97239 USA. [Grady-Weliky, Tana A.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Choi, Dongseok] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. RP Choi, D (reprint author), Oregon Hlth & Sci Univ, Div Grad Med Educ, 3181 SW Sam Jackson Pk Rd,CB669, Portland, OR 97239 USA. EM choid@ohsu.edu OI Bower, Elizabeth/0000-0001-5331-4378 NR 32 TC 9 Z9 9 U1 1 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0308-0110 J9 MED EDUC JI Med. Educ. PD OCT PY 2010 VL 44 IS 10 BP 977 EP 984 DI 10.1111/j.1365-2923.2010.03773.x PG 8 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 659BC UT WOS:000282541000007 PM 20880367 ER PT J AU Jeffreys, MD Leibowitz, RQ Finley, E Arar, N AF Jeffreys, Matthew D. Leibowitz, Ruth Q. Finley, Erin Arar, Nedal TI Trauma Disclosure to Health Care Professionals by Veterans: Clinical Implications SO MILITARY MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; ADMINISTERED PTSD SCALE; HELP-SEEKING; SEXUAL-ABUSE; DOMESTIC VIOLENCE; EMOTIONAL DISCLOSURE; CHILDHOOD RAPE; PANDORA BOX; EXPERIENCES; WOMENS AB Trauma disclosure is the initial step toward healing trauma-related distress. This study used qualitative methods to better understand factors facilitating and inhibiting change in the disclosure process. Fifty-six veterans were interviewed about their disclosure experiences between August 2004 and 2005. Emerging themes and barriers to disclosure from 23 of these interviews are reported in this article. Barriers to trauma disclosure included lack of trust in the provider, fears about the potential negative consequences of disclosure, and trauma avoidance. Providers perceived as caring and communicating at the same level as the participants facilitated disclosure, whereas providers perceived as uncaring or disinterested inhibited disclosure. Veterans reported both positive and negative reactions to initial disclosure, but nearly all agreed that disclosure was worthwhile over the long term. Improving patient provider communications and creating settings that facilitate trauma disclosure may improve healing after trauma. C1 [Jeffreys, Matthew D.; Finley, Erin; Arar, Nedal] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX 78229 USA. [Leibowitz, Ruth Q.] Salem Hosp Reg Rehabil Ctr, Salem, OR 97301 USA. RP Jeffreys, MD (reprint author), S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, 7400 Merton Minter, San Antonio, TX 78229 USA. OI Finley, Erin/0000-0003-4497-7721 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX Dr. Leibowitz acknowledges Dr. Polly Hitchcock Noel for her mentorship. The authors also acknowledge Drs. Dianne Dunn and John Casada for their work in interviewing study participants. This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development (PI: Ruth Leibowitz, PhD). NR 57 TC 5 Z9 5 U1 1 U2 4 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD OCT PY 2010 VL 175 IS 10 BP 719 EP 724 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 658CX UT WOS:000282468500005 PM 20968260 ER PT J AU Freedy, JR Magruder, KM Mainous, AG Frueh, BC Geesey, ME Camemolla, M AF Freedy, John R. Magruder, Kathryn M. Mainous, Arch G. Frueh, B. Chris Geesey, Mark E. Camemolla, Mark TI Gender Differences in Traumatic Event Exposure and Mental Health Among Veteran Primary Care Patients SO MILITARY MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; AFFAIRS PRIMARY-CARE; NEUROPSYCHIATRIC INTERVIEW MINI; ADMINISTERED PTSD SCALE; COLLABORATIVE CARE; PSYCHOMETRIC PROPERTIES; PHYSICAL SYMPTOMS; MILITARY TRAUMA; WOMEN VETERANS; WAR VETERANS AB Objective: This study evaluated gender differences in lifetime traumatic events. PTSD, and depression among VA primary care patients. Method: Participants were 865 adults attending primary care at one of four VA health centers (n = 681 males, 184 females). Results: Mental health findings included: male PTSD 12.3% vs. female PTSD 9.2% (p > 0.05); male depression 15.9% vs. female depression 29.3% (p < 0.001). Men reported more war zone exposure (p < 0.001). Women reported more physical and sexual victimization (p < 0.001). Male logistic regression equations determined PTSD was associated with disability (OR = 3.42; 1.74-6.72, 95% CI) and war zone exposure (OR = 7.14; 3.82-13.30, 95% CI); depression was associated with war zone exposure (OR = 2.27; 1.40-3.68, 95% CI) and interpersonal violence (OR = 1.75; 1.10-2.79, 95% CI). Female PTSD was associated with sexual victimization (OR = 4.50; 1.20-16.80, 95% CI); depression was not predicted. Conclusions: We discuss findings in terms of the crucial need to improve identification and management of PTSD within VA primary care settings. C1 [Freedy, John R.; Mainous, Arch G.; Geesey, Mark E.; Camemolla, Mark] Med Univ S Carolina, Dept Family Med, Charleston, SC 29425 USA. [Magruder, Kathryn M.; Frueh, B. Chris] Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. [Magruder, Kathryn M.; Frueh, B. Chris] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Freedy, JR (reprint author), Med Univ S Carolina, Dept Family Med, 295 Calhoun St, Charleston, SC 29425 USA. OI Mainous, Arch/0000-0002-2535-7685 FU Veterans Affairs Health Services Research and Development FX This research was partially supported by a grant from the Veterans Affairs Health Services Research and Development Program to Dr. Magruder. NR 78 TC 14 Z9 14 U1 1 U2 7 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD OCT PY 2010 VL 175 IS 10 BP 750 EP 758 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 658CX UT WOS:000282468500010 PM 20968265 ER PT J AU Duarte, VM Han, E Veena, MS Salvado, A Suh, JD Liang, LJ Faull, KF Srivatsan, ES Wang, MB AF Duarte, Victor M. Han, Eugene Veena, Mysore S. Salvado, Amanda Suh, Jeffrey D. Liang, Li-Jung Faull, Kym F. Srivatsan, Eri S. Wang, Marilene B. TI Curcumin Enhances the Effect of Cisplatin in Suppression of Head and Neck Squamous Cell Carcinoma via Inhibition of IKK beta Protein of the NF kappa B Pathway SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID LIPOSOME-ENCAPSULATED CURCUMIN; CANCER-CELLS; IN-VITRO; COLORECTAL-CANCER; GENE-EXPRESSION; GROWTH; APOPTOSIS; KINASE; ANGIOGENESIS; CETUXIMAB AB Previous experiments have shown that curcumin or cisplatin treatment suppresses growth of head and neck squamous cell carcinoma (HNSCC). To study the potential cooperative effect of both agents, two HNSCC cell lines were treated with curcumin or cisplatin alone or in combination. In vivo studies consisted of intravenous tail vein injection of liposomal curcumin, with intraperitoneal cisplatin, into nude mice growing xenograft HNSCC tumors. Introduction of curcumin and suboptimal concentrations of cisplatin showed a significant suppressive effect compared with treatment with either agent alone. Reduced expression of cyclin D1, I kappa B alpha, phospho-I kappa B alpha, and IKK beta occurred in cisplatin- and curcumin-treated cell lines. Confocal microscopy showed expression of IKK beta in the nucleus of the cell lines. Chromatin immunoprecipitation assay on DNA isolated from IKK beta immunoprecipitated samples showed PCR amplification of interleukin-8 promoter sequences, a binding site of NF kappa B, indicating an interaction between IKK beta and NF kappa B. Curcumin inhibited IKK beta in the cytoplasm and nucleus, leading to reduced NF kappa B activity, with no effect on phospho-AKT. In vivo studies showed significant growth inhibition of xenograft tumors treated with a combination of liposomal curcumin and cisplatin. The suppressive effect of curcumin was mediated through inhibition of cytoplasmic and nuclear IKK beta, resulting in inhibition of NF kappa B activity. Cisplatin treatment led to cellular senescence, indicating an effect mediated by p53 activation. The mechanisms of the two agents through different growth signaling pathways suggest potential for the clinical use of subtherapeutic doses of cisplatin in combination with curcumin, which will allow effective suppression of tumor growth while minimizing the toxic side effects of cisplatin. Mol Cancer Ther; 9(10); 2665-75. (C) 2010 AACR. C1 [Duarte, Victor M.; Han, Eugene; Veena, Mysore S.; Salvado, Amanda; Suh, Jeffrey D.; Srivatsan, Eri S.; Wang, Marilene B.] VA Greater Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Duarte, Victor M.; Salvado, Amanda; Wang, Marilene B.] UCLA David Geffen Sch Med, Div Head & Neck Surg, Neuropsychiat Semel Inst, Los Angeles, CA 90095 USA. [Liang, Li-Jung] UCLA David Geffen Sch Med, Dept Med, Neuropsychiat Semel Inst, Los Angeles, CA 90095 USA. UCLA David Geffen Sch Med, Pasarow Mass Spectrometry Lab, Neuropsychiat Semel Inst, Los Angeles, CA 90095 USA. RP Wang, MB (reprint author), UCLA David Geffen Sch Med, Div Head & Neck Surg, Neuropsychiat Semel Inst, 200 UCLA Med Plaza Suite 550, Los Angeles, CA 90095 USA. EM mbwang@ucla.edu FU VA Greater Los Angeles Healthcare; NIH [R21 CA116826-01]; Veterans Administration (Washington, DC); West Los Angeles Surgical Education Research Center; UCLA Academic Senate FX VA Greater Los Angeles Healthcare, West Los Angeles Surgical Education Research Center, and UCLA Academic Senate (M. B. Wang); NIH grant R21 CA116826-01 (M. B. Wang); and Veterans Administration (Washington, DC) Merit grant (E. S. Srivatsan). NR 31 TC 64 Z9 69 U1 1 U2 10 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD OCT PY 2010 VL 9 IS 10 BP 2665 EP 2675 DI 10.1158/1535-7163.MCT-10-0064 PG 11 WC Oncology SC Oncology GA 661JS UT WOS:000282724600003 PM 20937593 ER PT J AU Latif, R Michalek, K Davies, TF AF Latif, Rauf Michalek, Krzysztof Davies, Terry F. TI Subunit Interactions Influence TSHR Multimerization SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID HUMAN THYROTROPIN RECEPTOR; EXTRACELLULAR DOMAIN; OLIGOMERIZATION; ECTODOMAIN; CLEAVAGE; ACTIVATION; REVEALS; BINDING; SITES AB The TSH receptor (TSHR) is the key molecule influencing thyroid growth and development and is an antigenic target in autoimmune thyroid disease. The TSHR exists in monomeric and multimeric forms, and it has been shown previously that multimeric complexes of the TSHR preferentially localize in lipid rafts. However, unlike other glycoprotein hormone receptors, the TSHR exists in several forms on the cell membrane due to intramolecular cleavage of its ectodomain, which causes the production of alpha- and beta-subunits of various lengths. After cleavage and reduction of disulfide bonds, alpha-subunits consisting of the receptor ectodomain may be lost from the cell surface by receptor shedding, leading to accumulation of excess beta-subunits within the membrane. Because cell surface expression of these various forms of the TSHR is critical to receptor signaling and autoimmune responses, we set out to model the influence of beta-subunits on full-length TSHRs. To study this interaction, we generated three truncated ectodomain beta-subunits linked to green fluorescent protein (named beta-316, -366, and -409) as examples of native cleaved forms of the TSHR. These constructs were transfected into human embryonic kidney 293 cells in the presence and absence of the full-length receptor. Whereas the beta-316 and beta-366 forms showed cell surface expression, the expression of beta-409 was primarily intracellular. Cotransfection of the beta-subunits with a full-length hemagglutinin-tagged wild-type (WT) receptor (HT-WT-TSHR) in both transient and stable systems caused a significant decrease in surface expression of the full-length WT receptors. This decrease was not seen with control plasmid consisting of a plasma membrane-targeted protein tagged to red fluorescent protein. To ascertain if this response was due to homointeraction of the truncated beta-constructs with the WT-TSHRs, we immunoprecipitated membranes prepared from the cotransfected cells using antihemagglutinin and then probed with anti-green fluorescent protein. These studies confirmed dimerization of the beta-subunits with the WT full-length receptor, and this interaction was further observed in vivo by fluorescence resonance energy transfer. We then studied the functional consequences of this interaction on TSHR signaling by examining G alpha s-mediated signals. The well-expressed truncated constructs, when coexpressed with full-length TSHR, did not alter constitutive cAMP levels, but there was a significant decrease in TSH-induced cAMP generation. Furthermore, we observed that truncated beta-316 and beta-366 had faster internalization rate, which may lead to a significant decrease in the expression of the full-length receptor on the cell surface, thus contributing to the decreased signaling response. However, the decrease in surface receptors may also be due to inhibition of newly formed receptors reaching the surface as result of receptor-receptor interaction. It is well known that under normal physiological conditions both cleaved and uncleaved TSHR forms coexist on the cell surface of normal thyrocytes. Our studies allow us to conclude, therefore, that multimerization of cleaved/truncated forms of the beta-subunits with the full-length TSHR has a profound influence on TSHR internalization and signaling. Hence, the degree of intramolecular cleavage must also modulate TSHR signaling. (Molecular Endocrinology 24: 2009-2018, 2010) C1 [Latif, Rauf; Michalek, Krzysztof; Davies, Terry F.] James J Peters Vet Affairs Med Ctr, Mt Sinai Sch Med, Thyroid Res Unit, New York, NY 10468 USA. [Michalek, Krzysztof] Univ Med Sci, Dept Endocrinol, PL-60355 Poznan, Poland. RP Latif, R (reprint author), James J Peters Vet Affairs Med Ctr, Room 2F-30,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM rauf.latif@mssm.edu OI latif, rauf/0000-0002-4226-3728 FU Department of Endocrinology, University of Medical Sciences, Poznan, Poland; National Institute of Diabetes and Kidney and Digestive Diseases [DK069713]; Veterans Affairs [4535-05-074]; David Owen Segal Endowment FX We thank Zhong Yao (VAMC) for technical assistance and Professor Jerzy Sowinski (Department of Endocrinology, University of Medical Sciences, Poznan, Poland) for advice and support.; This work was supported by: National Institutes of Health Grant DK069713 from National Institute of Diabetes and Kidney and Digestive Diseases, the Veterans Affairs Merit Award program 4535-05-074 (to T. F. D.), and the David Owen Segal Endowment (to K.M.). NR 21 TC 7 Z9 7 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD OCT 1 PY 2010 VL 24 IS 10 BP 2009 EP 2018 DI 10.1210/me.2010-0001 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 655AY UT WOS:000282214700010 PM 20719860 ER PT J AU Seepersaud, R Bensing, BA Yen, YFT Sullam, PM AF Seepersaud, Ravin Bensing, Barbara A. Yen, Yihfen T. Sullam, Paul M. TI Asp3 mediates multiple protein-protein interactions within the accessory Sec system of Streptococcus gordonii SO MOLECULAR MICROBIOLOGY LA English DT Article ID SURFACE GLYCOPROTEINS GSPB; MOLECULAR CHAPERONE SECB; TRANSLOCATION CHANNEL; III SECRETION; IB-ALPHA; BINDING; EXPORT; MEMBRANE; HSA; GLYCOSYLATION AB P>Bacterial binding to human platelets is an important step in the pathogenesis of infective endocarditis. Streptococcus gordonii can mediate its platelet attachment through a cell wall glycoprotein termed GspB ('gordonii surface protein B'). GspB export is mediated by a seven-component accessory Sec system, containing two homologues of the general secretory pathway (SecA2 and SecY2) and five accessory Sec proteins (Asps1-5). Here we show that the Asps are required for optimal export of GspB independent of the glycosylation process. Furthermore, yeast two-hybrid screening of the accessory Sec system revealed interactions occurring between Asp3 and the other components of the system. Asp3 was shown to bind SecA2, Asp1, Asp2 and itself. Mutagenesis of Asp3 identified N- and C-terminal regions that are essential for GspB transport, and conserved residues within the C-terminal domain mediated Asp3 binding to other accessory Sec components. The loss of binding by Asp3 also resulted in an impaired ability of S. gordonii to secrete GspB. These studies indicate that Asp3 is a central element mediating multiple interactions among accessory Sec components that are essential for GspB transport to the cell surface. C1 [Seepersaud, Ravin; Bensing, Barbara A.; Yen, Yihfen T.; Sullam, Paul M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. RP Sullam, PM (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. EM paul.sullam@ucsf.edu FU Department of Veterans Affairs, National Institutes of Health [R01 AI41513, R01 AI057433] FX This study was supported by the Department of Veterans Affairs, the VA Merit Review programme, and grants R01 AI41513 and R01 AI057433 from the National Institutes of Health. We thank Jason McGovern for his help with the YTH assay. NR 42 TC 20 Z9 20 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0950-382X J9 MOL MICROBIOL JI Mol. Microbiol. PD OCT PY 2010 VL 78 IS 2 BP 490 EP 505 DI 10.1111/j.1365-2958.2010.07346.x PG 16 WC Biochemistry & Molecular Biology; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA 663IN UT WOS:000282876900017 PM 20807195 ER PT J AU Masters, SL Dunne, A Subramanian, SL Hull, RL Tannahill, GM Sharp, FA Becker, C Franchi, L Yoshihara, E Chen, Z Mullooly, N Mielke, LA Harris, J Coll, RC Mills, KHG Mok, KH Newsholme, P Nunez, G Yodoi, J Kahn, SE Lavelle, EC O'Neill, LAJ AF Masters, Seth L. Dunne, Aisling Subramanian, Shoba L. Hull, Rebecca L. Tannahill, Gillian M. Sharp, Fiona A. Becker, Christine Franchi, Luigi Yoshihara, Eiji Chen, Zhe Mullooly, Niamh Mielke, Lisa A. Harris, James Coll, Rebecca C. Mills, Kingston H. G. Mok, K. Hun Newsholme, Philip Nunez, Gabriel Yodoi, Junji Kahn, Steven E. Lavelle, Ed C. O'Neill, Luke A. J. TI Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 beta in type 2 diabetes SO NATURE IMMUNOLOGY LA English DT Article ID HUMAN PANCREATIC-ISLETS; LOW-DENSITY-LIPOPROTEIN; BETA-CELL MASS; NALP3 INFLAMMASOME; INSULIN-RESISTANCE; TRANSGENIC MICE; MOUSE MODEL; IN-VITRO; AMYLIN; MELLITUS AB Interleukin 1 beta (IL-1 beta) is an important inflammatory mediator of type 2 diabetes. Here we show that oligomers of islet amyloid polypeptide (IAPP), a protein that forms amyloid deposits in the pancreas during type 2 diabetes, triggered the NLRP3 inflammasome and generated mature IL-1 beta. One therapy for type 2 diabetes, glyburide, suppressed IAPP-mediated IL-1 beta production in vitro. Processing of IL-1 beta initiated by IAPP first required priming, a process that involved glucose metabolism and was facilitated by minimally oxidized low-density lipoprotein. Finally, mice transgenic for human IAPP had more IL-1 beta in pancreatic islets, which localized together with amyloid and macrophages. Our findings identify previously unknown mechanisms in the pathogenesis of type 2 diabetes and treatment of pathology caused by IAPP. C1 [Masters, Seth L.; Dunne, Aisling; Mielke, Lisa A.; Harris, James; Mills, Kingston H. G.; Lavelle, Ed C.; O'Neill, Luke A. J.] Trinity Coll Dublin, Sch Biochem & Immunol, Immunol Res Ctr, Dublin, Ireland. [Masters, Seth L.; Tannahill, Gillian M.; Becker, Christine; Coll, Rebecca C.; O'Neill, Luke A. J.] Trinity Coll Dublin, Sch Biochem & Immunol, Inflammat Res Grp, Dublin, Ireland. [Dunne, Aisling; Mielke, Lisa A.; Mills, Kingston H. G.] Trinity Coll Dublin, Sch Biochem & Immunol, Immune Regulat Res Grp, Dublin, Ireland. [Subramanian, Shoba L.; Hull, Rebecca L.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Subramanian, Shoba L.; Hull, Rebecca L.; Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Sharp, Fiona A.; Harris, James; Lavelle, Ed C.] Trinity Coll Dublin, Adjuvant Res Grp, Sch Biochem & Immunol, Dublin, Ireland. [Franchi, Luigi; Nunez, Gabriel] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA. [Franchi, Luigi; Nunez, Gabriel] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Yoshihara, Eiji; Chen, Zhe; Yodoi, Junji] Kyoto Univ, Dept Biol Responses, Inst Virus Res, Kyoto 6068501, Japan. [Mullooly, Niamh; Newsholme, Philip] Univ Coll Dublin, Sch Biomol & Biomed Sci, Conway Inst, Dublin 2, Ireland. [Mok, K. Hun] Trinity Coll Dublin, Sch Biochem & Immunol, Prot Folding & Biomol NMR Spect Grp, Dublin, Ireland. RP Masters, SL (reprint author), Trinity Coll Dublin, Sch Biochem & Immunol, Immunol Res Ctr, Dublin, Ireland. EM smasters@tcd.ie RI Chen, Zhe/F-6273-2010; Mok, K. Hun/C-2607-2009; Masters, Seth/N-2886-2013; Coll, Rebecca/J-2124-2014 OI Chen, Zhe/0000-0003-3626-9848; Masters, Seth/0000-0003-4763-576X; Coll, Rebecca/0000-0002-7359-6023; Newsholme, Philip/0000-0002-0500-6984; Harris, James/0000-0002-5634-9637; Hull, Rebecca/0000-0001-9690-4087 FU National Health and Medical Research Council [516783]; Science Foundation Ireland; United States Department of Veterans Affairs; US National Institutes of Health [DK-75998, AI063331]; Crohn's and Colitis Foundation FX We thank A. Mori for assistance with Nlrp3-/- mice; J. Tschopp (University of Lausanne) for Nlrp3-/- mice; and E. Latz (University of Bonn) for YFP-ASC BMDMs. Supported by the National Health and Medical Research Council (516783 to S.L.M.), Science Foundation Ireland (for work at Trinity College Dublin), the United States Department of Veterans Affairs (for work at the VA Puget Sound Health Care System), the US National Institutes of Health (DK-75998 to S.E.K. for work at VA Puget Sound Health Care System, and AI063331 for work at the University of Michigan) and the Crohn's and Colitis Foundation (L.F.). NR 53 TC 474 Z9 489 U1 6 U2 72 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1529-2908 J9 NAT IMMUNOL JI Nat. Immunol. PD OCT PY 2010 VL 11 IS 10 BP 897 EP U1501 DI 10.1038/ni.1935 PG 9 WC Immunology SC Immunology GA 651KP UT WOS:000281926900008 PM 20835230 ER PT J AU Ray, NB Durairaj, L Chen, BB McVerry, BJ Ryan, AJ Donahoe, M Waltenbaugh, AK O'Donnell, CP Henderson, FC Etscheidt, CA Mccoy, DM Agassandian, M Hayes-Rowan, EC Coon, TA Butler, PL Gakhar, L Mathur, SN Sieren, JC Tyurina, YY Kagan, VE McLennan, G Mallampalli, RK AF Ray, Nancy B. Durairaj, Lakshmi Chen, Bill B. McVerry, Bryan J. Ryan, Alan J. Donahoe, Michael Waltenbaugh, Alisa K. O'Donnell, Christopher P. Henderson, Florita C. Etscheidt, Christopher A. Mccoy, Diann M. Agassandian, Marianna Hayes-Rowan, Emily C. Coon, Tiffany A. Butler, Phillip L. Gakhar, Lokesh Mathur, Satya N. Sieren, Jessica C. Tyurina, Yulia Y. Kagan, Valerian E. McLennan, Geoffrey Mallampalli, Rama K. TI Dynamic regulation of cardiolipin by the lipid pump Atp8b1 determines the severity of lung injury in experimental pneumonia SO NATURE MEDICINE LA English DT Article ID CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; FAMILIAL INTRAHEPATIC CHOLESTASIS; PULMONARY-EDEMA; PROTEIN-A; IN-VIVO; SURFACTANT; DISEASE; GENE; PHOSPHOLIPIDS; PURIFICATION AB Pneumonia remains the leading cause of death from infection in the US, yet fundamentally new conceptual models underlying its pathogenesis have not emerged. We show that humans and mice with bacterial pneumonia have markedly elevated amounts of cardiolipin, a rare, mitochondrial-specific phospholipid, in lung fluid and find that it potently disrupts surfactant function. Intratracheal cardiolipin administration in mice recapitulates the clinical phenotype of pneumonia, including impaired lung mechanics, modulation of cell survival and cytokine networks and lung consolidation. We have identified and characterized the activity of a unique cardiolipin transporter, the P-type ATPase transmembrane lipid pump Atp8b1, a mutant version of which is associated with severe pneumonia in humans and mice. Atp8b1 bound and internalized cardiolipin from extracellular fluid via a basic residue-enriched motif. Administration of a peptide encompassing the cardiolipin binding motif or Atp8b1 gene transfer in mice lessened bacteria-induced lung injury and improved survival. The results unveil a new paradigm whereby Atp8b1 is a cardiolipin importer whose capacity to remove cardiolipin from lung fluid is exceeded during inflammation or when Atp8b1 is defective. This discovery opens the door for new therapeutic strategies directed at modulating the abundance or molecular interactions of cardiolipin in pneumonia. C1 [Chen, Bill B.; McVerry, Bryan J.; Donahoe, Michael; Waltenbaugh, Alisa K.; O'Donnell, Christopher P.; Hayes-Rowan, Emily C.; Coon, Tiffany A.; Mallampalli, Rama K.] Univ Pittsburgh, Dept Internal Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15260 USA. [Ray, Nancy B.; Durairaj, Lakshmi; Ryan, Alan J.; Henderson, Florita C.; Etscheidt, Christopher A.; Mccoy, Diann M.; Agassandian, Marianna; Mathur, Satya N.; Sieren, Jessica C.; McLennan, Geoffrey] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA. [Butler, Phillip L.; Gakhar, Lokesh] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA. [Tyurina, Yulia Y.; Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Radl & Antioxidant Hlth, Pittsburgh, PA USA. [McLennan, Geoffrey] Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA. [McLennan, Geoffrey] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Internal Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15260 USA. EM mallampallirk@upmc.edu RI Gakhar, Lokesh/F-2113-2010 FU US Department of Veterans Affairs; US National Institutes of Health [R01 HL068135, HL080229, HL081784, HL096376, HL097376, HL098174, HL70755, HL094488, NIOSH OH008282, K23 HL075402, U01 HL102288] FX We thank M. E. Anderson, M.J. Welsh, J. Zabner and M. Gladwin for critical review of the manuscript and helpful suggestions. The Atp8b1G308V/G308V 129S1/SvlmJ mutant mice14 were a generous gift from L. Bull (University of California-San Francisco). Nontypable H. influenza strain 12 bacteria were kindly provided by D. Look (University of Iowa) 29. Antibodies to ATP8b1 were generous gifts from D. Ortiz (Tufts University) 30 and M. Ananthanarayanan (Mount Sinai School of Medicine) 31. This material is based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs and US National Institutes of Health R01 grants HL068135, HL080229, HL081784, HL096376, HL097376 and HL098174 (to R. K. M.), HL70755, HL094488 and NIOSH OH008282 (to V. E. K.) and K23 HL075402 and U01 HL102288 (to L. D.). The contents do not represent the views of the Department of Veterans Affairs or the US government. NR 38 TC 67 Z9 70 U1 1 U2 12 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD OCT PY 2010 VL 16 IS 10 BP 1120 EP U1 DI 10.1038/nm.2213 PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 660LR UT WOS:000282644800042 PM 20852622 ER PT J AU Menon, V Katz, R Mukamal, K Kestenbaum, B de Boer, IH Siscovick, DS Sarnak, MJ Shlipak, MG AF Menon, Vandana Katz, Ronit Mukamal, Kenneth Kestenbaum, Bryan de Boer, Ian H. Siscovick, David S. Sarnak, Mark J. Shlipak, Michael G. TI Alcohol consumption and kidney function decline in the elderly Alcohol and Kidney Disease SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE alcohol; kidney disease; outcomes; progression ID STAGE RENAL-DISEASE; GLOMERULAR-FILTRATION-RATE; CORONARY-HEART-DISEASE; CARDIOVASCULAR HEALTH; OLDER-ADULTS; SERUM CREATININE; RISK-FACTORS; METAANALYSIS; ASSOCIATION; DAMAGE AB Methods. This prospective cohort study included 4343 subjects from the Cardiovascular Health Study, a longitudinal, community-based cohort of persons aged >= 65 from four US communities. We used previously defined categories based on weekly alcohol consumption: none, former, < 1 drink, 1-6 drinks, 7-13 drinks and >= 14 drinks. Cystatin C was measured at baseline, year 3 and year 7; eligible subjects had at least two measures. Estimated GFR(cys) was calculated from cystatin C. The primary outcome was rapid kidney function as an annual estimated GFR (eGFR(cys)) loss > 3 mL/min/1.73 m(2)/year. Results. Eight percent of the cohort reported former alcohol use and 52% reported current alcohol consumption. During a mean follow-up of 5.6 years, 1075 (25%) participants had rapid kidney function decline. In adjusted logistic regression models, there was no association between alcohol use and kidney function decline (odds ratio, 95% confidence interval: none = reference; former = 1.18, 0.89-1.56; < 1 drink = 1.20, 0.99-1.47; 1-6 = 1.18, 0.95-1.45; 7-13 = 1.10, 0.80-1.53; > 14 = 0.89, 0.61-1.13). Results were similar with kidney function decline as a continuous outcome. Conclusions. Our results suggest that moderate alcohol consumption has neither adverse nor beneficial effects on kidney function. Although clinicians will need to consider the potential deleterious effects associated with alcohol consumption, there does not appear to be a basis for recommending that older adults discontinue or initiate light to moderate alcohol consumption to protect against kidney disease. C1 [Menon, Vandana; Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Katz, Ronit] Univ Washington, Dept Biostat, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [Mukamal, Kenneth] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA USA. [Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Kestenbaum, Bryan; de Boer, Ian H.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Menon, V (reprint author), Tufts Med Ctr, Div Nephrol, Boston, MA USA. EM vmenon@tuftsmedicalcenter.org FU NIDDK [K23 DK067303, RO1 AG 027002]; American Heart Association; National Heart, Lung and Blood Institute [N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, U01 HL080295]; National Institute of Neurological Disorders and Stroke FX This study was supported by grants NIDDK K23 DK067303 and RO1 AG 027002. Dr Shlipak's work on this project was supported by RO1 DK066488-01 and the American Heart Association Established Investigator Award. This research was supported by N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133 and U01 HL080295 from the National Heart, Lung and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm. NR 25 TC 16 Z9 16 U1 2 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD OCT PY 2010 VL 25 IS 10 BP 3301 EP 3307 DI 10.1093/ndt/gfq188 PG 7 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 654ML UT WOS:000282172300028 PM 20400446 ER PT J AU Zhang, JH Fung, SJ Xi, MC Sampogna, S Chase, MH AF Zhang, Jian-Hua Fung, Simon J. Xi, Mingchu Sampogna, Sharon Chase, Michael H. TI Apnea produces neuronal degeneration in the pons and medulla of guinea pigs SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Apnea; Single-stranded DNA; lmmunohistochemistry; Guinea pig; Brainstem ID OBSTRUCTIVE SLEEP-APNEA; CHRONIC INTERMITTENT HYPOXIA; VENTRAL RESPIRATORY GROUP; DEMONSTRATING CELL-DEATH; LATERAL TEGMENTAL FIELD; RAT-BRAIN; DNA-DAMAGE; IN-VIVO; SUBNUCLEAR ORGANIZATION; CATECHOLAMINE NEURONS AB Obstructive sleep apnea and other sleep-related breathing disorders result in recurrent periods of oxygen deprivation (hypoxia), hypercapnia and an increase in the cellular production of reactive oxygen species (oxidative stress-related injury). Individuals with these disorders suffer from a variety of cellular abnormalities that result in cardiopulmonary dysfunctions, disturbances in sleep and other pathologies. In the present experiment, using an animal model of sleep apnea, we determined that the degeneration of neurons and glia, due to apoptosis, occurs in specific regions of the pons and medulla. Adult guinea pigs, which were divided into control (normoxic) and experimental (hypoxic) groups, were anesthetized with alpha-chloralose and immobilized with Flaxedil. Apnea (hypoxia) was induced by ventilatory arrest in order to desaturate the oxyhemoglobin to 75% SpO(2). A sequence of apnea, followed by ventilation with recovery to > 95% SpO(2), was repeated for a period of 3 h. At the end of the period of recurrent apnea, the animals were perfused and brain sections were immunostained with a mouse monoclonal antibody raised against single-stranded DNA (ssDNA). Apoptotic neurons and glia, which were not found in the control group of animals, were present in brainstem regions in hypoxic group of animals; these regions involved in the control of respiration (e.g., the parafacial respiratory group and the ventral respiratory group), cardiovascular functions (e.g., the nucleus ambiguus, the nucleus tractus solitarius and the dorsal motor nucleus of the vagus) as well as REM sleep (the nucleus pontis oralis) and wakefulness (e.g., the dorsal raphe and locus ceruleus). We suggest apoptotic neurons and glia in critical areas of the pons and medulla results in many of the comorbidities experienced by patients with sleep-disordered breathing pathologies. (c) 2010 Elsevier Inc. All rights reserved. C1 [Zhang, Jian-Hua; Fung, Simon J.; Xi, Mingchu; Sampogna, Sharon; Chase, Michael H.] WebSci Int, Los Angeles, CA 90024 USA. [Zhang, Jian-Hua; Fung, Simon J.; Xi, Mingchu; Chase, Michael H.] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Chase, Michael H.] Univ Calif Los Angeles, Dept Physiol, Sch Med, Los Angeles, CA 90025 USA. RP Zhang, JH (reprint author), WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA. EM jzhang@websciences.org NR 69 TC 15 Z9 16 U1 0 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD OCT PY 2010 VL 40 IS 1 SI SI BP 251 EP 264 DI 10.1016/j.nbd.2010.05.032 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 645OY UT WOS:000281473400030 PM 20554036 ER PT J AU Spreng, RN Rosen, HJ Strother, S Chow, TW Diehl-Schmid, J Freedman, M Graff-Radford, NR Hodges, JR Lipton, AM Mendez, MF Morelli, SA Black, SE Miller, BL Levine, B AF Spreng, R. Nathan Rosen, Howard J. Strother, Stephen Chow, Tiffany W. Diehl-Schmid, Janine Freedman, Morris Graff-Radford, Neill R. Hodges, John R. Lipton, Anne M. Mendez, Mario F. Morelli, Sylvia A. Black, Sandra E. Miller, Bruce L. Levine, Brian TI Occupation attributes relate to location of atrophy in frontotemporal lobar degeneration SO NEUROPSYCHOLOGIA LA English DT Article DE Frontotemporal dementia; Laterality; Reserve ID ALZHEIMERS-DISEASE; DEVELOPMENTAL DYSLEXIA; LIFETIME OCCUPATION; PROGRESSIVE APHASIA; RESERVE HYPOTHESIS; COGNITIVE RESERVE; SEMANTIC DEMENTIA; WORK GROUP; BRAIN; EDUCATION AB Frontotemporal lobar degeneration (FTLD) often presents with asymmetric atrophy We assessed whether premorbid occupations in FTLD patients were associated with these hemispheric asymmetries In a multi-center chart review of 588 patients occupation information was related to location of tissue loss or dysfunction Patients with atrophy lateralized to the right had professions more dependent on verbal abilities than patients with left-lateralized or symmetrical atrophy In a subgroup of 96 well-characterized patients with quantified neuroimaging data the lateralization effect was localized to the temporal lobes and Included verbal and mathematical ability Patients whose professions placed high demands on language and mathematics had relatively preserved left temporal relative to right temporal volumes Thus occupation selection occurring in early adulthood is related to lateralized brain asymmetry in patients who develop FTLD decades later in the relatively deficient hemisphere The finding suggests that verbal and mathematical occupations may have been pursued due to developmental right-lateralized functional impairment that precedes the neurodegeneranve process Alternatively long-term engagement of activities associated with these occupations contributed to left-lateralized reserve right-lateralized dysfunction or both (C) 2010 Elsevier Ltd All rights reserved C1 [Spreng, R. Nathan; Strother, Stephen; Chow, Tiffany W.; Levine, Brian] Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON, Canada. [Spreng, R. Nathan; Freedman, Morris; Black, Sandra E.; Levine, Brian] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada. [Rosen, Howard J.; Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Rosen, Howard J.; Miller, Bruce L.] UCSF Memory & Aging Ctr, San Francisco, CA USA. [Chow, Tiffany W.; Freedman, Morris; Black, Sandra E.; Levine, Brian] Univ Toronto, Dept Med Neurol, Toronto, ON M5S 1A1, Canada. [Chow, Tiffany W.] Univ Toronto, Dept Psychiat Geriatr Psychiat, Toronto, ON M5S 1A1, Canada. [Diehl-Schmid, Janine] Tech Univ Munich, Dept Psychiat, Munich, Germany. [Diehl-Schmid, Janine] Tech Univ Munich, Dept Psychotherapy, Munich, Germany. [Freedman, Morris] Baycrest Ctr Geriatr Care, Div Neurol, Behav Neurol Program, Toronto, ON, Canada. [Freedman, Morris] Mt Sinai Hosp, Dept Med, Div Neurol, Univ Hlth Network, Toronto, ON M5G 1X5, Canada. [Graff-Radford, Neill R.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Hodges, John R.] MRC, Cognit & Brain Sci Unit, Cambridge, England. [Lipton, Anne M.] Presbyterian Med Ctr, Dept Neurol, Dallas, TX USA. [Mendez, Mario F.] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. [Mendez, Mario F.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Mendez, Mario F.] W Los Angeles VA Med Ctr, Los Angeles, CA USA. [Morelli, Sylvia A.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. RP Spreng, RN (reprint author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA. RI Levine, Brian/G-4328-2010 OI Levine, Brian/0000-0003-4343-811X; Morelli, Sylvia/0000-0002-3353-678X; Spreng, R. Nathan/0000-0003-1530-8916; Black, Sandra/0000-0001-7093-8289; Strother, Stephen/0000-0002-3198-217X FU Canadian Institutes of Health Research [MGP-62963]; National Institute of Child Health and Human Development [HD42385-01] FX This study was supported by Canadian Institutes of Health Research (MGP-62963) and the National Institute of Child Health and Human Development (HD42385-01) grants to B Levine The authors declare no actual or potential conflicts of interest All appropriate approval and procedures were followed concerning human subjects We thank Morris Moscovitch for his involvement Pheth Sengdy Irina Nica and Namita Kumar for their assistance and Karen Spreng for her contributions during the course of this project NR 54 TC 9 Z9 9 U1 1 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD OCT PY 2010 VL 48 IS 12 BP 3634 EP 3641 DI 10.1016/j.neuropsychologia.2010.08.020 PG 8 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 677UM UT WOS:000284017300030 PM 20800604 ER PT J AU Larson, PS AF Larson, Paul S. TI Minimally Invasive Surgery for Movement Disorders SO NEUROSURGERY CLINICS OF NORTH AMERICA LA English DT Article DE Deep brain stimulation; Stereotactic surgery; Frameless deep brain stimulation; Interventional MRI; Gene transfer ID PHASE-I TRIAL; SUBTHALAMIC NUCLEUS; PARKINSONS-DISEASE; OPEN-LABEL; BRAIN; TOLERABILITY; SAFETY AB Movement disorders surgery, particularly deep brain stimulation (DBS), is already a minimally invasive procedure However new innovations in the delivery devices for DBS electrodes, new methods for target localization, and alternatives to implanted hardware are all strategies that can make movement disorders surgery less invasive Frameless DBS techniques can increase patient comfort and shorten operative time Interventional magnetic resonance imaging can further reduce operative time, and allows DBS placement to be done with a patient asleep and usually with a single brain penetration Finally, gene transfer eliminates the need for implanted hardware or batteries and simplifies postoperative care C1 [Larson, Paul S.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Larson, Paul S.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Larson, PS (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Box 0112, San Francisco, CA 94143 USA. FU Medtronic Inc; Surgivision Inc; Ceregene Inc; Genzyme Inc FX This article describes work that was supported by research grants and support to the author from Medtronic Inc Surgivision Inc Ceregene Inc and Genzyme Inc NR 11 TC 4 Z9 4 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1042-3680 J9 NEUROSURG CLIN N AM JI Neurosurg. Clin. N. Am. PD OCT PY 2010 VL 21 IS 4 BP 691 EP + DI 10.1016/j.nec.2010.07.012 PG 9 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 681DO UT WOS:000284291800011 PM 20947036 ER PT J AU Yenari, MA Kauppinen, TM Swanson, RA AF Yenari, Midori A. Kauppinen, Tiina M. Swanson, Raymond A. TI Microglial Activation in Stroke: Therapeutic Targets SO NEUROTHERAPEUTICS LA English DT Review DE NF-kappa B; AP-1; PARP-1; minocycline; inflammation; ischemia; TREM2 ID FOCAL CEREBRAL-ISCHEMIA; NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; METABOTROPIC GLUTAMATE RECEPTORS; TRANSIENT FOREBRAIN ISCHEMIA; TUMOR-NECROSIS-FACTOR; BLOOD-BRAIN-BARRIER; HEAT-SHOCK-PROTEIN; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; INDUCED NEURONAL DEATH AB Microglial activation is an early response to brain ischemia and many other stressors. Microglia continuously monitor and respond to changes in brain homeostasis and to specific signaling molecules expressed or released by neighboring cells. These signaling molecules, including ATP, glutamate, cytokines, prostaglandins, zinc, reactive oxygen species, and HSP60, may induce microglial proliferation and migration to the sites of injury. They also induce a nonspecific innate immune response that may exacerbate acute ischemic injury. This innate immune response includes release of reactive oxygen species, cytokines, and proteases. Microglial activation requires hours to days to fully develop, and thus presents a target for therapeutic intervention with a much longer window of opportunity than acute neuroprotection. Effective agents are now available for blocking both microglial receptor activation and the microglia effector responses that drive the inflammatory response after stroke. Effective agents are also available for targeting the signal transduction mechanisms linking these events. However, the innate immune response can have beneficial as well deleterious effects on outcome after stoke, and a challenge will be to find ways to selectively suppress the deleterious effects of microglial activation after stroke without compromising neurovascular repair and remodeling. C1 San Francisco VA Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. RP Swanson, RA (reprint author), VAMC, 4150 Clement St, San Francisco, CA 94121 USA. EM raymond.swanson@ucsf.edu OI Swanson, Raymond/0000-0002-3664-5359; Kauppinen, Tiina/0000-0001-7219-9862 FU Department of Veterans Affairs; Department of Defense [W81XH-05-2-0094, DAMD17-03-1-0532]; National Institutes of Health [NS14543, NS40516]; American Heart Association [0835222N] FX This work was supported by the Department of Veterans Affairs (R.A.S., M.A.Y.), the Department of Defense (W81XH-05-2-0094, R.A.S.; DAMD17-03-1-0532, M.A.Y.), the National Institutes of Health (NS14543, R.A.S.; NS40516, M.A.Y.), and the American Heart Association (0835222N, T.M.K.). NR 232 TC 123 Z9 127 U1 2 U2 39 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1933-7213 J9 NEUROTHERAPEUTICS JI Neurotherapeutics PD OCT PY 2010 VL 7 IS 4 BP 378 EP 391 PG 14 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 654VG UT WOS:000282198500005 PM 20880502 ER PT J AU Thompson, LR Boudreau, R Newman, AB Hannon, MJ Chu, CR Nevitt, MC Kwoh, CK AF Thompson, L. R. Boudreau, R. Newman, A. B. Hannon, M. J. Chu, C. R. Nevitt, M. C. Kwoh, C. Kent CA OAI Investigators TI The association of osteoarthritis risk factors with localized, regional and diffuse knee pain SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE Knee osteoarthritis; Pain localization; Risk factors; Knee pain ID NUTRITION EXAMINATION SURVEY; NATIONAL-HEALTH; PERCEPTION; EPIDEMIOLOGY; LOCATION; GENDER AB Objective: To identify determinants of different patterns of knee pain with a focus on risk factors for knee osteoarthritis (OA). Design: The Knee Pain Map is an interviewer-administered assessment that asks subjects to characterize their knee pain as localized, regional, or diffuse. A total of 2677 participants from the Osteoarthritis Initiative were studied. We used multinomial logistic regression to examine the relationship between risk factors for OA and knee pain patterns. We examined the bivariate and multivariate relationships of knee pain pattern with age, body mass index (BMI), sex, race, family history of total joint replacement, knee injury, knee surgery, and hand OA. Results: We compared 2462 knees with pain to 1805 knees without pain. In the bivariate analysis, age, sex, BMI, injury, surgery, and hand OR were associated with at least one pain pattern. In the multivariate model, all of these variables remained significantly associated with at least one pattern. When compared to knees without pain, higher BMI, injury, and surgery were associated with all patterns. BMI had its strongest association with diffuse pain. Older age was less likely to be associated with localized pain while female sex was associated with regional pain. Conclusions: We have shown that specific OA risk factors are associated with different knee pain patterns. Better understanding of the relationship between OA risk factors and knee pain patterns may help to characterize the heterogeneous subsets of knee OA. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International. C1 [Thompson, L. R.; Newman, A. B.; Hannon, M. J.; Chu, C. R.; Kwoh, C. Kent] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Boudreau, R.; Newman, A. B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Nevitt, M. C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kwoh, C. Kent] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Kwoh, CK (reprint author), S702 BSTWR,200 Lothrop St, Pittsburgh, PA 15261 USA. EM kwoh@pitt.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Boudreau, Robert/0000-0003-0162-5187 FU National Institutes of Health [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01AR-2-2261, N01-AR-2-2262]; Department of Health and Human Services; Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; Pfizer, Inc.; Foundation for the National Institutes of Health; National Institute of Aging (NIA) [AG 021885]; University of Pittsburgh FX The OAI is a public private partnership which comprised five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript has received the approval of the OAI Publications Committee based on a review of its scientific content and data interpretation.; This study was also supported by the National Institute of Aging (NIA) Ruth L Kirschstein National Research Service Award Institutional Research Training Grant AG 021885, and the University of Pittsburgh, School of Medicine Clinical Scientist Training Program. NR 24 TC 14 Z9 14 U1 1 U2 3 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD OCT PY 2010 VL 18 IS 10 BP 1244 EP 1249 DI 10.1016/j.joca.2010.05.014 PG 6 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 670UK UT WOS:000283452600002 PM 20633678 ER PT J AU Bethel-Brown, CS Zhang, HY Fowler, SC Chertoff, ME Watson, GS Stanford, JA AF Bethel-Brown, Crystal S. Zhang, Hongyu Fowler, Stephen C. Chertoff, Mark E. Watson, G. Stennis Stanford, John A. TI Within-session analysis of amphetamine-elicited rotation behavior reveals differences between young adult and middle-aged F344/BN rats with partial unilateral striatal dopamine depletion SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR LA English DT Article DE Parkinson's disease; Animal models; Behavioral assay; Basal ganglia; Rotation; Striatum; Amphetamine ID PARKINSONS-DISEASE; BASAL GANGLIA; PROGRESSIVE DEGENERATION; NIGROSTRIATAL PATHWAY; MOVEMENT INITIATION; FISCHER-344 RATS; PARTIAL LESIONS; 6-OHDA LESIONS; ANIMAL-MODEL; TIME-COURSE AB Preclinical modeling of Parkinson's disease using 6-hydroxydopamine (6-OHDA) has been valuable in developing and testing therapeutic strategies. Recent efforts have focused on modeling early stages of disease by infusing 6-OHDA into the striatum. The partial DA depletion that follows intrastriatal 6-OHDA is more variable than the near-complete depletion following medial forebrain bundle infusion, and behavioral screening assays are not as well characterized in the partial lesion model. We compared relationships between amphetamine-elicited rotation behavior and DA depletion following intrastriatal 6-OHDA (12.5 mu g) in 6 month vs. 18 month F344/BN rats, at 2-weeks and 6-weeks post-lesion. We compared the total number of rotations with within-session (bin-by-bin) parameters of rotation behavior as indicators of DA depletion. Striatal DA depletion was greater in the young adult than in the middle-aged rats at 2 weeks but not at 6 weeks post-lesion. The total number of rotations for the whole session and striatal DA depletion did not differ between the two age groups. Regression analysis revealed a greater relationship between within-session parameters of rotation behavior and DA depletion in the middle-aged group than in the young adult group. These results have implications for estimating DA depletion in preclinical studies using rats of different ages. (C) 2010 Elsevier Inc. All rights reserved. C1 [Stanford, John A.] Univ Kansas, Med Ctr, Dept Physiol, Landon Ctr Aging, Kansas City, KS 66160 USA. [Bethel-Brown, Crystal S.; Zhang, Hongyu] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA. [Chertoff, Mark E.] Univ Kansas, Med Ctr, Dept Speech & Hearing, Kansas City, KS 66160 USA. [Fowler, Stephen C.; Chertoff, Mark E.; Stanford, John A.] Univ Kansas, Med Ctr, Kansas Intellectual & Dev Disabil Res Ctr, Kansas City, KS 66160 USA. [Fowler, Stephen C.] Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA. [Fowler, Stephen C.] Univ Kansas, Schiefelbusch Inst Life Span Studies, Lawrence, KS 66045 USA. [Watson, G. Stennis] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA. [Watson, G. Stennis] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr GRECC, Seattle, WA 98108 USA. RP Stanford, JA (reprint author), Univ Kansas, Med Ctr, Dept Physiol, Landon Ctr Aging, Mailstop 3051,3901 Rainbow Blvd, Kansas City, KS 66160 USA. EM jstanford@kumc.edu FU NIH [AG023549, AG026491, MH43429, AG23640]; Smith Intellectual and Developmental Disabilities Research Center [HD02528]; Lied Endowed Basic Science Research Grant FX This study was supported by NIH grants AG023549 (JAS), AG026491 (JAS), MH43429 (SCF), AG23640 (GSW), the Smith Intellectual and Developmental Disabilities Research Center (HD02528), and a Lied Endowed Basic Science Research Grant (JAS). NR 42 TC 7 Z9 7 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0091-3057 J9 PHARMACOL BIOCHEM BE JI Pharmacol. Biochem. Behav. PD OCT PY 2010 VL 96 IS 4 BP 423 EP 428 DI 10.1016/j.pbb.2010.06.014 PG 6 WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy GA 653TT UT WOS:000282120500007 PM 20600242 ER PT J AU Collinger, JL Impink, BG Ozawa, H Boninger, ML AF Collinger, Jennifer L. Impink, Bradley G. Ozawa, Haishin Boninger, Michael L. TI Effect of an Intense Wheelchair Propulsion Task on Quantitative Ultrasound of Shoulder Tendons SO PM&R LA English DT Article AB Objective: To investigate acute ultrasound changes of biceps and supraspinatus tendon appearance after an intense wheelchair propulsion task, and how these changes relate to demographic and biomechanical risk factors. Design: A survey. Setting: Research laboratory and research space at the National Veterans Wheelchair Games. Participants: A convenience sample of 60 manual wheelchair users were recruited through research registries and rehabilitation clinics as well as from participants at the 2007 and 2008 National Veterans Wheelchair Games. The subjects were between 18 and 65 years of age at least 1 year after injury and did not have progressive disabilities. Main Outcome Measures: Quantitative ultrasound (QUS) measures of biceps and supraspinatus tendon appearance, stroke frequency, resultant force, tendinopathy score, and duration of wheelchair use. Results: Biceps tendon appearance after an intense propulsion task was significantly related to chronic biceps tendinopathy, duration of wheelchair use, stroke frequency, and resultant force. The subjects with a higher stroke frequency or resultant force tended to have a brighter, more organized tendon appearance compared with the prepropulsion imaging session (baseline). The subjects with tendinopathy or a longer duration of wheelchair use were more likely to have a darker, diffuse tendon appearance immediately after the propulsion task. Supraspinatus tendon appearance after propulsion was only significantly predicted by baseline QUS measures. Conclusions: QUS has proven to be sensitive to risk factors for tendon pathology. Future studies can apply grayscale-based QUS to study the development and prevention of repetitive strain injuries, particularly on an individual basis. PM R 2010;2:920-925 C1 [Collinger, Jennifer L.; Impink, Bradley G.; Ozawa, Haishin; Boninger, Michael L.] Dept Vet Affairs, Human Engn Res Labs, Pittsburgh, PA USA. [Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. [Collinger, Jennifer L.; Ozawa, Haishin; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Collinger, Jennifer L.; Impink, Bradley G.; Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Boninger, ML (reprint author), Dept Vet Affairs, Human Engn Res Labs, Pittsburgh, PA USA. EM boninger@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU Office of Research and Development, Rehabilitation Research & Development Service, Department of Veterans Affairs [B3142C]; National Institute of Health [R21HD054529]; National Institute on Disability and Rehabilitation Research Rehabilitation Engineering Research Center on Spinal Cord Injury [H133E070024]; National Science Foundation Graduate Research Fellowship FX This material is the result of work supported with resources and the use of facilities at the Human Engineering Research Laboratories, VA Pittsburgh Healthcare System. This study was supported by the Office of Research and Development, Rehabilitation Research & Development Service, Department of Veterans Affairs, Grant B3142C, the National Institute of Health, Grant R21HD054529, the National Institute on Disability and Rehabilitation Research Rehabilitation Engineering Research Center on Spinal Cord Injury, Grant H133E070024, and a National Science Foundation Graduate Research Fellowship. The contents of this paper do not represent the views of the Department of Veterans Affairs or the United States Government. NR 18 TC 10 Z9 10 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 J9 PM&R JI PM&R PD OCT PY 2010 VL 2 IS 10 BP 920 EP 925 DI 10.1016/j.pmrj.2010.06.007 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA V23SE UT WOS:000208361700007 PM 20970761 ER PT J AU Harris, AHS Bradley, KA Bowe, T Henderson, P Moos, R AF Harris, Alex H. S. Bradley, Katharine A. Bowe, Thomas Henderson, Patricia Moos, Rudolf TI Associations Between AUDIT-C and Mortality Vary by Age and Sex SO POPULATION HEALTH MANAGEMENT LA English DT Article ID ALCOHOL SCREENING SCORES; IDENTIFICATION TEST AUDIT; ALL-CAUSE MORTALITY; USE DISORDERS; GENERAL-POPULATION; RISK DRINKING; CONSUMPTION; QUESTIONNAIRES; WOMEN; COMORBIDITY AB We sought to determine the sex-and age-specific risk of mortality associated with scores on the 3-item Alcohol Use Disorder Identification Test-Consumption (AUDIT-C) questionnaire using data from a national sample of Veterans Health Administration (VHA) patients. Men (N = 215,924) and women (N = 9168) who completed the AUDIT-C in a patient survey were followed for 24 months. AUDIT-C categories (0, 1-4, 5-8, 9-12) were evaluated as predictors of mortality in logistic regression models, adjusted for age, race, education, marital status, smoking, depression, and comorbidities. For women, AUDIT-C scores of 9-12 were associated with a significantly increased risk of death compared to the AUDIT-C 1-4 group (odds ratio [OR] 7.09; 95% confidence interval [CI] = 2.67, 18.82). For men overall, AUDIT-C scores of 5-8 and 9-12 were associated with increased risk of death compared to the AUDIT-C 1-4 group (OR 1.13, 95% CI = 1.05, 1.21, and OR 1.63, 95% CI = 1.45, 1.84, respectively) but these associations varied by age. These results provide sex-and age-tailored risk information that clinicians can use in evidence-based conversations with patients about the health-related risks of their alcohol consumption. This study adds to the growing literature establishing the AUDIT-C as a scaled marker of alcohol-related risk or "vital sign" that might facilitate the detection and management of alcohol-related risks and problems. (Population Health Management 2010;13:263-268) C1 [Harris, Alex H. S.; Bowe, Thomas; Henderson, Patricia; Moos, Rudolf] Stanford Univ, Sch Med, VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Bradley, Katharine A.] Univ Washington, Sch Med, Seattle, WA USA. [Bradley, Katharine A.] Puget Sound HC Syst, Seattle, WA USA. RP Harris, AHS (reprint author), Stanford Univ, Sch Med, VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Alexander.Harris2@va.gov FU National Institute of Alcohol and Alcoholism [R03 AA016793-01]; VA Office of Quality and Performance FX This work was made possible through a grant from the National Institute of Alcohol and Alcoholism (R03 AA016793-01) and support from the VA Office of Quality and Performance. The views presented in this paper do not necessarily represent the views of the Department of Veterans Affairs. NR 33 TC 19 Z9 19 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1942-7891 J9 POPUL HEALTH MANAG JI Popul. Health Manag. PD OCT PY 2010 VL 13 IS 5 BP 263 EP 268 DI 10.1089/pop.2009.0060 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 658BJ UT WOS:000282463400005 PM 20879907 ER PT J AU Stetler, RA Gan, Y Zhang, WT Liou, AK Gao, YQ Cao, GD Chen, J AF Stetler, R. Anne Gan, Yu Zhang, Wenting Liou, Anthony K. Gao, Yanqin Cao, Guodong Chen, Jun TI Heat shock proteins: Cellular and molecular mechanisms in the central nervous system SO PROGRESS IN NEUROBIOLOGY LA English DT Review DE Heat shock protein; Synaptic transmission; Protein degradation; Cell death; Cerebral ischemia; Parkinson's disease; Huntington's disease; Alzheimer's disease; Prion; Charcot-Marie-Tooth ID CHAPERONE-MEDIATED AUTOPHAGY; FOCAL CEREBRAL-ISCHEMIA; ENDOPLASMIC-RETICULUM STRESS; CYSTEINE-STRING PROTEIN; ALPHA-SYNUCLEIN AGGREGATION; CLATHRIN-COATED VESICLES; N-TERMINAL KINASE; INHIBITS HUNTINGTIN AGGREGATION; HUMAN NEUROMUSCULAR DISORDERS; UBIQUITIN-PROTEASOME PATHWAY AB Emerging evidence indicates that heat shock proteins (HSPs) are critical regulators in normal neural physiological function as well as in cell stress responses. The functions of HSPs represent an enormous and diverse range of cellular activities, far beyond the originally identified roles in protein folding and chaperoning. HSPs are now understood to be involved in processes such as synaptic transmission, autophagy, ER stress response, protein kinase and cell death signaling. In addition, manipulation of HSPs has robust effects on the fate of cells in neurological injury and disease states. The ongoing exploration of multiple HSP superfamilies has underscored the pluripotent nature of HSPs in the cellular context, and has demanded the recent revamping of the nomenclature referring to these families to reflect a re-organization based on structure and function. In keeping with this re-organization, we first discuss the HSP superfamilies in terms of protein structure, regulation, expression and distribution in the brain. We then explore major cellular functions of HSPs that are relevant to neural physiological states, and from there we discuss known and proposed HSP impacts on major neurological disease states. This review article presents a three-part discussion on the array of HSP families relevant to neuronal tissue, their cellular functions, and the exploration of therapeutic targets of these proteins in the context of neurological diseases. Published by Elsevier Ltd. C1 [Stetler, R. Anne] Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Stetler, R. Anne; Cao, Guodong; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15261 USA. [Stetler, R. Anne; Gan, Yu; Zhang, Wenting; Gao, Yanqin; Cao, Guodong; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. RP Stetler, RA (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. EM stetlerra@upmc.edu; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU American Heart Association [09POST22006065]; National Institutes of Health [NS36736, NS43802, NS45048]; VA Merit Review Grant; Chinese National Science Foundation [30870794, 30670642] FX We thank Armando Signore for the artwork, Carol Culver and Sulaiman Hassan for editorial assistance, and Pat Strickler for secretarial support. This work was supported by funds from the American Heart Association (09POST22006065 to R.A.S.), the National Institutes of Health (NS36736, NS43802 and NS45048 to J.C.), the VA Merit Review Grant (to J.C.) and the Chinese National Science Foundation (30870794, 30670642 to Y.G.). NR 322 TC 85 Z9 89 U1 2 U2 39 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0301-0082 J9 PROG NEUROBIOL JI Prog. Neurobiol. PD OCT PY 2010 VL 92 IS 2 BP 184 EP 211 DI 10.1016/j.pneurobio.2010.05.002 PG 28 WC Neurosciences SC Neurosciences & Neurology GA 661LG UT WOS:000282729200005 PM 20685377 ER PT J AU McCarthy, JF Valenstein, M Zivin, K Zeber, JE Kilbourne, AM AF McCarthy, John F. Valenstein, Marcia Zivin, Kara Zeber, John E. Kilbourne, Amy M. TI Access-Related Measures and Out-of-System Utilization Among Veterans With Bipolar Disorder SO PSYCHIATRIC SERVICES LA English DT Article ID SERIOUS MENTAL-ILLNESS; HEALTH-CARE; MEDICAL-CARE; VA; SATISFACTION; SERVICES; BARRIERS AB Objective: This study examined associations between access-related measures and out-of-system health services utilization (general medicine and mental health services) among patients with bipolar disorder at a U.S. Department of Veterans Affairs (VA) medical center. Methods: VA patients (N=391) with bipolar disorder answered questions about health services access (non-VA insurance coverage, travel distance to their VA facility, service-connected disability status, and difficulty receiving needed mental health care) and out-of-system services utilization. Multivariable Tobit regression was used to evaluate associations between access measures and propensity to receive out-of-system services. Results: More than half the veterans (56%) reported some non-VA utilization. Out-of-system utilization was more likely among patients who were married, younger, homeless, with private insurance, without service-connected disabilities, and who reported access difficulties. Conclusions: Out-of-system utilization was associated with multiple measures of access and indicators specific to VA and non-VA providers. Enhancing health system access for patients with bipolar disorder may reduce out-of-system utilization, potentially enhancing continuity of care. (Psychiatric Services 61: 1035-1038, 2010) C1 [McCarthy, John F.] US Dept Vet Affairs, Natl Serious Mental Illness Treatment Resource &, Ann Arbor, MI 48113 USA. Ctr Clin Management Res, Ann Arbor, MI 48113 USA. RP McCarthy, JF (reprint author), US Dept Vet Affairs, Natl Serious Mental Illness Treatment Resource &, POB 130170, Ann Arbor, MI 48113 USA. EM john.mccarthy2@va.gov FU VA [IIR 02-283] FX This study was supported by VA grant IIR 02-283. NR 14 TC 3 Z9 3 U1 0 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD OCT PY 2010 VL 61 IS 10 BP 1035 EP 1038 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 657WB UT WOS:000282448500018 PM 20889645 ER PT J AU Zhang, XY Xiu, MH Chen, DC Yang, FD Wu, GY Lu, L Kosten, TA Kosten, TR AF Zhang, Xiang Yang Xiu, Mei Hong Chen, Da Chun Yang, Fu De Wu, Gui Ying Lu, Lin Kosten, Therese A. Kosten, Thomas R. TI Nicotine dependence and serum BDNF levels in male patients with schizophrenia SO PSYCHOPHARMACOLOGY LA English DT Article DE Schizophrenia; Smoking; Nicotine; Brain-derived neurotrophic factor; Neurotrophin ID NEUROTROPHIC FACTOR BDNF; FACTOR MESSENGER-RNA; LONG-TERM TREATMENT; RAT-BRAIN; EXPERIMENTAL PARKINSONISM; STRIATAL INCREASE; BIPOLAR DISORDER; DECREASED LEVELS; KNOCKOUT MICE; SMOKING AB Schizophrenia is associated with a significantly high prevalence of smoking. Upregulation of neurotrophins by nicotine is well established. Accumulating evidence shows that brain-derived neurotrophic factor (BDNF) may be involved in the pathophysiology of schizophrenia. The purposes of this study were to compare BDNF levels in smokers to nonsmokers with schizophrenia and examine the association between BDNF levels and psychopathological symptoms. Serum BDNF levels were measured in 139 male inpatients with DSM-IV schizophrenia: 102 smokers and 37 nonsmokers. Symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS). The positive PANSS symptoms were lower in smokers than in nonsmokers, while the negative symptoms were lower in those who smoked more cigarettes. BDNF levels were significantly higher in smokers than in nonsmokers (p < 0.05). Higher BDNF levels correlated with fewer negative symptoms and with smoking more cigarettes. The fewer positive symptoms in smokers and fewer negative symptoms in those who smoked more cigarettes may be associated with nicotine-induced upregulation of BDNF. C1 [Zhang, Xiang Yang; Kosten, Thomas R.] VA Med Ctr, Houston, TX 77030 USA. [Zhang, Xiang Yang; Xiu, Mei Hong; Chen, Da Chun; Yang, Fu De] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing 100096, Peoples R China. [Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100083, Peoples R China. [Zhang, Xiang Yang; Wu, Gui Ying; Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu; kosten@bcm.edu FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of Veterans Affairs; US National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639]; VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC) FX This study was funded by the Stanley Medical Research Institute (03T-459 and 05T-726) and the Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), US National Institute of Health K05-DA0454, P50-DA18827, and U01-MH79639. NR 63 TC 14 Z9 16 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD OCT PY 2010 VL 212 IS 3 BP 301 EP 307 DI 10.1007/s00213-010-1956-y PG 7 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 662RD UT WOS:000282828100002 PM 20661552 ER PT J AU Yehuda, R Flory, JD Pratchett, LC Buxbaum, J Ising, M Holsboer, F AF Yehuda, Rachel Flory, Janine D. Pratchett, Laura C. Buxbaum, Joseph Ising, Marcus Holsboer, Florian TI Putative biological mechanisms for the association between early life adversity and the subsequent development of PTSD SO PSYCHOPHARMACOLOGY LA English DT Article DE PTSD; Early life stress; Cortisol; Gene x environment interaction; Gene expression; Epigenetics; Glucocorticoid receptor ID POSTTRAUMATIC-STRESS-DISORDER; CHILDHOOD SEXUAL-ABUSE; PERIPHERAL MONONUCLEAR LEUKOCYTES; PITUITARY-ADRENAL RESPONSES; NATIONAL COMORBIDITY SURVEY; DEXAMETHASONE-SUPPRESSION; GLUCOCORTICOID-RECEPTOR; DNA METHYLATION; HOLOCAUST SURVIVORS; MATERNAL-BEHAVIOR AB Early Life Stress (ELS) increases risk for both adult traumatization and posttraumatic stress disorder (PTSD). Adult PTSD may also reflect a continuation of a response to an earlier exposure to adversity. Given similarities between neuroendocrine aspects of PTSD and ELS, such as in reduced cortisol signaling and glucocorticoid receptor (GR) responsiveness, some aspects of the biology of PTSD may reflect biological correlates of risk. This paper will examine how empirical findings regarding the biological basis of ELS can inform our understanding of the neuroendocrinology of PTSD. This paper will also propose a hypothetical model to guide future research that integrates genetic, epigenetic, neuroendocrine, and psychological observations to understand the contribution of ELS neurobiology to PTSD. Recent genetic findings demonstrate heritable aspects of at least some of these cortisol-related disturbances. Furthermore, ELS may produce at least some of the PTSD-associated changes in glucocorticoid responsiveness through epigenetic mechanisms such as developmental programming. These, then, may contribute to enduring changes in stress responsiveness as well as enhanced risk for adult exposure and PTSD. Molecular mechanisms associated with gene x environment interactions or GR programming are essential in explaining current observations in the neuroendocrinology of PTSD that have been difficult to understand through the lens of contemporary stress theory. C1 [Yehuda, Rachel; Flory, Janine D.; Pratchett, Laura C.] James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. [Yehuda, Rachel; Buxbaum, Joseph] Mt Sinai Sch Med, Dept Psychiat & Neurobiol, New York, NY USA. [Flory, Janine D.] CUNY, Queens Coll, Dept Psychol, New York, NY USA. [Flory, Janine D.] CUNY, Grad Ctr, New York, NY USA. [Ising, Marcus; Holsboer, Florian] Max Planck Inst Psychiat, D-80804 Munich, Germany. RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, Dept Psychiat, 526 OOMH,130 W Kingsbridge Rd, Bronx, NY USA. EM rachel.yehuda@va.gov OI Buxbaum, Joseph/0000-0001-8898-8313 FU NIMH [MH088101, DOD PT073577, 10164894] FX This work was supported by the following funding: NIMH MH088101, DOD PT073577 and 10164894, and VA Merit Review to RY. We thank Dr. Linda M. Bierer for her careful reading of this manuscript and thoughtful suggestions. NR 130 TC 80 Z9 83 U1 9 U2 39 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD OCT PY 2010 VL 212 IS 3 BP 405 EP 417 DI 10.1007/s00213-010-1969-6 PG 13 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 662RD UT WOS:000282828100011 PM 20706708 ER PT J AU Boockvar, KS Livote, EE Goldstein, N Nebeker, JR Siu, A Fried, T AF Boockvar, K. S. Livote, E. E. Goldstein, N. Nebeker, J. R. Siu, A. Fried, T. TI Electronic health records and adverse drug events after patient transfer SO QUALITY & SAFETY IN HEALTH CARE LA English DT Article ID MEDICATION RECONCILIATION; SYSTEM; CARE; DISCREPANCIES; SAFETY AB Background Our objective was to examine the frequencies of medication error and adverse drug events (ADEs) at the time of patient transfer in a system with an electronic health record (EHR) as compared with a system without an ERR. It was hypothesised that the frequencies of these events would be lower in the EHR system because of better information exchange across sites of care. Methods 469 patients transferred between seven nursing homes and three hospitals in New York and Connecticut between 1999 and 2005 were followed retrospectively. Two groups of patients were compared: OS Veterans Affairs (VA) patients, with an EHR, and non-VA patients, without an EHR, on the following measures: (1) medication prescribing discrepancies at nursing home/hospital transfer, (2) high-risk medication discrepancies and (3) ADEs caused by medication discrepancies according to structured medical record review by pairs of physician and pharmacist raters. Results The overall incidence of ADEs caused by medication discrepancies was 0.20 per hospitalisation episode. After controlling for demographic and clinical covariates, there were no significant differences between VA and non-VA groups in medication discrepancies (mean difference 0.02; 95% CI -0.81 to 0.85), high-risk medication discrepancies ( 0.18; 95%CI -0.22 to 0.58) or occurrence of an ADEs caused by a medication discrepancy (OR 0.96; 95% CI 0.18 to 5.01). Conclusions There was no difference, with and without an EHR, in the occurrence of medication discrepancies or ADEs caused by medication discrepancies at the time of transfer between sites of care. Reducing such problems may require specialised computer tools to facilitate medication review. C1 [Boockvar, K. S.; Livote, E. E.; Goldstein, N.; Siu, A.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA. [Boockvar, K. S.; Goldstein, N.; Siu, A.] Mt Sinai Sch Med, Dept Geriatr, New York, NY USA. [Boockvar, K. S.; Goldstein, N.; Siu, A.] Mt Sinai Sch Med, Dept Palliat Med, New York, NY USA. [Boockvar, K. S.] Jewish Home Lifecare, New York, NY USA. [Nebeker, J. R.] VA Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA. [Fried, T.] Yale Univ, Sch Med, New Haven, CT USA. [Fried, T.] VA Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA. RP Boockvar, KS (reprint author), James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM kenneth.boockvar@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 FU VA Health Services Research and Development Service; Now York State Department of Health; Mount Sinai Practice Improvement Cluster; NIH [5K23AG025933-04] FX Financial support was provided by the VA Health Services Research and Development Service, the Now York State Department of Health and the Mount Sinai Practice Improvement Cluster. Dr. Goldstein was supported by 5K23AG025933-04 from NIH. NR 24 TC 8 Z9 10 U1 2 U2 6 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1475-3898 J9 QUAL SAF HEALTH CARE JI Qual. Saf. Health Care PD OCT PY 2010 VL 19 IS 5 AR e16 DI 10.1136/qshc.2009.033050 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 690UB UT WOS:000285032700036 PM 20724395 ER PT J AU Singh, H Petersen, LA Daci, K Collins, C Khan, M El-Serag, HB AF Singh, Hardeep Petersen, Laura A. Daci, Kuang Collins, Clyde Khan, Myrna El-Serag, Hashem B. TI Reducing referral delays in colorectal cancer diagnosis: is it about how you ask? SO QUALITY & SAFETY IN HEALTH CARE LA English DT Article ID OCCULT BLOOD-TEST; SCREENING COLONOSCOPY; MALPRACTICE CLAIMS; FOLLOW-UP; COMMUNICATION; QUALITY; CONSULTATIONS; DETERMINANTS; SURVIVAL; IMPROVE AB Objectives Delays in colorectal cancer (CRC) diagnosis related to colonoscopy referrals are not well studied. The authors tested whether certain details of information transmitted through computerised provider order entry (CPOE)-based referrals affected timeliness of diagnostic colonoscopy for patients with newly diagnosed CRC. Methods The authors studied a 6-year cohort of all newly diagnosed patients with CRC at a large tertiary care Veterans Affairs hospital and its affiliated multispecialty clinics. Referring providers included primary care clinicians, resident trainees and other specialists. From the colonoscopy referral preceding CRC diagnosis, the authors determined request date, type and frequency of diagnostic clues provided (symptoms, signs, test results), notation of in and documented evidence of verbal contact between referring provider and consultant to expedite referral. The authors compared distributions of proportions of diagnostic clues between patients with a lag of >60 and <= 60 day, and examined predictors of lag time. Results Of 367 electronic referrals identified with a median lag of 57 days, 178 (48.5%) had a lag of >60 days. Referrals associated with longer lag times included those with 'positive faecal occult blood test' (92 days, p<0.0001), 'haematochesia' (75 days, p=0.02), 'history of polyps' (221 days, p=0.0006) and when 'screening' (vs specific symptoms) was given as the reason for diagnostic colonoscopy (203 days, p=0.002). Independent predictors of shorter wait times included three diagnostic clues, notation of urgency and documentation of verbal contact. Conclusions Attention to certain details of diagnostic information provided to consultants through CPOE-based referrals may help reduce delays in CRC diagnosis. C1 [Singh, Hardeep; Petersen, Laura A.; Khan, Myrna] Michael E DeBakey VA Med Ctr, Houston VA HSR&D Ctr Excellence, Houston, TX USA. [Singh, Hardeep; Petersen, Laura A.; Khan, Myrna] Michael E DeBakey VA Med Ctr, Ctr Inquiry Improve Outpatient Safety Effect Elec, Houston, TX USA. [Singh, Hardeep; Petersen, Laura A.; Khan, Myrna] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [El-Serag, Hashem B.] Michael E DeBakey VA Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX USA. [El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA. RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.tmc.edu FU NIH [K23, K23CA125585]; VA National Center of Patient Safely; Houston VA HSR&D Center of Excellence [HFP90-020] FX The study was supported by an NIH K23 career development award (K23CA125585) to HS. the VA National Center of Patient Safely, and in part the Houston VA HSR&D Center of Excellence (HFP90-020). NR 30 TC 17 Z9 17 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1475-3898 J9 QUAL SAF HEALTH CARE JI Qual. Saf. Health Care PD OCT PY 2010 VL 19 IS 5 AR e27 DI 10.1136/qshc.2009.033712 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 690UB UT WOS:000285032700047 PM 20584706 ER PT J AU Anzueto, A Miravitlles, M AF Anzueto, Antonio Miravitlles, Marc TI Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD SO RESPIRATORY MEDICINE LA English DT Review DE Chronic bronchitis; COPD; AECB; Fluoroquinolones; Duration of therapy; Short-course therapy ID OBSTRUCTIVE PULMONARY-DISEASE; ACUTE BACTERIAL EXACERBATION; LONG-TERM OUTCOMES; ANTIBIOTIC-TREATMENT; 5-DAY MOXIFLOXACIN; DOUBLE-BLIND; ANTIMICROBIAL TREATMENT; PSEUDOMONAS-AERUGINOSA; ORAL LEVOFLOXACIN; LUNG-FUNCTION AB Acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (COPD) are associated with significant healthcare costs and contribute to the progress of the disease. Although a number of factors may trigger these episodes, between 40% and 60% are bacterial in nature. Antimicrobial therapy can be effective in treating exacerbations, leading to improved peak expiratory flow rates, fewer hospitalizations, lower relapse rates, and greater clinical success. Evidence suggests that short-course antimicrobial therapy can be as effective as standard duration therapy (>7 days) in treating exacerbations. Randomized trials have shown that clinical and bacteriological success rates are comparable with both 5-day and standard antibiotic courses. Furthermore, 5-day fluoroquinolone therapy is associated with faster recovery, fewer relapses, prolonged duration between episodes, and less hospitalization when compared with standard therapy. Both moxifloxacin and gemifloxacin have received FDA-approval for 5-day therapy in AECB. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78229 USA. [Miravitlles, Marc] Hosp Clin Barcelona, IDIBAPS, Fudacio Clin, Barcelona 08036, Catalonia, Spain. RP Anzueto, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Med, 111E,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM anzueto@uthscsa.edu OI Miravitlles, Marc/0000-0002-9850-9520 FU Schering-Plough Corporation FX The authors would like to acknowledge the editorial assistance of Dr. Ching-Ling Chen in the preparation of this manuscript. Support for this assistance was provided by Schering-Plough Corporation. The authors accept full responsibility for the contents of this manuscript. NR 49 TC 7 Z9 9 U1 0 U2 4 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 J9 RESP MED JI Respir. Med. PD OCT PY 2010 VL 104 IS 10 BP 1396 EP 1403 DI 10.1016/j.rmed.2010.05.018 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA 655JW UT WOS:000282247300002 PM 20580215 ER PT J AU Gomez, M Church, LWP Judson, MA AF Gomez, Mario Church, L. W. Preston Judson, Marc A. TI Tuberculous mediastinal lymphadenitis that evolved into pulmonary tuberculosis following transbronchial needle aspiration SO RESPIROLOGY LA English DT Article DE bronchoscopy; lymphadenitis; transbronchial needle aspiration; tuberculosis ID LYMPHADENOPATHY; ADULTS AB This case report describes a patient with multi-drug-resistant mediastinal lymph node tuberculosis that evolved to smear-positive pulmonary tuberculosis following transbronchial needle aspiration. This is the first report of this complication, and bronchoscopists should be vigilant for its occurrence. C1 [Gomez, Mario; Judson, Marc A.] Med Univ S Carolina, Div Pulm Crit Care Allergy & Sleep Med, Charleston, SC 29425 USA. [Church, L. W. Preston] Ralph H Johnson VA Med Ctr, Div Infect Dis, Charleston, SC USA. RP Gomez, M (reprint author), Med Univ S Carolina, Div Pulm Crit Care Allergy & Sleep Med, 96 Jonathan Lucas St,Suite 812 CSB,POB 250630, Charleston, SC 29425 USA. EM mariogomezdel@gmail.com OI Judson, Marc/0000-0002-4663-7985 FU Centocor; Gilead; Celegene; Merck FX Drs Gomez and Church do not have any conflict of interest to declare. Dr Judson is a consultant to Lilly and Centocor. He is on the speaker's bureau for Bohringer-Ingelheim. He has received grants from Centocor, Gilead, Celegene and Merck. NR 10 TC 1 Z9 3 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1323-7799 J9 RESPIROLOGY JI Respirology PD OCT PY 2010 VL 15 IS 7 BP 1140 EP 1141 PG 2 WC Respiratory System SC Respiratory System GA 655DZ UT WOS:000282225400018 PM 20573061 ER PT J AU Chakraborty, BH Steinhauer, SR AF Chakraborty, Beatrice H. Steinhauer, Stuart R. TI Reporting of minority participation rates and racial differences in schizophrenia and psychophysiological research: Improving but still not adequate SO SCHIZOPHRENIA RESEARCH LA English DT Letter C1 [Chakraborty, Beatrice H.] VA Pittsburgh Healthcare Syst, Biometr Res Program, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Western Psychiat Inst & Clin, Sch Med, Pittsburgh, PA 15213 USA. RP Chakraborty, BH (reprint author), VA Pittsburgh Healthcare Syst, Biometr Res Program, 7180 Highland Dr,151R, Pittsburgh, PA 15206 USA. EM Bec27@pitt.edu; Sthauer@pitt.edu FU NCRR NIH HHS [RR024153]; NIMH NIH HHS [MH55762, R01 MH055762] NR 4 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2010 VL 123 IS 1 BP 90 EP 91 DI 10.1016/j.schres.2010.06.006 PG 2 WC Psychiatry SC Psychiatry GA 665IR UT WOS:000283029100015 PM 20837319 ER PT J AU Snelgrove, RJ Jackson, PL Hardison, MT Noerager, BD Kinloch, A Gaggar, A Shastry, S Rowe, SM Shim, YM Hussell, T Blalock, JE AF Snelgrove, Robert J. Jackson, Patricia L. Hardison, Matthew T. Noerager, Brett D. Kinloch, Andrew Gaggar, Amit Shastry, Suresh Rowe, Steven M. Shim, Yun M. Hussell, Tracy Blalock, J. Edwin TI A Critical Role for LTA(4)H in Limiting Chronic Pulmonary Neutrophilic Inflammation SO SCIENCE LA English DT Article ID LEUKOTRIENE A(4) HYDROLASE; CYSTIC-FIBROSIS; ENZYME; CHEMOATTRACTANT; PEPTIDASE; AMINOPEPTIDASE; ARGININE; DISEASE; CELLS; COPD AB Leukotriene A(4) hydrolase (LTA(4)H) is a proinflammatory enzyme that generates the inflammatory mediator leukotriene B-4 (LTB4). LTA(4)H also possesses aminopeptidase activity with unknown substrate and physiological importance; we identified the neutrophil chemoattractant proline-glycine-proline (PGP) as this physiological substrate. PGP is a biomarker for chronic obstructive pulmonary disease (COPD) and is implicated in neutrophil persistence in the lung. In acute neutrophil-driven inflammation, PGP was degraded by LTA(4)H, which facilitated the resolution of inflammation. In contrast, cigarette smoke, a major risk factor for the development of COPD, selectively inhibited LTA(4)H aminopeptidase activity, which led to the accumulation of PGP and neutrophils. These studies imply that therapeutic strategies inhibiting LTA(4)H to prevent LTB4 generation may not reduce neutrophil recruitment because of elevated levels of PGP. C1 [Snelgrove, Robert J.; Jackson, Patricia L.; Hardison, Matthew T.; Gaggar, Amit; Shastry, Suresh; Rowe, Steven M.; Blalock, J. Edwin] Univ Alabama, Dept Med, Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Snelgrove, Robert J.; Hussell, Tracy] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London SW7 2AZ, England. [Noerager, Brett D.] Univ Montevallo, Dept Biol Chem & Math, Montevallo, AL 35115 USA. [Kinloch, Andrew] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol, London W6 8LH, England. [Gaggar, Amit; Rowe, Steven M.; Blalock, J. Edwin] Univ Alabama, Gregory Fleming James Cyst Fibrosis Ctr, Birmingham, AL 35294 USA. [Gaggar, Amit] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Rowe, Steven M.] Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA. [Shim, Yun M.] Univ Virginia, Dept Med, Div Pulm & Crit Care Med, Charlottesville, VA 22908 USA. RP Snelgrove, RJ (reprint author), Univ Alabama, Dept Med, Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. EM rjs198@imperial.ac.uk RI Hussell, Tracy/O-4630-2014; Kinloch, Anthony/F-6042-2011 OI Hussell, Tracy/0000-0001-7186-6141; Kinloch, Anthony/0000-0002-8752-7184 FU Wellcome Trust [082727/Z/07/Z]; National Heart, Lung, and Blood Institute [HL07783, HL090999, HL087824, HL102371-A1, K08HL091127]; Cystic Fibrosis Foundation [GAGGAR07]; National Institute of Diabetes and Digestive and Kidney Diseases [1K23DK075788, 1R03DK084110-01]; Flight Attendant Medical Research Institute; Medical Research Council [P171/03/C1/048]; NIH [RR19231, P30CA13148, P50 AT00477, U54CA100949, P30AR050948, P30 DK079337] FX This project was supported by grants from the Wellcome Trust (082727/Z/07/Z to R.J.S.), the National Heart, Lung, and Blood Institute (HL07783, HL090999, and HL087824 to J.E.B. and HL102371-A1 to A. G.), the Cystic Fibrosis Foundation (GAGGAR07 to A. G.), the National Institute of Diabetes and Digestive and Kidney Diseases (1K23DK075788 and 1R03DK084110-01 to S. M. R.), the Flight Attendant Medical Research Institute (Young Clinical Scientist Award to Y.M.S.) and the National Heart, Lung, and Blood Institute (K08HL091127 to Y.M.S.), and the Medical Research Council (P171/03/C1/048 to T. H.). The Univ. of Alabama Birmingham (UAB) Lung Health Center Pulmonary Proteomics Laboratory is funded through the NIH (by grants RR19231, P30CA13148, P50 AT00477, U54CA100949, P30AR050948, and P30 DK079337). We thank R. Moore and L. Wilson of the UAB Targeted Metabolomics and Proteomics Laboratory for their technical assistance with mass spectrometry, D. Muccio of the UAB Chemistry Department for the use of his fast protein liquid chromatography system, G. Xia for technical assistance, and D. Saliba of the Kennedy Institute of Rheumatology, Imperial College London, for his technical assistance in the generation of murine LTA4H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the NIH. NR 30 TC 106 Z9 110 U1 1 U2 15 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD OCT 1 PY 2010 VL 330 IS 6000 BP 90 EP 94 DI 10.1126/science.1190594 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 656KW UT WOS:000282334500042 PM 20813919 ER PT J AU Zhang, WT Hu, XM Yang, W Gao, YQ Chen, J AF Zhang, Wenting Hu, Xiaoming Yang, Wei Gao, Yanqin Chen, Jun TI Omega-3 Polyunsaturated Fatty Acid Supplementation Confers Long-Term Neuroprotection Against Neonatal Hypoxic-Ischemic Brain Injury Through Anti-Inflammatory Actions SO STROKE LA English DT Article DE hypoxia/ischemia; inflammation; polyunsaturated fatty acids ID CEREBRAL-ISCHEMIA; ACTIVATION; PROTECTS AB Background and Purpose-Current available therapies for neonatal hypoxia/ischemia (H/I) brain injury are rather limited. Here, we investigated the effect of omega-3 polyunsaturated fatty acids on brain damage and long-term neurological function after H/I in neonates. Methods-Female rats were treated with or without an omega-3 polyunsaturated fatty acids-enriched diet from the second day of pregnancy until 14 days after parturition. Seven-day-old neonates were subjected to H/I and euthanized 5 weeks later for evaluation of tissue loss. Neurological impairment was assessed progressively for 5 weeks after H/I by grid walking, foot fault, and Morris water maze. Activation of microglia and production of inflammatory mediators were examined up to 7 days after H/I. Results-Omega-3 polyunsaturated fatty acid supplementation significantly reduced brain damage and improved long-term neurological outcomes up to 5 weeks after neonatal H/I injury. Omega-3 polyunsaturated fatty acids exerted an anti-inflammatory effect in microglia both in an in vivo model of H/I and in in vitro microglial cultures subjected to inflammatory stimuli by inhibiting NF-kappa B activation and subsequent release of inflammatory mediators. Conclusions-Our results suggest that omega-3 polyunsaturated fatty acids confer potent neuroprotection against neonatal H/I brain injury through, at least partially, suppressing a microglial-mediated inflammatory response. (Stroke. 2010;41:2341-2347.) C1 [Zhang, Wenting; Hu, Xiaoming; Gao, Yanqin; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Zhang, Wenting; Hu, Xiaoming; Gao, Yanqin; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Zhang, Wenting; Yang, Wei; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Zhang, Wenting; Yang, Wei; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China. [Hu, Xiaoming; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. EM yqgao@shmu.edu.cn; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU National Institutes of Health [NS45048, NS056118, NS036736]; Chinese Natural Science Foundation [30870794]; Shanghai Science & Technology Bureau [08410703000]; Chinese Ministry of Science Technology; American Heart Association [10POST4150028] FX This project was supported by National Institutes of Health grants NS45048, NS056118, and NS036736 (to J.C); Chinese Natural Science Foundation grant (30870794) and International Collaboration grant (08410703000) from Shanghai Science & Technology Bureau (to Y.G and J.C); and Special Research Funds from Chinese Ministry of Science & Technology to State Key laboratories. X.H. is supported by a fellowship award from the American Heart Association (10POST4150028). NR 20 TC 57 Z9 60 U1 2 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD OCT PY 2010 VL 41 IS 10 BP 2341 EP 2347 DI 10.1161/STROKEAHA.110.586081 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 655CY UT WOS:000282221700048 PM 20705927 ER PT J AU Wortzel, HS Gutierrez, PM Homaifar, BY Breshears, RE Harwood, JE AF Wortzel, Hal S. Gutierrez, Peter M. Homaifar, Beeta Y. Breshears, Ryan E. Harwood, Jeri E. TI Surrogate Endpoints in Suicide Research SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID TOWER-OF-BABEL; REVISED NOMENCLATURE; DECISION-MAKING; CLINICAL-TRIALS; BEHAVIORS; LETHALITY; ATTEMPTERS; FAMILIES; GENETICS AB Surrogate endpoints frequently substitute for rare outcomes in research. The ability to learn about completed suicides by investigating more readily available and proximate outcomes, such as suicide attempts, has obvious appeal. However, concerns with surrogates from the statistical science perspective exist, and mounting evidence from psychometric, neurochemical, genetic, and neuroimaging studies suggests that surrogates may be particularly problematic in suicide research. The need for greater phenotypic refinement of suicide-related behaviors, development of and adherence to a shared suicide nomenclature, and conservative interpretation of investigational results that are limited to the precise population and suicide-related behavior under examination are discussed. C1 [Wortzel, Hal S.; Gutierrez, Peter M.; Homaifar, Beeta Y.; Breshears, Ryan E.] Denver VA Med Ctr, VISN MIRECC 19, Denver, CO USA. [Wortzel, Hal S.; Gutierrez, Peter M.; Homaifar, Beeta Y.; Breshears, Ryan E.] Univ Colorado, Denver Sch Med, Dept Psychiat, Boulder, CO 80309 USA. [Harwood, Jeri E.] Univ Colorado, Denver Sch Med, Dept Pediat, Boulder, CO 80309 USA. RP Wortzel, HS (reprint author), Denver Vet Hosp, VISN MIRECC 19, 1055 Clermont St,Room 4E130, Denver, CO 80220 USA. EM hal.wortzel@ucdenver.edu OI Gutierrez, Peter/0000-0001-8981-8404 NR 25 TC 3 Z9 3 U1 0 U2 0 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0363-0234 J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD OCT PY 2010 VL 40 IS 5 BP 500 EP 505 PG 6 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 670GM UT WOS:000283409200008 PM 21034212 ER PT J AU Ingraham, AM Cohen, ME Bilimoria, KY Pritts, TA Ko, CY Esposito, TJ AF Ingraham, Angela M. Cohen, Mark E. Bilimoria, Karl Y. Pritts, Timothy A. Ko, Clifford Y. Esposito, Thomas J. TI Comparison of outcomes after laparoscopic versus open appendectomy for acute appendicitis at 222 ACS NSQIP hospitals SO SURGERY LA English DT Article; Proceedings Paper CT 67th Annual Meeting of the Central-Surgical-Association CY MAR 10-13, 2010 CL Chicago, IL SP Cent Surg Assoc ID PROSPECTIVE RANDOMIZED-TRIAL; CONVENTIONAL APPENDECTOMY; COMPLICATED APPENDICITIS; PERFORATED APPENDICITIS; CLINICAL-TRIAL; SURGICAL CARE; BLINDED TRIAL; METAANALYSIS; STANDARD; SURGERY AB Background. The benefit of laparoscopic (LA) versus open (OA) appendectomy, particularly for complicated appendicitis, remains unclear Our objectives were to assess 30-day outcomes after LA versus OA for acute appendicitis and complicated appendicitis, determine the incidence of specific outcomes after appendectomy, and examine factors influencing the utilization and duration of the operative approach with multi-institutional clinical data. Methods. Using the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database (2005-2008), patients were identified who underwent emergency appendectomy for acute appendicitis at 222 participating hospitals. Regression models, which included propensity scare adjustment to minimize the influence of treatment selection bias, were constructed. Models assessed the association between surgical approach (LA vs OA) and risk-adjusted overall morbidity, surgical site infliction (SSI), serious morbidity, and serious morbidity/mortality, as well as individual complications in patients with acute appendicitis and complicated appendicitis. The relationships between operative approach, operative duration, and extended duration of stay with hospital academic affiliation were also examined. Results. Of 32,683 patients, 24,969 (76.4%) underwent LA and 7,714 (23.6%) underwent OA. Patients who underwent OA were significantly older with more comorbidities compared with those who underwent LA. Patients treated with LA were less likely to experience an overall morbidity (4.5% vs 8.8%; odds ratio [OR], 0.60; 95% confidence interval [CI], 0.54-0.68) or a SSI (3.3% vs 6.7%; OR, 0.57; 95% CI, 0.50-0.65) but not a serious morbidity (2.6% vs 4.2%; OR, 0.86; 95% CI, 0.74-1.01) or a serious morbidity/mortality (2.6% vs 4.3%; OR, 0.87; 95% CI, 0.74-1.01) compared with those who underwent OA. All patients treated with LA were significantly less likely to develop individual infectious complications except for organ. space SSI. Among patients with complicated appendicitis, organ space SSI was significantly more common after laparoscopic appendectomy (6.3% vs 4.8%; OR, 1.35; 95% CI, 1.05-1.73). For all patients with acute appendicitis, those treated at academic-affiliated versus community hospitals were equally likely to undergo LA versus OA (77.0% vs 77.3%; P = .58). Operative duration at academic centers was significantly longer for both LA and OA (LA, 47 vs 38 minutes [P < .0001]; OA, 49 vs 44 minutes [P < .0001]). Median duration of stay after LA was I day at both academic-affiliated and community hospitals. Conclusion. Within ACS NSQIP hospitals, LA is associated with lower overall morbidity in selected patients. However patients with complicated appendicitis may have a greater risk of organ space SSI after LA. Academic affiliation does not seem to influence the operative approach. However; LA is associated with similar durations of stay but slightly putter operative times than OA at academic versus community hospitals. (Surgery 2010;148:625-37.) C1 [Ingraham, Angela M.; Cohen, Mark E.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Ingraham, Angela M.; Pritts, Timothy A.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA. [Bilimoria, Karl Y.; Esposito, Thomas J.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Esposito, Thomas J.] Loyola Univ Chicago, Stritch Sch Med, Dept Surg, Maywood, IL USA. RP Ingraham, AM (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,Floor 22NE, Chicago, IL 60611 USA. EM aingraham@facs.org NR 78 TC 88 Z9 94 U1 3 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD OCT PY 2010 VL 148 IS 4 BP 625 EP 635 DI 10.1016/j.surg.2010.07.025 PG 11 WC Surgery SC Surgery GA 654WJ UT WOS:000282201500004 PM 20797745 ER PT J AU Lin, R Hogen, V Cannon, S Marion, KM Fenton, MS Hershman, JM AF Lin, Rose Hogen, Victor Cannon, Sophie Marion, Kenneth M. Fenton, Mike S. Hershman, Jerome M. TI Stability of Recombinant Human Thyrotropin Potency Based on Bioassay in FRTL-5 Cells SO THYROID LA English DT Article ID DIFFERENTIATED THYROID-CANCER; MULTINODULAR GOITERS; RADIOIODINE TREATMENT; NODULAR GOITER; SINGLE; REDUCTION; THERAPY AB Background: Recombinant human thyrotropin (rhTSH; Thyrogen (R)) is approved for use in a 0.9mg dose/day for 2 consecutive days for diagnosis and treatment of differentiated thyroid cancer. It is recommended that it be injected immediately after reconstitution in the distilled water diluent supplied by the manufacturer. However, Thyrogen has been used off-label in doses less than the standard 0.9mg dose for stimulation of radioiodine uptake in the treatment of multinodular goiter. To determine whether the biologic activity of Thyrogen can be preserved after dilution, we designed experiments to assess the biologic stability of Thyrogen under different durations and temperatures of storage. Methods: rhTSH was diluted in 1% bovine serum albumin in phosphate-buffered saline to a concentration of 0.9mg/mL and further diluted to 0.1mg/mL. Aliquots of 0.5mL were stored at room temperature, 4 degrees 8C, -11 degrees C, and -60 degrees C for various lengths of time. In addition, rhTSH aliquots were also subjected to incubation for 1 hour at 50 degrees C and to 10 cycles of freezing in dry ice alternating with thawing at 37 degrees C. Bioassays were performed in FRTL-5 cells. rhTSH was added to the media at a final concentration of either 5 ng/mL or 20 ng/mL, and the cells were then incubated for 48 hours. Potency was assessed by measurement of (125)I-iodide uptake in comparison to cells treated with perchlorate to block iodide uptake. Samples were immunoassayed at day 185 of storage. Results: Samples stored at 4 degrees C, -11 degrees C, -60 degrees C, and room temperature retained activity after storage periods of up to 204 days. Samples subjected to 10 freeze-thaw cycles or heated to 50 degrees C for 1 hour retained full biologic activity. Immunoassay at day 185 showed no difference in immunoactivity in relation to the storage condition. Conclusion: rhTSH kept at 4 degrees C, -11 degrees C, -60 degrees C, and room temperature maintained good biologic potency for more than 6 months of storage when tested in vitro, indicating that the biologic activity is very stable. However, altered sialylation occurring during storage could have altered the half-life of rhTSH. Nevertheless, the data provide reassurance that storage in the cold for a few months does not result in significant loss of biologic activity. C1 [Hershman, Jerome M.] W Los Angeles Vet Affairs Med Ctr, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Hershman, JM (reprint author), W Los Angeles Vet Affairs Med Ctr, Endocrinol & Diabet Div, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jhershmn@ucla.edu OI Cannon, Sophie M/0000-0003-1643-6944 FU VA; UCLA FX This work was supported by VA and UCLA Medical Research Funds. The authors are grateful to Eduardo De Guia for performing the immunoassays and to Armen Okunyan for assistance with cell culture. NR 13 TC 6 Z9 8 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 J9 THYROID JI Thyroid PD OCT PY 2010 VL 20 IS 10 BP 1139 EP 1143 DI 10.1089/thy.2009.0408 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 656UL UT WOS:000282363700012 PM 20615135 ER PT J AU Dasgupta, SK Argaiz, ER Mercado, JEC Maul, HOE Garza, J Enriquez, AB Abdel-Monem, H Prakasam, A Andreeff, M Thiagarajan, P AF Dasgupta, Swapan Kumar Argaiz, Eduardo Rios Mercado, Jose Emmanel Chedid Maul, Hector Omar Elizondo Garza, Jorge Enriquez, Ana Bety Abdel-Monem, Hanan Prakasam, Anthony Andreeff, Michael Thiagarajan, Perumal TI Platelet senescence and phosphatidylserine exposure SO TRANSFUSION LA English DT Article ID PERMEABILITY TRANSITION PORE; PROTEIN-KINASE; EXPRESSION; MEMBRANE; MITOCHONDRIA; BINDING; CELLS AB BACKGROUND: The exposure of phosphatidylserine occurs during platelet (PLT) activation and during in vitro storage. Phosphatidylserine exposure also occurs during apoptosis after the release of mitochondrial cytochrome c. We have examined the role of cytochrome c release, mitochondrial membrane potential (Delta Psi m), and cyclophilin D (CypD) in phosphatidylserine exposure due to activation and storage. STUDY DESIGN AND METHODS: The exposure of phosphatidylserine and the loss of Delta Psi m were determined in a flow cytometer using fluorescein isothiocyanate-lactadherin and JC-1, a lipophilic cationic reporter dye. The role of CypD was determined with cyclosporin A and CypD-deficient murine PLTs. Cytochrome c-induced caspase-3 and Rho-associated kinase I (ROCK1) activation were determined by immunoblotting and using their inhibitors. RESULTS: Collagen- and thrombin-induced exposure of phosphatidylserine was accompanied by a decrease in Delta Psi m. Cyclosporin A inhibited the phosphatidylserine exposure and the loss of Delta Psi m. CypD-/- mice had decreased loss of Delta Psi m and impaired phosphatidylserine exposure. Collagen and thrombin did not induce the release of cytochrome c nor the activation of caspase-3 and ROCK1. In contrast, in PLTs stored for more than 5 days, the phosphatidylserine exposure was associated with cytochrome c-induced caspase-3 and ROCK1 activation. ABT737, a BH3 mimetic that induces mitochondrial pathway of apoptosis, induced cytochrome c release and activation of caspase-3 and ROCK1 and phosphatidylserine exposure independent of CypD. CONCLUSION: These results show that in stored PLTs cytochrome c release and the subsequent activation of caspase-3 and ROCK1 mediate phosphatidylserine exposure and it is distinct from activation-induced phosphatidylserine exposure. C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Pathol, Houston, TX 77030 USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA. RP Thiagarajan, P (reprint author), Michael E DeBakey VA Med Ctr, Mail Stop 113,2002 Holcombe Blvd, Houston, TX 77030 USA. EM perumalt@bcm.tmc.edu OI Thiagarajan, Perumal/0000-0003-2186-7036 FU Veterans Affairs Research Service; National Institutes of Health [T-32HL072754] FX Supported by grants from the Veterans Affairs Research Service and by a training grant from National Institutes of Health (T-32HL072754). NR 31 TC 25 Z9 25 U1 0 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0041-1132 J9 TRANSFUSION JI Transfusion PD OCT PY 2010 VL 50 IS 10 BP 2167 EP 2175 DI 10.1111/j.1537-2995.2010.02676.x PG 9 WC Hematology SC Hematology GA 661AF UT WOS:000282693500014 PM 20456701 ER PT J AU Forsberg, CW Goldberg, J Sporleder, J Smith, NL AF Forsberg, Christopher W. Goldberg, Jack Sporleder, Jennifer Smith, Nicholas L. TI Determining Zygosity in the Vietnam Era Twin Registry: An Update SO TWIN RESEARCH AND HUMAN GENETICS LA English DT Article DE Questionnaire Zygosity Determination; Vietnam Era Twin Registry; Twin Study ID QUESTIONNAIRE AB Our work assessed the accuracy of the original zygosity classification in the Vietnam Era Twin (VET) Registry using new information from DNA markers on a subset of participants. We then constructed an updated zygosity classification algorithm. The VET Registry includes 7,375 male-male twin pairs who served in the military during the Vietnam era. During the mid-1980s 4,774 twin pairs completed a zygosity questionnaire of 20 items. Additionally, military record information, including blood group, was available. Items from the zygosity questionnaire and blood group were used in the original zygosity classification. Between 1990-2009 DNA was obtained from 612 twin pairs and concordance between co-twins was used to classify zygosity. Next logistic regression was used to construct predicted probabilities of zygosity using items from the zygosity questionnaire with this subsample. All twins were reclassified according to the new zygosity prediction model and compared with the original zygosity assignment. The original and new predicted probabilities of zygosity were highly correlated (r = 0.962) and concordance for the classification of zygosity was similarly high (kappa = 0.936). Errors in the original zygosity assignment were primarily due to monozygotic twins that were misclassified as dizygotic based on military record blood group data. Removing the military record blood group data markedly improved the accuracy of the original classification. Zygosity assignment based on a zygosity questionnaire was highly predictive of DNA-based zygosity. Augmentation of such a zygosity classification from administrative data, military records, or other records, should be done with caution. C1 [Forsberg, Christopher W.; Goldberg, Jack; Sporleder, Jennifer; Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Dept Vet Affairs Off Res & Dev, Vietnam Era Twin Registry, Seattle, WA 98101 USA. [Goldberg, Jack; Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Smith, Nicholas L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. RP Forsberg, CW (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Dept Vet Affairs Off Res & Dev, Vietnam Era Twin Registry, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Christopher.Forsberg@va.gov FU United States Department of Veterans Affairs FX The United States Department of Veterans Affairs has provided financial support for the development and maintenance of the Vietnam Era Twin (VET) Registry. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Numerous organizations have provided invaluable assistance in the conduct of this study, including: Department of Defense; National Personnel Records Cente; National Archives and Records Administration; the Internal Revenue Service; National Institutes et Health; National Opinion Research Center; National Research Council, National Academy of Sciences; the Institute for Survey Research, Temple University. Most importantly, the authors gratefully acknowledge the continued cooperation and participation of the members of the VET Registry and their families. Without their contribution this research would not have been possible. NR 10 TC 11 Z9 12 U1 0 U2 0 PU AUSTRALIAN ACAD PRESS PI BOWEN HILLS PA 32 JEAYS ST, BOWEN HILLS, QLD 4006, AUSTRALIA SN 1832-4274 J9 TWIN RES HUM GENET JI Twin Res. Hum. Genet. PD OCT PY 2010 VL 13 IS 5 BP 461 EP 464 PG 4 WC Genetics & Heredity; Obstetrics & Gynecology SC Genetics & Heredity; Obstetrics & Gynecology GA 664YX UT WOS:000283001300008 PM 20874468 ER PT J AU Xiao, YH Isaacs, SN AF Xiao, Yuhong Isaacs, Stuart N. TI Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections SO VIRUSES-BASEL LA English DT Review DE orthopoxvirus; variola virus; vaccinia virus; monkeypox virus; post-exposure vaccination; Dryvax; Lister; modified vaccinia Ankara (MVA); vaccinia immune globulin (VIG); monoclonal antibodies ID ANTIVACCINIAL GAMMA-GLOBULIN; NEUTRALIZING MONOCLONAL-ANTIBODIES; SECONDARY POXVIRUS INFECTION; IMMUNE GLOBULIN; SMALLPOX VACCINATION; PROGRESSIVE VACCINIA; VIRUS-INFECTION; PROTECTIVE ANTIBODIES; ECZEMA VACCINATUM; IN-VITRO AB Despite the eradication of smallpox several decades ago, variola and monkeypox viruses still have the potential to become significant threats to public health. The current licensed live vaccinia virus-based smallpox vaccine is extremely effective as a prophylactic vaccine to prevent orthopoxvirus infections, but because of safety issues, it is no longer given as a routine vaccine to the general population. In the event of serious human orthopoxvirus infections, it is important to have treatments available for individual patients as well as their close contacts. The smallpox vaccine and vaccinia immune globulin (VIG) were used in the past as therapeutics for patients exposed to smallpox. VIG was also used in patients who were at high risk of developing complications from smallpox vaccination. Thus post-exposure vaccination and VIG treatments may again become important therapeutic modalities. This paper summarizes some of the historic use of the smallpox vaccine and immunoglobulins in the post-exposure setting in humans and reviews in detail the newer animal studies that address the use of therapeutic vaccines and immunoglobulins in orthopoxvirus infections as well as the development of new therapeutic monoclonal antibodies. C1 [Xiao, Yuhong; Isaacs, Stuart N.] Univ Penn, Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Isaacs, Stuart N.] Philadelphia Vet Affairs Med Ctr, Infect Dis Sect, Philadelphia, PA 19104 USA. RP Isaacs, SN (reprint author), Univ Penn, Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA. EM yuhong2@mail.med.upenn.edu; isaacs@mail.med.upenn.edu FU National Institute of Allergy and Infectious Disease (Middle Atlantic Regional Center of Excellence in Biodefense and Emerging Infectious Diseases) [U01-AI077913, U01-AI066333, U54-AI057168] FX We thank Matt Cohen for critical reading of the manuscript. S.N.I. is supported in part by Public Health Service grants U01-AI077913, U01-AI066333, and U54-AI057168 (Middle Atlantic Regional Center of Excellence in Biodefense and Emerging Infectious Diseases) from the National Institute of Allergy and Infectious Disease. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the University of Pennsylvania, the Department of Veterans Affairs or the United States government. NR 79 TC 4 Z9 5 U1 0 U2 0 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1999-4915 J9 VIRUSES-BASEL JI Viruses-Basel PD OCT PY 2010 VL 2 IS 10 BP 2381 EP 2403 DI 10.3390/v2102381 PG 23 WC Virology SC Virology GA 684VQ UT WOS:000284581900011 PM 21197387 ER PT J AU DeKosky, ST Ikonomovic, MD Gandy, S AF DeKosky, Steven T. Ikonomovic, Milos D. Gandy, Sam TI Traumatic Brain Injury -- Football, Warfare, and Long-Term Effects. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [DeKosky, Steven T.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Edu & Clin Ctr, Pittsburgh, PA USA. [Gandy, Sam] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Gandy, Sam] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Gandy, Sam] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY USA. [Gandy, Sam] James J Peters VA Med Ctr, New York, NY USA. RP DeKosky, ST (reprint author), Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA. FU NIA NIH HHS [P01 AG010491, P01 AG010491-14] NR 5 TC 123 Z9 125 U1 1 U2 13 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 30 PY 2010 VL 363 IS 14 BP 1293 EP 1296 DI 10.1056/NEJMp1007051 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 655TD UT WOS:000282271500001 PM 20879875 ER PT J AU Townsend, JD Eberhart, NK Bookheimer, SY Eisenberger, NI Foland-Ross, LC Cook, IA Sugar, CA Altshuler, LL AF Townsend, Jennifer D. Eberhart, Nicole K. Bookheimer, Susan Y. Eisenberger, Naomi I. Foland-Ross, Lara C. Cook, Ian A. Sugar, Catherine A. Altshuler, Lori L. TI fMRI activation in the amygdala and the orbitofrontal cortex in unmedicated subjects with major depressive disorder SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Amygdala; DLPFC; Emotion; Major depressive disorder ID FUNCTIONAL MAGNETIC-RESONANCE; MOOD REGULATING CIRCUIT; UNIPOLAR DEPRESSION; FACIAL EXPRESSIONS; ANTIDEPRESSANT TREATMENT; COGNITIVE-CONTROL; NEURAL RESPONSES; BRAIN IMAGES; RISK-FACTORS; CONNECTIVITY AB Although amygdala and frontal lobe functional abnormalities have been reported in patients with mood disorders, the literature regarding major depressive disorder (MDD) is inconsistent. Likely confounds include heterogeneity of patient samples, medication status, and analytic approach. This study evaluated the amygdala and frontal lobe activation in unmedicated MDD patients. Fifteen MDD patients and 15 matched healthy controls were scanned using fMRI during the performance of an emotional face task known to robustly activate the amygdala and prefrontal cortex (PFC). Whole-brain and region of interest analyses were performed, and correlations between clinical features and activation were examined. Significant amygdala and lateral PFC activation were seen within patient and control groups. In a between-group comparison, patients showed significantly reduced activation in the insula, temporal and occipital cortices. In MDD, the presence of anxiety symptoms was associated with decreased orbitofrontal activation. We found robust activation in both the MOD and control groups in fronto-limbic regions with no significant between-group differences using either analytic approach. The current study replicates previous research on unmedicated subjects showing no significant differences in amygdala function in depressed vs. control subjects with respect to simple tasks involving emotion observation. (c) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Townsend, Jennifer D.; Bookheimer, Susan Y.; Cook, Ian A.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Townsend, Jennifer D.; Bookheimer, Susan Y.; Cook, Ian A.; Altshuler, Lori L.] Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Eberhart, Nicole K.] RAND Corp, Santa Monica, CA USA. [Eisenberger, Naomi I.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Foland-Ross, Lara C.] Univ Calif Los Angeles, Sch Med, Dept Neurol, Lab NeuroImaging, Los Angeles, CA 90024 USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, W Los Angeles Healthcare Ctr, Los Angeles, CA USA. RP Altshuler, LL (reprint author), 300 UCLA Med Plaza,Suite 1544,Box 696824, Los Angeles, CA 90095 USA. EM laltshuler@mednet.ucla.edu FU Stein Oppenheimer Foundation; National Center for Research Resources (NCRR) [RR12169, RR13642, RR00865]; National Institutes of Health (NIH) FX We are grateful for funding from the Stein Oppenheimer Foundation which supported this research. For generous support the authors also wish to thank the Brain Mapping Medical Research Organization, Brain Mapping Support Foundation, Pierson-Lovelace Foundation, the Ahmanson Foundation, the William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation, the Tamkin Foundation, the Jennifer Jones-Simon Foundation, the Capital Group Companies Charitable Foundation, the Robson Family and the Northstar Fund. The project described was supported by Grant Numbers RR12169, RR13642 and RR00865 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH); its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCR or NIH. Cyberonics, Eli Lilly and Company, Forest laboratories, Janssen, Neuronetics, Scale Venture Partners, and the U.S. Department of Justice; and has been a member of the speakers bureau for Bristol-Myers Squibb, CME LLC, Medical Education Speakers Network, Pfizer, and Wyeth. Dr. Cook is not a shareholder in any pharmaceutical or medical device company; his patents are assigned to the University of California. In the past 5 years, Dr. Altshuler has received grant support from Abbott Laboratories; honoraria from Abbott Laboratories, Forest Laboratories and GlaxoS-mithldine; has served on advisory boards for Abbott Laboratories and Forest Laboratories; and has been a member of the speakers bureau for Forest Laboratories and GlaxoSmithKline. Dr. Altshuler is not a shareholder in any pharmaceutical or medical device company. The remaining authors have no conflicts of interest to declare. NR 71 TC 50 Z9 50 U1 3 U2 14 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD SEP 30 PY 2010 VL 183 IS 3 BP 209 EP 217 DI 10.1016/j.pscychresns.2010.06.001 PG 9 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 654BJ UT WOS:000282142800005 PM 20708906 ER PT J AU Brody, AL London, ED Olmstead, RE Allen-Martinez, Z Shulenberger, S Costello, MR Abrams, AL Scheibal, D Farahi, J Shoptaw, S Mandelkern, MA AF Brody, Arthur L. London, Edythe D. Olmstead, Richard E. Allen-Martinez, Zoe Shulenberger, Stephanie Costello, Matthew R. Abrams, Anna L. Scheibal, David Farahi, Judah Shoptaw, Steven Mandelkern, Mark A. TI Smoking-induced change in intrasynaptic dopamine concentration: Effect of treatment for Tobacco Dependence SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Tobacco Dependence; (11)C-raclopride; Positron emission tomography; Dopamine; Ventral striatum; Cigarette craving ID POSITRON-EMISSION-TOMOGRAPHY; SUSTAINED-RELEASE BUPROPION; SYNAPSE IN-VIVO; NUCLEUS-ACCUMBENS; CONTINUOUS-INFUSION; NICOTINE PATCH; HUMAN-BRAIN; RACLOPRIDE BINDING; EXTRACELLULAR DOPAMINE; C-11 RACLOPRIDE AB The aim of this study was to determine whether standard treatments for Tobacco Dependence affect smoking-induced changes in intrasynaptic dopamine (DA) concentration. Forty-three otherwise healthy adult cigarette smokers (10 to 40 cigarettes per day) were treated with either practical group counseling (PGC) psychotherapy (n = 14), bupropion HCl (n = 14), or matching pill placebo (n = 15) (random assignment) for 8 weeks. Before and after treatment, each subject underwent a bolus-plus-continuous-infusion (11)C-raclopride positron emission tomography (PET) scanning session, during which he or she smoked a regular cigarette. The PET scanning outcome measure of interest was percent change in smoking-induced 11C-raclopride binding potential (BP(ND)) in the ventral caudate/nucleus accumbens (VCD/NAc), as an indirect measure of DA release. Although the entire study sample had a smaller mean smoking-induced reduction in VCD/NAc BP(ND) after treatment (compared to before treatment), this change was highly correlated with smaller total cigarette puff volumes (and not other treatment variables). These data indicate that smoking-induced DA release is dose-dependent, and is not significantly affected by reductions in daily smoking levels or treatment type. Published by Elsevier Ireland Ltd. C1 [Brody, Arthur L.; London, Edythe D.; Allen-Martinez, Zoe; Costello, Matthew R.; Abrams, Anna L.; Scheibal, David] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA. [Brody, Arthur L.; Olmstead, Richard E.; Allen-Martinez, Zoe; Shulenberger, Stephanie; Costello, Matthew R.; Abrams, Anna L.; Scheibal, David; Farahi, Judah; Mandelkern, Mark A.] Greater Los Angeles VA Healthcare Syst, Dept Nucl Med, Los Angeles, CA USA. [Brody, Arthur L.; London, Edythe D.; Shoptaw, Steven] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. [London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Shoptaw, Steven] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90095 USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. RP Brody, AL (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM abrody@ucla.edu FU Tobacco-Related Disease Research Program [11RT-0024, 16RT-0098]; National Institute on Drug Abuse [R01 DA15059, DA20872]; Veterans Affairs Type I Merit Review Award; Office of National Drug Control Policy [DABT63-00-C-1003] FX Supported by the Tobacco-Related Disease Research Program (A.L.B. [11RT-0024 and 16RT-0098]), the National Institute on Drug Abuse (A.L.B. [R01 DA15059 and DA20872]), a Veterans Affairs Type I Merit Review Award (A.L.B.), and the Office of National Drug Control Policy (E.D.L [DABT63-00-C-1003]). The authors thank Josephine Ribe and Michael Clark for their technical support in performing positron emission tomography and magnetic resonance imaging scans, respectively. NR 73 TC 15 Z9 15 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD SEP 30 PY 2010 VL 183 IS 3 BP 218 EP 224 DI 10.1016/j.pscychresns.2009.06.004 PG 7 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 654BJ UT WOS:000282142800006 PM 20682457 ER PT J AU Hajcak, G Anderson, BS Arana, A Borckardt, J Takacs, I George, MS Nahas, Z AF Hajcak, G. Anderson, B. S. Arana, A. Borckardt, J. Takacs, I. George, M. S. Nahas, Z. TI DORSOLATERAL PREFRONTAL CORTEX STIMULATION MODULATES ELECTROCORTICAL MEASURES OF VISUAL ATTENTION: EVIDENCE FROM DIRECT BILATERAL EPIDURAL CORTICAL STIMULATION IN TREATMENT-RESISTANT MOOD DISORDER SO NEUROSCIENCE LA English DT Article DE brain stimulation; attention; IAPS; late positive potential ID EMOTIONAL PICTURES; MOTIVATED ATTENTION; AROUSING PICTURES; BRAIN POTENTIALS; NEURAL RESPONSE; ORGANIZATION; ASSOCIATION; PERCEPTION; AMYGDALA; FACILITATION AB Electrocortical activity is increasingly being used to study emotion regulation and the impact of cognitive control on neural response to visual stimuli. In the current study, we used direct epidural cortical stimulation (EpCS) to examine regional specificity of PFC stimulation on the parietally-maximal late positive potential (LPP), an event-related potential (ERP) biomarker of visual attention to salient stimuli. Five patients with treatment-resistant mood disorders were stereotactically implanted with stimulating paddles over frontopolar (FP) and dorsolateral (DL) prefrontal cortex bilaterally. On their first day of activation, patients underwent sham-controlled EpCS coupled with 64-channel electroencephalograph (EEG) recordings and passive viewing of aversive and neutral images. In addition to sham, patients had either FP or DL prefrontal cortex stimulated at 2 or 4 V while they viewed neutral and aversive pictures. As expected during the sham condition, LPP was larger for aversive compared to neutral stimuli (F(1,4)=232.07, P<.001). Stimulation of DL compared to FP prefrontal cortex resulted in a reduction of the LPP (F(1,4)=8.15, P=.048). These data provide additional and unique support to the role of the DL prefrontal cortex in regulating measures of neural activity that have been linked to emotional arousal and attention. Future studies with EpCS can help directly map out various prefrontal functions in treatment-resistant mood disorder. (C) 2010 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Hajcak, G.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA. [Anderson, B. S.; Arana, A.; Borckardt, J.; George, M. S.; Nahas, Z.] Med Univ S Carolina, Mood Disorders Program, Charleston, SC 29425 USA. [Anderson, B. S.; Arana, A.; Borckardt, J.; George, M. S.; Nahas, Z.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA. [Borckardt, J.; George, M. S.; Nahas, Z.] Med Univ S Carolina, CAIR, Charleston, SC 29425 USA. [Borckardt, J.; Takacs, I.; George, M. S.; Nahas, Z.] Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA. [Takacs, I.] Med Univ S Carolina, Dept Neurosurg, Charleston, SC 29425 USA. [George, M. S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Nahas, Z (reprint author), SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA. EM nahasz@musc.edu FU National Alliance of Research for Depression and Schizophrenia (NARSAD); Mood Disorders Program; Brain Stimulation Laboratory; General Clinical Research Center (GCRC); Center for Advanced Imaging Research (CAIR) at the Medical University of South Carolina FX Study funded primarily by a National Alliance of Research for Depression and Schizophrenia (NARSAD) Independent Investigator Award to ZN. Study was also made possible with general funds from the Mood Disorders Program, the Brain Stimulation Laboratory, the General Clinical Research Center (GCRC), the Center for Advanced Imaging Research (CAIR) at the Medical University of South Carolina. Medtronic Inc. (Minneapolis, Minnesota) donated the devices but was otherwise not involved in the study, particularly data acquisition, analysis, or drafting this manuscript. The authors would like to thank Mark Rise (Medtronic Inc.) for technical assistance in stimulation set ups. NR 59 TC 19 Z9 20 U1 6 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD SEP 29 PY 2010 VL 170 IS 1 BP 281 EP 288 DI 10.1016/j.neuroscience.2010.04.069 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 645OX UT WOS:000281473300029 PM 20451585 ER PT J AU Salinthone, S Yadav, V Schillace, RV Bourdette, DN Carr, DW AF Salinthone, Sonemany Yadav, Vijayshree Schillace, Robynn V. Bourdette, Dennis N. Carr, Daniel W. TI Lipoic Acid Attenuates Inflammation via cAMP and Protein Kinase A Signaling SO PLOS ONE LA English DT Article ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; T-CELL MIGRATION; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; MULTIPLE-SCLEROSIS; CYCLIC-AMP; DIABETIC POLYNEUROPATHY; CERAMIDE-1-PHOSPHATE ANALOG; INHIBITS EXPRESSION; DIAGNOSTIC-CRITERIA AB Background: Abnormal regulation of the inflammatory response is an important component of diseases such as diabetes, Alzheimer's disease and multiple sclerosis (MS). Lipoic acid (LA) has been shown to have antioxidant and anti-inflammatory properties and is being pursued as a therapy for these diseases. We first reported that LA stimulates cAMP production via activation of G-protein coupled receptors and adenylyl cyclases. LA also suppressed NK cell activation and cytotoxicity. In this study we present evidence supporting the hypothesis that the anti-inflammatory properties of LA are mediated by the cAMP/PKA signaling cascade. Additionally, we show that LA oral administration elevates cAMP levels in MS subjects. Methodology/Principal Findings: We determined the effects of LA on IL-6, IL-17 and IL-10 secretion using ELISAs. Treatment with 50 mg/ml and 100 mg/ml LA significantly reduced IL-6 levels by 19 and 34%, respectively, in T cell enriched PBMCs. IL-17 levels were also reduced by 35 and 50%, respectively. Though not significant, LA appeared to have a biphasic effect on IL-10 production. Thymidine incorporation studies showed LA inhibited T cell proliferation by 90%. T-cell activation was reduced by 50% as measured by IL-2 secretion. Western blot analysis showed that LA treatment increased phosphorylation of Lck, a downstream effector of protein kinase A. Pretreatment with a peptide inhibitor of PKA, PKI, blocked LA inhibition of IL-2 and IFN gamma production, indicating that PKA mediates these responses. Oral administration of 1200 mg LA to MS subjects resulted in increased cAMP levels in PBMCs four hours after ingestion. Average cAMP levels in 20 subjects were 43% higher than baseline. Conclusions/Significance: Oral administration of LA in vivo resulted in significant increases in cAMP concentration. The anti-inflammatory effects of LA are mediated in part by the cAMP/PKA signaling cascade. These novel findings enhance our understanding of the mechanisms of action of LA. C1 [Salinthone, Sonemany; Yadav, Vijayshree; Schillace, Robynn V.; Bourdette, Dennis N.; Carr, Daniel W.] Portland VA Med Ctr, Portland, OR USA. [Salinthone, Sonemany; Yadav, Vijayshree; Schillace, Robynn V.; Bourdette, Dennis N.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Carr, Daniel W.] Oregon Hlth & Sci Univ, Dept Endocrinol, Portland, OR 97201 USA. RP Salinthone, S (reprint author), Portland VA Med Ctr, Portland, OR USA. EM carrd@ohsu.edu FU Department of Veterans Affairs Biomedical Laboratory Research & Development Service; Collins Medical Trust; National Multiple Sclerosis Society [CA1055A]; Laura Fund for Innovation in Multiple Sclerosis Research and Nancy Davis Center Without Walls; National Center of Complementary and Alternative Medicine [K23 AT003258]; Oregon Clinical and Translational Research Institute (OCTRI); National Center for Research Resources, National Institutes of Health (NIH), NIH Roadmap for Medical Research [UL1RR024140] FX This research was supported by the Department of Veterans Affairs Biomedical Laboratory Research & Development Service (D.B and D.C), the Collins Medical Trust (S.S), National Multiple Sclerosis Society (CA1055A, D.B), the Laura Fund for Innovation in Multiple Sclerosis Research and Nancy Davis Center Without Walls (D.B), the National Center of Complementary and Alternative Medicine (K23 AT003258, D.B), Oregon Clinical and Translational Research Institute (OCTRI, V.Y)), National Center for Research Resources (UL1RR024140, V.Y.), components of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research (V.Y). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 68 TC 20 Z9 24 U1 3 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 28 PY 2010 VL 5 IS 9 AR e13058 DI 10.1371/journal.pone.0013058 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 654ZQ UT WOS:000282210700025 ER PT J AU Menconi, F Osman, R Monti, MC Greenberg, DA Concepcion, ES Tomer, Y AF Menconi, Francesca Osman, Roman Monti, Maria C. Greenberg, David A. Concepcion, Erlinda S. Tomer, Yaron TI Shared molecular amino acid signature in the HLA-DR peptide binding pocket predisposes to both autoimmune diabetes and thyroiditis SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE autoimmunity; gene; structure ID JOINT GENETIC SUSCEPTIBILITY; POLYGLANDULAR SYNDROMES; GRAVES-DISEASE; MELLITUS; FAMILIES; CHILDREN; COMMON; EPIDEMIOLOGY; ASSOCIATION; ADOLESCENTS AB There is strong genetic association between type 1A diabetes (T1D) and autoimmune thyroid disease (AITD). T1D and AITD frequently occur together in the same individual, a condition classified as a variant of the autoimmune polyglandular syndrome type 3 (APS3). Because T1D and AITD are individually strongly associated with different HLA class II sequences, we asked which HLA class II pocket sequence and structure confer joint susceptibility to both T1D and AITD in the same individual (APS3v). We sequenced the HLA-DR gene in 105 APS3v patients and 153 controls, and identified a pocket amino acid signature, DR beta-Tyr-26, DR beta-Leu-67, DR beta-Lys-71, and DR beta-Arg-74, that was strongly associated with APS3v (P = 5.4 x 10(-14), odds ratio = 8.38). Logistic regression analysis demonstrated that DR beta-Leu-67 (P = 9.4 x 10(-13)) and DR beta-Arg-74 (P = 1.21 x 10(-13)) gave strong independent effects on disease susceptibility. Structural modeling studies demonstrated that pocket 4 was critical for the development of T1D+AITD; all disease-associated amino acids were linked to areas of the pocket that interact directly with the peptide and, therefore, influence peptide binding. The disease-susceptible HLA-DR pocket was more positively charged (Lys-71, Arg-74) compared with the protective pocket (Ala-71, Gln-74). We conclude that a specific pocket amino acid signature confers joint susceptibility to T1D+AITD in the same individual by causing significant structural changes in the MHC II peptide binding pocket and influencing peptide binding and presentation. Moreover, Arg-74 is a major amino acid position for the development of several autoimmune diseases. These findings suggest that blocking the critical Arg-74 pocket might offer a method for treating certain autoimmune conditions. C1 [Menconi, Francesca; Concepcion, Erlinda S.; Tomer, Yaron] Mt Sinai Sch Med, Div Endocrinol, Dept Med, New York, NY 10029 USA. [Osman, Roman] Mt Sinai Sch Med, Dept Struct & Chem Biol, New York, NY 10029 USA. [Monti, Maria C.] Univ Pavia, Dept Appl Hlth Sci, I-27100 Pavia, Italy. [Greenberg, David A.] Columbia Univ, Div Stat Genet, New York, NY 10032 USA. [Tomer, Yaron] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA. RP Tomer, Y (reprint author), Mt Sinai Sch Med, Div Endocrinol, Dept Med, New York, NY 10029 USA. EM yaron.tomer@mssm.edu OI Monti, Maria Cristina/0000-0003-1586-527X FU National Institutes of Health [DK61659, DK067555, DK073681, MH48858, NS27941] FX This work was supported in part by Grants DK61659, DK067555, and DK073681 (to Y.T.) and MH48858 and NS27941 (to D.A.G.) from the National Institutes of Health. NR 33 TC 32 Z9 33 U1 0 U2 3 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD SEP 28 PY 2010 VL 107 IS 39 BP 16899 EP 16903 DI 10.1073/pnas.1009511107 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 655AA UT WOS:000282211700032 PM 20837527 ER PT J AU Spinale, FG Mukherjee, R Zavadzkas, JA Koval, CN Bouges, S Stroud, RE Dobrucki, LW Sinusas, AJ AF Spinale, Francis G. Mukherjee, Rupak Zavadzkas, Juozas A. Koval, Christine N. Bouges, Shenikqua Stroud, Robert E. Dobrucki, Lawrence W. Sinusas, Albert J. TI Cardiac Restricted Overexpression of Membrane Type-1 Matrix Metalloproteinase Causes Adverse Myocardial Remodeling following Myocardial Infarction SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID LEFT-VENTRICULAR FUNCTION; TGF-BETA; HEART-FAILURE; 1-MATRIX METALLOPROTEINASE; ACTIVATION; MICE; INHIBITION; MATRIX-METALLOPROTEINASE-9; TRANSCRIPTION; FIBROBLASTS AB The membrane type-1 matrix metalloproteinase (MT1MMP) is a unique member of the MMP family, but induction patterns and consequences of MT1-MMP overexpression (MT1-MMPexp), in a left ventricular (LV) remodeling process such as myocardial infarction (MI), have not been explored. MT1-MMP promoter activity (murine luciferase reporter) increased 20-fold at 3 days and 50-fold at 14 days post-MI. MI was then induced in mice with cardiac restricted MT1-MMPexp (n = 58) and wild type (WT, n = 60). Post-MI survival was reduced (67% versus 46%, p < 0.05), and LV ejection fraction was lower in the post-MI MT1-MMPexp mice compared with WT (41 +/- 2 versus 32 +/- 2%, p < 0.05). In the post-MI MT1-MMPexp mice, LV myocardial MMP activity, as assessed by radiotracer uptake, and MT1-MMP-specific proteolytic activity using a specific fluorogenic assay were both increased by 2-fold. LV collagen content was increased by nearly 2-fold in the post-MI MT1-MMPexp compared with WT. Using a validated fluorogenic construct, it was discovered that MT1-MMP proteolytically processed the pro-fibrotic molecule, latency-associated transforming growth factor-1 binding protein (LTBP-1), and MT1-MMP-specific LTBP-1 proteolytic activity was increased by 4-fold in the post-MIMT1-MMPexp group. Early and persistent MT1-MMP promoter activity occurred post-MI, and increased myocardial MT1-MMP levels resulted in poor survival, worsening of LV function, and significant fibrosis. A molecular mechanism for the adverse LV matrix remodeling with MT1-MMP induction is increased processing of pro-fibrotic signaling molecules. Thus, a proteolytically diverse portfolio exists for MT1-MMP within the myocardium and likely plays a mechanistic role in adverse LV remodeling. C1 [Spinale, Francis G.; Mukherjee, Rupak; Zavadzkas, Juozas A.; Koval, Christine N.; Bouges, Shenikqua; Stroud, Robert E.] Med Univ S Carolina, Charleston, SC 29425 USA. [Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Dobrucki, Lawrence W.; Sinusas, Albert J.] Yale Univ, Sch Med New Haven, New Haven, CT 06510 USA. RP Sinusas, AJ (reprint author), Room 625,770 MUSC Complex,114 Doughty St, Charleston, SC 29425 USA. EM wilburnm@musc.edu OI Dobrucki, Wawrzyniec/0000-0002-6807-217X FU National Institutes of Health [HL057952, HL059165, HL078825]; Veterans Affairs Health Administration FX This work was supported, in whole or in part, by National Institutes of Health Grants HL057952, HL059165, and HL078825. This work was also supported by a Merit Award from the Veterans Affairs Health Administration. NR 30 TC 34 Z9 34 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 24 PY 2010 VL 285 IS 39 BP 30316 EP 30327 DI 10.1074/jbc.M110.158196 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 652EK UT WOS:000281984300067 PM 20643648 ER PT J AU Hays, LE Keeble, WW Yates, JE Rathbun, RK Koretsky, T Olson, SB Sun, ZJ Clapp, DW Bagby, GC AF Hays, Laura E. Keeble, Winifred W. Yates, Jane E. Rathbun, R. K. Koretsky, Tara Olson, Susan B. Sun, Zejin Clapp, D. Wade Bagby, Grover C., Jr. TI Human FANCC is hypomorphic in murine Fancc-deficient cells SO BLOOD LA English DT Article ID C GENE; REPOPULATING ABILITY; STEM-CELLS; ANEMIA; EXPRESSION; MICE; INTERFERON; INACTIVATION; INSTABILITY; VECTORS AB Fancc suppresses cross-linker-induced genotoxicity, modulates growth-inhibitory cytokine responses, and modulates endotoxin responses. Although loss of the latter function is known to account for endotoxin-induced marrow failure in murine Fancc (mFancc)-deficient mice, some argue that cytokine and endotoxin hypersensitivities devolve simply from genomic instability. Seeking to resolve this question, we planned to ectopically express instructive human FANCC(hFANCC) mutants in murine Fancc-deficient hematopoietic stem cells. To first assure that hFANCC cDNA was competent in murine cells, we compared hFANCC and mFancc in complementation assays for cross-linking agent hypersensitivity and endotoxin hypersensitivity. We found that mFancc complemented murine Fancc-deficient cells in both assays, but that hFANCC fully suppressed only endotoxin hypersensitivity, not cross-linking agent hypersensitivity. These results support the notions that Fancc is multifunctional and that structural prerequisites for its genoprotective functions differ from those required to constrain endotoxin responses known to lead to marrow failure in Fancc-deficient mice. (Blood. 2010;116(12):2057-2060) C1 [Hays, Laura E.; Keeble, Winifred W.; Yates, Jane E.; Rathbun, R. K.; Koretsky, Tara; Bagby, Grover C., Jr.] Portland VA Med Ctr, Portland, OR 97239 USA. [Hays, Laura E.; Keeble, Winifred W.; Yates, Jane E.; Rathbun, R. K.; Koretsky, Tara; Olson, Susan B.; Bagby, Grover C., Jr.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Hays, Laura E.; Bagby, Grover C., Jr.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Olson, Susan B.; Bagby, Grover C., Jr.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA. [Sun, Zejin; Clapp, D. Wade] Indiana Univ Sch Med, Indianapolis, IN USA. RP Hays, LE (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,R&D-2, Portland, OR 97239 USA. EM haysl@ohsu.edu FU Fanconi Anemia Research Fund; Knight Cancer Institute at Oregon Health & Science University; Veterans Association; National Institutes of Health/National Heart, Lung, and Blood Institute [5P01-HL48546]; National Institutes of Health/ National Cancer Institute [1-R01-CA138237-01] FX This work was supported by Fanconi Anemia Research Fund (L.E.H.), the Knight Cancer Institute at Oregon Health & Science University, Veterans Association Merit Review (G.C.B.), National Institutes of Health/National Heart, Lung, and Blood Institute (5P01-HL48546; G.C.B., S.B.O.), and National Institutes of Health/ National Cancer Institute (1-R01-CA138237-01; D.W.C., G.C.B.). NR 20 TC 6 Z9 6 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD SEP 23 PY 2010 VL 116 IS 12 BP 2057 EP 2060 DI 10.1182/blood-2010-02-266411 PG 4 WC Hematology SC Hematology GA 653ZG UT WOS:000282137300012 PM 20554974 ER PT J AU De Gasperi, R Sosa, MAG Dracheva, S Elder, GA AF De Gasperi, Rita Sosa, Miguel A. Gama Dracheva, Stella Elder, Gregory A. TI Presenilin-1 regulates induction of hypoxia inducible factor-1 alpha: altered activation by a mutation associated with familial Alzheimer's disease SO MOLECULAR NEURODEGENERATION LA English DT Article ID AMYLOID PRECURSOR PROTEIN; GROWTH-FACTOR-I; PROMOTES TAU-PHOSPHORYLATION; GENE-EXPRESSION; SIGNALING PATHWAYS; GAMMA-SECRETASE; INSULIN-RESISTANCE; TYROSINE KINASE; TRANSGENIC MICE; TALKING POINT AB Background: Mutations in presenilin-1 (Psen1) cause familial Alzheimer's disease (FAD). Both hypoxia and ischemia have been implicated in the pathological cascade that leads to amyloid deposition in AD. Here we investigated whether Psen1 might regulate hypoxic responses by modulating induction of the transcription factor hypoxia inducible factor 1-alpha (HIF-1 alpha). Results: In fibroblasts that lack Psen1 induction of HIF-1 alpha was impaired in response to the hypoxia mimetic cobalt chloride, as well as was induction by insulin and calcium chelation. Reintroduction of human Psen1 using a lentiviral vector partially rescued the responsiveness of Psen1(-/-) fibroblasts to cobalt chloride induction. HIF-1 alpha induction did not require Psen1's associated gamma-secretase activity. In addition, the failure of insulin to induce HIF-1 alpha was not explicable on the basis of failed activation of the phosphatidylinositol 3-kinase (PI3K/Akt) pathway which activated normally in Psen1(-/-) fibroblasts. Rather we found that basal levels of HIF-1 alpha were lower in Psen1(-/-) fibroblasts and that the basis for lower constitutive levels of HIF-1 alpha was best explained by accelerated HIF-1 alpha degradation. We further found that Psen1 and HIF-1 alpha physically interact suggesting that Psen1 may protect HIF-1 alpha from degradation through the proteasome. In fibroblasts harboring the M146V Psen1 FAD mutation on a mouse Psen1 null background, metabolic induction of HIF-1 alpha by insulin was impaired but not hypoxic induction by cobalt chloride. Unlike Psen1(-/-) fibroblasts, basal levels of HIF-1 alpha were normal in FAD mutant fibroblasts but activation of the insulin-receptor pathway was impaired. Interestingly, in Psen1(-/-) primary neuronal cultures HIF-1 alpha was induced normally in response to cobalt chloride but insulin induction of HIF-1 alpha was impaired even though activation of the PI3K/Akt pathway by insulin proceeded normally in Psen1(-/-) neuronal cultures. Basal levels of HIF-1 alpha were not significantly different in Psen1(-/-) neurons and HIF-1 alpha levels were normal in Psen1(-/-) embryos. Conclusions: Collectively these studies show that Psen1 regulates induction of HIF-1 alpha although they indicate that cell type specific differences exist in the effect of Psen1 on induction. They also show that the M146V Psen1 FAD mutation impairs metabolic induction of HIF-1 alpha, an observation that may have pathophysiological significance for AD. C1 [Elder, Gregory A.] Vet Adm Med Ctr, James J Peters Dept, Neurol Serv, Bronx, NY 10468 USA. [De Gasperi, Rita; Sosa, Miguel A. Gama; Dracheva, Stella; Elder, Gregory A.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. RP Elder, GA (reprint author), Vet Adm Med Ctr, James J Peters Dept, Neurol Serv, Bronx, NY 10468 USA. EM gregory.elder@mssm.edu FU Department of Veterans Affairs [5I01BX000342-02]; National Institute on Aging [AG20139, AG02219, AG05138, AG029361]; Alzheimer's Association [IIRG-07-57318] FX This work was supported by a Merit Award from the Department of Veterans Affairs (5I01BX000342-02) and grants from the National Institute on Aging (AG20139, AG02219, AG05138, and AG029361), and the Alzheimer's Association (IIRG-07-57318). We thank Drs. Paul Mathews and Nikolaos Robakis for gifts of antibodies, Dr. Nikolaos Robakis for gift of Psen-/- fibroblasts and Ms. Gissel Perez for expert technical assistance. Dr. Vahram Haroutunian is thanked for critical reading of the manuscript. NR 89 TC 13 Z9 13 U1 1 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1750-1326 J9 MOL NEURODEGENER JI Mol. Neurodegener. PD SEP 23 PY 2010 VL 5 AR 38 DI 10.1186/1750-1326-5-38 PG 20 WC Neurosciences SC Neurosciences & Neurology GA 664QR UT WOS:000282977900001 PM 20863403 ER PT J AU Anzueto, A AF Anzueto, Antonio TI Endobronchial Valves to Reduce Lung Hyperinflation SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID COPD; SURGERY C1 [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, Antonio] S Texas Vet Hlth Care Ctr, San Antonio, TX USA. RP Anzueto, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 9 TC 1 Z9 1 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 23 PY 2010 VL 363 IS 13 BP 1280 EP 1281 DI 10.1056/NEJMe1008256 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 652ZA UT WOS:000282050000015 PM 20860512 ER PT J AU Azadani, AN Jaussaud, N Ge, L Chitsaz, S Chuter, TAM Tseng, EE AF Azadani, Ali N. Jaussaud, Nicolas Ge, Liang Chitsaz, Sam Chuter, Timothy A. M. Tseng, Elaine E. TI Impact of Orientation and Size Matched Transcatheter Aortic Valves on Valve-in-Valve Hemodynamics SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 22nd Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium CY SEP 21-25, 2010 CL Washington, DC SP Cardiovascular Res Fdn C1 UCSF Med Ctr, San Francisco, CA USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD SEP 21 PY 2010 VL 56 IS 13 SU S MA TCT-132 BP B31 EP B31 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA V45NV UT WOS:000209824200133 ER PT J AU Siderowf, A Xie, SX Hurtig, H Weintraub, D Duda, J Chen-Plotkin, A Shaw, M Van Deerlin, V Trojanowski, JQ Clark, C AF Siderowf, A. Xie, S. X. Hurtig, H. Weintraub, D. Duda, J. Chen-Plotkin, A. Shaw, L. M. Van Deerlin, V. Trojanowski, J. Q. Clark, C. TI CSF amyloid beta 1-42 predicts cognitive decline in Parkinson disease SO NEUROLOGY LA English DT Article ID CEREBROSPINAL-FLUID TAU; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; LEWY BODIES; FOLLOW-UP; DEMENTIA; BIOMARKERS; DIAGNOSIS; GENOTYPE; PLASMA AB Objective: Cognitive decline associated with Parkinson disease (PD) is common and highly disabling. Biomarkers that help identify patients at risk for cognitive decline would be useful additions to the clinical management of the disease. Methods: A total of 45 patients with PD were enrolled in this prospective cohort study and had at least 1 yearly longitudinal follow-up evaluation. CSF was collected at baseline and cognition was assessed at baseline and follow-up visits using the Mattis Dementia Rating Scale (DRS-2). CSF was tested for amyloid beta 1-42 (A beta(1-42)), p-tau(181p), and total tau levels using the Luminex xMAP platform. Mixed linear models were used to test for associations between baseline CSF biomarker levels and change in cognition over time. Results: Lower baseline CSF A beta(1-42) was associated with more rapid cognitive decline. Subjects with CSF A beta(1-42) levels <= 192 pg/mL declined an average of 5.85 (95% confidence interval 2.11-9.58, p = 0.002) points per year more rapidly on the DRS-2 than subjects above that cutoff, after adjustment for age, disease duration, and baseline cognitive status. CSF total tau and p-tau(181p) levels were not significantly associated with cognitive decline. Conclusions: Reduced CSF A beta(1-42) was an independent predictor of cognitive decline in patients with PD. This observation is consistent with previous research showing that Alzheimer disease pathology contributes to cognitive impairment in PD. This biomarker may provide clinically useful prognostic information, particularly if combined with other risk factors for cognitive impairment in PD. Neurology (R) 2010;75:1055-1061 C1 [Siderowf, A.; Hurtig, H.; Weintraub, D.; Chen-Plotkin, A.; Clark, C.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19107 USA. [Siderowf, A.; Xie, S. X.; Hurtig, H.; Weintraub, D.; Duda, J.; Chen-Plotkin, A.; Van Deerlin, V.; Trojanowski, J. Q.] Univ Penn, Sch Med, Morris K Udall Ctr Excellence Parkinsons Dis Res, Philadelphia, PA 19107 USA. [Xie, S. X.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19107 USA. [Weintraub, D.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19107 USA. [Shaw, L. M.; Van Deerlin, V.; Trojanowski, J. Q.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19107 USA. [Siderowf, A.; Shaw, L. M.; Trojanowski, J. Q.] Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19107 USA. [Weintraub, D.; Duda, J.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Siderowf, A (reprint author), Univ Penn, Sch Med, Dept Neurol, 330 S 9th St,2nd Floor, Philadelphia, PA 19107 USA. EM andrew.siderowf@uphs.upenn.edu FU NINDS [NS-053488, SAP4100027296]; Department of Health of the Commonwealth of Pennsylvania; NIH (NINDS) [NINDS U10 NS0444451, NINDS P50 NS053488, NINDS R43NS0636071, NINDS R01NS065087, NINDS P50 NS053488-01, NINDS U10 NS044451-023]; US Department of Defense; Department of Health, Commonwealth of Pennsylvania; NIH/NINDS [NS053488]; Michael J. Fox Foundation for Parkinson's Research; Teva Pharmaceutical Industries Ltd.; Boehringer Ingelheim; Bayer Schering Pharma; Kyowa Hakko Kirin Pharma, Inc.; PRA International; Novartis; Glaxo-SmithKline; Avid Radiopharmaceuticals, Inc.; St Jude Medical; Amarin Corporation; Prestwick Pharmaceutical, Inc.; HP Therapeutics Foundation, Inc.; Cephalon, Inc.; NIH [NS053488, K23 MH067894, K08 AG033101, AG024904, 1RC 2AG-036535, NIA P01 AG 09215-20, NIA P30 AG 10124-18, NIA PO1 AG 17586-10, NIA 1PO1 AG-19724-07, NIA 1 UO1 AG 024904-05, NINDS P50 NS053488-02, NIA UO1 AG029213-01, RC2NS069368, RC1AG035427, NIA P30AG036468]; Penn Center for Excellence in Research on Neurodegenerative Diseases (CERND); Department of Veterans Affairs; Department of Veterans Affairs, NIH [RO1 NS41265-01, RO1 NS44266]; Michael J. Fox Foundation; Samueli Foundation; Burroughs Wellcome Fund; Pfizer Inc.; Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring; Molecular Pathology in Clinical Practice; Marian S. Ware Alzheimer Program FX Supported by a Morris K. Udall Parkinson's Disease Research Center of Excellence grant from NINDS (NS-053488) and by SAP4100027296, a health research grant awarded by the Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement under Act 2001-77.; Dr. Siderowf serves on a scientific advisory board for and has received speaker honoraria from Teva Pharmaceutical Industries Ltd.; serves/has served as a consultant to Supernus Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Merck Serono, and Schering-Plough Corp.; receives research support from the NIH (NINDS U10 NS0444451 [site PI], NINDS P50 NS053488 [Co-I], NINDS R43NS0636071 [Co-I], and NINDS R01NS065087 [Co-I]), the US Department of Defense, and the Department of Health, Commonwealth of Pennsylvania; and has served as a consultant on manganese litigation. Dr. Xie receives research support from the NIH/NINDS (NS053488 [coinvestigator and core director]). Dr. Hurtig served on a grant review panel for the Michael J. Fox Foundation for Parkinson's Research; serves on the editorial board of Parkinsonism and Related Disorders; serves as Movement Disorders Section Editor for UpToDate; has received speaker honoraria from Teva Pharmaceutical Industries Ltd.; receives research support from Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bayer Schering Pharma, Kyowa Hakko Kirin Pharma, Inc., PRA International, Novartis, Glaxo-SmithKline, Avid Radiopharmaceuticals, Inc., St Jude Medical, Amarin Corporation, Prestwick Pharmaceutical, Inc., HP Therapeutics Foundation, Inc., Cephalon, Inc., NIH (NINDS P50 NS053488-01 [core leader and PI] and NINDS U10 NS044451-023 [site PI]); and holds stock in Teva Pharmaceutical Industries Ltd. Dr. Weintraub has served on a scientific advisory board for Boehringer Ingelheim; serves on the editorial board of Movement Disorders; has received honoraria from Boehringer Ingelheim, ACADIA Pharmaceuticals Inc., GE Healthcare, Novartis, Osmotica Pharmaceutical Corp., BrainCells Inc., Merck Serono, Sanofi-Aventis, Johnson & Johnson, Solvay Pharmaceuticals, Inc., and Pfizer Inc.; and receives research support from Boehringer Ingelheim, the NIH (K23 MH067894 [PI]), the Penn Center for Excellence in Research on Neurodegenerative Diseases (CERND), and the Michael J. Fox Foundation for Parkinson's Research. Dr. Duda served on a grant review panel for the Michael J. Fox Foundation for Parkinson's Research; serves/has served on a scientific advisory boards for Boehringer Ingelheim, the Lewy Body Dementia Association, and the Lewy Body Society; has received honoraria for interviews for articles in the PD Monitor and Commentary, a publication supported by an educational grant from Teva Pharmaceutical Industries Ltd.; receives research support from the Department of Veterans Affairs (Biomedical Laboratory Research and Development Service Merit Award [PI], Cooperative Studies Program 468 [site PI]), the NIH (RO1 NS41265-01 [Co-I], RO1 NS44266 [Co-I]), the Michael J. Fox Foundation, the Department of Health, Commonwealth of Pennsylvania, and the Samueli Foundation; and holds stock in C. R. Bard, Inc., Celgene, Clarient, and Johnson & Johnson. Dr. Chen-Plotkin receives research support from the Burroughs Wellcome Fund and the NIH (K08 AG033101 [PI]). Dr. Shaw has served on a scientific advisory board for Bristol-Myers Squibb; has received funding for travel and speaker honoraria from Pfizer Inc.; ; serves on the editorial board of Therapeutic Drug Monitoring; may potentially receive revenue for patent pending re: O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders, licensed by the University of Pennsylvania to Novartis; receives royalties from publication of Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring (Wolters Kluwer/ippincott Williams & Wilkins, 2005); receives research support from the NIH (AG024904 [Co-PI Biomarker Core Laboratory] and 1RC 2AG-036535 (ARRA) [PI Biomarker Core Laboratory]); and receives board of directors' compensation and holds stock options in Saladax Biomedical. Dr. Van Deerlin serves on the editorial board of Molecular Diagnosis and Therapy; has a patent pending re: Compositions and methods for the treatment of frontotemporal lobar degeneration with TDP-43 inclusions; receives royalties from the publication of Molecular Pathology in Clinical Practice (Springer, 2007); and receives research support from the NIH (NS053488 [Neuropathology and Genetics Core, Core Co-Leader] and AG010124 [Neuropathology Core, Co-I]). Dr. Trojanowski has received funding for travel and honoraria from Takeda Pharmaceutical Company Ltd.; has received speaker honoraria from Pfizer Inc.; serves as an Associate Editor of Alzheimer's & Dementia; may accrue revenue on patents re: Modified avidin-biotin technique, Method of stabilizing microtubules to treat Alzheimer's disease, Method of detecting abnormally phosphorylated tau, Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments, Compositions and methods for producing and using homogeneous neuronal cell transplants, Rat comprising straight filaments in its brain, Compositions and methods for producing and using homogeneous neuronal cell transplants to treat neurodegenerative disorders and brain and spinal cord injuries, Diagnostic methods for Alzheimer's disease by detection of multiple MRNAs, Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases, Compositions and methods for producing and using homogenous neuronal cell transplants, Method of identifying, diagnosing and treating alpha-synuclein positive neurodegenerative disorders, Mutation-specific functional impairments in distinct tau isoforms of hereditary frontotemporal dementia and parkinsonism linked to chromosome-17: genotype predicts phenotype, Microtubule stabilizing therapies for neurodegenerative disorders, and Treatment of Alzheimer's and related diseases with an antibody; and receives research support from the NIH (NIA P01 AG 09215-20 [PI], NIA P30 AG 10124-18 [PI], NIA PO1 AG 17586-10 [Project 4 Leader], NIA 1PO1 AG-19724-07 [Core C Leader], NIA 1 UO1 AG 024904-05 [Co-PI Biomarker Core Laboratory], NINDS P50 NS053488-02 [PI], NIA UO1 AG029213-01 (Co-I); RC2NS069368 (PI), RC1AG035427 (PI), and NIA P30AG036468 [PI]) and the Marian S. Ware Alzheimer Program. Dr. Clark serves as Medical Director of and holds stock options in Avid Radiopharmaceuticals, Inc.; has served on scientific advisory boards for Elan Corporation and Wyeth; and receives research support from the Department of Health, Commonwealth of Pennsylvania. NR 36 TC 138 Z9 140 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD SEP 21 PY 2010 VL 75 IS 12 BP 1055 EP 1061 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 658EZ UT WOS:000282474500006 PM 20720189 ER PT J AU Aarsland, D Bronnick, K Williams-Gray, C Weintraub, D Marder, K Kulisevsky, J Burn, D Barone, P Pagonabarraga, J Allcock, L Santangelo, G Foltynie, T Janvin, C Larsen, JP Barker, RA Emre, M AF Aarsland, D. Bronnick, K. Williams-Gray, C. Weintraub, D. Marder, K. Kulisevsky, J. Burn, D. Barone, P. Pagonabarraga, J. Allcock, L. Santangelo, G. Foltynie, T. Janvin, C. Larsen, J. P. Barker, R. A. Emre, M. TI Mild cognitive impairment in Parkinson disease A multicenter pooled analysis SO NEUROLOGY LA English DT Article ID ORTHOSTATIC HYPOTENSION; DIAGNOSTIC-CRITERIA; NORWEGIAN PARKWEST; CLINICAL-DIAGNOSIS; EXECUTIVE FUNCTION; RATING-SCALE; DEMENTIA; COHORT; RECOMMENDATIONS; INCIDENT AB Background: In studies of mild cognitive impairment (MCI) in Parkinson disease (PD), patients without dementia have reported variable prevalences and profiles of MCI, likely to be due to methodologic differences between the studies. Objective: The objective of this study was to determine frequency and the profile of MCI in a large, multicenter cohort of well-defined patients with PD using a standardized analytic method and a common definition of MCI. Methods: A total of 1,346 patients with PD from 8 different cohorts were included. Standardized analysis of verbal memory, visuospatial, and attentional/executive abilities was performed. Subjects were classified as having MCI if their age-and education-corrected z score on one or more cognitive domains was at least 1.5 standard deviations below the mean of either control subjects or normative data. Results: A total of 25.8% of subjects (95% confidence interval [CI] 23.5-28.2) were classified as having MCI. Memory impairment was most common (13.3%; 11.6-15.3), followed by visuospatial (11.0%; 9.4-13.0) and attention/executive ability impairment (10.1%; 8.6-11.9). Regarding cognitive profiles, 11.3% (9.7-13.1) were classified as nonamnestic single-domain MCI, 8.9% (7.0-9.9) as amnestic single-domain, 4.8% (3.8-6.1) as amnestic multiple-domain, and 1.3% (0.9-2.1) as nonamnestic multiple-domain MCI. Having MCI was associated with older age at assessment and at disease onset, male gender, depression, more severe motor symptoms, and advanced disease stage. Conclusions: MCI is common in patients with PD without dementia, affecting a range of cognitive domains, including memory, visual-spatial, and attention/executive abilities. Future studies of patients with PD with MCI need to determine risk factors for ongoing cognitive decline and assess interventions at a predementia stage. Neurology (R) 2010;75:1062-1069 C1 [Aarsland, D.; Janvin, C.] Stavanger Univ Hosp, Div Psychiat, N-4068 Stavanger, Norway. [Bronnick, K.; Larsen, J. P.] Stavanger Univ Hosp, Norwegian Ctr Movement Disorders, N-4068 Stavanger, Norway. [Aarsland, D.] Akershus Univ Hosp, Div Mental Hlth Serv, Oslo, Norway. Univ Oslo, Oslo, Norway. [Williams-Gray, C.; Barker, R. A.] Univ Cambridge, Dept Clin Neurosci, Ctr Brain Repair, Cambridge, England. [Weintraub, D.] Univ Penn, Dept Psychiat & Neurol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Parkinsons Dis & Mental Illness Res Educ & Clin C, Philadelphia, PA USA. [Marder, K.] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA. [Kulisevsky, J.; Pagonabarraga, J.] Autonomous Univ Barcelona, St Pau Hosp, Dept Neurol, Movement Disorders Unit, Barcelona, Spain. CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Barcelona, Spain. [Burn, D.; Allcock, L.] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne, Tyne & Wear, England. [Barone, P.; Santangelo, G.] ICD Hermitage Capodimonte, Dept Neurol Sci, Naples, Italy. [Foltynie, T.] UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London WC1E 6BT, England. [Emre, M.] Istanbul Univ, Istanbul Fac Med, Dept Neurol, Behav Neurol & Movement Disorders Unit, Istanbul, Turkey. RP Aarsland, D (reprint author), Stavanger Univ Hosp, Div Psychiat, POB 8100, N-4068 Stavanger, Norway. EM daarsland@gmail.com OI Santangelo, Gabriella/0000-0002-7728-852X; Bronnick, Kolbjorn/0000-0002-9156-1633; Aarsland, Dag/0000-0001-6314-216X FU Merck Serono; Lundbeck Inc.; Novartis; GE Healthcare; GlaxoSmithKline; Solvay Pharmaceuticals, Inc; Parkinson's Disease Society; Patrick Berthoud Trust; Boehringer Ingelheim; ACADIA Pharmaceuticals; Osmotica Pharmaceutical Corp.; BrainCells Inc.; Sanofi-Aventis; Johnson Johnson; Solvay Pharmaceuticals, Inc.; NIH [NIMH K23 MH067894, NINDS P50 NS053488-01, NIA RO1AG031348, NINDS R01NS065087, NS36630, 1UL1 RR024156-01, PO412196-G]; Michael J. Fox Foundation for Parkinson's Research; University of Pennsylvania; Amarin Corporation; Boehringer Ingelheim NeuroSearch; Parkinson Disease Foundation; Huntington's Disease Society of America; Parkinson Study Group; Instituto de Salud Carlos III, Spain; Wellcome Trust; NIHR Health Technology Assessment Programme; Michael J Fox Foundation; UCB; MDS Nordion; Orion Corporation; Brain Research Trust; Parkinson's Appeal; Western Norway Health Trust; Norwegian Research Counsel; Norwegian Parkinson's disease Association; Neuroscience at a Glance (Blackwell Publishing); UK Medical Research Council; NIHR; Parkinson Hastalydy (Gunes Tip Kitapevi); Dementia in Parkinson's Disease (Oxford University Press); Eli Lilly and Company FX Supported by an unrestricted grant from Merck Serono.; Dr. Aarsland serves on scientific advisory boards for Lundbeck Inc. and Merck Serono; has received funding for travel and speaker honoraria from Lundbeck Inc., Novartis, GE Healthcare, and GlaxoSmithKline; serves on the editorial boards of International Psychogeriatrics, Movement Disorders, and the Journal of Neurology, Neurosurgery, and Psychiatry; and receives research support from Lundbeck Inc. and Merck Serono. Dr. Bronnick has received funding for travel and speaker honoraria from Solvay Pharmaceuticals, Inc. Dr. Williams-Gray has received research support from the Parkinson's Disease Society and the Patrick Berthoud Trust. Dr. Weintraub has served on scientific advisory boards for Boehringer Ingelheim, ACADIA Pharmaceuticals, Novartis, Osmotica Pharmaceutical Corp., BrainCells Inc., Merck Serono, Sanofi-Aventis, GE Healthcare, Johnson & Johnson, and Solvay Pharmaceuticals, Inc.; serves on the editorial board of Movement Disorders; has received speaker honoraria from Boehringer Ingelheim and Pfizer Inc.; has received/receives research support from Boehringer Ingelheim, the NIH (NIMH K23 MH067894 [PI], NINDS P50 NS053488-01 [coinvestigator], NIA RO1AG031348 [site PI], and NINDS R01NS065087 [coinvestigator]), and the Michael J. Fox Foundation for Parkinson's Research; and receives payments from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease. Dr. Marder serves on the editorial board of Neurology (R) and receives research support from Amarin Corporation, Boehringer Ingelheim NeuroSearch, the NIH (NS36630 [PI], 1UL1 RR024156-01 [Director PCIR], PO412196-G [coinvestigator], and PO412196-G [coinvestigator]), the Parkinson Disease Foundation, the Huntington's Disease Society of America, and the Parkinson Study Group. Dr. Kulisevsky has served on scientific advisory boards for Merck Serono and Servier; has received honoraria from Merck Serono, Novartis, Lundbeck Inc., and Schwartz Biomedical, LLC.; serves as an Associate Editor for Revista de Neurologia; and receives research support from Lundbeck Inc. and Instituto de Salud Carlos III, Spain. Dr. Burn serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd. and Merck Serono; serves as a consultant for Archimedes, Inc.; serves as an Associate Editor for the Movement Disorder Journal; has received speaker honoraria from Teva Pharmaceutical Industries Ltd./Lundbeck Inc., Orion Corporation, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and UCB; and has received research support from the Wellcome Trust, the NIHR Health Technology Assessment Programme, the Michael J Fox Foundation, and the Parkinson's Disease Society. Dr. Barone serves on scientific advisory boards for and has received funding for travel and speaker honoraria from Boehringer Ingelheim, Merck Serono, Novartis, UCB, and Lundbeck Inc.; serves as an Associate Editor for the Journal of Neurodegenerative Disorders and Parkinson's Europe; and receives research support from Boehringer Ingelheim, Merck Serono, Novartis, UCB, Lundbeck Inc., and Solvay Pharmaceuticals, Inc. Dr. Pagonabarraga has served on a scientific advisory board for Novartis and has received honoraria from Boehringer Ingelheim, Novartis, Janssen, Lundbeck Inc., GlaxoSmithKline, and Schwartz Biomedical, LLC. Dr. Allcock holds stock in the C/N Group, Inc. Dr. Santangelo reports no disclosures. Dr. Foltynie has served on a scientific advisory board for Solvay Pharmaceuticals, Inc.; has received funding for travel or speaker honoraria from Teva Pharmaceutical Industries Ltd.; ,MDS Nordion, GlaxoSmithKline, and Orion Corporation; and has received research support from the Parkinson's Disease Society, Brain Research Trust, and Parkinson's Appeal. Dr. Janvin reports no disclosures. Dr. Larsen has served on scientific advisory boards for Lundbeck Inc. and GlaxoSmithKline; has received speaker honoraria from GlaxoSmithKline; and receives research support from the Western Norway Health Trust, the Norwegian Research Counsel, and the Norwegian Parkinson's disease Association. Dr. Barker serves on scientific advisory boards for and has received speaker honoraria from Teva Pharmaceutical Industries Ltd. and Lundbeck Inc.; serves as co-editor-in-Chief for the Journal of Neurology and ACNR and on the editorial board of Synapse, Cell Transplantation and Regenerative Medicine; receives royalties from the publication of Neuroscience at a Glance (Blackwell Publishing, 1999); and receives research support from the Parkinson's Disease Society, Wellcome Trust, the UK Medical Research Council, and NIHR Biomedical research award to Addenbrooke's University Hospital. Dr. Emre serves on scientific advisory boards for Merck Serono, Novartis, Schering-Plough Corp., Teva Pharmaceutical Industries Ltd./Lundbeck Inc., Orion Corporation, Noscira, and AC Immune SA; has received funding for travel from Lundbeck Inc.; serves on the editorial board of Practical Neurology; receives royalties from the publication of Parkinson Hastalydy (Gunes Tip Kitapevi, 2009) and Dementia in Parkinson's Disease (Oxford University Press, 2010); has received speaker honoraria from Novartis, Lundbeck Inc., Orion Corporation, Pfizer Inc., and Boehringer Ingelheim; and receives/has received research support from Novartis, Lundbeck Inc., and Eli Lilly and Company. NR 32 TC 242 Z9 252 U1 3 U2 28 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD SEP 21 PY 2010 VL 75 IS 12 BP 1062 EP 1069 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 658EZ UT WOS:000282474500007 PM 20855849 ER PT J AU Lee, SH Jung, SY Park, HA Kang, HB Kim, J Choo, DJ Handforth, A Lee, JY AF Lee, So Hyung Jung, Soo Yeon Park, Hang Ah Kang, Han Byul Kim, Jungahn Choo, Dong Joon Handforth, Adrian Lee, Jae Yeol TI Multi-Functional 3,4-Dihydroquinazoline Derivative as T-Type Calcium Channel Blocker: Pharmacokinetics and Anti-Tremor Activity SO BULLETIN OF THE KOREAN CHEMICAL SOCIETY LA English DT Article DE 3,4-Dihydroquinazoline; T-type calcium channel blocker; Pharmacokinetic parameters; Anti-tremor activity ID HUMAN CANCER-CELLS; CA2+ CHANNELS; DISCOVERY; MIBEFRADIL; PHARMACOLOGY; INHIBITION; GROWTH; POTENT C1 [Lee, So Hyung; Jung, Soo Yeon; Park, Hang Ah; Kang, Han Byul; Kim, Jungahn; Choo, Dong Joon; Lee, Jae Yeol] Kyung Hee Univ, Coll Sci, Res Inst Basic Sci, Seoul 130701, South Korea. [Lee, So Hyung; Jung, Soo Yeon; Park, Hang Ah; Kang, Han Byul; Kim, Jungahn; Choo, Dong Joon; Lee, Jae Yeol] Kyung Hee Univ, Coll Sci, Dept Chem, Seoul 130701, South Korea. [Handforth, Adrian] Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA USA. RP Lee, JY (reprint author), Kyung Hee Univ, Coll Sci, Res Inst Basic Sci, Seoul 130701, South Korea. EM ljy@khu.ac.kr OI Lee, Jae Yeol/0000-0001-6622-6692 NR 24 TC 1 Z9 1 U1 0 U2 1 PU KOREAN CHEMICAL SOC PI SEOUL PA 635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL 135-703, SOUTH KOREA SN 0253-2964 J9 B KOREAN CHEM SOC JI Bull. Korean Chem. Soc. PD SEP 20 PY 2010 VL 31 IS 9 BP 2451 EP 2452 DI 10.5012/bkcs.2010.31.9.2451 PG 2 WC Chemistry, Multidisciplinary SC Chemistry GA 676XV UT WOS:000283953600003 ER PT J AU Mao, ZH Sun, W Xu, RJ Novgorodov, S Szulc, ZM Bielawski, J Obeid, LM Mao, CG AF Mao, Zhehao Sun, Wei Xu, Ruijuan Novgorodov, Sergei Szulc, Zdzislaw M. Bielawski, Jacek Obeid, Lina M. Mao, Cungui TI Alkaline Ceramidase 2 (ACER2) and Its Product Dihydrosphingosine Mediate the Cytotoxicity of N-(4-Hydroxyphenyl)retinamide in Tumor Cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PERFORMANCE LIQUID-CHROMATOGRAPHY; FENRETINIDE-INDUCED APOPTOSIS; HUMAN NEUROBLASTOMA-CELLS; LONG-CHAIN CERAMIDES; COLON-CANCER CELLS; DIHYDROCERAMIDE DESATURASE; PROSTATE-CANCER; INDUCTION; SPHINGOSINE; CARCINOMA AB Increased generation of dihydrosphingosine (DHS), a bioactive sphingolipid, has been implicated in the cytotoxicity of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) in tumor cells. However, how 4-HPR increases DHS remains unclear. Here we demonstrate that 4-HPR increases the expression of ACER2, which catalyzes the hydrolysis of dihydroceramides to generate DHS, and that ACER2 up-regulation plays a key role in mediating the 4-HPR-induced generation of DHS as well as the cytotoxicity of 4-HPR in tumor cells. Treatment with 4-HPR induced the accumulation of dihydroceramides (DHCs) in tumor cells by inhibiting dihydroceramide desaturase (DES) activity, which catalyzes the conversion of DHCs to ceramides. Treatment with 4-HPR also increased ACER2 expression through a retinoic acid receptor-independent and caspase-dependent manner. Overexpression of ACER2 augmented the 4-HPR-induced generation of DHS as well as 4-HPR cytotoxicity, and 4-HPR-induced death in tumor cells, whereas knocking down ACER2 had the opposite effects. ACER2 overexpression, along with treatment with GT11, another DES inhibitor, markedly increased cellular DHS, leading to tumor cell death, whereas ACER2 overexpression or GT11 treatment alone failed to do so, suggesting that both ACER2 up-regulation and DES inhibition are necessary and sufficient to mediate 4-HPR-induced DHS accumulation, cytotoxicity, and death in tumor cells. Taken together, these results suggest that up-regulation of the ACER2/DHS pathway mediates the cytotoxicity of 4-HPR in tumor cells and that up-regulating or activating ACER2 may improve the anti-cancer activity of 4-HRR and other DHC-inducing agents. C1 [Obeid, Lina M.] Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA. [Szulc, Zdzislaw M.; Bielawski, Jacek; Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Obeid, Lina M.; Mao, Cungui] Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA. EM maoc@musc.edu FU National Institutes of Health [R01CA104834, P20RR017677]; Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health Grants R01CA104834 (to C. M.) and P20RR017677 (to L. M. O.). This work was also supported by a Veterans Affairs merit award (to L. M. O.). NR 48 TC 23 Z9 24 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 17 PY 2010 VL 285 IS 38 BP 29078 EP 29090 DI 10.1074/jbc.M110.105296 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 649BC UT WOS:000281740100009 PM 20628055 ER PT J AU Adeyemo, MA Spiegel, BMR Chang, L AF Adeyemo, M. A. Spiegel, B. M. R. Chang, L. TI Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Review ID FUNCTIONAL GASTROINTESTINAL DISORDERS; HEALTH-CARE SEEKING; GENDER-RELATED DIFFERENCES; ROME-II CRITERIA; QUALITY-OF-LIFE; MENSTRUAL-CYCLE; COLONIC TRANSIT; RISK-FACTORS; POSTMENOPAUSAL WOMEN; MANNING CRITERIA AB P>Background Studies suggest that sex and gender-related differences exist in irritable bowel syndrome (IBS), but data is often conflicting. Aim To evaluate gender differences and the effect of menstrual cycle and menopausal status on IBS symptoms. Methods We performed a systematic review of MEDLINE to search for studies comparing IBS symptoms between gender, menstrual cycle phases and menopausal states in IBS and/or healthy individuals. We performed meta-analyses to compare the relative risk (RR) of individual IBS symptoms between men and women. Results Twenty-two studies measured gender differences in IBS symptoms. Women were more likely to report abdominal pain (RR = 1.12, 95% CI: 1.02, 1.22) and constipation-related symptoms (RR = 1.12, 95% CI: 1.02, 1.23) than men (all P < 0.05). However, men with IBS were more likely to report diarrhoea-related symptoms than women with IBS (RR = 0.84, 95% CI: 0.75, 0.94, P < 0.05). A systematic review of 13 studies demonstrated that both IBS and healthy women reported increased IBS symptoms during menses vs. other phases. There were insufficient data to determine the effect of menopause and hormone supplementation on IBS symptoms. Conclusions In the general and IBS populations, gender differences in IBS symptoms exist, although these differences are modest. Studies suggest that female sex hormones influence the severity of IBS symptoms, but more studies are needed. C1 [Adeyemo, M. A.; Chang, L.] Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Spiegel, B. M. R.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Div Digest Dis, Los Angeles, CA 90024 USA. [Spiegel, B. M. R.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ CORE, Los Angeles, CA 90073 USA. RP Chang, L (reprint author), Ctr Neurobiol Stress, CHS 47-122,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM linchang@ucla.edu FU Takeda; Rose; Prometheus; Amgen; Shire; Novartis; NIH [P50 DK64539, R24 AT002681] FX Declaration of personal interests: The authors thank Melissa Alberto and Teresa Olivas for their assistance in the preparation of the work. Mopelola Adeyemo has nothing to declare. Brennan Spiegel has served as a consultant for Prometheus Laboratories, Astra-Zeneca, TAP, Takeda, Ironwood, and Novartis. He has received research funding from Takeda, Rose, Prometheus, Amgen, Shire, and Novartis. Lin Chang has served as a consultant for Prometheus Laboratories, Takeda, Forest, Albireo, McNeil, Rose Pharma, GlaxoSmithKline, Salix, Ocera and Movetis. She has received research funding from Takeda, Rose and Prometheus. Declaration of funding interests: This study was funded by NIH Grants Nos P50 DK64539 and R24 AT002681. NR 109 TC 58 Z9 62 U1 2 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD SEP 15 PY 2010 VL 32 IS 6 BP 738 EP 755 DI 10.1111/j.1365-2036.2010.04409.x PG 18 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 639JX UT WOS:000280972200004 PM 20662786 ER PT J AU Gastaldelli, A Harrison, S Belfort-Aguiar, R Hardies, J Balas, B Schenker, S Cusi, K AF Gastaldelli, A. Harrison, S. Belfort-Aguiar, R. Hardies, J. Balas, B. Schenker, S. Cusi, K. TI Pioglitazone in the treatment of NASH: the role of adiponectin SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID HEPATIC INSULIN-RESISTANCE; ACTIVATED PROTEIN-KINASE; PLACEBO-CONTROLLED TRIAL; FATTY LIVER-DISEASE; NONALCOHOLIC STEATOHEPATITIS; DIABETES-MELLITUS; FIBROSIS; GLUCOSE; MICE; METABOLISM AB P>Background Plasma adiponectin is decreased in NASH patients and the mechanism(s) for histological improvement during thiazolidinedione treatment remain(s) poorly understood. Aim To evaluate the relationship between changes in plasma adiponectin following pioglitazone treatment and metabolic/histological improvement. Methods We measured in 47 NASH patients and 20 controls: (i) fasting glucose, insulin, FFA and adiponectin concentrations; (ii) hepatic fat content by magnetic resonance spectroscopy; and (iii) peripheral/hepatic insulin sensitivity (by double-tracer oral glucose tolerance test). Patients were then treated with pioglitazone (45 mg/day) or placebo and all measurements were repeated after 6 months. Results Patients with NASH had decreased plasma adiponectin levels independent of the presence of obesity. Pioglitazone increased 2.3-fold plasma adiponectin and improved insulin resistance, glucose tolerance and glucose clearance, steatosis and necroinflammation (all P < 0.01-0.001 vs. placebo). In the pioglitazone group, plasma adiponectin was significantly associated (r = 0.52, P = 0.0001) with hepatic insulin sensitivity and with the change in both variables (r = 0.44, P = 0.03). Increase in adiponectin concentration was related also to histological improvement, in particular, to hepatic steatosis (r = -0.46, P = 0006) and necroinflammation (r = -0.56, P < 0.0001) but importantly also to fibrosis (r = -0.29, P = 0.03). Conclusions Adiponectin exerts an important metabolic role at the level of the liver, and its increase during pioglitazone treatment is critical to reverse insulin resistance and improve liver histology in NASH patients. C1 [Gastaldelli, A.; Belfort-Aguiar, R.; Balas, B.; Cusi, K.] Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, San Antonio, TX 78284 USA. [Gastaldelli, A.] CNR, Natl Res Council, Inst Clin Physiol, I-00185 Rome, Italy. [Harrison, S.] Brooke Army Med Ctr, Div Gastroenterol, San Antonio, TX USA. [Hardies, J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med & Radiol, San Antonio, TX 78284 USA. [Schenker, S.] Univ Texas Hlth Sci Ctr San Antonio, Div Gastroenterol, San Antonio, TX 78284 USA. [Cusi, K.] Brooke Army Med Ctr, Div Diabet, Audie L Murphy Vet Adm Med Ctr, San Antonio, TX USA. RP Cusi, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, Room 3-380S,7703 Floyd Curl Dr, San Antonio, TX 78284 USA. EM cusi@uthscsa.edu RI Hardies, Lou /F-2102-2010; Gastaldelli, Amalia/H-3319-2014 OI Gastaldelli, Amalia/0000-0003-2594-1651 FU Veterans Affairs Medical Research Fund; National Center for Research Resources [UL 1RR025767]; Italian National Research Council; Takeda Pharmaceuticals FX The authors thank the study volunteers, the nursing staff, and the nutrition and laboratory staff for their assistance in performing the described studies. Declaration of personal interests: Gastaldelli A, Harrison S, Belfort R, Hardies J, Balas B, Schenker S and Cusi K have no conflicts of interest. Declaration of funding interests: The project described (and Cusi K) was supported by the Veterans Affairs Medical Research Fund and by Award Number UL 1RR025767 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources of the National Institutes of Health. A. G. was supported by the Italian National Research Council. Partial support was received for the original study from Takeda Pharmaceuticals. NR 29 TC 47 Z9 52 U1 3 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD SEP 15 PY 2010 VL 32 IS 6 BP 769 EP 775 DI 10.1111/j.1365-2036.2010.04405.x PG 7 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 639JX UT WOS:000280972200007 PM 20662773 ER PT J AU Horberg, MA Aberg, JA Cheever, LW Renner, P Kaleba, EO Asch, SM AF Horberg, Michael A. Aberg, Judith A. Cheever, Laura W. Renner, Philip Kaleba, Erin O'Brien Asch, Steven M. TI Development of National and Multiagency HIV Care Quality Measures SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTIOUS-DISEASES-SOCIETY; IMMUNIZATION PRACTICES ACIP; PNEUMOCYSTIS-CARINII-PNEUMONIA; UNITED-STATES; MEDICINE ASSOCIATION; ADVISORY-COMMITTEE; OPPORTUNISTIC INFECTIONS; PNEUMOCOCCAL DISEASE; RISK-FACTORS AB Background. Human immunodeficiency virus (HIV) is now a complex, chronic disease requiring high quality care. Demonstration of quality HIV care requires uniform, aligned HIV care quality measurement. Methods. In September 2007, the National Committee for Quality Assurance, under contract with the Health Resources and Services Administration, the Physician Consortium for Performance Improvement of the American Medical Association, and HIV Medicine Association of the Infectious Disease Society of America jointly sponsored and convened an expert panel as a HIV/AIDS Work Group to draft national HIV/AIDS performance measures for individual patient-level and system-level quality improvement. Results. A total of 17 measures were developed to assess processes and outcomes of HIV/AIDS care for patients established in care, defined as having at least 2 visits in a 12-month period; thus, measures of HIV screening, testing, linkage, and access to care were not included. As a set, the measures assess a wide range of care, including patient retention, screening and prophylaxis for opportunistic infections, immunization, and initiation and monitoring of potent antiretroviral therapy. Since development, the HIV/AIDS measures' specifications have been fully determined and are being beta tested, and a majority have been endorsed by the National Quality Forum and have been adopted and implemented by the sponsoring organizations. Conclusions. HIV care quality measurement should be assessed with greater uniformity. The measures presented offer opportunities for such alignment. C1 [Horberg, Michael A.] Kaiser Permanente, HIV AIDS, HIV Interreg Initiat, Oakland, CA 94612 USA. [Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Asch, Steven M.] RAND Corp, Los Angeles, CA USA. [Aberg, Judith A.] NYU, Sch Med, Dept Med, New York, NY USA. [Cheever, Laura W.] US Hlth Resources & Serv Adm, HIV AIDS Bur, Rockville, MD 20857 USA. [Renner, Philip] Natl Comm Qual Assurance, Washington, DC USA. [Kaleba, Erin O'Brien] Alliance Chicago Community Hlth Serv, Chicago, IL USA. RP Horberg, MA (reprint author), Kaiser Permanente, HIV AIDS, HIV Interreg Initiat, 2000 Broadway, Oakland, CA 94612 USA. EM michael.horberg@kp.org FU National Committee for Quality Assurance; Physician Consortium for Performance Improvement of the American Medical Association; HIV Medicine Association of the Infectious Diseases Society of America; Health Resources and Services Administration FX Financial support. National Committee for Quality Assurance, the Physician Consortium for Performance Improvement of the American Medical Association, the HIV Medicine Association of the Infectious Diseases Society of America, and the Health Resources and Services Administration. NR 48 TC 39 Z9 39 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2010 VL 51 IS 6 BP 732 EP 738 DI 10.1086/655893 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 641QA UT WOS:000281143400015 PM 20715924 ER PT J AU Margolis, M Kaiser, L Christie, J AF Margolis, Mitchell Kaiser, Larry Christie, Jason TI Patient Decisions to Undergo Surgery for Early-Stage Lung Cancer SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID RACIAL-DIFFERENCES; BELIEF C1 [Margolis, Mitchell] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Kaiser, Larry] Univ Texas Houston Hlth Sci Ctr, Houston, TX USA. [Christie, Jason] Univ Penn, Philadelphia, PA 19104 USA. RP Margolis, M (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. EM mitchell.margolis@va.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 15 PY 2010 VL 304 IS 11 BP 1165 EP 1165 DI 10.1001/jama.2010.1311 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 649LF UT WOS:000281770600002 PM 20841526 ER PT J AU Boulware, DR Bonham, SC Meya, DB Wiesner, DL Park, GS Kambugu, A Janoff, EN Bohjanen, PR AF Boulware, David R. Bonham, Shulamith C. Meya, David B. Wiesner, Darin L. Park, Gregory S. Kambugu, Andrew Janoff, Edward N. Bohjanen, Paul R. TI Paucity of Initial Cerebrospinal Fluid Inflammation in Cryptococcal Meningitis Is Associated with Subsequent Immune Reconstitution Inflammatory Syndrome SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; COLONY-STIMULATING FACTOR; T-CELLS; NEOFORMANS INFECTION; DENDRITIC CELLS; CASE-DEFINITION; EARLY MORTALITY; AMPHOTERICIN-B; IFN-GAMMA; ACTIVATION AB Background. Cryptococcal meningitis (CM)-related immune reconstitution inflammatory syndrome (IRIS) complicates antiretroviral therapy (ART) in 20%-40% of ART-naive persons with AIDS and prior CM. Pathogenesis is unknown. Methods. We compared initial cerebrospinal fluid (CSF) cultures, inflammatory markers, and cytokine profiles in ART-naive patients with AIDS who did or did not subsequently develop IRIS after starting ART. We also compared results obtained at IRIS events or CM relapse. Results. Of 85 subjects with CM, 33 (39%) developed CM-related IRIS and 5 (6%) developed culture-positive CM relapse. At CM diagnosis, subjects subsequently developing IRIS had less inflammation, with decreased CSF leukocytes, protein, interferon-gamma, interleukin-6, interleukin-8, and tumor necrosis factor-alpha, compared with subjects not developing IRIS (P<.05, for each). Initial CSF white blood cell counts <= 25 cells/mu L and protein levels <= 50 mg/dL were associated with development of IRIS (odds ratio, 7.2 [95% confidence interval, 2.7-18.7]; P<.001). Compared with baseline levels, we identified CSF elevations of interferon-gamma, tumor necrosis factor-alpha, granulocyte colony-stimulating factor, vascular-endothelial growth factor, and eotaxin (CCL11) (P<.05, for each) at the time of IRIS but minimal inflammatory changes in those with CM relapse. Conclusions. Patients who subsequently develop CM-related IRIS exhibit less initial CSF inflammation at the time of CM diagnosis, compared with those who do not develop IRIS. The inflammatory CSF cytokine profiles observed at time of IRIS can distinguish IRIS from CM relapse. C1 [Boulware, David R.; Bonham, Shulamith C.; Meya, David B.; Kambugu, Andrew; Bohjanen, Paul R.] Univ Minnesota, Dept Med, Div Infect Dis & Int Med, Minneapolis, MN 55455 USA. [Boulware, David R.; Bonham, Shulamith C.; Wiesner, Darin L.; Park, Gregory S.; Bohjanen, Paul R.] Univ Minnesota, Ctr Infect Dis & Microbiol Translat Res, Minneapolis, MN 55455 USA. [Wiesner, Darin L.; Bohjanen, Paul R.] Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA. [Meya, David B.; Kambugu, Andrew] Makerere Univ, Infect Dis Inst, Kampala, Uganda. [Janoff, Edward N.] Univ Colorado, Denver Sch Med, Denver Vet Affairs Med Ctr, Mucosal & Vaccine Res Program Colorado,Div Infect, Denver, CO 80202 USA. RP Boulware, DR (reprint author), MMC 250,420 Delaware St SE, Minneapolis, MN 55455 USA. EM boulw001@umn.edu RI Boulware, David/B-5516-2011; Boulware, David/I-4533-2013; Bohjanen, Paul/B-2329-2015 OI Bohjanen, Paul/0000-0002-2772-3597; Meya, David/0000-0002-4138-240X; Boulware, David/0000-0002-4715-0060 FU NCRR NIH HHS [K12 RR023247, K12 RR023247-04, K12RR023247-04]; NIAID NIH HHS [L30 AI066779, K23 AI073192, K23 AI073192-01A2, K23AI073192-01A2, L30 AI066779-03, L30AI066779, R03 AI078750, R03 AI078750-02, R03AI078750-01, T32 AI055433, T32 AI055433-05, T32AI055433-05] NR 45 TC 82 Z9 83 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 15 PY 2010 VL 202 IS 6 BP 962 EP 970 DI 10.1086/655785 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 640YV UT WOS:000281091200019 PM 20677939 ER PT J AU Chen, DH Raskind, WH Parson, WW Sonnen, JA Vu, T Zheng, YL Matsushita, M Wolff, J Lipe, H Bird, TD AF Chen, Dong-Hui Raskind, Wendy H. Parson, William W. Sonnen, Joshua A. Vu, Tiffany Zheng, YunLin Matsushita, Mark Wolff, John Lipe, Hillary Bird, Thomas D. TI A novel mutation in FHL1 in a family with X-linked scapuloperoneal myopathy: Phenotypic spectrum and structural study of FHL1 mutations SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article DE X-linked myopathy; Scapuloperoneal; FHL1; Neurogenetics; Muscular dystrophy; Genetic diagnosis ID REDUCING BODY MYOPATHY; ELECTROSTATIC ENERGIES; BINDING PROTEIN; GENE; DOMINANT AB An X-linked myopathy was recently associated with mutations in the four-and-a-half-LIM domains 1 (FHL1) gene. We identified a family with late onset, slowly progressive weakness of scapuloperoneal muscles in three brothers and their mother. A novel missense mutation in the LIM2 domain of FHL1 (W122C) co-segregated with disease in the family. The phenotype was less severe than that in other reported families. Muscle biopsy revealed myopathic changes with FHL1 inclusions that were ubiquitin- and desmin-positive. This mutation provides additional evidence for X-linked myopathy caused by a narrow spectrum of mutations in FHL1, mostly in the LIM2 domain. Molecular dynamics (MD) simulations of the newly identified mutation and five previously published missense mutations in the LIM2 domain revealed no major distortions of the protein structure or disruption of zinc binding. There were, however, increases in the nonpolar, solvent-accessible surface area in one or both of two clusters of residues, suggesting that the mutant proteins have a variably increased propensity to aggregate. Review of the literature shows a wide range of phenotypes associated with mutations in FHL1. However, recognizing the typical scapuloperoneal phenotype and X-linked inheritance pattern will help clinicians arrive at the correct diagnosis. Published by Elsevier B.V. C1 [Chen, Dong-Hui; Lipe, Hillary; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Raskind, Wendy H.; Vu, Tiffany; Zheng, YunLin; Matsushita, Mark; Wolff, John; Bird, Thomas D.] Univ Washington, Dept Med, Seattle, WA USA. [Raskind, Wendy H.; Bird, Thomas D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Parson, William W.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA. [Sonnen, Joshua A.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Wolff, John; Lipe, Hillary; Bird, Thomas D.] Vet Affairs Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Raskind, Wendy H.] Vet Affairs Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. RP Bird, TD (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-182 GRECC, Seattle, WA 98108 USA. EM tomnroz@uw.edu RI Sonnen, 37382016/H-3738-2016 OI Sonnen, 37382016/0000-0001-9267-8705 FU Veterans Affairs; National Institutes of Health [NS069719]; National Science Foundation [MCB-0641640] FX This research was supported by the Veterans Affairs Medical Research funds (TDB, HL, WHR, and JW), National Institutes of Health grant NS069719 (WHR), and National Science Foundation grant MCB-0641640 (WWP). Randy Small, Department of Pathology, University of Washington, provided technical assistance for the histopathology studies. NR 24 TC 27 Z9 27 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD SEP 15 PY 2010 VL 296 IS 1-2 BP 22 EP 29 DI 10.1016/j.jns.2010.06.017 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 643CY UT WOS:000281272300004 PM 20633900 ER PT J AU Marsh, L AF Marsh, L. TI Depression and Cognitive Dysfunction in PD: What is the Relationship? SO MOVEMENT DISORDERS LA English DT Meeting Abstract C1 [Marsh, L.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP 15 PY 2010 VL 25 SU 3 BP S588 EP S588 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 655WO UT WOS:000282286300074 ER PT J AU Marsh, L AF Marsh, L. TI Neuropsychiatric Issues in Advancing PD: Clinical Spectrum and Resulting QOL Implications SO MOVEMENT DISORDERS LA English DT Meeting Abstract C1 [Marsh, L.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP 15 PY 2010 VL 25 SU 3 BP S570 EP S570 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 655WO UT WOS:000282286300007 ER PT J AU Pan, C Hwang, H Zhang, J Hancock, A Shi, M Chung, K Leverenz, J Zabetian, C Peskind, E Jankovic, J Quinn, J Galasko, D Zhang, J AF Pan, C. Hwang, H. Zhang, J. Hancock, A. Shi, M. Chung, K. Leverenz, J. Zabetian, C. Peskind, E. Jankovic, J. Quinn, J. Galasko, D. Zhang, J. TI Identification of Plasma Glycoproteins Unique to Diagnosis and Correlated with Severity of Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Meeting Abstract C1 [Pan, C.; Hwang, H.; Zhang, J.; Hancock, A.; Shi, M.; Zhang, J.] Univ Washington, Seattle, WA 98195 USA. [Chung, K.] Portland VA Med Ctr, Portland, OR USA. [Jankovic, J.] Baylor Coll Med, Houston, TX 77030 USA. [Quinn, J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Galasko, D.] Univ Calif San Diego, La Jolla, CA 92093 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP 15 PY 2010 VL 25 SU 3 BP S663 EP S663 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 655WO UT WOS:000282286300321 ER PT J AU Schmidt, PN Okun, MS Siderowf, A Nutt, JG O'Conner, GT Bloem, BR Olmstead, EM Guttman, M Simuni, T Cheng, E Parashos, S Marsh, L Malaty, IA Giladi, N Wu, S Oberdorf, J AF Schmidt, P. N. Okun, M. S. Siderowf, A. Nutt, J. G. O'Conner, G. T. Bloem, B. R. Olmstead, E. M. Guttman, M. Simuni, T. Cheng, E. Parashos, S. Marsh, L. Malaty, I. A. Giladi, N. Wu, S. Oberdorf, J. TI Are Results from PD Trials Generalizable? The NPF Database Reveals a Mismatch Between Typical Clinic Populations and Subjects in PD Trials SO MOVEMENT DISORDERS LA English DT Meeting Abstract C1 [Okun, M. S.; Malaty, I. A.; Wu, S.] Univ Florida, Gainesville, FL 32611 USA. [Siderowf, A.] Univ Penn, Philadelphia, PA 19104 USA. [Nutt, J. G.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [O'Conner, G. T.; Olmstead, E. M.] Dartmouth Med Sch, Hanover, NH USA. [Bloem, B. R.] Radboud Univ Nijmegen, Nijmegen, Netherlands. [Guttman, M.] Univ Toronto, Toronto, ON M5S 1A1, Canada. [Simuni, T.] Northwestern Univ, Evanston, IL 60208 USA. [Cheng, E.] W Los Angeles VA Med Ctr, Los Angeles, CA USA. [Giladi, N.] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel. RI Bloem, Bastiaan/E-3812-2010; Bloem, B.R./H-8013-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP 15 PY 2010 VL 25 SU 3 BP S640 EP S640 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 655WO UT WOS:000282286300252 ER PT J AU Watson, GS Thomas, S Zabetian, CP Gerton, BK Kim, HM Samii, A Schantz, A Leverenz, JB AF Watson, G. S. Thomas, S. Zabetian, C. P. Gerton, B. K. Kim, H. M. Samii, A. Schantz, A. Leverenz, J. B. TI How Well Can Screening Instruments Discriminate Among PD Patients with Normal Cognition, Mild Impairments, and Dementia? SO MOVEMENT DISORDERS LA English DT Meeting Abstract C1 [Watson, G. S.; Samii, A.; Schantz, A.] Univ Washington, VA Puget Sound HCS, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP 15 PY 2010 VL 25 SU 3 BP S692 EP S692 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 655WO UT WOS:000282286300407 ER PT J AU Holt, SK Kwon, EM Koopmeiners, JS Lin, DW Feng, ZD Ostrander, EA Peters, U Stanford, JL AF Holt, Sarah K. Kwon, Erika M. Koopmeiners, Joseph S. Lin, Daniel W. Feng, Ziding Ostrander, Elaine A. Peters, Ulrike Stanford, Janet L. TI Vitamin D Pathway Gene Variants and Prostate Cancer Prognosis SO PROSTATE LA English DT Article DE vitamin D receptor; 1-alpha-hydroxylase; 24-hydroxylase; prostatic neoplasms; outcomes ID D-RECEPTOR GENE; RADICAL PROSTATECTOMY; 25-HYDROXYVITAMIN D-1-ALPHA-HYDROXYLASE; UNITED-STATES; COLON-CANCER; RISK; POLYMORPHISMS; ASSOCIATION; EXPRESSION; DIAGNOSIS AB BACKGROUND. Observational studies linking vitamin D deficiency with increased prostate cancer (PCa) mortality and the pleiotropic anticancer effects of vitamin D in malignant prostate cell lines have initiated trials examining potential therapeutic benefits of vitamin D metabolites. There have been some successes but efforts have been hindered by risk of inducing hypercalcemia. A limited number of studies have investigated associations between variants in vitamin D pathway genes with aggressive forms of PCa. Increased understanding of relevant germline genetic variation with disease outcome could aid in the development of vitamin-D-based therapies. METHODS. We undertook a comprehensive analysis of 48 tagging single-nucleotide polymorphisms (tagSNPs) in genes encoding for vitamin D receptor (VDR), vitamin D activating enzyme 1-alpha-hydroxylase (CYP27B1), and deactivating enzyme 24-hydroxylase (CYP24A1) in a cohort of 1,294 Caucasian cases with an average of 8 years of follow-up. Disease recurrence/progression and PCa-specific mortality risks were estimated using adjusted Cox proportional hazards regression. RESULTS. There were 139 cases with recurrence/progression events and 57 cases who died of PCa. Significantly altered risks of recurrence/progression were observed in relation to genotype for two VDR tagSNPs (rs6823 and rs2071358) and two CYP24A1 tagSNPs (rs927650 and rs2762939). Three VDR tagSNPs (rs3782905, rs7299460, and rs11168314), one CYP27B1 tagSNP (rs3782130), and five CYP24A1 tagSNPs (rs3787557, rs4809960, rs2296241, rs2585428, and rs6022999) significantly altered risks of PCa death. CONCLUSIONS. Genetic variations in vitamin D pathway genes were found to alter both risk of recurrence/progression and PCa-specific mortality. Prostate 70: 1448-1460, 2010. (C) 2010 Wiley-Liss, Inc. C1 [Holt, Sarah K.; Koopmeiners, Joseph S.; Feng, Ziding; Peters, Ulrike; Stanford, Janet L.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Kwon, Erika M.; Ostrander, Elaine A.] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA. [Kwon, Erika M.] Johns Hopkins Univ, Sch Med, Program Human Genet & Mol Biol, Baltimore, MD USA. [Lin, Daniel W.] Univ Washington, Dept Urol, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Feng, Ziding] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Peters, Ulrike; Stanford, Janet L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Holt, SK (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Mailstop M4-A402,POB 19024, Seattle, WA 98109 USA. EM skholt@fhcrc.org OI Ostrander, Elaine/0000-0001-6075-9738 FU National Cancer Institute [RO1-CA056678, RO1-CA092579, RO1-CA082664, P50-CA097186] FX Grant sponsor: National Cancer Institute; Grant numbers: RO-CA056678, RO1-CA092579, RO1-CA082664, P50-CA097186.; This work was supported by grants RO1-CA056678, RO1-CA092579, RO1-CA082664, and P50-CA097186 from the National Cancer Institute; additional support was provided by the Fred Hutchinson Cancer Research Center, the Intramural Program of the National Human Genome Research Institute, and the Prostate Cancer Foundation Young Investigator Award Grant. NR 50 TC 41 Z9 41 U1 0 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-4137 J9 PROSTATE JI Prostate PD SEP 15 PY 2010 VL 70 IS 13 BP 1448 EP 1460 DI 10.1002/pros.21180 PG 13 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 646LM UT WOS:000281542100009 PM 20687218 ER PT J AU Teerlink, JR AF Teerlink, John R. TI Ivabradine in heart failure-no paradigm SHIFT ... yet SO LANCET LA English DT Editorial Material ID CARDIAC-INSUFFICIENCY BISOPROLOL; PLACEBO-CONTROLLED TRIAL; RATE REDUCTION; RANDOMIZED-TRIAL; I-F; CARVEDILOL; DISEASE; DYSFUNCTION; METOPROLOL; CIBIS C1 [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Teerlink, JR (reprint author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. EM john.teerlink@ucsf.edu RI Teerlink, John/D-2986-2012 NR 19 TC 25 Z9 27 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD SEP 11 PY 2010 VL 376 IS 9744 BP 847 EP 849 DI 10.1016/S0140-6736(10)61314-1 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 653DW UT WOS:000282069100004 PM 20801501 ER PT J AU Goebel, M Stengel, A Wang, LX Coskun, T Alsina-Fernandez, J Rivier, J Tache, Y AF Goebel, Miriam Stengel, Andreas Wang, Lixin Coskun, Tamer Alsina-Fernandez, Jorge Rivier, Jean Tache, Yvette TI Pattern of Fos expression in the brain induced by selective activation of somatostatin receptor 2 in rats SO BRAIN RESEARCH LA English DT Article DE Somatostatin receptor; Brain; Oxytocin; Vasopressin ID GENE-RELATED PEPTIDE; TRIGEMINAL SUBNUCLEUS CAUDALIS; LATERAL PARABRACHIAL NUCLEUS; NERVOUS-SYSTEM REGULATION; ARCUATE NUCLEUS; NEUROPEPTIDE-Y; GROWTH-HORMONE; IN-VITRO; C-FOS; SPINAL-CORD AB Central activation of somatostatin (sst) receptors by oligosomatostatin analogs inhibits growth hormone and stress-related rise in catecholamine plasma levels while stimulating grooming, feeding behaviors, gastric transit and acid secretion, which can be mimicked by selective sst(2) receptor agonist. To evaluate the pattern of neuronal activation induced by peptide sst receptor agonists, we assessed Fos-expression in rat brain after intracerebroventricular (icv) injection of a newly developed selective sst(2) agonist compared to the oligosomatostatin ODT8-SST, a pan-sst(1-5) agonist. Ninety min after injection of vehicle (10 mu l) or previously established maximal orexigenic dose of peptides (1 mu g = 1 nmol/rat), brains were assessed for Fos-immunohistochemistry and doublelabeling. Food and water were removed after injection. The sst(2) agonist and ODT8-SST induced a similar Fos distribution pattern except in the arcuate nucleus where only the sst(2) agonist increased Fos. Compared to ODT8-SST, the sst(2) agonist induced higher Fos-expression by 3.7-times in the basolateral amygdaloid nucleus, 1.2-times in the supraoptic nucleus (SON), 1.6-times in the magnocellular paraventricular hypothalamic nucleus (mPVN), 4.1-times in the external lateral parabrachial nucleus, and 2.6-times in both the inferior olivary nucleus and superficial layer of the caudal spinal trigeminal nucleus. Doublelabeling in the hypothalamus showed that ODT8-SST activates 36% of oxytocin, 63% of vasopressin and 79% of sst(2) immunoreactive neurons in the mPVN and 28%, 55% and 25% in the SON, respectively. Selective activation of sst(2) receptor results in a more robust neuronal activation than the pan-sst(1-5) agonist in various brain regions that may have relevance in sst(2) mediated alterations of behavioral, autonomic and endocrine functions. Published by Elsevier B.V. C1 [Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, Los Angeles, CA 90073 USA. [Goebel, Miriam; Stengel, Andreas; Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis,Dept Med, CURE Digest Dis Res Ctr,Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Coskun, Tamer; Alsina-Fernandez, Jorge] Eli Lilly & Co, Biotechnol Discovery Res, Indianapolis, IN 46285 USA. [Rivier, Jean] Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA USA. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, CURE Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU German Research Foundation [GO 1718/1-1, STE 1765/1-1]; VA Research Career Scientist Award; NIH, Center [R01 DK- 33061, DK-41301] FX This work was supported by German Research Foundation fellowship grants GO 1718/1-1 (M.G.) and STE 1765/1-1 (AS.), the VA Research Career Scientist Award (Y.T.), the NIH R01 DK- 33061 (Y.T.) and Center grant DK-41301 (Animal Core, Y.T.). J.R. is the Dr. Frederik Paulsen Chair in Neurosciences Professor. We are grateful to Mrs. Honghui Liang for her excellent technical support and Ms. Eugenia Hu for reviewing the manuscript. NR 109 TC 12 Z9 13 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD SEP 10 PY 2010 VL 1351 BP 150 EP 164 DI 10.1016/j.brainres.2010.07.024 PG 15 WC Neurosciences SC Neurosciences & Neurology GA 653UD UT WOS:000282121500015 PM 20637739 ER PT J AU Burgess, SJ Kelly, JX Shomloo, S Wittlin, S Brun, R Liebmann, K Peyton, DH AF Burgess, Steven J. Kelly, Jane X. Shomloo, Shawheen Wittlin, Sergio Brun, Reto Liebmann, Katherine Peyton, David H. TI Synthesis, Structure-Activity Relationship, and Mode-of-Action Studies of Antimalarial Reversed Chloroquine Compounds SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID BETA-HEMATIN FORMATION; PLASMODIUM-FALCIPARUM CHLOROQUINE; MALARIA PARASITES; QUINOLINE ANTIMALARIALS; RESISTANCE TRANSPORTER; DRUG RESISTANCE; IN-VITRO; MECHANISM; ASSAY; INHIBITION AB We have previously shown that a "reversed chloroquine (RCQ)" molecule, composed of a chloroquine-like moiety and a resistance reversal-like moiety, can overcome chloroquine resistance in P. falciparum (Burgess, S. J.; Selzer; A.; Kelly, J. X.; Smilkstein, M. J.; Riscoe, M. K.; Peyton, D. H. J. Med. Chem. 2006, 49, 5623. Andrews, S.; Burgess, S. J.; Skaalrud, D.; Kelly, J. X.; Peyton, D. H. J. Med. Chem. 2010, 53, 916). Here, we present an investigation into the structure-activity relationship of the RCQ structures, resulting in an orally active molecule with good in vitro and in vivo antimalarial activity. We also present evidence of the mode of action, indicating that the RCQ molecules inhibit hemozoin formation in the parasite's digestive vacuole in a manner similar to that of chloroquine. C1 [Burgess, Steven J.; Kelly, Jane X.; Shomloo, Shawheen; Liebmann, Katherine; Peyton, David H.] Portland State Univ, Dept Chem, Portland, OR 97207 USA. [Burgess, Steven J.; Shomloo, Shawheen; Peyton, David H.] DesignMedix Inc, Portland, OR 97201 USA. [Kelly, Jane X.] Portland VA Med Ctr, Portland, OR 97239 USA. [Wittlin, Sergio; Brun, Reto] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Wittlin, Sergio; Brun, Reto] Univ Basel, Basel, Switzerland. RP Peyton, DH (reprint author), Portland State Univ, Dept Chem, POB 751, Portland, OR 97207 USA. EM peytond@pdx.edu FU The Medical Research Foundation of Oregon [0530]; National Institutes of Health [AI067837, AI072923]; Murdock Charitable Trust FX The authors thank the following for supporting this research: The Medical Research Foundation of Oregon (Grant 0530) and the National Institutes of Health (Grants ) to D.H.P., as well as the Murdock Charitable Trust for a grant for the NMR instruments. The authors also thank Westin Morrill for his help in preparing this manuscript. NR 43 TC 30 Z9 30 U1 1 U2 6 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 J9 J MED CHEM JI J. Med. Chem. PD SEP 9 PY 2010 VL 53 IS 17 BP 6477 EP 6489 DI 10.1021/jm1006484 PG 13 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 644TM UT WOS:000281404200020 PM 20684562 ER PT J AU Marso, SP House, JA Rumsfeld, JS AF Marso, Steven P. House, John A. Rumsfeld, John S. TI Bleeding Avoidance Strategies and Percutaneous Coronary Intervention Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID VASCULAR CLOSURE DEVICES; CATHETERIZATION C1 [Marso, Steven P.; House, John A.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Marso, SP (reprint author), St Lukes Mid Amer Heart Inst, Kansas City, MO USA. EM smarso@saint-lukes.org NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 8 PY 2010 VL 304 IS 10 BP 1068 EP 1069 DI 10.1001/jama.2010.1256 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 646RM UT WOS:000281559800013 ER PT J AU Werner, RM AF Werner, Rachel M. TI Does Pay-for-Performance Steal From the Poor and Give to the Rich? SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID QUALITY-OF-CARE; HOSPITAL FINANCIAL CONDITION C1 [Werner, Rachel M.] Univ Penn, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Werner, RM (reprint author), Univ Penn, 1230 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@upenn.edu NR 12 TC 6 Z9 6 U1 1 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 7 PY 2010 VL 153 IS 5 BP 340 EP 341 DI 10.7326/0003-4819-153-5-201009070-00010 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 647GF UT WOS:000281605500009 PM 20820044 ER PT J AU Hoen, PW Whooley, MA Martens, EJ Na, B van Melle, JP de Jonge, P AF Hoen, Petra W. Whooley, Mary A. Martens, Elisabeth J. Na, Beeya van Melle, Joost P. de Jonge, Peter TI Differential Associations Between Specific Depressive Symptoms and Cardiovascular Prognosis in Patients With Stable Coronary Heart Disease SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE depression; stable coronary heart disease and prognosis ID POSTMYOCARDIAL INFARCTION DEPRESSION; ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-LIFE; RATE-VARIABILITY; BLOOD-INSTITUTE; NATIONAL-HEART; ARTERY-DISEASE; RISK-FACTOR; MORTALITY; METAANALYSIS AB Objectives The purpose of this research was to evaluate the relationship between cognitive and somatic depressive symptoms and cardiovascular prognosis. Background Depression in patients with stable coronary heart disease (CHD) is associated with poor cardiac prognosis. Whether certain depressive symptoms are more cardiotoxic than others is unknown. Methods In the Heart and Soul Study, 1,019 patients with stable CHD were assessed using the Patient Health Questionnaire to determine the presence of the 9 depressive symptoms included in the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition. The mean age of the patients was 67 years, and 82% were men. A comparison was made on a new cardiovascular event (myocardial infarction, stroke, transient ischemic attack, or congestive heart failure) or death (mean follow-up duration 6.1 +/- 2.0 years) on the basis of cognitive and somatic sum scores and for patients with or without each of those specific depressive symptoms. Demographic characteristics, cardiac risk factors, and cardiac medications were controlled for. Results After adjustment for demographic data and cardiac risk factors, each somatic symptom was associated with 14% greater risk for events (hazard ratio [HR]: 1.14; 95% confidence interval [CI]: 1.05 to 1.24; p = 0.002). Fatigue (HR: 1.34; 95% CI: 1.07 to 1.67; p = 0.01), appetite problems (HR: 1.46; 95% CI: 1.12 to 1.91; p = 0.005), and sleeping difficulties (HR: 1.26; 95% CI: 1.00 to 1.58; p = 0.05) were most strongly predictive of cardiovascular events. In contrast, cognitive symptoms (HR: 1.08; 95% CI: 0.99 to 1.17; p = 0.09) were not significantly associated with cardiovascular events. Conclusions In patients with stable CHD, somatic symptoms of depression were more strongly predictive of cardiovascular events than cognitive symptoms, although the CIs surrounding these estimates had substantial overlap. These findings are highly consistent with those of previous studies. Further research is needed to understand the pathophysiological processes by which somatic depressive symptoms contribute to prognosis in patients with CHD. (J Am Coll Cardiol 2010;56:838-44) (C) 2010 by the American College of Cardiology Foundation C1 [Hoen, Petra W.] Univ Groningen, Univ Med Ctr Groningen, Interdisciplinary Ctr Psychiat Epidemiol, Dept Psychiat, NL-9713 GZ Groningen, Netherlands. [van Melle, Joost P.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 GZ Groningen, Netherlands. [Martens, Elisabeth J.; de Jonge, Peter] Tilburg Univ, Dept Med Psychol, NL-5000 LE Tilburg, Netherlands. [Whooley, Mary A.; Na, Beeya] San Francisco VA Med Ctr, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Hoen, PW (reprint author), Univ Groningen, Univ Med Ctr Groningen, Interdisciplinary Ctr Psychiat Epidemiol, Dept Psychiat, CC72,Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM p.w.hoen@med.umcg.nl RI de Jonge, peter/L-6395-2013 OI de Jonge, peter/0000-0002-0866-6929 FU U.S. Department of Veterans Affairs; U.S. Department of Veterans Affairs Health Services Research and Development Service; National Heart, Lung, and Blood Institute [R01 HL079235]; American Federation for Aging Research; Robert Wood Johnson Foundation; Ischemia Research and Education Foundation; Nancy Kirwan Heart Research Fund; Dutch Medical Research Council [016.086.397] FX The Heart and Soul Study was supported by the U.S. Department of Veterans Affairs Epidemiology Merit Review Program; the U.S. Department of Veterans Affairs Health Services Research and Development Service; grant R01 HL079235 from the National Heart, Lung, and Blood Institute; the Paul Beeson Scholars Program of the American Federation for Aging Research; the Generalist Physician Faculty Scholars Program of the Robert Wood Johnson Foundation; the Ischemia Research and Education Foundation; and the Nancy Kirwan Heart Research Fund. The funding organizations had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript. Dr. de Jonge was supported by VIDI grant 016.086.397 from the Dutch Medical Research Council. All other authors have reported that they have no relationships to disclose. NR 38 TC 62 Z9 62 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD SEP 7 PY 2010 VL 56 IS 11 BP 838 EP 844 DI 10.1016/j.jacc.2010.03.080 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 645IT UT WOS:000281448500003 PM 20813281 ER PT J AU Furlong, CE Suzuki, SM Stevens, RC Marsillach, J Richter, RJ Jarvik, GP Checkoway, H Samii, A Costa, LG Griffith, A Roberts, JW Yearout, D Zabetian, CP AF Furlong, C. E. Suzuki, S. M. Stevens, R. C. Marsillach, J. Richter, R. J. Jarvik, G. P. Checkoway, H. Samii, A. Costa, L. G. Griffith, A. Roberts, J. W. Yearout, D. Zabetian, C. P. TI Human PON1, a biomarker of risk of disease and exposure SO CHEMICO-BIOLOGICAL INTERACTIONS LA English DT Article; Proceedings Paper CT 10th International Meeting on Cholinesterases CY SEP 20-25, 2009 CL Sibenik, CROATIA SP Inst Med Res & Occupat Hlth, Croatian Soc Biochem & Mole Biol, Croatian Acad Sci & Arts DE Paraoxonase 1; Parkinson disease; Organophosphate; Therapy for OP poisoning; Chlorpyrifos/chlorpyrifos oxon; Diazinon/diazoxon ID HUMAN-SERUM PARAOXONASE; CORONARY-HEART-DISEASE; APOLIPOPROTEIN-A-I; PARKINSONS-DISEASE; GENE POLYMORPHISMS; CARDIOVASCULAR-DISEASE; Q192R POLYMORPHISM; CHLORPYRIFOS-OXON; VASCULAR-DISEASE; MOLECULAR-BASIS AB Human paraoxonase 1 (PON1) is a high-density lipoprotein (HDL)-associated serum enzyme that exhibits a broad substrate specificity. In addition to protecting against exposure to some organophosphorus (OP) pesticides by hydrolyzing their toxic oxon metabolites. PON1 is important in protecting against vascular disease by metabolizing oxidized lipids. Recently, PON1 has also been shown to play a role in inactivating the quorum sensing factor N-(3-oxododecanoyl)-L-homoserine lactone (3OC12-HSL) of Pseudomonas aeruginosa. Native, untagged engineered recombinant human PON1 (rHuPON1) expressed in Escherichia coli and purified by conventional column chromatographic purification is stable, active, and capable of protecting PON1 knockout mice (PON1(-/-)) from exposure to high levels of the OP compound diazoxon. The bacterially derived rHuPON1 can be produced in large quantities and lacks the glycosylation of eukaryotic systems that can produce immunogenic complications when inappropriately glycosylated recombinant proteins are used as therapeutics. Previous studies have shown that the determination of PON1 status, which reveals both PON1(192) functional genotype and serum enzyme activity level, is required for a meaningful evaluation of PON1's role in risk of disease or exposure. We have developed a new two-substrate assay/analysis protocol that provides PON1 status without use of toxic OP substrates, allowing for use of this protocol in non-specialized laboratories. Factors were also determined for inter-converting rates of hydrolysis of different substrates. PON1 status also plays an important role in revealing changes in HDL-associated PON1 activities in male patients with Parkinson disease (PD). Immunolocalization studies of PONs 1, 2 and 3 in nearly all mouse tissues suggest that the functions of PONs 1 and 3 extend beyond the plasma and the HDL particle. (C) 2010 Published by Elsevier Ireland Ltd. C1 [Furlong, C. E.; Suzuki, S. M.; Stevens, R. C.; Marsillach, J.; Richter, R. J.; Jarvik, G. P.] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA. [Furlong, C. E.; Suzuki, S. M.; Stevens, R. C.; Marsillach, J.; Richter, R. J.; Jarvik, G. P.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Checkoway, H.; Costa, L. G.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA. [Checkoway, H.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Samii, A.; Yearout, D.; Zabetian, C. P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Samii, A.; Yearout, D.; Zabetian, C. P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Costa, L. G.] Univ Parma, Dept Human Anat Pharmacol & Forens Sci, I-43100 Parma, Italy. [Griffith, A.] Evergreen Hosp Med Ctr, Kirkland, WA USA. [Roberts, J. W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. RP Furlong, CE (reprint author), Univ Washington, Dept Med, Div Med Genet, Box 357720, Seattle, WA 98195 USA. EM clem@u.washington.edu RI Jarvik, Gail/N-6476-2014; Marsillach, Judit/I-1329-2015 OI Jarvik, Gail/0000-0002-6710-8708; Marsillach, Judit/0000-0002-3061-6266; Zabetian, Cyrus/0000-0002-7739-4306 FU NHLBI NIH HHS [HL67406, R01 HL067406, R01 HL067406-07]; NIEHS NIH HHS [ES04696, ES07033, ES09601, ES09883, P01 ES009601, P01 ES009601-10, P30 ES007033, P30 ES007033-14S1, P42 ES004696, P42 ES004696-23, P42 ES004696-235868, R01 ES009883, R01 ES009883-09A1]; NINDS NIH HHS [P50 NS062684, P50 NS062684-01A16218, R01 NS065070, R01 NS065070-01A1, R01 NS065070-02, R01 NS065070-03] NR 77 TC 44 Z9 46 U1 2 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0009-2797 J9 CHEM-BIOL INTERACT JI Chem.-Biol. Interact. PD SEP 6 PY 2010 VL 187 IS 1-3 SI SI BP 355 EP 361 DI 10.1016/j.cbi.2010.03.033 PG 7 WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology GA 641EW UT WOS:000281108600065 PM 20338154 ER PT J AU Pham, SV Pham, PCT Pham, PMT Miller, JM Pham, PTT Pham, PAT AF Pham, Son V. Pham, Phuong-Chi T. Pham, Phuong-Mai T. Miller, Jeffrey M. Pham, Phuong-Thu T. Pham, Phuong-Anh T. TI Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome SO DRUG DESIGN DEVELOPMENT AND THERAPY LA English DT Review DE acute coronary syndrome; percutaneous coronary intervention; aspirin; clopidogrel; glycoprotein IIb/IIIa inhibitors; bivalirudin AB In patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), both periprocedural acute myocardial infarction and bleeding complications have been shown to be associated with early and late mortality. Current standard antithrombotic therapy after coronary stent implantation consists of lifelong aspirin and clopidogrel for a variable period depending in part on the stent type. Despite its well-established efficacy in reducing cardiac-related death, myocardial infarction, and stroke, dual antiplatelet therapy with aspirin and clopidogrel is not without shortcomings. While clopidogrel may be of little beneficial effect if administered immediately prior to PCI and may even increase major bleeding risk if coronary artery bypass grafting is anticipated, early discontinuation of the drug may result in insufficient antiplatelet coverage with thrombotic complications. Optimal and rapid inhibition of platelet activity to suppress ischemic and thrombotic events while minimizing bleeding complications is an important therapeutic goal in the management of patients undergoing percutaneous coronary intervention. In this article we present an overview of the literature on clinical trials evaluating the different aspects of antithrombotic therapy in patients undergoing PCI and discuss the emerging role of these agents in the contemporary era of early invasive coronary intervention. Clinical trial acronyms and their full names are provided in Table 1. C1 [Pham, Phuong-Thu T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Nephrol Div,Kidney & Pancreas Transplant Program, Los Angeles, CA 90095 USA. [Pham, Phuong-Anh T.] Mercy Gen Hosp, Inst Heart & Vasc, Dept Cardiol, Sacramento, CA USA. [Pham, Son V.] Bay Pines VA Med Ctr, Dept Cardiol, Bay Pines, FL USA. [Pham, Phuong-Chi T.] Univ Calif Los Angeles, Olive View Med Ctr, Dept Med, Div Nephrol, Los Angeles, CA 90095 USA. [Miller, Jeffrey M.] Univ Calif Los Angeles, Olive View Med Ctr, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA. [Pham, Phuong-Mai T.] Greater Los Angeles VA Med Ctr, Dept Med, Los Angeles, CA USA. RP Pham, PTT (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Nephrol Div,Kidney & Pancreas Transplant Program, Los Angeles, CA 90095 USA. EM ppham@mednet.ucla.edu NR 53 TC 1 Z9 3 U1 0 U2 3 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-8881 J9 DRUG DES DEV THER JI Drug Des. Dev. Ther. PD SEP 6 PY 2010 VL 4 BP 203 EP 220 DI 10.2147/DDDT.S12056 PG 18 WC Chemistry, Medicinal; Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA V20YU UT WOS:000208176100001 PM 20856846 ER PT J AU Won, JS Im, YB Kim, J Singh, AK Singh, I AF Won, Je-Seong Im, Yeong-Bin Kim, Jinsu Singh, Avtar K. Singh, Inderjit TI Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesis SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE AMPK; Amyloid-beta; Amyloid precursor protein; Cholesterol; Lipid rafts; Sphingomyelin ID LIPID RAFTS; DISEASE; APP; CHOLESTEROL; GENERATION; OBESITY AB AMP-activated-protein-kinase (AMPK) is a key sensor and regulator of cellular and whole-body energy metabolism and plays a key role in regulation of lipid metabolism. Since lipid metabolism has been implicated in neuronal amyloid-beta (A beta) homeostasis and onset of Alzheimer's disease, we investigated the involvement of AMPK in neuronal lipid metabolism and A beta production. We observed in cultured rat cortical neurons that AD production was significantly reduced when the neurons were stimulated with AMPK activator, 5-aminoimidazole-4-carboxamide-1-D-ribofuranoside (AICAR), but increased when AMPK alpha 2 was knocked out, thus indicating the role of AMPK in amyloidogenesis. Although the detailed mechanisms by which AMPK regulates A beta generation is not well understood, AMPK-mediated alterations in cholesterol and sphingomyelin homeostasis and in turn the altered distribution of A beta precursor-protein (APP) in cholesterol and sphingomyelin rich membrane lipid rafts participate in A beta generation. Taken together, this is the first report on the role of AMPK in regulation of neuronal amyloidogenesis. (C) 2010 Published by Elsevier Inc. C1 [Won, Je-Seong; Im, Yeong-Bin; Kim, Jinsu; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charles P Darby Children Res Inst, Charleston, SC 29425 USA. [Won, Je-Seong] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson Vet Adm Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, Charles P Darby Children Res Inst, 504D,173 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu FU National Institute of Health [NS-22576, NS-34741, NS-37766, AG-25307, RR018823, RR015455] FX We thank Ms. Joyce Bryan for laboratory assistance and Ms. Chara Williams for secretarial assistance. This study was supported in part by grants from National Institute of Health (NS-22576, NS-34741, NS-37766, AG-25307, RR018823 and RR015455). We would like to thank Dr. Benoit Viollet in INSERM U567 for providing AMP-K alpha 2 knockout mice. NR 18 TC 33 Z9 38 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD SEP 3 PY 2010 VL 399 IS 4 BP 487 EP 491 DI 10.1016/j.bbrc.2010.07.081 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 650HQ UT WOS:000281840200005 PM 20659426 ER PT J AU Bendlin, BB Newman, LM Ries, ML Puglielli, L Carlsson, CM Sager, MA Rowley, HA Gallagher, CL Willette, AA Alexander, AL Asthana, S Johnson, SC AF Bendlin, Barbara B. Newman, Lisa M. Ries, Michele L. Puglielli, Luigi Carlsson, Cynthia M. Sager, Mark A. Rowley, Howard A. Gallagher, Catherine L. Willette, Auriel A. Alexander, Andrew L. Asthana, Sanjay Johnson, Sterling C. TI NSAIDs may protect against age-related brain atrophy SO FRONTIERS IN AGING NEUROSCIENCE LA English DT Article DE Alzheimer's disease; aging; risk factors; volumetric MRI; NSAIDs ID RANDOMIZED CONTROLLED-TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ALZHEIMER-TYPE PATHOLOGY; BETA-AMYLOID BURDEN; COGNITIVE DECLINE; CHRONIC NEUROINFLAMMATION; APOLIPOPROTEIN-E; TRANSGENIC MICE; GENETIC RISK; DISEASE PROGRESSION AB The use of non-steroidal anti-inflammatory drugs (NSAIDs) in humans is associated with brain differences including decreased number of activated microglia. In animals, NSAIDs are associated with reduced microglia, decreased amyloid burden, and neuronal preservation. Several studies suggest NSAIDs protect brain regions affected in the earliest stages of AD, including hippocampal and parahippocampal regions. In this cross-sectional study, we examined the protective effect of NSAID use on gray matter volume in a group of middle-aged and older NSAID users (n = 25) compared to non-user controls (n = 50). All participants underwent neuropsychological testing and T1-weighted magnetic resonance imaging. Non-user controls showed smaller volume in portions of the left hippocampus compared to NSAID users. Age-related loss of volume differed between groups, with controls showing greater medial temporal lobe volume loss with age compared to NSAID users. These results should be considered preliminary, but support previous reports that NSAIDs may modulate age-related loss of brain volume. C1 [Bendlin, Barbara B.; Newman, Lisa M.; Ries, Michele L.; Puglielli, Luigi; Carlsson, Cynthia M.; Sager, Mark A.; Gallagher, Catherine L.; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Bendlin, Barbara B.; Newman, Lisa M.; Ries, Michele L.; Puglielli, Luigi; Carlsson, Cynthia M.; Sager, Mark A.; Rowley, Howard A.; Gallagher, Catherine L.; Willette, Auriel A.; Asthana, Sanjay; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Willette, Auriel A.] Univ Wisconsin, Dept Psychol, Harlow Primate Lab, Madison, WI 53706 USA. [Alexander, Andrew L.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Alexander, Andrew L.] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Alexander, Andrew L.] Waisman Lab Brain Imaging & Behav, Madison, WI USA. RP Bendlin, BB (reprint author), Vet Adm Hosp, Geriatr Res Educ & Clin Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM bbb@medicine.wisc.edu OI Bendlin, Barbara/0000-0002-0580-9875 FU National Institutes of Health [AG021155, MH62015, R01 AG27161, P50 AG033514]; Merit Review Grant from the Department of Veterans Affairs FX This work was supported by the National Institutes of Health (AG021155 to Sterling C. Johnson, MH62015 to Andrew L. Alexander, and R01 AG27161 to Mark A. Sager, and P50 AG033514); a Merit Review Grant from the Department of Veterans Affairs (to Sterling C. Johnson), and by the facilities and resources at the William S. Middleton Memorial Veterans Hospital (GRECC manuscript number 2010-15). The authors gratefully acknowledge the assistance of Brent Thiel, Britta Jabbar, Michele Fitzgerald, Erik Kastman, Amy Hawley, and Sandra Harding at the University of Wisconsin-Madison for their roles in data collection and technical assistance. In addition, we would like to acknowledge the kind support of researchers and staff at the Waisman Center, University of Wisconsin-Madison, where MR imaging took place. Finally, we extend thanks to our volunteers who participated in this research. NR 62 TC 3 Z9 3 U1 0 U2 6 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1663-4365 J9 FRONT AGING NEUROSCI JI Front. Aging Neurosci. PD SEP 3 PY 2010 VL 2 AR 35 DI 10.3389/fnagi.2010.00035 PG 8 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA V26QS UT WOS:000208560700001 ER PT J AU Follett, K Weaver, F Stern, M AF Follett, Kenneth Weaver, Frances Stern, Matthew TI Deep-Brain Stimulation for Parkinson's Disease REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Follett, Kenneth] Iowa City Vet Affairs Med Ctr, Iowa City, IA USA. [Weaver, Frances] Hines Vet Affairs Hosp, Hines, IL USA. [Stern, Matthew] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Follett, K (reprint author), Iowa City Vet Affairs Med Ctr, Iowa City, IA USA. EM frances.weaver@va.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 2 PY 2010 VL 363 IS 10 BP 988 EP 988 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 645GW UT WOS:000281441500018 ER PT J AU Al Gadban, MM Smith, KJ Soodavar, F Piansay, C Chassereau, C Twal, WO Klein, RL Virella, G Lopes-Virella, MF Hammad, SM AF Al Gadban, Mohammed M. Smith, Kent J. Soodavar, Farzan Piansay, Christabelle Chassereau, Charlyne Twal, Waleed O. Klein, Richard L. Virella, Gabriel Lopes-Virella, Maria F. Hammad, Samar M. TI Differential Trafficking of Oxidized LDL and Oxidized LDL Immune Complexes in Macrophages: Impact on Oxidative Stress SO PLOS ONE LA English DT Article ID LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; SCAVENGER RECEPTORS; ANTIPHOSPHOLIPID SYNDROME; HEAT-SHOCK; CELLS; ATHEROSCLEROSIS; ANTIBODIES; OXLDL; ATHEROGENESIS AB Background: Oxidized low-density lipoproteins (oxLDL) and oxLDL-containing immune complexes (oxLDL-IC) contribute to formation of lipid-laden macrophages (foam cells). It has been shown that oxLDL-IC are considerably more efficient than oxLDL in induction of foam cell formation, inflammatory cytokines secretion, and cell survival promotion. Whereas oxLDL is taken up by several scavenger receptors, oxLDL-IC are predominantly internalized through the FCc receptor I (FCc RI). This study examined differences in intracellular trafficking of lipid and apolipoprotein moieties of oxLDL and oxLDL-IC and the impact on oxidative stress. Methodology/Findings: Fluorescently labeled lipid and protein moieties of oxLDL co-localized within endosomal and lysosomal compartments in U937 human monocytic cells. In contrast, the lipid moiety of oxLDL-IC was detected in the endosomal compartment, whereas its apolipoprotein moiety advanced to the lysosomal compartment. Cells treated with oxLDL-IC prior to oxLDL demonstrated co-localization of internalized lipid moieties from both oxLDL and oxLDL-IC in the endosomal compartment. This sequential treatment likely inhibited oxLDL lipid moieties from trafficking to the lysosomal compartment. In RAW 264.7 macrophages, oxLDL-IC but not oxLDL induced GFP-tagged heat shock protein 70 (HSP70) and HSP70B', which co-localized with the lipid moiety of oxLDL-IC in the endosomal compartment. This suggests that HSP70 family members might prevent the degradation of the internalized lipid moiety of oxLDL-IC by delaying its advancement to the lysosome. The data also showed that mitochondrial membrane potential was decreased and generation of reactive oxygen and nitrogen species was increased in U937 cell treated with oxLDL compared to oxLDL-IC. Conclusions/Significance: Findings suggest that lipid and apolipoprotein moieties of oxLDL-IC traffic to separate cellular compartments, and that HSP70/70B' might sequester the lipid moiety of oxLDL-IC in the endosomal compartment. This mechanism could ultimately influence macrophage function and survival. Furthermore, oxLDL-IC might regulate the intracellular trafficking of free oxLDL possibly through the induction of HSP70/70B'. C1 [Al Gadban, Mohammed M.; Smith, Kent J.; Soodavar, Farzan; Twal, Waleed O.; Hammad, Samar M.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Piansay, Christabelle] Med Univ S Carolina, Summer Undergrad Res Program, Coll Grad Studies, Charleston, SC 29425 USA. [Chassereau, Charlyne; Klein, Richard L.; Lopes-Virella, Maria F.] Med Univ S Carolina, Dept Med, Div Endocrinol, Charleston, SC 29425 USA. [Klein, Richard L.; Lopes-Virella, Maria F.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. RP Al Gadban, MM (reprint author), Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. EM hammadsm@musc.edu FU National Institutes of Health (NIH) [HL079274]; NIH (ARRA) [R01 HL079274-04S1]; NCRR [P20 RR17677]; NIH [P01 HL55782, R01 DK081352, R01 DK081352-02S1]; Department of Veterans Affairs FX This work was supported by the National Institutes of Health (NIH) grant HL079274, NIH (ARRA) grant R01 HL079274-04S1, and the South Carolina COBRE in Lipidomics and Pathobiology (P20 RR17677 from NCRR) to SMH, and NIH grants P01 HL55782, R01 DK081352 and R01 DK081352-02S1 (ARRA) to MLV, and funding from the Department of Veterans Affairs to MLV and RLK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 53 TC 9 Z9 9 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 2 PY 2010 VL 5 IS 9 AR e12534 DI 10.1371/journal.pone.0012534 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 645RB UT WOS:000281480900017 ER PT J AU Levy, C Pointer, L AF Levy, Cari Pointer, Lauren TI Identifying Hospice Eligible Nursing Home Residents SO JOURNAL OF PALLIATIVE CARE LA English DT Meeting Abstract C1 [Levy, Cari; Pointer, Lauren] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CENTRE RECHERCHE INSTITUT UNIV GERIATRIE MONTREAL PI MONTREAL PA 4565 CHEMIN QUEEN MARY, MONTREAL, QUEBEC H3W 1W5, CANADA SN 0825-8597 J9 J PALLIAT CARE JI J. Palliative Care PD FAL PY 2010 VL 26 IS 3 BP 244 EP 244 PG 1 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 802BE UT WOS:000293483500148 ER PT J AU Bersohn, M Shapiro, S Miller, DP Turner, MP Traiger, G Frost, AE AF Bersohn, M. Shapiro, S. Miller, D. P. Turner, M. P. Traiger, G. Frost, A. E. TI Prognostic value of heart rate and systemic systolic blood pressure in pulmonary arterial hypertension in the REVEAL registry SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT ESC Congress CY AUG 28-SEP 01, 2010 CL Stockholm, SWEDEN C1 [Bersohn, M.; Shapiro, S.; Traiger, G.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare, Los Angeles, CA USA. [Miller, D. P.; Turner, M. P.] ICON Clin Res, San Francisco, CA USA. [Frost, A. E.] Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD SEP PY 2010 VL 31 SU 1 BP 756 EP 756 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 646ID UT WOS:000281531905083 ER PT J AU Shah, A Lam, CS Cheng, S Verma, A Oparil, S Pitt, B Zile, MR Aurigemma, GP Solomon, SD AF Shah, A. Lam, C. S. Cheng, S. Verma, A. Oparil, S. Pitt, B. Zile, M. R. Aurigemma, G. P. Solomon, S. D. TI Albuminuria is associated with increased systolic ventricular-arterial stiffness in asymptomatic hypertensive subjects with diastolic dysfunction SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT ESC Congress CY AUG 28-SEP 01, 2010 CL Stockholm, SWEDEN C1 [Shah, A.; Lam, C. S.; Cheng, S.; Verma, A.; Solomon, S. D.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Oparil, S.] Univ Alabama, Birmingham, AL USA. [Pitt, B.] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Zile, M. R.] Med Univ S Carolina, Charleston, SC USA. [Zile, M. R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Aurigemma, G. P.] Univ Massachusetts, Worcester, MA 01605 USA. RI Solomon, Scott/I-5789-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD SEP PY 2010 VL 31 SU 1 BP 911 EP 911 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 646ID UT WOS:000281531906135 ER PT J AU Crenshaw, K Curry, W Salanitro, AH Safford, MM Houston, TK Allison, JJ Estrada, CA AF Crenshaw, Katie Curry, William Salanitro, Amanda H. Safford, Monika M. Houston, Thomas K. Allison, Jeroan J. Estrada, Carlos A. TI Is Physician Engagement With Web-Based CME Associated With Patients' Baseline Hemoglobin A1c Levels? The Rural Diabetes Online Care Study SO ACADEMIC MEDICINE LA English DT Article ID CONTINUING MEDICAL-EDUCATION; RANDOMIZED CONTROLLED-TRIAL; ACHIEVABLE BENCHMARKS; POISSON REGRESSION; SPACED EDUCATION; COUNT DATA; FEEDBACK; STUDENTS; QUALITY; HEALTH AB Purpose To investigate the association between physician participants' levels of engagement in a Web-based educational intervention and their patients' baseline diabetes measures. Method The authors conducted a randomized trial of online CME activities designed to improve diabetes care provided by family, general, and internal medicine physicians in rural areas of 11 southeastern states between September 2006 and July 2008. Using incidence rate ratios derived from negative binomial models, the relationship between physicians' engagement with the study Web site and baseline proportion of their patients having controlled diabetes (hemoglobin A1c <= 7%) was explored. Results One hundred thirty-three participants (intervention = 64; control = 69) provided information for 1,637 patients with diabetes. In the intervention group, physicians in practices in the worst quartiles of A1c control were least engaged with the study Web site in nearly all dimensions. Total number of pages viewed decreased as quartile of A1c control worsened (137, 73, 68, 57; P = .007); similarly, for a given 10% increase in proportion of patients with controlled A1c, participants viewed 1.13 times more pages (95% CI: 1.02-1.26, P = .02). In the control group, engagement was neither correlated with A1c control nor different across quartiles of A1c control. Conclusions Engagement in Web-based interventions is measurable and has important implications for research and education. Because physicians of patients with the greatest need for improvement in A1c control may not use online educational resources as intensely as others, other strategies may be necessary to engage these physicians in professional development activities. C1 [Crenshaw, Katie] Univ Alabama, Div Continuing Med Educ, Birmingham, AL 35294 USA. [Curry, William; Salanitro, Amanda H.; Estrada, Carlos A.] Univ Alabama, Div Gen Internal Med, Birmingham, AL 35294 USA. [Salanitro, Amanda H.; Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Vet Affairs Natl Qual Scholars Program, Birmingham, AL USA. [Safford, Monika M.] Univ Alabama, Div Prevent Med, Birmingham, AL 35294 USA. [Houston, Thomas K.] Bedford VAMC, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Houston, Thomas K.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Worcester, MA USA. [Allison, Jeroan J.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Deep S Ctr Effectiveness, REAP Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. RP Crenshaw, K (reprint author), Univ Alabama, Div Continuing Med Educ, 1670 Univ Blvd,VH Box 603, Birmingham, AL 35294 USA. EM kcrenshaw@uab.edu RI Houston, Thomas/F-2469-2013 OI Allison, Jeroan/0000-0003-4472-2112 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [5R18DK065001]; Veterans Affairs Quality Scholars fellowship FX This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5R18DK065001 to Dr. Allison. Dr. Salanitro was supported by a Veterans Affairs Quality Scholars fellowship. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. NR 32 TC 8 Z9 8 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD SEP PY 2010 VL 85 IS 9 BP 1511 EP 1517 DI 10.1097/ACM.0b013e3181eac036 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 647IH UT WOS:000281611300025 PM 20736679 ER PT J AU Gadomski, A Wissow, LS Slade, E Jenkins, P AF Gadomski, Anne Wissow, Lawrence S. Slade, Eric Jenkins, Paul TI Training Clinicians in Mental Health Communication Skills: Impact on Primary Care Utilization SO ACADEMIC PEDIATRICS LA English DT Article DE child mental health; primary care utilization; Strengths and Difficulties Questionnaire ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PEDIATRIC PRIMARY-CARE; DIFFICULTIES QUESTIONNAIRE; PSYCHOMETRIC PROPERTIES; PSYCHIATRIC-DISORDERS; MEDICAL-CARE; CHILDREN; STRENGTHS; PHYSICIANS; SERVICES AB OBJECTIVE: Although it is known that children with mental health problems utilize primary care services more than most other children, it is unknown how addressing mental health problems in primary care affects children's subsequent services utilization. This study measures primary care utilization in the context of a randomized trial of a communication skills training program for primary care clinicians that had a positive impact on child mental health outcomes. METHODS: From 2002 to 2005, 48 pediatric primary care clinicians at 13 sites in rural upstate New York, urban Maryland, and Washington, DC, were randomized to in-office training or to a control group. Consecutive primary care patients between the ages of 5 and 16 years were screened for mental health problems, as indicated by a possible or probable score on the Strengths and Difficulties Questionnaire (SDQ). For 397 screened children, primary care visits during the next 6 months were identified using chart review and administrative databases. Using generalized estimating equation regression to account for clustering at the clinician level, primary care utilization was compared by study group and SDQ status. RESULTS: The number of primary care visits to the trained clinicians did not differ significantly from those made to control clinicians (2.5 for both groups; P =.63). Children with possible or probable SDQ scores made, on average, 0.38 or 0.65 more visits on a per child basis, respectively, during the 6-month follow-up period than SDQ unlikely children (P =.0002). CONCLUSIONS: Seeing a trained clinician did not increase subsequent primary care utilization. However, primary care utilization was greater among children with mental health problems as measured by the SDQ. Addressing children's mental health in primary care does not increase the primary care visit burden. Research on overall health services utilization is needed. C1 [Gadomski, Anne; Jenkins, Paul] Bassett Healthcare, Res Inst, Ctr Comp, Cooperstown, NY 13326 USA. [Wissow, Lawrence S.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Slade, Eric] US Dept Vet Affairs, Mental Illness Res & Educ Clin Ctr VISN5, Baltimore, MD USA. RP Gadomski, A (reprint author), Bassett Healthcare, Res Inst, Ctr Comp, 1 Atwell Rd, Cooperstown, NY 13326 USA. EM anne.gadomski@bassett.org FU National Institute of Mental Health [R01-MH62469] FX We thank the families, clinicians, and research assistants who took part in the study. The study was funded by grant R01-MH62469 to Dr Lawrence S. Wissow by the National Institute of Mental Health. NR 37 TC 3 Z9 3 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 J9 ACAD PEDIATR JI Acad. Pediatr. PD SEP-OCT PY 2010 VL 10 IS 5 BP 346 EP 352 PG 7 WC Pediatrics SC Pediatrics GA 653PS UT WOS:000282109700012 PM 20685190 ER PT J AU Jakupcak, M Tull, MT McDermott, MJ Kaysen, D Hunt, S Simpson, T AF Jakupcak, Matthew Tull, Matthew T. McDermott, Michael J. Kaysen, Debra Hunt, Stephen Simpson, Tracy TI PTSD symptom clusters in relationship to alcohol misuse among Iraq and Afghanistan war veterans seeking post-deployment VA health care SO ADDICTIVE BEHAVIORS LA English DT Article DE Iraq and Afghanistan War Veterans; Alcohol misuse; PTSD; Depression ID POSTTRAUMATIC-STRESS-DISORDER; CONFIRMATORY FACTOR-ANALYSIS; DUTY MILITARY PERSONNEL; SUBSTANCE-ABUSE; COMBAT VETERANS; DRINKING; DIMENSIONALITY; SOLDIERS; BEHAVIOR; TRENDS AB Demographic factors, characteristics of military service, PTSD, and depression were examined as predictors of alcohol misuse in Iraq and Afghanistan War Veterans (N = 287) presenting for post-deployment Veteran Affairs (VA) health care. Results indicated that alcohol misuse was more common among younger male Veterans who served in the Army or Marine Corps. Accounting for demographic factors and characteristics of service, Veterans who screened positive for PTSD or depression were two times more likely to report alcohol misuse relative to Veterans who did not screen positive for these disorders. The examination of specific PTSD symptom clusters suggested that emotional numbing symptoms were most strongly associated with alcohol misuse. The implications for interventions for alcohol misuse in returning Veterans are discussed. Published by Elsevier Ltd. C1 [Jakupcak, Matthew; Simpson, Tracy] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA 98108 USA. [Jakupcak, Matthew; Kaysen, Debra; Simpson, Tracy] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Tull, Matthew T.] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA. [McDermott, Michael J.] Univ Mississippi, Dept Psychol, Oxford, MS USA. RP Jakupcak, M (reprint author), VA Puget Sound Hlth Care Syst, MIRECC, S-116,1660 S Columbian Way, Seattle, WA 98108 USA. EM matthew.jakupcak@va.gov FU VA Puget Sound Health Care System, Seattle, Washington FX This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington. NR 31 TC 79 Z9 79 U1 2 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD SEP PY 2010 VL 35 IS 9 BP 840 EP 843 DI 10.1016/j.addbeh.2010.03.023 PG 4 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 627HL UT WOS:000280030000006 PM 20471180 ER PT J AU Lee, HY Tong, YP Xing, S Cooke, CE AF Lee, Helen Y. Tong, Yvette P. Xing, Shan Cooke, Catherine E. TI Total costs and atrial fibrillation ablation success or failure in medicare-aged patients in the United States SO ADVANCES IN THERAPY LA English DT Article DE aspirin; cardiovascular disease; medication therapy management; women ID RANDOMIZED CONTROLLED-TRIALS; SERVICES TASK-FORCE; LOW-DOSE ASPIRIN; PRIMARY PREVENTION; CARDIOVASCULAR-DISEASE; COLLABORATIVE METAANALYSIS; SECONDARY PREVENTION; RISK; WOMEN; CARE AB Introduction: Cardiovascular disease is the largest single cause of death among women in the US. The American Heart Association guidelines recommend aspirin use in women >= 65 years of age if blood pressure is controlled and the benefits of cardiovascular risk reduction likely outweigh the risk of bleeding. The objective of this study is to determine the prevalence of aspirin use in elderly women and factors associated with use. Methods: This retrospective study evaluated aspirin use in women aged >= 65 years based on cardiovascular and gastrointestinal bleeding risk using a medication therapy management database within a large mid-Atlantic managed care organization. Logistic regression was used to analyze patient-related variables associated with aspirin use. Variables included clinical coronary heart disease (CHD), number of CHD risk factors, diabetes diagnosis, number of chronic medications and presence of contraindications to aspirin. Results: Aspirin use was reported in 50% of patients: 68.0% in the secondary prevention group and 46.3% in the primary prevention group. The percentage of patients using aspirin or with relative aspirin contraindications increased to 84% for the secondary prevention group and 65.9% for the primary prevention group. Patients with clinical CHD and those with diabetes and without clinical CHD were 5.88 (P=0.008) and 7.54 (P=0.012) times more likely to utilize aspirin, respectively, than patients with only one CHD risk factor of age. Patients with relative contraindications to aspirin were less likely to use aspirin (P<0.001). Conclusion: The high use of aspirin in patients at higher CHD risk supports national recommendations. Clinical practitioners need to carefully assess the value of aspirin in patients at low CHD risk and those 80 years of age and beyond where evidence of benefit should be weighed against risk. C1 [Cooke, Catherine E.] PosiHealth Inc, Ellicott City, MD 21043 USA. [Lee, Helen Y.] CareFirst BlueCross BlueShield, Baltimore, MD USA. [Tong, Yvette P.] Denver VA Med Ctr, Denver, CO USA. [Xing, Shan] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA. RP Cooke, CE (reprint author), PosiHealth Inc, 5106 Bonnie Branch Rd, Ellicott City, MD 21043 USA. EM cCooke@PosiHealth.com NR 24 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0741-238X J9 ADV THER JI Adv. Ther. PD SEP PY 2010 VL 27 IS 9 BP 613 EP 622 DI 10.1007/s12325-010-0060-3 PG 10 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 642UP UT WOS:000281246600004 PM 20607467 ER PT J AU Bendlin, BB Ries, ML Canu, E Sodhi, A Lazar, M Alexander, AL Carlsson, CM Sager, MA Asthana, S Johnson, SC AF Bendlin, Barbara B. Ries, Michele L. Canu, Elisa Sodhi, Aparna Lazar, Mariana Alexander, Andrew L. Carlsson, Cynthia M. Sager, Mark A. Asthana, Sanjay Johnson, Sterling C. TI White matter is altered with parental family history of Alzheimer's disease SO ALZHEIMERS & DEMENTIA LA English DT Article DE Alzheimer's disease; Family history; APOE epsilon 4;; Diffusion tensor imaging; MRI; White matter ID MILD COGNITIVE IMPAIRMENT; APOLIPOPROTEIN-E EPSILON-4; BRAIN GLUCOSE-METABOLISM; DIFFUSION-TENSOR MRI; MYELIN BREAKDOWN; NEUROPSYCHOLOGICAL ASSESSMENT; FRONTOTEMPORAL DEMENTIA; POSTERIOR CINGULATE; RECOGNITION MEMORY; CORPUS-CALLOSUM AB Background: Brain alterations in structure and function have been identified in people with risk factors for sporadic type Alzheimer's disease (AD), suggesting that alterations can be detected decades before AD diagnosis. Although the effect of apolipoprotein E (APOE) epsilon 4 on the brain is well-studied, less is known about the effect of family history of AD. We examined the main effects of family history and APOE epsilon 4 on brain integrity, in addition to assessing possible additive effects of these two risk factors. Methods: Diffusion tensor imaging was performed in 136 middle-aged asymptomatic participants stratified on family history and APOE epsilon 4. Mean diffusivity and fractional anisotropy (FA) were entered in factorial analyses to test the effect of AD risk on microstructural brain integrity. We performed a post hoc analysis of the three principal diffusivities (lambda 1, lambda 2, lambda 3) to provide potential additional insight on underlying tissue differences. Results: Parental family history of AD was associated with lower FA in regions of the brain known to be affected by AD, including cingulum, corpus callosum, tapetum, uncinate fasciculus, hippocampus, and adjacent white matter. Contrary to previous reports, there was no main effect of APOE epsilon 4; however, there was an additive effect of family history and APOE epsilon 4 in which family history positive participants who were also APOE epsilon 4 carriers had the lowest FA compared with the other groups. Conclusions: The data indicate that unknown risk factors contained in family history are associated with changes in microstructural brain integrity in areas of the brain known to be affected by AD. Importantly, the results provide further evidence that AD pathology might be detected before cognitive changes, perhaps decades before disease onset. (c) 2010 The Alzheimer's Association. All rights reserved. C1 [Bendlin, Barbara B.; Canu, Elisa; Sodhi, Aparna; Carlsson, Cynthia M.; Sager, Mark A.; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [Bendlin, Barbara B.; Ries, Michele L.; Canu, Elisa; Sodhi, Aparna; Carlsson, Cynthia M.; Sager, Mark A.; Asthana, Sanjay; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Lazar, Mariana] NYU, Sch Med, Dept Radiol, New York, NY USA. [Alexander, Andrew L.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Alexander, Andrew L.] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Alexander, Andrew L.] Waisman Lab Brain Imaging & Behav, Madison, WI USA. RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. EM scj@medicine.wisc.edu RI ; Canu, Elisa/K-1423-2016 OI Lazar, Mariana/0000-0001-9285-8124; Bendlin, Barbara/0000-0002-0580-9875; Canu, Elisa/0000-0001-5804-3378 FU National Institutes of Health [AG021155, MH62015, R01 AG27161]; Department of Veterans Affairs FX The authors gratefully acknowledge the assistance of Donald McLaren, Brent Thiel, Britta Jabbar, Michele Fitzgerald, and Erik Kastman. In addition, we would like to acknowledge the support of researchers and staff at the Waisman Center, University of Wisconsin-Madison, where MR imaging took place. Finally, we thank our volunteers for their participation in this research. This work was supported by the National Institutes of Health (AG021155 to S.C.J., MH62015 to A.L.A., and R01 AG27161 to M.A.S); a Merit Review Grant from the Department of Veterans Affairs (to S.C.J.), and by the facilities and resources at the William S. Middleton Memorial Veterans Hospital (GRECC manuscript number 2009-09). NR 89 TC 43 Z9 46 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD SEP PY 2010 VL 6 IS 5 BP 394 EP 403 DI 10.1016/j.jalz.2009.11.003 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 654HF UT WOS:000282158400004 PM 20713315 ER PT J AU Iles-Shih, L Collins, JF Holub, JL Lieberman, DA AF Iles-Shih, LuLu Collins, Judy F. Holub, Jennifer L. Lieberman, David A. TI Prevalence of Significant Neoplasia in FOBT-Positive Patients on Warfarin Compared With Those Not on Warfarin SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID FECAL OCCULT BLOOD; LOW-DOSE ASPIRIN; ACUTE GASTROINTESTINAL HEMORRHAGE; AMERICAN-CANCER-SOCIETY; COLORECTAL-CANCER; ANTICOAGULANT-THERAPY; ATRIAL-FIBRILLATION; TASK-FORCE; SURVEILLANCE; POLYPS AB OBJECTIVES: The fecal occult blood test (FOBT) is widely used for colorectal cancer screening. However, the impact of warfarin use on FOBT sensitivity and specificity remains unclear. This study compares the relative risk of neoplasia in FOBT-positive patients stratified by warfarin use. METHODS: The Clinical Outcomes Research Initiative database was used to identify patients with positive FOBT as the only indication for colonoscopy during 2005-2006. Patients were categorized on the basis of documented warfarin status within a 30-day period before FOBT. We compared the demographics and prevalence of significant colon findings (defined as polyp > 9 mm or suspected malignant tumor) among the two groups. After adjusting for confounding variables, logistic regression was used to estimate the odds ratio of significant findings in warfarin-positive vs. warfarin-negative patients. RESULTS: Of 10,266 patients with positive FOBT, 372 used warfarin, 9,265 did not use warfarin, and 629 were excluded because of missing warfarin status. Warfarin-positive patients were more likely male (65 vs. 50%; P < 0.0001), Caucasian (88 vs. 80%; P < 0.0001), and veterans (53 vs. 33%; P < 0.0001). The prevalence of a significant finding was greater in the warfarin group, 16 vs. 11.4% (P < 0.01). After adjusting for age and sex, the relative risk of significant colon findings among warfarin-positive patients was not significantly different from warfarin-negative patients (odds ratio 1.1, 95% confidence interval: 0.81-1.44). CONCLUSIONS: No increased risk for significant colonic findings among FOBT-positive patients according to warfarin use was identified. These findings suggest that continuing warfarin before FOBT will not affect the positive predictive value of this screening test. C1 [Iles-Shih, LuLu; Collins, Judy F.; Holub, Jennifer L.; Lieberman, David A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Collins, Judy F.; Lieberman, David A.] Portland VA Med Ctr, Portland, OR USA. RP Collins, JF (reprint author), VAMC, Dept Internal Med, Div Gastroenterol, P3-GI ,3710 SW Vet Hosp Rd, Portland, OR 97239 USA. EM collinsj@ohsu.edu FU NIDDK NIH HHS [R33 DK061778, U01 DK057132] NR 33 TC 11 Z9 12 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2010 VL 105 IS 9 BP 2030 EP 2034 DI 10.1038/ajg.2010.264 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 646SM UT WOS:000281563100018 PM 20683445 ER PT J AU Jutabha, R Jensen, DM Chavalitdhamrong, D AF Jutabha, Rome Jensen, Dennis M. Chavalitdhamrong, Disaya TI Hepatitis B Vaccine Administered by Intradermal Route in Patients With Celiac Disease Unresponsive to the Intramuscular Vaccination Schedule: A Pilot Study Response SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter ID LIGATION C1 [Jutabha, Rome] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. [Jutabha, Rome; Jensen, Dennis M.; Chavalitdhamrong, Disaya] Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA 90095 USA. RP Jutabha, R (reprint author), Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. EM rjutabha@mednet.ucla.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2010 VL 105 IS 9 BP 2119 EP 2119 DI 10.1038/ajg.2010.176 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 646SM UT WOS:000281563100041 PM 20818369 ER PT J AU Kasckow, J Fellows, I Golshan, S Solorzano, E Meeks, T Zisook, S AF Kasckow, John Fellows, Ian Golshan, Shahrokh Solorzano, Ellen Meeks, Thomas Zisook, Sidney TI Treatment of Subsyndromal Depressive Symptoms in Middle-Age and Older Patients With Schizophrenia: Effect of Age on Response SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Schizophrenia; age differences; citalopram; depression; psychopathology; quality of life ID SCALE AB Objective: The authors hypothesized that age would moderate the response of patients with schizophrenia and subsyndromal depression (SSD) treated citalopram with depressive symptoms and other outcomes. Also, older patients would exhibit more side effects with citalopram. Methods: Participants of 40 years or older had schizophrenia or schizoaffective disorder with SSD. Patients randomly received flexible dosing of citalopram or placebo augmentation of their antipsychotic medication. Linear regression determined whether age had any moderating effect on depressive symptoms, global psychopathology, negative symptoms, mental functioning, and quality of life. Age-related side effects were examined. Results: There were no significant drug group by age interaction in depressive or psychotic symptoms, mental Short Form-12, or quality of life scores. Similarly, there were few age-related side effect differences. Conclusion: Symptoms in younger and older patients with schizophrenia and SSD treated with citalopram seem to respond similarly. Adverse events do not seem to differ with age. (Am J Geriatr Psychiatry 2010; 18:853-857) C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, MIRECC & Behav Hlth Serv, Pittsburgh, PA 15206 USA. [Kasckow, John] Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA. [Fellows, Ian; Golshan, Shahrokh; Solorzano, Ellen; Meeks, Thomas; Zisook, Sidney] Univ Calif San Diego, VA San Diego Hlth Care Syst, Dept Psychiat, San Diego, CA 92103 USA. RP Kasckow, J (reprint author), VA Pittsburgh Hlth Care Syst, MIRECC & Behav Hlth Serv, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM kasckowjw@upmc.edu FU Cincinnati VA Medical Center; University of Cincinnati College Of Medicine; VISN 4; VISN 22 MIRECC; University of California, San Diego, CA.; Center for Community-based Research in Older People with Psychoses; Aspect Medical; PamLab; Forest; Astra Zeneca; Bristol Meyers Squibb; Pfizer; Johnson and Johnson; Solvay; Eli Lilly; [MH6398] FX The authors thank the Cincinnati VA Medical Center and the University of Cincinnati College Of Medicine for their support.; This work was supported by MH6398 (to SZ, JWK), the VISN 4 and VISN 22 MIRECC, and the University of California, San Diego, CA., Center for Community-based Research in Older People with Psychoses. Research support from Aspect Medical and PamLab and speaker's honoraria from Forest Pharmaceuticals, Inc. and GlaxoSmithKline (to SZ). Grant support as well as honoraria for speaking and consultation from Forest, Astra Zeneca, Bristol Meyers Squibb, Pfizer, Johnson and Johnson, Solvay and Eli Lilly (to JK). NR 10 TC 5 Z9 6 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD SEP PY 2010 VL 18 IS 9 BP 853 EP 857 DI 10.1097/JGP.0b013e3181dba12f PG 5 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 647HV UT WOS:000281610000010 PM 20808103 ER PT J AU Fromme, EK Smith, AK Hughes, MT Brokaw, FC Rosenfeld, KE Arnold, RM AF Fromme, Erik K. Smith, Alexander K. Hughes, Mark T. Brokaw, Frances C. Rosenfeld, Kenneth E. Arnold, Robert M. TI Update in Palliative Medicine SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Editorial Material ID CARE CONSULTATION; CANCER; DEPRESSION; OUTCOMES; PAIN C1 [Fromme, Erik K.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA. [Smith, Alexander K.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Hughes, Mark T.] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA. [Brokaw, Frances C.] Dartmouth Hitchcock Med Ctr, Div Gen Internal Med, Lebanon, NH 03766 USA. [Rosenfeld, Kenneth E.] VA Greater Los Angeles Healthcare Syst, Div Gen Med, Palliat Care Sect, Los Angeles, CA USA. [Arnold, Robert M.] Univ Pittsburgh, Div Gen Internal Med, Sect Palliat Care & Med Eth, Pittsburgh, PA USA. RP Fromme, EK (reprint author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, L586,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM frommee@ohsu.edu FU NCI NIH HHS [K07CA109511] NR 16 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD SEP PY 2010 VL 27 IS 6 BP 420 EP 427 DI 10.1177/1049909110370745 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 636DD UT WOS:000280707500010 PM 20555038 ER PT J AU Grota, PG Stone, PW Jordan, S Pogorzelska, M Larson, E AF Grota, Patti G. Stone, Patricia W. Jordan, Sarah Pogorzelska, Monika Larson, Elaine TI Electronic surveillance systems in infection prevention: Organizational support, program characteristics, and user satisfaction SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Surveillance; infection prevention programs; organizational support ID CARE-ASSOCIATED INFECTIONS; AUTOMATED SURVEILLANCE; HEALTH; TECHNOLOGY; EPIDEMIOLOGY AB Background: The use of electronic surveillance systems (ESSs) is gradually increasing in infection prevention and control programs. Little is known about the characteristics of hospitals that have a ESS, user satisfaction with ESSs, and organizational support for implementation of ESSs. Methods: A total of 350 acute care hospitals in California were invited to participate in a Web-based survey; 207 hospitals (59%) agreed to participate. The survey included a description of infection prevention and control department staff, where and how they spent their time, a measure of organizational support for infection prevention and control, and reported experience with ESSs. Results: Only 23% (44/192) of responding infection prevention and control departments had an ESS. No statistically significant difference was seen in how and where infection preventionists (IPs) who used an ESS and those who did not spend their time. The 2 significant predictors of whether an ESS was present were score on the Organizational Support Scale (odds ratio [OR], 1.10; 95% confidence interval [CI], 1.02-1.18) and hospital bed size (OR, 1.004; 95% CI, 1.00-1.007). Organizational support also was positively correlated with IP satisfaction with the ESS, as measured on the Computer Usability Scale (P = .02). Conclusion: Despite evidence that such systems may improve efficiency of data collection and potentially improve patient outcomes, ESSs remain relatively uncommon in infection prevention and control programs. Based on our findings, organizational support appears to be a major predictor of the presence, use, and satisfaction with ESSs in infection prevention and control programs. Key Words: Surveillance; infection prevention programs; organizational support. C1 [Stone, Patricia W.; Jordan, Sarah; Pogorzelska, Monika; Larson, Elaine] Columbia Univ, Sch Nursing, New York, NY 10035 USA. [Grota, Patti G.] Univ Texas Hlth Sci Ctr San Antonio, Infect Prevent Adm, S Texas Vet Healthcare Syst, San Antonio, TX 78229 USA. RP Larson, E (reprint author), Columbia Univ, Sch Nursing, 617 W 168th St, New York, NY 10035 USA. EM ell23@columbia.edu FU Blue Shield of California Foundation [BSCAFND 2490932] FX The authors thank all of the participating California hospitals. This study was funded by the Blue Shield of California Foundation (Grant BSCAFND 2490932) and conducted in collaboration with APIC. NR 23 TC 15 Z9 16 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD SEP PY 2010 VL 38 IS 7 SI SI BP 509 EP 514 DI 10.1016/j.ajic.2009.10.007 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 641SK UT WOS:000281149800002 PM 20176411 ER PT J AU Sambamoorthi, U Bean-Mayberry, B Findley, PA Yano, EM Banerjea, R AF Sambamoorthi, Usha Bean-Mayberry, Bevanne Findley, Patricia A. Yano, Elizabeth M. Banerjea, Ranjana TI Organization of Care and Diagnosed Depression Among Women Veterans SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID AFFAIRS PRIMARY-CARE; MENTAL-HEALTH-CARE; MEDICAL HOME; CLINICS; DISORDERS; ILLNESS; MANAGEMENT; INNOVATION; DELIVERY; QUALITY AB Objective: To analyze the association between the organizational features of integration of physical and mental healthcare in women's health clinics and the diagnosis of depression among women veterans with or at risk for cardiovascular conditions (ie, diabetes mellitus, heart disease, or hypertension). Study Design: Retrospective and observational secondary data analyses. Methods: We studied 27,972 women veterans from 118 facilities with diagnosed cardiovascular conditions in fiscal year 2001 (FY2001) using merged Medicare claims and Veterans Health Administration (VHA) data merged with the 1999 VHA Survey of Primary Care Practices and the 2001 VHA Survey of Women Veterans Health Programs and Practices. The dependent variable was a binary indicator for diagnosed depression during FY2001 at the individual level. We used a multilevel logistic regression model to control for clustering of women veterans within facilities. Individual-level independent variables included demographics, socioeconomic characteristics, and chronic physical conditions. Results: Overall, 27% of women veterans using the VHA were diagnosed as having depression in FY2001. Across facilities, rates of diagnosed depression varied from 13% to 41%. After controlling for individual-level and facility-level independent variables, women veterans who were served in separate women's health clinics with integrated physical and mental healthcare were more likely to have diagnosed depression. The adjusted odds ratio was 1.12 (95% confidence interval, 1.01-1.25). Conclusions: Existing women-specific VHA organizational features with integration of primary care and mental health seem effective in diagnosing depression. Emerging patient-centered medical home models may facilitate diagnosis and treatment of mental health issues among women with complex chronic conditions. (Am J Manag Care. 2010; 16(9): 657-665) C1 [Findley, Patricia A.] Rutgers State Univ, Sch Social Work, New Brunswick, NJ 08901 USA. [Sambamoorthi, Usha] W Virginia Univ, Dept Pharmaceut Syst & Policy, Morgantown, WV 26506 USA. [Sambamoorthi, Usha; Findley, Patricia A.; Banerjea, Ranjana] Dept Vet Affairs New Jersey Hlth Care Syst, HSR&D Ctr Healthcare Knowledge Management, E Orange, NJ USA. [Sambamoorthi, Usha] Morehouse Sch Med, Dept Community Hlth & Prevent Med, Atlanta, GA 30310 USA. [Bean-Mayberry, Bevanne; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Excellence, Sepulveda, CA USA. [Bean-Mayberry, Bevanne] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA. RP Findley, PA (reprint author), Rutgers State Univ, Sch Social Work, 536 George St, New Brunswick, NJ 08901 USA. EM pfindley@ssw.rutgers.edu OI Sambamoorthi, Usha/0000-0001-8311-1360 FU Department of Veterans Affairs-Health Services Research and Development Service [IAE-05-255, IIR-05-016] FX This research was supported by grants IAE-05-255, IIR-05-016, and the Diabetes Epidemiology Cohort II from the Department of Veterans Affairs-Health Services Research and Development Service. NR 35 TC 6 Z9 6 U1 1 U2 5 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD SEP PY 2010 VL 16 IS 9 BP 657 EP 665 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 660EA UT WOS:000282621400003 PM 20873953 ER PT J AU Singh, JA Sloan, JA Atherton, PJ Smith, T Hack, TF Huschka, MM Rummans, TA Clark, MM Diekmann, B Degner, LF AF Singh, Jasvinder A. Sloan, Jeff A. Atherton, Pamela J. Smith, Tenbroeck Hack, Thomas F. Huschka, Mashele M. Rummans, Teresa A. Clark, Matthew M. Diekmann, Brent Degner, Lesley F. TI Preferred Roles in Treatment Decision Making Among Patients With Cancer: A Pooled Analysis of Studies Using the Control Preferences Scale SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID BREAST-CANCER; URINARY-INCONTINENCE; CONTROLLED-TRIAL; UNITED-STATES; TREATMENT CONSULTATIONS; PROVIDING AUDIOTAPES; INVOLVEMENT; WOMEN; CARE; PARTICIPATION AB Objectives: To collect normative data, assess differences between demographic groups, and indirectly compare US and Canadian medical systems relative to patient expectations of involvement in cancer treatment decision making. Study Design: Meta-analysis. Methods: Individual patient data were compiled across 6 clinical studies among 3491 patients with cancer who completed the 2-item Control Preferences Scale indicating the roles they preferred versus actually experienced in treatment decision making. Results: The roles in treatment decision making that patients preferred were 26% active, 49% collaborative, and 25% passive. The roles that patients reported actually experiencing were 30% active, 34% collaborative, and 36% passive. Roughly 61% of patients reported having their preferred role; only 6% experienced extreme discordance between their preferred versus actual roles. More men than women (66% vs 60%, P = .001) and more US patients than Canadian patients (84% vs 54%, P < .001) reported concordance between their preferred versus actual roles. More Canadian patients than US patients preferred and actually experienced (42% vs 18%, P < .001) passive roles. More women than men reported taking a passive role (40% vs 24%, P < .001). Older patients preferred and were more likely than younger patients to assume a passive role. Conclusions: Roughly half of the studied patients with cancer indicated that they preferred to have a collaborative relationship with physicians. Although most patients had the decision-making role they preferred, about 40% experienced discordance. This highlights the need for incorporation of individualized patient communication styles into treatment plans. (Am J Manag Care. 2010; 16(9): 688--696) C1 [Singh, Jasvinder A.; Sloan, Jeff A.; Atherton, Pamela J.; Huschka, Mashele M.; Rummans, Teresa A.; Clark, Matthew M.; Diekmann, Brent] Mayo Clin, Rochester, MN USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama, Birmingham, AL USA. [Smith, Tenbroeck] Amer Canc Soc, Atlanta, GA 30329 USA. [Hack, Thomas F.; Degner, Lesley F.] Univ Manitoba, Winnipeg, MB, Canada. [Hack, Thomas F.; Degner, Lesley F.] St Boniface Gen Hosp, Res Ctr, Winnipeg, MB R2H 2A6, Canada. RP Singh, JA (reprint author), Minneapolis Vet Affairs Ctr, 1 Vet Dr 111R, Minneapolis, MN 55417 USA. EM jasvinder.md@gmail.com RI Hack, Thomas/C-5174-2012 OI Hack, Thomas/0000-0002-6913-8732; singh, jasvinder/0000-0003-3485-0006 FU National Institutes of Health [1 KL2 RR024151-01] FX Supported by clinical and translational science award 1 KL2 RR024151-01 from the National Institutes of Health (to the Mayo Clinic Center for Clinical and Translational Research). NR 42 TC 50 Z9 54 U1 3 U2 12 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD SEP PY 2010 VL 16 IS 9 BP 688 EP 696 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 660EA UT WOS:000282621400006 PM 20873956 ER PT J AU Borrero, S Moore, CG Creinin, MD Ibrahim, SA AF Borrero, Sonya Moore, Charity G. Creinin, Mitchell D. Ibrahim, Said A. TI Low Rates of Vasectomy Among Minorities: A Result of Differential Receipt of Counseling? SO AMERICAN JOURNAL OF MENS HEALTH LA English DT Article DE sterilization; vasectomy; disparities; health services; contraception ID HEALTH-SERVICES; UNITED-STATES; YOUNG MEN; STERILIZATION AB Male sterilization is a highly effective contraceptive method that is underused especially among minorities. This analysis examined the association between race/ethnicity and receipt of sterilization counseling. This study used data collected by the 2002 National Survey of Family Growth. The analysis included men 15 to 44 years old who had not undergone sterilization. The outcome was receipt of sterilization counseling in the 12 months prior to interview, and the primary predictor was race/ethnicity. Sociodemographic characteristics, history of fathering an unintended birth, intention for more children, and access to health care were examined as confounders. Sixty-one (1.7%) men reported receiving sterilization counseling. Although counseling was reported more commonly by Black and Hispanic men compared with White men, the rates were not significantly different (odds ratio [OR] = 2.4, 95% confidence interval [CI] = 0.8-7.1 and OR = 1.9, 95% CI = 0.9-4.1, respectively). In this nationally representative sample of men aged 15 to 44 years, there were exceedingly low rates of sterilization counseling for all men regardless of race/ethnicity. C1 [Borrero, Sonya; Moore, Charity G.; Ibrahim, Said A.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Borrero, Sonya; Ibrahim, Said A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Creinin, Mitchell D.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Biol, Pittsburgh, PA USA. [Creinin, Mitchell D.] Magee Womens Res Inst, Pittsburgh, PA USA. [Creinin, Mitchell D.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. RP Borrero, S (reprint author), Univ Pittsburgh, Sch Med, Div Gen Internal Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu OI Moore, Charity/0000-0002-0060-0124 FU NCATS NIH HHS [KL2 TR000146]; NCRR NIH HHS [1KL2 RR02415403, KL2 RR024154, KL2 RR024154-016500] NR 19 TC 4 Z9 4 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1557-9883 J9 AM J MENS HEALTH JI Am. J. Mens Health PD SEP PY 2010 VL 4 IS 3 BP 243 EP 249 DI 10.1177/1557988309337619 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 638WY UT WOS:000280930400008 PM 19706674 ER PT J AU Baker, AM Haeri, S Klein, RL Boggess, K AF Baker, Arthur M. Haeri, Sina Klein, Richard L. Boggess, Klim TI Association of midgestation paraoxonase 1 activity and pregnancies complicated by preterm birth SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT 30th Annual Meeting of the Society-for-Maternal-Fetal-Medicine CY FEB 01-06, 2010 CL Chicago, IL SP Soc Maternal Fetal Med, Univ Texas Med Branch, Dept Obstetrics & Gynecology DE oxidative stress; paraoxonase 1; preterm birth ID DEPENDENT DIABETES-MELLITUS; CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; DELIVERY; RISK; POLYMORPHISMS; LIPOPROTEINS; MORTALITY; COHORT AB OBJECTIVE: The objective of the study was to determine whether an association exists between low paraoxonase 1 activity and dyslipidemia at midgestation and preterm birth. STUDY DESIGN: We conducted a case-control study of 30 women with preterm birth and 90 women with uncomplicated term deliveries. Maternal serum collected at 15-20 weeks was used to measure lipid concentrations and paraoxonase 1 activity using 2 substrates: paraoxon and phenylacetate (arylesterase activity). RESULTS: The groups did not differ with respect to maternal demographics. Paraoxonase 1 activity (paraoxon) was significantly lower in women delivering preterm compared with controls (12.9 +/- 6.1 vs 16.6 +/- 7.7 dA/min; P = .02). Arylesterase activity and serum lipid concentrations were similar between women with preterm birth and controls. CONCLUSION: Midgestation paraoxonase 1 activity is lower in women who later experience spontaneous preterm birth compared with women who have term deliveries. Prospective studies are needed to determine the significance of paraoxonase 1 in the pathogenesis of preterm birth. C1 [Baker, Arthur M.; Haeri, Sina; Boggess, Klim] Univ N Carolina, Dept Obstet & Gynecol, Div Maternal Fetal Med, Chapel Hill, NC 27599 USA. [Klein, Richard L.] Med Univ S Carolina, Dept Med, Div Endocrinol Metab & Med Genet, Charleston, SC 29425 USA. [Klein, Richard L.] Vet Affairs Med Ctr, Res Serv, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP Baker, AM (reprint author), Univ N Carolina, Dept Obstet & Gynecol, Div Maternal Fetal Med, 3010 Old Clin Bldg,CB 7516, Chapel Hill, NC 27599 USA. EM abaker2@med.unc.edu NR 24 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD SEP PY 2010 VL 203 IS 3 AR 246.e1 DI 10.1016/j.ajog.2010.04.048 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 647FH UT WOS:000281602700025 PM 20541733 ER PT J AU Cowart, LA AF Cowart, L. Ashley TI A novel role for sphingolipid metabolism in oxidant-mediated skeletal muscle fatigue. Focus on "Sphingomyelinase stimulates oxidant signaling to weaken skeletal muscle and promote fatigue" SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article ID PROTEIN-KINASE-C; NEUTRAL SPHINGOMYELINASES; SPHINGOSINE INHIBITION; HUMAN-PLATELETS; CERAMIDE; DIFFERENTIATION; APOPTOSIS; EXERCISE; BASES C1 [Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Cowart, L. Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Cowart, LA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. EM cowartl@musc.edu NR 26 TC 2 Z9 2 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD SEP PY 2010 VL 299 IS 3 BP C549 EP C551 DI 10.1152/ajpcell.00236.2010 PG 3 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 644OR UT WOS:000281389100002 PM 20573998 ER PT J AU Ceppa, E Cattaruzza, F Lyo, V Amadesi, S Pelayo, JC Poole, DP Vaksman, N Liedtke, W Cohen, DM Grady, EF Bunnett, NW Kirkwood, KS AF Ceppa, Eugene Cattaruzza, Fiore Lyo, Victoria Amadesi, Silvia Pelayo, Juan-Carlos Poole, Daniel P. Vaksman, Natalya Liedtke, Wolfgang Cohen, David M. Grady, Eileen F. Bunnett, Nigel W. Kirkwood, Kimberly S. TI Transient receptor potential ion channels V4 and A1 contribute to pancreatitis pain in mice SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE neurogenic inflammation; TRP channels ID INDUCED NEUROGENIC INFLAMMATION; GENE-RELATED PEPTIDE; CAPSAICIN RECEPTOR; SENSORY NEURONS; ACTIVATED RECEPTOR-2; TRPV4 CHANNELS; RAT PANCREAS; MOUSE MODEL; TRPA1; HYPERALGESIA AB Ceppa E, Cattaruzza F, Lyo V, Amadesi S, Pelayo J, Poole DP, Vaksman N, Liedtke W, Cohen DM, Grady EF, Bunnett NW, Kirkwood KS. Transient receptor potential ion channels V4 and A1 contribute to pancreatitis pain in mice. Am J Physiol Gastrointest Liver Physiol 299: G556-G571, 2010. First published June 10, 2010; doi: 10.1152/ajpgi.00433.2009.-The mechanisms of pancreatic pain, a cardinal symptom of pancreatitis, are unknown. Proinflammatory agents that activate transient receptor potential (TRP) channels in nociceptive neurons can cause neurogenic inflammation and pain. We report a major role for TRPV4, which detects osmotic pressure and arachidonic acid metabolites, and TRPA1, which responds to 4-hydroxynonenal and cyclopentenone prostaglandins, in pancreatic inflammation and pain in mice. Immunoreactive TRPV4 and TRPA1 were detected in pancreatic nerve fibers and in dorsal root ganglia neurons innervating the pancreas, which were identified by retrograde tracing. Agonists of TRPV4 and TRPA1 increased intracellular Ca2+ concentration ([Ca2+](i)) in these neurons in culture, and neurons also responded to the TRPV1 agonist capsaicin and are thus nociceptors. Intraductal injection of TRPV4 and TRPA1 agonists increased c-Fos expression in spinal neurons, indicative of nociceptor activation, and intraductal TRPA1 agonists also caused pancreatic inflammation. The effects of TRPV4 and TRPA1 agonists on [Ca2+](i), pain and inflammation were markedly diminished or abolished in trpv4 and trpa1 knockout mice. The secretagogue cerulein induced pancreatitis, c-Fos expression in spinal neurons, and pain behavior in wild-type mice. Deletion of trpv4 or trpa1 suppressed c-Fos expression and pain behavior, and deletion of trpa1 attenuated pancreatitis. Thus TRPV4 and TRPA1 contribute to pancreatic pain, and TRPA1 also mediates pancreatic inflammation. Our results provide new information about the contributions of TRPV4 and TRPA1 to inflammatory pain and suggest that channel antagonists are an effective therapy for pancreatitis, when multiple proinflammatory agents are generated that can activate and sensitize these channels. C1 [Ceppa, Eugene; Cattaruzza, Fiore; Lyo, Victoria; Amadesi, Silvia; Pelayo, Juan-Carlos; Poole, Daniel P.; Vaksman, Natalya; Grady, Eileen F.; Bunnett, Nigel W.; Kirkwood, Kimberly S.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Bunnett, Nigel W.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA. [Liedtke, Wolfgang] Duke Univ Med Ctr, Dept Med & Neurobiol, Durham, NC USA. [Cohen, David M.] Portland VA Med Ctr, Portland, OR USA. RP Bunnett, NW (reprint author), Univ Calif San Francisco, Dept Surg, 513 Parnassus Ave,Rm S1268, San Francisco, CA 94143 USA. EM nigel.bunnett@ucsf.edu RI Liedtke, Wolfgang/G-4633-2011 FU National Institute of Diabetes and Digestive and Kidney Diseases [DK46285, DK57840, DK43207, DK39957, T32 DK07573]; Crohn's and Colitis Foundation [1730] FX This research was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants DK46285 (K. S. Kirkwood, N. W. Bunnett), DK57840 (N. W. Bunnett), DK43207 (N. W. Bunnett), DK39957 (N. W. Bunnett), and T32 DK07573 (E. Ceppa, N. W. Bunnett), and Crohn's and Colitis Foundation 1730 (E. F. Grady). NR 57 TC 44 Z9 45 U1 1 U2 8 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 EI 1522-1547 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD SEP PY 2010 VL 299 IS 3 BP G556 EP G571 DI 10.1152/ajpgi.00433.2009 PG 16 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 644MV UT WOS:000281382600002 PM 20539005 ER PT J AU Cheng, F McLaughlin, PJ Banks, WA Zagon, IS AF Cheng, Fan McLaughlin, Patricia J. Banks, William A. Zagon, Ian S. TI Internalization of the opioid growth factor, [Met(5)]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE human mesenchymal stem cells; active transport; DNA synthase; nucleocytoplasmic transport; siRNA ID FACTOR RECEPTOR OGFR; AXIS; PEPTIDES; BIOLOGY; CANCER; LOCALIZATION; CAVEOLIN-1; BRAIN; HEAD AB Cheng F, McLaughlin PJ, Banks WA, Zagon IS. Internalization of the opioid growth factor, [Met(5)]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation. Am J Physiol Regul Integr Comp Physiol 299: R774-R785, 2010. First published June 30, 2010; doi:10.1152/ajpregu.00318.2010.-The opioid growth factor (OGF; [Met(5)]-enkephalin), a constitutively expressed and tonically active inhibitory peptide, interacts with the OGF receptor (OGFr) to form an endogenous growth-regulating pathway in homeostasis. Amplification of OGF-OGFr interfacing in animal and clinical studies depresses development, neoplasia, angiogenesis, and immunity. Disruption of the OGF-OGFr axis accelerates cell proliferation and has been particularly important in wound repair. To investigate how OGF enters cells, OGF was labeled with 5,6-tetramethylrhodamine OGF (RhoOGF) to study its uptake in live cells. African green monkey kidney cells (COS-7) incubated with RhoOGF exhibited a temperature-dependent course of entry, being internalized at 37 C but not at 4 C. RhoOGF was detected in the cytoplasm 15 min after initial exposure, observed in both cytoplasm and nucleus within 30 min, and remained in the cells for as long as 5 h. A 100-fold excess of OGF or the opioid antagonist naltrexone, but not other opioid ligands (some selective for classic opioid receptors), markedly reduced entry of RhoOGF into cells. RhoOGF was functional because DNA synthesis in cells incubated with RhoOGF (10(-5) to 10(-8) M) was decreased 24-36%, and was comparable to cells treated with unlabeled OGF (reductions of 26-39%). OGF internalization was dependent on clathrin-mediated endocytosis, with addition of clathrin siRNA diminishing the uptake of RhoOGF and upregulating DNA synthesis. RhoOGF clathrin-mediated endocytosis was unrelated to endosomal or Golgi pathways. Taken together, these results suggest that OGF enters cells by active transport in a saturable manner that requires clathrin-mediated endocytosis. C1 [Cheng, Fan; McLaughlin, Patricia J.; Zagon, Ian S.] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Neural & Behav Sci, Hershey, PA 17033 USA. [Banks, William A.] Univ Washington, Sch Med, Ctr Geriatr Res Educ & Clin, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA. RP Zagon, IS (reprint author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Neural & Behav Sci, H109,500 Univ Dr,Rm C3729, Hershey, PA 17033 USA. EM isz1@psu.edu FU Paul K. and Anna E. Shockey Family Foundation; Zagon/Kostel families; Veterans Affairs Merit Review FX This study was supported, in part, by the Paul K. and Anna E. Shockey Family Foundation and the Zagon/Kostel families and a Veterans Affairs Merit Review (to W. A. Banks). NR 31 TC 8 Z9 8 U1 1 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD SEP PY 2010 VL 299 IS 3 BP R774 EP R785 DI 10.1152/ajpregu.00318.2010 PG 12 WC Physiology SC Physiology GA 646KA UT WOS:000281537500007 PM 20592180 ER PT J AU Martinez, CO McHale, MJ Wells, JT Ochoa, O Michalek, JE McManus, LM Shireman, PK AF Martinez, Carlo O. McHale, Matthew J. Wells, Jason T. Ochoa, Oscar Michalek, Joel E. McManus, Linda M. Shireman, Paula K. TI Regulation of skeletal muscle regeneration by CCR2-activating chemokines is directly related to macrophage recruitment SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE monocyte/macrophage; angiogenesis; CC chemokine receptor 2; MCP-1/CCL2; MCP-5/CCL12 ID STEM-CELLS; IN-VIVO; ALTERED INFLAMMATION; CC-CHEMOKINE; BONE-MARROW; CCR2-/-MICE; EXPRESSION; MCP-1; ACTIVATION; MONOCYTES AB Martinez CO, McHale MJ, Wells JT, Ochoa O, Michalek JE, McManus LM, Shireman PK. Regulation of skeletal muscle regeneration by CCR2-activating chemokines is directly related to macrophage recruitment. Am J Physiol Regul Integr Comp Physiol 299: R832-R842, 2010. First published July 14, 2010; doi:10.1152/ajpregu.00797.2009.-Muscle regeneration requires CC chemokine receptor 2 (CCR2) expression on bone marrow-derived cells; macrophages are a prominent CCR2-expressing cell in this process. CCR2-/- mice have severe impairments in angiogenesis, macrophage recruitment, and skeletal muscle regeneration following cardiotoxin (CTX)-induced injury. However, multiple chemokines activate CCR2, including monocyte chemotactic proteins (MCP)-1, -3, and -5. We hypothesized that MCP-1 is the chemokine ligand that mediates the impairments present in CCR2-/- mice. We examined muscle regeneration, capillary density, and cellular recruitment in MCP-1-/- and CCR2-/- mice following injury. Muscle regeneration and adipocyte accumulation, but not capillary density, were significantly impaired in MCP-1-/- compared with wild-type (WT) mice; however, muscle regeneration and adipocyte accumulation impairments were not as severe as observed in CCR2-/- mice. Although tissue levels of MCP-5 were elevated in MCP-1-/- mice compared with WT, the administration of MCP-5 neutralizing antibody did not alter muscle regeneration in MCP-1-/- mice. While neutrophil accumulation after injury was similar in all three mouse strains, macrophage recruitment was highest in WT mice, intermediate in MCP-1-/- mice, and severely impaired in CCR2-/- mice. In conclusion, while the absence of MCP-1 resulted in impaired macrophage recruitment and muscle regeneration, MCP-1-/- mice exhibit an intermediate phenotype compared with CCR2-/- mice. Intermediate macrophage recruitment in MCP-1-/- mice was associated with similar capillary density to WT, suggesting that fewer macrophages may be needed to restore angiogenesis vs. muscle regeneration. Finally, other chemokines, in addition to MCP-1 and MCP-5, may activate CCR2-dependent regenerative processes resulting in an intermediate phenotype in MCP-1-/- mice. C1 [Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Div Vasc Surg, Dept Surg, San Antonio, TX 78229 USA. [Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Michalek, Joel E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA. [McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Shireman, Paula K.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Shireman, PK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Vasc Surg, Dept Surg, 7703 Floyd Curl Dr MSC 7741, San Antonio, TX 78229 USA. EM shireman@uthscsa.edu FU Veterans Administration; National Heart, Lung, and Blood Institute [HL-070158, HL-074236]; University of Texas Health Science Center San Antonio; National Cancer Institute, Cancer Therapy & Research Center [P30-CA-054174] FX This work was supported, in part, by a Veterans Administration Merit Review grant and the National Heart, Lung, and Blood Institute Grants HL-070158 and HL-074236. Data was generated in the Core Flow Cytometry Facility, which is supported by the University of Texas Health Science Center San Antonio and National Cancer Institute Grant P30-CA-054174 (Cancer Therapy & Research Center). NR 38 TC 46 Z9 47 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD SEP PY 2010 VL 299 IS 3 BP R832 EP R842 DI 10.1152/ajpregu.00797.2009 PG 11 WC Physiology SC Physiology GA 646KA UT WOS:000281537500013 PM 20631294 ER PT J AU Melhorn, SJ Krause, EG Scott, KA Mooney, MR Johnson, JD Woods, SC Sakai, RR AF Melhorn, Susan J. Krause, Eric G. Scott, Karen A. Mooney, Marie R. Johnson, Jeffrey D. Woods, Stephen C. Sakai, Randall R. TI Meal patterns and hypothalamic NPY expression during chronic social stress and recovery SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE adiposity; meal size; body composition; food intake ID CORTICOTROPIN-RELEASING HORMONE; VISIBLE BURROW SYSTEM; PITUITARY-ADRENAL AXIS; FOOD-INTAKE; BODY-WEIGHT; GENE-EXPRESSION; NEUROPEPTIDE-Y; EATING BEHAVIOR; FEMALE RATS; SUBORDINATION STRESS AB Melhorn SJ, Krause EG, Scott KA, Mooney MR, Johnson JD, Woods SC, Sakai RR. Meal patterns and hypothalamic NPY expression during chronic social stress and recovery. Am J Physiol Regul Integr Comp Physiol 299: R813-R822, 2010. First published July 7, 2010; doi:10.1152/ajpregu.00820.2009.-In the present study, we examined meal patterns during and after exposure to the visible burrow system (VBS), a rodent model of chronic social stress, to determine how the microstructure of food intake relates to the metabolic consequences of social subordination. Male Long-Evans rats were housed in mixed-sex VBS colonies (4 male, 2 female) for 2 wk, during which time a dominance hierarchy formed [1 dominant male (DOM) and 3 subordinate males (SUB)], and then male rats were individually housed for a 3-wk recovery period. Controls were individually housed with females during the 2-wk VBS period and had no changes in ingestive behavior compared with a habituation period. During the hierarchy-formation phase of VBS housing, DOM and SUB had a reduced meal frequency, whereas SUB also had a reduced meal size. However, during the hierarchy-maintenance phase of VBS housing, DOM meal patterns did not differ from controls, whereas SUB continued to display a reduced food intake via less frequent meals. During recovery, DOM had comparable meal patterns to controls, whereas SUB had an increased meal size. Hypothalamic neuropeptide Y (NPY) mRNA levels were not different between these groups during the experimental period. Together, the results suggest that exposure to chronic social stress alters ingestive behavior both acutely and in the long term, which may influence the metabolic changes that accompany bouts of stress and recovery; however, these differences in meal patterns do not appear to be mediated by hypothalamic NPY. C1 [Melhorn, Susan J.; Krause, Eric G.; Scott, Karen A.; Woods, Stephen C.; Sakai, Randall R.] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH USA. [Melhorn, Susan J.; Scott, Karen A.] Univ Cincinnati, Coll Med, Program Neurosci, Cincinnati, OH USA. [Mooney, Marie R.; Johnson, Jeffrey D.] Univ Cincinnati, Coll Med, Dept Biomed Engn, Cincinnati, OH USA. RP Melhorn, SJ (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,151 Metab, Seattle, WA 98108 USA. EM smelhorn@u.washington.edu FU National Institute of Diabetes, Digestive and Kidney Diseases [RO1 DK066596-06] FX These studies were supported by the National Institute of Diabetes, Digestive and Kidney Diseases Grant RO1 DK066596-06 (to R. R. Sakai). NR 57 TC 21 Z9 22 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD SEP PY 2010 VL 299 IS 3 BP R813 EP R822 DI 10.1152/ajpregu.00820.2009 PG 10 WC Physiology SC Physiology GA 646KA UT WOS:000281537500011 PM 20610828 ER PT J AU Coviello, DM Cornish, JW Lynch, KG Alterman, AI O'Brien, CP AF Coviello, Donna M. Cornish, James W. Lynch, Kevin G. Alterman, Arthur I. O'Brien, Charles P. TI A Randomized Trial of Oral Naltrexone for Treating Opioid-Dependent Offenders SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID HEALTH-CARE PROFESSIONALS; ADDICTION SEVERITY INDEX; CLINICAL-EXPERIENCE; HEROIN-ADDICTION; FOLLOW-UP; NARCOTIC-ANTAGONIST; MATCHING ALCOHOLICS; METHADONE PATIENTS; MAINTENANCE; PHARMACOTHERAPY AB Offenders with a history of opioid dependence are a particularly difficult group to treat. A large proportion of offenders typically relapse shortly after release from prison, commit drug-related crimes, and then are arrested and eventually re-incarcerated. Previous research demonstrated that oral naltrexone was effective in reducing opioid use and preventing recidivism among offenders under federal supervision. The 111 opioid-dependent offenders in this study were under various levels of supervision that included county and federal probation/parole, a treatment court, an alternative disposition program, and an intermediate punishment program. Subjects were randomly assigned to receive 6 months of either 300 mg per week of oral naltrexone plus standard psychosocial treatment as usual (n = 56) or standard psychosocial treatment as usual (TAU) without naltrexone (n = 55). While the TAU subjects who remained in treatment used more opioids than the naltrexone subjects who remained, the high dropout rate for both groups made it difficult to assess the effectiveness of naltrexone. The study provides limited support for the use of oral naltrexone for offenders who are not closely monitored by the criminal justice system. (Am J Addict 2010;00:1-11). C1 [Coviello, Donna M.; Cornish, James W.; Lynch, Kevin G.; Alterman, Arthur I.; O'Brien, Charles P.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Cornish, James W.; O'Brien, Charles P.] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Coviello, DM (reprint author), Treatment Res Ctr, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA. EM coviello_d@mail.trc.upenn.edu FU NIDA NIH HHS [R01 DA012268, R01 DA012268-01A2, R01-DA-012268] NR 47 TC 20 Z9 20 U1 2 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD SEP-OCT PY 2010 VL 19 IS 5 BP 422 EP 432 DI 10.1111/j.1521-0391.2010.00070.x PG 11 WC Substance Abuse SC Substance Abuse GA 640NT UT WOS:000281059000006 PM 20716305 ER PT J AU Chakravorty, S Kuna, ST Zaharakis, N O'Brien, CP Kampman, KM Oslin, D AF Chakravorty, Subhajit Kuna, Samuel T. Zaharakis, Nikola O'Brien, Charles P. Kampman, Kyle M. Oslin, David TI Covariates of Craving in Actively Drinking Alcoholics SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PSYCHOMETRIC PROPERTIES; SOCIAL SUPPORT; NICOTINE DEPENDENCE; DOPAMINE SYNTHESIS; CUE REACTIVITY; MOOD STATES; DSM-IV; RELAPSE; NALTREXONE AB The goal of this cross-sectional study was to assess the relationship of alcohol craving with biopsychosocial and addiction factors that are clinically pertinent to alcoholism treatment. Alcohol craving was assessed in 315 treatment-seeking, alcohol dependent subjects using the Penn Alcohol Craving Scale questionnaire. Standard validated questionnaires were used to evaluate a variety of biological, addiction, psychological, psychiatric, and social factors. Individual covariates of craving included age, race, problematic consequences of drinking, heavy drinking, motivation for change, mood disturbance, sleep problems, and social supports. In a multivariate analysis (R2 = .34), alcohol craving was positively associated with mood disturbance, heavy drinking, readiness for change, and negatively associated with age. The results from this study suggest that alcohol craving is a complex phenomenon influenced by multiple factors. (Am J Addict 2010;00:1-8). C1 [Chakravorty, Subhajit; O'Brien, Charles P.; Oslin, David] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Vet Integrated Serv Network, Philadelphia, PA 19104 USA. [Chakravorty, Subhajit; Kuna, Samuel T.] Univ Penn, Ctr Sleep & Resp Neurobiol, Philadelphia, PA 19104 USA. [Chakravorty, Subhajit; O'Brien, Charles P.; Kampman, Kyle M.; Oslin, David] Univ Penn, Treatment Res Ctr, Ctr Study Addict, Philadelphia, PA 19104 USA. [Kuna, Samuel T.] Philadelphia VA Med Ctr, Pulm Crit Care & Sleep Sect, Philadelphia, PA 19104 USA. [Zaharakis, Nikola] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA. [Oslin, David] Univ Penn, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. RP Chakravorty, S (reprint author), Philadelphia VA Med Ctr, MIRECC VISN 4, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM Subhajit.Chakravorty@uphs.upenn.edu FU NIAAA NIH HHS [5R01AA014851, R01 AA014851, R01 AA014851-01, R01 AA014851-02, R01 AA014851-03, R01 AA014851-04, R01 AA014851-05] NR 62 TC 14 Z9 18 U1 6 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD SEP-OCT PY 2010 VL 19 IS 5 BP 450 EP 457 DI 10.1111/j.1521-0391.2010.00067.x PG 8 WC Substance Abuse SC Substance Abuse GA 640NT UT WOS:000281059000009 PM 20716308 ER PT J AU Badgett, RG Lawrence, VA Cohn, SL AF Badgett, Robert G. Lawrence, Valerie A. Cohn, Steven L. TI Variations in Pharmacology of beta-Blockers May Contribute to Heterogeneous Results in Trials of Perioperative beta-Blockade SO ANESTHESIOLOGY LA English DT Article ID RANDOMIZED-CONTROLLED-TRIAL; HIGH-RISK PATIENTS; NONCARDIAC SURGERY; MYOCARDIAL-INFARCTION; RECEPTOR GENOTYPE; MULTICENTER TRIAL; VASCULAR-SURGERY; HEART-FAILURE; METOPROLOL; MORTALITY AB Background: Randomized controlled trials and meta-analyses provide conflicting guidance on the role of beta-adrenergic receptor blockers (beta-blockers) in reducing perioperative complications. We hypothesize that variability in trial results may be due in part to heterogeneous properties of beta-blockers. First, we propose that the extent of beta-blocker metabolism by cytochrome P-450 and the time available to titrate the dosage before surgery (titration time) may interact; dependence on P-450 may be most harmful when titration time is short. Second, beta-blockers vary in their selectivity for the beta-1 receptor and reduced selectivity may contribute to cerebral ischemia. Methods: We used meta-analysis and meta-regression of existing trials to explore the role of these pharmacological properties. Results: We found that both of these pharmacological factors are significantly associated with reduced efficacy of beta-blockers. Conclusions: Pharmacological properties of beta-blockers may contribute to heterogeneous trial results. Many trials have used metoprolol, which is extensively metabolized by cytochrome P450 and is less selective for the beta-1 receptor. For these two reasons, the efficacy of metoprolol to prevent perioperative cardiac complications should be compared with the efficacy of other beta-blockers. C1 [Badgett, Robert G.; Lawrence, Valerie A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Badgett, Robert G.; Lawrence, Valerie A.] Audie L Murphy Mem Vet Affairs Hosp, San Antonio, TX USA. [Cohn, Steven L.] SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA. RP Badgett, RG (reprint author), Univ Kansas, Sch Med Wichita, Dept Med, 1010 N Kansas St, Wichita, KS 67214 USA. EM rbadgett@kumc.edu OI Badgett, Robert/0000-0003-2888-3303 NR 44 TC 29 Z9 31 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-3022 J9 ANESTHESIOLOGY JI Anesthesiology PD SEP PY 2010 VL 113 IS 3 BP 585 EP 592 DI 10.1097/ALN.0b013e3181e73eea PG 8 WC Anesthesiology SC Anesthesiology GA 642WL UT WOS:000281251600012 PM 20693881 ER PT J AU Isaacson, BM Stinstra, JG MacLeod, RS Pasquina, PF Bloebaum, RD AF Isaacson, Brad M. Stinstra, Jeroen G. MacLeod, Rob S. Pasquina, Paul F. Bloebaum, Roy D. TI Developing a Quantitative Measurement System for Assessing Heterotopic Ossification and Monitoring the Bioelectric Metrics from Electrically Induced Osseointegration in the Residual Limb of Service Members SO ANNALS OF BIOMEDICAL ENGINEERING LA English DT Article DE Electrical stimulation; Finite element analysis; Heterotopic ossification; Osseointegration; Residual limb; Service members ID TOTAL HIP-ARTHROPLASTY; HEAD-INJURED ADULTS; BONE-FORMATION; TRAUMATIC AMPUTEE; RISK-FACTORS; STIMULATION; FRACTURES; FIELD; FIBROBLASTS; PROSTHESES AB Poor prosthetic fit is often the result of heterotopic ossification (HO), a frequent problem following blast injuries for returning service members. Osseointegration technology offers an advantage for individuals with significant HO and poor socket tolerance by using direct skeletal attachment of a prosthesis to the distal residual limb, but remains limited due to prolonged post-operative rehabilitation regimens. Therefore, electrical stimulation has been proposed as a catalyst for expediting skeletal attachment and the bioelectric effects of HO were evaluated using finite element analysis in 11 servicemen with transfemoral amputations. Retrospective computed tomography (CT) scans provided accurate reconstructions, and volume conductor models demonstrated the variability in residual limb anatomy and necessity for patient-specific modeling to characterize electrical field variance if patients were to undergo a theoretical osseointegration of a prosthesis. In this investigation, the volume of HO was statistically significant when selecting the optimal potential difference for enhanced skeletal fixation, since higher HO volumes required increased voltages at the periprosthetic bone (p = 0.024, r = 0.670). Results from Spearman's rho correlations also indicated that the age of the subject and volume of HO were statistically significant and inversely proportional, in which younger service members had a higher frequency of HO (p = 0.041, r = -0.622). This study demonstrates that the volume of HO and age may affect the voltage threshold necessary to improve current osseointegration procedures. C1 [Isaacson, Brad M.; Bloebaum, Roy D.] US Dept Vet Affairs, Bone & Joint Res Lab, Salt Lake City, UT 84148 USA. [Pasquina, Paul F.] Walter Reed Army Med Ctr, Dept Orthopaed & Rehabil, Washington, DC 20307 USA. [Isaacson, Brad M.; MacLeod, Rob S.; Bloebaum, Roy D.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA. [Bloebaum, Roy D.] Univ Utah, Dept Orthopaed, Salt Lake City, UT USA. [Bloebaum, Roy D.] Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA. [Stinstra, Jeroen G.; MacLeod, Rob S.] Univ Utah, Sci Comp & Imagining Inst, Salt Lake City, UT USA. RP Bloebaum, RD (reprint author), US Dept Vet Affairs, Bone & Joint Res Lab 151F, Salt Lake City, UT 84148 USA. EM roy.bloebaum@hsc.utah.edu FU Veterans Affairs Office of Research and Development, Rehabilitation R&D Service, DVA SLC Health Care System, Salt Lake City, UT; Albert & Margaret Hofmann Chair and the Department of Orthopaedics, University of Utah School of Medicine, Salt Lake City, UT; Technology Commercialization Office, University of Utah, Salt Lake City, UT FX Gratitude is expressed to Gregory Stoddard for assistance and interpretation of statistical analysis, Darrell Swenson for support with image visualizations, and Gwenevere Shaw and Sharon Weeks for support with manuscript preparation. Grant & Financial Support: This material is based on study supported by the Veterans Affairs Office of Research and Development, Rehabilitation R&D Service, DVA SLC Health Care System, Salt Lake City, UT; the Albert & Margaret Hofmann Chair and the Department of Orthopaedics, University of Utah School of Medicine, Salt Lake City, UT; the Technology Commercialization Office, University of Utah, Salt Lake City, UT. Technical support for the simulations was provided by the Center for Integrative Biomedical Computing of Scientific Computing and Imaging Institute, and was made possible in part by software from the NIH/NCRR Center for Integrative Biomedical Computing, P41-RR12553-07. NR 56 TC 7 Z9 7 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0090-6964 J9 ANN BIOMED ENG JI Ann. Biomed. Eng. PD SEP PY 2010 VL 38 IS 9 BP 2968 EP 2978 DI 10.1007/s10439-010-0050-2 PG 11 WC Engineering, Biomedical SC Engineering GA 634PB UT WOS:000280594300016 PM 20458630 ER PT J AU Edwardsen, EA Dichter, ME Horwitz, SH Cerulli, C AF Edwardsen, E. A. Dichter, M. E. Horwitz, S. H. Cerulli, C. TI Instructional Curriculum Improves Medical Staff Understanding of the Importance for Routine Inquiry About Partner Violence and Appropriate Service Referral SO ANNALS OF EMERGENCY MEDICINE LA English DT Meeting Abstract CT Conference on American-College-of-Emergency-Physicians-Research-Forum CY SEP 28-29, 2010 CL Las Vegas, NV SP Amer Coll Emergency Phys Res Forum C1 Univ Rochester, Rochester, NY USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD SEP PY 2010 VL 56 IS 3 SU S BP S39 EP S40 PG 2 WC Emergency Medicine SC Emergency Medicine GA 645FY UT WOS:000281438000119 ER PT J AU Hsia, RY Asch, SM Weiss, RE Zingmond, DS Liang, L McCreath, H Sun, BC AF Hsia, R. Y. Asch, S. M. Weiss, R. E. Zingmond, D. S. Liang, L. McCreath, H. Sun, B. C. TI County and Hospital Determinants of Ambulance Diversion SO ANNALS OF EMERGENCY MEDICINE LA English DT Meeting Abstract CT Conference on American-College-of-Emergency-Physicians-Research-Forum CY SEP 28-29, 2010 CL Las Vegas, NV SP Amer Coll Emergency Phys Res Forum C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Calif Los Angeles, Los Angeles, CA USA. Greater Los Angeles VA Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD SEP PY 2010 VL 56 IS 3 SU S BP S93 EP S93 PG 1 WC Emergency Medicine SC Emergency Medicine GA 645FY UT WOS:000281438000283 ER PT J AU Parchman, ML Zeber, JE Palmer, RF AF Parchman, Michael L. Zeber, John E. Palmer, Raymond F. TI Participatory Decision Making, Patient Activation, Medication Adherence, and Intermediate Clinical Outcomes in Type 2 Diabetes: A STARNet Study SO ANNALS OF FAMILY MEDICINE LA English DT Article DE Patient-centered care; physician-patient relations; diabetes mellitus, type 2 ID SELF-MANAGEMENT; PRIMARY-CARE; PHYSICIAN; COMMUNICATION; INERTIA; HEMOGLOBIN; PREDICTORS; ALLIANCE; MELLITUS; QUALITY AB PURPOSE Participatory decision making (PDM) is associated with improved diabetes control. We examine a causal model linking PDM to improved clinical outcomes that included patient activation and medication adherence. METHODS This observational study was conducted in 5 family physician offices. Diabetic patients were recruited by mail and by completing a study interest card at the conclusion of their office visit. Two survey questionnaires, administered 12 months apart, elicited patients' ratings of their physician's PDM style at baseline and their level of activation and medication adherence both at baseline and at follow-up. Measures of glycated hemoglobin (hemoglobin A(1c)), systolic blood pressure, and low-density lipoprotein (LDL) cholesterol were abstracted from the medical record starting 12 months before the baseline survey to 12 months after the follow-up survey. A path analysis using a structural equation model was used to test hypotheses. RESULTS We mailed questionnaires to 236 participants; 166 (70%) returned the baseline questionnaire, and 141 (80%) returned the follow-up questionnaire. Hemoglobin A(1c) levels, systolic blood pressure, and LDL cholesterol values all declined significantly, and patient activation and medication adherence improved. PDM at baseline was associated with patient activation at follow-up. Patient activation at follow-up was associated with medication adherence at follow-up, and medication adherence at follow-up was associated with change in hemoglobin A(1c) levels and LDL cholesterol values but not with systolic blood pressure. CONCLUSIONS Participatory decision making during primary care encounters by patients with type 2 diabetes resulted in improvements in hemoglobin A(1c) levels and LDL cholesterol values by improving patient activation, which in turn improved medication adherence. C1 [Parchman, Michael L.; Zeber, John E.] S Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res Program, San Antonio, TX 78229 USA. [Parchman, Michael L.; Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Zeber, John E.] Scott & White Healthcare, Ctr Appl Hlth Res, Temple, TX USA. [Zeber, John E.] Cent Texan Vet Hlth Care Syst, Temple, TX USA. RP Parchman, ML (reprint author), S Texas Vet Hlth Care Syst, VERDICT 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM parchman@uthscsa.edu OI Parchman, Michael/0000-0001-7129-2889 FU National Institutes of Health, National Institute for Diabetes, Digestive and Kidney Disorders [DK067300-02]; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service FX This research was supported by the National Institutes of Health, National Institute for Diabetes, Digestive and Kidney Disorders (DK067300-02); and the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service. NR 40 TC 73 Z9 75 U1 3 U2 19 PU ANNALS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA SN 1544-1709 J9 ANN FAM MED JI Ann. Fam. Med. PD SEP-OCT PY 2010 VL 8 IS 5 BP 410 EP 417 DI 10.1370/afm.1161 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 662JT UT WOS:000282804300005 PM 20843882 ER PT J AU Tyler, KL AF Tyler, Kenneth L. TI Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies? SO ANNALS OF NEUROLOGY LA English DT Editorial Material ID JC VIRUS-DNA; MULTIPLE-SCLEROSIS; NATALIZUMAB; BRAIN; INFECTION; PROTEINS; LATENCY C1 [Tyler, Kenneth L.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO 80202 USA. [Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Tyler, KL (reprint author), Univ Colorado, Sch Med, Dept Neurol, Denver, CO 80202 USA. OI Tyler, Kenneth/0000-0003-3294-5888 NR 20 TC 21 Z9 21 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD SEP PY 2010 VL 68 IS 3 BP 271 EP 274 DI 10.1002/ana.22185 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 644ZX UT WOS:000281421800004 PM 20818784 ER PT J AU Wasif, N Ko, CY Farrell, J Wainberg, Z Hines, OJ Reber, H Tomlinson, JS AF Wasif, Nabil Ko, Clifford Y. Farrell, James Wainberg, Zev Hines, Oscar J. Reber, Howard Tomlinson, James S. TI Impact of Tumor Grade on Prognosis in Pancreatic Cancer: Should We Include Grade in AJCC Staging? SO ANNALS OF SURGICAL ONCOLOGY LA English DT Article ID SINGLE-INSTITUTION EXPERIENCE; LONG-TERM SURVIVAL; DUCTAL ADENOCARCINOMA; RESECTION; DATABASE; CHEMOTHERAPY; VALIDATION; NOMOGRAM; TRIAL AB Background. AJCC staging of pancreatic cancer (PAC) is used to determine prognosis, yet survival within each stage shows wide variation and remains unpredictable. We hypothesized that tumor grade might be responsible for some of this variation and that the addition of grade to current AJCC staging would provide improved prognostication. Methods. The Surveillance, Epidemiology, and End Results (SEER) database (1991-2005) was used to identify 8082 patients with resected PAC. The impact of grade on overall and stage-specific survival was assessed using Cox regression analysis. Variables in the model were age, sex, tumor size, lymph node status, and tumor grade. Results. For each AJCC stage, survival was significantly worse for high-grade versus low-grade tumors. On multivariate analysis, high tumor grade was an independent predictor of survival for the entire cohort (hazard ratio [HR] 1.40, 95% confidence interval [95% CI] 1.31-1.48) as well as for stage I (HR 1.28, 95% CI 1.07-1.54), stage IIA (HR 1.43, 95% CI 1.26-1.61), stage IIB (HR 1.38, 95% CI 1.27-1.50), stage III (HR 1.28, 95% CI 1.02-1.59), and stage IV (HR 1.58, 95% CI 1.21-2.05) patients. The addition of grade to staging results in a statistically significant survival discrimination between all stages. Conclusions. Tumor grade is an important prognostic variable of survival in PAC. We propose a novel staging system incorporating grade into current AJCC staging for pancreas cancer. The improved prognostication is more reflective of tumor biology and may impact therapy decisions and stratification of future clinical trials. C1 [Ko, Clifford Y.; Hines, Oscar J.; Reber, Howard; Tomlinson, James S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Wasif, Nabil] St Johns Hlth Ctr, John Wayne Canc Inst, Santa Monica, CA USA. [Ko, Clifford Y.; Tomlinson, James S.] Greater Los Angeles VA Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Farrell, James] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Wainberg, Zev] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol, Los Angeles, CA 90095 USA. RP Tomlinson, JS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. EM james.tomlinson@va.gov FU Gonda (Goldschmied) Research Laboratories of the John Wayne Cancer Institute at Saint John's Health Center; QVC; Fashion Footwear Association of New York Charitable Foundation (New York, NY); Margie and Robert E. Petersen Foundation (Los Angeles, CA); Los Angeles, CA; Associates for Breast and Prostate Cancer Studies (Santa Monica, CA); Family of Robert Novick (Los Angeles, CA); Ruth and Martin H. Weil Fund (Los Angeles, CA); Wrather Family Foundation (Los Alamos, CA) FX Supported by grants from the Gonda (Goldschmied) Research Laboratories of the John Wayne Cancer Institute at Saint John's Health Center. Supported by funding from QVC and the Fashion Footwear Association of New York Charitable Foundation (New York, NY), the Margie and Robert E. Petersen Foundation (Los Angeles, CA), Mrs. Lois Rosen (Los Angeles, CA), and the Associates for Breast and Prostate Cancer Studies (Santa Monica, CA). Supported by funding from the Family of Robert Novick (Los Angeles, CA), Ruth and Martin H. Weil Fund (Los Angeles, CA), and the Wrather Family Foundation (Los Alamos, CA). NR 28 TC 46 Z9 46 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD SEP PY 2010 VL 17 IS 9 BP 2312 EP 2320 DI 10.1245/s10434-010-1071-7 PG 9 WC Oncology; Surgery SC Oncology; Surgery GA 650OJ UT WOS:000281858600009 PM 20422460 ER PT J AU Wecht, JM Rosado-Rivera, D Handrakis, JP Radulovic, M Bauman, WA AF Wecht, Jill M. Rosado-Rivera, Dwindally Handrakis, John P. Radulovic, Miroslav Bauman, William A. TI Effects of Midodrine Hydrochloride on Blood Pressure and Cerebral Blood Flow During Orthostasis in Persons With Chronic Tetraplegia SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT Congress of Spinal Cord Medicine and Rehabilitation CY SEP 24, 2009 CL Dallas, TX DE Hypotension, orthostatic; Midodrine; Rehabilitation; Spinal cord injuries; Tilt-table test ID SPINAL-CORD-INJURY; COGNITIVE PERFORMANCE; TRANSCRANIAL DOPPLER; ESSENTIAL HYPOTENSION; DOUBLE-BLIND; MEN; EJACULATION; PLACEBO; STIMULATION; ENHANCEMENT AB Wecht JM, Rosado-Rivera D, Handrakis JP, Radulovic M. Bauman WA. Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia. Arch Phys Med Rehabil 2010;91:1429-35. Objective: To determine the mean arterial pressure (MAP) and middle cerebral artery mean blood flow velocity (MFV) responses to 5 and 10mg midodrine during head-up tilt (HUT) in persons with tetraplegia. Design: Prospective dose-response trial. Setting: James J. Peters Veterans Administration Medical Center. Participants: Persons (N=10) with chronic tetraplegia (duration of injury = 23 +/- 11y). Intervention: A dose titration study was performed over 3 testing days: control (no drug), 5mg midodrine (5mg), or 10mg midodrine (10mg) during 30 minutes of baseline (predrug/no drug), 30 minutes of supine rest postdrug/no drug, 15 minutes of progressive HUT (5 minutes at 15 degrees, 25 degrees, 35 degrees), and 45 minutes of 45 degrees HUT. Main Outcome Measures: MAP and MFV response to midodrine supine and during HUT. Results: Ten milligrams of midodrine significantly increased MAP while supine and during the HUT maneuver. Of note, the mean increase in MAP during HUT with 10mg was a result of a robust effect in 2 persons, with minimal change in the remaining 8 study subjects. The reduction in cerebral MFV during HUT was attenuated with 10mg. Conclusions: These findings suggest that midodrine 10mg may be efficacious for treatment of hypotension and orthostatic hypotension in select persons with tetraplegia. Although midodrine is routinely prescribed to treat orthostatic hypotension, the results of our work suggests limited efficacy of this agent, but additional studies in a larger sample of subjects with spinal cord injury should be performed. C1 [Wecht, Jill M.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Wecht, Jill M.; Rosado-Rivera, Dwindally; Handrakis, John P.; Radulovic, Miroslav; Bauman, William A.] Mt Sinai Sch Med, Ctr Excellence, New York, NY USA. [Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] Mt Sinai Sch Med, Med Serv, New York, NY USA. [Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] NYIT, Dept Med, Old Westbury, NY USA. [Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] NYIT, Dept Rehabil Med, Old Westbury, NY USA. [Handrakis, John P.] NYIT, Sch Hlth Profess, Old Westbury, NY USA. RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM JM.WECHT@VA.GOV NR 43 TC 14 Z9 14 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD SEP PY 2010 VL 91 IS 9 BP 1429 EP 1435 DI 10.1016/j.apmr.2010.06.017 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 651IM UT WOS:000281921400018 PM 20801263 ER PT J AU Ingraham, AM Cohen, ME Bilimoria, KY Ko, CY Hall, BL Russell, TR Nathens, AB AF Ingraham, Angela M. Cohen, Mark E. Bilimoria, Karl Y. Ko, Clifford Y. Hall, Bruce L. Russell, Thomas R. Nathens, Avery B. TI Effect of Delay to Operation on Outcomes in Adults With Acute Appendicitis SO ARCHIVES OF SURGERY LA English DT Article ID SURGICAL CARE; APPENDECTOMY; SURGERY; QUALITY; TRIAL; NIGHT; NSQIP; RISK AB Objective: To examine the effect of delay from surgical admission to induction of anesthesia on outcomes after appendectomy for acute appendicitis in adults. Design: Retrospective cohort study with the principal exposure being time to operation. Regression models yielded probabilities of outcomes adjusted for patient and operative risk factors. Setting: Data were submitted to the American College of Surgeons National Surgical Quality Improvement Program database from January 1, 2005, through December 31, 2008. Patients: Patients with acute appendicitis who underwent an appendectomy. Main Outcome Measures: Thirty-day overall morbidity and serious morbidity/mortality. Results: Of 32 782 patients, 24 647 (75.2%) underwent operations within 6 hours of surgical admission, 4934(15.1%) underwent operations more than 6 through 12 hours, and 3201 (9.8%) underwent operations more than 12 hours after surgical admission. Differences in operative duration (51, 50, and 55 minutes, respectively; P<.001) were statistically significant but not clinically meaningful. The length of postoperative stay (2.2 days for the >12-hour group vs 1.8 days for the remaining groups; P<.001) was statistically significant but not clinically meaningful. No significant differences were found in adjusted overall morbidity (5.5%, 5.4%, and 6.1%, respectively; P=.33) or serious morbidity/mortality (3.0%, 3.6%, and 3.0%, respectively; P=.17). Duration from surgical admission to induction of anesthesia was not predictive in regression models for overall morbidity or serious morbidity/mortality. Conclusions: In this retrospective study, delay of appendectomy for acute appendicitis in adults does not appear to adversely affect 30-day outcomes. This information can guide the use of potentially limited operative and professional resources allocated for emergency care. C1 [Ingraham, Angela M.; Cohen, Mark E.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Bilimoria, Karl Y.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. [Ingraham, Angela M.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce L.] Washington Univ, Sch Med, Dept Surg, John Cochran Vet Affairs Med Ctr, St Louis, MO 63110 USA. [Hall, Bruce L.] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO 63110 USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO 63110 USA. [Russell, Thomas R.] Univ Calif San Francisco, Div Surg, San Francisco, CA 94143 USA. [Nathens, Avery B.] St Michaels Hosp, Div Surg & Trauma, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada. RP Ingraham, AM (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,Floor 22NE, Chicago, IL 60611 USA. EM aingraham@facs.org FU American College of Surgeons; Northwestern University; Canada Research Chair in Systems of Trauma Care; Center for Health Policy, Washington University in St Louis FX Dr Ingraham is supported by the Clinical Scholar in Residence Program at the American College of Surgeons. Dr Bilimoria is supported by a Priority Grant from Northwestern University. Dr Nathens is supported by a Canada Research Chair in Systems of Trauma Care. Dr Hall is supported by the Center for Health Policy, Washington University in St Louis. NR 23 TC 47 Z9 49 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD SEP PY 2010 VL 145 IS 9 BP 886 EP 892 PG 7 WC Surgery SC Surgery GA 649JH UT WOS:000281764400020 PM 20855760 ER EF